id	sid	tid	token	lemma	pos
10_1101-2020_01_28_923532	1	1	The	the	DT
10_1101-2020_01_28_923532	1	2	Landscape	Landscape	NNP
10_1101-2020_01_28_923532	1	3	of	of	IN
10_1101-2020_01_28_923532	1	4	Precision	Precision	NNP
10_1101-2020_01_28_923532	1	5	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	1	6	Combination	Combination	NNP
10_1101-2020_01_28_923532	1	7	Therapy	therapy	NN
10_1101-2020_01_28_923532	1	8	:	:	:
10_1101-2020_01_28_923532	1	9	A	a	DT
10_1101-2020_01_28_923532	1	10	Single	single	JJ
10_1101-2020_01_28_923532	1	11	-	-	HYPH
10_1101-2020_01_28_923532	1	12	Cell	cell	NN
10_1101-2020_01_28_923532	1	13	Perspective	perspective	NN
10_1101-2020_01_28_923532	1	14	1	1	CD
10_1101-2020_01_28_923532	1	15	The	the	DT
10_1101-2020_01_28_923532	1	16	Landscape	Landscape	NNP
10_1101-2020_01_28_923532	1	17	of	of	IN
10_1101-2020_01_28_923532	1	18	Precision	Precision	NNP
10_1101-2020_01_28_923532	1	19	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	1	20	Combination	Combination	NNP
10_1101-2020_01_28_923532	1	21	Therapy	therapy	NN
10_1101-2020_01_28_923532	1	22	:	:	:
10_1101-2020_01_28_923532	1	23	A	a	DT
10_1101-2020_01_28_923532	1	24	Single	single	JJ
10_1101-2020_01_28_923532	1	25	-	-	HYPH
10_1101-2020_01_28_923532	1	26	Cell	Cell	NNP
10_1101-2020_01_28_923532	1	27	Perspective	Perspective	NNP
10_1101-2020_01_28_923532	1	28	Saba	Saba	NNP
10_1101-2020_01_28_923532	1	29	Ahmadi1,7^	Ahmadi1,7^	NNP
10_1101-2020_01_28_923532	1	30	,	,	,
10_1101-2020_01_28_923532	1	31	Pattara	Pattara	NNP
10_1101-2020_01_28_923532	1	32	Sukprasert2,8^	sukprasert2,8^	CD
10_1101-2020_01_28_923532	1	33	,	,	,
10_1101-2020_01_28_923532	1	34	Rahulsimham	Rahulsimham	NNP
10_1101-2020_01_28_923532	1	35	Vegesna3	Vegesna3	NNP
10_1101-2020_01_28_923532	1	36	,	,	,
10_1101-2020_01_28_923532	1	37	Sanju	Sanju	NNP
10_1101-2020_01_28_923532	1	38	Sinha3	Sinha3	NNP
10_1101-2020_01_28_923532	1	39	,	,	,
10_1101-2020_01_28_923532	1	40	Fiorella	Fiorella	NNP
10_1101-2020_01_28_923532	1	41	Schischlik3	Schischlik3	NNP
10_1101-2020_01_28_923532	1	42	,	,	,
10_1101-2020_01_28_923532	1	43	Natalie	Natalie	NNP
10_1101-2020_01_28_923532	1	44	Artzi4,5,6	Artzi4,5,6	NNP
10_1101-2020_01_28_923532	1	45	,	,	,
10_1101-2020_01_28_923532	1	46	Samir	Samir	NNP
10_1101-2020_01_28_923532	1	47	Khuller2,8	Khuller2,8	NFP
10_1101-2020_01_28_923532	1	48	,	,	,
10_1101-2020_01_28_923532	1	49	Alejandro	Alejandro	NNP
10_1101-2020_01_28_923532	1	50	A.	A.	NNP
10_1101-2020_01_28_923532	1	51	Schäffer3	Schäffer3	NNP
10_1101-2020_01_28_923532	1	52	*	*	NFP
10_1101-2020_01_28_923532	1	53	,	,	,
10_1101-2020_01_28_923532	1	54	Eytan	Eytan	NNP
10_1101-2020_01_28_923532	1	55	Ruppin3	Ruppin3	NNP
10_1101-2020_01_28_923532	1	56	*	*	NFP
10_1101-2020_01_28_923532	1	57	1	1	CD
10_1101-2020_01_28_923532	1	58	Dept	dept	NN
10_1101-2020_01_28_923532	1	59	.	.	.
10_1101-2020_01_28_923532	2	1	of	of	IN
10_1101-2020_01_28_923532	2	2	Computer	Computer	NNP
10_1101-2020_01_28_923532	2	3	Science	Science	NNP
10_1101-2020_01_28_923532	2	4	,	,	,
10_1101-2020_01_28_923532	2	5	University	University	NNP
10_1101-2020_01_28_923532	2	6	of	of	IN
10_1101-2020_01_28_923532	2	7	Maryland	Maryland	NNP
10_1101-2020_01_28_923532	2	8	,	,	,
10_1101-2020_01_28_923532	2	9	College	College	NNP
10_1101-2020_01_28_923532	2	10	Park	Park	NNP
10_1101-2020_01_28_923532	2	11	MD	MD	NNP
10_1101-2020_01_28_923532	2	12	20742	20742	CD
10_1101-2020_01_28_923532	2	13	USA	USA	NNP
10_1101-2020_01_28_923532	2	14	2	2	CD
10_1101-2020_01_28_923532	2	15	Dept	Dept	NNP
10_1101-2020_01_28_923532	2	16	.	.	.
10_1101-2020_01_28_923532	3	1	of	of	IN
10_1101-2020_01_28_923532	3	2	Computer	Computer	NNP
10_1101-2020_01_28_923532	3	3	Science	Science	NNP
10_1101-2020_01_28_923532	3	4	,	,	,
10_1101-2020_01_28_923532	3	5	Northwestern	Northwestern	NNP
10_1101-2020_01_28_923532	3	6	University	University	NNP
10_1101-2020_01_28_923532	3	7	,	,	,
10_1101-2020_01_28_923532	3	8	Evanston	Evanston	NNP
10_1101-2020_01_28_923532	3	9	IL	IL	NNP
10_1101-2020_01_28_923532	3	10	60208	60208	CD
10_1101-2020_01_28_923532	3	11	USA	USA	NNP
10_1101-2020_01_28_923532	3	12	3	3	CD
10_1101-2020_01_28_923532	3	13	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	3	14	Data	Data	NNP
10_1101-2020_01_28_923532	3	15	Science	Science	NNP
10_1101-2020_01_28_923532	3	16	Laboratory	Laboratory	NNP
10_1101-2020_01_28_923532	3	17	,	,	,
10_1101-2020_01_28_923532	3	18	National	National	NNP
10_1101-2020_01_28_923532	3	19	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	3	20	Institute	Institute	NNP
10_1101-2020_01_28_923532	3	21	,	,	,
10_1101-2020_01_28_923532	3	22	Bethesda	Bethesda	NNP
10_1101-2020_01_28_923532	3	23	,	,	,
10_1101-2020_01_28_923532	3	24	MD	MD	NNP
10_1101-2020_01_28_923532	3	25	20892	20892	CD
10_1101-2020_01_28_923532	3	26	USA	USA	NNP
10_1101-2020_01_28_923532	3	27	4	4	CD
10_1101-2020_01_28_923532	3	28	Dept	Dept	NNP
10_1101-2020_01_28_923532	3	29	.	.	.
10_1101-2020_01_28_923532	4	1	of	of	IN
10_1101-2020_01_28_923532	4	2	Medicine	Medicine	NNP
10_1101-2020_01_28_923532	4	3	,	,	,
10_1101-2020_01_28_923532	4	4	Engineering	Engineering	NNP
10_1101-2020_01_28_923532	4	5	in	in	IN
10_1101-2020_01_28_923532	4	6	Medicine	Medicine	NNP
10_1101-2020_01_28_923532	4	7	Division	Division	NNP
10_1101-2020_01_28_923532	4	8	,	,	,
10_1101-2020_01_28_923532	4	9	Brigham	Brigham	NNP
10_1101-2020_01_28_923532	4	10	and	and	CC
10_1101-2020_01_28_923532	4	11	Women	Women	NNP
10_1101-2020_01_28_923532	4	12	’s	’s	POS
10_1101-2020_01_28_923532	4	13	Hospital	Hospital	NNP
10_1101-2020_01_28_923532	4	14	,	,	,
10_1101-2020_01_28_923532	4	15	Harvard	Harvard	NNP
10_1101-2020_01_28_923532	4	16	Medical	Medical	NNP
10_1101-2020_01_28_923532	4	17	School	School	NNP
10_1101-2020_01_28_923532	4	18	,	,	,
10_1101-2020_01_28_923532	4	19	Boston	Boston	NNP
10_1101-2020_01_28_923532	4	20	,	,	,
10_1101-2020_01_28_923532	4	21	MA	MA	NNP
10_1101-2020_01_28_923532	4	22	02139	02139	CD
10_1101-2020_01_28_923532	4	23	USA	USA	NNP
10_1101-2020_01_28_923532	4	24	5	5	CD
10_1101-2020_01_28_923532	4	25	Broad	Broad	NNP
10_1101-2020_01_28_923532	4	26	Institute	Institute	NNP
10_1101-2020_01_28_923532	4	27	of	of	IN
10_1101-2020_01_28_923532	4	28	Harvard	Harvard	NNP
10_1101-2020_01_28_923532	4	29	and	and	CC
10_1101-2020_01_28_923532	4	30	MIT	MIT	NNP
10_1101-2020_01_28_923532	4	31	,	,	,
10_1101-2020_01_28_923532	4	32	Cambridge	Cambridge	NNP
10_1101-2020_01_28_923532	4	33	,	,	,
10_1101-2020_01_28_923532	4	34	MA	MA	NNP
10_1101-2020_01_28_923532	4	35	02139	02139	CD
10_1101-2020_01_28_923532	4	36	USA	USA	NNP
10_1101-2020_01_28_923532	4	37	6	6	CD
10_1101-2020_01_28_923532	4	38	Institute	Institute	NNP
10_1101-2020_01_28_923532	4	39	for	for	IN
10_1101-2020_01_28_923532	4	40	Medical	Medical	NNP
10_1101-2020_01_28_923532	4	41	Engineering	Engineering	NNP
10_1101-2020_01_28_923532	4	42	and	and	CC
10_1101-2020_01_28_923532	4	43	Science	Science	NNP
10_1101-2020_01_28_923532	4	44	,	,	,
10_1101-2020_01_28_923532	4	45	MIT	MIT	NNP
10_1101-2020_01_28_923532	4	46	,	,	,
10_1101-2020_01_28_923532	4	47	Cambridge	Cambridge	NNP
10_1101-2020_01_28_923532	4	48	,	,	,
10_1101-2020_01_28_923532	4	49	MA	MA	NNP
10_1101-2020_01_28_923532	4	50	02139	02139	CD
10_1101-2020_01_28_923532	4	51	USA	USA	NNP
10_1101-2020_01_28_923532	4	52	7	7	CD
10_1101-2020_01_28_923532	4	53	Part	Part	NNP
10_1101-2020_01_28_923532	4	54	of	of	IN
10_1101-2020_01_28_923532	4	55	this	this	DT
10_1101-2020_01_28_923532	4	56	research	research	NN
10_1101-2020_01_28_923532	4	57	done	do	VBN
10_1101-2020_01_28_923532	4	58	while	while	IN
10_1101-2020_01_28_923532	4	59	at	at	IN
10_1101-2020_01_28_923532	4	60	Dept	Dept	NNP
10_1101-2020_01_28_923532	4	61	.	.	.
10_1101-2020_01_28_923532	5	1	of	of	IN
10_1101-2020_01_28_923532	5	2	Computer	Computer	NNP
10_1101-2020_01_28_923532	5	3	Science	Science	NNP
10_1101-2020_01_28_923532	5	4	,	,	,
10_1101-2020_01_28_923532	5	5	Northwestern	Northwestern	NNP
10_1101-2020_01_28_923532	5	6	University	University	NNP
10_1101-2020_01_28_923532	5	7	,	,	,
10_1101-2020_01_28_923532	5	8	Evanston	Evanston	NNP
10_1101-2020_01_28_923532	5	9	IL	IL	NNP
10_1101-2020_01_28_923532	5	10	60208	60208	CD
10_1101-2020_01_28_923532	5	11	USA	USA	NNP
10_1101-2020_01_28_923532	5	12	8	8	CD
10_1101-2020_01_28_923532	5	13	Part	part	NN
10_1101-2020_01_28_923532	5	14	of	of	IN
10_1101-2020_01_28_923532	5	15	this	this	DT
10_1101-2020_01_28_923532	5	16	research	research	NN
10_1101-2020_01_28_923532	5	17	was	be	VBD
10_1101-2020_01_28_923532	5	18	done	do	VBN
10_1101-2020_01_28_923532	5	19	while	while	IN
10_1101-2020_01_28_923532	5	20	at	at	IN
10_1101-2020_01_28_923532	5	21	Dept	Dept	NNP
10_1101-2020_01_28_923532	5	22	.	.	.
10_1101-2020_01_28_923532	6	1	Computer	Computer	NNP
10_1101-2020_01_28_923532	6	2	Science	Science	NNP
10_1101-2020_01_28_923532	6	3	,	,	,
10_1101-2020_01_28_923532	6	4	University	University	NNP
10_1101-2020_01_28_923532	6	5	of	of	IN
10_1101-2020_01_28_923532	6	6	Maryland	Maryland	NNP
10_1101-2020_01_28_923532	6	7	,	,	,
10_1101-2020_01_28_923532	6	8	College	College	NNP
10_1101-2020_01_28_923532	6	9	Park	Park	NNP
10_1101-2020_01_28_923532	6	10	MD	MD	NNP
10_1101-2020_01_28_923532	6	11	20742	20742	CD
10_1101-2020_01_28_923532	6	12	USA	USA	NNP
10_1101-2020_01_28_923532	6	13	^	^	NN
10_1101-2020_01_28_923532	6	14	Equally	equally	RB
10_1101-2020_01_28_923532	6	15	contributing	contribute	VBG
10_1101-2020_01_28_923532	6	16	first	first	JJ
10_1101-2020_01_28_923532	6	17	authors	author	NNS
10_1101-2020_01_28_923532	6	18	*	*	NFP
10_1101-2020_01_28_923532	6	19	Equally	equally	RB
10_1101-2020_01_28_923532	6	20	contributing	contribute	VBG
10_1101-2020_01_28_923532	6	21	corresponding	corresponding	JJ
10_1101-2020_01_28_923532	6	22	authors	author	NNS
10_1101-2020_01_28_923532	6	23	Correspondence	Correspondence	NNP
10_1101-2020_01_28_923532	6	24	should	should	MD
10_1101-2020_01_28_923532	6	25	be	be	VB
10_1101-2020_01_28_923532	6	26	addressed	address	VBN
10_1101-2020_01_28_923532	6	27	to	to	IN
10_1101-2020_01_28_923532	6	28	alejandro.schaffer@nih.gov	alejandro.schaffer@nih.gov	NNP
10_1101-2020_01_28_923532	6	29	and	and	CC
10_1101-2020_01_28_923532	6	30	eytan.ruppin@nih.gov	eytan.ruppin@nih.gov	NN
10_1101-2020_01_28_923532	6	31	.	.	.
10_1101-2020_01_28_923532	7	1	Physical	physical	JJ
10_1101-2020_01_28_923532	7	2	address	address	NN
10_1101-2020_01_28_923532	7	3	:	:	:
10_1101-2020_01_28_923532	7	4	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	7	5	Data	Data	NNP
10_1101-2020_01_28_923532	7	6	Science	Science	NNP
10_1101-2020_01_28_923532	7	7	Laboratory	Laboratory	NNP
10_1101-2020_01_28_923532	7	8	,	,	,
10_1101-2020_01_28_923532	7	9	National	National	NNP
10_1101-2020_01_28_923532	7	10	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	7	11	Institute	Institute	NNP
10_1101-2020_01_28_923532	7	12	,	,	,
10_1101-2020_01_28_923532	7	13	Bldg	Bldg	NNP
10_1101-2020_01_28_923532	7	14	.	.	.
10_1101-2020_01_28_923532	8	1	15-C1	15-c1	LS
10_1101-2020_01_28_923532	8	2	,	,	,
10_1101-2020_01_28_923532	8	3	Bethesda	Bethesda	NNP
10_1101-2020_01_28_923532	8	4	,	,	,
10_1101-2020_01_28_923532	8	5	MD	MD	NNP
10_1101-2020_01_28_923532	8	6	20892	20892	CD
10_1101-2020_01_28_923532	8	7	USA	USA	NNP
10_1101-2020_01_28_923532	8	8	Keywords	Keywords	NNPS
10_1101-2020_01_28_923532	8	9	:	:	:
10_1101-2020_01_28_923532	8	10	targeted	target	VBN
10_1101-2020_01_28_923532	8	11	cancer	cancer	NN
10_1101-2020_01_28_923532	8	12	therapy	therapy	NN
10_1101-2020_01_28_923532	8	13	,	,	,
10_1101-2020_01_28_923532	8	14	combination	combination	NN
10_1101-2020_01_28_923532	8	15	therapy	therapy	NN
10_1101-2020_01_28_923532	8	16	,	,	,
10_1101-2020_01_28_923532	8	17	personalized	personalize	VBD
10_1101-2020_01_28_923532	8	18	medicine	medicine	NN
10_1101-2020_01_28_923532	8	19	,	,	,
10_1101-2020_01_28_923532	8	20	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	8	21	optimization	optimization	NN
10_1101-2020_01_28_923532	8	22	,	,	,
10_1101-2020_01_28_923532	8	23	hitting	hit	VBG
10_1101-2020_01_28_923532	8	24	set	set	VBN
10_1101-2020_01_28_923532	8	25	,	,	,
10_1101-2020_01_28_923532	8	26	single	single	JJ
10_1101-2020_01_28_923532	8	27	-	-	HYPH
10_1101-2020_01_28_923532	8	28	cell	cell	NN
10_1101-2020_01_28_923532	8	29	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	8	30	105	105	CD
10_1101-2020_01_28_923532	8	31	and	and	CC
10_1101-2020_01_28_923532	8	32	is	be	VBZ
10_1101-2020_01_28_923532	8	33	also	also	RB
10_1101-2020_01_28_923532	8	34	made	make	VBN
10_1101-2020_01_28_923532	8	35	available	available	JJ
10_1101-2020_01_28_923532	8	36	for	for	IN
10_1101-2020_01_28_923532	8	37	use	use	NN
10_1101-2020_01_28_923532	8	38	under	under	IN
10_1101-2020_01_28_923532	8	39	a	a	DT
10_1101-2020_01_28_923532	8	40	CC0	CC0	NNP
10_1101-2020_01_28_923532	8	41	license	license	NN
10_1101-2020_01_28_923532	8	42	.	.	.
10_1101-2020_01_28_923532	9	1	(	(	-LRB-
10_1101-2020_01_28_923532	9	2	which	which	WDT
10_1101-2020_01_28_923532	9	3	was	be	VBD
10_1101-2020_01_28_923532	9	4	not	not	RB
10_1101-2020_01_28_923532	9	5	certified	certify	VBN
10_1101-2020_01_28_923532	9	6	by	by	IN
10_1101-2020_01_28_923532	9	7	peer	peer	NN
10_1101-2020_01_28_923532	9	8	review	review	NN
10_1101-2020_01_28_923532	9	9	)	)	-RRB-
10_1101-2020_01_28_923532	9	10	is	be	VBZ
10_1101-2020_01_28_923532	9	11	the	the	DT
10_1101-2020_01_28_923532	9	12	author	author	NN
10_1101-2020_01_28_923532	9	13	/	/	SYM
10_1101-2020_01_28_923532	9	14	funder	funder	NN
10_1101-2020_01_28_923532	9	15	.	.	.
10_1101-2020_01_28_923532	10	1	This	this	DT
10_1101-2020_01_28_923532	10	2	article	article	NN
10_1101-2020_01_28_923532	10	3	is	be	VBZ
10_1101-2020_01_28_923532	10	4	a	a	DT
10_1101-2020_01_28_923532	10	5	US	US	NNP
10_1101-2020_01_28_923532	10	6	Government	Government	NNP
10_1101-2020_01_28_923532	10	7	work	work	NN
10_1101-2020_01_28_923532	10	8	.	.	.
10_1101-2020_01_28_923532	11	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	11	2	is	be	VBZ
10_1101-2020_01_28_923532	11	3	not	not	RB
10_1101-2020_01_28_923532	11	4	subject	subject	JJ
10_1101-2020_01_28_923532	11	5	to	to	IN
10_1101-2020_01_28_923532	11	6	copyright	copyright	NN
10_1101-2020_01_28_923532	11	7	under	under	IN
10_1101-2020_01_28_923532	11	8	17	17	CD
10_1101-2020_01_28_923532	11	9	USC	usc	NN
10_1101-2020_01_28_923532	11	10	The	the	DT
10_1101-2020_01_28_923532	11	11	copyright	copyright	NN
10_1101-2020_01_28_923532	11	12	holder	holder	NN
10_1101-2020_01_28_923532	11	13	for	for	IN
10_1101-2020_01_28_923532	11	14	this	this	DT
10_1101-2020_01_28_923532	11	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	11	16	version	version	NN
10_1101-2020_01_28_923532	11	17	posted	post	VBD
10_1101-2020_01_28_923532	11	18	February	February	NNP
10_1101-2020_01_28_923532	11	19	12	12	CD
10_1101-2020_01_28_923532	11	20	,	,	,
10_1101-2020_01_28_923532	11	21	2021	2021	CD
10_1101-2020_01_28_923532	11	22	.	.	.
10_1101-2020_01_28_923532	11	23	;	;	:
10_1101-2020_01_28_923532	11	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	11	25	:	:	:
10_1101-2020_01_28_923532	11	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	11	27	preprint	preprint	NN
10_1101-2020_01_28_923532	11	28	mailto:alejandro.schaffer@nih.gov	mailto:alejandro.schaffer@nih.gov	NNP
10_1101-2020_01_28_923532	11	29	mailto:eytan.ruppin@nih.gov	mailto:eytan.ruppin@nih.gov	NNP
10_1101-2020_01_28_923532	11	30	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	NNP
10_1101-2020_01_28_923532	11	31	2	2	CD
10_1101-2020_01_28_923532	11	32	Abbreviations	Abbreviations	NNPS
10_1101-2020_01_28_923532	11	33	:	:	:
10_1101-2020_01_28_923532	11	34	CTS	CTS	NNP
10_1101-2020_01_28_923532	11	35	:	:	:
10_1101-2020_01_28_923532	11	36	cohort	cohort	NN
10_1101-2020_01_28_923532	11	37	target	target	NN
10_1101-2020_01_28_923532	11	38	set	set	VBN
10_1101-2020_01_28_923532	11	39	,	,	,
10_1101-2020_01_28_923532	11	40	synonym	synonym	NN
10_1101-2020_01_28_923532	11	41	of	of	IN
10_1101-2020_01_28_923532	11	42	global	global	JJ
10_1101-2020_01_28_923532	11	43	hitting	hitting	NN
10_1101-2020_01_28_923532	11	44	set	set	VBN
10_1101-2020_01_28_923532	11	45	GEO	GEO	NNP
10_1101-2020_01_28_923532	11	46	:	:	:
10_1101-2020_01_28_923532	11	47	Gene	Gene	NNP
10_1101-2020_01_28_923532	11	48	Expression	Expression	NNP
10_1101-2020_01_28_923532	11	49	Omnibus	Omnibus	NNP
10_1101-2020_01_28_923532	11	50	GHS	GHS	NNP
10_1101-2020_01_28_923532	11	51	:	:	:
10_1101-2020_01_28_923532	11	52	global	global	JJ
10_1101-2020_01_28_923532	11	53	hitting	hitting	NN
10_1101-2020_01_28_923532	11	54	set	set	NN
10_1101-2020_01_28_923532	11	55	,	,	,
10_1101-2020_01_28_923532	11	56	synonym	synonym	NN
10_1101-2020_01_28_923532	11	57	of	of	IN
10_1101-2020_01_28_923532	11	58	cohort	cohort	NN
10_1101-2020_01_28_923532	11	59	target	target	NN
10_1101-2020_01_28_923532	11	60	set	set	VBN
10_1101-2020_01_28_923532	11	61	GTEx	GTEx	NNS
10_1101-2020_01_28_923532	11	62	:	:	:
10_1101-2020_01_28_923532	11	63	Genotype	Genotype	NNP
10_1101-2020_01_28_923532	11	64	-	-	HYPH
10_1101-2020_01_28_923532	11	65	Tissue	Tissue	NNP
10_1101-2020_01_28_923532	11	66	Expression	Expression	NNP
10_1101-2020_01_28_923532	11	67	(	(	-LRB-
10_1101-2020_01_28_923532	11	68	project	project	NN
10_1101-2020_01_28_923532	11	69	or	or	CC
10_1101-2020_01_28_923532	11	70	consortium	consortium	NN
10_1101-2020_01_28_923532	11	71	)	)	-RRB-
10_1101-2020_01_28_923532	11	72	HPA	HPA	NNP
10_1101-2020_01_28_923532	11	73	:	:	:
10_1101-2020_01_28_923532	11	74	Human	Human	NNP
10_1101-2020_01_28_923532	11	75	Protein	Protein	NNP
10_1101-2020_01_28_923532	11	76	Atlas	Atlas	NNP
10_1101-2020_01_28_923532	11	77	HUGO	HUGO	NNP
10_1101-2020_01_28_923532	11	78	:	:	:
10_1101-2020_01_28_923532	11	79	Human	Human	NNP
10_1101-2020_01_28_923532	11	80	Genome	Genome	NNP
10_1101-2020_01_28_923532	11	81	Organization	Organization	NNP
10_1101-2020_01_28_923532	11	82	IHS	IHS	NNP
10_1101-2020_01_28_923532	11	83	:	:	:
10_1101-2020_01_28_923532	11	84	individual	individual	JJ
10_1101-2020_01_28_923532	11	85	hitting	hitting	NN
10_1101-2020_01_28_923532	11	86	set	set	NN
10_1101-2020_01_28_923532	11	87	,	,	,
10_1101-2020_01_28_923532	11	88	synonym	synonym	NN
10_1101-2020_01_28_923532	11	89	of	of	IN
10_1101-2020_01_28_923532	11	90	individual	individual	JJ
10_1101-2020_01_28_923532	11	91	target	target	NN
10_1101-2020_01_28_923532	11	92	set	set	VBN
10_1101-2020_01_28_923532	11	93	ILP	ILP	NNP
10_1101-2020_01_28_923532	11	94	:	:	:
10_1101-2020_01_28_923532	11	95	integer	integer	NN
10_1101-2020_01_28_923532	11	96	linear	linear	NNP
10_1101-2020_01_28_923532	11	97	programming	programming	NN
10_1101-2020_01_28_923532	11	98	ITS	its	PRP$
10_1101-2020_01_28_923532	11	99	:	:	:
10_1101-2020_01_28_923532	11	100	individual	individual	JJ
10_1101-2020_01_28_923532	11	101	target	target	NN
10_1101-2020_01_28_923532	11	102	set	set	VBN
10_1101-2020_01_28_923532	11	103	lb	lb	RB
10_1101-2020_01_28_923532	11	104	:	:	:
10_1101-2020_01_28_923532	11	105	lower	lower	RBR
10_1101-2020_01_28_923532	11	106	bound	bind	VBN
10_1101-2020_01_28_923532	11	107	on	on	IN
10_1101-2020_01_28_923532	11	108	fraction	fraction	NN
10_1101-2020_01_28_923532	11	109	of	of	IN
10_1101-2020_01_28_923532	11	110	tumor	tumor	NN
10_1101-2020_01_28_923532	11	111	cells	cell	NNS
10_1101-2020_01_28_923532	11	112	killed	kill	VBD
10_1101-2020_01_28_923532	11	113	RME	RME	NNP
10_1101-2020_01_28_923532	11	114	:	:	:
10_1101-2020_01_28_923532	11	115	receptor	receptor	NN
10_1101-2020_01_28_923532	11	116	-	-	HYPH
10_1101-2020_01_28_923532	11	117	mediated	mediate	VBN
10_1101-2020_01_28_923532	11	118	endocytosis	endocytosis	NN
10_1101-2020_01_28_923532	11	119	TPM	TPM	NNP
10_1101-2020_01_28_923532	11	120	:	:	:
10_1101-2020_01_28_923532	11	121	transcripts	transcript	NNS
10_1101-2020_01_28_923532	11	122	per	per	IN
10_1101-2020_01_28_923532	11	123	million	million	CD
10_1101-2020_01_28_923532	11	124	ub	ub	IN
10_1101-2020_01_28_923532	11	125	:	:	:
10_1101-2020_01_28_923532	11	126	upper	upper	NNP
10_1101-2020_01_28_923532	11	127	bound	bind	VBN
10_1101-2020_01_28_923532	11	128	on	on	IN
10_1101-2020_01_28_923532	11	129	fraction	fraction	NN
10_1101-2020_01_28_923532	11	130	of	of	IN
10_1101-2020_01_28_923532	11	131	non	non	JJ
10_1101-2020_01_28_923532	11	132	-	-	JJ
10_1101-2020_01_28_923532	11	133	tumor	tumor	JJ
10_1101-2020_01_28_923532	11	134	cells	cell	NNS
10_1101-2020_01_28_923532	11	135	killed	kill	VBD
10_1101-2020_01_28_923532	11	136	105	105	CD
10_1101-2020_01_28_923532	11	137	and	and	CC
10_1101-2020_01_28_923532	11	138	is	be	VBZ
10_1101-2020_01_28_923532	11	139	also	also	RB
10_1101-2020_01_28_923532	11	140	made	make	VBN
10_1101-2020_01_28_923532	11	141	available	available	JJ
10_1101-2020_01_28_923532	11	142	for	for	IN
10_1101-2020_01_28_923532	11	143	use	use	NN
10_1101-2020_01_28_923532	11	144	under	under	IN
10_1101-2020_01_28_923532	11	145	a	a	DT
10_1101-2020_01_28_923532	11	146	CC0	CC0	NNP
10_1101-2020_01_28_923532	11	147	license	license	NN
10_1101-2020_01_28_923532	11	148	.	.	.
10_1101-2020_01_28_923532	12	1	(	(	-LRB-
10_1101-2020_01_28_923532	12	2	which	which	WDT
10_1101-2020_01_28_923532	12	3	was	be	VBD
10_1101-2020_01_28_923532	12	4	not	not	RB
10_1101-2020_01_28_923532	12	5	certified	certify	VBN
10_1101-2020_01_28_923532	12	6	by	by	IN
10_1101-2020_01_28_923532	12	7	peer	peer	NN
10_1101-2020_01_28_923532	12	8	review	review	NN
10_1101-2020_01_28_923532	12	9	)	)	-RRB-
10_1101-2020_01_28_923532	12	10	is	be	VBZ
10_1101-2020_01_28_923532	12	11	the	the	DT
10_1101-2020_01_28_923532	12	12	author	author	NN
10_1101-2020_01_28_923532	12	13	/	/	SYM
10_1101-2020_01_28_923532	12	14	funder	funder	NN
10_1101-2020_01_28_923532	12	15	.	.	.
10_1101-2020_01_28_923532	13	1	This	this	DT
10_1101-2020_01_28_923532	13	2	article	article	NN
10_1101-2020_01_28_923532	13	3	is	be	VBZ
10_1101-2020_01_28_923532	13	4	a	a	DT
10_1101-2020_01_28_923532	13	5	US	US	NNP
10_1101-2020_01_28_923532	13	6	Government	Government	NNP
10_1101-2020_01_28_923532	13	7	work	work	NN
10_1101-2020_01_28_923532	13	8	.	.	.
10_1101-2020_01_28_923532	14	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	14	2	is	be	VBZ
10_1101-2020_01_28_923532	14	3	not	not	RB
10_1101-2020_01_28_923532	14	4	subject	subject	JJ
10_1101-2020_01_28_923532	14	5	to	to	IN
10_1101-2020_01_28_923532	14	6	copyright	copyright	NN
10_1101-2020_01_28_923532	14	7	under	under	IN
10_1101-2020_01_28_923532	14	8	17	17	CD
10_1101-2020_01_28_923532	14	9	USC	usc	NN
10_1101-2020_01_28_923532	14	10	The	the	DT
10_1101-2020_01_28_923532	14	11	copyright	copyright	NN
10_1101-2020_01_28_923532	14	12	holder	holder	NN
10_1101-2020_01_28_923532	14	13	for	for	IN
10_1101-2020_01_28_923532	14	14	this	this	DT
10_1101-2020_01_28_923532	14	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	14	16	version	version	NN
10_1101-2020_01_28_923532	14	17	posted	post	VBD
10_1101-2020_01_28_923532	14	18	February	February	NNP
10_1101-2020_01_28_923532	14	19	12	12	CD
10_1101-2020_01_28_923532	14	20	,	,	,
10_1101-2020_01_28_923532	14	21	2021	2021	CD
10_1101-2020_01_28_923532	14	22	.	.	.
10_1101-2020_01_28_923532	14	23	;	;	:
10_1101-2020_01_28_923532	14	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	14	25	:	:	:
10_1101-2020_01_28_923532	14	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	14	27	preprint	preprint	NN
10_1101-2020_01_28_923532	14	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	14	29	3	3	CD
10_1101-2020_01_28_923532	14	30	Abstract	Abstract	NNP
10_1101-2020_01_28_923532	14	31	The	the	DT
10_1101-2020_01_28_923532	14	32	availability	availability	NN
10_1101-2020_01_28_923532	14	33	of	of	IN
10_1101-2020_01_28_923532	14	34	single	single	JJ
10_1101-2020_01_28_923532	14	35	-	-	HYPH
10_1101-2020_01_28_923532	14	36	cell	cell	NN
10_1101-2020_01_28_923532	14	37	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	14	38	data	datum	NNS
10_1101-2020_01_28_923532	14	39	opens	open	VBZ
10_1101-2020_01_28_923532	14	40	new	new	JJ
10_1101-2020_01_28_923532	14	41	opportunities	opportunity	NNS
10_1101-2020_01_28_923532	14	42	for	for	IN
10_1101-2020_01_28_923532	14	43	rational	rational	JJ
10_1101-2020_01_28_923532	14	44	design	design	NN
10_1101-2020_01_28_923532	14	45	of	of	IN
10_1101-2020_01_28_923532	14	46	combination	combination	NN
10_1101-2020_01_28_923532	14	47	cancer	cancer	NN
10_1101-2020_01_28_923532	14	48	treatments	treatment	NNS
10_1101-2020_01_28_923532	14	49	in	in	IN
10_1101-2020_01_28_923532	14	50	a	a	DT
10_1101-2020_01_28_923532	14	51	systematic	systematic	JJ
10_1101-2020_01_28_923532	14	52	manner	manner	NN
10_1101-2020_01_28_923532	14	53	.	.	.
10_1101-2020_01_28_923532	15	1	Mining	mine	VBG
10_1101-2020_01_28_923532	15	2	such	such	JJ
10_1101-2020_01_28_923532	15	3	data	datum	NNS
10_1101-2020_01_28_923532	15	4	,	,	,
10_1101-2020_01_28_923532	15	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	15	6	employed	employ	VBD
10_1101-2020_01_28_923532	15	7	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	15	8	optimization	optimization	NN
10_1101-2020_01_28_923532	15	9	techniques	technique	NNS
10_1101-2020_01_28_923532	15	10	to	to	TO
10_1101-2020_01_28_923532	15	11	explore	explore	VB
10_1101-2020_01_28_923532	15	12	the	the	DT
10_1101-2020_01_28_923532	15	13	landscape	landscape	NN
10_1101-2020_01_28_923532	15	14	of	of	IN
10_1101-2020_01_28_923532	15	15	optimal	optimal	JJ
10_1101-2020_01_28_923532	15	16	combination	combination	NN
10_1101-2020_01_28_923532	15	17	therapies	therapy	NNS
10_1101-2020_01_28_923532	15	18	in	in	IN
10_1101-2020_01_28_923532	15	19	solid	solid	JJ
10_1101-2020_01_28_923532	15	20	tumors	tumor	NNS
10_1101-2020_01_28_923532	15	21	,	,	,
10_1101-2020_01_28_923532	15	22	including	include	VBG
10_1101-2020_01_28_923532	15	23	brain	brain	NN
10_1101-2020_01_28_923532	15	24	,	,	,
10_1101-2020_01_28_923532	15	25	head	head	NN
10_1101-2020_01_28_923532	15	26	and	and	CC
10_1101-2020_01_28_923532	15	27	neck	neck	NN
10_1101-2020_01_28_923532	15	28	,	,	,
10_1101-2020_01_28_923532	15	29	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	15	30	,	,	,
10_1101-2020_01_28_923532	15	31	lung	lung	NN
10_1101-2020_01_28_923532	15	32	,	,	,
10_1101-2020_01_28_923532	15	33	breast	breast	NN
10_1101-2020_01_28_923532	15	34	and	and	CC
10_1101-2020_01_28_923532	15	35	colon	colon	NN
10_1101-2020_01_28_923532	15	36	cancers	cancer	NNS
10_1101-2020_01_28_923532	15	37	.	.	.
10_1101-2020_01_28_923532	16	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	16	2	assume	assume	VBP
10_1101-2020_01_28_923532	16	3	that	that	IN
10_1101-2020_01_28_923532	16	4	each	each	DT
10_1101-2020_01_28_923532	16	5	individual	individual	JJ
10_1101-2020_01_28_923532	16	6	therapy	therapy	NN
10_1101-2020_01_28_923532	16	7	can	can	MD
10_1101-2020_01_28_923532	16	8	target	target	VB
10_1101-2020_01_28_923532	16	9	any	any	DT
10_1101-2020_01_28_923532	16	10	one	one	CD
10_1101-2020_01_28_923532	16	11	of	of	IN
10_1101-2020_01_28_923532	16	12	1269	1269	CD
10_1101-2020_01_28_923532	16	13	genes	gene	NNS
10_1101-2020_01_28_923532	16	14	encoding	encode	VBG
10_1101-2020_01_28_923532	16	15	cell	cell	NN
10_1101-2020_01_28_923532	16	16	surface	surface	NN
10_1101-2020_01_28_923532	16	17	receptors	receptor	NNS
10_1101-2020_01_28_923532	16	18	,	,	,
10_1101-2020_01_28_923532	16	19	which	which	WDT
10_1101-2020_01_28_923532	16	20	may	may	MD
10_1101-2020_01_28_923532	16	21	be	be	VB
10_1101-2020_01_28_923532	16	22	targets	target	NNS
10_1101-2020_01_28_923532	16	23	of	of	IN
10_1101-2020_01_28_923532	16	24	CAR	CAR	NNP
10_1101-2020_01_28_923532	16	25	-	-	HYPH
10_1101-2020_01_28_923532	16	26	T	T	NNP
10_1101-2020_01_28_923532	16	27	,	,	,
10_1101-2020_01_28_923532	16	28	conjugated	conjugate	VBD
10_1101-2020_01_28_923532	16	29	antibodies	antibody	NNS
10_1101-2020_01_28_923532	16	30	or	or	CC
10_1101-2020_01_28_923532	16	31	coated	coat	VBN
10_1101-2020_01_28_923532	16	32	nanoparticle	nanoparticle	NN
10_1101-2020_01_28_923532	16	33	therapies	therapy	NNS
10_1101-2020_01_28_923532	16	34	.	.	.
10_1101-2020_01_28_923532	17	1	In	in	IN
10_1101-2020_01_28_923532	17	2	most	most	JJS
10_1101-2020_01_28_923532	17	3	cancer	cancer	NN
10_1101-2020_01_28_923532	17	4	types	type	NNS
10_1101-2020_01_28_923532	17	5	,	,	,
10_1101-2020_01_28_923532	17	6	personalized	personalize	VBN
10_1101-2020_01_28_923532	17	7	combinations	combination	NNS
10_1101-2020_01_28_923532	17	8	composed	compose	VBN
10_1101-2020_01_28_923532	17	9	of	of	IN
10_1101-2020_01_28_923532	17	10	at	at	IN
10_1101-2020_01_28_923532	17	11	most	most	RBS
10_1101-2020_01_28_923532	17	12	four	four	CD
10_1101-2020_01_28_923532	17	13	targets	target	NNS
10_1101-2020_01_28_923532	17	14	are	be	VBP
10_1101-2020_01_28_923532	17	15	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	17	16	to	to	TO
10_1101-2020_01_28_923532	17	17	kill	kill	VB
10_1101-2020_01_28_923532	17	18	at	at	RB
10_1101-2020_01_28_923532	17	19	least	least	RBS
10_1101-2020_01_28_923532	17	20	80	80	CD
10_1101-2020_01_28_923532	17	21	%	%	NN
10_1101-2020_01_28_923532	17	22	of	of	IN
10_1101-2020_01_28_923532	17	23	the	the	DT
10_1101-2020_01_28_923532	17	24	tumor	tumor	NN
10_1101-2020_01_28_923532	17	25	cells	cell	NNS
10_1101-2020_01_28_923532	17	26	while	while	IN
10_1101-2020_01_28_923532	17	27	killing	kill	VBG
10_1101-2020_01_28_923532	17	28	at	at	IN
10_1101-2020_01_28_923532	17	29	most	most	RBS
10_1101-2020_01_28_923532	17	30	10	10	CD
10_1101-2020_01_28_923532	17	31	%	%	NN
10_1101-2020_01_28_923532	17	32	of	of	IN
10_1101-2020_01_28_923532	17	33	the	the	DT
10_1101-2020_01_28_923532	17	34	non	non	JJ
10_1101-2020_01_28_923532	17	35	-	-	JJ
10_1101-2020_01_28_923532	17	36	tumor	tumor	JJ
10_1101-2020_01_28_923532	17	37	cells	cell	NNS
10_1101-2020_01_28_923532	17	38	in	in	IN
10_1101-2020_01_28_923532	17	39	each	each	DT
10_1101-2020_01_28_923532	17	40	patient	patient	NN
10_1101-2020_01_28_923532	17	41	.	.	.
10_1101-2020_01_28_923532	18	1	The	the	DT
10_1101-2020_01_28_923532	18	2	number	number	NN
10_1101-2020_01_28_923532	18	3	of	of	IN
10_1101-2020_01_28_923532	18	4	distinct	distinct	JJ
10_1101-2020_01_28_923532	18	5	targets	target	NNS
10_1101-2020_01_28_923532	18	6	needed	need	VBN
10_1101-2020_01_28_923532	18	7	to	to	TO
10_1101-2020_01_28_923532	18	8	do	do	VB
10_1101-2020_01_28_923532	18	9	that	that	DT
10_1101-2020_01_28_923532	18	10	for	for	IN
10_1101-2020_01_28_923532	18	11	all	all	DT
10_1101-2020_01_28_923532	18	12	patients	patient	NNS
10_1101-2020_01_28_923532	18	13	in	in	IN
10_1101-2020_01_28_923532	18	14	8	8	CD
10_1101-2020_01_28_923532	18	15	of	of	IN
10_1101-2020_01_28_923532	18	16	the	the	DT
10_1101-2020_01_28_923532	18	17	9	9	CD
10_1101-2020_01_28_923532	18	18	cohorts	cohort	NNS
10_1101-2020_01_28_923532	18	19	we	-PRON-	PRP
10_1101-2020_01_28_923532	18	20	studied	study	VBD
10_1101-2020_01_28_923532	18	21	is	be	VBZ
10_1101-2020_01_28_923532	18	22	at	at	IN
10_1101-2020_01_28_923532	18	23	most	most	JJS
10_1101-2020_01_28_923532	18	24	11	11	CD
10_1101-2020_01_28_923532	18	25	,	,	,
10_1101-2020_01_28_923532	18	26	while	while	IN
10_1101-2020_01_28_923532	18	27	one	one	CD
10_1101-2020_01_28_923532	18	28	larger	large	JJR
10_1101-2020_01_28_923532	18	29	melanoma	melanoma	NN
10_1101-2020_01_28_923532	18	30	cohort	cohort	NN
10_1101-2020_01_28_923532	18	31	requires	require	VBZ
10_1101-2020_01_28_923532	18	32	over	over	IN
10_1101-2020_01_28_923532	18	33	30	30	CD
10_1101-2020_01_28_923532	18	34	distinct	distinct	JJ
10_1101-2020_01_28_923532	18	35	targets	target	NNS
10_1101-2020_01_28_923532	18	36	.	.	.
10_1101-2020_01_28_923532	19	1	Further	further	RB
10_1101-2020_01_28_923532	19	2	requiring	require	VBG
10_1101-2020_01_28_923532	19	3	that	that	IN
10_1101-2020_01_28_923532	19	4	the	the	DT
10_1101-2020_01_28_923532	19	5	target	target	NN
10_1101-2020_01_28_923532	19	6	genes	gene	NNS
10_1101-2020_01_28_923532	19	7	be	be	VB
10_1101-2020_01_28_923532	19	8	lowly	lowly	RB
10_1101-2020_01_28_923532	19	9	expressed	express	VBN
10_1101-2020_01_28_923532	19	10	across	across	IN
10_1101-2020_01_28_923532	19	11	many	many	JJ
10_1101-2020_01_28_923532	19	12	different	different	JJ
10_1101-2020_01_28_923532	19	13	healthy	healthy	JJ
10_1101-2020_01_28_923532	19	14	tissues	tissue	NNS
10_1101-2020_01_28_923532	19	15	uncovers	uncover	NNS
10_1101-2020_01_28_923532	19	16	qualitatively	qualitatively	RB
10_1101-2020_01_28_923532	19	17	similar	similar	JJ
10_1101-2020_01_28_923532	19	18	trends	trend	NNS
10_1101-2020_01_28_923532	19	19	.	.	.
10_1101-2020_01_28_923532	20	1	However	however	RB
10_1101-2020_01_28_923532	20	2	,	,	,
10_1101-2020_01_28_923532	20	3	as	as	IN
10_1101-2020_01_28_923532	20	4	one	one	CD
10_1101-2020_01_28_923532	20	5	requires	require	VBZ
10_1101-2020_01_28_923532	20	6	either	either	CC
10_1101-2020_01_28_923532	20	7	more	more	RBR
10_1101-2020_01_28_923532	20	8	stringent	stringent	JJ
10_1101-2020_01_28_923532	20	9	killing	kill	VBG
10_1101-2020_01_28_923532	20	10	thresholds	threshold	NNS
10_1101-2020_01_28_923532	20	11	or	or	CC
10_1101-2020_01_28_923532	20	12	more	more	RBR
10_1101-2020_01_28_923532	20	13	stringent	stringent	JJ
10_1101-2020_01_28_923532	20	14	sparing	sparing	NN
10_1101-2020_01_28_923532	20	15	of	of	IN
10_1101-2020_01_28_923532	20	16	non	non	JJ
10_1101-2020_01_28_923532	20	17	-	-	JJ
10_1101-2020_01_28_923532	20	18	cancerous	cancerous	JJ
10_1101-2020_01_28_923532	20	19	tissues	tissue	NNS
10_1101-2020_01_28_923532	20	20	beyond	beyond	IN
10_1101-2020_01_28_923532	20	21	these	these	DT
10_1101-2020_01_28_923532	20	22	baseline	baseline	JJ
10_1101-2020_01_28_923532	20	23	values	value	NNS
10_1101-2020_01_28_923532	20	24	,	,	,
10_1101-2020_01_28_923532	20	25	the	the	DT
10_1101-2020_01_28_923532	20	26	number	number	NN
10_1101-2020_01_28_923532	20	27	of	of	IN
10_1101-2020_01_28_923532	20	28	targets	target	NNS
10_1101-2020_01_28_923532	20	29	needed	need	VBN
10_1101-2020_01_28_923532	20	30	rises	rise	VBZ
10_1101-2020_01_28_923532	20	31	rapidly	rapidly	RB
10_1101-2020_01_28_923532	20	32	.	.	.
10_1101-2020_01_28_923532	21	1	Emerging	emerge	VBG
10_1101-2020_01_28_923532	21	2	promising	promise	VBG
10_1101-2020_01_28_923532	21	3	targets	target	NNS
10_1101-2020_01_28_923532	21	4	include	include	VBP
10_1101-2020_01_28_923532	21	5	the	the	DT
10_1101-2020_01_28_923532	21	6	gene	gene	NN
10_1101-2020_01_28_923532	21	7	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	21	8	,	,	,
10_1101-2020_01_28_923532	21	9	which	which	WDT
10_1101-2020_01_28_923532	21	10	is	be	VBZ
10_1101-2020_01_28_923532	21	11	frequently	frequently	RB
10_1101-2020_01_28_923532	21	12	found	find	VBN
10_1101-2020_01_28_923532	21	13	in	in	IN
10_1101-2020_01_28_923532	21	14	the	the	DT
10_1101-2020_01_28_923532	21	15	optimal	optimal	JJ
10_1101-2020_01_28_923532	21	16	combinations	combination	NNS
10_1101-2020_01_28_923532	21	17	for	for	IN
10_1101-2020_01_28_923532	21	18	brain	brain	NN
10_1101-2020_01_28_923532	21	19	and	and	CC
10_1101-2020_01_28_923532	21	20	head	head	NN
10_1101-2020_01_28_923532	21	21	and	and	CC
10_1101-2020_01_28_923532	21	22	neck	neck	NN
10_1101-2020_01_28_923532	21	23	cancers	cancer	NNS
10_1101-2020_01_28_923532	21	24	,	,	,
10_1101-2020_01_28_923532	21	25	and	and	CC
10_1101-2020_01_28_923532	21	26	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	21	27	,	,	,
10_1101-2020_01_28_923532	21	28	a	a	DT
10_1101-2020_01_28_923532	21	29	recurring	recur	VBG
10_1101-2020_01_28_923532	21	30	target	target	NN
10_1101-2020_01_28_923532	21	31	in	in	IN
10_1101-2020_01_28_923532	21	32	multiple	multiple	JJ
10_1101-2020_01_28_923532	21	33	tumor	tumor	NN
10_1101-2020_01_28_923532	21	34	types	type	NNS
10_1101-2020_01_28_923532	21	35	.	.	.
10_1101-2020_01_28_923532	22	1	In	in	IN
10_1101-2020_01_28_923532	22	2	sum	sum	NN
10_1101-2020_01_28_923532	22	3	,	,	,
10_1101-2020_01_28_923532	22	4	this	this	DT
10_1101-2020_01_28_923532	22	5	is	be	VBZ
10_1101-2020_01_28_923532	22	6	the	the	DT
10_1101-2020_01_28_923532	22	7	first	first	JJ
10_1101-2020_01_28_923532	22	8	systematic	systematic	JJ
10_1101-2020_01_28_923532	22	9	single	single	JJ
10_1101-2020_01_28_923532	22	10	-	-	HYPH
10_1101-2020_01_28_923532	22	11	cell	cell	NN
10_1101-2020_01_28_923532	22	12	based	base	VBN
10_1101-2020_01_28_923532	22	13	characterization	characterization	NN
10_1101-2020_01_28_923532	22	14	of	of	IN
10_1101-2020_01_28_923532	22	15	the	the	DT
10_1101-2020_01_28_923532	22	16	landscape	landscape	NN
10_1101-2020_01_28_923532	22	17	of	of	IN
10_1101-2020_01_28_923532	22	18	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	22	19	receptor	receptor	NN
10_1101-2020_01_28_923532	22	20	-	-	HYPH
10_1101-2020_01_28_923532	22	21	mediated	mediate	VBN
10_1101-2020_01_28_923532	22	22	cancer	cancer	NN
10_1101-2020_01_28_923532	22	23	treatments	treatment	NNS
10_1101-2020_01_28_923532	22	24	,	,	,
10_1101-2020_01_28_923532	22	25	identifying	identify	VBG
10_1101-2020_01_28_923532	22	26	promising	promise	VBG
10_1101-2020_01_28_923532	22	27	targets	target	NNS
10_1101-2020_01_28_923532	22	28	for	for	IN
10_1101-2020_01_28_923532	22	29	future	future	JJ
10_1101-2020_01_28_923532	22	30	development	development	NN
10_1101-2020_01_28_923532	22	31	.	.	.
10_1101-2020_01_28_923532	23	1	105	105	CD
10_1101-2020_01_28_923532	23	2	and	and	CC
10_1101-2020_01_28_923532	23	3	is	be	VBZ
10_1101-2020_01_28_923532	23	4	also	also	RB
10_1101-2020_01_28_923532	23	5	made	make	VBN
10_1101-2020_01_28_923532	23	6	available	available	JJ
10_1101-2020_01_28_923532	23	7	for	for	IN
10_1101-2020_01_28_923532	23	8	use	use	NN
10_1101-2020_01_28_923532	23	9	under	under	IN
10_1101-2020_01_28_923532	23	10	a	a	DT
10_1101-2020_01_28_923532	23	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	23	12	license	license	NN
10_1101-2020_01_28_923532	23	13	.	.	.
10_1101-2020_01_28_923532	24	1	(	(	-LRB-
10_1101-2020_01_28_923532	24	2	which	which	WDT
10_1101-2020_01_28_923532	24	3	was	be	VBD
10_1101-2020_01_28_923532	24	4	not	not	RB
10_1101-2020_01_28_923532	24	5	certified	certify	VBN
10_1101-2020_01_28_923532	24	6	by	by	IN
10_1101-2020_01_28_923532	24	7	peer	peer	NN
10_1101-2020_01_28_923532	24	8	review	review	NN
10_1101-2020_01_28_923532	24	9	)	)	-RRB-
10_1101-2020_01_28_923532	24	10	is	be	VBZ
10_1101-2020_01_28_923532	24	11	the	the	DT
10_1101-2020_01_28_923532	24	12	author	author	NN
10_1101-2020_01_28_923532	24	13	/	/	SYM
10_1101-2020_01_28_923532	24	14	funder	funder	NN
10_1101-2020_01_28_923532	24	15	.	.	.
10_1101-2020_01_28_923532	25	1	This	this	DT
10_1101-2020_01_28_923532	25	2	article	article	NN
10_1101-2020_01_28_923532	25	3	is	be	VBZ
10_1101-2020_01_28_923532	25	4	a	a	DT
10_1101-2020_01_28_923532	25	5	US	US	NNP
10_1101-2020_01_28_923532	25	6	Government	Government	NNP
10_1101-2020_01_28_923532	25	7	work	work	NN
10_1101-2020_01_28_923532	25	8	.	.	.
10_1101-2020_01_28_923532	26	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	26	2	is	be	VBZ
10_1101-2020_01_28_923532	26	3	not	not	RB
10_1101-2020_01_28_923532	26	4	subject	subject	JJ
10_1101-2020_01_28_923532	26	5	to	to	IN
10_1101-2020_01_28_923532	26	6	copyright	copyright	NN
10_1101-2020_01_28_923532	26	7	under	under	IN
10_1101-2020_01_28_923532	26	8	17	17	CD
10_1101-2020_01_28_923532	26	9	USC	usc	NN
10_1101-2020_01_28_923532	26	10	The	the	DT
10_1101-2020_01_28_923532	26	11	copyright	copyright	NN
10_1101-2020_01_28_923532	26	12	holder	holder	NN
10_1101-2020_01_28_923532	26	13	for	for	IN
10_1101-2020_01_28_923532	26	14	this	this	DT
10_1101-2020_01_28_923532	26	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	26	16	version	version	NN
10_1101-2020_01_28_923532	26	17	posted	post	VBD
10_1101-2020_01_28_923532	26	18	February	February	NNP
10_1101-2020_01_28_923532	26	19	12	12	CD
10_1101-2020_01_28_923532	26	20	,	,	,
10_1101-2020_01_28_923532	26	21	2021	2021	CD
10_1101-2020_01_28_923532	26	22	.	.	.
10_1101-2020_01_28_923532	26	23	;	;	:
10_1101-2020_01_28_923532	26	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	26	25	:	:	:
10_1101-2020_01_28_923532	26	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	26	27	preprint	preprint	NN
10_1101-2020_01_28_923532	26	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	26	29	4	4	CD
10_1101-2020_01_28_923532	26	30	Introduction	Introduction	NNP
10_1101-2020_01_28_923532	26	31	Personalized	Personalized	NNP
10_1101-2020_01_28_923532	26	32	oncology	oncology	NN
10_1101-2020_01_28_923532	26	33	offers	offer	VBZ
10_1101-2020_01_28_923532	26	34	hope	hope	NN
10_1101-2020_01_28_923532	26	35	that	that	IN
10_1101-2020_01_28_923532	26	36	each	each	DT
10_1101-2020_01_28_923532	26	37	patient	patient	NN
10_1101-2020_01_28_923532	26	38	's	's	POS
10_1101-2020_01_28_923532	26	39	cancer	cancer	NN
10_1101-2020_01_28_923532	26	40	can	can	MD
10_1101-2020_01_28_923532	26	41	be	be	VB
10_1101-2020_01_28_923532	26	42	treated	treat	VBN
10_1101-2020_01_28_923532	26	43	based	base	VBN
10_1101-2020_01_28_923532	26	44	on	on	IN
10_1101-2020_01_28_923532	26	45	its	-PRON-	PRP$
10_1101-2020_01_28_923532	26	46	genomic	genomic	JJ
10_1101-2020_01_28_923532	26	47	characteristics1,2	characteristics1,2	NN
10_1101-2020_01_28_923532	26	48	.	.	.
10_1101-2020_01_28_923532	27	1	Several	several	JJ
10_1101-2020_01_28_923532	27	2	trials	trial	NNS
10_1101-2020_01_28_923532	27	3	have	have	VBP
10_1101-2020_01_28_923532	27	4	suggested	suggest	VBN
10_1101-2020_01_28_923532	27	5	that	that	IN
10_1101-2020_01_28_923532	27	6	it	-PRON-	PRP
10_1101-2020_01_28_923532	27	7	is	be	VBZ
10_1101-2020_01_28_923532	27	8	possible	possible	JJ
10_1101-2020_01_28_923532	27	9	to	to	TO
10_1101-2020_01_28_923532	27	10	collect	collect	VB
10_1101-2020_01_28_923532	27	11	genomics	genomic	NNS
10_1101-2020_01_28_923532	27	12	data	datum	NNS
10_1101-2020_01_28_923532	27	13	fast	fast	RB
10_1101-2020_01_28_923532	27	14	enough	enough	RB
10_1101-2020_01_28_923532	27	15	to	to	TO
10_1101-2020_01_28_923532	27	16	inform	inform	VB
10_1101-2020_01_28_923532	27	17	treatment	treatment	NN
10_1101-2020_01_28_923532	27	18	decisions3	decisions3	NN
10_1101-2020_01_28_923532	27	19	-	-	HYPH
10_1101-2020_01_28_923532	27	20	5	5	CD
10_1101-2020_01_28_923532	27	21	.	.	.
10_1101-2020_01_28_923532	28	1	Meta	meta	JJ
10_1101-2020_01_28_923532	28	2	-	-	HYPH
10_1101-2020_01_28_923532	28	3	analysis	analysis	NN
10_1101-2020_01_28_923532	28	4	of	of	IN
10_1101-2020_01_28_923532	28	5	Phase	Phase	NNP
10_1101-2020_01_28_923532	28	6	I	-PRON-	PRP
10_1101-2020_01_28_923532	28	7	clinical	clinical	JJ
10_1101-2020_01_28_923532	28	8	trials	trial	NNS
10_1101-2020_01_28_923532	28	9	completed	complete	VBN
10_1101-2020_01_28_923532	28	10	during	during	IN
10_1101-2020_01_28_923532	28	11	2011	2011	CD
10_1101-2020_01_28_923532	28	12	-	-	SYM
10_1101-2020_01_28_923532	28	13	2013	2013	CD
10_1101-2020_01_28_923532	28	14	showed	show	VBD
10_1101-2020_01_28_923532	28	15	that	that	IN
10_1101-2020_01_28_923532	28	16	overall	overall	RB
10_1101-2020_01_28_923532	28	17	,	,	,
10_1101-2020_01_28_923532	28	18	trials	trial	NNS
10_1101-2020_01_28_923532	28	19	that	that	WDT
10_1101-2020_01_28_923532	28	20	used	use	VBD
10_1101-2020_01_28_923532	28	21	molecular	molecular	JJ
10_1101-2020_01_28_923532	28	22	biomarker	biomarker	NN
10_1101-2020_01_28_923532	28	23	information	information	NN
10_1101-2020_01_28_923532	28	24	to	to	TO
10_1101-2020_01_28_923532	28	25	influence	influence	VB
10_1101-2020_01_28_923532	28	26	treatment	treatment	NN
10_1101-2020_01_28_923532	28	27	plans	plan	NNS
10_1101-2020_01_28_923532	28	28	gave	give	VBD
10_1101-2020_01_28_923532	28	29	better	well	JJR
10_1101-2020_01_28_923532	28	30	results	result	NNS
10_1101-2020_01_28_923532	28	31	than	than	IN
10_1101-2020_01_28_923532	28	32	trials	trial	NNS
10_1101-2020_01_28_923532	28	33	that	that	WDT
10_1101-2020_01_28_923532	28	34	did	do	VBD
10_1101-2020_01_28_923532	28	35	not6	not6	RB
10_1101-2020_01_28_923532	28	36	.	.	.
10_1101-2020_01_28_923532	29	1	However	however	RB
10_1101-2020_01_28_923532	29	2	,	,	,
10_1101-2020_01_28_923532	29	3	most	most	JJS
10_1101-2020_01_28_923532	29	4	precision	precision	NN
10_1101-2020_01_28_923532	29	5	oncology	oncology	NN
10_1101-2020_01_28_923532	29	6	treatments	treatment	NNS
10_1101-2020_01_28_923532	29	7	utilize	utilize	VBP
10_1101-2020_01_28_923532	29	8	only	only	RB
10_1101-2020_01_28_923532	29	9	one	one	CD
10_1101-2020_01_28_923532	29	10	or	or	CC
10_1101-2020_01_28_923532	29	11	two	two	CD
10_1101-2020_01_28_923532	29	12	medicines	medicine	NNS
10_1101-2020_01_28_923532	29	13	,	,	,
10_1101-2020_01_28_923532	29	14	and	and	CC
10_1101-2020_01_28_923532	29	15	resistant	resistant	JJ
10_1101-2020_01_28_923532	29	16	clones	clone	NNS
10_1101-2020_01_28_923532	29	17	frequently	frequently	RB
10_1101-2020_01_28_923532	29	18	emerge	emerge	VBP
10_1101-2020_01_28_923532	29	19	,	,	,
10_1101-2020_01_28_923532	29	20	emphasizing	emphasize	VBG
10_1101-2020_01_28_923532	29	21	the	the	DT
10_1101-2020_01_28_923532	29	22	need	need	NN
10_1101-2020_01_28_923532	29	23	to	to	TO
10_1101-2020_01_28_923532	29	24	deliver	deliver	VB
10_1101-2020_01_28_923532	29	25	personalized	personalized	JJ
10_1101-2020_01_28_923532	29	26	medicine	medicine	NN
10_1101-2020_01_28_923532	29	27	as	as	IN
10_1101-2020_01_28_923532	29	28	multiple	multiple	JJ
10_1101-2020_01_28_923532	29	29	agents	agent	NNS
10_1101-2020_01_28_923532	29	30	combined6	combined6	NN
10_1101-2020_01_28_923532	29	31	-	-	HYPH
10_1101-2020_01_28_923532	29	32	11	11	CD
10_1101-2020_01_28_923532	29	33	.	.	.
10_1101-2020_01_28_923532	30	1	Important	important	JJ
10_1101-2020_01_28_923532	30	2	opportunities	opportunity	NNS
10_1101-2020_01_28_923532	30	3	to	to	TO
10_1101-2020_01_28_923532	30	4	combine	combine	VB
10_1101-2020_01_28_923532	30	5	systems	system	NNS
10_1101-2020_01_28_923532	30	6	biology	biology	NN
10_1101-2020_01_28_923532	30	7	and	and	CC
10_1101-2020_01_28_923532	30	8	design	design	NN
10_1101-2020_01_28_923532	30	9	of	of	IN
10_1101-2020_01_28_923532	30	10	nanomaterials	nanomaterial	NNS
10_1101-2020_01_28_923532	30	11	have	have	VBP
10_1101-2020_01_28_923532	30	12	been	be	VBN
10_1101-2020_01_28_923532	30	13	recognized	recognize	VBN
10_1101-2020_01_28_923532	30	14	to	to	TO
10_1101-2020_01_28_923532	30	15	deliver	deliver	VB
10_1101-2020_01_28_923532	30	16	medicines	medicine	NNS
10_1101-2020_01_28_923532	30	17	in	in	IN
10_1101-2020_01_28_923532	30	18	combination	combination	NN
10_1101-2020_01_28_923532	30	19	to	to	TO
10_1101-2020_01_28_923532	30	20	overcome	overcome	VB
10_1101-2020_01_28_923532	30	21	drug	drug	NN
10_1101-2020_01_28_923532	30	22	resistance	resistance	NN
10_1101-2020_01_28_923532	30	23	and	and	CC
10_1101-2020_01_28_923532	30	24	combine	combine	VB
10_1101-2020_01_28_923532	30	25	biological	biological	NNP
10_1101-2020_01_28_923532	30	26	effects12	effects12	NNP
10_1101-2020_01_28_923532	30	27	.	.	.
10_1101-2020_01_28_923532	31	1	Here	here	RB
10_1101-2020_01_28_923532	31	2	,	,	,
10_1101-2020_01_28_923532	31	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	31	4	propose	propose	VBP
10_1101-2020_01_28_923532	31	5	and	and	CC
10_1101-2020_01_28_923532	31	6	rigorously	rigorously	RB
10_1101-2020_01_28_923532	31	7	study	study	VB
10_1101-2020_01_28_923532	31	8	a	a	DT
10_1101-2020_01_28_923532	31	9	new	new	JJ
10_1101-2020_01_28_923532	31	10	conceptual	conceptual	JJ
10_1101-2020_01_28_923532	31	11	framework	framework	NN
10_1101-2020_01_28_923532	31	12	for	for	IN
10_1101-2020_01_28_923532	31	13	designing	design	VBG
10_1101-2020_01_28_923532	31	14	future	future	JJ
10_1101-2020_01_28_923532	31	15	precision	precision	NN
10_1101-2020_01_28_923532	31	16	oncology	oncology	NN
10_1101-2020_01_28_923532	31	17	treatments	treatment	NNS
10_1101-2020_01_28_923532	31	18	.	.	.
10_1101-2020_01_28_923532	32	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	32	2	is	be	VBZ
10_1101-2020_01_28_923532	32	3	motivated	motivate	VBN
10_1101-2020_01_28_923532	32	4	by	by	IN
10_1101-2020_01_28_923532	32	5	the	the	DT
10_1101-2020_01_28_923532	32	6	growing	grow	VBG
10_1101-2020_01_28_923532	32	7	recognition	recognition	NN
10_1101-2020_01_28_923532	32	8	that	that	IN
10_1101-2020_01_28_923532	32	9	tumors	tumor	NNS
10_1101-2020_01_28_923532	32	10	typically	typically	RB
10_1101-2020_01_28_923532	32	11	have	have	VBP
10_1101-2020_01_28_923532	32	12	considerable	considerable	JJ
10_1101-2020_01_28_923532	32	13	intra	intra	JJ
10_1101-2020_01_28_923532	32	14	-	-	JJ
10_1101-2020_01_28_923532	32	15	tumor	tumor	JJ
10_1101-2020_01_28_923532	32	16	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	32	17	(	(	-LRB-
10_1101-2020_01_28_923532	32	18	ITH)13,14	ITH)13,14	NNP
10_1101-2020_01_28_923532	32	19	and	and	CC
10_1101-2020_01_28_923532	32	20	thus	thus	RB
10_1101-2020_01_28_923532	32	21	need	need	VBP
10_1101-2020_01_28_923532	32	22	to	to	TO
10_1101-2020_01_28_923532	32	23	be	be	VB
10_1101-2020_01_28_923532	32	24	targeted	target	VBN
10_1101-2020_01_28_923532	32	25	with	with	IN
10_1101-2020_01_28_923532	32	26	a	a	DT
10_1101-2020_01_28_923532	32	27	combination	combination	NN
10_1101-2020_01_28_923532	32	28	of	of	IN
10_1101-2020_01_28_923532	32	29	medicines	medicine	NNS
10_1101-2020_01_28_923532	32	30	such	such	JJ
10_1101-2020_01_28_923532	32	31	that	that	IN
10_1101-2020_01_28_923532	32	32	as	as	RB
10_1101-2020_01_28_923532	32	33	many	many	JJ
10_1101-2020_01_28_923532	32	34	as	as	IN
10_1101-2020_01_28_923532	32	35	possible	possible	JJ
10_1101-2020_01_28_923532	32	36	tumor	tumor	NN
10_1101-2020_01_28_923532	32	37	cells	cell	NNS
10_1101-2020_01_28_923532	32	38	are	be	VBP
10_1101-2020_01_28_923532	32	39	hit	hit	VBN
10_1101-2020_01_28_923532	32	40	by	by	IN
10_1101-2020_01_28_923532	32	41	at	at	RB
10_1101-2020_01_28_923532	32	42	least	least	RBS
10_1101-2020_01_28_923532	32	43	one	one	CD
10_1101-2020_01_28_923532	32	44	medicine	medicine	NN
10_1101-2020_01_28_923532	32	45	.	.	.
10_1101-2020_01_28_923532	33	1	Our	-PRON-	PRP$
10_1101-2020_01_28_923532	33	2	analysis	analysis	NN
10_1101-2020_01_28_923532	33	3	is	be	VBZ
10_1101-2020_01_28_923532	33	4	based	base	VBN
10_1101-2020_01_28_923532	33	5	on	on	IN
10_1101-2020_01_28_923532	33	6	two	two	CD
10_1101-2020_01_28_923532	33	7	recently	recently	RB
10_1101-2020_01_28_923532	33	8	emerging	emerge	VBG
10_1101-2020_01_28_923532	33	9	technologies	technology	NNS
10_1101-2020_01_28_923532	33	10	:	:	:
10_1101-2020_01_28_923532	33	11	(	(	-LRB-
10_1101-2020_01_28_923532	33	12	1	1	LS
10_1101-2020_01_28_923532	33	13	)	)	-RRB-
10_1101-2020_01_28_923532	33	14	the	the	DT
10_1101-2020_01_28_923532	33	15	advancement	advancement	NN
10_1101-2020_01_28_923532	33	16	of	of	IN
10_1101-2020_01_28_923532	33	17	single	single	JJ
10_1101-2020_01_28_923532	33	18	-	-	HYPH
10_1101-2020_01_28_923532	33	19	cell	cell	NN
10_1101-2020_01_28_923532	33	20	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	33	21	and	and	CC
10_1101-2020_01_28_923532	33	22	proteomics	proteomic	NNS
10_1101-2020_01_28_923532	33	23	measurements	measurement	NNS
10_1101-2020_01_28_923532	33	24	from	from	IN
10_1101-2020_01_28_923532	33	25	patients	patient	NNS
10_1101-2020_01_28_923532	33	26	’	’	POS
10_1101-2020_01_28_923532	33	27	tumors	tumor	NNS
10_1101-2020_01_28_923532	33	28	,	,	,
10_1101-2020_01_28_923532	33	29	which	which	WDT
10_1101-2020_01_28_923532	33	30	is	be	VBZ
10_1101-2020_01_28_923532	33	31	anticipated	anticipate	VBN
10_1101-2020_01_28_923532	33	32	to	to	TO
10_1101-2020_01_28_923532	33	33	gradually	gradually	RB
10_1101-2020_01_28_923532	33	34	enter	enter	VB
10_1101-2020_01_28_923532	33	35	into	into	IN
10_1101-2020_01_28_923532	33	36	clinical	clinical	JJ
10_1101-2020_01_28_923532	33	37	use15	use15	NNP
10_1101-2020_01_28_923532	33	38	,	,	,
10_1101-2020_01_28_923532	33	39	and	and	CC
10_1101-2020_01_28_923532	33	40	(	(	-LRB-
10_1101-2020_01_28_923532	33	41	2	2	LS
10_1101-2020_01_28_923532	33	42	)	)	-RRB-
10_1101-2020_01_28_923532	33	43	the	the	DT
10_1101-2020_01_28_923532	33	44	introduction	introduction	NN
10_1101-2020_01_28_923532	33	45	of	of	IN
10_1101-2020_01_28_923532	33	46	“	"	``
10_1101-2020_01_28_923532	33	47	modular	modular	JJ
10_1101-2020_01_28_923532	33	48	”	"	''
10_1101-2020_01_28_923532	33	49	treatments	treatment	NNS
10_1101-2020_01_28_923532	33	50	that	that	WDT
10_1101-2020_01_28_923532	33	51	target	target	VBP
10_1101-2020_01_28_923532	33	52	specific	specific	JJ
10_1101-2020_01_28_923532	33	53	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	33	54	genes	gene	NNS
10_1101-2020_01_28_923532	33	55	/	/	SYM
10_1101-2020_01_28_923532	33	56	proteins	protein	NNS
10_1101-2020_01_28_923532	33	57	to	to	TO
10_1101-2020_01_28_923532	33	58	recognize	recognize	VB
10_1101-2020_01_28_923532	33	59	cells	cell	NNS
10_1101-2020_01_28_923532	33	60	in	in	IN
10_1101-2020_01_28_923532	33	61	a	a	DT
10_1101-2020_01_28_923532	33	62	specific	specific	JJ
10_1101-2020_01_28_923532	33	63	manner	manner	NN
10_1101-2020_01_28_923532	33	64	and	and	CC
10_1101-2020_01_28_923532	33	65	then	then	RB
10_1101-2020_01_28_923532	33	66	use	use	VBP
10_1101-2020_01_28_923532	33	67	either	either	CC
10_1101-2020_01_28_923532	33	68	the	the	DT
10_1101-2020_01_28_923532	33	69	T	T	NNP
10_1101-2020_01_28_923532	33	70	cell	cell	NN
10_1101-2020_01_28_923532	33	71	immune	immune	JJ
10_1101-2020_01_28_923532	33	72	response	response	NN
10_1101-2020_01_28_923532	33	73	or	or	CC
10_1101-2020_01_28_923532	33	74	a	a	DT
10_1101-2020_01_28_923532	33	75	lethal	lethal	JJ
10_1101-2020_01_28_923532	33	76	toxin	toxin	NN
10_1101-2020_01_28_923532	33	77	to	to	TO
10_1101-2020_01_28_923532	33	78	kill	kill	VB
10_1101-2020_01_28_923532	33	79	the	the	DT
10_1101-2020_01_28_923532	33	80	tumor	tumor	NN
10_1101-2020_01_28_923532	33	81	cells	cell	NNS
10_1101-2020_01_28_923532	33	82	preferentially	preferentially	RB
10_1101-2020_01_28_923532	33	83	.	.	.
10_1101-2020_01_28_923532	34	1	Based	base	VBN
10_1101-2020_01_28_923532	34	2	on	on	IN
10_1101-2020_01_28_923532	34	3	these	these	DT
10_1101-2020_01_28_923532	34	4	two	two	CD
10_1101-2020_01_28_923532	34	5	foundations	foundation	NNS
10_1101-2020_01_28_923532	34	6	,	,	,
10_1101-2020_01_28_923532	34	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	34	8	formulate	formulate	VBP
10_1101-2020_01_28_923532	34	9	and	and	CC
10_1101-2020_01_28_923532	34	10	systematically	systematically	RB
10_1101-2020_01_28_923532	34	11	answer	answer	VB
10_1101-2020_01_28_923532	34	12	two	two	CD
10_1101-2020_01_28_923532	34	13	basic	basic	JJ
10_1101-2020_01_28_923532	34	14	questions	question	NNS
10_1101-2020_01_28_923532	34	15	.	.	.
10_1101-2020_01_28_923532	35	1	First	first	RB
10_1101-2020_01_28_923532	35	2	,	,	,
10_1101-2020_01_28_923532	35	3	how	how	WRB
10_1101-2020_01_28_923532	35	4	many	many	JJ
10_1101-2020_01_28_923532	35	5	targeted	target	VBN
10_1101-2020_01_28_923532	35	6	treatments	treatment	NNS
10_1101-2020_01_28_923532	35	7	are	be	VBP
10_1101-2020_01_28_923532	35	8	needed	need	VBN
10_1101-2020_01_28_923532	35	9	to	to	TO
10_1101-2020_01_28_923532	35	10	selectively	selectively	RB
10_1101-2020_01_28_923532	35	11	kill	kill	VB
10_1101-2020_01_28_923532	35	12	most	most	JJS
10_1101-2020_01_28_923532	35	13	tumor	tumor	NN
10_1101-2020_01_28_923532	35	14	cells	cell	NNS
10_1101-2020_01_28_923532	35	15	while	while	IN
10_1101-2020_01_28_923532	35	16	sparing	spare	VBG
10_1101-2020_01_28_923532	35	17	most	most	JJS
10_1101-2020_01_28_923532	35	18	of	of	IN
10_1101-2020_01_28_923532	35	19	the	the	DT
10_1101-2020_01_28_923532	35	20	non	non	JJ
10_1101-2020_01_28_923532	35	21	-	-	JJ
10_1101-2020_01_28_923532	35	22	tumor	tumor	JJ
10_1101-2020_01_28_923532	35	23	cells	cell	NNS
10_1101-2020_01_28_923532	35	24	in	in	IN
10_1101-2020_01_28_923532	35	25	a	a	DT
10_1101-2020_01_28_923532	35	26	given	give	VBN
10_1101-2020_01_28_923532	35	27	patient	patient	NN
10_1101-2020_01_28_923532	35	28	?	?	.
10_1101-2020_01_28_923532	36	1	And	and	CC
10_1101-2020_01_28_923532	36	2	second	second	RB
10_1101-2020_01_28_923532	36	3	,	,	,
10_1101-2020_01_28_923532	36	4	given	give	VBN
10_1101-2020_01_28_923532	36	5	a	a	DT
10_1101-2020_01_28_923532	36	6	cohort	cohort	NN
10_1101-2020_01_28_923532	36	7	of	of	IN
10_1101-2020_01_28_923532	36	8	patients	patient	NNS
10_1101-2020_01_28_923532	36	9	to	to	TO
10_1101-2020_01_28_923532	36	10	treat	treat	VB
10_1101-2020_01_28_923532	36	11	,	,	,
10_1101-2020_01_28_923532	36	12	how	how	WRB
10_1101-2020_01_28_923532	36	13	many	many	JJ
10_1101-2020_01_28_923532	36	14	distinct	distinct	JJ
10_1101-2020_01_28_923532	36	15	single	single	JJ
10_1101-2020_01_28_923532	36	16	-	-	HYPH
10_1101-2020_01_28_923532	36	17	target	target	NN
10_1101-2020_01_28_923532	36	18	treatments	treatment	NNS
10_1101-2020_01_28_923532	36	19	need	need	VBP
10_1101-2020_01_28_923532	36	20	to	to	TO
10_1101-2020_01_28_923532	36	21	be	be	VB
10_1101-2020_01_28_923532	36	22	prepared	prepare	VBN
10_1101-2020_01_28_923532	36	23	beforehand	beforehand	RB
10_1101-2020_01_28_923532	36	24	so	so	IN
10_1101-2020_01_28_923532	36	25	that	that	IN
10_1101-2020_01_28_923532	36	26	there	there	EX
10_1101-2020_01_28_923532	36	27	is	be	VBZ
10_1101-2020_01_28_923532	36	28	a	a	DT
10_1101-2020_01_28_923532	36	29	combination	combination	NN
10_1101-2020_01_28_923532	36	30	that	that	WDT
10_1101-2020_01_28_923532	36	31	kills	kill	VBZ
10_1101-2020_01_28_923532	36	32	at	at	IN
10_1101-2020_01_28_923532	36	33	least	least	JJS
10_1101-2020_01_28_923532	36	34	a	a	DT
10_1101-2020_01_28_923532	36	35	specified	specify	VBN
10_1101-2020_01_28_923532	36	36	proportion	proportion	NN
10_1101-2020_01_28_923532	36	37	of	of	IN
10_1101-2020_01_28_923532	36	38	the	the	DT
10_1101-2020_01_28_923532	36	39	tumor	tumor	NN
10_1101-2020_01_28_923532	36	40	cells	cell	NNS
10_1101-2020_01_28_923532	36	41	of	of	IN
10_1101-2020_01_28_923532	36	42	each	each	DT
10_1101-2020_01_28_923532	36	43	patient	patient	NN
10_1101-2020_01_28_923532	36	44	?	?	.
10_1101-2020_01_28_923532	37	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	37	2	focus	focus	VBP
10_1101-2020_01_28_923532	37	3	our	-PRON-	PRP$
10_1101-2020_01_28_923532	37	4	analysis	analysis	NN
10_1101-2020_01_28_923532	37	5	on	on	IN
10_1101-2020_01_28_923532	37	6	genes	gene	NNS
10_1101-2020_01_28_923532	37	7	encoding	encode	VBG
10_1101-2020_01_28_923532	37	8	protein	protein	NN
10_1101-2020_01_28_923532	37	9	targets	target	NNS
10_1101-2020_01_28_923532	37	10	that	that	WDT
10_1101-2020_01_28_923532	37	11	encode	encode	VBP
10_1101-2020_01_28_923532	37	12	receptors	receptor	NNS
10_1101-2020_01_28_923532	37	13	on	on	IN
10_1101-2020_01_28_923532	37	14	the	the	DT
10_1101-2020_01_28_923532	37	15	cell	cell	NN
10_1101-2020_01_28_923532	37	16	surface	surface	NN
10_1101-2020_01_28_923532	37	17	,	,	,
10_1101-2020_01_28_923532	37	18	as	as	IN
10_1101-2020_01_28_923532	37	19	these	these	DT
10_1101-2020_01_28_923532	37	20	may	may	MD
10_1101-2020_01_28_923532	37	21	be	be	VB
10_1101-2020_01_28_923532	37	22	precisely	precisely	RB
10_1101-2020_01_28_923532	37	23	targeted	target	VBN
10_1101-2020_01_28_923532	37	24	by	by	IN
10_1101-2020_01_28_923532	37	25	any	any	DT
10_1101-2020_01_28_923532	37	26	one	one	CD
10_1101-2020_01_28_923532	37	27	of	of	IN
10_1101-2020_01_28_923532	37	28	at	at	RB
10_1101-2020_01_28_923532	37	29	least	least	JJS
10_1101-2020_01_28_923532	37	30	six	six	CD
10_1101-2020_01_28_923532	37	31	technologies	technology	NNS
10_1101-2020_01_28_923532	37	32	:	:	:
10_1101-2020_01_28_923532	37	33	e.g.	e.g.	RB
10_1101-2020_01_28_923532	37	34	,	,	,
10_1101-2020_01_28_923532	37	35	by	by	IN
10_1101-2020_01_28_923532	37	36	CAR-	CAR-	NNP
10_1101-2020_01_28_923532	37	37	T	T	NNP
10_1101-2020_01_28_923532	37	38	therapy16	therapy16	NN
10_1101-2020_01_28_923532	37	39	,	,	,
10_1101-2020_01_28_923532	37	40	immunotoxins	immunotoxin	NNS
10_1101-2020_01_28_923532	37	41	ligated	ligate	VBN
10_1101-2020_01_28_923532	37	42	to	to	IN
10_1101-2020_01_28_923532	37	43	antibodies17	antibodies17	CD
10_1101-2020_01_28_923532	37	44	-	-	SYM
10_1101-2020_01_28_923532	37	45	18	18	CD
10_1101-2020_01_28_923532	37	46	,	,	,
10_1101-2020_01_28_923532	37	47	immunotoxins	immunotoxin	NNS
10_1101-2020_01_28_923532	37	48	ligated	ligate	VBN
10_1101-2020_01_28_923532	37	49	to	to	IN
10_1101-2020_01_28_923532	37	50	mimicking	mimic	VBG
10_1101-2020_01_28_923532	37	51	105	105	CD
10_1101-2020_01_28_923532	37	52	and	and	CC
10_1101-2020_01_28_923532	37	53	is	be	VBZ
10_1101-2020_01_28_923532	37	54	also	also	RB
10_1101-2020_01_28_923532	37	55	made	make	VBN
10_1101-2020_01_28_923532	37	56	available	available	JJ
10_1101-2020_01_28_923532	37	57	for	for	IN
10_1101-2020_01_28_923532	37	58	use	use	NN
10_1101-2020_01_28_923532	37	59	under	under	IN
10_1101-2020_01_28_923532	37	60	a	a	DT
10_1101-2020_01_28_923532	37	61	CC0	CC0	NNP
10_1101-2020_01_28_923532	37	62	license	license	NN
10_1101-2020_01_28_923532	37	63	.	.	.
10_1101-2020_01_28_923532	38	1	(	(	-LRB-
10_1101-2020_01_28_923532	38	2	which	which	WDT
10_1101-2020_01_28_923532	38	3	was	be	VBD
10_1101-2020_01_28_923532	38	4	not	not	RB
10_1101-2020_01_28_923532	38	5	certified	certify	VBN
10_1101-2020_01_28_923532	38	6	by	by	IN
10_1101-2020_01_28_923532	38	7	peer	peer	NN
10_1101-2020_01_28_923532	38	8	review	review	NN
10_1101-2020_01_28_923532	38	9	)	)	-RRB-
10_1101-2020_01_28_923532	38	10	is	be	VBZ
10_1101-2020_01_28_923532	38	11	the	the	DT
10_1101-2020_01_28_923532	38	12	author	author	NN
10_1101-2020_01_28_923532	38	13	/	/	SYM
10_1101-2020_01_28_923532	38	14	funder	funder	NN
10_1101-2020_01_28_923532	38	15	.	.	.
10_1101-2020_01_28_923532	39	1	This	this	DT
10_1101-2020_01_28_923532	39	2	article	article	NN
10_1101-2020_01_28_923532	39	3	is	be	VBZ
10_1101-2020_01_28_923532	39	4	a	a	DT
10_1101-2020_01_28_923532	39	5	US	US	NNP
10_1101-2020_01_28_923532	39	6	Government	Government	NNP
10_1101-2020_01_28_923532	39	7	work	work	NN
10_1101-2020_01_28_923532	39	8	.	.	.
10_1101-2020_01_28_923532	40	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	40	2	is	be	VBZ
10_1101-2020_01_28_923532	40	3	not	not	RB
10_1101-2020_01_28_923532	40	4	subject	subject	JJ
10_1101-2020_01_28_923532	40	5	to	to	IN
10_1101-2020_01_28_923532	40	6	copyright	copyright	NN
10_1101-2020_01_28_923532	40	7	under	under	IN
10_1101-2020_01_28_923532	40	8	17	17	CD
10_1101-2020_01_28_923532	40	9	USC	usc	NN
10_1101-2020_01_28_923532	40	10	The	the	DT
10_1101-2020_01_28_923532	40	11	copyright	copyright	NN
10_1101-2020_01_28_923532	40	12	holder	holder	NN
10_1101-2020_01_28_923532	40	13	for	for	IN
10_1101-2020_01_28_923532	40	14	this	this	DT
10_1101-2020_01_28_923532	40	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	40	16	version	version	NN
10_1101-2020_01_28_923532	40	17	posted	post	VBD
10_1101-2020_01_28_923532	40	18	February	February	NNP
10_1101-2020_01_28_923532	40	19	12	12	CD
10_1101-2020_01_28_923532	40	20	,	,	,
10_1101-2020_01_28_923532	40	21	2021	2021	CD
10_1101-2020_01_28_923532	40	22	.	.	.
10_1101-2020_01_28_923532	40	23	;	;	:
10_1101-2020_01_28_923532	40	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	40	25	:	:	:
10_1101-2020_01_28_923532	40	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	40	27	preprint	preprint	NN
10_1101-2020_01_28_923532	40	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	40	29	5	5	CD
10_1101-2020_01_28_923532	40	30	peptides19	peptides19	NN
10_1101-2020_01_28_923532	40	31	,	,	,
10_1101-2020_01_28_923532	40	32	conventional	conventional	JJ
10_1101-2020_01_28_923532	40	33	chemotherapy	chemotherapy	NN
10_1101-2020_01_28_923532	40	34	ligated	ligate	VBN
10_1101-2020_01_28_923532	40	35	to	to	IN
10_1101-2020_01_28_923532	40	36	nanoparticles20	nanoparticles20	NNP
10_1101-2020_01_28_923532	40	37	,	,	,
10_1101-2020_01_28_923532	40	38	degraders	degrader	NNS
10_1101-2020_01_28_923532	40	39	associated	associate	VBN
10_1101-2020_01_28_923532	40	40	with	with	IN
10_1101-2020_01_28_923532	40	41	ubiquitin	ubiquitin	NNP
10_1101-2020_01_28_923532	40	42	E3	E3	NNP
10_1101-2020_01_28_923532	40	43	ligases21	ligases21	NN
10_1101-2020_01_28_923532	40	44	and	and	CC
10_1101-2020_01_28_923532	40	45	designed	design	VBN
10_1101-2020_01_28_923532	40	46	ankyrin	ankyrin	NN
10_1101-2020_01_28_923532	40	47	repeat	repeat	NN
10_1101-2020_01_28_923532	40	48	proteins	protein	NNS
10_1101-2020_01_28_923532	40	49	(	(	-LRB-
10_1101-2020_01_28_923532	40	50	DARPins)22,23	darpins)22,23	UH
10_1101-2020_01_28_923532	40	51	.	.	.
10_1101-2020_01_28_923532	41	1	These	these	DT
10_1101-2020_01_28_923532	41	2	treatments	treatment	NNS
10_1101-2020_01_28_923532	41	3	are	be	VBP
10_1101-2020_01_28_923532	41	4	all	all	RB
10_1101-2020_01_28_923532	41	5	“	"	``
10_1101-2020_01_28_923532	41	6	modular	modular	JJ
10_1101-2020_01_28_923532	41	7	”	"	''
10_1101-2020_01_28_923532	41	8	,	,	,
10_1101-2020_01_28_923532	41	9	including	include	VBG
10_1101-2020_01_28_923532	41	10	one	one	CD
10_1101-2020_01_28_923532	41	11	part	part	NN
10_1101-2020_01_28_923532	41	12	that	that	WDT
10_1101-2020_01_28_923532	41	13	specifically	specifically	RB
10_1101-2020_01_28_923532	41	14	targets	target	VBZ
10_1101-2020_01_28_923532	41	15	the	the	DT
10_1101-2020_01_28_923532	41	16	tumor	tumor	NN
10_1101-2020_01_28_923532	41	17	cell	cell	NN
10_1101-2020_01_28_923532	41	18	via	via	IN
10_1101-2020_01_28_923532	41	19	one	one	CD
10_1101-2020_01_28_923532	41	20	gene	gene	NN
10_1101-2020_01_28_923532	41	21	/	/	SYM
10_1101-2020_01_28_923532	41	22	protein	protein	NN
10_1101-2020_01_28_923532	41	23	and	and	CC
10_1101-2020_01_28_923532	41	24	another	another	DT
10_1101-2020_01_28_923532	41	25	part	part	NN
10_1101-2020_01_28_923532	41	26	,	,	,
10_1101-2020_01_28_923532	41	27	the	the	DT
10_1101-2020_01_28_923532	41	28	cytotoxic	cytotoxic	JJ
10_1101-2020_01_28_923532	41	29	mechanism	mechanism	NN
10_1101-2020_01_28_923532	41	30	that	that	WDT
10_1101-2020_01_28_923532	41	31	kills	kill	VBZ
10_1101-2020_01_28_923532	41	32	the	the	DT
10_1101-2020_01_28_923532	41	33	cells	cell	NNS
10_1101-2020_01_28_923532	41	34	.	.	.
10_1101-2020_01_28_923532	42	1	Two	two	CD
10_1101-2020_01_28_923532	42	2	recent	recent	JJ
10_1101-2020_01_28_923532	42	3	genome	genome	NN
10_1101-2020_01_28_923532	42	4	-	-	HYPH
10_1101-2020_01_28_923532	42	5	wide	wide	JJ
10_1101-2020_01_28_923532	42	6	analyses	analysis	NNS
10_1101-2020_01_28_923532	42	7	of	of	IN
10_1101-2020_01_28_923532	42	8	modular	modular	JJ
10_1101-2020_01_28_923532	42	9	therapies	therapy	NNS
10_1101-2020_01_28_923532	42	10	have	have	VBP
10_1101-2020_01_28_923532	42	11	focused	focus	VBN
10_1101-2020_01_28_923532	42	12	on	on	IN
10_1101-2020_01_28_923532	42	13	CAR	CAR	NNP
10_1101-2020_01_28_923532	42	14	-	-	HYPH
10_1101-2020_01_28_923532	42	15	T	T	NNP
10_1101-2020_01_28_923532	42	16	therapy24,25	therapy24,25	NNP
10_1101-2020_01_28_923532	42	17	,	,	,
10_1101-2020_01_28_923532	42	18	so	so	RB
10_1101-2020_01_28_923532	42	19	we	-PRON-	PRP
10_1101-2020_01_28_923532	42	20	focus	focus	VBP
10_1101-2020_01_28_923532	42	21	first	first	RB
10_1101-2020_01_28_923532	42	22	on	on	IN
10_1101-2020_01_28_923532	42	23	this	this	DT
10_1101-2020_01_28_923532	42	24	technology	technology	NN
10_1101-2020_01_28_923532	42	25	to	to	TO
10_1101-2020_01_28_923532	42	26	put	put	VB
10_1101-2020_01_28_923532	42	27	our	-PRON-	PRP$
10_1101-2020_01_28_923532	42	28	work	work	NN
10_1101-2020_01_28_923532	42	29	in	in	IN
10_1101-2020_01_28_923532	42	30	context	context	NN
10_1101-2020_01_28_923532	42	31	.	.	.
10_1101-2020_01_28_923532	43	1	In	in	IN
10_1101-2020_01_28_923532	43	2	the	the	DT
10_1101-2020_01_28_923532	43	3	original	original	JJ
10_1101-2020_01_28_923532	43	4	formulation	formulation	NN
10_1101-2020_01_28_923532	43	5	,	,	,
10_1101-2020_01_28_923532	43	6	CAR	CAR	NNP
10_1101-2020_01_28_923532	43	7	-	-	HYPH
10_1101-2020_01_28_923532	43	8	T	t	NN
10_1101-2020_01_28_923532	43	9	therapy	therapy	NN
10_1101-2020_01_28_923532	43	10	used	use	VBD
10_1101-2020_01_28_923532	43	11	one	one	CD
10_1101-2020_01_28_923532	43	12	cell	cell	NN
10_1101-2020_01_28_923532	43	13	surface	surface	NN
10_1101-2020_01_28_923532	43	14	target	target	NN
10_1101-2020_01_28_923532	43	15	that	that	WDT
10_1101-2020_01_28_923532	43	16	marks	mark	VBZ
10_1101-2020_01_28_923532	43	17	the	the	DT
10_1101-2020_01_28_923532	43	18	cells	cell	NNS
10_1101-2020_01_28_923532	43	19	of	of	IN
10_1101-2020_01_28_923532	43	20	interest	interest	NN
10_1101-2020_01_28_923532	43	21	,	,	,
10_1101-2020_01_28_923532	43	22	such	such	JJ
10_1101-2020_01_28_923532	43	23	as	as	IN
10_1101-2020_01_28_923532	43	24	CD19	CD19	NNP
10_1101-2020_01_28_923532	43	25	as	as	IN
10_1101-2020_01_28_923532	43	26	a	a	DT
10_1101-2020_01_28_923532	43	27	marker	marker	NN
10_1101-2020_01_28_923532	43	28	for	for	IN
10_1101-2020_01_28_923532	43	29	B	b	NN
10_1101-2020_01_28_923532	43	30	cells	cell	NNS
10_1101-2020_01_28_923532	43	31	.	.	.
10_1101-2020_01_28_923532	44	1	To	to	IN
10_1101-2020_01_28_923532	44	2	date	date	NN
10_1101-2020_01_28_923532	44	3	,	,	,
10_1101-2020_01_28_923532	44	4	CAR	CAR	NNP
10_1101-2020_01_28_923532	44	5	-	-	HYPH
10_1101-2020_01_28_923532	44	6	T	t	NN
10_1101-2020_01_28_923532	44	7	therapy	therapy	NN
10_1101-2020_01_28_923532	44	8	has	have	VBZ
10_1101-2020_01_28_923532	44	9	been	be	VBN
10_1101-2020_01_28_923532	44	10	effective	effective	JJ
10_1101-2020_01_28_923532	44	11	in	in	IN
10_1101-2020_01_28_923532	44	12	achieving	achieve	VBG
10_1101-2020_01_28_923532	44	13	remissions	remission	NNS
10_1101-2020_01_28_923532	44	14	for	for	IN
10_1101-2020_01_28_923532	44	15	some	some	DT
10_1101-2020_01_28_923532	44	16	blood	blood	NN
10_1101-2020_01_28_923532	44	17	cancers16,26	cancers16,26	NN
10_1101-2020_01_28_923532	44	18	,	,	,
10_1101-2020_01_28_923532	44	19	but	but	CC
10_1101-2020_01_28_923532	44	20	less	less	RBR
10_1101-2020_01_28_923532	44	21	effective	effective	JJ
10_1101-2020_01_28_923532	44	22	for	for	IN
10_1101-2020_01_28_923532	44	23	solid	solid	JJ
10_1101-2020_01_28_923532	44	24	tumors	tumor	NNS
10_1101-2020_01_28_923532	44	25	.	.	.
10_1101-2020_01_28_923532	45	1	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	45	2	et	et	NNP
10_1101-2020_01_28_923532	45	3	al.25	al.25	IN
10_1101-2020_01_28_923532	45	4	focused	focus	VBD
10_1101-2020_01_28_923532	45	5	primarily	primarily	RB
10_1101-2020_01_28_923532	45	6	on	on	IN
10_1101-2020_01_28_923532	45	7	single	single	JJ
10_1101-2020_01_28_923532	45	8	targets	target	NNS
10_1101-2020_01_28_923532	45	9	and	and	CC
10_1101-2020_01_28_923532	45	10	looked	look	VBD
10_1101-2020_01_28_923532	45	11	at	at	IN
10_1101-2020_01_28_923532	45	12	combinations	combination	NNS
10_1101-2020_01_28_923532	45	13	of	of	IN
10_1101-2020_01_28_923532	45	14	two	two	CD
10_1101-2020_01_28_923532	45	15	targets	target	NNS
10_1101-2020_01_28_923532	45	16	and	and	CC
10_1101-2020_01_28_923532	45	17	did	do	VBD
10_1101-2020_01_28_923532	45	18	all	all	DT
10_1101-2020_01_28_923532	45	19	analysis	analysis	NN
10_1101-2020_01_28_923532	45	20	in	in	IN
10_1101-2020_01_28_923532	45	21	silico	silico	NNP
10_1101-2020_01_28_923532	45	22	.	.	.
10_1101-2020_01_28_923532	46	1	Dannenfelser	Dannenfelser	NNP
10_1101-2020_01_28_923532	46	2	et	et	NNP
10_1101-2020_01_28_923532	46	3	al.24	al.24	NNP
10_1101-2020_01_28_923532	46	4	focused	focus	VBD
10_1101-2020_01_28_923532	46	5	on	on	IN
10_1101-2020_01_28_923532	46	6	predicting	predict	VBG
10_1101-2020_01_28_923532	46	7	combinations	combination	NNS
10_1101-2020_01_28_923532	46	8	of	of	IN
10_1101-2020_01_28_923532	46	9	two	two	CD
10_1101-2020_01_28_923532	46	10	and	and	CC
10_1101-2020_01_28_923532	46	11	three	three	CD
10_1101-2020_01_28_923532	46	12	targets	target	NNS
10_1101-2020_01_28_923532	46	13	and	and	CC
10_1101-2020_01_28_923532	46	14	did	do	VBD
10_1101-2020_01_28_923532	46	15	most	most	JJS
10_1101-2020_01_28_923532	46	16	of	of	IN
10_1101-2020_01_28_923532	46	17	their	-PRON-	PRP$
10_1101-2020_01_28_923532	46	18	work	work	NN
10_1101-2020_01_28_923532	46	19	in	in	IN
10_1101-2020_01_28_923532	46	20	silico	silico	NN
10_1101-2020_01_28_923532	46	21	,	,	,
10_1101-2020_01_28_923532	46	22	with	with	IN
10_1101-2020_01_28_923532	46	23	in	in	IN
10_1101-2020_01_28_923532	46	24	vitro	vitro	FW
10_1101-2020_01_28_923532	46	25	validation	validation	NN
10_1101-2020_01_28_923532	46	26	of	of	IN
10_1101-2020_01_28_923532	46	27	two	two	CD
10_1101-2020_01_28_923532	46	28	high	high	RB
10_1101-2020_01_28_923532	46	29	-	-	HYPH
10_1101-2020_01_28_923532	46	30	scoring	score	VBG
10_1101-2020_01_28_923532	46	31	predicted	predict	VBN
10_1101-2020_01_28_923532	46	32	combinations	combination	NNS
10_1101-2020_01_28_923532	46	33	in	in	IN
10_1101-2020_01_28_923532	46	34	renal	renal	JJ
10_1101-2020_01_28_923532	46	35	cancer	cancer	NN
10_1101-2020_01_28_923532	46	36	.	.	.
10_1101-2020_01_28_923532	47	1	Importantly	importantly	RB
10_1101-2020_01_28_923532	47	2	,	,	,
10_1101-2020_01_28_923532	47	3	these	these	DT
10_1101-2020_01_28_923532	47	4	studies	study	NNS
10_1101-2020_01_28_923532	47	5	have	have	VBP
10_1101-2020_01_28_923532	47	6	analyzed	analyze	VBN
10_1101-2020_01_28_923532	47	7	bulk	bulk	JJ
10_1101-2020_01_28_923532	47	8	tumor	tumor	NN
10_1101-2020_01_28_923532	47	9	and	and	CC
10_1101-2020_01_28_923532	47	10	normal	normal	JJ
10_1101-2020_01_28_923532	47	11	expression	expression	NN
10_1101-2020_01_28_923532	47	12	data	datum	NNS
10_1101-2020_01_28_923532	47	13	to	to	TO
10_1101-2020_01_28_923532	47	14	identify	identify	VB
10_1101-2020_01_28_923532	47	15	likely	likely	JJ
10_1101-2020_01_28_923532	47	16	targets	target	NNS
10_1101-2020_01_28_923532	47	17	.	.	.
10_1101-2020_01_28_923532	48	1	Here	here	RB
10_1101-2020_01_28_923532	48	2	we	-PRON-	PRP
10_1101-2020_01_28_923532	48	3	present	present	VBP
10_1101-2020_01_28_923532	48	4	the	the	DT
10_1101-2020_01_28_923532	48	5	first	first	JJ
10_1101-2020_01_28_923532	48	6	analysis	analysis	NN
10_1101-2020_01_28_923532	48	7	that	that	WDT
10_1101-2020_01_28_923532	48	8	aims	aim	VBZ
10_1101-2020_01_28_923532	48	9	to	to	TO
10_1101-2020_01_28_923532	48	10	identify	identify	VB
10_1101-2020_01_28_923532	48	11	modular	modular	JJ
10_1101-2020_01_28_923532	48	12	targets	target	NNS
10_1101-2020_01_28_923532	48	13	based	base	VBN
10_1101-2020_01_28_923532	48	14	on	on	IN
10_1101-2020_01_28_923532	48	15	the	the	DT
10_1101-2020_01_28_923532	48	16	analysis	analysis	NN
10_1101-2020_01_28_923532	48	17	of	of	IN
10_1101-2020_01_28_923532	48	18	tumor	tumor	NN
10_1101-2020_01_28_923532	48	19	single	single	JJ
10_1101-2020_01_28_923532	48	20	-	-	HYPH
10_1101-2020_01_28_923532	48	21	cell	cell	NN
10_1101-2020_01_28_923532	48	22	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	48	23	.	.	.
10_1101-2020_01_28_923532	49	1	This	this	DT
10_1101-2020_01_28_923532	49	2	enables	enable	VBZ
10_1101-2020_01_28_923532	49	3	to	to	TO
10_1101-2020_01_28_923532	49	4	study	study	VB
10_1101-2020_01_28_923532	49	5	the	the	DT
10_1101-2020_01_28_923532	49	6	research	research	NN
10_1101-2020_01_28_923532	49	7	questions	question	NNS
10_1101-2020_01_28_923532	49	8	at	at	IN
10_1101-2020_01_28_923532	49	9	a	a	DT
10_1101-2020_01_28_923532	49	10	higher	high	JJR
10_1101-2020_01_28_923532	49	11	resolution	resolution	NN
10_1101-2020_01_28_923532	49	12	but	but	CC
10_1101-2020_01_28_923532	49	13	presents	present	VBZ
10_1101-2020_01_28_923532	49	14	new	new	JJ
10_1101-2020_01_28_923532	49	15	analytical	analytical	JJ
10_1101-2020_01_28_923532	49	16	challenges	challenge	NNS
10_1101-2020_01_28_923532	49	17	that	that	WDT
10_1101-2020_01_28_923532	49	18	need	need	VBP
10_1101-2020_01_28_923532	49	19	to	to	TO
10_1101-2020_01_28_923532	49	20	be	be	VB
10_1101-2020_01_28_923532	49	21	addressed	address	VBN
10_1101-2020_01_28_923532	49	22	.	.	.
10_1101-2020_01_28_923532	50	1	Two	two	CD
10_1101-2020_01_28_923532	50	2	related	related	JJ
10_1101-2020_01_28_923532	50	3	difficulties	difficulty	NNS
10_1101-2020_01_28_923532	50	4	with	with	IN
10_1101-2020_01_28_923532	50	5	CAR	CAR	NNP
10_1101-2020_01_28_923532	50	6	-	-	HYPH
10_1101-2020_01_28_923532	50	7	T	t	NN
10_1101-2020_01_28_923532	50	8	therapy	therapy	NN
10_1101-2020_01_28_923532	50	9	are	be	VBP
10_1101-2020_01_28_923532	50	10	i	i	PRP
10_1101-2020_01_28_923532	50	11	)	)	-RRB-
10_1101-2020_01_28_923532	50	12	toxicity	toxicity	NN
10_1101-2020_01_28_923532	50	13	to	to	IN
10_1101-2020_01_28_923532	50	14	non	non	JJ
10_1101-2020_01_28_923532	50	15	-	-	JJ
10_1101-2020_01_28_923532	50	16	cancer	cancer	JJ
10_1101-2020_01_28_923532	50	17	cells27,28	cells27,28	NNP
10_1101-2020_01_28_923532	50	18	and	and	CC
10_1101-2020_01_28_923532	50	19	ii	ii	NNP
10_1101-2020_01_28_923532	50	20	)	)	-RRB-
10_1101-2020_01_28_923532	50	21	difficulty	difficulty	NN
10_1101-2020_01_28_923532	50	22	in	in	IN
10_1101-2020_01_28_923532	50	23	finding	find	VBG
10_1101-2020_01_28_923532	50	24	single	single	JJ
10_1101-2020_01_28_923532	50	25	targets	target	NNS
10_1101-2020_01_28_923532	50	26	that	that	WDT
10_1101-2020_01_28_923532	50	27	are	be	VBP
10_1101-2020_01_28_923532	50	28	sufficiently	sufficiently	RB
10_1101-2020_01_28_923532	50	29	selective25	selective25	JJ
10_1101-2020_01_28_923532	50	30	.	.	.
10_1101-2020_01_28_923532	51	1	To	to	TO
10_1101-2020_01_28_923532	51	2	address	address	VB
10_1101-2020_01_28_923532	51	3	the	the	DT
10_1101-2020_01_28_923532	51	4	toxicity	toxicity	NN
10_1101-2020_01_28_923532	51	5	problem	problem	NN
10_1101-2020_01_28_923532	51	6	,	,	,
10_1101-2020_01_28_923532	51	7	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	51	8	et	et	NNP
10_1101-2020_01_28_923532	51	9	al.25	al.25	IN
10_1101-2020_01_28_923532	51	10	selected	select	VBD
10_1101-2020_01_28_923532	51	11	533	533	CD
10_1101-2020_01_28_923532	51	12	targets	target	NNS
10_1101-2020_01_28_923532	51	13	that	that	WDT
10_1101-2020_01_28_923532	51	14	had	have	VBD
10_1101-2020_01_28_923532	51	15	low	low	JJ
10_1101-2020_01_28_923532	51	16	expression	expression	NN
10_1101-2020_01_28_923532	51	17	in	in	IN
10_1101-2020_01_28_923532	51	18	most	most	JJS
10_1101-2020_01_28_923532	51	19	tissues	tissue	NNS
10_1101-2020_01_28_923532	51	20	in	in	IN
10_1101-2020_01_28_923532	51	21	the	the	DT
10_1101-2020_01_28_923532	51	22	Genotype	Genotype	NNP
10_1101-2020_01_28_923532	51	23	-	-	HYPH
10_1101-2020_01_28_923532	51	24	Tissue	Tissue	NNP
10_1101-2020_01_28_923532	51	25	Expression	Expression	NNP
10_1101-2020_01_28_923532	51	26	(	(	-LRB-
10_1101-2020_01_28_923532	51	27	GTEx	GTEx	NNP
10_1101-2020_01_28_923532	51	28	)	)	-RRB-
10_1101-2020_01_28_923532	51	29	data	datum	NNS
10_1101-2020_01_28_923532	51	30	;	;	:
10_1101-2020_01_28_923532	51	31	however	however	RB
10_1101-2020_01_28_923532	51	32	,	,	,
10_1101-2020_01_28_923532	51	33	their	-PRON-	PRP$
10_1101-2020_01_28_923532	51	34	analysis	analysis	NN
10_1101-2020_01_28_923532	51	35	did	do	VBD
10_1101-2020_01_28_923532	51	36	not	not	RB
10_1101-2020_01_28_923532	51	37	require	require	VB
10_1101-2020_01_28_923532	51	38	that	that	IN
10_1101-2020_01_28_923532	51	39	the	the	DT
10_1101-2020_01_28_923532	51	40	targets	target	NNS
10_1101-2020_01_28_923532	51	41	are	be	VBP
10_1101-2020_01_28_923532	51	42	cell	cell	NN
10_1101-2020_01_28_923532	51	43	surface	surface	NN
10_1101-2020_01_28_923532	51	44	proteins	protein	NNS
10_1101-2020_01_28_923532	51	45	.	.	.
10_1101-2020_01_28_923532	52	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	52	2	proceed	proceed	VBP
10_1101-2020_01_28_923532	52	3	in	in	IN
10_1101-2020_01_28_923532	52	4	a	a	DT
10_1101-2020_01_28_923532	52	5	stepwise	stepwise	NN
10_1101-2020_01_28_923532	52	6	manner	manner	NN
10_1101-2020_01_28_923532	52	7	;	;	:
10_1101-2020_01_28_923532	52	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	52	9	start	start	VBP
10_1101-2020_01_28_923532	52	10	with	with	IN
10_1101-2020_01_28_923532	52	11	a	a	DT
10_1101-2020_01_28_923532	52	12	formal	formal	JJ
10_1101-2020_01_28_923532	52	13	analysis	analysis	NN
10_1101-2020_01_28_923532	52	14	of	of	IN
10_1101-2020_01_28_923532	52	15	a	a	DT
10_1101-2020_01_28_923532	52	16	space	space	NN
10_1101-2020_01_28_923532	52	17	of	of	IN
10_1101-2020_01_28_923532	52	18	1269	1269	CD
10_1101-2020_01_28_923532	52	19	candidate	candidate	NN
10_1101-2020_01_28_923532	52	20	cell	cell	NN
10_1101-2020_01_28_923532	52	21	surface	surface	NN
10_1101-2020_01_28_923532	52	22	receptors	receptor	NNS
10_1101-2020_01_28_923532	52	23	.	.	.
10_1101-2020_01_28_923532	53	1	Then	then	RB
10_1101-2020_01_28_923532	53	2	,	,	,
10_1101-2020_01_28_923532	53	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	53	4	proceed	proceed	VBP
10_1101-2020_01_28_923532	53	5	to	to	TO
10_1101-2020_01_28_923532	53	6	add	add	VB
10_1101-2020_01_28_923532	53	7	a	a	DT
10_1101-2020_01_28_923532	53	8	low	low	JJ
10_1101-2020_01_28_923532	53	9	-	-	HYPH
10_1101-2020_01_28_923532	53	10	expression	expression	NN
10_1101-2020_01_28_923532	53	11	requirement	requirement	NN
10_1101-2020_01_28_923532	53	12	like	like	IN
10_1101-2020_01_28_923532	53	13	that	that	DT
10_1101-2020_01_28_923532	53	14	of	of	IN
10_1101-2020_01_28_923532	53	15	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	53	16	et	et	NNP
10_1101-2020_01_28_923532	53	17	al.25	al.25	FW
10_1101-2020_01_28_923532	53	18	and	and	CC
10_1101-2020_01_28_923532	53	19	parameterized	parameterize	VBN
10_1101-2020_01_28_923532	53	20	by	by	IN
10_1101-2020_01_28_923532	53	21	a	a	DT
10_1101-2020_01_28_923532	53	22	transcripts	transcript	NNS
10_1101-2020_01_28_923532	53	23	per	per	IN
10_1101-2020_01_28_923532	53	24	million	million	CD
10_1101-2020_01_28_923532	53	25	(	(	-LRB-
10_1101-2020_01_28_923532	53	26	TPM	TPM	NNP
10_1101-2020_01_28_923532	53	27	)	)	-RRB-
10_1101-2020_01_28_923532	53	28	expression	expression	NN
10_1101-2020_01_28_923532	53	29	threshold	threshold	NN
10_1101-2020_01_28_923532	53	30	.	.	.
10_1101-2020_01_28_923532	54	1	For	for	IN
10_1101-2020_01_28_923532	54	2	completeness	completeness	JJ
10_1101-2020_01_28_923532	54	3	,	,	,
10_1101-2020_01_28_923532	54	4	we	-PRON-	PRP
10_1101-2020_01_28_923532	54	5	also	also	RB
10_1101-2020_01_28_923532	54	6	tested	test	VBD
10_1101-2020_01_28_923532	54	7	their	-PRON-	PRP$
10_1101-2020_01_28_923532	54	8	set	set	NN
10_1101-2020_01_28_923532	54	9	of	of	IN
10_1101-2020_01_28_923532	54	10	533	533	CD
10_1101-2020_01_28_923532	54	11	genes	gene	NNS
10_1101-2020_01_28_923532	54	12	.	.	.
10_1101-2020_01_28_923532	55	1	To	to	TO
10_1101-2020_01_28_923532	55	2	address	address	VB
10_1101-2020_01_28_923532	55	3	the	the	DT
10_1101-2020_01_28_923532	55	4	selectivity	selectivity	NN
10_1101-2020_01_28_923532	55	5	problem	problem	NN
10_1101-2020_01_28_923532	55	6	,	,	,
10_1101-2020_01_28_923532	55	7	various	various	JJ
10_1101-2020_01_28_923532	55	8	groups	group	NNS
10_1101-2020_01_28_923532	55	9	have	have	VBP
10_1101-2020_01_28_923532	55	10	engineered	engineer	VBN
10_1101-2020_01_28_923532	55	11	composite	composite	JJ
10_1101-2020_01_28_923532	55	12	forms	form	NNS
10_1101-2020_01_28_923532	55	13	of	of	IN
10_1101-2020_01_28_923532	55	14	CAR	CAR	NNP
10_1101-2020_01_28_923532	55	15	-	-	HYPH
10_1101-2020_01_28_923532	55	16	T	t	NN
10_1101-2020_01_28_923532	55	17	treatments	treatment	NNS
10_1101-2020_01_28_923532	55	18	that	that	WDT
10_1101-2020_01_28_923532	55	19	implement	implement	VBP
10_1101-2020_01_28_923532	55	20	Boolean	Boolean	NNP
10_1101-2020_01_28_923532	55	21	AND	and	CC
10_1101-2020_01_28_923532	55	22	,	,	,
10_1101-2020_01_28_923532	55	23	OR	or	CC
10_1101-2020_01_28_923532	55	24	,	,	,
10_1101-2020_01_28_923532	55	25	and	and	CC
10_1101-2020_01_28_923532	55	26	NOT	not	RB
10_1101-2020_01_28_923532	55	27	gates	gate	NNS
10_1101-2020_01_28_923532	55	28	that	that	WDT
10_1101-2020_01_28_923532	55	29	have	have	VBP
10_1101-2020_01_28_923532	55	30	been	be	VBN
10_1101-2020_01_28_923532	55	31	tested	test	VBN
10_1101-2020_01_28_923532	55	32	for	for	IN
10_1101-2020_01_28_923532	55	33	combinations	combination	NNS
10_1101-2020_01_28_923532	55	34	of	of	IN
10_1101-2020_01_28_923532	55	35	up	up	IN
10_1101-2020_01_28_923532	55	36	to	to	TO
10_1101-2020_01_28_923532	55	37	three	three	CD
10_1101-2020_01_28_923532	55	38	target	target	NN
10_1101-2020_01_28_923532	55	39	proteins29	proteins29	NNP
10_1101-2020_01_28_923532	55	40	-	-	HYPH
10_1101-2020_01_28_923532	55	41	33	33	CD
10_1101-2020_01_28_923532	55	42	.	.	.
10_1101-2020_01_28_923532	56	1	Both	both	DT
10_1101-2020_01_28_923532	56	2	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	56	3	et	et	FW
10_1101-2020_01_28_923532	56	4	al	al	NNP
10_1101-2020_01_28_923532	56	5	.	.	.
10_1101-2020_01_28_923532	57	1	and	and	CC
10_1101-2020_01_28_923532	57	2	Dannenfelser	Dannenfelser	NNP
10_1101-2020_01_28_923532	57	3	et	et	FW
10_1101-2020_01_28_923532	57	4	al	al	NNP
10_1101-2020_01_28_923532	57	5	.	.	.
10_1101-2020_01_28_923532	58	1	presented	present	VBN
10_1101-2020_01_28_923532	58	2	in	in	IN
10_1101-2020_01_28_923532	58	3	silico	silico	NN
10_1101-2020_01_28_923532	58	4	methods	method	NNS
10_1101-2020_01_28_923532	58	5	focusing	focus	VBG
10_1101-2020_01_28_923532	58	6	on	on	IN
10_1101-2020_01_28_923532	58	7	AND	and	CC
10_1101-2020_01_28_923532	58	8	gates	gate	NNS
10_1101-2020_01_28_923532	58	9	and	and	CC
10_1101-2020_01_28_923532	58	10	pairs	pair	NNS
10_1101-2020_01_28_923532	58	11	or	or	CC
10_1101-2020_01_28_923532	58	12	trios	trio	NNS
10_1101-2020_01_28_923532	58	13	of	of	IN
10_1101-2020_01_28_923532	58	14	targets	target	NNS
10_1101-2020_01_28_923532	58	15	;	;	:
10_1101-2020_01_28_923532	58	16	Dannenfelser	Dannenfelser	NNP
10_1101-2020_01_28_923532	58	17	et	et	FW
10_1101-2020_01_28_923532	58	18	al	al	NNP
10_1101-2020_01_28_923532	58	19	.	.	.
10_1101-2020_01_28_923532	59	1	analyzed	analyze	VBN
10_1101-2020_01_28_923532	59	2	2538	2538	CD
10_1101-2020_01_28_923532	59	3	likely	likely	JJ
10_1101-2020_01_28_923532	59	4	cell	cell	NN
10_1101-2020_01_28_923532	59	5	surface	surface	NN
10_1101-2020_01_28_923532	59	6	proteins	protein	NNS
10_1101-2020_01_28_923532	59	7	that	that	WDT
10_1101-2020_01_28_923532	59	8	are	be	VBP
10_1101-2020_01_28_923532	59	9	not	not	RB
10_1101-2020_01_28_923532	59	10	necessarily	necessarily	RB
10_1101-2020_01_28_923532	59	11	receptors	receptor	NNS
10_1101-2020_01_28_923532	59	12	.	.	.
10_1101-2020_01_28_923532	60	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	60	2	have	have	VBP
10_1101-2020_01_28_923532	60	3	chosen	choose	VBN
10_1101-2020_01_28_923532	60	4	105	105	CD
10_1101-2020_01_28_923532	60	5	and	and	CC
10_1101-2020_01_28_923532	60	6	is	be	VBZ
10_1101-2020_01_28_923532	60	7	also	also	RB
10_1101-2020_01_28_923532	60	8	made	make	VBN
10_1101-2020_01_28_923532	60	9	available	available	JJ
10_1101-2020_01_28_923532	60	10	for	for	IN
10_1101-2020_01_28_923532	60	11	use	use	NN
10_1101-2020_01_28_923532	60	12	under	under	IN
10_1101-2020_01_28_923532	60	13	a	a	DT
10_1101-2020_01_28_923532	60	14	CC0	CC0	NNP
10_1101-2020_01_28_923532	60	15	license	license	NN
10_1101-2020_01_28_923532	60	16	.	.	.
10_1101-2020_01_28_923532	61	1	(	(	-LRB-
10_1101-2020_01_28_923532	61	2	which	which	WDT
10_1101-2020_01_28_923532	61	3	was	be	VBD
10_1101-2020_01_28_923532	61	4	not	not	RB
10_1101-2020_01_28_923532	61	5	certified	certify	VBN
10_1101-2020_01_28_923532	61	6	by	by	IN
10_1101-2020_01_28_923532	61	7	peer	peer	NN
10_1101-2020_01_28_923532	61	8	review	review	NN
10_1101-2020_01_28_923532	61	9	)	)	-RRB-
10_1101-2020_01_28_923532	61	10	is	be	VBZ
10_1101-2020_01_28_923532	61	11	the	the	DT
10_1101-2020_01_28_923532	61	12	author	author	NN
10_1101-2020_01_28_923532	61	13	/	/	SYM
10_1101-2020_01_28_923532	61	14	funder	funder	NN
10_1101-2020_01_28_923532	61	15	.	.	.
10_1101-2020_01_28_923532	62	1	This	this	DT
10_1101-2020_01_28_923532	62	2	article	article	NN
10_1101-2020_01_28_923532	62	3	is	be	VBZ
10_1101-2020_01_28_923532	62	4	a	a	DT
10_1101-2020_01_28_923532	62	5	US	US	NNP
10_1101-2020_01_28_923532	62	6	Government	Government	NNP
10_1101-2020_01_28_923532	62	7	work	work	NN
10_1101-2020_01_28_923532	62	8	.	.	.
10_1101-2020_01_28_923532	63	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	63	2	is	be	VBZ
10_1101-2020_01_28_923532	63	3	not	not	RB
10_1101-2020_01_28_923532	63	4	subject	subject	JJ
10_1101-2020_01_28_923532	63	5	to	to	IN
10_1101-2020_01_28_923532	63	6	copyright	copyright	NN
10_1101-2020_01_28_923532	63	7	under	under	IN
10_1101-2020_01_28_923532	63	8	17	17	CD
10_1101-2020_01_28_923532	63	9	USC	usc	NN
10_1101-2020_01_28_923532	63	10	The	the	DT
10_1101-2020_01_28_923532	63	11	copyright	copyright	NN
10_1101-2020_01_28_923532	63	12	holder	holder	NN
10_1101-2020_01_28_923532	63	13	for	for	IN
10_1101-2020_01_28_923532	63	14	this	this	DT
10_1101-2020_01_28_923532	63	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	63	16	version	version	NN
10_1101-2020_01_28_923532	63	17	posted	post	VBD
10_1101-2020_01_28_923532	63	18	February	February	NNP
10_1101-2020_01_28_923532	63	19	12	12	CD
10_1101-2020_01_28_923532	63	20	,	,	,
10_1101-2020_01_28_923532	63	21	2021	2021	CD
10_1101-2020_01_28_923532	63	22	.	.	.
10_1101-2020_01_28_923532	63	23	;	;	:
10_1101-2020_01_28_923532	63	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	63	25	:	:	:
10_1101-2020_01_28_923532	63	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	63	27	preprint	preprint	NN
10_1101-2020_01_28_923532	63	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	63	29	6	6	CD
10_1101-2020_01_28_923532	63	30	to	to	TO
10_1101-2020_01_28_923532	63	31	focus	focus	VB
10_1101-2020_01_28_923532	63	32	on	on	IN
10_1101-2020_01_28_923532	63	33	the	the	DT
10_1101-2020_01_28_923532	63	34	simpler	simple	JJR
10_1101-2020_01_28_923532	63	35	logical	logical	JJ
10_1101-2020_01_28_923532	63	36	OR	or	CC
10_1101-2020_01_28_923532	63	37	construction	construction	NN
10_1101-2020_01_28_923532	63	38	because	because	IN
10_1101-2020_01_28_923532	63	39	that	that	DT
10_1101-2020_01_28_923532	63	40	can	can	MD
10_1101-2020_01_28_923532	63	41	be	be	VB
10_1101-2020_01_28_923532	63	42	achieved	achieve	VBN
10_1101-2020_01_28_923532	63	43	not	not	RB
10_1101-2020_01_28_923532	63	44	only	only	RB
10_1101-2020_01_28_923532	63	45	by	by	IN
10_1101-2020_01_28_923532	63	46	CAR	CAR	NNP
10_1101-2020_01_28_923532	63	47	-	-	HYPH
10_1101-2020_01_28_923532	63	48	T	T	NNP
10_1101-2020_01_28_923532	63	49	technology30,31	technology30,31	NNP
10_1101-2020_01_28_923532	63	50	,	,	,
10_1101-2020_01_28_923532	63	51	but	but	CC
10_1101-2020_01_28_923532	63	52	can	can	MD
10_1101-2020_01_28_923532	63	53	also	also	RB
10_1101-2020_01_28_923532	63	54	be	be	VB
10_1101-2020_01_28_923532	63	55	implemented	implement	VBN
10_1101-2020_01_28_923532	63	56	via	via	IN
10_1101-2020_01_28_923532	63	57	other	other	JJ
10_1101-2020_01_28_923532	63	58	modular	modular	JJ
10_1101-2020_01_28_923532	63	59	treatment	treatment	NN
10_1101-2020_01_28_923532	63	60	technologies	technology	NNS
10_1101-2020_01_28_923532	63	61	by	by	IN
10_1101-2020_01_28_923532	63	62	combining	combine	VBG
10_1101-2020_01_28_923532	63	63	multiple	multiple	JJ
10_1101-2020_01_28_923532	63	64	single	single	JJ
10_1101-2020_01_28_923532	63	65	-	-	HYPH
10_1101-2020_01_28_923532	63	66	target	target	NN
10_1101-2020_01_28_923532	63	67	treatments	treatment	NNS
10_1101-2020_01_28_923532	63	68	,	,	,
10_1101-2020_01_28_923532	63	69	assuming	assume	VBG
10_1101-2020_01_28_923532	63	70	that	that	IN
10_1101-2020_01_28_923532	63	71	the	the	DT
10_1101-2020_01_28_923532	63	72	composite	composite	JJ
10_1101-2020_01_28_923532	63	73	treatment	treatment	NN
10_1101-2020_01_28_923532	63	74	kills	kill	VBZ
10_1101-2020_01_28_923532	63	75	a	a	DT
10_1101-2020_01_28_923532	63	76	cell	cell	NN
10_1101-2020_01_28_923532	63	77	if	if	IN
10_1101-2020_01_28_923532	63	78	any	any	DT
10_1101-2020_01_28_923532	63	79	one	one	CD
10_1101-2020_01_28_923532	63	80	of	of	IN
10_1101-2020_01_28_923532	63	81	the	the	DT
10_1101-2020_01_28_923532	63	82	single	single	JJ
10_1101-2020_01_28_923532	63	83	treatments	treatment	NNS
10_1101-2020_01_28_923532	63	84	kill	kill	VBP
10_1101-2020_01_28_923532	63	85	the	the	DT
10_1101-2020_01_28_923532	63	86	cell	cell	NN
10_1101-2020_01_28_923532	63	87	.	.	.
10_1101-2020_01_28_923532	64	1	Conceptually	conceptually	RB
10_1101-2020_01_28_923532	64	2	,	,	,
10_1101-2020_01_28_923532	64	3	such	such	PDT
10_1101-2020_01_28_923532	64	4	a	a	DT
10_1101-2020_01_28_923532	64	5	logical	logical	JJ
10_1101-2020_01_28_923532	64	6	OR	or	CC
10_1101-2020_01_28_923532	64	7	combination	combination	NN
10_1101-2020_01_28_923532	64	8	treatment	treatment	NN
10_1101-2020_01_28_923532	64	9	can	can	MD
10_1101-2020_01_28_923532	64	10	still	still	RB
10_1101-2020_01_28_923532	64	11	achieve	achieve	VB
10_1101-2020_01_28_923532	64	12	selectivity	selectivity	NN
10_1101-2020_01_28_923532	64	13	by	by	IN
10_1101-2020_01_28_923532	64	14	choosing	choose	VBG
10_1101-2020_01_28_923532	64	15	targets	target	NNS
10_1101-2020_01_28_923532	64	16	,	,	,
10_1101-2020_01_28_923532	64	17	each	each	DT
10_1101-2020_01_28_923532	64	18	of	of	IN
10_1101-2020_01_28_923532	64	19	which	which	WDT
10_1101-2020_01_28_923532	64	20	is	be	VBZ
10_1101-2020_01_28_923532	64	21	expressed	express	VBN
10_1101-2020_01_28_923532	64	22	on	on	IN
10_1101-2020_01_28_923532	64	23	a	a	DT
10_1101-2020_01_28_923532	64	24	much	much	RB
10_1101-2020_01_28_923532	64	25	higher	high	JJR
10_1101-2020_01_28_923532	64	26	proportion	proportion	NN
10_1101-2020_01_28_923532	64	27	of	of	IN
10_1101-2020_01_28_923532	64	28	cancer	cancer	NN
10_1101-2020_01_28_923532	64	29	cells	cell	NNS
10_1101-2020_01_28_923532	64	30	than	than	IN
10_1101-2020_01_28_923532	64	31	non	non	JJ
10_1101-2020_01_28_923532	64	32	-	-	JJ
10_1101-2020_01_28_923532	64	33	cancer	cancer	JJ
10_1101-2020_01_28_923532	64	34	cells	cell	NNS
10_1101-2020_01_28_923532	64	35	.	.	.
10_1101-2020_01_28_923532	65	1	One	one	CD
10_1101-2020_01_28_923532	65	2	of	of	IN
10_1101-2020_01_28_923532	65	3	our	-PRON-	PRP$
10_1101-2020_01_28_923532	65	4	key	key	JJ
10_1101-2020_01_28_923532	65	5	contributions	contribution	NNS
10_1101-2020_01_28_923532	65	6	is	be	VBZ
10_1101-2020_01_28_923532	65	7	to	to	TO
10_1101-2020_01_28_923532	65	8	show	show	VB
10_1101-2020_01_28_923532	65	9	that	that	IN
10_1101-2020_01_28_923532	65	10	by	by	IN
10_1101-2020_01_28_923532	65	11	using	use	VBG
10_1101-2020_01_28_923532	65	12	techniques	technique	NNS
10_1101-2020_01_28_923532	65	13	from	from	IN
10_1101-2020_01_28_923532	65	14	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	65	15	optimization	optimization	NN
10_1101-2020_01_28_923532	65	16	,	,	,
10_1101-2020_01_28_923532	65	17	one	one	PRP
10_1101-2020_01_28_923532	65	18	can	can	MD
10_1101-2020_01_28_923532	65	19	find	find	VB
10_1101-2020_01_28_923532	65	20	such	such	JJ
10_1101-2020_01_28_923532	65	21	effective	effective	JJ
10_1101-2020_01_28_923532	65	22	combinations	combination	NNS
10_1101-2020_01_28_923532	65	23	involving	involve	VBG
10_1101-2020_01_28_923532	65	24	a	a	DT
10_1101-2020_01_28_923532	65	25	large	large	JJ
10_1101-2020_01_28_923532	65	26	number	number	NN
10_1101-2020_01_28_923532	65	27	of	of	IN
10_1101-2020_01_28_923532	65	28	targets	target	NNS
10_1101-2020_01_28_923532	65	29	,	,	,
10_1101-2020_01_28_923532	65	30	while	while	IN
10_1101-2020_01_28_923532	65	31	previous	previous	JJ
10_1101-2020_01_28_923532	65	32	studies	study	NNS
10_1101-2020_01_28_923532	65	33	were	be	VBD
10_1101-2020_01_28_923532	65	34	limited	limit	VBN
10_1101-2020_01_28_923532	65	35	to	to	IN
10_1101-2020_01_28_923532	65	36	at	at	RB
10_1101-2020_01_28_923532	65	37	most	most	RBS
10_1101-2020_01_28_923532	65	38	three	three	CD
10_1101-2020_01_28_923532	65	39	targets	target	NNS
10_1101-2020_01_28_923532	65	40	.	.	.
10_1101-2020_01_28_923532	66	1	Beyond	beyond	IN
10_1101-2020_01_28_923532	66	2	CAR	CAR	NNP
10_1101-2020_01_28_923532	66	3	-	-	HYPH
10_1101-2020_01_28_923532	66	4	T	T	NNP
10_1101-2020_01_28_923532	66	5	,	,	,
10_1101-2020_01_28_923532	66	6	our	-PRON-	PRP$
10_1101-2020_01_28_923532	66	7	analysis	analysis	NN
10_1101-2020_01_28_923532	66	8	applies	apply	VBZ
10_1101-2020_01_28_923532	66	9	to	to	IN
10_1101-2020_01_28_923532	66	10	several	several	JJ
10_1101-2020_01_28_923532	66	11	additional	additional	JJ
10_1101-2020_01_28_923532	66	12	types	type	NNS
10_1101-2020_01_28_923532	66	13	of	of	IN
10_1101-2020_01_28_923532	66	14	modular	modular	JJ
10_1101-2020_01_28_923532	66	15	treatment	treatment	NN
10_1101-2020_01_28_923532	66	16	technologies	technology	NNS
10_1101-2020_01_28_923532	66	17	that	that	WDT
10_1101-2020_01_28_923532	66	18	rely	rely	VBP
10_1101-2020_01_28_923532	66	19	instead	instead	RB
10_1101-2020_01_28_923532	66	20	on	on	IN
10_1101-2020_01_28_923532	66	21	receptor	receptor	NN
10_1101-2020_01_28_923532	66	22	-	-	HYPH
10_1101-2020_01_28_923532	66	23	mediated	mediate	VBN
10_1101-2020_01_28_923532	66	24	endocytosis	endocytosis	NN
10_1101-2020_01_28_923532	66	25	(	(	-LRB-
10_1101-2020_01_28_923532	66	26	RME	RME	NNP
10_1101-2020_01_28_923532	66	27	)	)	-RRB-
10_1101-2020_01_28_923532	66	28	delivering	deliver	VBG
10_1101-2020_01_28_923532	66	29	a	a	DT
10_1101-2020_01_28_923532	66	30	toxin	toxin	NN
10_1101-2020_01_28_923532	66	31	via	via	IN
10_1101-2020_01_28_923532	66	32	a	a	DT
10_1101-2020_01_28_923532	66	33	targeted	target	VBN
10_1101-2020_01_28_923532	66	34	receptor	receptor	NN
10_1101-2020_01_28_923532	66	35	to	to	TO
10_1101-2020_01_28_923532	66	36	enter	enter	VB
10_1101-2020_01_28_923532	66	37	the	the	DT
10_1101-2020_01_28_923532	66	38	cell34,35	cell34,35	NNP
10_1101-2020_01_28_923532	66	39	.	.	.
10_1101-2020_01_28_923532	67	1	Like	like	IN
10_1101-2020_01_28_923532	67	2	CAR	CAR	NNP
10_1101-2020_01_28_923532	67	3	-	-	HYPH
10_1101-2020_01_28_923532	67	4	T	T	NNP
10_1101-2020_01_28_923532	67	5	,	,	,
10_1101-2020_01_28_923532	67	6	these	these	DT
10_1101-2020_01_28_923532	67	7	RME	rme	NN
10_1101-2020_01_28_923532	67	8	-	-	HYPH
10_1101-2020_01_28_923532	67	9	based	base	VBN
10_1101-2020_01_28_923532	67	10	technologies	technology	NNS
10_1101-2020_01_28_923532	67	11	do	do	VBP
10_1101-2020_01_28_923532	67	12	not	not	RB
10_1101-2020_01_28_923532	67	13	downregulate	downregulate	VB
10_1101-2020_01_28_923532	67	14	the	the	DT
10_1101-2020_01_28_923532	67	15	target	target	NN
10_1101-2020_01_28_923532	67	16	receptor	receptor	NN
10_1101-2020_01_28_923532	67	17	.	.	.
10_1101-2020_01_28_923532	68	1	For	for	IN
10_1101-2020_01_28_923532	68	2	RME	rme	NN
10_1101-2020_01_28_923532	68	3	technologies	technology	NNS
10_1101-2020_01_28_923532	68	4	and	and	CC
10_1101-2020_01_28_923532	68	5	other	other	JJ
10_1101-2020_01_28_923532	68	6	technologies	technology	NNS
10_1101-2020_01_28_923532	68	7	that	that	WDT
10_1101-2020_01_28_923532	68	8	work	work	VBP
10_1101-2020_01_28_923532	68	9	intracellularly	intracellularly	RB
10_1101-2020_01_28_923532	68	10	,	,	,
10_1101-2020_01_28_923532	68	11	we	-PRON-	PRP
10_1101-2020_01_28_923532	68	12	anticipate	anticipate	VBP
10_1101-2020_01_28_923532	68	13	combining	combine	VBG
10_1101-2020_01_28_923532	68	14	modular	modular	JJ
10_1101-2020_01_28_923532	68	15	treatments	treatment	NNS
10_1101-2020_01_28_923532	68	16	from	from	IN
10_1101-2020_01_28_923532	68	17	one	one	CD
10_1101-2020_01_28_923532	68	18	technology	technology	NN
10_1101-2020_01_28_923532	68	19	such	such	JJ
10_1101-2020_01_28_923532	68	20	that	that	IN
10_1101-2020_01_28_923532	68	21	all	all	DT
10_1101-2020_01_28_923532	68	22	treatments	treatment	NNS
10_1101-2020_01_28_923532	68	23	use	use	VBP
10_1101-2020_01_28_923532	68	24	the	the	DT
10_1101-2020_01_28_923532	68	25	same	same	JJ
10_1101-2020_01_28_923532	68	26	toxin	toxin	NN
10_1101-2020_01_28_923532	68	27	or	or	CC
10_1101-2020_01_28_923532	68	28	mechanism	mechanism	NN
10_1101-2020_01_28_923532	68	29	of	of	IN
10_1101-2020_01_28_923532	68	30	cell	cell	NN
10_1101-2020_01_28_923532	68	31	killing	killing	NN
10_1101-2020_01_28_923532	68	32	,	,	,
10_1101-2020_01_28_923532	68	33	thereby	thereby	RB
10_1101-2020_01_28_923532	68	34	mitigating	mitigate	VBG
10_1101-2020_01_28_923532	68	35	the	the	DT
10_1101-2020_01_28_923532	68	36	need	need	NN
10_1101-2020_01_28_923532	68	37	to	to	TO
10_1101-2020_01_28_923532	68	38	test	test	VB
10_1101-2020_01_28_923532	68	39	for	for	IN
10_1101-2020_01_28_923532	68	40	interaction	interaction	NN
10_1101-2020_01_28_923532	68	41	effects	effect	NNS
10_1101-2020_01_28_923532	68	42	between	between	IN
10_1101-2020_01_28_923532	68	43	pairs	pair	NNS
10_1101-2020_01_28_923532	68	44	of	of	IN
10_1101-2020_01_28_923532	68	45	different	different	JJ
10_1101-2020_01_28_923532	68	46	treatments	treatment	NNS
10_1101-2020_01_28_923532	68	47	.	.	.
10_1101-2020_01_28_923532	69	1	To	to	TO
10_1101-2020_01_28_923532	69	2	address	address	VB
10_1101-2020_01_28_923532	69	3	these	these	DT
10_1101-2020_01_28_923532	69	4	research	research	NN
10_1101-2020_01_28_923532	69	5	questions	question	NNS
10_1101-2020_01_28_923532	69	6	,	,	,
10_1101-2020_01_28_923532	69	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	69	8	designed	design	VBD
10_1101-2020_01_28_923532	69	9	and	and	CC
10_1101-2020_01_28_923532	69	10	implemented	implement	VBD
10_1101-2020_01_28_923532	69	11	a	a	DT
10_1101-2020_01_28_923532	69	12	computational	computational	JJ
10_1101-2020_01_28_923532	69	13	approach	approach	NN
10_1101-2020_01_28_923532	69	14	named	name	VBN
10_1101-2020_01_28_923532	69	15	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	69	16	(	(	-LRB-
10_1101-2020_01_28_923532	69	17	after	after	IN
10_1101-2020_01_28_923532	69	18	the	the	DT
10_1101-2020_01_28_923532	69	19	Mad	Mad	NNP
10_1101-2020_01_28_923532	69	20	Hatter	Hatter	NNP
10_1101-2020_01_28_923532	69	21	from	from	IN
10_1101-2020_01_28_923532	69	22	Alice	Alice	NNP
10_1101-2020_01_28_923532	69	23	in	in	IN
10_1101-2020_01_28_923532	69	24	Wonderland	Wonderland	NNP
10_1101-2020_01_28_923532	69	25	)	)	-RRB-
10_1101-2020_01_28_923532	69	26	to	to	TO
10_1101-2020_01_28_923532	69	27	identify	identify	VB
10_1101-2020_01_28_923532	69	28	optimal	optimal	JJ
10_1101-2020_01_28_923532	69	29	precision	precision	NN
10_1101-2020_01_28_923532	69	30	combination	combination	NN
10_1101-2020_01_28_923532	69	31	treatments	treatment	NNS
10_1101-2020_01_28_923532	69	32	that	that	WDT
10_1101-2020_01_28_923532	69	33	target	target	VBP
10_1101-2020_01_28_923532	69	34	membrane	membrane	NN
10_1101-2020_01_28_923532	69	35	receptors	receptor	NNS
10_1101-2020_01_28_923532	69	36	(	(	-LRB-
10_1101-2020_01_28_923532	69	37	Figure	figure	NN
10_1101-2020_01_28_923532	69	38	1	1	CD
10_1101-2020_01_28_923532	69	39	,	,	,
10_1101-2020_01_28_923532	69	40	A	A	NNP
10_1101-2020_01_28_923532	69	41	-	-	HYPH
10_1101-2020_01_28_923532	69	42	C	C	NNP
10_1101-2020_01_28_923532	69	43	)	)	-RRB-
10_1101-2020_01_28_923532	69	44	.	.	.
10_1101-2020_01_28_923532	70	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	70	2	define	define	VBP
10_1101-2020_01_28_923532	70	3	three	three	CD
10_1101-2020_01_28_923532	70	4	key	key	JJ
10_1101-2020_01_28_923532	70	5	parameters	parameter	NNS
10_1101-2020_01_28_923532	70	6	related	relate	VBN
10_1101-2020_01_28_923532	70	7	to	to	IN
10_1101-2020_01_28_923532	70	8	the	the	DT
10_1101-2020_01_28_923532	70	9	stringency	stringency	NN
10_1101-2020_01_28_923532	70	10	of	of	IN
10_1101-2020_01_28_923532	70	11	killing	kill	VBG
10_1101-2020_01_28_923532	70	12	the	the	DT
10_1101-2020_01_28_923532	70	13	tumor	tumor	NN
10_1101-2020_01_28_923532	70	14	and	and	CC
10_1101-2020_01_28_923532	70	15	protecting	protect	VBG
10_1101-2020_01_28_923532	70	16	the	the	DT
10_1101-2020_01_28_923532	70	17	non	non	JJ
10_1101-2020_01_28_923532	70	18	-	-	JJ
10_1101-2020_01_28_923532	70	19	tumor	tumor	JJ
10_1101-2020_01_28_923532	70	20	cells	cell	NNS
10_1101-2020_01_28_923532	70	21	and	and	CC
10_1101-2020_01_28_923532	70	22	explore	explore	VB
10_1101-2020_01_28_923532	70	23	how	how	WRB
10_1101-2020_01_28_923532	70	24	the	the	DT
10_1101-2020_01_28_923532	70	25	optimal	optimal	JJ
10_1101-2020_01_28_923532	70	26	treatments	treatment	NNS
10_1101-2020_01_28_923532	70	27	vary	vary	VBP
10_1101-2020_01_28_923532	70	28	with	with	IN
10_1101-2020_01_28_923532	70	29	those	those	DT
10_1101-2020_01_28_923532	70	30	parameters	parameter	NNS
10_1101-2020_01_28_923532	70	31	(	(	-LRB-
10_1101-2020_01_28_923532	70	32	Figure	figure	NN
10_1101-2020_01_28_923532	70	33	1B	1b	NN
10_1101-2020_01_28_923532	70	34	,	,	,
10_1101-2020_01_28_923532	70	35	C	C	NNP
10_1101-2020_01_28_923532	70	36	)	)	-RRB-
10_1101-2020_01_28_923532	70	37	.	.	.
10_1101-2020_01_28_923532	71	1	Solving	solve	VBG
10_1101-2020_01_28_923532	71	2	this	this	DT
10_1101-2020_01_28_923532	71	3	problem	problem	NN
10_1101-2020_01_28_923532	71	4	is	be	VBZ
10_1101-2020_01_28_923532	71	5	analogous	analogous	JJ
10_1101-2020_01_28_923532	71	6	to	to	IN
10_1101-2020_01_28_923532	71	7	solving	solve	VBG
10_1101-2020_01_28_923532	71	8	the	the	DT
10_1101-2020_01_28_923532	71	9	classical	classical	JJ
10_1101-2020_01_28_923532	71	10	“	"	``
10_1101-2020_01_28_923532	71	11	hitting	hit	VBG
10_1101-2020_01_28_923532	71	12	set	set	NN
10_1101-2020_01_28_923532	71	13	problem	problem	NN
10_1101-2020_01_28_923532	71	14	”	"	''
10_1101-2020_01_28_923532	71	15	in	in	IN
10_1101-2020_01_28_923532	71	16	combinatorial	combinatorial	NN
10_1101-2020_01_28_923532	71	17	algorithms36	algorithms36	NNP
10_1101-2020_01_28_923532	71	18	,	,	,
10_1101-2020_01_28_923532	71	19	which	which	WDT
10_1101-2020_01_28_923532	71	20	is	be	VBZ
10_1101-2020_01_28_923532	71	21	formally	formally	RB
10_1101-2020_01_28_923532	71	22	defined	define	VBN
10_1101-2020_01_28_923532	71	23	in	in	IN
10_1101-2020_01_28_923532	71	24	the	the	DT
10_1101-2020_01_28_923532	71	25	Methods	Methods	NNPS
10_1101-2020_01_28_923532	71	26	(	(	-LRB-
10_1101-2020_01_28_923532	71	27	see	see	VB
10_1101-2020_01_28_923532	71	28	also	also	RB
10_1101-2020_01_28_923532	71	29	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	71	30	Materials	material	NNS
10_1101-2020_01_28_923532	71	31	1	1	CD
10_1101-2020_01_28_923532	71	32	)	)	-RRB-
10_1101-2020_01_28_923532	71	33	.	.	.
10_1101-2020_01_28_923532	72	1	Unlike	unlike	IN
10_1101-2020_01_28_923532	72	2	the	the	DT
10_1101-2020_01_28_923532	72	3	previous	previous	JJ
10_1101-2020_01_28_923532	72	4	studies	study	NNS
10_1101-2020_01_28_923532	72	5	on	on	IN
10_1101-2020_01_28_923532	72	6	CAR	CAR	NNP
10_1101-2020_01_28_923532	72	7	-	-	HYPH
10_1101-2020_01_28_923532	72	8	T	t	NN
10_1101-2020_01_28_923532	72	9	targets	target	NNS
10_1101-2020_01_28_923532	72	10	,	,	,
10_1101-2020_01_28_923532	72	11	we	-PRON-	PRP
10_1101-2020_01_28_923532	72	12	define	define	VBP
10_1101-2020_01_28_923532	72	13	the	the	DT
10_1101-2020_01_28_923532	72	14	problem	problem	NN
10_1101-2020_01_28_923532	72	15	in	in	IN
10_1101-2020_01_28_923532	72	16	a	a	DT
10_1101-2020_01_28_923532	72	17	personalized	personalized	JJ
10_1101-2020_01_28_923532	72	18	manner	manner	NN
10_1101-2020_01_28_923532	72	19	,	,	,
10_1101-2020_01_28_923532	72	20	intending	intend	VBG
10_1101-2020_01_28_923532	72	21	that	that	IN
10_1101-2020_01_28_923532	72	22	each	each	DT
10_1101-2020_01_28_923532	72	23	patient	patient	NN
10_1101-2020_01_28_923532	72	24	will	will	MD
10_1101-2020_01_28_923532	72	25	get	get	VB
10_1101-2020_01_28_923532	72	26	optimal	optimal	JJ
10_1101-2020_01_28_923532	72	27	treatments	treatment	NNS
10_1101-2020_01_28_923532	72	28	for	for	IN
10_1101-2020_01_28_923532	72	29	her	-PRON-	PRP
10_1101-2020_01_28_923532	72	30	or	or	CC
10_1101-2020_01_28_923532	72	31	his	-PRON-	PRP$
10_1101-2020_01_28_923532	72	32	tumor	tumor	NN
10_1101-2020_01_28_923532	72	33	from	from	IN
10_1101-2020_01_28_923532	72	34	among	among	IN
10_1101-2020_01_28_923532	72	35	a	a	DT
10_1101-2020_01_28_923532	72	36	collection	collection	NN
10_1101-2020_01_28_923532	72	37	of	of	IN
10_1101-2020_01_28_923532	72	38	available	available	JJ
10_1101-2020_01_28_923532	72	39	treatments	treatment	NNS
10_1101-2020_01_28_923532	72	40	.	.	.
10_1101-2020_01_28_923532	73	1	105	105	CD
10_1101-2020_01_28_923532	73	2	and	and	CC
10_1101-2020_01_28_923532	73	3	is	be	VBZ
10_1101-2020_01_28_923532	73	4	also	also	RB
10_1101-2020_01_28_923532	73	5	made	make	VBN
10_1101-2020_01_28_923532	73	6	available	available	JJ
10_1101-2020_01_28_923532	73	7	for	for	IN
10_1101-2020_01_28_923532	73	8	use	use	NN
10_1101-2020_01_28_923532	73	9	under	under	IN
10_1101-2020_01_28_923532	73	10	a	a	DT
10_1101-2020_01_28_923532	73	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	73	12	license	license	NN
10_1101-2020_01_28_923532	73	13	.	.	.
10_1101-2020_01_28_923532	74	1	(	(	-LRB-
10_1101-2020_01_28_923532	74	2	which	which	WDT
10_1101-2020_01_28_923532	74	3	was	be	VBD
10_1101-2020_01_28_923532	74	4	not	not	RB
10_1101-2020_01_28_923532	74	5	certified	certify	VBN
10_1101-2020_01_28_923532	74	6	by	by	IN
10_1101-2020_01_28_923532	74	7	peer	peer	NN
10_1101-2020_01_28_923532	74	8	review	review	NN
10_1101-2020_01_28_923532	74	9	)	)	-RRB-
10_1101-2020_01_28_923532	74	10	is	be	VBZ
10_1101-2020_01_28_923532	74	11	the	the	DT
10_1101-2020_01_28_923532	74	12	author	author	NN
10_1101-2020_01_28_923532	74	13	/	/	SYM
10_1101-2020_01_28_923532	74	14	funder	funder	NN
10_1101-2020_01_28_923532	74	15	.	.	.
10_1101-2020_01_28_923532	75	1	This	this	DT
10_1101-2020_01_28_923532	75	2	article	article	NN
10_1101-2020_01_28_923532	75	3	is	be	VBZ
10_1101-2020_01_28_923532	75	4	a	a	DT
10_1101-2020_01_28_923532	75	5	US	US	NNP
10_1101-2020_01_28_923532	75	6	Government	Government	NNP
10_1101-2020_01_28_923532	75	7	work	work	NN
10_1101-2020_01_28_923532	75	8	.	.	.
10_1101-2020_01_28_923532	76	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	76	2	is	be	VBZ
10_1101-2020_01_28_923532	76	3	not	not	RB
10_1101-2020_01_28_923532	76	4	subject	subject	JJ
10_1101-2020_01_28_923532	76	5	to	to	IN
10_1101-2020_01_28_923532	76	6	copyright	copyright	NN
10_1101-2020_01_28_923532	76	7	under	under	IN
10_1101-2020_01_28_923532	76	8	17	17	CD
10_1101-2020_01_28_923532	76	9	USC	usc	NN
10_1101-2020_01_28_923532	76	10	The	the	DT
10_1101-2020_01_28_923532	76	11	copyright	copyright	NN
10_1101-2020_01_28_923532	76	12	holder	holder	NN
10_1101-2020_01_28_923532	76	13	for	for	IN
10_1101-2020_01_28_923532	76	14	this	this	DT
10_1101-2020_01_28_923532	76	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	76	16	version	version	NN
10_1101-2020_01_28_923532	76	17	posted	post	VBD
10_1101-2020_01_28_923532	76	18	February	February	NNP
10_1101-2020_01_28_923532	76	19	12	12	CD
10_1101-2020_01_28_923532	76	20	,	,	,
10_1101-2020_01_28_923532	76	21	2021	2021	CD
10_1101-2020_01_28_923532	76	22	.	.	.
10_1101-2020_01_28_923532	76	23	;	;	:
10_1101-2020_01_28_923532	76	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	76	25	:	:	:
10_1101-2020_01_28_923532	76	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	76	27	preprint	preprint	NN
10_1101-2020_01_28_923532	76	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	76	29	7	7	CD
10_1101-2020_01_28_923532	76	30	Figure	figure	NN
10_1101-2020_01_28_923532	76	31	1	1	CD
10_1101-2020_01_28_923532	76	32	.	.	.
10_1101-2020_01_28_923532	77	1	Conceptual	conceptual	JJ
10_1101-2020_01_28_923532	77	2	schematic	schematic	JJ
10_1101-2020_01_28_923532	77	3	example	example	NN
10_1101-2020_01_28_923532	77	4	of	of	IN
10_1101-2020_01_28_923532	77	5	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	77	6	analysis	analysis	NN
10_1101-2020_01_28_923532	77	7	of	of	IN
10_1101-2020_01_28_923532	77	8	single	single	JJ
10_1101-2020_01_28_923532	77	9	-	-	HYPH
10_1101-2020_01_28_923532	77	10	cell	cell	NN
10_1101-2020_01_28_923532	77	11	data	datum	NNS
10_1101-2020_01_28_923532	77	12	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	77	13	from	from	IN
10_1101-2020_01_28_923532	77	14	three	three	CD
10_1101-2020_01_28_923532	77	15	cancer	cancer	NN
10_1101-2020_01_28_923532	77	16	patients	patient	NNS
10_1101-2020_01_28_923532	77	17	.	.	.
10_1101-2020_01_28_923532	78	1	(	(	-LRB-
10_1101-2020_01_28_923532	78	2	A	a	NN
10_1101-2020_01_28_923532	78	3	)	)	-RRB-
10_1101-2020_01_28_923532	78	4	A	a	DT
10_1101-2020_01_28_923532	78	5	cohort	cohort	NN
10_1101-2020_01_28_923532	78	6	of	of	IN
10_1101-2020_01_28_923532	78	7	patients	patient	NNS
10_1101-2020_01_28_923532	78	8	(	(	-LRB-
10_1101-2020_01_28_923532	78	9	three	three	CD
10_1101-2020_01_28_923532	78	10	in	in	IN
10_1101-2020_01_28_923532	78	11	this	this	DT
10_1101-2020_01_28_923532	78	12	example	example	NN
10_1101-2020_01_28_923532	78	13	)	)	-RRB-
10_1101-2020_01_28_923532	78	14	arrives	arrive	VBZ
10_1101-2020_01_28_923532	78	15	for	for	IN
10_1101-2020_01_28_923532	78	16	a	a	DT
10_1101-2020_01_28_923532	78	17	study	study	NN
10_1101-2020_01_28_923532	78	18	in	in	IN
10_1101-2020_01_28_923532	78	19	which	which	WDT
10_1101-2020_01_28_923532	78	20	single	single	JJ
10_1101-2020_01_28_923532	78	21	-	-	HYPH
10_1101-2020_01_28_923532	78	22	cell	cell	NN
10_1101-2020_01_28_923532	78	23	tumor	tumor	NN
10_1101-2020_01_28_923532	78	24	microenvironment	microenvironment	NN
10_1101-2020_01_28_923532	78	25	(	(	-LRB-
10_1101-2020_01_28_923532	78	26	TME	TME	NNP
10_1101-2020_01_28_923532	78	27	)	)	-RRB-
10_1101-2020_01_28_923532	78	28	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	78	29	data	datum	NNS
10_1101-2020_01_28_923532	78	30	are	be	VBP
10_1101-2020_01_28_923532	78	31	collected	collect	VBN
10_1101-2020_01_28_923532	78	32	from	from	IN
10_1101-2020_01_28_923532	78	33	each	each	DT
10_1101-2020_01_28_923532	78	34	patient	patient	NN
10_1101-2020_01_28_923532	78	35	;	;	:
10_1101-2020_01_28_923532	78	36	the	the	DT
10_1101-2020_01_28_923532	78	37	data	datum	NNS
10_1101-2020_01_28_923532	78	38	are	be	VBP
10_1101-2020_01_28_923532	78	39	analyzed	analyze	VBN
10_1101-2020_01_28_923532	78	40	with	with	IN
10_1101-2020_01_28_923532	78	41	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	78	42	and	and	CC
10_1101-2020_01_28_923532	78	43	each	each	DT
10_1101-2020_01_28_923532	78	44	patient	patient	NN
10_1101-2020_01_28_923532	78	45	receives	receive	VBZ
10_1101-2020_01_28_923532	78	46	an	an	DT
10_1101-2020_01_28_923532	78	47	optimal	optimal	JJ
10_1101-2020_01_28_923532	78	48	personalized	personalize	VBN
10_1101-2020_01_28_923532	78	49	combination	combination	NN
10_1101-2020_01_28_923532	78	50	of	of	IN
10_1101-2020_01_28_923532	78	51	targeted	target	VBN
10_1101-2020_01_28_923532	78	52	therapies	therapy	NNS
10_1101-2020_01_28_923532	78	53	from	from	IN
10_1101-2020_01_28_923532	78	54	a	a	DT
10_1101-2020_01_28_923532	78	55	pre-	pre-	RB
10_1101-2020_01_28_923532	78	56	specified	specify	VBN
10_1101-2020_01_28_923532	78	57	set	set	NN
10_1101-2020_01_28_923532	78	58	(	(	-LRB-
10_1101-2020_01_28_923532	78	59	pill	pill	NNP
10_1101-2020_01_28_923532	78	60	bottle	bottle	NNP
10_1101-2020_01_28_923532	78	61	)	)	-RRB-
10_1101-2020_01_28_923532	78	62	.	.	.
10_1101-2020_01_28_923532	79	1	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	79	2	is	be	VBZ
10_1101-2020_01_28_923532	79	3	aimed	aim	VBN
10_1101-2020_01_28_923532	79	4	at	at	IN
10_1101-2020_01_28_923532	79	5	optimizing	optimize	VBG
10_1101-2020_01_28_923532	79	6	combinations	combination	NNS
10_1101-2020_01_28_923532	79	7	of	of	IN
10_1101-2020_01_28_923532	79	8	targeted	target	VBN
10_1101-2020_01_28_923532	79	9	therapies	therapy	NNS
10_1101-2020_01_28_923532	79	10	that	that	WDT
10_1101-2020_01_28_923532	79	11	are	be	VBP
10_1101-2020_01_28_923532	79	12	modular	modular	JJ
10_1101-2020_01_28_923532	79	13	,	,	,
10_1101-2020_01_28_923532	79	14	that	that	RB
10_1101-2020_01_28_923532	79	15	is	is	RB
10_1101-2020_01_28_923532	79	16	,	,	,
10_1101-2020_01_28_923532	79	17	having	have	VBG
10_1101-2020_01_28_923532	79	18	a	a	DT
10_1101-2020_01_28_923532	79	19	recognition	recognition	NN
10_1101-2020_01_28_923532	79	20	unit	unit	NN
10_1101-2020_01_28_923532	79	21	that	that	WDT
10_1101-2020_01_28_923532	79	22	is	be	VBZ
10_1101-2020_01_28_923532	79	23	gene	gene	NN
10_1101-2020_01_28_923532	79	24	/	/	SYM
10_1101-2020_01_28_923532	79	25	protein	protein	NN
10_1101-2020_01_28_923532	79	26	-	-	HYPH
10_1101-2020_01_28_923532	79	27	specific	specific	JJ
10_1101-2020_01_28_923532	79	28	,	,	,
10_1101-2020_01_28_923532	79	29	and	and	CC
10_1101-2020_01_28_923532	79	30	a	a	DT
10_1101-2020_01_28_923532	79	31	joint	joint	JJ
10_1101-2020_01_28_923532	79	32	killing	killing	NN
10_1101-2020_01_28_923532	79	33	subunit	subunit	NN
10_1101-2020_01_28_923532	79	34	(	(	-LRB-
10_1101-2020_01_28_923532	79	35	similar	similar	JJ
10_1101-2020_01_28_923532	79	36	for	for	IN
10_1101-2020_01_28_923532	79	37	all	all	DT
10_1101-2020_01_28_923532	79	38	gene	gene	NN
10_1101-2020_01_28_923532	79	39	targets	target	NNS
10_1101-2020_01_28_923532	79	40	)	)	-RRB-
10_1101-2020_01_28_923532	79	41	.	.	.
10_1101-2020_01_28_923532	80	1	Icons	icon	NNS
10_1101-2020_01_28_923532	80	2	of	of	IN
10_1101-2020_01_28_923532	80	3	four	four	CD
10_1101-2020_01_28_923532	80	4	such	such	JJ
10_1101-2020_01_28_923532	80	5	modular	modular	JJ
10_1101-2020_01_28_923532	80	6	therapies	therapy	NNS
10_1101-2020_01_28_923532	80	7	are	be	VBP
10_1101-2020_01_28_923532	80	8	shown	show	VBN
10_1101-2020_01_28_923532	80	9	;	;	:
10_1101-2020_01_28_923532	80	10	for	for	IN
10_1101-2020_01_28_923532	80	11	three	three	CD
10_1101-2020_01_28_923532	80	12	of	of	IN
10_1101-2020_01_28_923532	80	13	these	these	DT
10_1101-2020_01_28_923532	80	14	,	,	,
10_1101-2020_01_28_923532	80	15	the	the	DT
10_1101-2020_01_28_923532	80	16	target	target	NN
10_1101-2020_01_28_923532	80	17	protein	protein	NN
10_1101-2020_01_28_923532	80	18	must	must	MD
10_1101-2020_01_28_923532	80	19	be	be	VB
10_1101-2020_01_28_923532	80	20	on	on	IN
10_1101-2020_01_28_923532	80	21	the	the	DT
10_1101-2020_01_28_923532	80	22	cell	cell	NN
10_1101-2020_01_28_923532	80	23	surface	surface	NN
10_1101-2020_01_28_923532	80	24	and	and	CC
10_1101-2020_01_28_923532	80	25	for	for	IN
10_1101-2020_01_28_923532	80	26	two	two	CD
10_1101-2020_01_28_923532	80	27	it	-PRON-	PRP
10_1101-2020_01_28_923532	80	28	must	must	MD
10_1101-2020_01_28_923532	80	29	be	be	VB
10_1101-2020_01_28_923532	80	30	a	a	DT
10_1101-2020_01_28_923532	80	31	receptor	receptor	NN
10_1101-2020_01_28_923532	80	32	,	,	,
10_1101-2020_01_28_923532	80	33	so	so	CC
10_1101-2020_01_28_923532	80	34	we	-PRON-	PRP
10_1101-2020_01_28_923532	80	35	focus	focus	VBP
10_1101-2020_01_28_923532	80	36	our	-PRON-	PRP$
10_1101-2020_01_28_923532	80	37	analyses	analysis	NNS
10_1101-2020_01_28_923532	80	38	on	on	IN
10_1101-2020_01_28_923532	80	39	cell	cell	NN
10_1101-2020_01_28_923532	80	40	surface	surface	NN
10_1101-2020_01_28_923532	80	41	receptors	receptor	NNS
10_1101-2020_01_28_923532	80	42	.	.	.
10_1101-2020_01_28_923532	81	1	Three	three	CD
10_1101-2020_01_28_923532	81	2	main	main	JJ
10_1101-2020_01_28_923532	81	3	algorithm	algorithm	NN
10_1101-2020_01_28_923532	81	4	parameters	parameter	NNS
10_1101-2020_01_28_923532	81	5	are	be	VBP
10_1101-2020_01_28_923532	81	6	denoted	denote	VBN
10_1101-2020_01_28_923532	81	7	near	near	IN
10_1101-2020_01_28_923532	81	8	the	the	DT
10_1101-2020_01_28_923532	81	9	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	81	10	icon	icon	NN
10_1101-2020_01_28_923532	81	11	in	in	IN
10_1101-2020_01_28_923532	81	12	panel	panel	NN
10_1101-2020_01_28_923532	81	13	A	A	NNP
10_1101-2020_01_28_923532	81	14	and	and	CC
10_1101-2020_01_28_923532	81	15	explained	explain	VBD
10_1101-2020_01_28_923532	81	16	in	in	IN
10_1101-2020_01_28_923532	81	17	the	the	DT
10_1101-2020_01_28_923532	81	18	later	later	JJ
10_1101-2020_01_28_923532	81	19	panels	panel	NNS
10_1101-2020_01_28_923532	81	20	.	.	.
10_1101-2020_01_28_923532	82	1	(	(	-LRB-
10_1101-2020_01_28_923532	82	2	B	b	NN
10_1101-2020_01_28_923532	82	3	)	)	-RRB-
10_1101-2020_01_28_923532	82	4	The	the	DT
10_1101-2020_01_28_923532	82	5	105	105	CD
10_1101-2020_01_28_923532	82	6	and	and	CC
10_1101-2020_01_28_923532	82	7	is	be	VBZ
10_1101-2020_01_28_923532	82	8	also	also	RB
10_1101-2020_01_28_923532	82	9	made	make	VBN
10_1101-2020_01_28_923532	82	10	available	available	JJ
10_1101-2020_01_28_923532	82	11	for	for	IN
10_1101-2020_01_28_923532	82	12	use	use	NN
10_1101-2020_01_28_923532	82	13	under	under	IN
10_1101-2020_01_28_923532	82	14	a	a	DT
10_1101-2020_01_28_923532	82	15	CC0	CC0	NNP
10_1101-2020_01_28_923532	82	16	license	license	NN
10_1101-2020_01_28_923532	82	17	.	.	.
10_1101-2020_01_28_923532	83	1	(	(	-LRB-
10_1101-2020_01_28_923532	83	2	which	which	WDT
10_1101-2020_01_28_923532	83	3	was	be	VBD
10_1101-2020_01_28_923532	83	4	not	not	RB
10_1101-2020_01_28_923532	83	5	certified	certify	VBN
10_1101-2020_01_28_923532	83	6	by	by	IN
10_1101-2020_01_28_923532	83	7	peer	peer	NN
10_1101-2020_01_28_923532	83	8	review	review	NN
10_1101-2020_01_28_923532	83	9	)	)	-RRB-
10_1101-2020_01_28_923532	83	10	is	be	VBZ
10_1101-2020_01_28_923532	83	11	the	the	DT
10_1101-2020_01_28_923532	83	12	author	author	NN
10_1101-2020_01_28_923532	83	13	/	/	SYM
10_1101-2020_01_28_923532	83	14	funder	funder	NN
10_1101-2020_01_28_923532	83	15	.	.	.
10_1101-2020_01_28_923532	84	1	This	this	DT
10_1101-2020_01_28_923532	84	2	article	article	NN
10_1101-2020_01_28_923532	84	3	is	be	VBZ
10_1101-2020_01_28_923532	84	4	a	a	DT
10_1101-2020_01_28_923532	84	5	US	US	NNP
10_1101-2020_01_28_923532	84	6	Government	Government	NNP
10_1101-2020_01_28_923532	84	7	work	work	NN
10_1101-2020_01_28_923532	84	8	.	.	.
10_1101-2020_01_28_923532	85	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	85	2	is	be	VBZ
10_1101-2020_01_28_923532	85	3	not	not	RB
10_1101-2020_01_28_923532	85	4	subject	subject	JJ
10_1101-2020_01_28_923532	85	5	to	to	IN
10_1101-2020_01_28_923532	85	6	copyright	copyright	NN
10_1101-2020_01_28_923532	85	7	under	under	IN
10_1101-2020_01_28_923532	85	8	17	17	CD
10_1101-2020_01_28_923532	85	9	USC	usc	NN
10_1101-2020_01_28_923532	85	10	The	the	DT
10_1101-2020_01_28_923532	85	11	copyright	copyright	NN
10_1101-2020_01_28_923532	85	12	holder	holder	NN
10_1101-2020_01_28_923532	85	13	for	for	IN
10_1101-2020_01_28_923532	85	14	this	this	DT
10_1101-2020_01_28_923532	85	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	85	16	version	version	NN
10_1101-2020_01_28_923532	85	17	posted	post	VBD
10_1101-2020_01_28_923532	85	18	February	February	NNP
10_1101-2020_01_28_923532	85	19	12	12	CD
10_1101-2020_01_28_923532	85	20	,	,	,
10_1101-2020_01_28_923532	85	21	2021	2021	CD
10_1101-2020_01_28_923532	85	22	.	.	.
10_1101-2020_01_28_923532	85	23	;	;	:
10_1101-2020_01_28_923532	85	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	85	25	:	:	:
10_1101-2020_01_28_923532	85	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	85	27	preprint	preprint	NN
10_1101-2020_01_28_923532	85	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	85	29	8	8	CD
10_1101-2020_01_28_923532	85	30	single	single	JJ
10_1101-2020_01_28_923532	85	31	-	-	HYPH
10_1101-2020_01_28_923532	85	32	cell	cell	NN
10_1101-2020_01_28_923532	85	33	TME	TME	NNP
10_1101-2020_01_28_923532	85	34	data	datum	NNS
10_1101-2020_01_28_923532	85	35	are	be	VBP
10_1101-2020_01_28_923532	85	36	represented	represent	VBN
10_1101-2020_01_28_923532	85	37	in	in	IN
10_1101-2020_01_28_923532	85	38	two	two	CD
10_1101-2020_01_28_923532	85	39	matrices	matrix	NNS
10_1101-2020_01_28_923532	85	40	with	with	IN
10_1101-2020_01_28_923532	85	41	the	the	DT
10_1101-2020_01_28_923532	85	42	genes	gene	NNS
10_1101-2020_01_28_923532	85	43	as	as	IN
10_1101-2020_01_28_923532	85	44	rows	row	NNS
10_1101-2020_01_28_923532	85	45	and	and	CC
10_1101-2020_01_28_923532	85	46	cells	cell	NNS
10_1101-2020_01_28_923532	85	47	as	as	IN
10_1101-2020_01_28_923532	85	48	columns	column	NNS
10_1101-2020_01_28_923532	85	49	,	,	,
10_1101-2020_01_28_923532	85	50	partitioned	partition	VBN
10_1101-2020_01_28_923532	85	51	into	into	IN
10_1101-2020_01_28_923532	85	52	tumor	tumor	NN
10_1101-2020_01_28_923532	85	53	(	(	-LRB-
10_1101-2020_01_28_923532	85	54	T	t	NN
10_1101-2020_01_28_923532	85	55	)	)	-RRB-
10_1101-2020_01_28_923532	85	56	and	and	CC
10_1101-2020_01_28_923532	85	57	non	non	JJ
10_1101-2020_01_28_923532	85	58	-	-	JJ
10_1101-2020_01_28_923532	85	59	tumor	tumor	JJ
10_1101-2020_01_28_923532	85	60	(	(	-LRB-
10_1101-2020_01_28_923532	85	61	N	n	NN
10_1101-2020_01_28_923532	85	62	)	)	-RRB-
10_1101-2020_01_28_923532	85	63	cells	cell	NNS
10_1101-2020_01_28_923532	85	64	.	.	.
10_1101-2020_01_28_923532	86	1	The	the	DT
10_1101-2020_01_28_923532	86	2	expression	expression	NN
10_1101-2020_01_28_923532	86	3	ratio	ratio	NN
10_1101-2020_01_28_923532	86	4	r	r	NN
10_1101-2020_01_28_923532	86	5	determines	determine	VBZ
10_1101-2020_01_28_923532	86	6	by	by	IN
10_1101-2020_01_28_923532	86	7	how	how	WRB
10_1101-2020_01_28_923532	86	8	much	much	JJ
10_1101-2020_01_28_923532	86	9	a	a	DT
10_1101-2020_01_28_923532	86	10	gene	gene	NN
10_1101-2020_01_28_923532	86	11	must	must	MD
10_1101-2020_01_28_923532	86	12	be	be	VB
10_1101-2020_01_28_923532	86	13	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	86	14	for	for	IN
10_1101-2020_01_28_923532	86	15	a	a	DT
10_1101-2020_01_28_923532	86	16	cell	cell	NN
10_1101-2020_01_28_923532	86	17	to	to	TO
10_1101-2020_01_28_923532	86	18	be	be	VB
10_1101-2020_01_28_923532	86	19	considered	consider	VBN
10_1101-2020_01_28_923532	86	20	as	as	IN
10_1101-2020_01_28_923532	86	21	a	a	DT
10_1101-2020_01_28_923532	86	22	targeted	target	VBN
10_1101-2020_01_28_923532	86	23	.	.	.
10_1101-2020_01_28_923532	87	1	A	a	DT
10_1101-2020_01_28_923532	87	2	gene	gene	NN
10_1101-2020_01_28_923532	87	3	is	be	VBZ
10_1101-2020_01_28_923532	87	4	considered	consider	VBN
10_1101-2020_01_28_923532	87	5	‘	'	``
10_1101-2020_01_28_923532	87	6	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	87	7	’	'	''
10_1101-2020_01_28_923532	87	8	in	in	IN
10_1101-2020_01_28_923532	87	9	either	either	CC
10_1101-2020_01_28_923532	87	10	a	a	DT
10_1101-2020_01_28_923532	87	11	non-	non-	NN
10_1101-2020_01_28_923532	87	12	tumor	tumor	NN
10_1101-2020_01_28_923532	87	13	cell	cell	NN
10_1101-2020_01_28_923532	87	14	or	or	CC
10_1101-2020_01_28_923532	87	15	a	a	DT
10_1101-2020_01_28_923532	87	16	tumor	tumor	NN
10_1101-2020_01_28_923532	87	17	cell	cell	NN
10_1101-2020_01_28_923532	87	18	if	if	IN
10_1101-2020_01_28_923532	87	19	its	-PRON-	PRP$
10_1101-2020_01_28_923532	87	20	expression	expression	NN
10_1101-2020_01_28_923532	87	21	is	be	VBZ
10_1101-2020_01_28_923532	87	22	at	at	IN
10_1101-2020_01_28_923532	87	23	least	least	JJS
10_1101-2020_01_28_923532	87	24	r	r	NN
10_1101-2020_01_28_923532	87	25	times	time	NNS
10_1101-2020_01_28_923532	87	26	the	the	DT
10_1101-2020_01_28_923532	87	27	mean	mean	NN
10_1101-2020_01_28_923532	87	28	,	,	,
10_1101-2020_01_28_923532	87	29	reference	reference	NN
10_1101-2020_01_28_923532	87	30	level	level	NN
10_1101-2020_01_28_923532	87	31	;	;	:
10_1101-2020_01_28_923532	87	32	e.g	e.g	NNP
10_1101-2020_01_28_923532	87	33	,	,	,
10_1101-2020_01_28_923532	87	34	the	the	DT
10_1101-2020_01_28_923532	87	35	reference	reference	NN
10_1101-2020_01_28_923532	87	36	level	level	NN
10_1101-2020_01_28_923532	87	37	for	for	IN
10_1101-2020_01_28_923532	87	38	FLT1	FLT1	NNP
10_1101-2020_01_28_923532	87	39	is	be	VBZ
10_1101-2020_01_28_923532	87	40	(	(	-LRB-
10_1101-2020_01_28_923532	87	41	7	7	CD
10_1101-2020_01_28_923532	87	42	+	+	SYM
10_1101-2020_01_28_923532	87	43	11	11	CD
10_1101-2020_01_28_923532	87	44	+	+	SYM
10_1101-2020_01_28_923532	87	45	9)/3	9)/3	CD
10_1101-2020_01_28_923532	87	46	=	=	SYM
10_1101-2020_01_28_923532	87	47	9	9	CD
10_1101-2020_01_28_923532	87	48	and	and	CC
10_1101-2020_01_28_923532	87	49	only	only	JJ
10_1101-2020_01_28_923532	87	50	cell	cell	NN
10_1101-2020_01_28_923532	87	51	T3	t3	NN
10_1101-2020_01_28_923532	87	52	has	have	VBZ
10_1101-2020_01_28_923532	87	53	FLT1	FLT1	NNP
10_1101-2020_01_28_923532	87	54	expression	expression	NN
10_1101-2020_01_28_923532	87	55	above	above	IN
10_1101-2020_01_28_923532	87	56	9×2	9×2	CD
10_1101-2020_01_28_923532	87	57	=	=	SYM
10_1101-2020_01_28_923532	87	58	18	18	CD
10_1101-2020_01_28_923532	87	59	.	.	.
10_1101-2020_01_28_923532	88	1	The	the	DT
10_1101-2020_01_28_923532	88	2	matrices	matrix	NNS
10_1101-2020_01_28_923532	88	3	on	on	IN
10_1101-2020_01_28_923532	88	4	the	the	DT
10_1101-2020_01_28_923532	88	5	right	right	JJ
10_1101-2020_01_28_923532	88	6	side	side	NN
10_1101-2020_01_28_923532	88	7	show	show	VBP
10_1101-2020_01_28_923532	88	8	a	a	DT
10_1101-2020_01_28_923532	88	9	Boolean	boolean	JJ
10_1101-2020_01_28_923532	88	10	representation	representation	NN
10_1101-2020_01_28_923532	88	11	of	of	IN
10_1101-2020_01_28_923532	88	12	which	which	WDT
10_1101-2020_01_28_923532	88	13	targets	target	NNS
10_1101-2020_01_28_923532	88	14	kill	kill	VB
10_1101-2020_01_28_923532	88	15	which	which	WDT
10_1101-2020_01_28_923532	88	16	cells	cell	NNS
10_1101-2020_01_28_923532	88	17	,	,	,
10_1101-2020_01_28_923532	88	18	based	base	VBN
10_1101-2020_01_28_923532	88	19	on	on	IN
10_1101-2020_01_28_923532	88	20	the	the	DT
10_1101-2020_01_28_923532	88	21	expression	expression	NN
10_1101-2020_01_28_923532	88	22	values	value	NNS
10_1101-2020_01_28_923532	88	23	presented	present	VBN
10_1101-2020_01_28_923532	88	24	in	in	IN
10_1101-2020_01_28_923532	88	25	this	this	DT
10_1101-2020_01_28_923532	88	26	toy	toy	NN
10_1101-2020_01_28_923532	88	27	problem	problem	NN
10_1101-2020_01_28_923532	88	28	in	in	IN
10_1101-2020_01_28_923532	88	29	matrix	matrix	NN
10_1101-2020_01_28_923532	88	30	B	b	NN
10_1101-2020_01_28_923532	88	31	and	and	CC
10_1101-2020_01_28_923532	88	32	taking	take	VBG
10_1101-2020_01_28_923532	88	33	r=2	r=2	NN
10_1101-2020_01_28_923532	88	34	.	.	.
10_1101-2020_01_28_923532	89	1	Accordingly	accordingly	RB
10_1101-2020_01_28_923532	89	2	,	,	,
10_1101-2020_01_28_923532	89	3	the	the	DT
10_1101-2020_01_28_923532	89	4	combination	combination	NN
10_1101-2020_01_28_923532	89	5	of	of	IN
10_1101-2020_01_28_923532	89	6	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	89	7	and	and	CC
10_1101-2020_01_28_923532	89	8	KDR	KDR	NNP
10_1101-2020_01_28_923532	89	9	would	would	MD
10_1101-2020_01_28_923532	89	10	kill	kill	VB
10_1101-2020_01_28_923532	89	11	all	all	DT
10_1101-2020_01_28_923532	89	12	tumor	tumor	NN
10_1101-2020_01_28_923532	89	13	cells	cell	NNS
10_1101-2020_01_28_923532	89	14	and	and	CC
10_1101-2020_01_28_923532	89	15	would	would	MD
10_1101-2020_01_28_923532	89	16	spare	spare	VB
10_1101-2020_01_28_923532	89	17	all	all	DT
10_1101-2020_01_28_923532	89	18	non	non	JJ
10_1101-2020_01_28_923532	89	19	-	-	JJ
10_1101-2020_01_28_923532	89	20	tumor	tumor	JJ
10_1101-2020_01_28_923532	89	21	cells	cell	NNS
10_1101-2020_01_28_923532	89	22	.	.	.
10_1101-2020_01_28_923532	90	1	(	(	-LRB-
10_1101-2020_01_28_923532	90	2	C	C	NNP
10_1101-2020_01_28_923532	90	3	)	)	-RRB-
10_1101-2020_01_28_923532	90	4	The	the	DT
10_1101-2020_01_28_923532	90	5	main	main	JJ
10_1101-2020_01_28_923532	90	6	algorithm	algorithm	NN
10_1101-2020_01_28_923532	90	7	in	in	IN
10_1101-2020_01_28_923532	90	8	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	90	9	seeks	seek	VBZ
10_1101-2020_01_28_923532	90	10	a	a	DT
10_1101-2020_01_28_923532	90	11	combination	combination	NN
10_1101-2020_01_28_923532	90	12	of	of	IN
10_1101-2020_01_28_923532	90	13	targets	target	NNS
10_1101-2020_01_28_923532	90	14	that	that	WDT
10_1101-2020_01_28_923532	90	15	is	be	VBZ
10_1101-2020_01_28_923532	90	16	as	as	RB
10_1101-2020_01_28_923532	90	17	small	small	JJ
10_1101-2020_01_28_923532	90	18	as	as	IN
10_1101-2020_01_28_923532	90	19	possible	possible	JJ
10_1101-2020_01_28_923532	90	20	and	and	CC
10_1101-2020_01_28_923532	90	21	would	would	MD
10_1101-2020_01_28_923532	90	22	kill	kill	VB
10_1101-2020_01_28_923532	90	23	many	many	JJ
10_1101-2020_01_28_923532	90	24	tumor	tumor	NN
10_1101-2020_01_28_923532	90	25	cells	cell	NNS
10_1101-2020_01_28_923532	90	26	and	and	CC
10_1101-2020_01_28_923532	90	27	few	few	JJ
10_1101-2020_01_28_923532	90	28	non	non	JJ
10_1101-2020_01_28_923532	90	29	-	-	JJ
10_1101-2020_01_28_923532	90	30	tumor	tumor	JJ
10_1101-2020_01_28_923532	90	31	cells	cell	NNS
10_1101-2020_01_28_923532	90	32	,	,	,
10_1101-2020_01_28_923532	90	33	in	in	IN
10_1101-2020_01_28_923532	90	34	a	a	DT
10_1101-2020_01_28_923532	90	35	patient-	patient-	JJ
10_1101-2020_01_28_923532	90	36	specific	specific	JJ
10_1101-2020_01_28_923532	90	37	manner	manner	NN
10_1101-2020_01_28_923532	90	38	.	.	.
10_1101-2020_01_28_923532	91	1	The	the	DT
10_1101-2020_01_28_923532	91	2	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	91	3	and	and	CC
10_1101-2020_01_28_923532	91	4	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	91	5	parameters	parameter	NNS
10_1101-2020_01_28_923532	91	6	are	be	VBP
10_1101-2020_01_28_923532	91	7	the	the	DT
10_1101-2020_01_28_923532	91	8	lower	low	JJR
10_1101-2020_01_28_923532	91	9	bound	bind	VBN
10_1101-2020_01_28_923532	91	10	on	on	IN
10_1101-2020_01_28_923532	91	11	the	the	DT
10_1101-2020_01_28_923532	91	12	fraction	fraction	NN
10_1101-2020_01_28_923532	91	13	of	of	IN
10_1101-2020_01_28_923532	91	14	tumor	tumor	NN
10_1101-2020_01_28_923532	91	15	cells	cell	NNS
10_1101-2020_01_28_923532	91	16	killed	kill	VBN
10_1101-2020_01_28_923532	91	17	and	and	CC
10_1101-2020_01_28_923532	91	18	the	the	DT
10_1101-2020_01_28_923532	91	19	upper	upper	JJ
10_1101-2020_01_28_923532	91	20	bound	bind	VBN
10_1101-2020_01_28_923532	91	21	on	on	IN
10_1101-2020_01_28_923532	91	22	the	the	DT
10_1101-2020_01_28_923532	91	23	fraction	fraction	NN
10_1101-2020_01_28_923532	91	24	of	of	IN
10_1101-2020_01_28_923532	91	25	non	non	JJ
10_1101-2020_01_28_923532	91	26	-	-	JJ
10_1101-2020_01_28_923532	91	27	tumor	tumor	JJ
10_1101-2020_01_28_923532	91	28	cells	cell	NNS
10_1101-2020_01_28_923532	91	29	whose	whose	WP$
10_1101-2020_01_28_923532	91	30	killing	killing	NN
10_1101-2020_01_28_923532	91	31	is	be	VBZ
10_1101-2020_01_28_923532	91	32	tolerated	tolerate	VBN
10_1101-2020_01_28_923532	91	33	,	,	,
10_1101-2020_01_28_923532	91	34	respectively	respectively	RB
10_1101-2020_01_28_923532	91	35	.	.	.
10_1101-2020_01_28_923532	92	1	Baseline	baseline	JJ
10_1101-2020_01_28_923532	92	2	settings	setting	NNS
10_1101-2020_01_28_923532	92	3	used	use	VBN
10_1101-2020_01_28_923532	92	4	in	in	IN
10_1101-2020_01_28_923532	92	5	our	-PRON-	PRP$
10_1101-2020_01_28_923532	92	6	analyses	analysis	NNS
10_1101-2020_01_28_923532	92	7	are	be	VBP
10_1101-2020_01_28_923532	92	8	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	92	9	=	=	SYM
10_1101-2020_01_28_923532	92	10	2	2	CD
10_1101-2020_01_28_923532	92	11	,	,	,
10_1101-2020_01_28_923532	92	12	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	92	13	=	=	SYM
10_1101-2020_01_28_923532	92	14	0.8	0.8	CD
10_1101-2020_01_28_923532	92	15	and	and	CC
10_1101-2020_01_28_923532	92	16	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	92	17	=	=	SYM
10_1101-2020_01_28_923532	92	18	0.1	0.1	CD
10_1101-2020_01_28_923532	92	19	,	,	,
10_1101-2020_01_28_923532	92	20	and	and	CC
10_1101-2020_01_28_923532	92	21	are	be	VBP
10_1101-2020_01_28_923532	92	22	varied	varied	JJ
10_1101-2020_01_28_923532	92	23	in	in	IN
10_1101-2020_01_28_923532	92	24	some	some	DT
10_1101-2020_01_28_923532	92	25	of	of	IN
10_1101-2020_01_28_923532	92	26	the	the	DT
10_1101-2020_01_28_923532	92	27	analyses	analysis	NNS
10_1101-2020_01_28_923532	92	28	.	.	.
10_1101-2020_01_28_923532	93	1	The	the	DT
10_1101-2020_01_28_923532	93	2	right	right	JJ
10_1101-2020_01_28_923532	93	3	side	side	NN
10_1101-2020_01_28_923532	93	4	of	of	IN
10_1101-2020_01_28_923532	93	5	the	the	DT
10_1101-2020_01_28_923532	93	6	panel	panel	NN
10_1101-2020_01_28_923532	93	7	shows	show	VBZ
10_1101-2020_01_28_923532	93	8	a	a	DT
10_1101-2020_01_28_923532	93	9	hypothetical	hypothetical	JJ
10_1101-2020_01_28_923532	93	10	example	example	NN
10_1101-2020_01_28_923532	93	11	of	of	IN
10_1101-2020_01_28_923532	93	12	the	the	DT
10_1101-2020_01_28_923532	93	13	tradeoff	tradeoff	NN
10_1101-2020_01_28_923532	93	14	between	between	IN
10_1101-2020_01_28_923532	93	15	killing	kill	VBG
10_1101-2020_01_28_923532	93	16	tumor	tumor	NN
10_1101-2020_01_28_923532	93	17	cells	cell	NNS
10_1101-2020_01_28_923532	93	18	and	and	CC
10_1101-2020_01_28_923532	93	19	sparing	spare	VBG
10_1101-2020_01_28_923532	93	20	non	non	JJ
10_1101-2020_01_28_923532	93	21	-	-	JJ
10_1101-2020_01_28_923532	93	22	tumor	tumor	JJ
10_1101-2020_01_28_923532	93	23	cells	cell	NNS
10_1101-2020_01_28_923532	93	24	.	.	.
10_1101-2020_01_28_923532	94	1	While	while	IN
10_1101-2020_01_28_923532	94	2	target	target	NN
10_1101-2020_01_28_923532	94	3	set	set	VBN
10_1101-2020_01_28_923532	94	4	A	a	NN
10_1101-2020_01_28_923532	94	5	could	could	MD
10_1101-2020_01_28_923532	94	6	kill	kill	VB
10_1101-2020_01_28_923532	94	7	a	a	DT
10_1101-2020_01_28_923532	94	8	larger	large	JJR
10_1101-2020_01_28_923532	94	9	fraction	fraction	NN
10_1101-2020_01_28_923532	94	10	of	of	IN
10_1101-2020_01_28_923532	94	11	tumor	tumor	NN
10_1101-2020_01_28_923532	94	12	cells	cell	NNS
10_1101-2020_01_28_923532	94	13	than	than	IN
10_1101-2020_01_28_923532	94	14	target	target	VB
10_1101-2020_01_28_923532	94	15	set	set	VBN
10_1101-2020_01_28_923532	94	16	B	b	NN
10_1101-2020_01_28_923532	94	17	,	,	,
10_1101-2020_01_28_923532	94	18	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	94	19	would	would	MD
10_1101-2020_01_28_923532	94	20	select	select	VB
10_1101-2020_01_28_923532	94	21	target	target	NN
10_1101-2020_01_28_923532	94	22	set	set	VBN
10_1101-2020_01_28_923532	94	23	B	b	NN
10_1101-2020_01_28_923532	94	24	since	since	IN
10_1101-2020_01_28_923532	94	25	only	only	RB
10_1101-2020_01_28_923532	94	26	it	-PRON-	PRP
10_1101-2020_01_28_923532	94	27	satisfies	satisfy	VBZ
10_1101-2020_01_28_923532	94	28	both	both	CC
10_1101-2020_01_28_923532	94	29	our	-PRON-	PRP$
10_1101-2020_01_28_923532	94	30	baseline	baseline	JJ
10_1101-2020_01_28_923532	94	31	settings	setting	NNS
10_1101-2020_01_28_923532	94	32	and	and	CC
10_1101-2020_01_28_923532	94	33	kills	kill	NNS
10_1101-2020_01_28_923532	94	34	at	at	IN
10_1101-2020_01_28_923532	94	35	most	most	JJS
10_1101-2020_01_28_923532	94	36	0.1	0.1	CD
10_1101-2020_01_28_923532	94	37	fraction	fraction	NN
10_1101-2020_01_28_923532	94	38	of	of	IN
10_1101-2020_01_28_923532	94	39	the	the	DT
10_1101-2020_01_28_923532	94	40	non	non	JJ
10_1101-2020_01_28_923532	94	41	-	-	JJ
10_1101-2020_01_28_923532	94	42	tumor	tumor	JJ
10_1101-2020_01_28_923532	94	43	cells	cell	NNS
10_1101-2020_01_28_923532	94	44	.	.	.
10_1101-2020_01_28_923532	95	1	105	105	CD
10_1101-2020_01_28_923532	95	2	and	and	CC
10_1101-2020_01_28_923532	95	3	is	be	VBZ
10_1101-2020_01_28_923532	95	4	also	also	RB
10_1101-2020_01_28_923532	95	5	made	make	VBN
10_1101-2020_01_28_923532	95	6	available	available	JJ
10_1101-2020_01_28_923532	95	7	for	for	IN
10_1101-2020_01_28_923532	95	8	use	use	NN
10_1101-2020_01_28_923532	95	9	under	under	IN
10_1101-2020_01_28_923532	95	10	a	a	DT
10_1101-2020_01_28_923532	95	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	95	12	license	license	NN
10_1101-2020_01_28_923532	95	13	.	.	.
10_1101-2020_01_28_923532	96	1	(	(	-LRB-
10_1101-2020_01_28_923532	96	2	which	which	WDT
10_1101-2020_01_28_923532	96	3	was	be	VBD
10_1101-2020_01_28_923532	96	4	not	not	RB
10_1101-2020_01_28_923532	96	5	certified	certify	VBN
10_1101-2020_01_28_923532	96	6	by	by	IN
10_1101-2020_01_28_923532	96	7	peer	peer	NN
10_1101-2020_01_28_923532	96	8	review	review	NN
10_1101-2020_01_28_923532	96	9	)	)	-RRB-
10_1101-2020_01_28_923532	96	10	is	be	VBZ
10_1101-2020_01_28_923532	96	11	the	the	DT
10_1101-2020_01_28_923532	96	12	author	author	NN
10_1101-2020_01_28_923532	96	13	/	/	SYM
10_1101-2020_01_28_923532	96	14	funder	funder	NN
10_1101-2020_01_28_923532	96	15	.	.	.
10_1101-2020_01_28_923532	97	1	This	this	DT
10_1101-2020_01_28_923532	97	2	article	article	NN
10_1101-2020_01_28_923532	97	3	is	be	VBZ
10_1101-2020_01_28_923532	97	4	a	a	DT
10_1101-2020_01_28_923532	97	5	US	US	NNP
10_1101-2020_01_28_923532	97	6	Government	Government	NNP
10_1101-2020_01_28_923532	97	7	work	work	NN
10_1101-2020_01_28_923532	97	8	.	.	.
10_1101-2020_01_28_923532	98	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	98	2	is	be	VBZ
10_1101-2020_01_28_923532	98	3	not	not	RB
10_1101-2020_01_28_923532	98	4	subject	subject	JJ
10_1101-2020_01_28_923532	98	5	to	to	IN
10_1101-2020_01_28_923532	98	6	copyright	copyright	NN
10_1101-2020_01_28_923532	98	7	under	under	IN
10_1101-2020_01_28_923532	98	8	17	17	CD
10_1101-2020_01_28_923532	98	9	USC	usc	NN
10_1101-2020_01_28_923532	98	10	The	the	DT
10_1101-2020_01_28_923532	98	11	copyright	copyright	NN
10_1101-2020_01_28_923532	98	12	holder	holder	NN
10_1101-2020_01_28_923532	98	13	for	for	IN
10_1101-2020_01_28_923532	98	14	this	this	DT
10_1101-2020_01_28_923532	98	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	98	16	version	version	NN
10_1101-2020_01_28_923532	98	17	posted	post	VBD
10_1101-2020_01_28_923532	98	18	February	February	NNP
10_1101-2020_01_28_923532	98	19	12	12	CD
10_1101-2020_01_28_923532	98	20	,	,	,
10_1101-2020_01_28_923532	98	21	2021	2021	CD
10_1101-2020_01_28_923532	98	22	.	.	.
10_1101-2020_01_28_923532	98	23	;	;	:
10_1101-2020_01_28_923532	98	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	98	25	:	:	:
10_1101-2020_01_28_923532	98	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	98	27	preprint	preprint	NN
10_1101-2020_01_28_923532	98	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	98	29	9	9	CD
10_1101-2020_01_28_923532	98	30	Results	result	NNS
10_1101-2020_01_28_923532	98	31	The	the	DT
10_1101-2020_01_28_923532	98	32	Data	Data	NNPS
10_1101-2020_01_28_923532	98	33	and	and	CC
10_1101-2020_01_28_923532	98	34	the	the	DT
10_1101-2020_01_28_923532	98	35	Combinatorial	Combinatorial	NNP
10_1101-2020_01_28_923532	98	36	Optimization	Optimization	NNP
10_1101-2020_01_28_923532	98	37	Framework	Framework	NNP
10_1101-2020_01_28_923532	98	38	We	-PRON-	PRP
10_1101-2020_01_28_923532	98	39	focused	focus	VBD
10_1101-2020_01_28_923532	98	40	our	-PRON-	PRP$
10_1101-2020_01_28_923532	98	41	analysis	analysis	NN
10_1101-2020_01_28_923532	98	42	searching	search	VBG
10_1101-2020_01_28_923532	98	43	for	for	IN
10_1101-2020_01_28_923532	98	44	optimal	optimal	JJ
10_1101-2020_01_28_923532	98	45	treatment	treatment	NN
10_1101-2020_01_28_923532	98	46	combinations	combination	NNS
10_1101-2020_01_28_923532	98	47	in	in	IN
10_1101-2020_01_28_923532	98	48	nine	nine	CD
10_1101-2020_01_28_923532	98	49	single	single	JJ
10_1101-2020_01_28_923532	98	50	-	-	HYPH
10_1101-2020_01_28_923532	98	51	cell	cell	NN
10_1101-2020_01_28_923532	98	52	RNAseq	RNAseq	NNP
10_1101-2020_01_28_923532	98	53	data	datum	NNS
10_1101-2020_01_28_923532	98	54	sets	set	NNS
10_1101-2020_01_28_923532	98	55	that	that	WDT
10_1101-2020_01_28_923532	98	56	include	include	VBP
10_1101-2020_01_28_923532	98	57	tumor	tumor	NN
10_1101-2020_01_28_923532	98	58	cells	cell	NNS
10_1101-2020_01_28_923532	98	59	and	and	CC
10_1101-2020_01_28_923532	98	60	non	non	JJ
10_1101-2020_01_28_923532	98	61	-	-	JJ
10_1101-2020_01_28_923532	98	62	tumor	tumor	JJ
10_1101-2020_01_28_923532	98	63	cells	cell	NNS
10_1101-2020_01_28_923532	98	64	from	from	IN
10_1101-2020_01_28_923532	98	65	at	at	RB
10_1101-2020_01_28_923532	98	66	least	least	RBS
10_1101-2020_01_28_923532	98	67	three	three	CD
10_1101-2020_01_28_923532	98	68	patients	patient	NNS
10_1101-2020_01_28_923532	98	69	for	for	IN
10_1101-2020_01_28_923532	98	70	that	that	DT
10_1101-2020_01_28_923532	98	71	were	be	VBD
10_1101-2020_01_28_923532	98	72	publicly	publicly	RB
10_1101-2020_01_28_923532	98	73	available	available	JJ
10_1101-2020_01_28_923532	98	74	at	at	IN
10_1101-2020_01_28_923532	98	75	the	the	DT
10_1101-2020_01_28_923532	98	76	onset	onset	NN
10_1101-2020_01_28_923532	98	77	of	of	IN
10_1101-2020_01_28_923532	98	78	our	-PRON-	PRP$
10_1101-2020_01_28_923532	98	79	investigation	investigation	NN
10_1101-2020_01_28_923532	98	80	(	(	-LRB-
10_1101-2020_01_28_923532	98	81	Methods	method	NNS
10_1101-2020_01_28_923532	98	82	;	;	,
10_1101-2020_01_28_923532	98	83	Table	table	NN
10_1101-2020_01_28_923532	98	84	1	1	CD
10_1101-2020_01_28_923532	98	85	)	)	-RRB-
10_1101-2020_01_28_923532	98	86	.	.	.
10_1101-2020_01_28_923532	99	1	Those	those	DT
10_1101-2020_01_28_923532	99	2	data	data	NN
10_1101-2020_01_28_923532	99	3	sets	set	NNS
10_1101-2020_01_28_923532	99	4	include	include	VBP
10_1101-2020_01_28_923532	99	5	four	four	CD
10_1101-2020_01_28_923532	99	6	brain	brain	NN
10_1101-2020_01_28_923532	99	7	cancer	cancer	NN
10_1101-2020_01_28_923532	99	8	data	datum	NNS
10_1101-2020_01_28_923532	99	9	sets	set	NNS
10_1101-2020_01_28_923532	99	10	and	and	CC
10_1101-2020_01_28_923532	99	11	one	one	CD
10_1101-2020_01_28_923532	99	12	each	each	DT
10_1101-2020_01_28_923532	99	13	from	from	IN
10_1101-2020_01_28_923532	99	14	head	head	NN
10_1101-2020_01_28_923532	99	15	and	and	CC
10_1101-2020_01_28_923532	99	16	neck	neck	NN
10_1101-2020_01_28_923532	99	17	,	,	,
10_1101-2020_01_28_923532	99	18	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	99	19	,	,	,
10_1101-2020_01_28_923532	99	20	lung	lung	NN
10_1101-2020_01_28_923532	99	21	,	,	,
10_1101-2020_01_28_923532	99	22	breast	breast	NN
10_1101-2020_01_28_923532	99	23	and	and	CC
10_1101-2020_01_28_923532	99	24	colon	colon	NN
10_1101-2020_01_28_923532	99	25	cancers	cancer	NNS
10_1101-2020_01_28_923532	99	26	.	.	.
10_1101-2020_01_28_923532	100	1	Most	Most	JJS
10_1101-2020_01_28_923532	100	2	analyses	analysis	NNS
10_1101-2020_01_28_923532	100	3	were	be	VBD
10_1101-2020_01_28_923532	100	4	done	do	VBN
10_1101-2020_01_28_923532	100	5	for	for	IN
10_1101-2020_01_28_923532	100	6	all	all	DT
10_1101-2020_01_28_923532	100	7	data	data	NN
10_1101-2020_01_28_923532	100	8	sets	set	NNS
10_1101-2020_01_28_923532	100	9	,	,	,
10_1101-2020_01_28_923532	100	10	but	but	CC
10_1101-2020_01_28_923532	100	11	for	for	IN
10_1101-2020_01_28_923532	100	12	clarity	clarity	NN
10_1101-2020_01_28_923532	100	13	of	of	IN
10_1101-2020_01_28_923532	100	14	exposition	exposition	NN
10_1101-2020_01_28_923532	100	15	,	,	,
10_1101-2020_01_28_923532	100	16	we	-PRON-	PRP
10_1101-2020_01_28_923532	100	17	focused	focus	VBD
10_1101-2020_01_28_923532	100	18	in	in	IN
10_1101-2020_01_28_923532	100	19	the	the	DT
10_1101-2020_01_28_923532	100	20	main	main	JJ
10_1101-2020_01_28_923532	100	21	text	text	NN
10_1101-2020_01_28_923532	100	22	analyses	analyse	VBZ
10_1101-2020_01_28_923532	100	23	on	on	IN
10_1101-2020_01_28_923532	100	24	four	four	CD
10_1101-2020_01_28_923532	100	25	data	data	NN
10_1101-2020_01_28_923532	100	26	sets	set	NNS
10_1101-2020_01_28_923532	100	27	from	from	IN
10_1101-2020_01_28_923532	100	28	four	four	CD
10_1101-2020_01_28_923532	100	29	different	different	JJ
10_1101-2020_01_28_923532	100	30	cancer	cancer	NN
10_1101-2020_01_28_923532	100	31	types	type	NNS
10_1101-2020_01_28_923532	100	32	(	(	-LRB-
10_1101-2020_01_28_923532	100	33	brain	brain	NN
10_1101-2020_01_28_923532	100	34	,	,	,
10_1101-2020_01_28_923532	100	35	head	head	NN
10_1101-2020_01_28_923532	100	36	and	and	CC
10_1101-2020_01_28_923532	100	37	neck	neck	NN
10_1101-2020_01_28_923532	100	38	,	,	,
10_1101-2020_01_28_923532	100	39	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	100	40	,	,	,
10_1101-2020_01_28_923532	100	41	lung	lung	NN
10_1101-2020_01_28_923532	100	42	)	)	-RRB-
10_1101-2020_01_28_923532	100	43	that	that	WDT
10_1101-2020_01_28_923532	100	44	are	be	VBP
10_1101-2020_01_28_923532	100	45	larger	large	JJR
10_1101-2020_01_28_923532	100	46	than	than	IN
10_1101-2020_01_28_923532	100	47	the	the	DT
10_1101-2020_01_28_923532	100	48	other	other	JJ
10_1101-2020_01_28_923532	100	49	five	five	CD
10_1101-2020_01_28_923532	100	50	and	and	CC
10_1101-2020_01_28_923532	100	51	hence	hence	RB
10_1101-2020_01_28_923532	100	52	,	,	,
10_1101-2020_01_28_923532	100	53	make	make	VB
10_1101-2020_01_28_923532	100	54	the	the	DT
10_1101-2020_01_28_923532	100	55	optimization	optimization	NN
10_1101-2020_01_28_923532	100	56	problems	problem	NNS
10_1101-2020_01_28_923532	100	57	more	more	RBR
10_1101-2020_01_28_923532	100	58	challenging	challenging	JJ
10_1101-2020_01_28_923532	100	59	.	.	.
10_1101-2020_01_28_923532	101	1	Results	result	NNS
10_1101-2020_01_28_923532	101	2	on	on	IN
10_1101-2020_01_28_923532	101	3	the	the	DT
10_1101-2020_01_28_923532	101	4	other	other	JJ
10_1101-2020_01_28_923532	101	5	five	five	CD
10_1101-2020_01_28_923532	101	6	data	datum	NNS
10_1101-2020_01_28_923532	101	7	sets	set	NNS
10_1101-2020_01_28_923532	101	8	are	be	VBP
10_1101-2020_01_28_923532	101	9	provided	provide	VBN
10_1101-2020_01_28_923532	101	10	in	in	IN
10_1101-2020_01_28_923532	101	11	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	101	12	Materials	Materials	NNP
10_1101-2020_01_28_923532	101	13	2	2	CD
10_1101-2020_01_28_923532	101	14	.	.	.
10_1101-2020_01_28_923532	102	1	Analyzing	analyze	VBG
10_1101-2020_01_28_923532	102	2	separately	separately	RB
10_1101-2020_01_28_923532	102	3	each	each	DT
10_1101-2020_01_28_923532	102	4	of	of	IN
10_1101-2020_01_28_923532	102	5	these	these	DT
10_1101-2020_01_28_923532	102	6	data	data	NN
10_1101-2020_01_28_923532	102	7	sets	set	NNS
10_1101-2020_01_28_923532	102	8	,	,	,
10_1101-2020_01_28_923532	102	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	102	10	ask	ask	VBP
10_1101-2020_01_28_923532	102	11	how	how	WRB
10_1101-2020_01_28_923532	102	12	many	many	JJ
10_1101-2020_01_28_923532	102	13	targets	target	NNS
10_1101-2020_01_28_923532	102	14	are	be	VBP
10_1101-2020_01_28_923532	102	15	needed	need	VBN
10_1101-2020_01_28_923532	102	16	to	to	TO
10_1101-2020_01_28_923532	102	17	kill	kill	VB
10_1101-2020_01_28_923532	102	18	most	most	JJS
10_1101-2020_01_28_923532	102	19	cells	cell	NNS
10_1101-2020_01_28_923532	102	20	of	of	IN
10_1101-2020_01_28_923532	102	21	a	a	DT
10_1101-2020_01_28_923532	102	22	given	give	VBN
10_1101-2020_01_28_923532	102	23	tumor	tumor	NN
10_1101-2020_01_28_923532	102	24	and	and	CC
10_1101-2020_01_28_923532	102	25	what	what	WP
10_1101-2020_01_28_923532	102	26	is	be	VBZ
10_1101-2020_01_28_923532	102	27	the	the	DT
10_1101-2020_01_28_923532	102	28	tradeoff	tradeoff	NN
10_1101-2020_01_28_923532	102	29	between	between	IN
10_1101-2020_01_28_923532	102	30	cancer	cancer	NN
10_1101-2020_01_28_923532	102	31	cells	cell	NNS
10_1101-2020_01_28_923532	102	32	killed	kill	VBN
10_1101-2020_01_28_923532	102	33	and	and	CC
10_1101-2020_01_28_923532	102	34	non	non	JJ
10_1101-2020_01_28_923532	102	35	-	-	JJ
10_1101-2020_01_28_923532	102	36	cancer	cancer	JJ
10_1101-2020_01_28_923532	102	37	cells	cell	NNS
10_1101-2020_01_28_923532	102	38	spared	spare	VBN
10_1101-2020_01_28_923532	102	39	?	?	.
10_1101-2020_01_28_923532	103	1	Figure	figure	NN
10_1101-2020_01_28_923532	103	2	2	2	CD
10_1101-2020_01_28_923532	103	3	shows	show	VBZ
10_1101-2020_01_28_923532	103	4	a	a	DT
10_1101-2020_01_28_923532	103	5	small	small	JJ
10_1101-2020_01_28_923532	103	6	schematic	schematic	JJ
10_1101-2020_01_28_923532	103	7	example	example	NN
10_1101-2020_01_28_923532	103	8	in	in	IN
10_1101-2020_01_28_923532	103	9	which	which	WDT
10_1101-2020_01_28_923532	103	10	there	there	EX
10_1101-2020_01_28_923532	103	11	are	be	VBP
10_1101-2020_01_28_923532	103	12	alternative	alternative	JJ
10_1101-2020_01_28_923532	103	13	target	target	NN
10_1101-2020_01_28_923532	103	14	sets	set	NNS
10_1101-2020_01_28_923532	103	15	of	of	IN
10_1101-2020_01_28_923532	103	16	sizes	size	NNS
10_1101-2020_01_28_923532	103	17	two	two	CD
10_1101-2020_01_28_923532	103	18	and	and	CC
10_1101-2020_01_28_923532	103	19	three	three	CD
10_1101-2020_01_28_923532	103	20	.	.	.
10_1101-2020_01_28_923532	104	1	One	one	PRP
10_1101-2020_01_28_923532	104	2	would	would	MD
10_1101-2020_01_28_923532	104	3	prefer	prefer	VB
10_1101-2020_01_28_923532	104	4	the	the	DT
10_1101-2020_01_28_923532	104	5	target	target	NN
10_1101-2020_01_28_923532	104	6	set	set	VBN
10_1101-2020_01_28_923532	104	7	of	of	IN
10_1101-2020_01_28_923532	104	8	size	size	NN
10_1101-2020_01_28_923532	104	9	two	two	CD
10_1101-2020_01_28_923532	104	10	because	because	IN
10_1101-2020_01_28_923532	104	11	the	the	DT
10_1101-2020_01_28_923532	104	12	patients	patient	NNS
10_1101-2020_01_28_923532	104	13	would	would	MD
10_1101-2020_01_28_923532	104	14	need	need	VB
10_1101-2020_01_28_923532	104	15	to	to	TO
10_1101-2020_01_28_923532	104	16	receive	receive	VB
10_1101-2020_01_28_923532	104	17	only	only	RB
10_1101-2020_01_28_923532	104	18	two	two	CD
10_1101-2020_01_28_923532	104	19	distinct	distinct	JJ
10_1101-2020_01_28_923532	104	20	treatments	treatment	NNS
10_1101-2020_01_28_923532	104	21	rather	rather	RB
10_1101-2020_01_28_923532	104	22	than	than	IN
10_1101-2020_01_28_923532	104	23	three	three	CD
10_1101-2020_01_28_923532	104	24	treatments	treatment	NNS
10_1101-2020_01_28_923532	104	25	.	.	.
10_1101-2020_01_28_923532	105	1	Figure	figure	NN
10_1101-2020_01_28_923532	105	2	2	2	CD
10_1101-2020_01_28_923532	105	3	.	.	.
10_1101-2020_01_28_923532	106	1	A	a	DT
10_1101-2020_01_28_923532	106	2	schematic	schematic	JJ
10_1101-2020_01_28_923532	106	3	small	small	JJ
10_1101-2020_01_28_923532	106	4	example	example	NN
10_1101-2020_01_28_923532	106	5	of	of	IN
10_1101-2020_01_28_923532	106	6	killing	kill	VBG
10_1101-2020_01_28_923532	106	7	a	a	DT
10_1101-2020_01_28_923532	106	8	four	four	CD
10_1101-2020_01_28_923532	106	9	tumor	tumor	NN
10_1101-2020_01_28_923532	106	10	cells	cell	NNS
10_1101-2020_01_28_923532	106	11	illustrating	illustrate	VBG
10_1101-2020_01_28_923532	106	12	why	why	WRB
10_1101-2020_01_28_923532	106	13	choosing	choose	VBG
10_1101-2020_01_28_923532	106	14	a	a	DT
10_1101-2020_01_28_923532	106	15	minimum	minimum	JJ
10_1101-2020_01_28_923532	106	16	-	-	HYPH
10_1101-2020_01_28_923532	106	17	size	size	NN
10_1101-2020_01_28_923532	106	18	combination	combination	NN
10_1101-2020_01_28_923532	106	19	of	of	IN
10_1101-2020_01_28_923532	106	20	targets	target	NNS
10_1101-2020_01_28_923532	106	21	may	may	MD
10_1101-2020_01_28_923532	106	22	be	be	VB
10_1101-2020_01_28_923532	106	23	non	non	JJ
10_1101-2020_01_28_923532	106	24	-	-	JJ
10_1101-2020_01_28_923532	106	25	trivial	trivial	JJ
10_1101-2020_01_28_923532	106	26	.	.	.
10_1101-2020_01_28_923532	107	1	The	the	DT
10_1101-2020_01_28_923532	107	2	schematic	schematic	JJ
10_1101-2020_01_28_923532	107	3	tumor	tumor	NN
10_1101-2020_01_28_923532	107	4	has	have	VBZ
10_1101-2020_01_28_923532	107	5	four	four	CD
10_1101-2020_01_28_923532	107	6	cancer	cancer	NN
10_1101-2020_01_28_923532	107	7	cells	cell	NNS
10_1101-2020_01_28_923532	107	8	(	(	-LRB-
10_1101-2020_01_28_923532	107	9	A	a	NN
10_1101-2020_01_28_923532	107	10	,	,	,
10_1101-2020_01_28_923532	107	11	B	b	NN
10_1101-2020_01_28_923532	107	12	,	,	,
10_1101-2020_01_28_923532	107	13	C	C	NNP
10_1101-2020_01_28_923532	107	14	,	,	,
10_1101-2020_01_28_923532	107	15	D	d	NN
10_1101-2020_01_28_923532	107	16	in	in	IN
10_1101-2020_01_28_923532	107	17	separate	separate	JJ
10_1101-2020_01_28_923532	107	18	columns	column	NNS
10_1101-2020_01_28_923532	107	19	)	)	-RRB-
10_1101-2020_01_28_923532	107	20	,	,	,
10_1101-2020_01_28_923532	107	21	which	which	WDT
10_1101-2020_01_28_923532	107	22	may	may	MD
10_1101-2020_01_28_923532	107	23	express	express	VB
10_1101-2020_01_28_923532	107	24	any	any	DT
10_1101-2020_01_28_923532	107	25	of	of	IN
10_1101-2020_01_28_923532	107	26	five	five	CD
10_1101-2020_01_28_923532	107	27	cell	cell	NN
10_1101-2020_01_28_923532	107	28	-	-	HYPH
10_1101-2020_01_28_923532	107	29	surface	surface	NN
10_1101-2020_01_28_923532	107	30	receptor	receptor	NN
10_1101-2020_01_28_923532	107	31	genes	gene	NNS
10_1101-2020_01_28_923532	107	32	(	(	-LRB-
10_1101-2020_01_28_923532	107	33	rows	row	NNS
10_1101-2020_01_28_923532	107	34	)	)	-RRB-
10_1101-2020_01_28_923532	107	35	that	that	WDT
10_1101-2020_01_28_923532	107	36	may	may	MD
10_1101-2020_01_28_923532	107	37	be	be	VB
10_1101-2020_01_28_923532	107	38	targeted	target	VBN
10_1101-2020_01_28_923532	107	39	selectively	selectively	RB
10_1101-2020_01_28_923532	107	40	by	by	IN
10_1101-2020_01_28_923532	107	41	modular	modular	JJ
10_1101-2020_01_28_923532	107	42	treatments	treatment	NNS
10_1101-2020_01_28_923532	107	43	(	(	-LRB-
10_1101-2020_01_28_923532	107	44	pills	pill	NNS
10_1101-2020_01_28_923532	107	45	)	)	-RRB-
10_1101-2020_01_28_923532	107	46	.	.	.
10_1101-2020_01_28_923532	108	1	If	if	IN
10_1101-2020_01_28_923532	108	2	one	one	CD
10_1101-2020_01_28_923532	108	3	targets	target	VBZ
10_1101-2020_01_28_923532	108	4	{	{	-LRB-
10_1101-2020_01_28_923532	108	5	APP	APP	NNP
10_1101-2020_01_28_923532	108	6	,	,	,
10_1101-2020_01_28_923532	108	7	KDR	KDR	NNP
10_1101-2020_01_28_923532	108	8	,	,	,
10_1101-2020_01_28_923532	108	9	MET	MET	NNP
10_1101-2020_01_28_923532	108	10	}	}	-RRB-
10_1101-2020_01_28_923532	108	11	,	,	,
10_1101-2020_01_28_923532	108	12	all	all	DT
10_1101-2020_01_28_923532	108	13	cancer	cancer	NN
10_1101-2020_01_28_923532	108	14	105	105	CD
10_1101-2020_01_28_923532	108	15	and	and	CC
10_1101-2020_01_28_923532	108	16	is	be	VBZ
10_1101-2020_01_28_923532	108	17	also	also	RB
10_1101-2020_01_28_923532	108	18	made	make	VBN
10_1101-2020_01_28_923532	108	19	available	available	JJ
10_1101-2020_01_28_923532	108	20	for	for	IN
10_1101-2020_01_28_923532	108	21	use	use	NN
10_1101-2020_01_28_923532	108	22	under	under	IN
10_1101-2020_01_28_923532	108	23	a	a	DT
10_1101-2020_01_28_923532	108	24	CC0	CC0	NNP
10_1101-2020_01_28_923532	108	25	license	license	NN
10_1101-2020_01_28_923532	108	26	.	.	.
10_1101-2020_01_28_923532	109	1	(	(	-LRB-
10_1101-2020_01_28_923532	109	2	which	which	WDT
10_1101-2020_01_28_923532	109	3	was	be	VBD
10_1101-2020_01_28_923532	109	4	not	not	RB
10_1101-2020_01_28_923532	109	5	certified	certify	VBN
10_1101-2020_01_28_923532	109	6	by	by	IN
10_1101-2020_01_28_923532	109	7	peer	peer	NN
10_1101-2020_01_28_923532	109	8	review	review	NN
10_1101-2020_01_28_923532	109	9	)	)	-RRB-
10_1101-2020_01_28_923532	109	10	is	be	VBZ
10_1101-2020_01_28_923532	109	11	the	the	DT
10_1101-2020_01_28_923532	109	12	author	author	NN
10_1101-2020_01_28_923532	109	13	/	/	SYM
10_1101-2020_01_28_923532	109	14	funder	funder	NN
10_1101-2020_01_28_923532	109	15	.	.	.
10_1101-2020_01_28_923532	110	1	This	this	DT
10_1101-2020_01_28_923532	110	2	article	article	NN
10_1101-2020_01_28_923532	110	3	is	be	VBZ
10_1101-2020_01_28_923532	110	4	a	a	DT
10_1101-2020_01_28_923532	110	5	US	US	NNP
10_1101-2020_01_28_923532	110	6	Government	Government	NNP
10_1101-2020_01_28_923532	110	7	work	work	NN
10_1101-2020_01_28_923532	110	8	.	.	.
10_1101-2020_01_28_923532	111	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	111	2	is	be	VBZ
10_1101-2020_01_28_923532	111	3	not	not	RB
10_1101-2020_01_28_923532	111	4	subject	subject	JJ
10_1101-2020_01_28_923532	111	5	to	to	IN
10_1101-2020_01_28_923532	111	6	copyright	copyright	NN
10_1101-2020_01_28_923532	111	7	under	under	IN
10_1101-2020_01_28_923532	111	8	17	17	CD
10_1101-2020_01_28_923532	111	9	USC	usc	NN
10_1101-2020_01_28_923532	111	10	The	the	DT
10_1101-2020_01_28_923532	111	11	copyright	copyright	NN
10_1101-2020_01_28_923532	111	12	holder	holder	NN
10_1101-2020_01_28_923532	111	13	for	for	IN
10_1101-2020_01_28_923532	111	14	this	this	DT
10_1101-2020_01_28_923532	111	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	111	16	version	version	NN
10_1101-2020_01_28_923532	111	17	posted	post	VBD
10_1101-2020_01_28_923532	111	18	February	February	NNP
10_1101-2020_01_28_923532	111	19	12	12	CD
10_1101-2020_01_28_923532	111	20	,	,	,
10_1101-2020_01_28_923532	111	21	2021	2021	CD
10_1101-2020_01_28_923532	111	22	.	.	.
10_1101-2020_01_28_923532	111	23	;	;	:
10_1101-2020_01_28_923532	111	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	111	25	:	:	:
10_1101-2020_01_28_923532	111	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	111	27	preprint	preprint	NN
10_1101-2020_01_28_923532	111	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	111	29	10	10	CD
10_1101-2020_01_28_923532	111	30	cells	cell	NNS
10_1101-2020_01_28_923532	111	31	will	will	MD
10_1101-2020_01_28_923532	111	32	be	be	VB
10_1101-2020_01_28_923532	111	33	killed	kill	VBN
10_1101-2020_01_28_923532	111	34	(	(	-LRB-
10_1101-2020_01_28_923532	111	35	left	leave	VBN
10_1101-2020_01_28_923532	111	36	panel	panel	NN
10_1101-2020_01_28_923532	111	37	)	)	-RRB-
10_1101-2020_01_28_923532	111	38	.	.	.
10_1101-2020_01_28_923532	112	1	However	however	RB
10_1101-2020_01_28_923532	112	2	,	,	,
10_1101-2020_01_28_923532	112	3	if	if	IN
10_1101-2020_01_28_923532	112	4	,	,	,
10_1101-2020_01_28_923532	112	5	instead	instead	RB
10_1101-2020_01_28_923532	112	6	,	,	,
10_1101-2020_01_28_923532	112	7	one	one	PRP
10_1101-2020_01_28_923532	112	8	would	would	MD
10_1101-2020_01_28_923532	112	9	target	target	VB
10_1101-2020_01_28_923532	112	10	{	{	-LRB-
10_1101-2020_01_28_923532	112	11	CR2	CR2	NNP
10_1101-2020_01_28_923532	112	12	,	,	,
10_1101-2020_01_28_923532	112	13	TEK	TEK	NNP
10_1101-2020_01_28_923532	112	14	}	}	-RRB-
10_1101-2020_01_28_923532	112	15	then	then	RB
10_1101-2020_01_28_923532	112	16	all	all	DT
10_1101-2020_01_28_923532	112	17	cancer	cancer	NN
10_1101-2020_01_28_923532	112	18	cells	cell	NNS
10_1101-2020_01_28_923532	112	19	in	in	IN
10_1101-2020_01_28_923532	112	20	the	the	DT
10_1101-2020_01_28_923532	112	21	given	give	VBN
10_1101-2020_01_28_923532	112	22	example	example	NN
10_1101-2020_01_28_923532	112	23	tumor	tumor	NN
10_1101-2020_01_28_923532	112	24	will	will	MD
10_1101-2020_01_28_923532	112	25	be	be	VB
10_1101-2020_01_28_923532	112	26	killed	kill	VBN
10_1101-2020_01_28_923532	112	27	with	with	IN
10_1101-2020_01_28_923532	112	28	just	just	RB
10_1101-2020_01_28_923532	112	29	two	two	CD
10_1101-2020_01_28_923532	112	30	targets	target	NNS
10_1101-2020_01_28_923532	112	31	(	(	-LRB-
10_1101-2020_01_28_923532	112	32	right	right	JJ
10_1101-2020_01_28_923532	112	33	panel	panel	NN
10_1101-2020_01_28_923532	112	34	)	)	-RRB-
10_1101-2020_01_28_923532	112	35	instead	instead	RB
10_1101-2020_01_28_923532	112	36	of	of	IN
10_1101-2020_01_28_923532	112	37	three	three	CD
10_1101-2020_01_28_923532	112	38	,	,	,
10_1101-2020_01_28_923532	112	39	providing	provide	VBG
10_1101-2020_01_28_923532	112	40	a	a	DT
10_1101-2020_01_28_923532	112	41	smaller	small	JJR
10_1101-2020_01_28_923532	112	42	solution	solution	NN
10_1101-2020_01_28_923532	112	43	.	.	.
10_1101-2020_01_28_923532	113	1	To	to	TO
10_1101-2020_01_28_923532	113	2	formalize	formalize	VB
10_1101-2020_01_28_923532	113	3	our	-PRON-	PRP$
10_1101-2020_01_28_923532	113	4	questions	question	NNS
10_1101-2020_01_28_923532	113	5	as	as	IN
10_1101-2020_01_28_923532	113	6	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	113	7	optimization	optimization	NN
10_1101-2020_01_28_923532	113	8	hitting	hit	VBG
10_1101-2020_01_28_923532	113	9	set	set	NN
10_1101-2020_01_28_923532	113	10	problems	problem	NNS
10_1101-2020_01_28_923532	113	11	,	,	,
10_1101-2020_01_28_923532	113	12	we	-PRON-	PRP
10_1101-2020_01_28_923532	113	13	define	define	VBP
10_1101-2020_01_28_923532	113	14	the	the	DT
10_1101-2020_01_28_923532	113	15	following	follow	VBG
10_1101-2020_01_28_923532	113	16	parameters	parameter	NNS
10_1101-2020_01_28_923532	113	17	and	and	CC
10_1101-2020_01_28_923532	113	18	baseline	baseline	JJ
10_1101-2020_01_28_923532	113	19	values	value	NNS
10_1101-2020_01_28_923532	113	20	and	and	CC
10_1101-2020_01_28_923532	113	21	explore	explore	VB
10_1101-2020_01_28_923532	113	22	how	how	WRB
10_1101-2020_01_28_923532	113	23	the	the	DT
10_1101-2020_01_28_923532	113	24	optimal	optimal	JJ
10_1101-2020_01_28_923532	113	25	answers	answer	NNS
10_1101-2020_01_28_923532	113	26	vary	vary	VBP
10_1101-2020_01_28_923532	113	27	as	as	IN
10_1101-2020_01_28_923532	113	28	functions	function	NNS
10_1101-2020_01_28_923532	113	29	of	of	IN
10_1101-2020_01_28_923532	113	30	these	these	DT
10_1101-2020_01_28_923532	113	31	parameters	parameter	NNS
10_1101-2020_01_28_923532	113	32	:	:	:
10_1101-2020_01_28_923532	113	33	We	-PRON-	PRP
10_1101-2020_01_28_923532	113	34	specify	specify	VBP
10_1101-2020_01_28_923532	113	35	a	a	DT
10_1101-2020_01_28_923532	113	36	lower	low	JJR
10_1101-2020_01_28_923532	113	37	bound	bind	VBN
10_1101-2020_01_28_923532	113	38	on	on	IN
10_1101-2020_01_28_923532	113	39	the	the	DT
10_1101-2020_01_28_923532	113	40	fraction	fraction	NN
10_1101-2020_01_28_923532	113	41	of	of	IN
10_1101-2020_01_28_923532	113	42	tumor	tumor	NN
10_1101-2020_01_28_923532	113	43	cells	cell	NNS
10_1101-2020_01_28_923532	113	44	that	that	WDT
10_1101-2020_01_28_923532	113	45	should	should	MD
10_1101-2020_01_28_923532	113	46	be	be	VB
10_1101-2020_01_28_923532	113	47	killed	kill	VBN
10_1101-2020_01_28_923532	113	48	,	,	,
10_1101-2020_01_28_923532	113	49	𝑙𝑏	𝑙𝑏	UH
10_1101-2020_01_28_923532	113	50	,	,	,
10_1101-2020_01_28_923532	113	51	which	which	WDT
10_1101-2020_01_28_923532	113	52	ranges	range	VBZ
10_1101-2020_01_28_923532	113	53	from	from	IN
10_1101-2020_01_28_923532	113	54	0	0	CD
10_1101-2020_01_28_923532	113	55	to	to	IN
10_1101-2020_01_28_923532	113	56	1	1	CD
10_1101-2020_01_28_923532	113	57	.	.	.
10_1101-2020_01_28_923532	114	1	Similarly	similarly	RB
10_1101-2020_01_28_923532	114	2	,	,	,
10_1101-2020_01_28_923532	114	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	114	4	define	define	VBP
10_1101-2020_01_28_923532	114	5	an	an	DT
10_1101-2020_01_28_923532	114	6	upper	upper	JJ
10_1101-2020_01_28_923532	114	7	bound	bind	VBN
10_1101-2020_01_28_923532	114	8	on	on	IN
10_1101-2020_01_28_923532	114	9	the	the	DT
10_1101-2020_01_28_923532	114	10	fraction	fraction	NN
10_1101-2020_01_28_923532	114	11	of	of	IN
10_1101-2020_01_28_923532	114	12	non	non	JJ
10_1101-2020_01_28_923532	114	13	-	-	JJ
10_1101-2020_01_28_923532	114	14	tumor	tumor	JJ
10_1101-2020_01_28_923532	114	15	cells	cell	NNS
10_1101-2020_01_28_923532	114	16	killed	kill	VBN
10_1101-2020_01_28_923532	114	17	,	,	,
10_1101-2020_01_28_923532	114	18	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	114	19	,	,	,
10_1101-2020_01_28_923532	114	20	which	which	WDT
10_1101-2020_01_28_923532	114	21	also	also	RB
10_1101-2020_01_28_923532	114	22	ranges	range	VBZ
10_1101-2020_01_28_923532	114	23	from	from	IN
10_1101-2020_01_28_923532	114	24	0	0	CD
10_1101-2020_01_28_923532	114	25	to	to	IN
10_1101-2020_01_28_923532	114	26	1	1	CD
10_1101-2020_01_28_923532	114	27	.	.	.
10_1101-2020_01_28_923532	115	1	Our	-PRON-	PRP$
10_1101-2020_01_28_923532	115	2	baseline	baseline	JJ
10_1101-2020_01_28_923532	115	3	settings	setting	NNS
10_1101-2020_01_28_923532	115	4	are	be	VBP
10_1101-2020_01_28_923532	115	5	𝑙𝑏	𝑙𝑏	IN
10_1101-2020_01_28_923532	115	6	=	=	SYM
10_1101-2020_01_28_923532	115	7	0.8	0.8	CD
10_1101-2020_01_28_923532	115	8	and	and	CC
10_1101-2020_01_28_923532	115	9	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	115	10	=	=	SYM
10_1101-2020_01_28_923532	115	11	0.1	0.1	CD
10_1101-2020_01_28_923532	115	12	.	.	.
10_1101-2020_01_28_923532	116	1	To	to	TO
10_1101-2020_01_28_923532	116	2	represent	represent	VB
10_1101-2020_01_28_923532	116	3	the	the	DT
10_1101-2020_01_28_923532	116	4	concept	concept	NN
10_1101-2020_01_28_923532	116	5	that	that	IN
10_1101-2020_01_28_923532	116	6	only	only	RB
10_1101-2020_01_28_923532	116	7	cells	cell	NNS
10_1101-2020_01_28_923532	116	8	that	that	WDT
10_1101-2020_01_28_923532	116	9	overexpress	overexpress	VBP
10_1101-2020_01_28_923532	116	10	the	the	DT
10_1101-2020_01_28_923532	116	11	target	target	NN
10_1101-2020_01_28_923532	116	12	,	,	,
10_1101-2020_01_28_923532	116	13	we	-PRON-	PRP
10_1101-2020_01_28_923532	116	14	introduce	introduce	VBP
10_1101-2020_01_28_923532	116	15	an	an	DT
10_1101-2020_01_28_923532	116	16	additional	additional	JJ
10_1101-2020_01_28_923532	116	17	parameter	parameter	NN
10_1101-2020_01_28_923532	116	18	𝑟.	𝑟.	NN
10_1101-2020_01_28_923532	117	1	The	the	DT
10_1101-2020_01_28_923532	117	2	expression	expression	NN
10_1101-2020_01_28_923532	117	3	ratio	ratio	NN
10_1101-2020_01_28_923532	117	4	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	117	5	defines	define	NNS
10_1101-2020_01_28_923532	117	6	which	which	WDT
10_1101-2020_01_28_923532	117	7	cells	cell	NNS
10_1101-2020_01_28_923532	117	8	are	be	VBP
10_1101-2020_01_28_923532	117	9	killed	kill	VBN
10_1101-2020_01_28_923532	117	10	,	,	,
10_1101-2020_01_28_923532	117	11	as	as	IN
10_1101-2020_01_28_923532	117	12	follows	follow	VBZ
10_1101-2020_01_28_923532	117	13	(	(	-LRB-
10_1101-2020_01_28_923532	117	14	Figure	figure	NN
10_1101-2020_01_28_923532	117	15	1B	1b	NN
10_1101-2020_01_28_923532	117	16	)	)	-RRB-
10_1101-2020_01_28_923532	117	17	:	:	:
10_1101-2020_01_28_923532	117	18	Denote	denote	VB
10_1101-2020_01_28_923532	117	19	the	the	DT
10_1101-2020_01_28_923532	117	20	mean	mean	JJ
10_1101-2020_01_28_923532	117	21	expression	expression	NN
10_1101-2020_01_28_923532	117	22	of	of	IN
10_1101-2020_01_28_923532	117	23	a	a	DT
10_1101-2020_01_28_923532	117	24	gene	gene	NN
10_1101-2020_01_28_923532	117	25	𝑔	𝑔	NN
10_1101-2020_01_28_923532	117	26	in	in	IN
10_1101-2020_01_28_923532	117	27	non	non	JJ
10_1101-2020_01_28_923532	117	28	-	-	JJ
10_1101-2020_01_28_923532	117	29	cancer	cancer	JJ
10_1101-2020_01_28_923532	117	30	cells	cell	NNS
10_1101-2020_01_28_923532	117	31	that	that	WDT
10_1101-2020_01_28_923532	117	32	have	have	VBP
10_1101-2020_01_28_923532	117	33	non-	non-	NN
10_1101-2020_01_28_923532	117	34	zero	zero	CD
10_1101-2020_01_28_923532	117	35	expression	expression	NN
10_1101-2020_01_28_923532	117	36	by	by	IN
10_1101-2020_01_28_923532	117	37	E(𝑔	e(𝑔	NN
10_1101-2020_01_28_923532	117	38	)	)	-RRB-
10_1101-2020_01_28_923532	117	39	.	.	.
10_1101-2020_01_28_923532	118	1	A	a	DT
10_1101-2020_01_28_923532	118	2	given	give	VBN
10_1101-2020_01_28_923532	118	3	cell	cell	NN
10_1101-2020_01_28_923532	118	4	is	be	VBZ
10_1101-2020_01_28_923532	118	5	considered	consider	VBN
10_1101-2020_01_28_923532	118	6	killed	kill	VBN
10_1101-2020_01_28_923532	118	7	if	if	IN
10_1101-2020_01_28_923532	118	8	gene	gene	NN
10_1101-2020_01_28_923532	118	9	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	118	10	is	be	VBZ
10_1101-2020_01_28_923532	118	11	targeted	target	VBN
10_1101-2020_01_28_923532	118	12	and	and	CC
10_1101-2020_01_28_923532	118	13	its	-PRON-	PRP$
10_1101-2020_01_28_923532	118	14	expression	expression	NN
10_1101-2020_01_28_923532	118	15	level	level	NN
10_1101-2020_01_28_923532	118	16	in	in	IN
10_1101-2020_01_28_923532	118	17	that	that	DT
10_1101-2020_01_28_923532	118	18	cell	cell	NN
10_1101-2020_01_28_923532	118	19	is	be	VBZ
10_1101-2020_01_28_923532	118	20	at	at	IN
10_1101-2020_01_28_923532	118	21	least	least	JJS
10_1101-2020_01_28_923532	118	22	𝑟	𝑟	NN
10_1101-2020_01_28_923532	118	23	×	×	NNP
10_1101-2020_01_28_923532	118	24	𝐸(𝑔	𝐸(𝑔	NNP
10_1101-2020_01_28_923532	118	25	)	)	-RRB-
10_1101-2020_01_28_923532	118	26	.	.	.
10_1101-2020_01_28_923532	119	1	Higher	high	JJR
10_1101-2020_01_28_923532	119	2	values	value	NNS
10_1101-2020_01_28_923532	119	3	of	of	IN
10_1101-2020_01_28_923532	119	4	𝑟	𝑟	DT
10_1101-2020_01_28_923532	119	5	thus	thus	RB
10_1101-2020_01_28_923532	119	6	model	model	NN
10_1101-2020_01_28_923532	119	7	more	more	RBR
10_1101-2020_01_28_923532	119	8	selective	selective	JJ
10_1101-2020_01_28_923532	119	9	killing	killing	NN
10_1101-2020_01_28_923532	119	10	.	.	.
10_1101-2020_01_28_923532	120	1	Having	have	VBG
10_1101-2020_01_28_923532	120	2	𝑟	𝑟	XX
10_1101-2020_01_28_923532	120	3	as	as	IN
10_1101-2020_01_28_923532	120	4	a	a	DT
10_1101-2020_01_28_923532	120	5	modifiable	modifiable	JJ
10_1101-2020_01_28_923532	120	6	parameter	parameter	NN
10_1101-2020_01_28_923532	120	7	anticipates	anticipate	VBZ
10_1101-2020_01_28_923532	120	8	that	that	IN
10_1101-2020_01_28_923532	120	9	in	in	IN
10_1101-2020_01_28_923532	120	10	the	the	DT
10_1101-2020_01_28_923532	120	11	future	future	NN
10_1101-2020_01_28_923532	120	12	one	one	PRP
10_1101-2020_01_28_923532	120	13	could	could	MD
10_1101-2020_01_28_923532	120	14	experimentally	experimentally	RB
10_1101-2020_01_28_923532	120	15	tune	tune	VB
10_1101-2020_01_28_923532	120	16	the	the	DT
10_1101-2020_01_28_923532	120	17	overexpression	overexpression	NN
10_1101-2020_01_28_923532	120	18	level	level	NN
10_1101-2020_01_28_923532	120	19	at	at	IN
10_1101-2020_01_28_923532	120	20	which	which	WDT
10_1101-2020_01_28_923532	120	21	cell	cell	NN
10_1101-2020_01_28_923532	120	22	killing	killing	NN
10_1101-2020_01_28_923532	120	23	occurs24	occurs24	RB
10_1101-2020_01_28_923532	120	24	.	.	.
10_1101-2020_01_28_923532	121	1	In	in	IN
10_1101-2020_01_28_923532	121	2	this	this	DT
10_1101-2020_01_28_923532	121	3	respect	respect	NN
10_1101-2020_01_28_923532	121	4	,	,	,
10_1101-2020_01_28_923532	121	5	technologies	technology	NNS
10_1101-2020_01_28_923532	121	6	that	that	WDT
10_1101-2020_01_28_923532	121	7	rely	rely	VBP
10_1101-2020_01_28_923532	121	8	on	on	IN
10_1101-2020_01_28_923532	121	9	RME	RME	NNP
10_1101-2020_01_28_923532	121	10	to	to	TO
10_1101-2020_01_28_923532	121	11	get	get	VB
10_1101-2020_01_28_923532	121	12	a	a	DT
10_1101-2020_01_28_923532	121	13	toxin	toxin	NN
10_1101-2020_01_28_923532	121	14	into	into	IN
10_1101-2020_01_28_923532	121	15	the	the	DT
10_1101-2020_01_28_923532	121	16	cell	cell	NN
10_1101-2020_01_28_923532	121	17	are	be	VBP
10_1101-2020_01_28_923532	121	18	particularly	particularly	RB
10_1101-2020_01_28_923532	121	19	tunable	tunable	JJ
10_1101-2020_01_28_923532	121	20	because	because	IN
10_1101-2020_01_28_923532	121	21	there	there	EX
10_1101-2020_01_28_923532	121	22	is	be	VBZ
10_1101-2020_01_28_923532	121	23	known	know	VBN
10_1101-2020_01_28_923532	121	24	to	to	TO
10_1101-2020_01_28_923532	121	25	be	be	VB
10_1101-2020_01_28_923532	121	26	a	a	DT
10_1101-2020_01_28_923532	121	27	non	non	JJ
10_1101-2020_01_28_923532	121	28	-	-	JJ
10_1101-2020_01_28_923532	121	29	linear	linear	JJ
10_1101-2020_01_28_923532	121	30	relationship	relationship	NN
10_1101-2020_01_28_923532	121	31	between	between	IN
10_1101-2020_01_28_923532	121	32	the	the	DT
10_1101-2020_01_28_923532	121	33	number	number	NN
10_1101-2020_01_28_923532	121	34	of	of	IN
10_1101-2020_01_28_923532	121	35	protein	protein	NN
10_1101-2020_01_28_923532	121	36	copies	copy	NNS
10_1101-2020_01_28_923532	121	37	on	on	IN
10_1101-2020_01_28_923532	121	38	the	the	DT
10_1101-2020_01_28_923532	121	39	cell	cell	NN
10_1101-2020_01_28_923532	121	40	surface	surface	NN
10_1101-2020_01_28_923532	121	41	and	and	CC
10_1101-2020_01_28_923532	121	42	the	the	DT
10_1101-2020_01_28_923532	121	43	probability	probability	NN
10_1101-2020_01_28_923532	121	44	that	that	WDT
10_1101-2020_01_28_923532	121	45	RME	RME	NNP
10_1101-2020_01_28_923532	121	46	occurs	occur	VBZ
10_1101-2020_01_28_923532	121	47	successfully37	successfully37	NNP
10_1101-2020_01_28_923532	121	48	.	.	.
10_1101-2020_01_28_923532	122	1	In	in	IN
10_1101-2020_01_28_923532	122	2	these	these	DT
10_1101-2020_01_28_923532	122	3	technologies	technology	NNS
10_1101-2020_01_28_923532	122	4	,	,	,
10_1101-2020_01_28_923532	122	5	the	the	DT
10_1101-2020_01_28_923532	122	6	toxin	toxin	NN
10_1101-2020_01_28_923532	122	7	or	or	CC
10_1101-2020_01_28_923532	122	8	other	other	JJ
10_1101-2020_01_28_923532	122	9	therapy	therapy	NN
10_1101-2020_01_28_923532	122	10	delivered	deliver	VBN
10_1101-2020_01_28_923532	122	11	by	by	IN
10_1101-2020_01_28_923532	122	12	the	the	DT
10_1101-2020_01_28_923532	122	13	modular	modular	JJ
10_1101-2020_01_28_923532	122	14	treatment	treatment	NN
10_1101-2020_01_28_923532	122	15	enters	enter	VBZ
10_1101-2020_01_28_923532	122	16	cells	cell	NNS
10_1101-2020_01_28_923532	122	17	in	in	IN
10_1101-2020_01_28_923532	122	18	a	a	DT
10_1101-2020_01_28_923532	122	19	gene	gene	NN
10_1101-2020_01_28_923532	122	20	-	-	HYPH
10_1101-2020_01_28_923532	122	21	specific	specific	JJ
10_1101-2020_01_28_923532	122	22	manner38	manner38	NNS
10_1101-2020_01_28_923532	122	23	,	,	,
10_1101-2020_01_28_923532	122	24	while	while	IN
10_1101-2020_01_28_923532	122	25	CAR-	CAR-	NNP
10_1101-2020_01_28_923532	122	26	T	T	NNP
10_1101-2020_01_28_923532	122	27	therapy	therapy	NN
10_1101-2020_01_28_923532	122	28	activates	activate	VBZ
10_1101-2020_01_28_923532	122	29	T	t	NN
10_1101-2020_01_28_923532	122	30	-	-	HYPH
10_1101-2020_01_28_923532	122	31	cell	cell	NN
10_1101-2020_01_28_923532	122	32	killing	killing	NN
10_1101-2020_01_28_923532	122	33	against	against	IN
10_1101-2020_01_28_923532	122	34	cells	cell	NNS
10_1101-2020_01_28_923532	122	35	in	in	IN
10_1101-2020_01_28_923532	122	36	a	a	DT
10_1101-2020_01_28_923532	122	37	gene	gene	NN
10_1101-2020_01_28_923532	122	38	-	-	HYPH
10_1101-2020_01_28_923532	122	39	specific	specific	JJ
10_1101-2020_01_28_923532	122	40	manner24,25	manner24,25	NNP
10_1101-2020_01_28_923532	122	41	.	.	.
10_1101-2020_01_28_923532	123	1	For	for	IN
10_1101-2020_01_28_923532	123	2	most	most	JJS
10_1101-2020_01_28_923532	123	3	of	of	IN
10_1101-2020_01_28_923532	123	4	our	-PRON-	PRP$
10_1101-2020_01_28_923532	123	5	analyses	analysis	NNS
10_1101-2020_01_28_923532	123	6	,	,	,
10_1101-2020_01_28_923532	123	7	the	the	DT
10_1101-2020_01_28_923532	123	8	expression	expression	NN
10_1101-2020_01_28_923532	123	9	ratio	ratio	NN
10_1101-2020_01_28_923532	123	10	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	123	11	is	be	VBZ
10_1101-2020_01_28_923532	123	12	varied	varied	JJ
10_1101-2020_01_28_923532	123	13	from	from	IN
10_1101-2020_01_28_923532	123	14	1.5	1.5	CD
10_1101-2020_01_28_923532	123	15	to	to	IN
10_1101-2020_01_28_923532	123	16	3.0	3.0	CD
10_1101-2020_01_28_923532	123	17	,	,	,
10_1101-2020_01_28_923532	123	18	with	with	IN
10_1101-2020_01_28_923532	123	19	a	a	DT
10_1101-2020_01_28_923532	123	20	baseline	baseline	NN
10_1101-2020_01_28_923532	123	21	of	of	IN
10_1101-2020_01_28_923532	123	22	2.0	2.0	CD
10_1101-2020_01_28_923532	123	23	,	,	,
10_1101-2020_01_28_923532	123	24	based	base	VBN
10_1101-2020_01_28_923532	123	25	on	on	IN
10_1101-2020_01_28_923532	123	26	experiments	experiment	NNS
10_1101-2020_01_28_923532	123	27	in	in	IN
10_1101-2020_01_28_923532	123	28	the	the	DT
10_1101-2020_01_28_923532	123	29	lab	lab	NN
10_1101-2020_01_28_923532	123	30	of	of	IN
10_1101-2020_01_28_923532	123	31	N.A.	N.A.	NNP
10_1101-2020_01_28_923532	124	1	and	and	CC
10_1101-2020_01_28_923532	124	2	related	relate	VBN
10_1101-2020_01_28_923532	124	3	to	to	IN
10_1101-2020_01_28_923532	124	4	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	124	5	chemistry	chemistry	NN
10_1101-2020_01_28_923532	124	6	modeling37	modeling37	NN
10_1101-2020_01_28_923532	124	7	;	;	:
10_1101-2020_01_28_923532	124	8	in	in	IN
10_1101-2020_01_28_923532	124	9	one	one	CD
10_1101-2020_01_28_923532	124	10	analysis	analysis	NN
10_1101-2020_01_28_923532	124	11	,	,	,
10_1101-2020_01_28_923532	124	12	we	-PRON-	PRP
10_1101-2020_01_28_923532	124	13	varied	vary	VBD
10_1101-2020_01_28_923532	124	14	r	r	NNP
10_1101-2020_01_28_923532	124	15	up	up	IN
10_1101-2020_01_28_923532	124	16	to	to	TO
10_1101-2020_01_28_923532	124	17	5.0	5.0	CD
10_1101-2020_01_28_923532	124	18	(	(	-LRB-
10_1101-2020_01_28_923532	124	19	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	124	20	Table	Table	NNP
10_1101-2020_01_28_923532	124	21	S1	S1	NNS
10_1101-2020_01_28_923532	124	22	)	)	-RRB-
10_1101-2020_01_28_923532	124	23	.	.	.
10_1101-2020_01_28_923532	125	1	Given	give	VBN
10_1101-2020_01_28_923532	125	2	these	these	DT
10_1101-2020_01_28_923532	125	3	definitions	definition	NNS
10_1101-2020_01_28_923532	125	4	,	,	,
10_1101-2020_01_28_923532	125	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	125	6	solve	solve	VBP
10_1101-2020_01_28_923532	125	7	the	the	DT
10_1101-2020_01_28_923532	125	8	following	follow	VBG
10_1101-2020_01_28_923532	125	9	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	125	10	optimization	optimization	NN
10_1101-2020_01_28_923532	125	11	hitting	hit	VBG
10_1101-2020_01_28_923532	125	12	set	set	NN
10_1101-2020_01_28_923532	125	13	problem	problem	NN
10_1101-2020_01_28_923532	125	14	(	(	-LRB-
10_1101-2020_01_28_923532	125	15	Methods	Methods	NNP
10_1101-2020_01_28_923532	125	16	)	)	-RRB-
10_1101-2020_01_28_923532	125	17	:	:	:
10_1101-2020_01_28_923532	125	18	Given	give	VBN
10_1101-2020_01_28_923532	125	19	an	an	DT
10_1101-2020_01_28_923532	125	20	input	input	NN
10_1101-2020_01_28_923532	125	21	of	of	IN
10_1101-2020_01_28_923532	125	22	a	a	DT
10_1101-2020_01_28_923532	125	23	single	single	JJ
10_1101-2020_01_28_923532	125	24	-	-	HYPH
10_1101-2020_01_28_923532	125	25	cell	cell	NN
10_1101-2020_01_28_923532	125	26	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	125	27	sample	sample	NN
10_1101-2020_01_28_923532	125	28	of	of	IN
10_1101-2020_01_28_923532	125	29	non	non	JJ
10_1101-2020_01_28_923532	125	30	-	-	JJ
10_1101-2020_01_28_923532	125	31	tumor	tumor	JJ
10_1101-2020_01_28_923532	125	32	and	and	CC
10_1101-2020_01_28_923532	125	33	tumor	tumor	NN
10_1101-2020_01_28_923532	125	34	cells	cell	NNS
10_1101-2020_01_28_923532	125	35	for	for	IN
10_1101-2020_01_28_923532	125	36	each	each	DT
10_1101-2020_01_28_923532	125	37	patient	patient	NN
10_1101-2020_01_28_923532	125	38	in	in	IN
10_1101-2020_01_28_923532	125	39	a	a	DT
10_1101-2020_01_28_923532	125	40	cohort	cohort	NN
10_1101-2020_01_28_923532	125	41	of	of	IN
10_1101-2020_01_28_923532	125	42	multiple	multiple	JJ
10_1101-2020_01_28_923532	125	43	patients	patient	NNS
10_1101-2020_01_28_923532	125	44	,	,	,
10_1101-2020_01_28_923532	125	45	bounds	bound	NNS
10_1101-2020_01_28_923532	125	46	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	125	47	and	and	CC
10_1101-2020_01_28_923532	125	48	𝑙𝑏	𝑙𝑏	NNP
10_1101-2020_01_28_923532	125	49	,	,	,
10_1101-2020_01_28_923532	125	50	ratio	ratio	NN
10_1101-2020_01_28_923532	125	51	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	125	52	,	,	,
10_1101-2020_01_28_923532	125	53	and	and	CC
10_1101-2020_01_28_923532	125	54	a	a	DT
10_1101-2020_01_28_923532	125	55	set	set	NN
10_1101-2020_01_28_923532	125	56	of	of	IN
10_1101-2020_01_28_923532	125	57	target	target	NN
10_1101-2020_01_28_923532	125	58	genes	gene	NNS
10_1101-2020_01_28_923532	125	59	,	,	,
10_1101-2020_01_28_923532	125	60	we	-PRON-	PRP
10_1101-2020_01_28_923532	125	61	seek	seek	VBP
10_1101-2020_01_28_923532	125	62	to	to	TO
10_1101-2020_01_28_923532	125	63	find	find	VB
10_1101-2020_01_28_923532	125	64	a	a	DT
10_1101-2020_01_28_923532	125	65	solution	solution	NN
10_1101-2020_01_28_923532	125	66	that	that	WDT
10_1101-2020_01_28_923532	125	67	finds	find	VBZ
10_1101-2020_01_28_923532	125	68	a	a	DT
10_1101-2020_01_28_923532	125	69	minimum	minimum	JJ
10_1101-2020_01_28_923532	125	70	-	-	HYPH
10_1101-2020_01_28_923532	125	71	size	size	NN
10_1101-2020_01_28_923532	125	72	combination	combination	NN
10_1101-2020_01_28_923532	125	73	of	of	IN
10_1101-2020_01_28_923532	125	74	targets	target	NNS
10_1101-2020_01_28_923532	125	75	in	in	IN
10_1101-2020_01_28_923532	125	76	each	each	DT
10_1101-2020_01_28_923532	125	77	individual	individual	JJ
10_1101-2020_01_28_923532	125	78	patient	patient	NN
10_1101-2020_01_28_923532	125	79	,	,	,
10_1101-2020_01_28_923532	125	80	while	while	IN
10_1101-2020_01_28_923532	125	81	additionally	additionally	RB
10_1101-2020_01_28_923532	125	82	minimizing	minimize	VBG
10_1101-2020_01_28_923532	125	83	the	the	DT
10_1101-2020_01_28_923532	125	84	size	size	NN
10_1101-2020_01_28_923532	125	85	of	of	IN
10_1101-2020_01_28_923532	125	86	all	all	DT
10_1101-2020_01_28_923532	125	87	targets	target	NNS
10_1101-2020_01_28_923532	125	88	given	give	VBN
10_1101-2020_01_28_923532	125	89	to	to	IN
10_1101-2020_01_28_923532	125	90	the	the	DT
10_1101-2020_01_28_923532	125	91	patients	patient	NNS
10_1101-2020_01_28_923532	125	92	cohort	cohort	NN
10_1101-2020_01_28_923532	125	93	.	.	.
10_1101-2020_01_28_923532	126	1	The	the	DT
10_1101-2020_01_28_923532	126	2	latter	latter	NN
10_1101-2020_01_28_923532	126	3	is	be	VBZ
10_1101-2020_01_28_923532	126	4	termed	term	VBN
10_1101-2020_01_28_923532	126	5	the	the	DT
10_1101-2020_01_28_923532	126	6	global	global	JJ
10_1101-2020_01_28_923532	126	7	minimum	minimum	JJ
10_1101-2020_01_28_923532	126	8	-	-	HYPH
10_1101-2020_01_28_923532	126	9	size	size	NN
10_1101-2020_01_28_923532	126	10	hitting	hitting	NN
10_1101-2020_01_28_923532	126	11	set	set	NN
10_1101-2020_01_28_923532	126	12	(	(	-LRB-
10_1101-2020_01_28_923532	126	13	GHS	GHS	NNP
10_1101-2020_01_28_923532	126	14	)	)	-RRB-
10_1101-2020_01_28_923532	126	15	in	in	IN
10_1101-2020_01_28_923532	126	16	computer	computer	NN
10_1101-2020_01_28_923532	126	17	science	science	NN
10_1101-2020_01_28_923532	126	18	terminology	terminology	NN
10_1101-2020_01_28_923532	126	19	or	or	CC
10_1101-2020_01_28_923532	126	20	the	the	DT
10_1101-2020_01_28_923532	126	21	cohort	cohort	NN
10_1101-2020_01_28_923532	126	22	target	target	NN
10_1101-2020_01_28_923532	126	23	set	set	VBN
10_1101-2020_01_28_923532	126	24	(	(	-LRB-
10_1101-2020_01_28_923532	126	25	CTS	CTS	NNP
10_1101-2020_01_28_923532	126	26	)	)	-RRB-
10_1101-2020_01_28_923532	126	27	in	in	IN
10_1101-2020_01_28_923532	126	28	terminology	terminology	NN
10_1101-2020_01_28_923532	126	29	specific	specific	JJ
10_1101-2020_01_28_923532	126	30	to	to	IN
10_1101-2020_01_28_923532	126	31	our	-PRON-	PRP$
10_1101-2020_01_28_923532	126	32	problem	problem	NN
10_1101-2020_01_28_923532	126	33	,	,	,
10_1101-2020_01_28_923532	126	34	while	while	IN
10_1101-2020_01_28_923532	126	35	the	the	DT
10_1101-2020_01_28_923532	126	36	105	105	CD
10_1101-2020_01_28_923532	126	37	and	and	CC
10_1101-2020_01_28_923532	126	38	is	be	VBZ
10_1101-2020_01_28_923532	126	39	also	also	RB
10_1101-2020_01_28_923532	126	40	made	make	VBN
10_1101-2020_01_28_923532	126	41	available	available	JJ
10_1101-2020_01_28_923532	126	42	for	for	IN
10_1101-2020_01_28_923532	126	43	use	use	NN
10_1101-2020_01_28_923532	126	44	under	under	IN
10_1101-2020_01_28_923532	126	45	a	a	DT
10_1101-2020_01_28_923532	126	46	CC0	CC0	NNP
10_1101-2020_01_28_923532	126	47	license	license	NN
10_1101-2020_01_28_923532	126	48	.	.	.
10_1101-2020_01_28_923532	127	1	(	(	-LRB-
10_1101-2020_01_28_923532	127	2	which	which	WDT
10_1101-2020_01_28_923532	127	3	was	be	VBD
10_1101-2020_01_28_923532	127	4	not	not	RB
10_1101-2020_01_28_923532	127	5	certified	certify	VBN
10_1101-2020_01_28_923532	127	6	by	by	IN
10_1101-2020_01_28_923532	127	7	peer	peer	NN
10_1101-2020_01_28_923532	127	8	review	review	NN
10_1101-2020_01_28_923532	127	9	)	)	-RRB-
10_1101-2020_01_28_923532	127	10	is	be	VBZ
10_1101-2020_01_28_923532	127	11	the	the	DT
10_1101-2020_01_28_923532	127	12	author	author	NN
10_1101-2020_01_28_923532	127	13	/	/	SYM
10_1101-2020_01_28_923532	127	14	funder	funder	NN
10_1101-2020_01_28_923532	127	15	.	.	.
10_1101-2020_01_28_923532	128	1	This	this	DT
10_1101-2020_01_28_923532	128	2	article	article	NN
10_1101-2020_01_28_923532	128	3	is	be	VBZ
10_1101-2020_01_28_923532	128	4	a	a	DT
10_1101-2020_01_28_923532	128	5	US	US	NNP
10_1101-2020_01_28_923532	128	6	Government	Government	NNP
10_1101-2020_01_28_923532	128	7	work	work	NN
10_1101-2020_01_28_923532	128	8	.	.	.
10_1101-2020_01_28_923532	129	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	129	2	is	be	VBZ
10_1101-2020_01_28_923532	129	3	not	not	RB
10_1101-2020_01_28_923532	129	4	subject	subject	JJ
10_1101-2020_01_28_923532	129	5	to	to	IN
10_1101-2020_01_28_923532	129	6	copyright	copyright	NN
10_1101-2020_01_28_923532	129	7	under	under	IN
10_1101-2020_01_28_923532	129	8	17	17	CD
10_1101-2020_01_28_923532	129	9	USC	usc	NN
10_1101-2020_01_28_923532	129	10	The	the	DT
10_1101-2020_01_28_923532	129	11	copyright	copyright	NN
10_1101-2020_01_28_923532	129	12	holder	holder	NN
10_1101-2020_01_28_923532	129	13	for	for	IN
10_1101-2020_01_28_923532	129	14	this	this	DT
10_1101-2020_01_28_923532	129	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	129	16	version	version	NN
10_1101-2020_01_28_923532	129	17	posted	post	VBD
10_1101-2020_01_28_923532	129	18	February	February	NNP
10_1101-2020_01_28_923532	129	19	12	12	CD
10_1101-2020_01_28_923532	129	20	,	,	,
10_1101-2020_01_28_923532	129	21	2021	2021	CD
10_1101-2020_01_28_923532	129	22	.	.	.
10_1101-2020_01_28_923532	129	23	;	;	:
10_1101-2020_01_28_923532	129	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	129	25	:	:	:
10_1101-2020_01_28_923532	129	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	129	27	preprint	preprint	NN
10_1101-2020_01_28_923532	129	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	129	29	11	11	CD
10_1101-2020_01_28_923532	129	30	optimal	optimal	JJ
10_1101-2020_01_28_923532	129	31	hitting	hit	VBG
10_1101-2020_01_28_923532	129	32	set	set	NN
10_1101-2020_01_28_923532	129	33	of	of	IN
10_1101-2020_01_28_923532	129	34	genes	gene	NNS
10_1101-2020_01_28_923532	129	35	targeting	target	VBG
10_1101-2020_01_28_923532	129	36	one	one	CD
10_1101-2020_01_28_923532	129	37	patient	patient	NN
10_1101-2020_01_28_923532	129	38	is	be	VBZ
10_1101-2020_01_28_923532	129	39	termed	term	VBN
10_1101-2020_01_28_923532	129	40	the	the	DT
10_1101-2020_01_28_923532	129	41	individual	individual	JJ
10_1101-2020_01_28_923532	129	42	target	target	NN
10_1101-2020_01_28_923532	129	43	set	set	VBN
10_1101-2020_01_28_923532	129	44	(	(	-LRB-
10_1101-2020_01_28_923532	129	45	ITS	its	PRP$
10_1101-2020_01_28_923532	129	46	)	)	-RRB-
10_1101-2020_01_28_923532	129	47	.	.	.
10_1101-2020_01_28_923532	130	1	This	this	DT
10_1101-2020_01_28_923532	130	2	optimum	optimum	JJ
10_1101-2020_01_28_923532	130	3	hitting	hit	VBG
10_1101-2020_01_28_923532	130	4	set	set	NN
10_1101-2020_01_28_923532	130	5	problem	problem	NN
10_1101-2020_01_28_923532	130	6	with	with	IN
10_1101-2020_01_28_923532	130	7	constraints	constraint	NNS
10_1101-2020_01_28_923532	130	8	can	can	MD
10_1101-2020_01_28_923532	130	9	be	be	VB
10_1101-2020_01_28_923532	130	10	solved	solve	VBN
10_1101-2020_01_28_923532	130	11	to	to	IN
10_1101-2020_01_28_923532	130	12	optimality	optimality	NN
10_1101-2020_01_28_923532	130	13	using	use	VBG
10_1101-2020_01_28_923532	130	14	integer	integer	NN
10_1101-2020_01_28_923532	130	15	linear	linear	NNP
10_1101-2020_01_28_923532	130	16	programming	programming	NN
10_1101-2020_01_28_923532	130	17	(	(	-LRB-
10_1101-2020_01_28_923532	130	18	ILP	ILP	NNP
10_1101-2020_01_28_923532	130	19	)	)	-RRB-
10_1101-2020_01_28_923532	130	20	(	(	-LRB-
10_1101-2020_01_28_923532	130	21	Methods	Methods	NNP
10_1101-2020_01_28_923532	130	22	)	)	-RRB-
10_1101-2020_01_28_923532	130	23	.	.	.
10_1101-2020_01_28_923532	131	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	131	2	solve	solve	VBP
10_1101-2020_01_28_923532	131	3	different	different	JJ
10_1101-2020_01_28_923532	131	4	optimization	optimization	NN
10_1101-2020_01_28_923532	131	5	problem	problem	NN
10_1101-2020_01_28_923532	131	6	instances	instance	NNS
10_1101-2020_01_28_923532	131	7	,	,	,
10_1101-2020_01_28_923532	131	8	each	each	DT
10_1101-2020_01_28_923532	131	9	of	of	IN
10_1101-2020_01_28_923532	131	10	which	which	WDT
10_1101-2020_01_28_923532	131	11	considers	consider	VBZ
10_1101-2020_01_28_923532	131	12	a	a	DT
10_1101-2020_01_28_923532	131	13	different	different	JJ
10_1101-2020_01_28_923532	131	14	set	set	NN
10_1101-2020_01_28_923532	131	15	of	of	IN
10_1101-2020_01_28_923532	131	16	candidate	candidate	NN
10_1101-2020_01_28_923532	131	17	target	target	NN
10_1101-2020_01_28_923532	131	18	genes	gene	NNS
10_1101-2020_01_28_923532	131	19	:	:	:
10_1101-2020_01_28_923532	131	20	1269	1269	CD
10_1101-2020_01_28_923532	131	21	genes	gene	NNS
10_1101-2020_01_28_923532	131	22	encoding	encode	VBG
10_1101-2020_01_28_923532	131	23	cell	cell	NN
10_1101-2020_01_28_923532	131	24	surface	surface	NN
10_1101-2020_01_28_923532	131	25	receptor	receptor	NN
10_1101-2020_01_28_923532	131	26	proteins	protein	NNS
10_1101-2020_01_28_923532	131	27	,	,	,
10_1101-2020_01_28_923532	131	28	and	and	CC
10_1101-2020_01_28_923532	131	29	subset	subset	NN
10_1101-2020_01_28_923532	131	30	of	of	IN
10_1101-2020_01_28_923532	131	31	58	58	CD
10_1101-2020_01_28_923532	131	32	out	out	IN
10_1101-2020_01_28_923532	131	33	of	of	IN
10_1101-2020_01_28_923532	131	34	these	these	DT
10_1101-2020_01_28_923532	131	35	1269	1269	CD
10_1101-2020_01_28_923532	131	36	genes	gene	NNS
10_1101-2020_01_28_923532	131	37	that	that	WDT
10_1101-2020_01_28_923532	131	38	already	already	RB
10_1101-2020_01_28_923532	131	39	have	have	VBP
10_1101-2020_01_28_923532	131	40	published	publish	VBN
10_1101-2020_01_28_923532	131	41	ligand-	ligand-	NN
10_1101-2020_01_28_923532	131	42	mimicking	mimicking	NN
10_1101-2020_01_28_923532	131	43	peptides	peptide	NNS
10_1101-2020_01_28_923532	131	44	,	,	,
10_1101-2020_01_28_923532	131	45	and	and	CC
10_1101-2020_01_28_923532	131	46	a	a	DT
10_1101-2020_01_28_923532	131	47	nested	nest	VBN
10_1101-2020_01_28_923532	131	48	collection	collection	NN
10_1101-2020_01_28_923532	131	49	of	of	IN
10_1101-2020_01_28_923532	131	50	sets	set	NNS
10_1101-2020_01_28_923532	131	51	of	of	IN
10_1101-2020_01_28_923532	131	52	424	424	CD
10_1101-2020_01_28_923532	131	53	-	-	SYM
10_1101-2020_01_28_923532	131	54	900	900	CD
10_1101-2020_01_28_923532	131	55	out	out	IN
10_1101-2020_01_28_923532	131	56	of	of	IN
10_1101-2020_01_28_923532	131	57	the	the	DT
10_1101-2020_01_28_923532	131	58	1269	1269	CD
10_1101-2020_01_28_923532	131	59	genes	gene	NNS
10_1101-2020_01_28_923532	131	60	that	that	WDT
10_1101-2020_01_28_923532	131	61	are	be	VBP
10_1101-2020_01_28_923532	131	62	lowly	lowly	RB
10_1101-2020_01_28_923532	131	63	expressed	express	VBN
10_1101-2020_01_28_923532	131	64	below	below	IN
10_1101-2020_01_28_923532	131	65	a	a	DT
10_1101-2020_01_28_923532	131	66	series	series	NN
10_1101-2020_01_28_923532	131	67	of	of	IN
10_1101-2020_01_28_923532	131	68	decreasing	decrease	VBG
10_1101-2020_01_28_923532	131	69	gene	gene	NN
10_1101-2020_01_28_923532	131	70	expression	expression	NN
10_1101-2020_01_28_923532	131	71	thresholds25	thresholds25	CD
10_1101-2020_01_28_923532	131	72	.	.	.
10_1101-2020_01_28_923532	132	1	From	from	IN
10_1101-2020_01_28_923532	132	2	a	a	DT
10_1101-2020_01_28_923532	132	3	computational	computational	JJ
10_1101-2020_01_28_923532	132	4	standpoint	standpoint	NN
10_1101-2020_01_28_923532	132	5	,	,	,
10_1101-2020_01_28_923532	132	6	there	there	EX
10_1101-2020_01_28_923532	132	7	is	be	VBZ
10_1101-2020_01_28_923532	132	8	no	no	DT
10_1101-2020_01_28_923532	132	9	inherent	inherent	JJ
10_1101-2020_01_28_923532	132	10	limit	limit	NN
10_1101-2020_01_28_923532	132	11	on	on	IN
10_1101-2020_01_28_923532	132	12	the	the	DT
10_1101-2020_01_28_923532	132	13	size	size	NN
10_1101-2020_01_28_923532	132	14	of	of	IN
10_1101-2020_01_28_923532	132	15	the	the	DT
10_1101-2020_01_28_923532	132	16	candidate	candidate	NN
10_1101-2020_01_28_923532	132	17	gene	gene	NN
10_1101-2020_01_28_923532	132	18	set	set	NN
10_1101-2020_01_28_923532	132	19	.	.	.
10_1101-2020_01_28_923532	133	1	Our	-PRON-	PRP$
10_1101-2020_01_28_923532	133	2	formulation	formulation	NN
10_1101-2020_01_28_923532	133	3	is	be	VBZ
10_1101-2020_01_28_923532	133	4	personalized	personalize	VBN
10_1101-2020_01_28_923532	133	5	as	as	IN
10_1101-2020_01_28_923532	133	6	each	each	DT
10_1101-2020_01_28_923532	133	7	patient	patient	NN
10_1101-2020_01_28_923532	133	8	receives	receive	VBZ
10_1101-2020_01_28_923532	133	9	the	the	DT
10_1101-2020_01_28_923532	133	10	minimum	minimum	JJ
10_1101-2020_01_28_923532	133	11	possible	possible	JJ
10_1101-2020_01_28_923532	133	12	number	number	NN
10_1101-2020_01_28_923532	133	13	of	of	IN
10_1101-2020_01_28_923532	133	14	treatments	treatment	NNS
10_1101-2020_01_28_923532	133	15	.	.	.
10_1101-2020_01_28_923532	134	1	The	the	DT
10_1101-2020_01_28_923532	134	2	global	global	JJ
10_1101-2020_01_28_923532	134	3	optimization	optimization	NN
10_1101-2020_01_28_923532	134	4	comes	come	VBZ
10_1101-2020_01_28_923532	134	5	into	into	IN
10_1101-2020_01_28_923532	134	6	play	play	NN
10_1101-2020_01_28_923532	134	7	only	only	RB
10_1101-2020_01_28_923532	134	8	when	when	WRB
10_1101-2020_01_28_923532	134	9	there	there	EX
10_1101-2020_01_28_923532	134	10	are	be	VBP
10_1101-2020_01_28_923532	134	11	multiple	multiple	JJ
10_1101-2020_01_28_923532	134	12	solutions	solution	NNS
10_1101-2020_01_28_923532	134	13	of	of	IN
10_1101-2020_01_28_923532	134	14	the	the	DT
10_1101-2020_01_28_923532	134	15	same	same	JJ
10_1101-2020_01_28_923532	134	16	size	size	NN
10_1101-2020_01_28_923532	134	17	to	to	TO
10_1101-2020_01_28_923532	134	18	treat	treat	VB
10_1101-2020_01_28_923532	134	19	a	a	DT
10_1101-2020_01_28_923532	134	20	patient	patient	NN
10_1101-2020_01_28_923532	134	21	.	.	.
10_1101-2020_01_28_923532	135	1	For	for	IN
10_1101-2020_01_28_923532	135	2	example	example	NN
10_1101-2020_01_28_923532	135	3	,	,	,
10_1101-2020_01_28_923532	135	4	suppose	suppose	VB
10_1101-2020_01_28_923532	135	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	135	6	have	have	VBP
10_1101-2020_01_28_923532	135	7	two	two	CD
10_1101-2020_01_28_923532	135	8	patients	patient	NNS
10_1101-2020_01_28_923532	135	9	such	such	JJ
10_1101-2020_01_28_923532	135	10	that	that	IN
10_1101-2020_01_28_923532	135	11	patient	patient	NN
10_1101-2020_01_28_923532	135	12	A	a	DT
10_1101-2020_01_28_923532	135	13	could	could	MD
10_1101-2020_01_28_923532	135	14	be	be	VB
10_1101-2020_01_28_923532	135	15	treated	treat	VBN
10_1101-2020_01_28_923532	135	16	by	by	IN
10_1101-2020_01_28_923532	135	17	targeting	target	VBG
10_1101-2020_01_28_923532	135	18	either	either	CC
10_1101-2020_01_28_923532	135	19	{	{	-LRB-
10_1101-2020_01_28_923532	135	20	EGFR	egfr	NN
10_1101-2020_01_28_923532	135	21	,	,	,
10_1101-2020_01_28_923532	135	22	FGFR2	FGFR2	''
10_1101-2020_01_28_923532	135	23	}	}	-RRB-
10_1101-2020_01_28_923532	135	24	or	or	CC
10_1101-2020_01_28_923532	135	25	{	{	-LRB-
10_1101-2020_01_28_923532	135	26	MET	MET	NNP
10_1101-2020_01_28_923532	135	27	,	,	,
10_1101-2020_01_28_923532	135	28	FGFR2	FGFR2	''
10_1101-2020_01_28_923532	135	29	}	}	-RRB-
10_1101-2020_01_28_923532	135	30	and	and	CC
10_1101-2020_01_28_923532	135	31	patient	patient	JJ
10_1101-2020_01_28_923532	135	32	B	B	NNP
10_1101-2020_01_28_923532	135	33	could	could	MD
10_1101-2020_01_28_923532	135	34	be	be	VB
10_1101-2020_01_28_923532	135	35	treated	treat	VBN
10_1101-2020_01_28_923532	135	36	by	by	IN
10_1101-2020_01_28_923532	135	37	targeting	target	VBG
10_1101-2020_01_28_923532	135	38	either	either	CC
10_1101-2020_01_28_923532	135	39	{	{	-LRB-
10_1101-2020_01_28_923532	135	40	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	135	41	,	,	,
10_1101-2020_01_28_923532	135	42	CD44	CD44	NNP
10_1101-2020_01_28_923532	135	43	}	}	-RRB-
10_1101-2020_01_28_923532	135	44	or	or	CC
10_1101-2020_01_28_923532	135	45	{	{	-LRB-
10_1101-2020_01_28_923532	135	46	ANPEP	anpep	NN
10_1101-2020_01_28_923532	135	47	,	,	,
10_1101-2020_01_28_923532	135	48	CD44	CD44	NNP
10_1101-2020_01_28_923532	135	49	}	}	-RRB-
10_1101-2020_01_28_923532	135	50	.	.	.
10_1101-2020_01_28_923532	136	1	Then	then	RB
10_1101-2020_01_28_923532	136	2	we	-PRON-	PRP
10_1101-2020_01_28_923532	136	3	prefer	prefer	VBP
10_1101-2020_01_28_923532	136	4	the	the	DT
10_1101-2020_01_28_923532	136	5	CTS	CTS	NNP
10_1101-2020_01_28_923532	136	6	{	{	-LRB-
10_1101-2020_01_28_923532	136	7	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	136	8	,	,	,
10_1101-2020_01_28_923532	136	9	FGFR2	FGFR2	''
10_1101-2020_01_28_923532	136	10	,	,	,
10_1101-2020_01_28_923532	136	11	CD44	CD44	NNP
10_1101-2020_01_28_923532	136	12	}	}	-RRB-
10_1101-2020_01_28_923532	136	13	of	of	IN
10_1101-2020_01_28_923532	136	14	size	size	NN
10_1101-2020_01_28_923532	136	15	3	3	CD
10_1101-2020_01_28_923532	136	16	and	and	CC
10_1101-2020_01_28_923532	136	17	we	-PRON-	PRP
10_1101-2020_01_28_923532	136	18	treat	treat	VBP
10_1101-2020_01_28_923532	136	19	patient	patient	JJ
10_1101-2020_01_28_923532	136	20	A	A	NNP
10_1101-2020_01_28_923532	136	21	by	by	IN
10_1101-2020_01_28_923532	136	22	targeting	target	VBG
10_1101-2020_01_28_923532	136	23	{	{	-LRB-
10_1101-2020_01_28_923532	136	24	EGFR	egfr	NN
10_1101-2020_01_28_923532	136	25	,	,	,
10_1101-2020_01_28_923532	136	26	FGFR2	FGFR2	''
10_1101-2020_01_28_923532	136	27	}	}	-RRB-
10_1101-2020_01_28_923532	136	28	and	and	CC
10_1101-2020_01_28_923532	136	29	patient	patient	JJ
10_1101-2020_01_28_923532	136	30	B	b	NN
10_1101-2020_01_28_923532	136	31	by	by	IN
10_1101-2020_01_28_923532	136	32	targeting	target	VBG
10_1101-2020_01_28_923532	136	33	{	{	-LRB-
10_1101-2020_01_28_923532	136	34	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	136	35	,	,	,
10_1101-2020_01_28_923532	136	36	CD44	CD44	NNP
10_1101-2020_01_28_923532	136	37	}	}	-RRB-
10_1101-2020_01_28_923532	136	38	.	.	.
10_1101-2020_01_28_923532	137	1	As	as	IN
10_1101-2020_01_28_923532	137	2	the	the	DT
10_1101-2020_01_28_923532	137	3	number	number	NN
10_1101-2020_01_28_923532	137	4	of	of	IN
10_1101-2020_01_28_923532	137	5	cells	cell	NNS
10_1101-2020_01_28_923532	137	6	per	per	IN
10_1101-2020_01_28_923532	137	7	patient	patient	JJ
10_1101-2020_01_28_923532	137	8	varies	varie	NNS
10_1101-2020_01_28_923532	137	9	by	by	IN
10_1101-2020_01_28_923532	137	10	three	three	CD
10_1101-2020_01_28_923532	137	11	orders	order	NNS
10_1101-2020_01_28_923532	137	12	of	of	IN
10_1101-2020_01_28_923532	137	13	magnitude	magnitude	NN
10_1101-2020_01_28_923532	137	14	across	across	IN
10_1101-2020_01_28_923532	137	15	data	data	NN
10_1101-2020_01_28_923532	137	16	sets	set	NNS
10_1101-2020_01_28_923532	137	17	,	,	,
10_1101-2020_01_28_923532	137	18	we	-PRON-	PRP
10_1101-2020_01_28_923532	137	19	use	use	VBP
10_1101-2020_01_28_923532	137	20	random	random	JJ
10_1101-2020_01_28_923532	137	21	sampling	sampling	NN
10_1101-2020_01_28_923532	137	22	to	to	TO
10_1101-2020_01_28_923532	137	23	obtain	obtain	VB
10_1101-2020_01_28_923532	137	24	hitting	hit	VBG
10_1101-2020_01_28_923532	137	25	set	set	VBN
10_1101-2020_01_28_923532	137	26	instances	instance	NNS
10_1101-2020_01_28_923532	137	27	of	of	IN
10_1101-2020_01_28_923532	137	28	comparable	comparable	JJ
10_1101-2020_01_28_923532	137	29	sizes	size	NNS
10_1101-2020_01_28_923532	137	30	and	and	CC
10_1101-2020_01_28_923532	137	31	yet	yet	CC
10_1101-2020_01_28_923532	137	32	adequately	adequately	RB
10_1101-2020_01_28_923532	137	33	capture	capture	VB
10_1101-2020_01_28_923532	137	34	tumor	tumor	NN
10_1101-2020_01_28_923532	137	35	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	137	36	.	.	.
10_1101-2020_01_28_923532	138	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	138	2	found	find	VBD
10_1101-2020_01_28_923532	138	3	that	that	IN
10_1101-2020_01_28_923532	138	4	sampling	sample	VBG
10_1101-2020_01_28_923532	138	5	hundreds	hundred	NNS
10_1101-2020_01_28_923532	138	6	of	of	IN
10_1101-2020_01_28_923532	138	7	cells	cell	NNS
10_1101-2020_01_28_923532	138	8	from	from	IN
10_1101-2020_01_28_923532	138	9	the	the	DT
10_1101-2020_01_28_923532	138	10	tumor	tumor	NN
10_1101-2020_01_28_923532	138	11	is	be	VBZ
10_1101-2020_01_28_923532	138	12	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	138	13	to	to	TO
10_1101-2020_01_28_923532	138	14	get	get	VB
10_1101-2020_01_28_923532	138	15	enough	enough	JJ
10_1101-2020_01_28_923532	138	16	data	datum	NNS
10_1101-2020_01_28_923532	138	17	to	to	TO
10_1101-2020_01_28_923532	138	18	represent	represent	VB
10_1101-2020_01_28_923532	138	19	all	all	DT
10_1101-2020_01_28_923532	138	20	cells	cell	NNS
10_1101-2020_01_28_923532	138	21	.	.	.
10_1101-2020_01_28_923532	139	1	In	in	IN
10_1101-2020_01_28_923532	139	2	most	most	JJS
10_1101-2020_01_28_923532	139	3	of	of	IN
10_1101-2020_01_28_923532	139	4	the	the	DT
10_1101-2020_01_28_923532	139	5	experiments	experiment	NNS
10_1101-2020_01_28_923532	139	6	shown	show	VBN
10_1101-2020_01_28_923532	139	7	,	,	,
10_1101-2020_01_28_923532	139	8	the	the	DT
10_1101-2020_01_28_923532	139	9	number	number	NN
10_1101-2020_01_28_923532	139	10	of	of	IN
10_1101-2020_01_28_923532	139	11	cells	cell	NNS
10_1101-2020_01_28_923532	139	12	sampled	sample	VBN
10_1101-2020_01_28_923532	139	13	,	,	,
10_1101-2020_01_28_923532	139	14	which	which	WDT
10_1101-2020_01_28_923532	139	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	139	16	denote	denote	VBP
10_1101-2020_01_28_923532	139	17	by	by	IN
10_1101-2020_01_28_923532	139	18	𝑐	𝑐	NNP
10_1101-2020_01_28_923532	139	19	,	,	,
10_1101-2020_01_28_923532	139	20	was	be	VBD
10_1101-2020_01_28_923532	139	21	500	500	CD
10_1101-2020_01_28_923532	139	22	.	.	.
10_1101-2020_01_28_923532	140	1	In	in	IN
10_1101-2020_01_28_923532	140	2	some	some	DT
10_1101-2020_01_28_923532	140	3	smaller	small	JJR
10_1101-2020_01_28_923532	140	4	data	data	NN
10_1101-2020_01_28_923532	140	5	sets	set	NNS
10_1101-2020_01_28_923532	140	6	,	,	,
10_1101-2020_01_28_923532	140	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	140	8	had	have	VBD
10_1101-2020_01_28_923532	140	9	to	to	TO
10_1101-2020_01_28_923532	140	10	sample	sample	VB
10_1101-2020_01_28_923532	140	11	smaller	small	JJR
10_1101-2020_01_28_923532	140	12	numbers	number	NNS
10_1101-2020_01_28_923532	140	13	of	of	IN
10_1101-2020_01_28_923532	140	14	cells	cell	NNS
10_1101-2020_01_28_923532	140	15	(	(	-LRB-
10_1101-2020_01_28_923532	140	16	Methods	Methods	NNP
10_1101-2020_01_28_923532	140	17	)	)	-RRB-
10_1101-2020_01_28_923532	140	18	.	.	.
10_1101-2020_01_28_923532	141	1	As	as	IN
10_1101-2020_01_28_923532	141	2	shown	show	VBN
10_1101-2020_01_28_923532	141	3	in	in	IN
10_1101-2020_01_28_923532	141	4	(	(	-LRB-
10_1101-2020_01_28_923532	141	5	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	141	6	Materials	material	NNS
10_1101-2020_01_28_923532	141	7	2	2	CD
10_1101-2020_01_28_923532	141	8	,	,	,
10_1101-2020_01_28_923532	141	9	Figures	Figures	NNP
10_1101-2020_01_28_923532	141	10	S1-S2	S1-S2	NNP
10_1101-2020_01_28_923532	141	11	)	)	-RRB-
10_1101-2020_01_28_923532	141	12	,	,	,
10_1101-2020_01_28_923532	141	13	500	500	CD
10_1101-2020_01_28_923532	141	14	cells	cell	NNS
10_1101-2020_01_28_923532	141	15	,	,	,
10_1101-2020_01_28_923532	141	16	when	when	WRB
10_1101-2020_01_28_923532	141	17	available	available	JJ
10_1101-2020_01_28_923532	141	18	,	,	,
10_1101-2020_01_28_923532	141	19	are	be	VBP
10_1101-2020_01_28_923532	141	20	roughly	roughly	RB
10_1101-2020_01_28_923532	141	21	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	141	22	for	for	IN
10_1101-2020_01_28_923532	141	23	CTS	CTS	NNP
10_1101-2020_01_28_923532	141	24	size	size	NN
10_1101-2020_01_28_923532	141	25	to	to	IN
10_1101-2020_01_28_923532	141	26	plateau	plateau	NN
10_1101-2020_01_28_923532	141	27	for	for	IN
10_1101-2020_01_28_923532	141	28	our	-PRON-	PRP$
10_1101-2020_01_28_923532	141	29	baseline	baseline	JJ
10_1101-2020_01_28_923532	141	30	parameter	parameter	NN
10_1101-2020_01_28_923532	141	31	settings	setting	NNS
10_1101-2020_01_28_923532	141	32	,	,	,
10_1101-2020_01_28_923532	141	33	𝑙𝑏	𝑙𝑏	NNP
10_1101-2020_01_28_923532	141	34	=	=	SYM
10_1101-2020_01_28_923532	141	35	0.8	0.8	CD
10_1101-2020_01_28_923532	141	36	,	,	,
10_1101-2020_01_28_923532	141	37	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	141	38	=	=	SYM
10_1101-2020_01_28_923532	141	39	0.1	0.1	CD
10_1101-2020_01_28_923532	141	40	,	,	,
10_1101-2020_01_28_923532	141	41	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	141	42	=	=	SYM
10_1101-2020_01_28_923532	141	43	2.0	2.0	CD
10_1101-2020_01_28_923532	141	44	.	.	.
10_1101-2020_01_28_923532	142	1	For	for	IN
10_1101-2020_01_28_923532	142	2	each	each	DT
10_1101-2020_01_28_923532	142	3	individual	individual	NN
10_1101-2020_01_28_923532	142	4	within	within	IN
10_1101-2020_01_28_923532	142	5	a	a	DT
10_1101-2020_01_28_923532	142	6	data	data	NN
10_1101-2020_01_28_923532	142	7	set	set	NN
10_1101-2020_01_28_923532	142	8	,	,	,
10_1101-2020_01_28_923532	142	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	142	10	performed	perform	VBD
10_1101-2020_01_28_923532	142	11	independent	independent	JJ
10_1101-2020_01_28_923532	142	12	sampling	sampling	NN
10_1101-2020_01_28_923532	142	13	of	of	IN
10_1101-2020_01_28_923532	142	14	c	c	NNP
10_1101-2020_01_28_923532	142	15	cells	cell	NNS
10_1101-2020_01_28_923532	142	16	20	20	CD
10_1101-2020_01_28_923532	142	17	times	time	NNS
10_1101-2020_01_28_923532	142	18	and	and	CC
10_1101-2020_01_28_923532	142	19	their	-PRON-	PRP$
10_1101-2020_01_28_923532	142	20	results	result	NNS
10_1101-2020_01_28_923532	142	21	were	be	VBD
10_1101-2020_01_28_923532	142	22	summarized	summarize	VBN
10_1101-2020_01_28_923532	142	23	.	.	.
10_1101-2020_01_28_923532	143	1	105	105	CD
10_1101-2020_01_28_923532	143	2	and	and	CC
10_1101-2020_01_28_923532	143	3	is	be	VBZ
10_1101-2020_01_28_923532	143	4	also	also	RB
10_1101-2020_01_28_923532	143	5	made	make	VBN
10_1101-2020_01_28_923532	143	6	available	available	JJ
10_1101-2020_01_28_923532	143	7	for	for	IN
10_1101-2020_01_28_923532	143	8	use	use	NN
10_1101-2020_01_28_923532	143	9	under	under	IN
10_1101-2020_01_28_923532	143	10	a	a	DT
10_1101-2020_01_28_923532	143	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	143	12	license	license	NN
10_1101-2020_01_28_923532	143	13	.	.	.
10_1101-2020_01_28_923532	144	1	(	(	-LRB-
10_1101-2020_01_28_923532	144	2	which	which	WDT
10_1101-2020_01_28_923532	144	3	was	be	VBD
10_1101-2020_01_28_923532	144	4	not	not	RB
10_1101-2020_01_28_923532	144	5	certified	certify	VBN
10_1101-2020_01_28_923532	144	6	by	by	IN
10_1101-2020_01_28_923532	144	7	peer	peer	NN
10_1101-2020_01_28_923532	144	8	review	review	NN
10_1101-2020_01_28_923532	144	9	)	)	-RRB-
10_1101-2020_01_28_923532	144	10	is	be	VBZ
10_1101-2020_01_28_923532	144	11	the	the	DT
10_1101-2020_01_28_923532	144	12	author	author	NN
10_1101-2020_01_28_923532	144	13	/	/	SYM
10_1101-2020_01_28_923532	144	14	funder	funder	NN
10_1101-2020_01_28_923532	144	15	.	.	.
10_1101-2020_01_28_923532	145	1	This	this	DT
10_1101-2020_01_28_923532	145	2	article	article	NN
10_1101-2020_01_28_923532	145	3	is	be	VBZ
10_1101-2020_01_28_923532	145	4	a	a	DT
10_1101-2020_01_28_923532	145	5	US	US	NNP
10_1101-2020_01_28_923532	145	6	Government	Government	NNP
10_1101-2020_01_28_923532	145	7	work	work	NN
10_1101-2020_01_28_923532	145	8	.	.	.
10_1101-2020_01_28_923532	146	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	146	2	is	be	VBZ
10_1101-2020_01_28_923532	146	3	not	not	RB
10_1101-2020_01_28_923532	146	4	subject	subject	JJ
10_1101-2020_01_28_923532	146	5	to	to	IN
10_1101-2020_01_28_923532	146	6	copyright	copyright	NN
10_1101-2020_01_28_923532	146	7	under	under	IN
10_1101-2020_01_28_923532	146	8	17	17	CD
10_1101-2020_01_28_923532	146	9	USC	usc	NN
10_1101-2020_01_28_923532	146	10	The	the	DT
10_1101-2020_01_28_923532	146	11	copyright	copyright	NN
10_1101-2020_01_28_923532	146	12	holder	holder	NN
10_1101-2020_01_28_923532	146	13	for	for	IN
10_1101-2020_01_28_923532	146	14	this	this	DT
10_1101-2020_01_28_923532	146	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	146	16	version	version	NN
10_1101-2020_01_28_923532	146	17	posted	post	VBD
10_1101-2020_01_28_923532	146	18	February	February	NNP
10_1101-2020_01_28_923532	146	19	12	12	CD
10_1101-2020_01_28_923532	146	20	,	,	,
10_1101-2020_01_28_923532	146	21	2021	2021	CD
10_1101-2020_01_28_923532	146	22	.	.	.
10_1101-2020_01_28_923532	146	23	;	;	:
10_1101-2020_01_28_923532	146	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	146	25	:	:	:
10_1101-2020_01_28_923532	146	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	146	27	preprint	preprint	NN
10_1101-2020_01_28_923532	146	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	146	29	12	12	CD
10_1101-2020_01_28_923532	146	30	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	146	31	and	and	CC
10_1101-2020_01_28_923532	146	32	Individual	Individual	NNP
10_1101-2020_01_28_923532	146	33	Target	Target	NNP
10_1101-2020_01_28_923532	146	34	Set	Set	NNP
10_1101-2020_01_28_923532	146	35	Sizes	size	NNS
10_1101-2020_01_28_923532	146	36	as	as	IN
10_1101-2020_01_28_923532	146	37	Functions	function	NNS
10_1101-2020_01_28_923532	146	38	of	of	IN
10_1101-2020_01_28_923532	146	39	Tumor	Tumor	NNP
10_1101-2020_01_28_923532	146	40	Killing	Killing	NNP
10_1101-2020_01_28_923532	146	41	and	and	CC
10_1101-2020_01_28_923532	146	42	Non	Non	NNP
10_1101-2020_01_28_923532	146	43	-	-	JJ
10_1101-2020_01_28_923532	146	44	Tumor	tumor	JJ
10_1101-2020_01_28_923532	146	45	Sparing	Sparing	NNP
10_1101-2020_01_28_923532	146	46	Goals	Goals	NNPS
10_1101-2020_01_28_923532	146	47	Given	give	VBN
10_1101-2020_01_28_923532	146	48	the	the	DT
10_1101-2020_01_28_923532	146	49	single	single	JJ
10_1101-2020_01_28_923532	146	50	-	-	HYPH
10_1101-2020_01_28_923532	146	51	cell	cell	NN
10_1101-2020_01_28_923532	146	52	tumor	tumor	NN
10_1101-2020_01_28_923532	146	53	data	datum	NNS
10_1101-2020_01_28_923532	146	54	sets	set	NNS
10_1101-2020_01_28_923532	146	55	and	and	CC
10_1101-2020_01_28_923532	146	56	the	the	DT
10_1101-2020_01_28_923532	146	57	ILP	ILP	NNP
10_1101-2020_01_28_923532	146	58	optimization	optimization	NN
10_1101-2020_01_28_923532	146	59	framework	framework	NN
10_1101-2020_01_28_923532	146	60	described	describe	VBN
10_1101-2020_01_28_923532	146	61	above	above	RB
10_1101-2020_01_28_923532	146	62	,	,	,
10_1101-2020_01_28_923532	146	63	we	-PRON-	PRP
10_1101-2020_01_28_923532	146	64	first	first	RB
10_1101-2020_01_28_923532	146	65	studied	study	VBD
10_1101-2020_01_28_923532	146	66	how	how	WRB
10_1101-2020_01_28_923532	146	67	the	the	DT
10_1101-2020_01_28_923532	146	68	resulting	result	VBG
10_1101-2020_01_28_923532	146	69	optimal	optimal	JJ
10_1101-2020_01_28_923532	146	70	cohort	cohort	NN
10_1101-2020_01_28_923532	146	71	target	target	NN
10_1101-2020_01_28_923532	146	72	set	set	VBN
10_1101-2020_01_28_923532	146	73	(	(	-LRB-
10_1101-2020_01_28_923532	146	74	CTS	CTS	NNP
10_1101-2020_01_28_923532	146	75	)	)	-RRB-
10_1101-2020_01_28_923532	146	76	may	may	MD
10_1101-2020_01_28_923532	146	77	vary	vary	VB
10_1101-2020_01_28_923532	146	78	as	as	IN
10_1101-2020_01_28_923532	146	79	a	a	DT
10_1101-2020_01_28_923532	146	80	function	function	NN
10_1101-2020_01_28_923532	146	81	of	of	IN
10_1101-2020_01_28_923532	146	82	the	the	DT
10_1101-2020_01_28_923532	146	83	parameters	parameter	NNS
10_1101-2020_01_28_923532	146	84	defining	define	VBG
10_1101-2020_01_28_923532	146	85	the	the	DT
10_1101-2020_01_28_923532	146	86	optimization	optimization	NN
10_1101-2020_01_28_923532	146	87	objectives	objective	NNS
10_1101-2020_01_28_923532	146	88	in	in	IN
10_1101-2020_01_28_923532	146	89	different	different	JJ
10_1101-2020_01_28_923532	146	90	cancer	cancer	NN
10_1101-2020_01_28_923532	146	91	types	type	NNS
10_1101-2020_01_28_923532	146	92	.	.	.
10_1101-2020_01_28_923532	147	1	Figures	figure	NNS
10_1101-2020_01_28_923532	147	2	3	3	CD
10_1101-2020_01_28_923532	147	3	and	and	CC
10_1101-2020_01_28_923532	147	4	S3-S7	S3-S7	NNP
10_1101-2020_01_28_923532	147	5	in	in	IN
10_1101-2020_01_28_923532	147	6	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	147	7	Materials	material	NNS
10_1101-2020_01_28_923532	147	8	3	3	CD
10_1101-2020_01_28_923532	147	9	show	show	VBP
10_1101-2020_01_28_923532	147	10	heatmaps	heatmap	NNS
10_1101-2020_01_28_923532	147	11	of	of	IN
10_1101-2020_01_28_923532	147	12	CTS	CTS	NNP
10_1101-2020_01_28_923532	147	13	sizes	size	NNS
10_1101-2020_01_28_923532	147	14	when	when	WRB
10_1101-2020_01_28_923532	147	15	varying	vary	VBG
10_1101-2020_01_28_923532	147	16	lb	lb	RB
10_1101-2020_01_28_923532	147	17	,	,	,
10_1101-2020_01_28_923532	147	18	ub	ub	NNP
10_1101-2020_01_28_923532	147	19	,	,	,
10_1101-2020_01_28_923532	147	20	and	and	CC
10_1101-2020_01_28_923532	147	21	r	r	LS
10_1101-2020_01_28_923532	147	22	around	around	IN
10_1101-2020_01_28_923532	147	23	the	the	DT
10_1101-2020_01_28_923532	147	24	baseline	baseline	JJ
10_1101-2020_01_28_923532	147	25	values	value	NNS
10_1101-2020_01_28_923532	147	26	of	of	IN
10_1101-2020_01_28_923532	147	27	0.8	0.8	CD
10_1101-2020_01_28_923532	147	28	,	,	,
10_1101-2020_01_28_923532	147	29	0.1	0.1	CD
10_1101-2020_01_28_923532	147	30	,	,	,
10_1101-2020_01_28_923532	147	31	and	and	CC
10_1101-2020_01_28_923532	147	32	2.0	2.0	CD
10_1101-2020_01_28_923532	147	33	,	,	,
10_1101-2020_01_28_923532	147	34	respectively	respectively	RB
10_1101-2020_01_28_923532	147	35	.	.	.
10_1101-2020_01_28_923532	148	1	The	the	DT
10_1101-2020_01_28_923532	148	2	CTS	CTS	NNP
10_1101-2020_01_28_923532	148	3	sizes	size	VBZ
10_1101-2020_01_28_923532	148	4	for	for	IN
10_1101-2020_01_28_923532	148	5	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	148	6	were	be	VBD
10_1101-2020_01_28_923532	148	7	largest	large	JJS
10_1101-2020_01_28_923532	148	8	,	,	,
10_1101-2020_01_28_923532	148	9	partly	partly	RB
10_1101-2020_01_28_923532	148	10	due	due	JJ
10_1101-2020_01_28_923532	148	11	to	to	IN
10_1101-2020_01_28_923532	148	12	the	the	DT
10_1101-2020_01_28_923532	148	13	larger	large	JJR
10_1101-2020_01_28_923532	148	14	number	number	NN
10_1101-2020_01_28_923532	148	15	of	of	IN
10_1101-2020_01_28_923532	148	16	patients	patient	NNS
10_1101-2020_01_28_923532	148	17	in	in	IN
10_1101-2020_01_28_923532	148	18	that	that	DT
10_1101-2020_01_28_923532	148	19	data	data	NN
10_1101-2020_01_28_923532	148	20	set	set	NN
10_1101-2020_01_28_923532	148	21	(	(	-LRB-
10_1101-2020_01_28_923532	148	22	Table	table	NN
10_1101-2020_01_28_923532	148	23	1	1	CD
10_1101-2020_01_28_923532	148	24	)	)	-RRB-
10_1101-2020_01_28_923532	148	25	.	.	.
10_1101-2020_01_28_923532	149	1	Indeed	indeed	RB
10_1101-2020_01_28_923532	149	2	,	,	,
10_1101-2020_01_28_923532	149	3	as	as	IN
10_1101-2020_01_28_923532	149	4	we	-PRON-	PRP
10_1101-2020_01_28_923532	149	5	sampled	sample	VBD
10_1101-2020_01_28_923532	149	6	subsets	subset	NNS
10_1101-2020_01_28_923532	149	7	of	of	IN
10_1101-2020_01_28_923532	149	8	5	5	CD
10_1101-2020_01_28_923532	149	9	or	or	CC
10_1101-2020_01_28_923532	149	10	10	10	CD
10_1101-2020_01_28_923532	149	11	patients	patient	NNS
10_1101-2020_01_28_923532	149	12	uniformly	uniformly	JJ
10_1101-2020_01_28_923532	149	13	and	and	CC
10_1101-2020_01_28_923532	149	14	observed	observe	VBD
10_1101-2020_01_28_923532	149	15	that	that	IN
10_1101-2020_01_28_923532	149	16	the	the	DT
10_1101-2020_01_28_923532	149	17	mean	mean	JJ
10_1101-2020_01_28_923532	149	18	CTS	CTS	NNP
10_1101-2020_01_28_923532	149	19	sizes	size	NNS
10_1101-2020_01_28_923532	149	20	grew	grow	VBD
10_1101-2020_01_28_923532	149	21	from	from	IN
10_1101-2020_01_28_923532	149	22	7.9	7.9	CD
10_1101-2020_01_28_923532	149	23	(	(	-LRB-
10_1101-2020_01_28_923532	149	24	5	5	CD
10_1101-2020_01_28_923532	149	25	patient	patient	JJ
10_1101-2020_01_28_923532	149	26	subsets	subset	NNS
10_1101-2020_01_28_923532	149	27	)	)	-RRB-
10_1101-2020_01_28_923532	149	28	to	to	IN
10_1101-2020_01_28_923532	149	29	12.3	12.3	CD
10_1101-2020_01_28_923532	149	30	(	(	-LRB-
10_1101-2020_01_28_923532	149	31	10	10	CD
10_1101-2020_01_28_923532	149	32	patient	patient	JJ
10_1101-2020_01_28_923532	149	33	subsets	subset	NNS
10_1101-2020_01_28_923532	149	34	)	)	-RRB-
10_1101-2020_01_28_923532	149	35	to	to	IN
10_1101-2020_01_28_923532	149	36	31.0	31.0	CD
10_1101-2020_01_28_923532	149	37	(	(	-LRB-
10_1101-2020_01_28_923532	149	38	all	all	DT
10_1101-2020_01_28_923532	149	39	patients	patient	NNS
10_1101-2020_01_28_923532	149	40	,	,	,
10_1101-2020_01_28_923532	149	41	as	as	IN
10_1101-2020_01_28_923532	149	42	shown	show	VBN
10_1101-2020_01_28_923532	149	43	in	in	IN
10_1101-2020_01_28_923532	149	44	Figure	Figure	NNP
10_1101-2020_01_28_923532	149	45	3	3	CD
10_1101-2020_01_28_923532	149	46	)	)	-RRB-
10_1101-2020_01_28_923532	149	47	.	.	.
10_1101-2020_01_28_923532	150	1	Encouragingly	encouragingly	RB
10_1101-2020_01_28_923532	150	2	,	,	,
10_1101-2020_01_28_923532	150	3	for	for	IN
10_1101-2020_01_28_923532	150	4	most	most	JJS
10_1101-2020_01_28_923532	150	5	data	data	NN
10_1101-2020_01_28_923532	150	6	sets	set	NNS
10_1101-2020_01_28_923532	150	7	and	and	CC
10_1101-2020_01_28_923532	150	8	parameter	parameter	NN
10_1101-2020_01_28_923532	150	9	settings	setting	NNS
10_1101-2020_01_28_923532	150	10	,	,	,
10_1101-2020_01_28_923532	150	11	the	the	DT
10_1101-2020_01_28_923532	150	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	150	13	CTS	CTS	NNP
10_1101-2020_01_28_923532	150	14	sizes	size	NNS
10_1101-2020_01_28_923532	150	15	are	be	VBP
10_1101-2020_01_28_923532	150	16	in	in	IN
10_1101-2020_01_28_923532	150	17	the	the	DT
10_1101-2020_01_28_923532	150	18	single	single	JJ
10_1101-2020_01_28_923532	150	19	digits	digit	NNS
10_1101-2020_01_28_923532	150	20	.	.	.
10_1101-2020_01_28_923532	151	1	However	however	RB
10_1101-2020_01_28_923532	151	2	,	,	,
10_1101-2020_01_28_923532	151	3	in	in	IN
10_1101-2020_01_28_923532	151	4	several	several	JJ
10_1101-2020_01_28_923532	151	5	data	data	NN
10_1101-2020_01_28_923532	151	6	sets	set	NNS
10_1101-2020_01_28_923532	151	7	,	,	,
10_1101-2020_01_28_923532	151	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	151	9	observe	observe	VBP
10_1101-2020_01_28_923532	151	10	a	a	DT
10_1101-2020_01_28_923532	151	11	sharp	sharp	JJ
10_1101-2020_01_28_923532	151	12	increase	increase	NN
10_1101-2020_01_28_923532	151	13	in	in	IN
10_1101-2020_01_28_923532	151	14	CTS	CTS	NNP
10_1101-2020_01_28_923532	151	15	size	size	NN
10_1101-2020_01_28_923532	151	16	as	as	IN
10_1101-2020_01_28_923532	151	17	𝑙𝑏	𝑙𝑏	NNP
10_1101-2020_01_28_923532	151	18	values	value	NNS
10_1101-2020_01_28_923532	151	19	are	be	VBP
10_1101-2020_01_28_923532	151	20	increased	increase	VBN
10_1101-2020_01_28_923532	151	21	above	above	IN
10_1101-2020_01_28_923532	151	22	0.8	0.8	CD
10_1101-2020_01_28_923532	151	23	and/or	and/or	CC
10_1101-2020_01_28_923532	151	24	as	as	IN
10_1101-2020_01_28_923532	151	25	the	the	DT
10_1101-2020_01_28_923532	151	26	𝑢𝑏	𝑢𝑏	NN
10_1101-2020_01_28_923532	151	27	is	be	VBZ
10_1101-2020_01_28_923532	151	28	decreased	decrease	VBN
10_1101-2020_01_28_923532	151	29	below	below	IN
10_1101-2020_01_28_923532	151	30	0.1	0.1	CD
10_1101-2020_01_28_923532	151	31	,	,	,
10_1101-2020_01_28_923532	151	32	with	with	IN
10_1101-2020_01_28_923532	151	33	a	a	DT
10_1101-2020_01_28_923532	151	34	more	more	RBR
10_1101-2020_01_28_923532	151	35	pronounced	pronounced	JJ
10_1101-2020_01_28_923532	151	36	effect	effect	NN
10_1101-2020_01_28_923532	151	37	of	of	IN
10_1101-2020_01_28_923532	151	38	varying	vary	VBG
10_1101-2020_01_28_923532	151	39	𝑙𝑏.	𝑙𝑏.	NN
10_1101-2020_01_28_923532	152	1	This	this	DT
10_1101-2020_01_28_923532	152	2	transition	transition	NN
10_1101-2020_01_28_923532	152	3	is	be	VBZ
10_1101-2020_01_28_923532	152	4	more	more	RBR
10_1101-2020_01_28_923532	152	5	discernable	discernable	JJ
10_1101-2020_01_28_923532	152	6	at	at	IN
10_1101-2020_01_28_923532	152	7	the	the	DT
10_1101-2020_01_28_923532	152	8	lowest	low	JJS
10_1101-2020_01_28_923532	152	9	value	value	NN
10_1101-2020_01_28_923532	152	10	of	of	IN
10_1101-2020_01_28_923532	152	11	𝑟	𝑟	NN
10_1101-2020_01_28_923532	152	12	(	(	-LRB-
10_1101-2020_01_28_923532	152	13	1.5	1.5	CD
10_1101-2020_01_28_923532	152	14	)	)	-RRB-
10_1101-2020_01_28_923532	152	15	,	,	,
10_1101-2020_01_28_923532	152	16	probably	probably	RB
10_1101-2020_01_28_923532	152	17	because	because	IN
10_1101-2020_01_28_923532	152	18	when	when	WRB
10_1101-2020_01_28_923532	152	19	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	152	20	is	be	VBZ
10_1101-2020_01_28_923532	152	21	lower	low	JJR
10_1101-2020_01_28_923532	152	22	,	,	,
10_1101-2020_01_28_923532	152	23	it	-PRON-	PRP
10_1101-2020_01_28_923532	152	24	becomes	become	VBZ
10_1101-2020_01_28_923532	152	25	harder	hard	JJR
10_1101-2020_01_28_923532	152	26	to	to	TO
10_1101-2020_01_28_923532	152	27	find	find	VB
10_1101-2020_01_28_923532	152	28	genes	gene	NNS
10_1101-2020_01_28_923532	152	29	that	that	WDT
10_1101-2020_01_28_923532	152	30	are	be	VBP
10_1101-2020_01_28_923532	152	31	individually	individually	RB
10_1101-2020_01_28_923532	152	32	selective	selective	JJ
10_1101-2020_01_28_923532	152	33	in	in	IN
10_1101-2020_01_28_923532	152	34	killing	kill	VBG
10_1101-2020_01_28_923532	152	35	tumor	tumor	NN
10_1101-2020_01_28_923532	152	36	cells	cell	NNS
10_1101-2020_01_28_923532	152	37	and	and	CC
10_1101-2020_01_28_923532	152	38	sparing	spare	VBG
10_1101-2020_01_28_923532	152	39	non	non	JJ
10_1101-2020_01_28_923532	152	40	-	-	JJ
10_1101-2020_01_28_923532	152	41	tumor	tumor	JJ
10_1101-2020_01_28_923532	152	42	cells	cell	NNS
10_1101-2020_01_28_923532	152	43	(	(	-LRB-
10_1101-2020_01_28_923532	152	44	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	152	45	Figures	Figures	NNPS
10_1101-2020_01_28_923532	152	46	S3-S7	S3-S7	NNP
10_1101-2020_01_28_923532	152	47	)	)	-RRB-
10_1101-2020_01_28_923532	152	48	.	.	.
10_1101-2020_01_28_923532	153	1	The	the	DT
10_1101-2020_01_28_923532	153	2	qualitative	qualitative	JJ
10_1101-2020_01_28_923532	153	3	transition	transition	NN
10_1101-2020_01_28_923532	153	4	observed	observe	VBN
10_1101-2020_01_28_923532	153	5	in	in	IN
10_1101-2020_01_28_923532	153	6	CTS	CTS	NNP
10_1101-2020_01_28_923532	153	7	sizes	size	NNS
10_1101-2020_01_28_923532	153	8	occurs	occur	VBZ
10_1101-2020_01_28_923532	153	9	robustly	robustly	RB
10_1101-2020_01_28_923532	153	10	regardless	regardless	RB
10_1101-2020_01_28_923532	153	11	of	of	IN
10_1101-2020_01_28_923532	153	12	the	the	DT
10_1101-2020_01_28_923532	153	13	threshold	threshold	NN
10_1101-2020_01_28_923532	153	14	for	for	IN
10_1101-2020_01_28_923532	153	15	filtering	filter	VBG
10_1101-2020_01_28_923532	153	16	out	out	RP
10_1101-2020_01_28_923532	153	17	low	low	JJ
10_1101-2020_01_28_923532	153	18	expressing	express	VBG
10_1101-2020_01_28_923532	153	19	cells	cell	NNS
10_1101-2020_01_28_923532	153	20	when	when	WRB
10_1101-2020_01_28_923532	153	21	preprocessing	preprocesse	VBG
10_1101-2020_01_28_923532	153	22	the	the	DT
10_1101-2020_01_28_923532	153	23	data	datum	NNS
10_1101-2020_01_28_923532	153	24	(	(	-LRB-
10_1101-2020_01_28_923532	153	25	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	153	26	Materials	Materials	NNP
10_1101-2020_01_28_923532	153	27	4	4	CD
10_1101-2020_01_28_923532	153	28	,	,	,
10_1101-2020_01_28_923532	153	29	Figures	Figures	NNPS
10_1101-2020_01_28_923532	153	30	S8-S10	S8-S10	NNP
10_1101-2020_01_28_923532	153	31	)	)	-RRB-
10_1101-2020_01_28_923532	153	32	.	.	.
10_1101-2020_01_28_923532	154	1	105	105	CD
10_1101-2020_01_28_923532	154	2	and	and	CC
10_1101-2020_01_28_923532	154	3	is	be	VBZ
10_1101-2020_01_28_923532	154	4	also	also	RB
10_1101-2020_01_28_923532	154	5	made	make	VBN
10_1101-2020_01_28_923532	154	6	available	available	JJ
10_1101-2020_01_28_923532	154	7	for	for	IN
10_1101-2020_01_28_923532	154	8	use	use	NN
10_1101-2020_01_28_923532	154	9	under	under	IN
10_1101-2020_01_28_923532	154	10	a	a	DT
10_1101-2020_01_28_923532	154	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	154	12	license	license	NN
10_1101-2020_01_28_923532	154	13	.	.	.
10_1101-2020_01_28_923532	155	1	(	(	-LRB-
10_1101-2020_01_28_923532	155	2	which	which	WDT
10_1101-2020_01_28_923532	155	3	was	be	VBD
10_1101-2020_01_28_923532	155	4	not	not	RB
10_1101-2020_01_28_923532	155	5	certified	certify	VBN
10_1101-2020_01_28_923532	155	6	by	by	IN
10_1101-2020_01_28_923532	155	7	peer	peer	NN
10_1101-2020_01_28_923532	155	8	review	review	NN
10_1101-2020_01_28_923532	155	9	)	)	-RRB-
10_1101-2020_01_28_923532	155	10	is	be	VBZ
10_1101-2020_01_28_923532	155	11	the	the	DT
10_1101-2020_01_28_923532	155	12	author	author	NN
10_1101-2020_01_28_923532	155	13	/	/	SYM
10_1101-2020_01_28_923532	155	14	funder	funder	NN
10_1101-2020_01_28_923532	155	15	.	.	.
10_1101-2020_01_28_923532	156	1	This	this	DT
10_1101-2020_01_28_923532	156	2	article	article	NN
10_1101-2020_01_28_923532	156	3	is	be	VBZ
10_1101-2020_01_28_923532	156	4	a	a	DT
10_1101-2020_01_28_923532	156	5	US	US	NNP
10_1101-2020_01_28_923532	156	6	Government	Government	NNP
10_1101-2020_01_28_923532	156	7	work	work	NN
10_1101-2020_01_28_923532	156	8	.	.	.
10_1101-2020_01_28_923532	157	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	157	2	is	be	VBZ
10_1101-2020_01_28_923532	157	3	not	not	RB
10_1101-2020_01_28_923532	157	4	subject	subject	JJ
10_1101-2020_01_28_923532	157	5	to	to	IN
10_1101-2020_01_28_923532	157	6	copyright	copyright	NN
10_1101-2020_01_28_923532	157	7	under	under	IN
10_1101-2020_01_28_923532	157	8	17	17	CD
10_1101-2020_01_28_923532	157	9	USC	usc	NN
10_1101-2020_01_28_923532	157	10	The	the	DT
10_1101-2020_01_28_923532	157	11	copyright	copyright	NN
10_1101-2020_01_28_923532	157	12	holder	holder	NN
10_1101-2020_01_28_923532	157	13	for	for	IN
10_1101-2020_01_28_923532	157	14	this	this	DT
10_1101-2020_01_28_923532	157	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	157	16	version	version	NN
10_1101-2020_01_28_923532	157	17	posted	post	VBD
10_1101-2020_01_28_923532	157	18	February	February	NNP
10_1101-2020_01_28_923532	157	19	12	12	CD
10_1101-2020_01_28_923532	157	20	,	,	,
10_1101-2020_01_28_923532	157	21	2021	2021	CD
10_1101-2020_01_28_923532	157	22	.	.	.
10_1101-2020_01_28_923532	157	23	;	;	:
10_1101-2020_01_28_923532	157	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	157	25	:	:	:
10_1101-2020_01_28_923532	157	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	157	27	preprint	preprint	NN
10_1101-2020_01_28_923532	157	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	157	29	13	13	CD
10_1101-2020_01_28_923532	157	30	Figure	figure	NN
10_1101-2020_01_28_923532	157	31	3	3	CD
10_1101-2020_01_28_923532	157	32	.	.	.
10_1101-2020_01_28_923532	158	1	Heat	heat	NN
10_1101-2020_01_28_923532	158	2	maps	map	NNS
10_1101-2020_01_28_923532	158	3	showing	show	VBG
10_1101-2020_01_28_923532	158	4	how	how	WRB
10_1101-2020_01_28_923532	158	5	the	the	DT
10_1101-2020_01_28_923532	158	6	cohort	cohort	NN
10_1101-2020_01_28_923532	158	7	target	target	NN
10_1101-2020_01_28_923532	158	8	set	set	VBN
10_1101-2020_01_28_923532	158	9	size	size	NN
10_1101-2020_01_28_923532	158	10	(	(	-LRB-
10_1101-2020_01_28_923532	158	11	CTS	CTS	NNP
10_1101-2020_01_28_923532	158	12	)	)	-RRB-
10_1101-2020_01_28_923532	158	13	varies	vary	VBZ
10_1101-2020_01_28_923532	158	14	as	as	IN
10_1101-2020_01_28_923532	158	15	a	a	DT
10_1101-2020_01_28_923532	158	16	function	function	NN
10_1101-2020_01_28_923532	158	17	of	of	IN
10_1101-2020_01_28_923532	158	18	𝒍𝒃	𝒍𝒃	NNP
10_1101-2020_01_28_923532	158	19	,	,	,
10_1101-2020_01_28_923532	158	20	𝒖𝒃	𝒖𝒃	NNP
10_1101-2020_01_28_923532	158	21	,	,	,
10_1101-2020_01_28_923532	158	22	𝒓	𝒓	NNP
10_1101-2020_01_28_923532	158	23	and	and	CC
10_1101-2020_01_28_923532	158	24	across	across	IN
10_1101-2020_01_28_923532	158	25	data	datum	NNS
10_1101-2020_01_28_923532	158	26	sets	set	NNS
10_1101-2020_01_28_923532	158	27	.	.	.
10_1101-2020_01_28_923532	159	1	For	for	IN
10_1101-2020_01_28_923532	159	2	each	each	DT
10_1101-2020_01_28_923532	159	3	plot	plot	NN
10_1101-2020_01_28_923532	159	4	the	the	DT
10_1101-2020_01_28_923532	159	5	x	x	NN
10_1101-2020_01_28_923532	159	6	-	-	:
10_1101-2020_01_28_923532	159	7	axis	axis	NN
10_1101-2020_01_28_923532	159	8	and	and	CC
10_1101-2020_01_28_923532	159	9	y	y	NN
10_1101-2020_01_28_923532	159	10	-	-	:
10_1101-2020_01_28_923532	159	11	axis	axis	NNP
10_1101-2020_01_28_923532	159	12	represent	represent	VBP
10_1101-2020_01_28_923532	159	13	lb	lb	JJ
10_1101-2020_01_28_923532	159	14	and	and	CC
10_1101-2020_01_28_923532	159	15	ub	ub	IN
10_1101-2020_01_28_923532	159	16	parameter	parameter	NN
10_1101-2020_01_28_923532	159	17	values	value	NNS
10_1101-2020_01_28_923532	159	18	,	,	,
10_1101-2020_01_28_923532	159	19	respectively	respectively	RB
10_1101-2020_01_28_923532	159	20	.	.	.
10_1101-2020_01_28_923532	160	1	The	the	DT
10_1101-2020_01_28_923532	160	2	scale	scale	NN
10_1101-2020_01_28_923532	160	3	on	on	IN
10_1101-2020_01_28_923532	160	4	the	the	DT
10_1101-2020_01_28_923532	160	5	right	right	NN
10_1101-2020_01_28_923532	160	6	shows	show	VBZ
10_1101-2020_01_28_923532	160	7	the	the	DT
10_1101-2020_01_28_923532	160	8	cohort	cohort	NN
10_1101-2020_01_28_923532	160	9	target	target	NN
10_1101-2020_01_28_923532	160	10	set	set	VBN
10_1101-2020_01_28_923532	160	11	sizes	size	NNS
10_1101-2020_01_28_923532	160	12	by	by	IN
10_1101-2020_01_28_923532	160	13	color	color	NN
10_1101-2020_01_28_923532	160	14	scale	scale	NN
10_1101-2020_01_28_923532	160	15	.	.	.
10_1101-2020_01_28_923532	161	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	161	2	show	show	VBP
10_1101-2020_01_28_923532	161	3	separate	separate	JJ
10_1101-2020_01_28_923532	161	4	plots	plot	NNS
10_1101-2020_01_28_923532	161	5	for	for	IN
10_1101-2020_01_28_923532	161	6	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	161	7	=	=	SYM
10_1101-2020_01_28_923532	161	8	2.0	2.0	CD
10_1101-2020_01_28_923532	161	9	,	,	,
10_1101-2020_01_28_923532	161	10	3.0	3.0	CD
10_1101-2020_01_28_923532	161	11	here	here	RB
10_1101-2020_01_28_923532	161	12	and	and	CC
10_1101-2020_01_28_923532	161	13	a	a	DT
10_1101-2020_01_28_923532	161	14	larger	large	JJR
10_1101-2020_01_28_923532	161	15	set	set	NN
10_1101-2020_01_28_923532	161	16	{	{	-LRB-
10_1101-2020_01_28_923532	161	17	1.5	1.5	CD
10_1101-2020_01_28_923532	161	18	,	,	,
10_1101-2020_01_28_923532	161	19	2.0	2.0	CD
10_1101-2020_01_28_923532	161	20	,	,	,
10_1101-2020_01_28_923532	161	21	2.5	2.5	CD
10_1101-2020_01_28_923532	161	22	,	,	,
10_1101-2020_01_28_923532	161	23	3.0	3.0	CD
10_1101-2020_01_28_923532	161	24	}	}	-RRB-
10_1101-2020_01_28_923532	161	25	in	in	IN
10_1101-2020_01_28_923532	161	26	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	161	27	Materials	Materials	NNP
10_1101-2020_01_28_923532	161	28	3	3	CD
10_1101-2020_01_28_923532	161	29	.	.	.
10_1101-2020_01_28_923532	162	1	Individual	individual	JJ
10_1101-2020_01_28_923532	162	2	values	value	NNS
10_1101-2020_01_28_923532	162	3	are	be	VBP
10_1101-2020_01_28_923532	162	4	not	not	RB
10_1101-2020_01_28_923532	162	5	necessarily	necessarily	RB
10_1101-2020_01_28_923532	162	6	integers	integer	NNS
10_1101-2020_01_28_923532	162	7	because	because	IN
10_1101-2020_01_28_923532	162	8	each	each	DT
10_1101-2020_01_28_923532	162	9	value	value	NN
10_1101-2020_01_28_923532	162	10	represents	represent	VBZ
10_1101-2020_01_28_923532	162	11	the	the	DT
10_1101-2020_01_28_923532	162	12	mean	mean	NN
10_1101-2020_01_28_923532	162	13	of	of	IN
10_1101-2020_01_28_923532	162	14	20	20	CD
10_1101-2020_01_28_923532	162	15	replicates	replicate	NNS
10_1101-2020_01_28_923532	162	16	of	of	IN
10_1101-2020_01_28_923532	162	17	sampling	sample	VBG
10_1101-2020_01_28_923532	162	18	𝑐	𝑐	NN
10_1101-2020_01_28_923532	162	19	(	(	-LRB-
10_1101-2020_01_28_923532	162	20	500	500	CD
10_1101-2020_01_28_923532	162	21	for	for	IN
10_1101-2020_01_28_923532	162	22	each	each	DT
10_1101-2020_01_28_923532	162	23	of	of	IN
10_1101-2020_01_28_923532	162	24	the	the	DT
10_1101-2020_01_28_923532	162	25	data	data	NN
10_1101-2020_01_28_923532	162	26	sets	set	NNS
10_1101-2020_01_28_923532	162	27	shown	show	VBN
10_1101-2020_01_28_923532	162	28	here	here	RB
10_1101-2020_01_28_923532	162	29	)	)	-RRB-
10_1101-2020_01_28_923532	162	30	cells	cell	NNS
10_1101-2020_01_28_923532	162	31	(	(	-LRB-
10_1101-2020_01_28_923532	162	32	Figure	figure	NN
10_1101-2020_01_28_923532	162	33	S1	s1	NN
10_1101-2020_01_28_923532	162	34	)	)	-RRB-
10_1101-2020_01_28_923532	162	35	.	.	.
10_1101-2020_01_28_923532	163	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	163	2	next	next	RB
10_1101-2020_01_28_923532	163	3	examined	examine	VBD
10_1101-2020_01_28_923532	163	4	what	what	WP
10_1101-2020_01_28_923532	163	5	are	be	VBP
10_1101-2020_01_28_923532	163	6	the	the	DT
10_1101-2020_01_28_923532	163	7	resulting	result	VBG
10_1101-2020_01_28_923532	163	8	individual	individual	JJ
10_1101-2020_01_28_923532	163	9	target	target	NN
10_1101-2020_01_28_923532	163	10	set	set	VBN
10_1101-2020_01_28_923532	163	11	(	(	-LRB-
10_1101-2020_01_28_923532	163	12	ITS	its	PRP$
10_1101-2020_01_28_923532	163	13	)	)	-RRB-
10_1101-2020_01_28_923532	163	14	sizes	size	NNS
10_1101-2020_01_28_923532	163	15	obtained	obtain	VBN
10_1101-2020_01_28_923532	163	16	in	in	IN
10_1101-2020_01_28_923532	163	17	the	the	DT
10_1101-2020_01_28_923532	163	18	optimal	optimal	JJ
10_1101-2020_01_28_923532	163	19	combinations	combination	NNS
10_1101-2020_01_28_923532	163	20	under	under	IN
10_1101-2020_01_28_923532	163	21	the	the	DT
10_1101-2020_01_28_923532	163	22	same	same	JJ
10_1101-2020_01_28_923532	163	23	conditions	condition	NNS
10_1101-2020_01_28_923532	163	24	.	.	.
10_1101-2020_01_28_923532	164	1	In	in	IN
10_1101-2020_01_28_923532	164	2	all	all	DT
10_1101-2020_01_28_923532	164	3	data	data	NN
10_1101-2020_01_28_923532	164	4	sets	set	NNS
10_1101-2020_01_28_923532	164	5	,	,	,
10_1101-2020_01_28_923532	164	6	the	the	DT
10_1101-2020_01_28_923532	164	7	mean	mean	JJ
10_1101-2020_01_28_923532	164	8	ITS	its	PRP$
10_1101-2020_01_28_923532	164	9	sizes	size	NNS
10_1101-2020_01_28_923532	164	10	are	be	VBP
10_1101-2020_01_28_923532	164	11	in	in	IN
10_1101-2020_01_28_923532	164	12	the	the	DT
10_1101-2020_01_28_923532	164	13	single	single	JJ
10_1101-2020_01_28_923532	164	14	digits	digit	NNS
10_1101-2020_01_28_923532	164	15	for	for	IN
10_1101-2020_01_28_923532	164	16	most	most	JJS
10_1101-2020_01_28_923532	164	17	values	value	NNS
10_1101-2020_01_28_923532	164	18	of	of	IN
10_1101-2020_01_28_923532	164	19	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	164	20	and	and	CC
10_1101-2020_01_28_923532	164	21	𝑢𝑏.	𝑢𝑏.	NN
10_1101-2020_01_28_923532	165	1	The	the	DT
10_1101-2020_01_28_923532	165	2	distributions	distribution	NNS
10_1101-2020_01_28_923532	165	3	of	of	IN
10_1101-2020_01_28_923532	165	4	ITS	its	PRP$
10_1101-2020_01_28_923532	165	5	sizes	size	NNS
10_1101-2020_01_28_923532	165	6	are	be	VBP
10_1101-2020_01_28_923532	165	7	shown	show	VBN
10_1101-2020_01_28_923532	165	8	for	for	IN
10_1101-2020_01_28_923532	165	9	four	four	CD
10_1101-2020_01_28_923532	165	10	data	data	NN
10_1101-2020_01_28_923532	165	11	sets	set	NNS
10_1101-2020_01_28_923532	165	12	and	and	CC
10_1101-2020_01_28_923532	165	13	two	two	CD
10_1101-2020_01_28_923532	165	14	combinations	combination	NNS
10_1101-2020_01_28_923532	165	15	of	of	IN
10_1101-2020_01_28_923532	165	16	(	(	-LRB-
10_1101-2020_01_28_923532	165	17	𝑙𝑏	𝑙𝑏	UH
10_1101-2020_01_28_923532	165	18	,	,	,
10_1101-2020_01_28_923532	165	19	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	165	20	)	)	-RRB-
10_1101-2020_01_28_923532	165	21	(	(	-LRB-
10_1101-2020_01_28_923532	165	22	Figure	figure	NN
10_1101-2020_01_28_923532	165	23	4	4	CD
10_1101-2020_01_28_923532	165	24	)	)	-RRB-
10_1101-2020_01_28_923532	165	25	and	and	CC
10_1101-2020_01_28_923532	165	26	for	for	IN
10_1101-2020_01_28_923532	165	27	additional	additional	JJ
10_1101-2020_01_28_923532	165	28	data	data	NN
10_1101-2020_01_28_923532	165	29	sets	set	NNS
10_1101-2020_01_28_923532	165	30	in	in	IN
10_1101-2020_01_28_923532	165	31	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	165	32	Materials	material	NNS
10_1101-2020_01_28_923532	165	33	5	5	CD
10_1101-2020_01_28_923532	165	34	,	,	,
10_1101-2020_01_28_923532	165	35	Figure	Figure	NNP
10_1101-2020_01_28_923532	165	36	S11	S11	NNP
10_1101-2020_01_28_923532	165	37	.	.	.
10_1101-2020_01_28_923532	166	1	Overall	overall	RB
10_1101-2020_01_28_923532	166	2	,	,	,
10_1101-2020_01_28_923532	166	3	the	the	DT
10_1101-2020_01_28_923532	166	4	mean	mean	JJ
10_1101-2020_01_28_923532	166	5	ITS	its	PRP$
10_1101-2020_01_28_923532	166	6	sizes	size	NNS
10_1101-2020_01_28_923532	166	7	with	with	IN
10_1101-2020_01_28_923532	166	8	the	the	DT
10_1101-2020_01_28_923532	166	9	baseline	baseline	JJ
10_1101-2020_01_28_923532	166	10	parameter	parameter	NN
10_1101-2020_01_28_923532	166	11	values	value	NNS
10_1101-2020_01_28_923532	166	12	(	(	-LRB-
10_1101-2020_01_28_923532	166	13	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	166	14	=	=	SYM
10_1101-2020_01_28_923532	166	15	2.0	2.0	CD
10_1101-2020_01_28_923532	166	16	,	,	,
10_1101-2020_01_28_923532	166	17	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	166	18	=	=	SYM
10_1101-2020_01_28_923532	166	19	0.8	0.8	CD
10_1101-2020_01_28_923532	166	20	,	,	,
10_1101-2020_01_28_923532	166	21	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	166	22	=	=	SYM
10_1101-2020_01_28_923532	166	23	0.1	0.1	CD
10_1101-2020_01_28_923532	166	24	)	)	-RRB-
10_1101-2020_01_28_923532	166	25	range	range	VBP
10_1101-2020_01_28_923532	166	26	from	from	IN
10_1101-2020_01_28_923532	166	27	1.0	1.0	CD
10_1101-2020_01_28_923532	166	28	to	to	TO
10_1101-2020_01_28_923532	166	29	3.91	3.91	CD
10_1101-2020_01_28_923532	166	30	among	among	IN
10_1101-2020_01_28_923532	166	31	the	the	DT
10_1101-2020_01_28_923532	166	32	nine	nine	CD
10_1101-2020_01_28_923532	166	33	data	data	NN
10_1101-2020_01_28_923532	166	34	sets	set	NNS
10_1101-2020_01_28_923532	166	35	studied	study	VBN
10_1101-2020_01_28_923532	166	36	(	(	-LRB-
10_1101-2020_01_28_923532	166	37	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	166	38	Table	Table	NNP
10_1101-2020_01_28_923532	166	39	S2	S2	NNP
10_1101-2020_01_28_923532	166	40	)	)	-RRB-
10_1101-2020_01_28_923532	166	41	;	;	:
10_1101-2020_01_28_923532	166	42	on	on	IN
10_1101-2020_01_28_923532	166	43	average	average	JJ
10_1101-2020_01_28_923532	166	44	4	4	CD
10_1101-2020_01_28_923532	166	45	targets	target	NNS
10_1101-2020_01_28_923532	166	46	per	per	IN
10_1101-2020_01_28_923532	166	47	patient	patient	NN
10_1101-2020_01_28_923532	166	48	should	should	MD
10_1101-2020_01_28_923532	166	49	hence	hence	RB
10_1101-2020_01_28_923532	166	50	suffice	suffice	VB
10_1101-2020_01_28_923532	166	51	if	if	IN
10_1101-2020_01_28_923532	166	52	enough	enough	JJ
10_1101-2020_01_28_923532	166	53	single	single	JJ
10_1101-2020_01_28_923532	166	54	-	-	HYPH
10_1101-2020_01_28_923532	166	55	target	target	NN
10_1101-2020_01_28_923532	166	56	treatments	treatment	NNS
10_1101-2020_01_28_923532	166	57	are	be	VBP
10_1101-2020_01_28_923532	166	58	available	available	JJ
10_1101-2020_01_28_923532	166	59	in	in	IN
10_1101-2020_01_28_923532	166	60	the	the	DT
10_1101-2020_01_28_923532	166	61	cohort	cohort	NN
10_1101-2020_01_28_923532	166	62	target	target	NN
10_1101-2020_01_28_923532	166	63	set	set	VBN
10_1101-2020_01_28_923532	166	64	.	.	.
10_1101-2020_01_28_923532	167	1	However	however	RB
10_1101-2020_01_28_923532	167	2	,	,	,
10_1101-2020_01_28_923532	167	3	there	there	EX
10_1101-2020_01_28_923532	167	4	is	be	VBZ
10_1101-2020_01_28_923532	167	5	considerable	considerable	JJ
10_1101-2020_01_28_923532	167	6	variability	variability	NN
10_1101-2020_01_28_923532	167	7	across	across	IN
10_1101-2020_01_28_923532	167	8	patients	patient	NNS
10_1101-2020_01_28_923532	167	9	.	.	.
10_1101-2020_01_28_923532	168	1	Evidently	evidently	RB
10_1101-2020_01_28_923532	168	2	,	,	,
10_1101-2020_01_28_923532	168	3	as	as	IN
10_1101-2020_01_28_923532	168	4	we	-PRON-	PRP
10_1101-2020_01_28_923532	168	5	make	make	VBP
10_1101-2020_01_28_923532	168	6	the	the	DT
10_1101-2020_01_28_923532	168	7	treatment	treatment	NN
10_1101-2020_01_28_923532	168	8	requirements	requirement	NNS
10_1101-2020_01_28_923532	168	9	more	more	RBR
10_1101-2020_01_28_923532	168	10	stringent	stringent	JJ
10_1101-2020_01_28_923532	168	11	(	(	-LRB-
10_1101-2020_01_28_923532	168	12	by	by	IN
10_1101-2020_01_28_923532	168	13	increasing	increase	VBG
10_1101-2020_01_28_923532	168	14	𝑙𝑏	𝑙𝑏	RB
10_1101-2020_01_28_923532	168	15	from	from	IN
10_1101-2020_01_28_923532	168	16	0.8	0.8	CD
10_1101-2020_01_28_923532	168	17	to	to	IN
10_1101-2020_01_28_923532	168	18	0.9	0.9	CD
10_1101-2020_01_28_923532	168	19	and	and	CC
10_1101-2020_01_28_923532	168	20	decreasing	decrease	VBG
10_1101-2020_01_28_923532	168	21	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	168	22	from	from	IN
10_1101-2020_01_28_923532	168	23	0.1	0.1	CD
10_1101-2020_01_28_923532	168	24	to	to	IN
10_1101-2020_01_28_923532	168	25	0.05	0.05	CD
10_1101-2020_01_28_923532	168	26	)	)	-RRB-
10_1101-2020_01_28_923532	168	27	,	,	,
10_1101-2020_01_28_923532	168	28	the	the	DT
10_1101-2020_01_28_923532	168	29	variability	variability	NN
10_1101-2020_01_28_923532	168	30	in	in	IN
10_1101-2020_01_28_923532	168	31	ITS	its	PRP$
10_1101-2020_01_28_923532	168	32	size	size	NN
10_1101-2020_01_28_923532	168	33	across	across	IN
10_1101-2020_01_28_923532	168	34	patients	patient	NNS
10_1101-2020_01_28_923532	168	35	became	become	VBD
10_1101-2020_01_28_923532	168	36	105	105	CD
10_1101-2020_01_28_923532	168	37	and	and	CC
10_1101-2020_01_28_923532	168	38	is	be	VBZ
10_1101-2020_01_28_923532	168	39	also	also	RB
10_1101-2020_01_28_923532	168	40	made	make	VBN
10_1101-2020_01_28_923532	168	41	available	available	JJ
10_1101-2020_01_28_923532	168	42	for	for	IN
10_1101-2020_01_28_923532	168	43	use	use	NN
10_1101-2020_01_28_923532	168	44	under	under	IN
10_1101-2020_01_28_923532	168	45	a	a	DT
10_1101-2020_01_28_923532	168	46	CC0	CC0	NNP
10_1101-2020_01_28_923532	168	47	license	license	NN
10_1101-2020_01_28_923532	168	48	.	.	.
10_1101-2020_01_28_923532	169	1	(	(	-LRB-
10_1101-2020_01_28_923532	169	2	which	which	WDT
10_1101-2020_01_28_923532	169	3	was	be	VBD
10_1101-2020_01_28_923532	169	4	not	not	RB
10_1101-2020_01_28_923532	169	5	certified	certify	VBN
10_1101-2020_01_28_923532	169	6	by	by	IN
10_1101-2020_01_28_923532	169	7	peer	peer	NN
10_1101-2020_01_28_923532	169	8	review	review	NN
10_1101-2020_01_28_923532	169	9	)	)	-RRB-
10_1101-2020_01_28_923532	169	10	is	be	VBZ
10_1101-2020_01_28_923532	169	11	the	the	DT
10_1101-2020_01_28_923532	169	12	author	author	NN
10_1101-2020_01_28_923532	169	13	/	/	SYM
10_1101-2020_01_28_923532	169	14	funder	funder	NN
10_1101-2020_01_28_923532	169	15	.	.	.
10_1101-2020_01_28_923532	170	1	This	this	DT
10_1101-2020_01_28_923532	170	2	article	article	NN
10_1101-2020_01_28_923532	170	3	is	be	VBZ
10_1101-2020_01_28_923532	170	4	a	a	DT
10_1101-2020_01_28_923532	170	5	US	US	NNP
10_1101-2020_01_28_923532	170	6	Government	Government	NNP
10_1101-2020_01_28_923532	170	7	work	work	NN
10_1101-2020_01_28_923532	170	8	.	.	.
10_1101-2020_01_28_923532	171	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	171	2	is	be	VBZ
10_1101-2020_01_28_923532	171	3	not	not	RB
10_1101-2020_01_28_923532	171	4	subject	subject	JJ
10_1101-2020_01_28_923532	171	5	to	to	IN
10_1101-2020_01_28_923532	171	6	copyright	copyright	NN
10_1101-2020_01_28_923532	171	7	under	under	IN
10_1101-2020_01_28_923532	171	8	17	17	CD
10_1101-2020_01_28_923532	171	9	USC	usc	NN
10_1101-2020_01_28_923532	171	10	The	the	DT
10_1101-2020_01_28_923532	171	11	copyright	copyright	NN
10_1101-2020_01_28_923532	171	12	holder	holder	NN
10_1101-2020_01_28_923532	171	13	for	for	IN
10_1101-2020_01_28_923532	171	14	this	this	DT
10_1101-2020_01_28_923532	171	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	171	16	version	version	NN
10_1101-2020_01_28_923532	171	17	posted	post	VBD
10_1101-2020_01_28_923532	171	18	February	February	NNP
10_1101-2020_01_28_923532	171	19	12	12	CD
10_1101-2020_01_28_923532	171	20	,	,	,
10_1101-2020_01_28_923532	171	21	2021	2021	CD
10_1101-2020_01_28_923532	171	22	.	.	.
10_1101-2020_01_28_923532	171	23	;	;	:
10_1101-2020_01_28_923532	171	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	171	25	:	:	:
10_1101-2020_01_28_923532	171	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	171	27	preprint	preprint	NN
10_1101-2020_01_28_923532	171	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	171	29	14	14	CD
10_1101-2020_01_28_923532	171	30	larger	large	JJR
10_1101-2020_01_28_923532	171	31	.	.	.
10_1101-2020_01_28_923532	172	1	Importantly	importantly	RB
10_1101-2020_01_28_923532	172	2	,	,	,
10_1101-2020_01_28_923532	172	3	this	this	DT
10_1101-2020_01_28_923532	172	4	analysis	analysis	NN
10_1101-2020_01_28_923532	172	5	provides	provide	VBZ
10_1101-2020_01_28_923532	172	6	rigorous	rigorous	JJ
10_1101-2020_01_28_923532	172	7	quantifiable	quantifiable	JJ
10_1101-2020_01_28_923532	172	8	evidence	evidence	NN
10_1101-2020_01_28_923532	172	9	grounding	ground	VBG
10_1101-2020_01_28_923532	172	10	the	the	DT
10_1101-2020_01_28_923532	172	11	prevailing	prevail	VBG
10_1101-2020_01_28_923532	172	12	observation	observation	NN
10_1101-2020_01_28_923532	172	13	that	that	IN
10_1101-2020_01_28_923532	172	14	among	among	IN
10_1101-2020_01_28_923532	172	15	tumors	tumor	NNS
10_1101-2020_01_28_923532	172	16	of	of	IN
10_1101-2020_01_28_923532	172	17	the	the	DT
10_1101-2020_01_28_923532	172	18	same	same	JJ
10_1101-2020_01_28_923532	172	19	type	type	NN
10_1101-2020_01_28_923532	172	20	,	,	,
10_1101-2020_01_28_923532	172	21	some	some	DT
10_1101-2020_01_28_923532	172	22	individual	individual	JJ
10_1101-2020_01_28_923532	172	23	tumors	tumor	NNS
10_1101-2020_01_28_923532	172	24	may	may	MD
10_1101-2020_01_28_923532	172	25	be	be	VB
10_1101-2020_01_28_923532	172	26	much	much	RB
10_1101-2020_01_28_923532	172	27	harder	hard	JJR
10_1101-2020_01_28_923532	172	28	to	to	TO
10_1101-2020_01_28_923532	172	29	treat	treat	VB
10_1101-2020_01_28_923532	172	30	than	than	IN
10_1101-2020_01_28_923532	172	31	others	other	NNS
10_1101-2020_01_28_923532	172	32	.	.	.
10_1101-2020_01_28_923532	173	1	Taken	take	VBN
10_1101-2020_01_28_923532	173	2	together	together	RB
10_1101-2020_01_28_923532	173	3	,	,	,
10_1101-2020_01_28_923532	173	4	these	these	DT
10_1101-2020_01_28_923532	173	5	results	result	NNS
10_1101-2020_01_28_923532	173	6	show	show	VBP
10_1101-2020_01_28_923532	173	7	that	that	IN
10_1101-2020_01_28_923532	173	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	173	9	can	can	MD
10_1101-2020_01_28_923532	173	10	compute	compute	VB
10_1101-2020_01_28_923532	173	11	precise	precise	JJ
10_1101-2020_01_28_923532	173	12	estimates	estimate	NNS
10_1101-2020_01_28_923532	173	13	of	of	IN
10_1101-2020_01_28_923532	173	14	the	the	DT
10_1101-2020_01_28_923532	173	15	number	number	NN
10_1101-2020_01_28_923532	173	16	of	of	IN
10_1101-2020_01_28_923532	173	17	targets	target	NNS
10_1101-2020_01_28_923532	173	18	needed	need	VBN
10_1101-2020_01_28_923532	173	19	for	for	IN
10_1101-2020_01_28_923532	173	20	cohorts	cohort	NNS
10_1101-2020_01_28_923532	173	21	(	(	-LRB-
10_1101-2020_01_28_923532	173	22	in	in	IN
10_1101-2020_01_28_923532	173	23	the	the	DT
10_1101-2020_01_28_923532	173	24	tens	ten	NNS
10_1101-2020_01_28_923532	173	25	)	)	-RRB-
10_1101-2020_01_28_923532	173	26	and	and	CC
10_1101-2020_01_28_923532	173	27	individual	individual	JJ
10_1101-2020_01_28_923532	173	28	patients	patient	NNS
10_1101-2020_01_28_923532	173	29	(	(	-LRB-
10_1101-2020_01_28_923532	173	30	in	in	IN
10_1101-2020_01_28_923532	173	31	the	the	DT
10_1101-2020_01_28_923532	173	32	single	single	JJ
10_1101-2020_01_28_923532	173	33	digits	digit	NNS
10_1101-2020_01_28_923532	173	34	usually	usually	RB
10_1101-2020_01_28_923532	173	35	)	)	-RRB-
10_1101-2020_01_28_923532	173	36	and	and	CC
10_1101-2020_01_28_923532	173	37	that	that	IN
10_1101-2020_01_28_923532	173	38	these	these	DT
10_1101-2020_01_28_923532	173	39	estimates	estimate	NNS
10_1101-2020_01_28_923532	173	40	are	be	VBP
10_1101-2020_01_28_923532	173	41	sensitive	sensitive	JJ
10_1101-2020_01_28_923532	173	42	to	to	IN
10_1101-2020_01_28_923532	173	43	the	the	DT
10_1101-2020_01_28_923532	173	44	killing	kill	VBG
10_1101-2020_01_28_923532	173	45	stringency	stringency	NN
10_1101-2020_01_28_923532	173	46	,	,	,
10_1101-2020_01_28_923532	173	47	especially	especially	RB
10_1101-2020_01_28_923532	173	48	when	when	WRB
10_1101-2020_01_28_923532	173	49	the	the	DT
10_1101-2020_01_28_923532	173	50	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	173	51	increases	increase	VBZ
10_1101-2020_01_28_923532	173	52	above	above	IN
10_1101-2020_01_28_923532	173	53	0.8	0.8	CD
10_1101-2020_01_28_923532	173	54	.	.	.
10_1101-2020_01_28_923532	174	1	The	the	DT
10_1101-2020_01_28_923532	174	2	variation	variation	NN
10_1101-2020_01_28_923532	174	3	for	for	IN
10_1101-2020_01_28_923532	174	4	more	more	RBR
10_1101-2020_01_28_923532	174	5	aggressive	aggressive	JJ
10_1101-2020_01_28_923532	174	6	killing	killing	NN
10_1101-2020_01_28_923532	174	7	regimes	regime	NNS
10_1101-2020_01_28_923532	174	8	,	,	,
10_1101-2020_01_28_923532	174	9	with	with	IN
10_1101-2020_01_28_923532	174	10	values	value	NNS
10_1101-2020_01_28_923532	174	11	of	of	IN
10_1101-2020_01_28_923532	174	12	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	174	13	up	up	IN
10_1101-2020_01_28_923532	174	14	to	to	TO
10_1101-2020_01_28_923532	174	15	0.99	0.99	CD
10_1101-2020_01_28_923532	174	16	for	for	IN
10_1101-2020_01_28_923532	174	17	the	the	DT
10_1101-2020_01_28_923532	174	18	baseline	baseline	NN
10_1101-2020_01_28_923532	174	19	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	174	20	=	=	SYM
10_1101-2020_01_28_923532	174	21	2.0	2.0	CD
10_1101-2020_01_28_923532	174	22	is	be	VBZ
10_1101-2020_01_28_923532	174	23	displayed	display	VBN
10_1101-2020_01_28_923532	174	24	in	in	IN
10_1101-2020_01_28_923532	174	25	Figures	Figures	NNP
10_1101-2020_01_28_923532	174	26	S12-S13	S12-S13	NNP
10_1101-2020_01_28_923532	174	27	in	in	IN
10_1101-2020_01_28_923532	174	28	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	174	29	Materials	Materials	NNP
10_1101-2020_01_28_923532	174	30	6	6	CD
10_1101-2020_01_28_923532	174	31	.	.	.
10_1101-2020_01_28_923532	175	1	For	for	IN
10_1101-2020_01_28_923532	175	2	fixed	fixed	JJ
10_1101-2020_01_28_923532	175	3	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	175	4	=	=	SYM
10_1101-2020_01_28_923532	175	5	0.8	0.8	CD
10_1101-2020_01_28_923532	175	6	,	,	,
10_1101-2020_01_28_923532	175	7	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	175	8	=	=	SYM
10_1101-2020_01_28_923532	175	9	0.1	0.1	CD
10_1101-2020_01_28_923532	175	10	and	and	CC
10_1101-2020_01_28_923532	175	11	varying	vary	VBG
10_1101-2020_01_28_923532	175	12	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	175	13	,	,	,
10_1101-2020_01_28_923532	175	14	smallest	small	JJS
10_1101-2020_01_28_923532	175	15	CTS	CTS	NNP
10_1101-2020_01_28_923532	175	16	sizes	size	NNS
10_1101-2020_01_28_923532	175	17	are	be	VBP
10_1101-2020_01_28_923532	175	18	typically	typically	RB
10_1101-2020_01_28_923532	175	19	obtained	obtain	VBN
10_1101-2020_01_28_923532	175	20	for	for	IN
10_1101-2020_01_28_923532	175	21	𝑟	𝑟	DT
10_1101-2020_01_28_923532	175	22	values	value	NNS
10_1101-2020_01_28_923532	175	23	close	close	JJ
10_1101-2020_01_28_923532	175	24	to	to	IN
10_1101-2020_01_28_923532	175	25	2.0	2.0	CD
10_1101-2020_01_28_923532	175	26	,	,	,
10_1101-2020_01_28_923532	175	27	further	further	RB
10_1101-2020_01_28_923532	175	28	motivating	motivate	VBG
10_1101-2020_01_28_923532	175	29	our	-PRON-	PRP$
10_1101-2020_01_28_923532	175	30	choice	choice	NN
10_1101-2020_01_28_923532	175	31	of	of	IN
10_1101-2020_01_28_923532	175	32	𝑟	𝑟	NN
10_1101-2020_01_28_923532	175	33	=	=	SYM
10_1101-2020_01_28_923532	175	34	2	2	CD
10_1101-2020_01_28_923532	175	35	as	as	IN
10_1101-2020_01_28_923532	175	36	the	the	DT
10_1101-2020_01_28_923532	175	37	default	default	NN
10_1101-2020_01_28_923532	175	38	value	value	NN
10_1101-2020_01_28_923532	175	39	(	(	-LRB-
10_1101-2020_01_28_923532	175	40	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	175	41	Materials	Materials	NNP
10_1101-2020_01_28_923532	175	42	7	7	CD
10_1101-2020_01_28_923532	175	43	,	,	,
10_1101-2020_01_28_923532	175	44	Figures	Figures	NNP
10_1101-2020_01_28_923532	175	45	S14-S15	S14-S15	NNP
10_1101-2020_01_28_923532	175	46	,	,	,
10_1101-2020_01_28_923532	175	47	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	175	48	Table	Table	NNP
10_1101-2020_01_28_923532	175	49	S1	S1	NNS
10_1101-2020_01_28_923532	175	50	)	)	-RRB-
10_1101-2020_01_28_923532	175	51	.	.	.
10_1101-2020_01_28_923532	176	1	Finally	finally	RB
10_1101-2020_01_28_923532	176	2	,	,	,
10_1101-2020_01_28_923532	176	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	176	4	show	show	VBP
10_1101-2020_01_28_923532	176	5	that	that	IN
10_1101-2020_01_28_923532	176	6	,	,	,
10_1101-2020_01_28_923532	176	7	as	as	IN
10_1101-2020_01_28_923532	176	8	expected	expect	VBN
10_1101-2020_01_28_923532	176	9	,	,	,
10_1101-2020_01_28_923532	176	10	a	a	DT
10_1101-2020_01_28_923532	176	11	‘	'	``
10_1101-2020_01_28_923532	176	12	control	control	NN
10_1101-2020_01_28_923532	176	13	’	'	''
10_1101-2020_01_28_923532	176	14	greedy	greedy	JJ
10_1101-2020_01_28_923532	176	15	heuristic	heuristic	JJ
10_1101-2020_01_28_923532	176	16	algorithm	algorithm	NNP
10_1101-2020_01_28_923532	176	17	searching	search	VBG
10_1101-2020_01_28_923532	176	18	for	for	IN
10_1101-2020_01_28_923532	176	19	small	small	JJ
10_1101-2020_01_28_923532	176	20	and	and	CC
10_1101-2020_01_28_923532	176	21	effective	effective	JJ
10_1101-2020_01_28_923532	176	22	target	target	NN
10_1101-2020_01_28_923532	176	23	combinations	combination	NNS
10_1101-2020_01_28_923532	176	24	finds	find	VBZ
10_1101-2020_01_28_923532	176	25	ITS	its	PRP$
10_1101-2020_01_28_923532	176	26	sizes	size	NNS
10_1101-2020_01_28_923532	176	27	substantially	substantially	RB
10_1101-2020_01_28_923532	176	28	larger	large	JJR
10_1101-2020_01_28_923532	176	29	than	than	IN
10_1101-2020_01_28_923532	176	30	the	the	DT
10_1101-2020_01_28_923532	176	31	optimal	optimal	JJ
10_1101-2020_01_28_923532	176	32	ITS	its	PRP$
10_1101-2020_01_28_923532	176	33	sizes	size	NNS
10_1101-2020_01_28_923532	176	34	identified	identify	VBN
10_1101-2020_01_28_923532	176	35	using	use	VBG
10_1101-2020_01_28_923532	176	36	our	-PRON-	PRP$
10_1101-2020_01_28_923532	176	37	optimization	optimization	NN
10_1101-2020_01_28_923532	176	38	algorithm	algorithm	NN
10_1101-2020_01_28_923532	176	39	(	(	-LRB-
10_1101-2020_01_28_923532	176	40	Figure	figure	NN
10_1101-2020_01_28_923532	176	41	4	4	CD
10_1101-2020_01_28_923532	176	42	)	)	-RRB-
10_1101-2020_01_28_923532	176	43	.	.	.
10_1101-2020_01_28_923532	177	1	The	the	DT
10_1101-2020_01_28_923532	177	2	greedy	greedy	JJ
10_1101-2020_01_28_923532	177	3	CTS	CTS	NNP
10_1101-2020_01_28_923532	177	4	size	size	NN
10_1101-2020_01_28_923532	177	5	is	be	VBZ
10_1101-2020_01_28_923532	177	6	greater	great	JJR
10_1101-2020_01_28_923532	177	7	than	than	IN
10_1101-2020_01_28_923532	177	8	the	the	DT
10_1101-2020_01_28_923532	177	9	ILP	ILP	NNP
10_1101-2020_01_28_923532	177	10	optimal	optimal	JJ
10_1101-2020_01_28_923532	177	11	CTS	CTS	NNP
10_1101-2020_01_28_923532	177	12	size	size	NN
10_1101-2020_01_28_923532	177	13	for	for	IN
10_1101-2020_01_28_923532	177	14	eight	eight	CD
10_1101-2020_01_28_923532	177	15	out	out	IN
10_1101-2020_01_28_923532	177	16	of	of	IN
10_1101-2020_01_28_923532	177	17	nine	nine	CD
10_1101-2020_01_28_923532	177	18	data	data	NN
10_1101-2020_01_28_923532	177	19	sets	set	NNS
10_1101-2020_01_28_923532	177	20	(	(	-LRB-
10_1101-2020_01_28_923532	177	21	Table	table	NN
10_1101-2020_01_28_923532	177	22	S2	s2	NN
10_1101-2020_01_28_923532	177	23	in	in	IN
10_1101-2020_01_28_923532	177	24	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	177	25	Materials	Materials	NNP
10_1101-2020_01_28_923532	177	26	8	8	CD
10_1101-2020_01_28_923532	177	27	,	,	,
10_1101-2020_01_28_923532	177	28	Methods	Methods	NNP
10_1101-2020_01_28_923532	177	29	)	)	-RRB-
10_1101-2020_01_28_923532	177	30	.	.	.
10_1101-2020_01_28_923532	178	1	105	105	CD
10_1101-2020_01_28_923532	178	2	and	and	CC
10_1101-2020_01_28_923532	178	3	is	be	VBZ
10_1101-2020_01_28_923532	178	4	also	also	RB
10_1101-2020_01_28_923532	178	5	made	make	VBN
10_1101-2020_01_28_923532	178	6	available	available	JJ
10_1101-2020_01_28_923532	178	7	for	for	IN
10_1101-2020_01_28_923532	178	8	use	use	NN
10_1101-2020_01_28_923532	178	9	under	under	IN
10_1101-2020_01_28_923532	178	10	a	a	DT
10_1101-2020_01_28_923532	178	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	178	12	license	license	NN
10_1101-2020_01_28_923532	178	13	.	.	.
10_1101-2020_01_28_923532	179	1	(	(	-LRB-
10_1101-2020_01_28_923532	179	2	which	which	WDT
10_1101-2020_01_28_923532	179	3	was	be	VBD
10_1101-2020_01_28_923532	179	4	not	not	RB
10_1101-2020_01_28_923532	179	5	certified	certify	VBN
10_1101-2020_01_28_923532	179	6	by	by	IN
10_1101-2020_01_28_923532	179	7	peer	peer	NN
10_1101-2020_01_28_923532	179	8	review	review	NN
10_1101-2020_01_28_923532	179	9	)	)	-RRB-
10_1101-2020_01_28_923532	179	10	is	be	VBZ
10_1101-2020_01_28_923532	179	11	the	the	DT
10_1101-2020_01_28_923532	179	12	author	author	NN
10_1101-2020_01_28_923532	179	13	/	/	SYM
10_1101-2020_01_28_923532	179	14	funder	funder	NN
10_1101-2020_01_28_923532	179	15	.	.	.
10_1101-2020_01_28_923532	180	1	This	this	DT
10_1101-2020_01_28_923532	180	2	article	article	NN
10_1101-2020_01_28_923532	180	3	is	be	VBZ
10_1101-2020_01_28_923532	180	4	a	a	DT
10_1101-2020_01_28_923532	180	5	US	US	NNP
10_1101-2020_01_28_923532	180	6	Government	Government	NNP
10_1101-2020_01_28_923532	180	7	work	work	NN
10_1101-2020_01_28_923532	180	8	.	.	.
10_1101-2020_01_28_923532	181	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	181	2	is	be	VBZ
10_1101-2020_01_28_923532	181	3	not	not	RB
10_1101-2020_01_28_923532	181	4	subject	subject	JJ
10_1101-2020_01_28_923532	181	5	to	to	IN
10_1101-2020_01_28_923532	181	6	copyright	copyright	NN
10_1101-2020_01_28_923532	181	7	under	under	IN
10_1101-2020_01_28_923532	181	8	17	17	CD
10_1101-2020_01_28_923532	181	9	USC	usc	NN
10_1101-2020_01_28_923532	181	10	The	the	DT
10_1101-2020_01_28_923532	181	11	copyright	copyright	NN
10_1101-2020_01_28_923532	181	12	holder	holder	NN
10_1101-2020_01_28_923532	181	13	for	for	IN
10_1101-2020_01_28_923532	181	14	this	this	DT
10_1101-2020_01_28_923532	181	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	181	16	version	version	NN
10_1101-2020_01_28_923532	181	17	posted	post	VBD
10_1101-2020_01_28_923532	181	18	February	February	NNP
10_1101-2020_01_28_923532	181	19	12	12	CD
10_1101-2020_01_28_923532	181	20	,	,	,
10_1101-2020_01_28_923532	181	21	2021	2021	CD
10_1101-2020_01_28_923532	181	22	.	.	.
10_1101-2020_01_28_923532	181	23	;	;	:
10_1101-2020_01_28_923532	181	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	181	25	:	:	:
10_1101-2020_01_28_923532	181	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	181	27	preprint	preprint	NN
10_1101-2020_01_28_923532	181	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	181	29	15	15	CD
10_1101-2020_01_28_923532	181	30	Figure	figure	NN
10_1101-2020_01_28_923532	181	31	4	4	CD
10_1101-2020_01_28_923532	181	32	.	.	.
10_1101-2020_01_28_923532	182	1	The	the	DT
10_1101-2020_01_28_923532	182	2	distribution	distribution	NN
10_1101-2020_01_28_923532	182	3	of	of	IN
10_1101-2020_01_28_923532	182	4	optimal	optimal	JJ
10_1101-2020_01_28_923532	182	5	and	and	CC
10_1101-2020_01_28_923532	182	6	greedy	greedy	JJ
10_1101-2020_01_28_923532	182	7	individual	individual	JJ
10_1101-2020_01_28_923532	182	8	treatment	treatment	NN
10_1101-2020_01_28_923532	182	9	combination	combination	NN
10_1101-2020_01_28_923532	182	10	sizes	size	NNS
10_1101-2020_01_28_923532	182	11	(	(	-LRB-
10_1101-2020_01_28_923532	182	12	ITS	its	PRP$
10_1101-2020_01_28_923532	182	13	)	)	-RRB-
10_1101-2020_01_28_923532	182	14	values	value	NNS
10_1101-2020_01_28_923532	182	15	in	in	IN
10_1101-2020_01_28_923532	182	16	four	four	CD
10_1101-2020_01_28_923532	182	17	different	different	JJ
10_1101-2020_01_28_923532	182	18	cancer	cancer	NN
10_1101-2020_01_28_923532	182	19	types	type	NNS
10_1101-2020_01_28_923532	182	20	.	.	.
10_1101-2020_01_28_923532	183	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	183	2	study	study	VBP
10_1101-2020_01_28_923532	183	3	both	both	CC
10_1101-2020_01_28_923532	183	4	our	-PRON-	PRP$
10_1101-2020_01_28_923532	183	5	baseline	baseline	NN
10_1101-2020_01_28_923532	183	6	parameter	parameter	NN
10_1101-2020_01_28_923532	183	7	setting	setting	NN
10_1101-2020_01_28_923532	183	8	(	(	-LRB-
10_1101-2020_01_28_923532	183	9	upper	upper	JJ
10_1101-2020_01_28_923532	183	10	row	row	NN
10_1101-2020_01_28_923532	183	11	panels	panel	NNS
10_1101-2020_01_28_923532	183	12	)	)	-RRB-
10_1101-2020_01_28_923532	183	13	and	and	CC
10_1101-2020_01_28_923532	183	14	a	a	DT
10_1101-2020_01_28_923532	183	15	markedly	markedly	RB
10_1101-2020_01_28_923532	183	16	more	more	RBR
10_1101-2020_01_28_923532	183	17	stringent	stringent	JJ
10_1101-2020_01_28_923532	183	18	one	one	CD
10_1101-2020_01_28_923532	183	19	(	(	-LRB-
10_1101-2020_01_28_923532	183	20	middle	middle	JJ
10_1101-2020_01_28_923532	183	21	row	row	NN
10_1101-2020_01_28_923532	183	22	plots	plot	NNS
10_1101-2020_01_28_923532	183	23	)	)	-RRB-
10_1101-2020_01_28_923532	183	24	.	.	.
10_1101-2020_01_28_923532	184	1	For	for	IN
10_1101-2020_01_28_923532	184	2	the	the	DT
10_1101-2020_01_28_923532	184	3	more	more	RBR
10_1101-2020_01_28_923532	184	4	stringent	stringent	JJ
10_1101-2020_01_28_923532	184	5	parameter	parameter	NN
10_1101-2020_01_28_923532	184	6	setting	setting	NN
10_1101-2020_01_28_923532	184	7	,	,	,
10_1101-2020_01_28_923532	184	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	184	9	compare	compare	VBP
10_1101-2020_01_28_923532	184	10	the	the	DT
10_1101-2020_01_28_923532	184	11	ITS	its	PRP$
10_1101-2020_01_28_923532	184	12	sizes	size	NNS
10_1101-2020_01_28_923532	184	13	obtained	obtain	VBN
10_1101-2020_01_28_923532	184	14	using	use	VBG
10_1101-2020_01_28_923532	184	15	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	184	16	(	(	-LRB-
10_1101-2020_01_28_923532	184	17	middle	middle	JJ
10_1101-2020_01_28_923532	184	18	row	row	NN
10_1101-2020_01_28_923532	184	19	plots	plot	NNS
10_1101-2020_01_28_923532	184	20	)	)	-RRB-
10_1101-2020_01_28_923532	184	21	and	and	CC
10_1101-2020_01_28_923532	184	22	a	a	DT
10_1101-2020_01_28_923532	184	23	greedy	greedy	JJ
10_1101-2020_01_28_923532	184	24	algorithm	algorithm	NN
10_1101-2020_01_28_923532	184	25	that	that	WDT
10_1101-2020_01_28_923532	184	26	tries	try	VBZ
10_1101-2020_01_28_923532	184	27	to	to	TO
10_1101-2020_01_28_923532	184	28	add	add	VB
10_1101-2020_01_28_923532	184	29	pairs	pair	NNS
10_1101-2020_01_28_923532	184	30	of	of	IN
10_1101-2020_01_28_923532	184	31	genes	gene	NNS
10_1101-2020_01_28_923532	184	32	at	at	IN
10_1101-2020_01_28_923532	184	33	a	a	DT
10_1101-2020_01_28_923532	184	34	time	time	NN
10_1101-2020_01_28_923532	184	35	(	(	-LRB-
10_1101-2020_01_28_923532	184	36	bottom	bottom	NN
10_1101-2020_01_28_923532	184	37	row	row	NN
10_1101-2020_01_28_923532	184	38	plots	plot	NNS
10_1101-2020_01_28_923532	184	39	)	)	-RRB-
10_1101-2020_01_28_923532	184	40	.	.	.
10_1101-2020_01_28_923532	185	1	In	in	IN
10_1101-2020_01_28_923532	185	2	each	each	DT
10_1101-2020_01_28_923532	185	3	plot	plot	NN
10_1101-2020_01_28_923532	185	4	,	,	,
10_1101-2020_01_28_923532	185	5	the	the	DT
10_1101-2020_01_28_923532	185	6	patients	patient	NNS
10_1101-2020_01_28_923532	185	7	are	be	VBP
10_1101-2020_01_28_923532	185	8	sorted	sort	VBN
10_1101-2020_01_28_923532	185	9	from	from	IN
10_1101-2020_01_28_923532	185	10	left	leave	VBN
10_1101-2020_01_28_923532	185	11	to	to	IN
10_1101-2020_01_28_923532	185	12	right	right	NN
10_1101-2020_01_28_923532	185	13	according	accord	VBG
10_1101-2020_01_28_923532	185	14	to	to	IN
10_1101-2020_01_28_923532	185	15	their	-PRON-	PRP$
10_1101-2020_01_28_923532	185	16	mean	mean	JJ
10_1101-2020_01_28_923532	185	17	ITS	its	PRP$
10_1101-2020_01_28_923532	185	18	values	value	NNS
10_1101-2020_01_28_923532	185	19	in	in	IN
10_1101-2020_01_28_923532	185	20	the	the	DT
10_1101-2020_01_28_923532	185	21	optimal	optimal	JJ
10_1101-2020_01_28_923532	185	22	stringent	stringent	JJ
10_1101-2020_01_28_923532	185	23	regime	regime	NN
10_1101-2020_01_28_923532	185	24	.	.	.
10_1101-2020_01_28_923532	186	1	Additional	additional	JJ
10_1101-2020_01_28_923532	186	2	comparisons	comparison	NNS
10_1101-2020_01_28_923532	186	3	between	between	IN
10_1101-2020_01_28_923532	186	4	ITS	its	PRP$
10_1101-2020_01_28_923532	186	5	sizes	size	NNS
10_1101-2020_01_28_923532	186	6	at	at	IN
10_1101-2020_01_28_923532	186	7	different	different	JJ
10_1101-2020_01_28_923532	186	8	parameter	parameter	NN
10_1101-2020_01_28_923532	186	9	settings	setting	NNS
10_1101-2020_01_28_923532	186	10	can	can	MD
10_1101-2020_01_28_923532	186	11	be	be	VB
10_1101-2020_01_28_923532	186	12	found	find	VBN
10_1101-2020_01_28_923532	186	13	in	in	IN
10_1101-2020_01_28_923532	186	14	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	186	15	Materials	Materials	NNP
10_1101-2020_01_28_923532	186	16	5	5	CD
10_1101-2020_01_28_923532	186	17	.	.	.
10_1101-2020_01_28_923532	187	1	Description	description	NN
10_1101-2020_01_28_923532	187	2	of	of	IN
10_1101-2020_01_28_923532	187	3	the	the	DT
10_1101-2020_01_28_923532	187	4	greedy	greedy	JJ
10_1101-2020_01_28_923532	187	5	algorithm	algorithm	NN
10_1101-2020_01_28_923532	187	6	and	and	CC
10_1101-2020_01_28_923532	187	7	more	more	JJR
10_1101-2020_01_28_923532	187	8	comparisons	comparison	NNS
10_1101-2020_01_28_923532	187	9	between	between	IN
10_1101-2020_01_28_923532	187	10	the	the	DT
10_1101-2020_01_28_923532	187	11	optimal	optimal	JJ
10_1101-2020_01_28_923532	187	12	and	and	CC
10_1101-2020_01_28_923532	187	13	greedy	greedy	JJ
10_1101-2020_01_28_923532	187	14	algorithms	algorithm	NNS
10_1101-2020_01_28_923532	187	15	are	be	VBP
10_1101-2020_01_28_923532	187	16	provided	provide	VBN
10_1101-2020_01_28_923532	187	17	in	in	IN
10_1101-2020_01_28_923532	187	18	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	187	19	Materials	Materials	NNP
10_1101-2020_01_28_923532	187	20	8	8	CD
10_1101-2020_01_28_923532	187	21	.	.	.
10_1101-2020_01_28_923532	188	1	105	105	CD
10_1101-2020_01_28_923532	188	2	and	and	CC
10_1101-2020_01_28_923532	188	3	is	be	VBZ
10_1101-2020_01_28_923532	188	4	also	also	RB
10_1101-2020_01_28_923532	188	5	made	make	VBN
10_1101-2020_01_28_923532	188	6	available	available	JJ
10_1101-2020_01_28_923532	188	7	for	for	IN
10_1101-2020_01_28_923532	188	8	use	use	NN
10_1101-2020_01_28_923532	188	9	under	under	IN
10_1101-2020_01_28_923532	188	10	a	a	DT
10_1101-2020_01_28_923532	188	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	188	12	license	license	NN
10_1101-2020_01_28_923532	188	13	.	.	.
10_1101-2020_01_28_923532	189	1	(	(	-LRB-
10_1101-2020_01_28_923532	189	2	which	which	WDT
10_1101-2020_01_28_923532	189	3	was	be	VBD
10_1101-2020_01_28_923532	189	4	not	not	RB
10_1101-2020_01_28_923532	189	5	certified	certify	VBN
10_1101-2020_01_28_923532	189	6	by	by	IN
10_1101-2020_01_28_923532	189	7	peer	peer	NN
10_1101-2020_01_28_923532	189	8	review	review	NN
10_1101-2020_01_28_923532	189	9	)	)	-RRB-
10_1101-2020_01_28_923532	189	10	is	be	VBZ
10_1101-2020_01_28_923532	189	11	the	the	DT
10_1101-2020_01_28_923532	189	12	author	author	NN
10_1101-2020_01_28_923532	189	13	/	/	SYM
10_1101-2020_01_28_923532	189	14	funder	funder	NN
10_1101-2020_01_28_923532	189	15	.	.	.
10_1101-2020_01_28_923532	190	1	This	this	DT
10_1101-2020_01_28_923532	190	2	article	article	NN
10_1101-2020_01_28_923532	190	3	is	be	VBZ
10_1101-2020_01_28_923532	190	4	a	a	DT
10_1101-2020_01_28_923532	190	5	US	US	NNP
10_1101-2020_01_28_923532	190	6	Government	Government	NNP
10_1101-2020_01_28_923532	190	7	work	work	NN
10_1101-2020_01_28_923532	190	8	.	.	.
10_1101-2020_01_28_923532	191	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	191	2	is	be	VBZ
10_1101-2020_01_28_923532	191	3	not	not	RB
10_1101-2020_01_28_923532	191	4	subject	subject	JJ
10_1101-2020_01_28_923532	191	5	to	to	IN
10_1101-2020_01_28_923532	191	6	copyright	copyright	NN
10_1101-2020_01_28_923532	191	7	under	under	IN
10_1101-2020_01_28_923532	191	8	17	17	CD
10_1101-2020_01_28_923532	191	9	USC	usc	NN
10_1101-2020_01_28_923532	191	10	The	the	DT
10_1101-2020_01_28_923532	191	11	copyright	copyright	NN
10_1101-2020_01_28_923532	191	12	holder	holder	NN
10_1101-2020_01_28_923532	191	13	for	for	IN
10_1101-2020_01_28_923532	191	14	this	this	DT
10_1101-2020_01_28_923532	191	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	191	16	version	version	NN
10_1101-2020_01_28_923532	191	17	posted	post	VBD
10_1101-2020_01_28_923532	191	18	February	February	NNP
10_1101-2020_01_28_923532	191	19	12	12	CD
10_1101-2020_01_28_923532	191	20	,	,	,
10_1101-2020_01_28_923532	191	21	2021	2021	CD
10_1101-2020_01_28_923532	191	22	.	.	.
10_1101-2020_01_28_923532	191	23	;	;	:
10_1101-2020_01_28_923532	191	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	191	25	:	:	:
10_1101-2020_01_28_923532	191	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	191	27	preprint	preprint	NN
10_1101-2020_01_28_923532	191	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	191	29	16	16	CD
10_1101-2020_01_28_923532	191	30	The	the	DT
10_1101-2020_01_28_923532	191	31	Landscape	Landscape	NNP
10_1101-2020_01_28_923532	191	32	of	of	IN
10_1101-2020_01_28_923532	191	33	Combinations	Combinations	NNPS
10_1101-2020_01_28_923532	191	34	Achievable	achievable	JJ
10_1101-2020_01_28_923532	191	35	with	with	IN
10_1101-2020_01_28_923532	191	36	Receptors	receptor	NNS
10_1101-2020_01_28_923532	191	37	Currently	currently	RB
10_1101-2020_01_28_923532	191	38	Targetable	Targetable	NNP
10_1101-2020_01_28_923532	191	39	by	by	IN
10_1101-2020_01_28_923532	191	40	Published	publish	VBN
10_1101-2020_01_28_923532	191	41	Ligand	Ligand	NNP
10_1101-2020_01_28_923532	191	42	-	-	HYPH
10_1101-2020_01_28_923532	191	43	Mimicking	Mimicking	NNP
10_1101-2020_01_28_923532	191	44	Peptides	Peptides	NNPS
10_1101-2020_01_28_923532	191	45	To	to	TO
10_1101-2020_01_28_923532	191	46	get	get	VB
10_1101-2020_01_28_923532	191	47	a	a	DT
10_1101-2020_01_28_923532	191	48	view	view	NN
10_1101-2020_01_28_923532	191	49	of	of	IN
10_1101-2020_01_28_923532	191	50	the	the	DT
10_1101-2020_01_28_923532	191	51	combination	combination	NN
10_1101-2020_01_28_923532	191	52	treatments	treatment	NNS
10_1101-2020_01_28_923532	191	53	that	that	WDT
10_1101-2020_01_28_923532	191	54	are	be	VBP
10_1101-2020_01_28_923532	191	55	possible	possible	JJ
10_1101-2020_01_28_923532	191	56	with	with	IN
10_1101-2020_01_28_923532	191	57	receptor	receptor	NN
10_1101-2020_01_28_923532	191	58	targets	target	NNS
10_1101-2020_01_28_923532	191	59	for	for	IN
10_1101-2020_01_28_923532	191	60	which	which	WDT
10_1101-2020_01_28_923532	191	61	there	there	EX
10_1101-2020_01_28_923532	191	62	are	be	VBP
10_1101-2020_01_28_923532	191	63	already	already	RB
10_1101-2020_01_28_923532	191	64	existing	exist	VBG
10_1101-2020_01_28_923532	191	65	modular	modular	JJ
10_1101-2020_01_28_923532	191	66	targeting	target	VBG
10_1101-2020_01_28_923532	191	67	reagents	reagent	NNS
10_1101-2020_01_28_923532	191	68	,	,	,
10_1101-2020_01_28_923532	191	69	we	-PRON-	PRP
10_1101-2020_01_28_923532	191	70	conducted	conduct	VBD
10_1101-2020_01_28_923532	191	71	a	a	DT
10_1101-2020_01_28_923532	191	72	literature	literature	NN
10_1101-2020_01_28_923532	191	73	search	search	NN
10_1101-2020_01_28_923532	191	74	identifying	identify	VBG
10_1101-2020_01_28_923532	191	75	58	58	CD
10_1101-2020_01_28_923532	191	76	out	out	IN
10_1101-2020_01_28_923532	191	77	of	of	IN
10_1101-2020_01_28_923532	191	78	the	the	DT
10_1101-2020_01_28_923532	191	79	1269	1269	CD
10_1101-2020_01_28_923532	191	80	genes	gene	NNS
10_1101-2020_01_28_923532	191	81	with	with	IN
10_1101-2020_01_28_923532	191	82	published	publish	VBN
10_1101-2020_01_28_923532	191	83	ligand	ligand	NN
10_1101-2020_01_28_923532	191	84	-	-	HYPH
10_1101-2020_01_28_923532	191	85	mimicking	mimicking	NN
10_1101-2020_01_28_923532	191	86	peptides	peptide	NNS
10_1101-2020_01_28_923532	191	87	that	that	WDT
10_1101-2020_01_28_923532	191	88	have	have	VBP
10_1101-2020_01_28_923532	191	89	been	be	VBN
10_1101-2020_01_28_923532	191	90	already	already	RB
10_1101-2020_01_28_923532	191	91	tested	test	VBN
10_1101-2020_01_28_923532	191	92	in	in	RP
10_1101-2020_01_28_923532	191	93	in	in	FW
10_1101-2020_01_28_923532	191	94	vitro	vitro	FW
10_1101-2020_01_28_923532	191	95	models	model	NNS
10_1101-2020_01_28_923532	191	96	,	,	,
10_1101-2020_01_28_923532	191	97	usually	usually	RB
10_1101-2020_01_28_923532	191	98	cancer	cancer	NN
10_1101-2020_01_28_923532	191	99	models	model	NNS
10_1101-2020_01_28_923532	191	100	(	(	-LRB-
10_1101-2020_01_28_923532	191	101	Methods	method	NNS
10_1101-2020_01_28_923532	191	102	;	;	:
10_1101-2020_01_28_923532	191	103	Tables	table	NNS
10_1101-2020_01_28_923532	191	104	3	3	CD
10_1101-2020_01_28_923532	191	105	and	and	CC
10_1101-2020_01_28_923532	191	106	4	4	CD
10_1101-2020_01_28_923532	191	107	)	)	-RRB-
10_1101-2020_01_28_923532	191	108	.	.	.
10_1101-2020_01_28_923532	192	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	192	2	asked	ask	VBD
10_1101-2020_01_28_923532	192	3	whether	whether	IN
10_1101-2020_01_28_923532	192	4	we	-PRON-	PRP
10_1101-2020_01_28_923532	192	5	could	could	MD
10_1101-2020_01_28_923532	192	6	find	find	VB
10_1101-2020_01_28_923532	192	7	feasible	feasible	JJ
10_1101-2020_01_28_923532	192	8	optimal	optimal	JJ
10_1101-2020_01_28_923532	192	9	combinations	combination	NNS
10_1101-2020_01_28_923532	192	10	in	in	IN
10_1101-2020_01_28_923532	192	11	this	this	DT
10_1101-2020_01_28_923532	192	12	case	case	NN
10_1101-2020_01_28_923532	192	13	and	and	CC
10_1101-2020_01_28_923532	192	14	if	if	IN
10_1101-2020_01_28_923532	192	15	so	so	RB
10_1101-2020_01_28_923532	192	16	,	,	,
10_1101-2020_01_28_923532	192	17	how	how	WRB
10_1101-2020_01_28_923532	192	18	do	do	VBP
10_1101-2020_01_28_923532	192	19	the	the	DT
10_1101-2020_01_28_923532	192	20	optimal	optimal	JJ
10_1101-2020_01_28_923532	192	21	CTS	CTS	NNP
10_1101-2020_01_28_923532	192	22	and	and	CC
10_1101-2020_01_28_923532	192	23	ITS	its	PRP$
10_1101-2020_01_28_923532	192	24	sizes	size	NNS
10_1101-2020_01_28_923532	192	25	compare	compare	VBP
10_1101-2020_01_28_923532	192	26	vs.	vs.	IN
10_1101-2020_01_28_923532	192	27	those	those	DT
10_1101-2020_01_28_923532	192	28	computed	compute	VBN
10_1101-2020_01_28_923532	192	29	for	for	IN
10_1101-2020_01_28_923532	192	30	all	all	DT
10_1101-2020_01_28_923532	192	31	1269	1269	CD
10_1101-2020_01_28_923532	192	32	genes	gene	NNS
10_1101-2020_01_28_923532	192	33	?	?	.
10_1101-2020_01_28_923532	193	1	Figure	figure	NN
10_1101-2020_01_28_923532	193	2	5	5	CD
10_1101-2020_01_28_923532	193	3	.	.	.
10_1101-2020_01_28_923532	194	1	Comparison	comparison	NN
10_1101-2020_01_28_923532	194	2	of	of	IN
10_1101-2020_01_28_923532	194	3	Individual	Individual	NNP
10_1101-2020_01_28_923532	194	4	Target	Target	NNP
10_1101-2020_01_28_923532	194	5	Set	Set	NNP
10_1101-2020_01_28_923532	194	6	Sizes	size	NNS
10_1101-2020_01_28_923532	194	7	with	with	IN
10_1101-2020_01_28_923532	194	8	1269	1269	CD
10_1101-2020_01_28_923532	194	9	or	or	CC
10_1101-2020_01_28_923532	194	10	58	58	CD
10_1101-2020_01_28_923532	194	11	targets	target	NNS
10_1101-2020_01_28_923532	194	12	for	for	IN
10_1101-2020_01_28_923532	194	13	three	three	CD
10_1101-2020_01_28_923532	194	14	out	out	IN
10_1101-2020_01_28_923532	194	15	of	of	IN
10_1101-2020_01_28_923532	194	16	the	the	DT
10_1101-2020_01_28_923532	194	17	six	six	CD
10_1101-2020_01_28_923532	194	18	data	data	NN
10_1101-2020_01_28_923532	194	19	sets	set	NNS
10_1101-2020_01_28_923532	194	20	that	that	WDT
10_1101-2020_01_28_923532	194	21	have	have	VBP
10_1101-2020_01_28_923532	194	22	feasible	feasible	JJ
10_1101-2020_01_28_923532	194	23	solutions	solution	NNS
10_1101-2020_01_28_923532	194	24	.	.	.
10_1101-2020_01_28_923532	195	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	195	2	attempted	attempt	VBD
10_1101-2020_01_28_923532	195	3	to	to	TO
10_1101-2020_01_28_923532	195	4	find	find	VB
10_1101-2020_01_28_923532	195	5	feasible	feasible	JJ
10_1101-2020_01_28_923532	195	6	solutions	solution	NNS
10_1101-2020_01_28_923532	195	7	for	for	IN
10_1101-2020_01_28_923532	195	8	all	all	DT
10_1101-2020_01_28_923532	195	9	patients	patient	NNS
10_1101-2020_01_28_923532	195	10	using	use	VBG
10_1101-2020_01_28_923532	195	11	58	58	CD
10_1101-2020_01_28_923532	195	12	cell	cell	NN
10_1101-2020_01_28_923532	195	13	surface	surface	NN
10_1101-2020_01_28_923532	195	14	receptors	receptor	NNS
10_1101-2020_01_28_923532	195	15	that	that	WDT
10_1101-2020_01_28_923532	195	16	have	have	VBP
10_1101-2020_01_28_923532	195	17	published	publish	VBN
10_1101-2020_01_28_923532	195	18	ligand	ligand	NN
10_1101-2020_01_28_923532	195	19	-	-	HYPH
10_1101-2020_01_28_923532	195	20	mimicking	mimicking	NN
10_1101-2020_01_28_923532	195	21	peptides	peptide	NNS
10_1101-2020_01_28_923532	195	22	that	that	WDT
10_1101-2020_01_28_923532	195	23	have	have	VBP
10_1101-2020_01_28_923532	195	24	been	be	VBN
10_1101-2020_01_28_923532	195	25	tested	test	VBN
10_1101-2020_01_28_923532	195	26	in	in	IN
10_1101-2020_01_28_923532	195	27	vitro	vitro	FW
10_1101-2020_01_28_923532	195	28	or	or	CC
10_1101-2020_01_28_923532	195	29	in	in	IN
10_1101-2020_01_28_923532	195	30	pre	pre	JJ
10_1101-2020_01_28_923532	195	31	-	-	JJ
10_1101-2020_01_28_923532	195	32	clinical	clinical	JJ
10_1101-2020_01_28_923532	195	33	models	model	NNS
10_1101-2020_01_28_923532	195	34	.	.	.
10_1101-2020_01_28_923532	196	1	There	there	EX
10_1101-2020_01_28_923532	196	2	are	be	VBP
10_1101-2020_01_28_923532	196	3	feasible	feasible	JJ
10_1101-2020_01_28_923532	196	4	solutions	solution	NNS
10_1101-2020_01_28_923532	196	5	for	for	IN
10_1101-2020_01_28_923532	196	6	all	all	DT
10_1101-2020_01_28_923532	196	7	patients	patient	NNS
10_1101-2020_01_28_923532	196	8	in	in	IN
10_1101-2020_01_28_923532	196	9	six	six	CD
10_1101-2020_01_28_923532	196	10	data	data	NN
10_1101-2020_01_28_923532	196	11	sets	set	NNS
10_1101-2020_01_28_923532	196	12	,	,	,
10_1101-2020_01_28_923532	196	13	but	but	CC
10_1101-2020_01_28_923532	196	14	not	not	RB
10_1101-2020_01_28_923532	196	15	for	for	IN
10_1101-2020_01_28_923532	196	16	the	the	DT
10_1101-2020_01_28_923532	196	17	brain	brain	NN
10_1101-2020_01_28_923532	196	18	(	(	-LRB-
10_1101-2020_01_28_923532	196	19	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	196	20	)	)	-RRB-
10_1101-2020_01_28_923532	196	21	,	,	,
10_1101-2020_01_28_923532	196	22	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	196	23	(	(	-LRB-
10_1101-2020_01_28_923532	196	24	GSE115978	GSE115978	NNP
10_1101-2020_01_28_923532	196	25	)	)	-RRB-
10_1101-2020_01_28_923532	196	26	,	,	,
10_1101-2020_01_28_923532	196	27	and	and	CC
10_1101-2020_01_28_923532	196	28	lung	lung	NN
10_1101-2020_01_28_923532	196	29	(	(	-LRB-
10_1101-2020_01_28_923532	196	30	E	E	NNP
10_1101-2020_01_28_923532	196	31	-	-	NNP
10_1101-2020_01_28_923532	196	32	MTAB-6149	MTAB-6149	NNP
10_1101-2020_01_28_923532	196	33	)	)	-RRB-
10_1101-2020_01_28_923532	196	34	,	,	,
10_1101-2020_01_28_923532	196	35	which	which	WDT
10_1101-2020_01_28_923532	196	36	were	be	VBD
10_1101-2020_01_28_923532	196	37	displayed	display	VBN
10_1101-2020_01_28_923532	196	38	in	in	IN
10_1101-2020_01_28_923532	196	39	previous	previous	JJ
10_1101-2020_01_28_923532	196	40	figures	figure	NNS
10_1101-2020_01_28_923532	196	41	.	.	.
10_1101-2020_01_28_923532	197	1	Instead	instead	RB
10_1101-2020_01_28_923532	197	2	,	,	,
10_1101-2020_01_28_923532	197	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	197	4	show	show	VBP
10_1101-2020_01_28_923532	197	5	here	here	RB
10_1101-2020_01_28_923532	197	6	results	result	VBZ
10_1101-2020_01_28_923532	197	7	for	for	IN
10_1101-2020_01_28_923532	197	8	breast	breast	NN
10_1101-2020_01_28_923532	197	9	and	and	CC
10_1101-2020_01_28_923532	197	10	colorectal	colorectal	JJ
10_1101-2020_01_28_923532	197	11	cancers	cancer	NNS
10_1101-2020_01_28_923532	197	12	,	,	,
10_1101-2020_01_28_923532	197	13	for	for	IN
10_1101-2020_01_28_923532	197	14	which	which	WDT
10_1101-2020_01_28_923532	197	15	other	other	JJ
10_1101-2020_01_28_923532	197	16	analyses	analysis	NNS
10_1101-2020_01_28_923532	197	17	,	,	,
10_1101-2020_01_28_923532	197	18	such	such	JJ
10_1101-2020_01_28_923532	197	19	as	as	IN
10_1101-2020_01_28_923532	197	20	those	those	DT
10_1101-2020_01_28_923532	197	21	in	in	IN
10_1101-2020_01_28_923532	197	22	Figures	Figures	NNP
10_1101-2020_01_28_923532	197	23	3	3	CD
10_1101-2020_01_28_923532	197	24	and	and	CC
10_1101-2020_01_28_923532	197	25	4	4	CD
10_1101-2020_01_28_923532	197	26	,	,	,
10_1101-2020_01_28_923532	197	27	are	be	VBP
10_1101-2020_01_28_923532	197	28	in	in	IN
10_1101-2020_01_28_923532	197	29	the	the	DT
10_1101-2020_01_28_923532	197	30	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	197	31	Materials	Materials	NNPS
10_1101-2020_01_28_923532	197	32	.	.	.
10_1101-2020_01_28_923532	198	1	Some	some	DT
10_1101-2020_01_28_923532	198	2	of	of	IN
10_1101-2020_01_28_923532	198	3	the	the	DT
10_1101-2020_01_28_923532	198	4	optimal	optimal	JJ
10_1101-2020_01_28_923532	198	5	solutions	solution	NNS
10_1101-2020_01_28_923532	198	6	obtained	obtain	VBN
10_1101-2020_01_28_923532	198	7	on	on	IN
10_1101-2020_01_28_923532	198	8	the	the	DT
10_1101-2020_01_28_923532	198	9	58-receptors	58-receptors	CD
10_1101-2020_01_28_923532	198	10	restricted	restricted	JJ
10_1101-2020_01_28_923532	198	11	set	set	NN
10_1101-2020_01_28_923532	198	12	are	be	VBP
10_1101-2020_01_28_923532	198	13	of	of	IN
10_1101-2020_01_28_923532	198	14	the	the	DT
10_1101-2020_01_28_923532	198	15	same	same	JJ
10_1101-2020_01_28_923532	198	16	size	size	NN
10_1101-2020_01_28_923532	198	17	to	to	IN
10_1101-2020_01_28_923532	198	18	those	those	DT
10_1101-2020_01_28_923532	198	19	obtained	obtain	VBN
10_1101-2020_01_28_923532	198	20	on	on	IN
10_1101-2020_01_28_923532	198	21	the	the	DT
10_1101-2020_01_28_923532	198	22	whole	whole	JJ
10_1101-2020_01_28_923532	198	23	receptors	receptor	NNS
10_1101-2020_01_28_923532	198	24	set	set	VBN
10_1101-2020_01_28_923532	198	25	and	and	CC
10_1101-2020_01_28_923532	198	26	some	some	DT
10_1101-2020_01_28_923532	198	27	are	be	VBP
10_1101-2020_01_28_923532	198	28	larger	large	JJR
10_1101-2020_01_28_923532	198	29	.	.	.
10_1101-2020_01_28_923532	199	1	Computing	compute	VBG
10_1101-2020_01_28_923532	199	2	the	the	DT
10_1101-2020_01_28_923532	199	3	optimal	optimal	JJ
10_1101-2020_01_28_923532	199	4	CTS	CTS	NNP
10_1101-2020_01_28_923532	199	5	and	and	CC
10_1101-2020_01_28_923532	199	6	ITS	its	PRP$
10_1101-2020_01_28_923532	199	7	solutions	solution	NNS
10_1101-2020_01_28_923532	199	8	for	for	IN
10_1101-2020_01_28_923532	199	9	this	this	DT
10_1101-2020_01_28_923532	199	10	basket	basket	NN
10_1101-2020_01_28_923532	199	11	of	of	IN
10_1101-2020_01_28_923532	199	12	58	58	CD
10_1101-2020_01_28_923532	199	13	targets	target	NNS
10_1101-2020_01_28_923532	199	14	,	,	,
10_1101-2020_01_28_923532	199	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	199	16	found	find	VBD
10_1101-2020_01_28_923532	199	17	feasible	feasible	JJ
10_1101-2020_01_28_923532	199	18	solutions	solution	NNS
10_1101-2020_01_28_923532	199	19	for	for	IN
10_1101-2020_01_28_923532	199	20	six	six	CD
10_1101-2020_01_28_923532	199	21	of	of	IN
10_1101-2020_01_28_923532	199	22	the	the	DT
10_1101-2020_01_28_923532	199	23	data	data	NN
10_1101-2020_01_28_923532	199	24	sets	set	NNS
10_1101-2020_01_28_923532	199	25	across	across	IN
10_1101-2020_01_28_923532	199	26	all	all	DT
10_1101-2020_01_28_923532	199	27	parameter	parameter	NN
10_1101-2020_01_28_923532	199	28	combinations	combination	NNS
10_1101-2020_01_28_923532	199	29	we	-PRON-	PRP
10_1101-2020_01_28_923532	199	30	surveyed	survey	VBD
10_1101-2020_01_28_923532	199	31	and	and	CC
10_1101-2020_01_28_923532	199	32	105	105	CD
10_1101-2020_01_28_923532	199	33	and	and	CC
10_1101-2020_01_28_923532	199	34	is	be	VBZ
10_1101-2020_01_28_923532	199	35	also	also	RB
10_1101-2020_01_28_923532	199	36	made	make	VBN
10_1101-2020_01_28_923532	199	37	available	available	JJ
10_1101-2020_01_28_923532	199	38	for	for	IN
10_1101-2020_01_28_923532	199	39	use	use	NN
10_1101-2020_01_28_923532	199	40	under	under	IN
10_1101-2020_01_28_923532	199	41	a	a	DT
10_1101-2020_01_28_923532	199	42	CC0	CC0	NNP
10_1101-2020_01_28_923532	199	43	license	license	NN
10_1101-2020_01_28_923532	199	44	.	.	.
10_1101-2020_01_28_923532	200	1	(	(	-LRB-
10_1101-2020_01_28_923532	200	2	which	which	WDT
10_1101-2020_01_28_923532	200	3	was	be	VBD
10_1101-2020_01_28_923532	200	4	not	not	RB
10_1101-2020_01_28_923532	200	5	certified	certify	VBN
10_1101-2020_01_28_923532	200	6	by	by	IN
10_1101-2020_01_28_923532	200	7	peer	peer	NN
10_1101-2020_01_28_923532	200	8	review	review	NN
10_1101-2020_01_28_923532	200	9	)	)	-RRB-
10_1101-2020_01_28_923532	200	10	is	be	VBZ
10_1101-2020_01_28_923532	200	11	the	the	DT
10_1101-2020_01_28_923532	200	12	author	author	NN
10_1101-2020_01_28_923532	200	13	/	/	SYM
10_1101-2020_01_28_923532	200	14	funder	funder	NN
10_1101-2020_01_28_923532	200	15	.	.	.
10_1101-2020_01_28_923532	201	1	This	this	DT
10_1101-2020_01_28_923532	201	2	article	article	NN
10_1101-2020_01_28_923532	201	3	is	be	VBZ
10_1101-2020_01_28_923532	201	4	a	a	DT
10_1101-2020_01_28_923532	201	5	US	US	NNP
10_1101-2020_01_28_923532	201	6	Government	Government	NNP
10_1101-2020_01_28_923532	201	7	work	work	NN
10_1101-2020_01_28_923532	201	8	.	.	.
10_1101-2020_01_28_923532	202	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	202	2	is	be	VBZ
10_1101-2020_01_28_923532	202	3	not	not	RB
10_1101-2020_01_28_923532	202	4	subject	subject	JJ
10_1101-2020_01_28_923532	202	5	to	to	IN
10_1101-2020_01_28_923532	202	6	copyright	copyright	NN
10_1101-2020_01_28_923532	202	7	under	under	IN
10_1101-2020_01_28_923532	202	8	17	17	CD
10_1101-2020_01_28_923532	202	9	USC	usc	NN
10_1101-2020_01_28_923532	202	10	The	the	DT
10_1101-2020_01_28_923532	202	11	copyright	copyright	NN
10_1101-2020_01_28_923532	202	12	holder	holder	NN
10_1101-2020_01_28_923532	202	13	for	for	IN
10_1101-2020_01_28_923532	202	14	this	this	DT
10_1101-2020_01_28_923532	202	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	202	16	version	version	NN
10_1101-2020_01_28_923532	202	17	posted	post	VBD
10_1101-2020_01_28_923532	202	18	February	February	NNP
10_1101-2020_01_28_923532	202	19	12	12	CD
10_1101-2020_01_28_923532	202	20	,	,	,
10_1101-2020_01_28_923532	202	21	2021	2021	CD
10_1101-2020_01_28_923532	202	22	.	.	.
10_1101-2020_01_28_923532	202	23	;	;	:
10_1101-2020_01_28_923532	202	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	202	25	:	:	:
10_1101-2020_01_28_923532	202	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	202	27	preprint	preprint	NN
10_1101-2020_01_28_923532	202	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	202	29	17	17	CD
10_1101-2020_01_28_923532	202	30	three	three	CD
10_1101-2020_01_28_923532	202	31	of	of	IN
10_1101-2020_01_28_923532	202	32	these	these	DT
10_1101-2020_01_28_923532	202	33	six	six	CD
10_1101-2020_01_28_923532	202	34	are	be	VBP
10_1101-2020_01_28_923532	202	35	illustrated	illustrate	VBN
10_1101-2020_01_28_923532	202	36	for	for	IN
10_1101-2020_01_28_923532	202	37	each	each	DT
10_1101-2020_01_28_923532	202	38	patient	patient	NN
10_1101-2020_01_28_923532	202	39	in	in	IN
10_1101-2020_01_28_923532	202	40	Figure	Figure	NNP
10_1101-2020_01_28_923532	202	41	5	5	CD
10_1101-2020_01_28_923532	202	42	.	.	.
10_1101-2020_01_28_923532	203	1	However	however	RB
10_1101-2020_01_28_923532	203	2	,	,	,
10_1101-2020_01_28_923532	203	3	for	for	IN
10_1101-2020_01_28_923532	203	4	three	three	CD
10_1101-2020_01_28_923532	203	5	data	datum	NNS
10_1101-2020_01_28_923532	203	6	sets	set	NNS
10_1101-2020_01_28_923532	203	7	,	,	,
10_1101-2020_01_28_923532	203	8	in	in	IN
10_1101-2020_01_28_923532	203	9	numerous	numerous	JJ
10_1101-2020_01_28_923532	203	10	parameter	parameter	NN
10_1101-2020_01_28_923532	203	11	combinations	combination	NNS
10_1101-2020_01_28_923532	203	12	we	-PRON-	PRP
10_1101-2020_01_28_923532	203	13	could	could	MD
10_1101-2020_01_28_923532	203	14	not	not	RB
10_1101-2020_01_28_923532	203	15	find	find	VB
10_1101-2020_01_28_923532	203	16	optimal	optimal	JJ
10_1101-2020_01_28_923532	203	17	solutions	solution	NNS
10_1101-2020_01_28_923532	203	18	that	that	WDT
10_1101-2020_01_28_923532	203	19	satisfy	satisfy	VBP
10_1101-2020_01_28_923532	203	20	the	the	DT
10_1101-2020_01_28_923532	203	21	optimization	optimization	NN
10_1101-2020_01_28_923532	203	22	constraints	constraint	NNS
10_1101-2020_01_28_923532	203	23	(	(	-LRB-
10_1101-2020_01_28_923532	203	24	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	203	25	Materials	Materials	NNP
10_1101-2020_01_28_923532	203	26	9	9	CD
10_1101-2020_01_28_923532	203	27	,	,	,
10_1101-2020_01_28_923532	203	28	Figures	Figures	NNPS
10_1101-2020_01_28_923532	203	29	S16-S18	S16-S18	NNP
10_1101-2020_01_28_923532	203	30	)	)	-RRB-
10_1101-2020_01_28_923532	203	31	.	.	.
10_1101-2020_01_28_923532	204	1	That	that	RB
10_1101-2020_01_28_923532	204	2	is	is	RB
10_1101-2020_01_28_923532	204	3	,	,	,
10_1101-2020_01_28_923532	204	4	the	the	DT
10_1101-2020_01_28_923532	204	5	currently	currently	RB
10_1101-2020_01_28_923532	204	6	available	available	JJ
10_1101-2020_01_28_923532	204	7	targets	target	NNS
10_1101-2020_01_28_923532	204	8	do	do	VBP
10_1101-2020_01_28_923532	204	9	not	not	RB
10_1101-2020_01_28_923532	204	10	allow	allow	VB
10_1101-2020_01_28_923532	204	11	one	one	PRP
10_1101-2020_01_28_923532	204	12	to	to	TO
10_1101-2020_01_28_923532	204	13	design	design	VB
10_1101-2020_01_28_923532	204	14	treatments	treatment	NNS
10_1101-2020_01_28_923532	204	15	that	that	WDT
10_1101-2020_01_28_923532	204	16	may	may	MD
10_1101-2020_01_28_923532	204	17	achieve	achieve	VB
10_1101-2020_01_28_923532	204	18	the	the	DT
10_1101-2020_01_28_923532	204	19	specified	specify	VBN
10_1101-2020_01_28_923532	204	20	selective	selective	JJ
10_1101-2020_01_28_923532	204	21	killing	killing	NN
10_1101-2020_01_28_923532	204	22	objectives	objective	NNS
10_1101-2020_01_28_923532	204	23	,	,	,
10_1101-2020_01_28_923532	204	24	underscoring	underscore	VBG
10_1101-2020_01_28_923532	204	25	the	the	DT
10_1101-2020_01_28_923532	204	26	need	need	NN
10_1101-2020_01_28_923532	204	27	to	to	TO
10_1101-2020_01_28_923532	204	28	develop	develop	VB
10_1101-2020_01_28_923532	204	29	new	new	JJ
10_1101-2020_01_28_923532	204	30	targeted	target	VBN
10_1101-2020_01_28_923532	204	31	cancer	cancer	NN
10_1101-2020_01_28_923532	204	32	therapies	therapy	NNS
10_1101-2020_01_28_923532	204	33	,	,	,
10_1101-2020_01_28_923532	204	34	to	to	TO
10_1101-2020_01_28_923532	204	35	make	make	VB
10_1101-2020_01_28_923532	204	36	personalized	personalized	JJ
10_1101-2020_01_28_923532	204	37	medicine	medicine	NN
10_1101-2020_01_28_923532	204	38	more	more	RBR
10_1101-2020_01_28_923532	204	39	effective	effective	JJ
10_1101-2020_01_28_923532	204	40	for	for	IN
10_1101-2020_01_28_923532	204	41	more	more	JJR
10_1101-2020_01_28_923532	204	42	patients	patient	NNS
10_1101-2020_01_28_923532	204	43	.	.	.
10_1101-2020_01_28_923532	205	1	Overall	overall	RB
10_1101-2020_01_28_923532	205	2	,	,	,
10_1101-2020_01_28_923532	205	3	comparing	compare	VBG
10_1101-2020_01_28_923532	205	4	the	the	DT
10_1101-2020_01_28_923532	205	5	optimal	optimal	JJ
10_1101-2020_01_28_923532	205	6	solutions	solution	NNS
10_1101-2020_01_28_923532	205	7	obtained	obtain	VBN
10_1101-2020_01_28_923532	205	8	with	with	IN
10_1101-2020_01_28_923532	205	9	58	58	CD
10_1101-2020_01_28_923532	205	10	targets	target	NNS
10_1101-2020_01_28_923532	205	11	to	to	IN
10_1101-2020_01_28_923532	205	12	those	those	DT
10_1101-2020_01_28_923532	205	13	we	-PRON-	PRP
10_1101-2020_01_28_923532	205	14	have	have	VBP
10_1101-2020_01_28_923532	205	15	obtained	obtain	VBN
10_1101-2020_01_28_923532	205	16	with	with	IN
10_1101-2020_01_28_923532	205	17	the	the	DT
10_1101-2020_01_28_923532	205	18	1269	1269	CD
10_1101-2020_01_28_923532	205	19	targets	target	NNS
10_1101-2020_01_28_923532	205	20	,	,	,
10_1101-2020_01_28_923532	205	21	three	three	CD
10_1101-2020_01_28_923532	205	22	qualitatively	qualitatively	RB
10_1101-2020_01_28_923532	205	23	different	different	JJ
10_1101-2020_01_28_923532	205	24	behaviors	behavior	NNS
10_1101-2020_01_28_923532	205	25	are	be	VBP
10_1101-2020_01_28_923532	205	26	observed	observe	VBN
10_1101-2020_01_28_923532	205	27	(	(	-LRB-
10_1101-2020_01_28_923532	205	28	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	205	29	Materials	Materials	NNP
10_1101-2020_01_28_923532	205	30	9	9	CD
10_1101-2020_01_28_923532	205	31	,	,	,
10_1101-2020_01_28_923532	205	32	Figures	Figures	NNPS
10_1101-2020_01_28_923532	205	33	S16-S18	S16-S18	NNP
10_1101-2020_01_28_923532	205	34	)	)	-RRB-
10_1101-2020_01_28_923532	205	35	:	:	:
10_1101-2020_01_28_923532	205	36	(	(	-LRB-
10_1101-2020_01_28_923532	205	37	1	1	LS
10_1101-2020_01_28_923532	205	38	)	)	-RRB-
10_1101-2020_01_28_923532	205	39	In	in	IN
10_1101-2020_01_28_923532	205	40	some	some	DT
10_1101-2020_01_28_923532	205	41	datasets	dataset	NNS
10_1101-2020_01_28_923532	205	42	,	,	,
10_1101-2020_01_28_923532	205	43	it	-PRON-	PRP
10_1101-2020_01_28_923532	205	44	is	be	VBZ
10_1101-2020_01_28_923532	205	45	just	just	RB
10_1101-2020_01_28_923532	205	46	a	a	DT
10_1101-2020_01_28_923532	205	47	little	little	JJ
10_1101-2020_01_28_923532	205	48	bit	bit	NN
10_1101-2020_01_28_923532	205	49	more	more	RBR
10_1101-2020_01_28_923532	205	50	difficult	difficult	JJ
10_1101-2020_01_28_923532	205	51	to	to	TO
10_1101-2020_01_28_923532	205	52	find	find	VB
10_1101-2020_01_28_923532	205	53	optimal	optimal	JJ
10_1101-2020_01_28_923532	205	54	ITS	ITS	NNP
10_1101-2020_01_28_923532	205	55	and	and	CC
10_1101-2020_01_28_923532	205	56	CTS	CTS	NNP
10_1101-2020_01_28_923532	205	57	solutions	solution	NNS
10_1101-2020_01_28_923532	205	58	with	with	IN
10_1101-2020_01_28_923532	205	59	the	the	DT
10_1101-2020_01_28_923532	205	60	58-gene	58-gene	CD
10_1101-2020_01_28_923532	205	61	pool	pool	NN
10_1101-2020_01_28_923532	205	62	,	,	,
10_1101-2020_01_28_923532	205	63	while	while	IN
10_1101-2020_01_28_923532	205	64	in	in	IN
10_1101-2020_01_28_923532	205	65	others	other	NNS
10_1101-2020_01_28_923532	205	66	,	,	,
10_1101-2020_01_28_923532	205	67	the	the	DT
10_1101-2020_01_28_923532	205	68	restriction	restriction	NN
10_1101-2020_01_28_923532	205	69	to	to	IN
10_1101-2020_01_28_923532	205	70	a	a	DT
10_1101-2020_01_28_923532	205	71	smaller	small	JJR
10_1101-2020_01_28_923532	205	72	pool	pool	NN
10_1101-2020_01_28_923532	205	73	can	can	MD
10_1101-2020_01_28_923532	205	74	be	be	VB
10_1101-2020_01_28_923532	205	75	a	a	DT
10_1101-2020_01_28_923532	205	76	severe	severe	JJ
10_1101-2020_01_28_923532	205	77	constraint	constraint	NN
10_1101-2020_01_28_923532	205	78	making	make	VBG
10_1101-2020_01_28_923532	205	79	the	the	DT
10_1101-2020_01_28_923532	205	80	optimization	optimization	NN
10_1101-2020_01_28_923532	205	81	problem	problem	NN
10_1101-2020_01_28_923532	205	82	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	205	83	.	.	.
10_1101-2020_01_28_923532	206	1	(	(	-LRB-
10_1101-2020_01_28_923532	206	2	2	2	LS
10_1101-2020_01_28_923532	206	3	)	)	-RRB-
10_1101-2020_01_28_923532	206	4	The	the	DT
10_1101-2020_01_28_923532	206	5	smaller	small	JJR
10_1101-2020_01_28_923532	206	6	basket	basket	NN
10_1101-2020_01_28_923532	206	7	of	of	IN
10_1101-2020_01_28_923532	206	8	gene	gene	NN
10_1101-2020_01_28_923532	206	9	targets	target	NNS
10_1101-2020_01_28_923532	206	10	may	may	MD
10_1101-2020_01_28_923532	206	11	force	force	VB
10_1101-2020_01_28_923532	206	12	more	more	JJR
10_1101-2020_01_28_923532	206	13	patients	patient	NNS
10_1101-2020_01_28_923532	206	14	to	to	TO
10_1101-2020_01_28_923532	206	15	receive	receive	VB
10_1101-2020_01_28_923532	206	16	similar	similar	JJ
10_1101-2020_01_28_923532	206	17	individual	individual	JJ
10_1101-2020_01_28_923532	206	18	treatment	treatment	NN
10_1101-2020_01_28_923532	206	19	sets	set	NNS
10_1101-2020_01_28_923532	206	20	and	and	CC
10_1101-2020_01_28_923532	206	21	thereby	thereby	RB
10_1101-2020_01_28_923532	206	22	reduces	reduce	VBZ
10_1101-2020_01_28_923532	206	23	the	the	DT
10_1101-2020_01_28_923532	206	24	size	size	NN
10_1101-2020_01_28_923532	206	25	of	of	IN
10_1101-2020_01_28_923532	206	26	the	the	DT
10_1101-2020_01_28_923532	206	27	CTS	CTS	NNP
10_1101-2020_01_28_923532	206	28	.	.	.
10_1101-2020_01_28_923532	207	1	(	(	-LRB-
10_1101-2020_01_28_923532	207	2	3	3	LS
10_1101-2020_01_28_923532	207	3	)	)	-RRB-
10_1101-2020_01_28_923532	207	4	Unlike	unlike	IN
10_1101-2020_01_28_923532	207	5	the	the	DT
10_1101-2020_01_28_923532	207	6	CTS	CTS	NNP
10_1101-2020_01_28_923532	207	7	size	size	NN
10_1101-2020_01_28_923532	207	8	,	,	,
10_1101-2020_01_28_923532	207	9	the	the	DT
10_1101-2020_01_28_923532	207	10	ITS	ITS	NNP
10_1101-2020_01_28_923532	207	11	size	size	NN
10_1101-2020_01_28_923532	207	12	must	must	MD
10_1101-2020_01_28_923532	207	13	stay	stay	VB
10_1101-2020_01_28_923532	207	14	the	the	DT
10_1101-2020_01_28_923532	207	15	same	same	JJ
10_1101-2020_01_28_923532	207	16	or	or	CC
10_1101-2020_01_28_923532	207	17	increase	increase	VB
10_1101-2020_01_28_923532	207	18	when	when	WRB
10_1101-2020_01_28_923532	207	19	the	the	DT
10_1101-2020_01_28_923532	207	20	pool	pool	NN
10_1101-2020_01_28_923532	207	21	of	of	IN
10_1101-2020_01_28_923532	207	22	genes	gene	NNS
10_1101-2020_01_28_923532	207	23	is	be	VBZ
10_1101-2020_01_28_923532	207	24	reduced	reduce	VBN
10_1101-2020_01_28_923532	207	25	,	,	,
10_1101-2020_01_28_923532	207	26	because	because	IN
10_1101-2020_01_28_923532	207	27	we	-PRON-	PRP
10_1101-2020_01_28_923532	207	28	find	find	VBP
10_1101-2020_01_28_923532	207	29	the	the	DT
10_1101-2020_01_28_923532	207	30	optimal	optimal	JJ
10_1101-2020_01_28_923532	207	31	ITS	its	PRP$
10_1101-2020_01_28_923532	207	32	size	size	NN
10_1101-2020_01_28_923532	207	33	for	for	IN
10_1101-2020_01_28_923532	207	34	each	each	DT
10_1101-2020_01_28_923532	207	35	patient	patient	NN
10_1101-2020_01_28_923532	207	36	.	.	.
10_1101-2020_01_28_923532	208	1	Overall	overall	RB
10_1101-2020_01_28_923532	208	2	,	,	,
10_1101-2020_01_28_923532	208	3	the	the	DT
10_1101-2020_01_28_923532	208	4	average	average	JJ
10_1101-2020_01_28_923532	208	5	ITS	its	PRP$
10_1101-2020_01_28_923532	208	6	sizes	size	NNS
10_1101-2020_01_28_923532	208	7	across	across	IN
10_1101-2020_01_28_923532	208	8	each	each	DT
10_1101-2020_01_28_923532	208	9	cohort	cohort	NN
10_1101-2020_01_28_923532	208	10	using	use	VBG
10_1101-2020_01_28_923532	208	11	the	the	DT
10_1101-2020_01_28_923532	208	12	pool	pool	NN
10_1101-2020_01_28_923532	208	13	of	of	IN
10_1101-2020_01_28_923532	208	14	58	58	CD
10_1101-2020_01_28_923532	208	15	genes	gene	NNS
10_1101-2020_01_28_923532	208	16	for	for	IN
10_1101-2020_01_28_923532	208	17	baseline	baseline	NN
10_1101-2020_01_28_923532	208	18	settings	setting	NNS
10_1101-2020_01_28_923532	208	19	range	range	VBP
10_1101-2020_01_28_923532	208	20	from	from	IN
10_1101-2020_01_28_923532	208	21	1.16	1.16	CD
10_1101-2020_01_28_923532	208	22	to	to	IN
10_1101-2020_01_28_923532	208	23	4.0	4.0	CD
10_1101-2020_01_28_923532	208	24	.	.	.
10_1101-2020_01_28_923532	209	1	Among	among	IN
10_1101-2020_01_28_923532	209	2	cases	case	NNS
10_1101-2020_01_28_923532	209	3	that	that	WDT
10_1101-2020_01_28_923532	209	4	have	have	VBP
10_1101-2020_01_28_923532	209	5	any	any	DT
10_1101-2020_01_28_923532	209	6	solution	solution	NN
10_1101-2020_01_28_923532	209	7	,	,	,
10_1101-2020_01_28_923532	209	8	the	the	DT
10_1101-2020_01_28_923532	209	9	average	average	JJ
10_1101-2020_01_28_923532	209	10	increases	increase	NNS
10_1101-2020_01_28_923532	209	11	in	in	IN
10_1101-2020_01_28_923532	209	12	the	the	DT
10_1101-2020_01_28_923532	209	13	ITS	its	PRP$
10_1101-2020_01_28_923532	209	14	sizes	size	NNS
10_1101-2020_01_28_923532	209	15	at	at	IN
10_1101-2020_01_28_923532	209	16	baseline	baseline	JJ
10_1101-2020_01_28_923532	209	17	settings	setting	NNS
10_1101-2020_01_28_923532	209	18	in	in	IN
10_1101-2020_01_28_923532	209	19	the	the	DT
10_1101-2020_01_28_923532	209	20	58	58	CD
10_1101-2020_01_28_923532	209	21	genes	gene	NNS
10_1101-2020_01_28_923532	209	22	case	case	NN
10_1101-2020_01_28_923532	209	23	vs.	vs.	IN
10_1101-2020_01_28_923532	209	24	that	that	DT
10_1101-2020_01_28_923532	209	25	of	of	IN
10_1101-2020_01_28_923532	209	26	the	the	DT
10_1101-2020_01_28_923532	209	27	1269	1269	CD
10_1101-2020_01_28_923532	209	28	case	case	NN
10_1101-2020_01_28_923532	209	29	were	be	VBD
10_1101-2020_01_28_923532	209	30	moderate	moderate	JJ
10_1101-2020_01_28_923532	209	31	,	,	,
10_1101-2020_01_28_923532	209	32	ranging	range	VBG
10_1101-2020_01_28_923532	209	33	from	from	IN
10_1101-2020_01_28_923532	209	34	0.16	0.16	CD
10_1101-2020_01_28_923532	209	35	to	to	IN
10_1101-2020_01_28_923532	209	36	1.33	1.33	CD
10_1101-2020_01_28_923532	209	37	.	.	.
10_1101-2020_01_28_923532	210	1	Optimal	Optimal	NNP
10_1101-2020_01_28_923532	210	2	Fairness	Fairness	NNP
10_1101-2020_01_28_923532	210	3	-	-	HYPH
10_1101-2020_01_28_923532	210	4	Based	base	VBN
10_1101-2020_01_28_923532	210	5	Combination	Combination	NNP
10_1101-2020_01_28_923532	210	6	Therapies	Therapies	NNPS
10_1101-2020_01_28_923532	210	7	for	for	IN
10_1101-2020_01_28_923532	210	8	a	a	DT
10_1101-2020_01_28_923532	210	9	Given	give	VBN
10_1101-2020_01_28_923532	210	10	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	210	11	of	of	IN
10_1101-2020_01_28_923532	210	12	Patients	Patients	NNPS
10_1101-2020_01_28_923532	210	13	Until	until	IN
10_1101-2020_01_28_923532	210	14	now	now	RB
10_1101-2020_01_28_923532	210	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	210	16	have	have	VBP
10_1101-2020_01_28_923532	210	17	adhered	adhere	VBN
10_1101-2020_01_28_923532	210	18	to	to	IN
10_1101-2020_01_28_923532	210	19	a	a	DT
10_1101-2020_01_28_923532	210	20	patient	patient	NN
10_1101-2020_01_28_923532	210	21	-	-	HYPH
10_1101-2020_01_28_923532	210	22	centered	center	VBN
10_1101-2020_01_28_923532	210	23	approach	approach	NN
10_1101-2020_01_28_923532	210	24	that	that	WDT
10_1101-2020_01_28_923532	210	25	aims	aim	VBZ
10_1101-2020_01_28_923532	210	26	to	to	TO
10_1101-2020_01_28_923532	210	27	find	find	VB
10_1101-2020_01_28_923532	210	28	the	the	DT
10_1101-2020_01_28_923532	210	29	minimum	minimum	NN
10_1101-2020_01_28_923532	210	30	-	-	HYPH
10_1101-2020_01_28_923532	210	31	size	size	NN
10_1101-2020_01_28_923532	210	32	ITS	ITS	NNP
10_1101-2020_01_28_923532	210	33	for	for	IN
10_1101-2020_01_28_923532	210	34	each	each	DT
10_1101-2020_01_28_923532	210	35	patient	patient	JJ
10_1101-2020_01_28_923532	210	36	,	,	,
10_1101-2020_01_28_923532	210	37	first	first	JJ
10_1101-2020_01_28_923532	210	38	and	and	CC
10_1101-2020_01_28_923532	210	39	foremost	foremost	RB
10_1101-2020_01_28_923532	210	40	.	.	.
10_1101-2020_01_28_923532	211	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	211	2	now	now	RB
10_1101-2020_01_28_923532	211	3	study	study	VBP
10_1101-2020_01_28_923532	211	4	a	a	DT
10_1101-2020_01_28_923532	211	5	different	different	JJ
10_1101-2020_01_28_923532	211	6	,	,	,
10_1101-2020_01_28_923532	211	7	cohort	cohort	NN
10_1101-2020_01_28_923532	211	8	-	-	HYPH
10_1101-2020_01_28_923532	211	9	centered	center	VBN
10_1101-2020_01_28_923532	211	10	approach	approach	NN
10_1101-2020_01_28_923532	211	11	,	,	,
10_1101-2020_01_28_923532	211	12	where	where	WRB
10_1101-2020_01_28_923532	211	13	given	give	VBN
10_1101-2020_01_28_923532	211	14	a	a	DT
10_1101-2020_01_28_923532	211	15	cohort	cohort	NN
10_1101-2020_01_28_923532	211	16	of	of	IN
10_1101-2020_01_28_923532	211	17	patients	patient	NNS
10_1101-2020_01_28_923532	211	18	,	,	,
10_1101-2020_01_28_923532	211	19	we	-PRON-	PRP
10_1101-2020_01_28_923532	211	20	seek	seek	VBP
10_1101-2020_01_28_923532	211	21	to	to	TO
10_1101-2020_01_28_923532	211	22	minimize	minimize	VB
10_1101-2020_01_28_923532	211	23	the	the	DT
10_1101-2020_01_28_923532	211	24	total	total	JJ
10_1101-2020_01_28_923532	211	25	size	size	NN
10_1101-2020_01_28_923532	211	26	of	of	IN
10_1101-2020_01_28_923532	211	27	the	the	DT
10_1101-2020_01_28_923532	211	28	overall	overall	JJ
10_1101-2020_01_28_923532	211	29	CTS	CTS	NNP
10_1101-2020_01_28_923532	211	30	size	size	NN
10_1101-2020_01_28_923532	211	31	,	,	,
10_1101-2020_01_28_923532	211	32	while	while	IN
10_1101-2020_01_28_923532	211	33	allowing	allow	VBG
10_1101-2020_01_28_923532	211	34	for	for	IN
10_1101-2020_01_28_923532	211	35	some	some	DT
10_1101-2020_01_28_923532	211	36	increase	increase	NN
10_1101-2020_01_28_923532	211	37	in	in	IN
10_1101-2020_01_28_923532	211	38	the	the	DT
10_1101-2020_01_28_923532	211	39	ITS	its	PRP$
10_1101-2020_01_28_923532	211	40	sizes	size	NNS
10_1101-2020_01_28_923532	211	41	.	.	.
10_1101-2020_01_28_923532	212	1	The	the	DT
10_1101-2020_01_28_923532	212	2	key	key	JJ
10_1101-2020_01_28_923532	212	3	question	question	NN
10_1101-2020_01_28_923532	212	4	is	be	VBZ
10_1101-2020_01_28_923532	212	5	how	how	WRB
10_1101-2020_01_28_923532	212	6	much	much	RB
10_1101-2020_01_28_923532	212	7	larger	large	JJR
10_1101-2020_01_28_923532	212	8	are	be	VBP
10_1101-2020_01_28_923532	212	9	the	the	DT
10_1101-2020_01_28_923532	212	10	resulting	result	VBG
10_1101-2020_01_28_923532	212	11	ITS	its	PRP$
10_1101-2020_01_28_923532	212	12	sizes	size	NNS
10_1101-2020_01_28_923532	212	13	if	if	IN
10_1101-2020_01_28_923532	212	14	we	-PRON-	PRP
10_1101-2020_01_28_923532	212	15	optimize	optimize	VBP
10_1101-2020_01_28_923532	212	16	for	for	IN
10_1101-2020_01_28_923532	212	17	minimizing	minimize	VBG
10_1101-2020_01_28_923532	212	18	the	the	DT
10_1101-2020_01_28_923532	212	19	cohort	cohort	NN
10_1101-2020_01_28_923532	212	20	(	(	-LRB-
10_1101-2020_01_28_923532	212	21	CTS	CTS	NNP
10_1101-2020_01_28_923532	212	22	size	size	NN
10_1101-2020_01_28_923532	212	23	)	)	-RRB-
10_1101-2020_01_28_923532	212	24	,	,	,
10_1101-2020_01_28_923532	212	25	rather	rather	RB
10_1101-2020_01_28_923532	212	26	than	than	IN
10_1101-2020_01_28_923532	212	27	the	the	DT
10_1101-2020_01_28_923532	212	28	individuals	individual	NNS
10_1101-2020_01_28_923532	212	29	(	(	-LRB-
10_1101-2020_01_28_923532	212	30	ITS	its	PRP$
10_1101-2020_01_28_923532	212	31	size	size	NN
10_1101-2020_01_28_923532	212	32	)	)	-RRB-
10_1101-2020_01_28_923532	212	33	?	?	.
10_1101-2020_01_28_923532	213	1	This	this	DT
10_1101-2020_01_28_923532	213	2	challenge	challenge	NN
10_1101-2020_01_28_923532	213	3	is	be	VBZ
10_1101-2020_01_28_923532	213	4	motivated	motivate	VBN
10_1101-2020_01_28_923532	213	5	by	by	IN
10_1101-2020_01_28_923532	213	6	a	a	DT
10_1101-2020_01_28_923532	213	7	‘	'	``
10_1101-2020_01_28_923532	213	8	fairness	fairness	NN
10_1101-2020_01_28_923532	213	9	’	'	''
10_1101-2020_01_28_923532	213	10	perspective	perspective	NN
10_1101-2020_01_28_923532	213	11	(	(	-LRB-
10_1101-2020_01_28_923532	213	12	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	213	13	Materials	material	NNS
10_1101-2020_01_28_923532	213	14	1	1	CD
10_1101-2020_01_28_923532	213	15	)	)	-RRB-
10_1101-2020_01_28_923532	213	16	,	,	,
10_1101-2020_01_28_923532	213	17	where	where	WRB
10_1101-2020_01_28_923532	213	18	we	-PRON-	PRP
10_1101-2020_01_28_923532	213	19	seek	seek	VBP
10_1101-2020_01_28_923532	213	20	solutions	solution	NNS
10_1101-2020_01_28_923532	213	21	that	that	WDT
10_1101-2020_01_28_923532	213	22	are	be	VBP
10_1101-2020_01_28_923532	213	23	beneficial	beneficial	JJ
10_1101-2020_01_28_923532	213	24	for	for	IN
10_1101-2020_01_28_923532	213	25	the	the	DT
10_1101-2020_01_28_923532	213	26	entire	entire	JJ
10_1101-2020_01_28_923532	213	27	community	community	NN
10_1101-2020_01_28_923532	213	28	from	from	IN
10_1101-2020_01_28_923532	213	29	a	a	DT
10_1101-2020_01_28_923532	213	30	social	social	JJ
10_1101-2020_01_28_923532	213	31	or	or	CC
10_1101-2020_01_28_923532	213	32	economic	economic	JJ
10_1101-2020_01_28_923532	213	33	perspective	perspective	NN
10_1101-2020_01_28_923532	213	34	(	(	-LRB-
10_1101-2020_01_28_923532	213	35	in	in	IN
10_1101-2020_01_28_923532	213	36	terms	term	NNS
10_1101-2020_01_28_923532	213	37	of	of	IN
10_1101-2020_01_28_923532	213	38	CTS	CTS	NNP
10_1101-2020_01_28_923532	213	39	size	size	NN
10_1101-2020_01_28_923532	213	40	)	)	-RRB-
10_1101-2020_01_28_923532	213	41	even	even	RB
10_1101-2020_01_28_923532	213	42	if	if	IN
10_1101-2020_01_28_923532	213	43	they	-PRON-	PRP
10_1101-2020_01_28_923532	213	44	are	be	VBP
10_1101-2020_01_28_923532	213	45	potentially	potentially	RB
10_1101-2020_01_28_923532	213	46	sub	sub	JJ
10_1101-2020_01_28_923532	213	47	-	-	JJ
10_1101-2020_01_28_923532	213	48	optimal	optimal	JJ
10_1101-2020_01_28_923532	213	49	at	at	IN
10_1101-2020_01_28_923532	213	50	the	the	DT
10_1101-2020_01_28_923532	213	51	individual	individual	JJ
10_1101-2020_01_28_923532	213	52	level	level	NN
10_1101-2020_01_28_923532	213	53	(	(	-LRB-
10_1101-2020_01_28_923532	213	54	in	in	IN
10_1101-2020_01_28_923532	213	55	terms	term	NNS
10_1101-2020_01_28_923532	213	56	of	of	IN
10_1101-2020_01_28_923532	213	57	ITS	its	PRP$
10_1101-2020_01_28_923532	213	58	sizes	size	NNS
10_1101-2020_01_28_923532	213	59	)	)	-RRB-
10_1101-2020_01_28_923532	213	60	.	.	.
10_1101-2020_01_28_923532	214	1	Here	here	RB
10_1101-2020_01_28_923532	214	2	,	,	,
10_1101-2020_01_28_923532	214	3	the	the	DT
10_1101-2020_01_28_923532	214	4	potential	potential	JJ
10_1101-2020_01_28_923532	214	5	benefit	benefit	NN
10_1101-2020_01_28_923532	214	6	is	be	VBZ
10_1101-2020_01_28_923532	214	7	economic	economic	JJ
10_1101-2020_01_28_923532	214	8	since	since	IN
10_1101-2020_01_28_923532	214	9	running	run	VBG
10_1101-2020_01_28_923532	214	10	a	a	DT
10_1101-2020_01_28_923532	214	11	105	105	CD
10_1101-2020_01_28_923532	214	12	and	and	CC
10_1101-2020_01_28_923532	214	13	is	be	VBZ
10_1101-2020_01_28_923532	214	14	also	also	RB
10_1101-2020_01_28_923532	214	15	made	make	VBN
10_1101-2020_01_28_923532	214	16	available	available	JJ
10_1101-2020_01_28_923532	214	17	for	for	IN
10_1101-2020_01_28_923532	214	18	use	use	NN
10_1101-2020_01_28_923532	214	19	under	under	IN
10_1101-2020_01_28_923532	214	20	a	a	DT
10_1101-2020_01_28_923532	214	21	CC0	CC0	NNP
10_1101-2020_01_28_923532	214	22	license	license	NN
10_1101-2020_01_28_923532	214	23	.	.	.
10_1101-2020_01_28_923532	215	1	(	(	-LRB-
10_1101-2020_01_28_923532	215	2	which	which	WDT
10_1101-2020_01_28_923532	215	3	was	be	VBD
10_1101-2020_01_28_923532	215	4	not	not	RB
10_1101-2020_01_28_923532	215	5	certified	certify	VBN
10_1101-2020_01_28_923532	215	6	by	by	IN
10_1101-2020_01_28_923532	215	7	peer	peer	NN
10_1101-2020_01_28_923532	215	8	review	review	NN
10_1101-2020_01_28_923532	215	9	)	)	-RRB-
10_1101-2020_01_28_923532	215	10	is	be	VBZ
10_1101-2020_01_28_923532	215	11	the	the	DT
10_1101-2020_01_28_923532	215	12	author	author	NN
10_1101-2020_01_28_923532	215	13	/	/	SYM
10_1101-2020_01_28_923532	215	14	funder	funder	NN
10_1101-2020_01_28_923532	215	15	.	.	.
10_1101-2020_01_28_923532	216	1	This	this	DT
10_1101-2020_01_28_923532	216	2	article	article	NN
10_1101-2020_01_28_923532	216	3	is	be	VBZ
10_1101-2020_01_28_923532	216	4	a	a	DT
10_1101-2020_01_28_923532	216	5	US	US	NNP
10_1101-2020_01_28_923532	216	6	Government	Government	NNP
10_1101-2020_01_28_923532	216	7	work	work	NN
10_1101-2020_01_28_923532	216	8	.	.	.
10_1101-2020_01_28_923532	217	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	217	2	is	be	VBZ
10_1101-2020_01_28_923532	217	3	not	not	RB
10_1101-2020_01_28_923532	217	4	subject	subject	JJ
10_1101-2020_01_28_923532	217	5	to	to	IN
10_1101-2020_01_28_923532	217	6	copyright	copyright	NN
10_1101-2020_01_28_923532	217	7	under	under	IN
10_1101-2020_01_28_923532	217	8	17	17	CD
10_1101-2020_01_28_923532	217	9	USC	usc	NN
10_1101-2020_01_28_923532	217	10	The	the	DT
10_1101-2020_01_28_923532	217	11	copyright	copyright	NN
10_1101-2020_01_28_923532	217	12	holder	holder	NN
10_1101-2020_01_28_923532	217	13	for	for	IN
10_1101-2020_01_28_923532	217	14	this	this	DT
10_1101-2020_01_28_923532	217	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	217	16	version	version	NN
10_1101-2020_01_28_923532	217	17	posted	post	VBD
10_1101-2020_01_28_923532	217	18	February	February	NNP
10_1101-2020_01_28_923532	217	19	12	12	CD
10_1101-2020_01_28_923532	217	20	,	,	,
10_1101-2020_01_28_923532	217	21	2021	2021	CD
10_1101-2020_01_28_923532	217	22	.	.	.
10_1101-2020_01_28_923532	217	23	;	;	:
10_1101-2020_01_28_923532	217	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	217	25	:	:	:
10_1101-2020_01_28_923532	217	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	217	27	preprint	preprint	NN
10_1101-2020_01_28_923532	217	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	217	29	18	18	CD
10_1101-2020_01_28_923532	217	30	basket	basket	NN
10_1101-2020_01_28_923532	217	31	trial	trial	NN
10_1101-2020_01_28_923532	217	32	would	would	MD
10_1101-2020_01_28_923532	217	33	be	be	VB
10_1101-2020_01_28_923532	217	34	less	less	RBR
10_1101-2020_01_28_923532	217	35	expensive	expensive	JJ
10_1101-2020_01_28_923532	217	36	if	if	IN
10_1101-2020_01_28_923532	217	37	one	one	PRP
10_1101-2020_01_28_923532	217	38	reduces	reduce	VBZ
10_1101-2020_01_28_923532	217	39	the	the	DT
10_1101-2020_01_28_923532	217	40	size	size	NN
10_1101-2020_01_28_923532	217	41	of	of	IN
10_1101-2020_01_28_923532	217	42	the	the	DT
10_1101-2020_01_28_923532	217	43	basket	basket	NN
10_1101-2020_01_28_923532	217	44	of	of	IN
10_1101-2020_01_28_923532	217	45	available	available	JJ
10_1101-2020_01_28_923532	217	46	treatments	treatment	NNS
10_1101-2020_01_28_923532	217	47	(	(	-LRB-
10_1101-2020_01_28_923532	217	48	Figure	figure	VB
10_1101-2020_01_28_923532	217	49	6A	6a	NN
10_1101-2020_01_28_923532	217	50	-	-	HYPH
10_1101-2020_01_28_923532	217	51	B	b	NN
10_1101-2020_01_28_923532	217	52	)	)	-RRB-
10_1101-2020_01_28_923532	217	53	.	.	.
10_1101-2020_01_28_923532	218	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	218	2	formalized	formalize	VBD
10_1101-2020_01_28_923532	218	3	this	this	DT
10_1101-2020_01_28_923532	218	4	‘	'	``
10_1101-2020_01_28_923532	218	5	fair	fair	JJ
10_1101-2020_01_28_923532	218	6	CTS	CTS	NNP
10_1101-2020_01_28_923532	218	7	problem	problem	NN
10_1101-2020_01_28_923532	218	8	’	'	''
10_1101-2020_01_28_923532	218	9	by	by	IN
10_1101-2020_01_28_923532	218	10	adding	add	VBG
10_1101-2020_01_28_923532	218	11	a	a	DT
10_1101-2020_01_28_923532	218	12	cost	cost	NN
10_1101-2020_01_28_923532	218	13	parameter	parameter	NN
10_1101-2020_01_28_923532	218	14	𝛼	𝛼	LS
10_1101-2020_01_28_923532	218	15	that	that	WDT
10_1101-2020_01_28_923532	218	16	specifies	specify	VBZ
10_1101-2020_01_28_923532	218	17	the	the	DT
10_1101-2020_01_28_923532	218	18	limit	limit	NN
10_1101-2020_01_28_923532	218	19	on	on	IN
10_1101-2020_01_28_923532	218	20	the	the	DT
10_1101-2020_01_28_923532	218	21	excess	excess	JJ
10_1101-2020_01_28_923532	218	22	number	number	NN
10_1101-2020_01_28_923532	218	23	of	of	IN
10_1101-2020_01_28_923532	218	24	(	(	-LRB-
10_1101-2020_01_28_923532	218	25	ITS	its	PRP$
10_1101-2020_01_28_923532	218	26	)	)	-RRB-
10_1101-2020_01_28_923532	218	27	targets	target	NNS
10_1101-2020_01_28_923532	218	28	selected	select	VBN
10_1101-2020_01_28_923532	218	29	for	for	IN
10_1101-2020_01_28_923532	218	30	any	any	DT
10_1101-2020_01_28_923532	218	31	individual	individual	JJ
10_1101-2020_01_28_923532	218	32	patient	patient	NN
10_1101-2020_01_28_923532	218	33	,	,	,
10_1101-2020_01_28_923532	218	34	compared	compare	VBN
10_1101-2020_01_28_923532	218	35	to	to	IN
10_1101-2020_01_28_923532	218	36	the	the	DT
10_1101-2020_01_28_923532	218	37	number	number	NN
10_1101-2020_01_28_923532	218	38	selected	select	VBN
10_1101-2020_01_28_923532	218	39	in	in	IN
10_1101-2020_01_28_923532	218	40	the	the	DT
10_1101-2020_01_28_923532	218	41	individual	individual	NN
10_1101-2020_01_28_923532	218	42	-	-	HYPH
10_1101-2020_01_28_923532	218	43	based	base	VBN
10_1101-2020_01_28_923532	218	44	approach	approach	NN
10_1101-2020_01_28_923532	218	45	that	that	WDT
10_1101-2020_01_28_923532	218	46	was	be	VBD
10_1101-2020_01_28_923532	218	47	studied	study	VBN
10_1101-2020_01_28_923532	218	48	up	up	RP
10_1101-2020_01_28_923532	218	49	until	until	IN
10_1101-2020_01_28_923532	218	50	now	now	RB
10_1101-2020_01_28_923532	218	51	(	(	-LRB-
10_1101-2020_01_28_923532	218	52	formally	formally	RB
10_1101-2020_01_28_923532	218	53	,	,	,
10_1101-2020_01_28_923532	218	54	the	the	DT
10_1101-2020_01_28_923532	218	55	latter	latter	JJ
10_1101-2020_01_28_923532	218	56	corresponds	correspond	NNS
10_1101-2020_01_28_923532	218	57	to	to	IN
10_1101-2020_01_28_923532	218	58	setting	set	VBG
10_1101-2020_01_28_923532	218	59	𝛼	𝛼	XX
10_1101-2020_01_28_923532	218	60	=	=	SYM
10_1101-2020_01_28_923532	218	61	0	0	CD
10_1101-2020_01_28_923532	218	62	)	)	-RRB-
10_1101-2020_01_28_923532	218	63	.	.	.
10_1101-2020_01_28_923532	219	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	219	2	formulated	formulate	VBD
10_1101-2020_01_28_923532	219	3	and	and	CC
10_1101-2020_01_28_923532	219	4	solved	solve	VBD
10_1101-2020_01_28_923532	219	5	via	via	IN
10_1101-2020_01_28_923532	219	6	ILP	ILP	NNP
10_1101-2020_01_28_923532	219	7	this	this	DT
10_1101-2020_01_28_923532	219	8	fair	fair	JJ
10_1101-2020_01_28_923532	219	9	CTS	CTS	NNP
10_1101-2020_01_28_923532	219	10	problem	problem	NN
10_1101-2020_01_28_923532	219	11	for	for	IN
10_1101-2020_01_28_923532	219	12	up	up	IN
10_1101-2020_01_28_923532	219	13	to	to	TO
10_1101-2020_01_28_923532	219	14	1269	1269	CD
10_1101-2020_01_28_923532	219	15	possible	possible	JJ
10_1101-2020_01_28_923532	219	16	targets	target	NNS
10_1101-2020_01_28_923532	219	17	on	on	IN
10_1101-2020_01_28_923532	219	18	all	all	DT
10_1101-2020_01_28_923532	219	19	nine	nine	CD
10_1101-2020_01_28_923532	219	20	data	data	NN
10_1101-2020_01_28_923532	219	21	sets	set	NNS
10_1101-2020_01_28_923532	219	22	(	(	-LRB-
10_1101-2020_01_28_923532	219	23	Methods	Methods	NNP
10_1101-2020_01_28_923532	219	24	)	)	-RRB-
10_1101-2020_01_28_923532	219	25	.	.	.
10_1101-2020_01_28_923532	220	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	220	2	fixed	fix	VBD
10_1101-2020_01_28_923532	220	3	𝑟	𝑟	NN
10_1101-2020_01_28_923532	220	4	=	=	SYM
10_1101-2020_01_28_923532	220	5	2	2	CD
10_1101-2020_01_28_923532	220	6	and	and	CC
10_1101-2020_01_28_923532	220	7	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	220	8	=	=	SYM
10_1101-2020_01_28_923532	220	9	0.1	0.1	CD
10_1101-2020_01_28_923532	220	10	while	while	IN
10_1101-2020_01_28_923532	220	11	varying	vary	VBG
10_1101-2020_01_28_923532	220	12	𝛼	𝛼	NN
10_1101-2020_01_28_923532	220	13	and	and	CC
10_1101-2020_01_28_923532	220	14	𝑙𝑏.	𝑙𝑏.	NNP
10_1101-2020_01_28_923532	221	1	Figure	figure	NN
10_1101-2020_01_28_923532	221	2	6C	6c	NN
10_1101-2020_01_28_923532	221	3	and	and	CC
10_1101-2020_01_28_923532	221	4	Figures	figure	NNS
10_1101-2020_01_28_923532	221	5	S19-S23	S19-S23	NNP
10_1101-2020_01_28_923532	221	6	in	in	IN
10_1101-2020_01_28_923532	221	7	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	221	8	Materials	Materials	NNP
10_1101-2020_01_28_923532	221	9	10	10	CD
10_1101-2020_01_28_923532	221	10	show	show	VBP
10_1101-2020_01_28_923532	221	11	the	the	DT
10_1101-2020_01_28_923532	221	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	221	13	CTS	CTS	NNP
10_1101-2020_01_28_923532	221	14	and	and	CC
10_1101-2020_01_28_923532	221	15	ITS	its	PRP$
10_1101-2020_01_28_923532	221	16	sizes	size	NNS
10_1101-2020_01_28_923532	221	17	for	for	IN
10_1101-2020_01_28_923532	221	18	𝛼	𝛼	NNS
10_1101-2020_01_28_923532	221	19	=	=	SYM
10_1101-2020_01_28_923532	221	20	0	0	CD
10_1101-2020_01_28_923532	221	21	,	,	,
10_1101-2020_01_28_923532	221	22	.	.	.
10_1101-2020_01_28_923532	222	1	.	.	.
10_1101-2020_01_28_923532	223	1	.	.	.
10_1101-2020_01_28_923532	224	1	,	,	,
10_1101-2020_01_28_923532	224	2	5	5	CD
10_1101-2020_01_28_923532	224	3	.	.	.
10_1101-2020_01_28_923532	225	1	105	105	CD
10_1101-2020_01_28_923532	225	2	and	and	CC
10_1101-2020_01_28_923532	225	3	is	be	VBZ
10_1101-2020_01_28_923532	225	4	also	also	RB
10_1101-2020_01_28_923532	225	5	made	make	VBN
10_1101-2020_01_28_923532	225	6	available	available	JJ
10_1101-2020_01_28_923532	225	7	for	for	IN
10_1101-2020_01_28_923532	225	8	use	use	NN
10_1101-2020_01_28_923532	225	9	under	under	IN
10_1101-2020_01_28_923532	225	10	a	a	DT
10_1101-2020_01_28_923532	225	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	225	12	license	license	NN
10_1101-2020_01_28_923532	225	13	.	.	.
10_1101-2020_01_28_923532	226	1	(	(	-LRB-
10_1101-2020_01_28_923532	226	2	which	which	WDT
10_1101-2020_01_28_923532	226	3	was	be	VBD
10_1101-2020_01_28_923532	226	4	not	not	RB
10_1101-2020_01_28_923532	226	5	certified	certify	VBN
10_1101-2020_01_28_923532	226	6	by	by	IN
10_1101-2020_01_28_923532	226	7	peer	peer	NN
10_1101-2020_01_28_923532	226	8	review	review	NN
10_1101-2020_01_28_923532	226	9	)	)	-RRB-
10_1101-2020_01_28_923532	226	10	is	be	VBZ
10_1101-2020_01_28_923532	226	11	the	the	DT
10_1101-2020_01_28_923532	226	12	author	author	NN
10_1101-2020_01_28_923532	226	13	/	/	SYM
10_1101-2020_01_28_923532	226	14	funder	funder	NN
10_1101-2020_01_28_923532	226	15	.	.	.
10_1101-2020_01_28_923532	227	1	This	this	DT
10_1101-2020_01_28_923532	227	2	article	article	NN
10_1101-2020_01_28_923532	227	3	is	be	VBZ
10_1101-2020_01_28_923532	227	4	a	a	DT
10_1101-2020_01_28_923532	227	5	US	US	NNP
10_1101-2020_01_28_923532	227	6	Government	Government	NNP
10_1101-2020_01_28_923532	227	7	work	work	NN
10_1101-2020_01_28_923532	227	8	.	.	.
10_1101-2020_01_28_923532	228	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	228	2	is	be	VBZ
10_1101-2020_01_28_923532	228	3	not	not	RB
10_1101-2020_01_28_923532	228	4	subject	subject	JJ
10_1101-2020_01_28_923532	228	5	to	to	IN
10_1101-2020_01_28_923532	228	6	copyright	copyright	NN
10_1101-2020_01_28_923532	228	7	under	under	IN
10_1101-2020_01_28_923532	228	8	17	17	CD
10_1101-2020_01_28_923532	228	9	USC	usc	NN
10_1101-2020_01_28_923532	228	10	The	the	DT
10_1101-2020_01_28_923532	228	11	copyright	copyright	NN
10_1101-2020_01_28_923532	228	12	holder	holder	NN
10_1101-2020_01_28_923532	228	13	for	for	IN
10_1101-2020_01_28_923532	228	14	this	this	DT
10_1101-2020_01_28_923532	228	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	228	16	version	version	NN
10_1101-2020_01_28_923532	228	17	posted	post	VBD
10_1101-2020_01_28_923532	228	18	February	February	NNP
10_1101-2020_01_28_923532	228	19	12	12	CD
10_1101-2020_01_28_923532	228	20	,	,	,
10_1101-2020_01_28_923532	228	21	2021	2021	CD
10_1101-2020_01_28_923532	228	22	.	.	.
10_1101-2020_01_28_923532	228	23	;	;	:
10_1101-2020_01_28_923532	228	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	228	25	:	:	:
10_1101-2020_01_28_923532	228	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	228	27	preprint	preprint	NN
10_1101-2020_01_28_923532	228	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	228	29	19	19	CD
10_1101-2020_01_28_923532	228	30	Figure	figure	NN
10_1101-2020_01_28_923532	228	31	6	6	CD
10_1101-2020_01_28_923532	228	32	.	.	.
10_1101-2020_01_28_923532	229	1	A	a	DT
10_1101-2020_01_28_923532	229	2	schematic	schematic	JJ
10_1101-2020_01_28_923532	229	3	example	example	NN
10_1101-2020_01_28_923532	229	4	demonstrating	demonstrate	VBG
10_1101-2020_01_28_923532	229	5	the	the	DT
10_1101-2020_01_28_923532	229	6	rationale	rationale	NN
10_1101-2020_01_28_923532	229	7	and	and	CC
10_1101-2020_01_28_923532	229	8	workings	working	NNS
10_1101-2020_01_28_923532	229	9	of	of	IN
10_1101-2020_01_28_923532	229	10	fairness	fairness	NN
10_1101-2020_01_28_923532	229	11	-	-	HYPH
10_1101-2020_01_28_923532	229	12	based	base	VBN
10_1101-2020_01_28_923532	229	13	solutions	solution	NNS
10_1101-2020_01_28_923532	229	14	.	.	.
10_1101-2020_01_28_923532	230	1	(	(	-LRB-
10_1101-2020_01_28_923532	230	2	A	a	DT
10_1101-2020_01_28_923532	230	3	,	,	,
10_1101-2020_01_28_923532	230	4	B	b	NN
10_1101-2020_01_28_923532	230	5	)	)	-RRB-
10_1101-2020_01_28_923532	230	6	Let	let	VB
10_1101-2020_01_28_923532	230	7	us	-PRON-	PRP
10_1101-2020_01_28_923532	230	8	assume	assume	VB
10_1101-2020_01_28_923532	230	9	that	that	IN
10_1101-2020_01_28_923532	230	10	each	each	DT
10_1101-2020_01_28_923532	230	11	of	of	IN
10_1101-2020_01_28_923532	230	12	three	three	CD
10_1101-2020_01_28_923532	230	13	patients	patient	NNS
10_1101-2020_01_28_923532	230	14	has	have	VBZ
10_1101-2020_01_28_923532	230	15	two	two	CD
10_1101-2020_01_28_923532	230	16	tumor	tumor	NN
10_1101-2020_01_28_923532	230	17	cells	cell	NNS
10_1101-2020_01_28_923532	230	18	(	(	-LRB-
10_1101-2020_01_28_923532	230	19	columns	column	NNS
10_1101-2020_01_28_923532	230	20	)	)	-RRB-
10_1101-2020_01_28_923532	230	21	,	,	,
10_1101-2020_01_28_923532	230	22	each	each	DT
10_1101-2020_01_28_923532	230	23	displaying	display	VBG
10_1101-2020_01_28_923532	230	24	five	five	CD
10_1101-2020_01_28_923532	230	25	membrane	membrane	NN
10_1101-2020_01_28_923532	230	26	receptors	receptor	NNS
10_1101-2020_01_28_923532	230	27	that	that	WDT
10_1101-2020_01_28_923532	230	28	are	be	VBP
10_1101-2020_01_28_923532	230	29	highly	highly	RB
10_1101-2020_01_28_923532	230	30	expressed	express	VBN
10_1101-2020_01_28_923532	230	31	only	only	RB
10_1101-2020_01_28_923532	230	32	on	on	IN
10_1101-2020_01_28_923532	230	33	the	the	DT
10_1101-2020_01_28_923532	230	34	tumor	tumor	NN
10_1101-2020_01_28_923532	230	35	cells	cell	NNS
10_1101-2020_01_28_923532	230	36	and	and	CC
10_1101-2020_01_28_923532	230	37	not	not	RB
10_1101-2020_01_28_923532	230	38	on	on	IN
10_1101-2020_01_28_923532	230	39	the	the	DT
10_1101-2020_01_28_923532	230	40	non	non	JJ
10_1101-2020_01_28_923532	230	41	-	-	JJ
10_1101-2020_01_28_923532	230	42	tumor	tumor	JJ
10_1101-2020_01_28_923532	230	43	ones	one	NNS
10_1101-2020_01_28_923532	230	44	(	(	-LRB-
10_1101-2020_01_28_923532	230	45	rows	row	NNS
10_1101-2020_01_28_923532	230	46	)	)	-RRB-
10_1101-2020_01_28_923532	230	47	.	.	.
10_1101-2020_01_28_923532	231	1	If	if	IN
10_1101-2020_01_28_923532	231	2	we	-PRON-	PRP
10_1101-2020_01_28_923532	231	3	target	target	VBP
10_1101-2020_01_28_923532	231	4	{	{	-LRB-
10_1101-2020_01_28_923532	231	5	APP	APP	NNP
10_1101-2020_01_28_923532	231	6	,	,	,
10_1101-2020_01_28_923532	231	7	MET	MET	NNP
10_1101-2020_01_28_923532	231	8	}	}	-RRB-
10_1101-2020_01_28_923532	231	9	(	(	-LRB-
10_1101-2020_01_28_923532	231	10	panel	panel	NN
10_1101-2020_01_28_923532	231	11	A	a	NN
10_1101-2020_01_28_923532	231	12	,	,	,
10_1101-2020_01_28_923532	231	13	𝛼	𝛼	NN
10_1101-2020_01_28_923532	231	14	=	=	SYM
10_1101-2020_01_28_923532	231	15	1	1	CD
10_1101-2020_01_28_923532	231	16	)	)	-RRB-
10_1101-2020_01_28_923532	231	17	in	in	IN
10_1101-2020_01_28_923532	231	18	all	all	DT
10_1101-2020_01_28_923532	231	19	patients	patient	NNS
10_1101-2020_01_28_923532	231	20	,	,	,
10_1101-2020_01_28_923532	231	21	then	then	RB
10_1101-2020_01_28_923532	231	22	this	this	DT
10_1101-2020_01_28_923532	231	23	achieves	achieve	VBZ
10_1101-2020_01_28_923532	231	24	a	a	DT
10_1101-2020_01_28_923532	231	25	CTS	CTS	NNP
10_1101-2020_01_28_923532	231	26	size	size	NN
10_1101-2020_01_28_923532	231	27	of	of	IN
10_1101-2020_01_28_923532	231	28	2	2	CD
10_1101-2020_01_28_923532	231	29	,	,	,
10_1101-2020_01_28_923532	231	30	which	which	WDT
10_1101-2020_01_28_923532	231	31	is	be	VBZ
10_1101-2020_01_28_923532	231	32	the	the	DT
10_1101-2020_01_28_923532	231	33	minimum	minimum	NN
10_1101-2020_01_28_923532	231	34	possible	possible	JJ
10_1101-2020_01_28_923532	231	35	.	.	.
10_1101-2020_01_28_923532	232	1	Employing	employ	VBG
10_1101-2020_01_28_923532	232	2	the	the	DT
10_1101-2020_01_28_923532	232	3	original	original	JJ
10_1101-2020_01_28_923532	232	4	individual-	individual-	NN
10_1101-2020_01_28_923532	232	5	based	base	VBN
10_1101-2020_01_28_923532	232	6	optimizing	optimize	VBG
10_1101-2020_01_28_923532	232	7	objective	objective	NN
10_1101-2020_01_28_923532	232	8	,	,	,
10_1101-2020_01_28_923532	232	9	each	each	DT
10_1101-2020_01_28_923532	232	10	patient	patient	NN
10_1101-2020_01_28_923532	232	11	could	could	MD
10_1101-2020_01_28_923532	232	12	instead	instead	RB
10_1101-2020_01_28_923532	232	13	be	be	VB
10_1101-2020_01_28_923532	232	14	treated	treat	VBN
10_1101-2020_01_28_923532	232	15	by	by	IN
10_1101-2020_01_28_923532	232	16	an	an	DT
10_1101-2020_01_28_923532	232	17	ITS	ITS	NNP
10_1101-2020_01_28_923532	232	18	of	of	IN
10_1101-2020_01_28_923532	232	19	size	size	NN
10_1101-2020_01_28_923532	232	20	1	1	CD
10_1101-2020_01_28_923532	232	21	by	by	IN
10_1101-2020_01_28_923532	232	22	targeting	target	VBG
10_1101-2020_01_28_923532	232	23	the	the	DT
10_1101-2020_01_28_923532	232	24	distinct	distinct	JJ
10_1101-2020_01_28_923532	232	25	receptors	receptor	NNS
10_1101-2020_01_28_923532	232	26	called	call	VBD
10_1101-2020_01_28_923532	232	27	Target	Target	NNP
10_1101-2020_01_28_923532	232	28	1	1	CD
10_1101-2020_01_28_923532	232	29	(	(	-LRB-
10_1101-2020_01_28_923532	232	30	specific	specific	JJ
10_1101-2020_01_28_923532	232	31	to	to	IN
10_1101-2020_01_28_923532	232	32	Patient	Patient	NNP
10_1101-2020_01_28_923532	232	33	1	1	CD
10_1101-2020_01_28_923532	232	34	)	)	-RRB-
10_1101-2020_01_28_923532	232	35	,	,	,
10_1101-2020_01_28_923532	232	36	Target	Target	NNP
10_1101-2020_01_28_923532	232	37	2	2	CD
10_1101-2020_01_28_923532	232	38	and	and	CC
10_1101-2020_01_28_923532	232	39	Target	Target	NNP
10_1101-2020_01_28_923532	232	40	3	3	CD
10_1101-2020_01_28_923532	232	41	,	,	,
10_1101-2020_01_28_923532	232	42	respectively	respectively	RB
10_1101-2020_01_28_923532	232	43	,	,	,
10_1101-2020_01_28_923532	232	44	but	but	CC
10_1101-2020_01_28_923532	232	45	this	this	DT
10_1101-2020_01_28_923532	232	46	would	would	MD
10_1101-2020_01_28_923532	232	47	result	result	VB
10_1101-2020_01_28_923532	232	48	in	in	IN
10_1101-2020_01_28_923532	232	49	an	an	DT
10_1101-2020_01_28_923532	232	50	optimal	optimal	JJ
10_1101-2020_01_28_923532	232	51	CTS	CTS	NNP
10_1101-2020_01_28_923532	232	52	of	of	IN
10_1101-2020_01_28_923532	232	53	size	size	NN
10_1101-2020_01_28_923532	232	54	3	3	CD
10_1101-2020_01_28_923532	232	55	(	(	-LRB-
10_1101-2020_01_28_923532	232	56	panel	panel	NN
10_1101-2020_01_28_923532	232	57	B	b	NN
10_1101-2020_01_28_923532	232	58	,	,	,
10_1101-2020_01_28_923532	232	59	𝛼	𝛼	LS
10_1101-2020_01_28_923532	232	60	=	=	SYM
10_1101-2020_01_28_923532	232	61	0	0	CD
10_1101-2020_01_28_923532	232	62	)	)	-RRB-
10_1101-2020_01_28_923532	232	63	.	.	.
10_1101-2020_01_28_923532	233	1	The	the	DT
10_1101-2020_01_28_923532	233	2	solution	solution	NN
10_1101-2020_01_28_923532	233	3	in	in	IN
10_1101-2020_01_28_923532	233	4	panel	panel	NN
10_1101-2020_01_28_923532	233	5	A	a	DT
10_1101-2020_01_28_923532	233	6	has	have	VBZ
10_1101-2020_01_28_923532	233	7	an	an	DT
10_1101-2020_01_28_923532	233	8	unfairness	unfairness	JJ
10_1101-2020_01_28_923532	233	9	value	value	NN
10_1101-2020_01_28_923532	233	10	𝛼	𝛼	NN
10_1101-2020_01_28_923532	233	11	=	=	SYM
10_1101-2020_01_28_923532	233	12	1	1	CD
10_1101-2020_01_28_923532	233	13	because	because	IN
10_1101-2020_01_28_923532	233	14	the	the	DT
10_1101-2020_01_28_923532	233	15	worst	bad	JJS
10_1101-2020_01_28_923532	233	16	difference	difference	NN
10_1101-2020_01_28_923532	233	17	among	among	IN
10_1101-2020_01_28_923532	233	18	all	all	DT
10_1101-2020_01_28_923532	233	19	patients	patient	NNS
10_1101-2020_01_28_923532	233	20	is	be	VBZ
10_1101-2020_01_28_923532	233	21	that	that	IN
10_1101-2020_01_28_923532	233	22	a	a	DT
10_1101-2020_01_28_923532	233	23	patient	patient	JJ
10_1101-2020_01_28_923532	233	24	105	105	CD
10_1101-2020_01_28_923532	233	25	and	and	CC
10_1101-2020_01_28_923532	233	26	is	be	VBZ
10_1101-2020_01_28_923532	233	27	also	also	RB
10_1101-2020_01_28_923532	233	28	made	make	VBN
10_1101-2020_01_28_923532	233	29	available	available	JJ
10_1101-2020_01_28_923532	233	30	for	for	IN
10_1101-2020_01_28_923532	233	31	use	use	NN
10_1101-2020_01_28_923532	233	32	under	under	IN
10_1101-2020_01_28_923532	233	33	a	a	DT
10_1101-2020_01_28_923532	233	34	CC0	CC0	NNP
10_1101-2020_01_28_923532	233	35	license	license	NN
10_1101-2020_01_28_923532	233	36	.	.	.
10_1101-2020_01_28_923532	234	1	(	(	-LRB-
10_1101-2020_01_28_923532	234	2	which	which	WDT
10_1101-2020_01_28_923532	234	3	was	be	VBD
10_1101-2020_01_28_923532	234	4	not	not	RB
10_1101-2020_01_28_923532	234	5	certified	certify	VBN
10_1101-2020_01_28_923532	234	6	by	by	IN
10_1101-2020_01_28_923532	234	7	peer	peer	NN
10_1101-2020_01_28_923532	234	8	review	review	NN
10_1101-2020_01_28_923532	234	9	)	)	-RRB-
10_1101-2020_01_28_923532	234	10	is	be	VBZ
10_1101-2020_01_28_923532	234	11	the	the	DT
10_1101-2020_01_28_923532	234	12	author	author	NN
10_1101-2020_01_28_923532	234	13	/	/	SYM
10_1101-2020_01_28_923532	234	14	funder	funder	NN
10_1101-2020_01_28_923532	234	15	.	.	.
10_1101-2020_01_28_923532	235	1	This	this	DT
10_1101-2020_01_28_923532	235	2	article	article	NN
10_1101-2020_01_28_923532	235	3	is	be	VBZ
10_1101-2020_01_28_923532	235	4	a	a	DT
10_1101-2020_01_28_923532	235	5	US	US	NNP
10_1101-2020_01_28_923532	235	6	Government	Government	NNP
10_1101-2020_01_28_923532	235	7	work	work	NN
10_1101-2020_01_28_923532	235	8	.	.	.
10_1101-2020_01_28_923532	236	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	236	2	is	be	VBZ
10_1101-2020_01_28_923532	236	3	not	not	RB
10_1101-2020_01_28_923532	236	4	subject	subject	JJ
10_1101-2020_01_28_923532	236	5	to	to	IN
10_1101-2020_01_28_923532	236	6	copyright	copyright	NN
10_1101-2020_01_28_923532	236	7	under	under	IN
10_1101-2020_01_28_923532	236	8	17	17	CD
10_1101-2020_01_28_923532	236	9	USC	usc	NN
10_1101-2020_01_28_923532	236	10	The	the	DT
10_1101-2020_01_28_923532	236	11	copyright	copyright	NN
10_1101-2020_01_28_923532	236	12	holder	holder	NN
10_1101-2020_01_28_923532	236	13	for	for	IN
10_1101-2020_01_28_923532	236	14	this	this	DT
10_1101-2020_01_28_923532	236	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	236	16	version	version	NN
10_1101-2020_01_28_923532	236	17	posted	post	VBD
10_1101-2020_01_28_923532	236	18	February	February	NNP
10_1101-2020_01_28_923532	236	19	12	12	CD
10_1101-2020_01_28_923532	236	20	,	,	,
10_1101-2020_01_28_923532	236	21	2021	2021	CD
10_1101-2020_01_28_923532	236	22	.	.	.
10_1101-2020_01_28_923532	236	23	;	;	:
10_1101-2020_01_28_923532	236	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	236	25	:	:	:
10_1101-2020_01_28_923532	236	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	236	27	preprint	preprint	NN
10_1101-2020_01_28_923532	236	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	236	29	20	20	CD
10_1101-2020_01_28_923532	236	30	receives	receive	VBZ
10_1101-2020_01_28_923532	236	31	1	1	CD
10_1101-2020_01_28_923532	236	32	more	more	JJR
10_1101-2020_01_28_923532	236	33	treatment	treatment	NN
10_1101-2020_01_28_923532	236	34	than	than	IN
10_1101-2020_01_28_923532	236	35	necessary	necessary	JJ
10_1101-2020_01_28_923532	236	36	.	.	.
10_1101-2020_01_28_923532	237	1	(	(	-LRB-
10_1101-2020_01_28_923532	237	2	C	c	NN
10_1101-2020_01_28_923532	237	3	)	)	-RRB-
10_1101-2020_01_28_923532	237	4	Heatmaps	Heatmaps	NNP
10_1101-2020_01_28_923532	237	5	showing	show	VBG
10_1101-2020_01_28_923532	237	6	how	how	WRB
10_1101-2020_01_28_923532	237	7	the	the	DT
10_1101-2020_01_28_923532	237	8	CTS	CTS	NNP
10_1101-2020_01_28_923532	237	9	size	size	NN
10_1101-2020_01_28_923532	237	10	varies	vary	VBZ
10_1101-2020_01_28_923532	237	11	as	as	IN
10_1101-2020_01_28_923532	237	12	𝛼	𝛼	NN
10_1101-2020_01_28_923532	237	13	increases	increase	NNS
10_1101-2020_01_28_923532	237	14	(	(	-LRB-
10_1101-2020_01_28_923532	237	15	y	y	NNP
10_1101-2020_01_28_923532	237	16	-	-	HYPH
10_1101-2020_01_28_923532	237	17	axis	axis	NNP
10_1101-2020_01_28_923532	237	18	)	)	-RRB-
10_1101-2020_01_28_923532	237	19	,	,	,
10_1101-2020_01_28_923532	237	20	starting	start	VBG
10_1101-2020_01_28_923532	237	21	from	from	IN
10_1101-2020_01_28_923532	237	22	its	-PRON-	PRP$
10_1101-2020_01_28_923532	237	23	baseline	baseline	NN
10_1101-2020_01_28_923532	237	24	value	value	NN
10_1101-2020_01_28_923532	237	25	of	of	IN
10_1101-2020_01_28_923532	237	26	0	0	CD
10_1101-2020_01_28_923532	237	27	where	where	WRB
10_1101-2020_01_28_923532	237	28	each	each	DT
10_1101-2020_01_28_923532	237	29	patient	patient	NN
10_1101-2020_01_28_923532	237	30	is	be	VBZ
10_1101-2020_01_28_923532	237	31	assigned	assign	VBN
10_1101-2020_01_28_923532	237	32	a	a	DT
10_1101-2020_01_28_923532	237	33	minimum	minimum	JJ
10_1101-2020_01_28_923532	237	34	-	-	HYPH
10_1101-2020_01_28_923532	237	35	sizes	size	NNS
10_1101-2020_01_28_923532	237	36	individual	individual	JJ
10_1101-2020_01_28_923532	237	37	treatment	treatment	NN
10_1101-2020_01_28_923532	237	38	set	set	VBN
10_1101-2020_01_28_923532	237	39	(	(	-LRB-
10_1101-2020_01_28_923532	237	40	top	top	JJ
10_1101-2020_01_28_923532	237	41	row	row	NN
10_1101-2020_01_28_923532	237	42	)	)	-RRB-
10_1101-2020_01_28_923532	237	43	.	.	.
10_1101-2020_01_28_923532	238	1	The	the	DT
10_1101-2020_01_28_923532	238	2	lower	lower	RBR
10_1101-2020_01_28_923532	238	3	bound	bind	VBN
10_1101-2020_01_28_923532	238	4	on	on	IN
10_1101-2020_01_28_923532	238	5	tumor	tumor	NN
10_1101-2020_01_28_923532	238	6	cells	cell	NNS
10_1101-2020_01_28_923532	238	7	killed	kill	VBN
10_1101-2020_01_28_923532	238	8	(	(	-LRB-
10_1101-2020_01_28_923532	238	9	x-	x-	UH
10_1101-2020_01_28_923532	238	10	axis	axis	NNP
10_1101-2020_01_28_923532	238	11	)	)	-RRB-
10_1101-2020_01_28_923532	238	12	is	be	VBZ
10_1101-2020_01_28_923532	238	13	also	also	RB
10_1101-2020_01_28_923532	238	14	varied	varied	JJ
10_1101-2020_01_28_923532	238	15	while	while	IN
10_1101-2020_01_28_923532	238	16	the	the	DT
10_1101-2020_01_28_923532	238	17	upper	upper	JJ
10_1101-2020_01_28_923532	238	18	bound	bind	VBN
10_1101-2020_01_28_923532	238	19	on	on	IN
10_1101-2020_01_28_923532	238	20	non	non	JJ
10_1101-2020_01_28_923532	238	21	-	-	JJ
10_1101-2020_01_28_923532	238	22	tumor	tumor	JJ
10_1101-2020_01_28_923532	238	23	cells	cell	NNS
10_1101-2020_01_28_923532	238	24	killed	kill	VBN
10_1101-2020_01_28_923532	238	25	is	be	VBZ
10_1101-2020_01_28_923532	238	26	kept	keep	VBN
10_1101-2020_01_28_923532	238	27	fixed	fix	VBN
10_1101-2020_01_28_923532	238	28	at	at	IN
10_1101-2020_01_28_923532	238	29	0.1	0.1	CD
10_1101-2020_01_28_923532	238	30	.	.	.
10_1101-2020_01_28_923532	239	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	239	2	are	be	VBP
10_1101-2020_01_28_923532	239	3	particularly	particularly	RB
10_1101-2020_01_28_923532	239	4	interested	interested	JJ
10_1101-2020_01_28_923532	239	5	in	in	IN
10_1101-2020_01_28_923532	239	6	finding	find	VBG
10_1101-2020_01_28_923532	239	7	the	the	DT
10_1101-2020_01_28_923532	239	8	smallest	small	JJS
10_1101-2020_01_28_923532	239	9	value	value	NN
10_1101-2020_01_28_923532	239	10	on	on	IN
10_1101-2020_01_28_923532	239	11	the	the	DT
10_1101-2020_01_28_923532	239	12	y	y	NN
10_1101-2020_01_28_923532	239	13	-	-	:
10_1101-2020_01_28_923532	239	14	axis	axis	NNP
10_1101-2020_01_28_923532	239	15	at	at	IN
10_1101-2020_01_28_923532	239	16	which	which	WDT
10_1101-2020_01_28_923532	239	17	the	the	DT
10_1101-2020_01_28_923532	239	18	CTS	CTS	NNP
10_1101-2020_01_28_923532	239	19	size	size	NN
10_1101-2020_01_28_923532	239	20	reaches	reach	VBZ
10_1101-2020_01_28_923532	239	21	its	-PRON-	PRP$
10_1101-2020_01_28_923532	239	22	minimum	minimum	JJ
10_1101-2020_01_28_923532	239	23	value	value	NN
10_1101-2020_01_28_923532	239	24	,	,	,
10_1101-2020_01_28_923532	239	25	which	which	WDT
10_1101-2020_01_28_923532	239	26	is	be	VBZ
10_1101-2020_01_28_923532	239	27	circled	circle	VBN
10_1101-2020_01_28_923532	239	28	for	for	IN
10_1101-2020_01_28_923532	239	29	the	the	DT
10_1101-2020_01_28_923532	239	30	baseline	baseline	NN
10_1101-2020_01_28_923532	239	31	𝑙𝑏	𝑙𝑏	NN
10_1101-2020_01_28_923532	239	32	=	=	SYM
10_1101-2020_01_28_923532	239	33	0.8	0.8	CD
10_1101-2020_01_28_923532	239	34	,	,	,
10_1101-2020_01_28_923532	239	35	because	because	IN
10_1101-2020_01_28_923532	239	36	this	this	DT
10_1101-2020_01_28_923532	239	37	bounds	bound	VBZ
10_1101-2020_01_28_923532	239	38	the	the	DT
10_1101-2020_01_28_923532	239	39	tradeoff	tradeoff	NN
10_1101-2020_01_28_923532	239	40	between	between	IN
10_1101-2020_01_28_923532	239	41	the	the	DT
10_1101-2020_01_28_923532	239	42	achievable	achievable	JJ
10_1101-2020_01_28_923532	239	43	reduction	reduction	NN
10_1101-2020_01_28_923532	239	44	in	in	IN
10_1101-2020_01_28_923532	239	45	the	the	DT
10_1101-2020_01_28_923532	239	46	number	number	NN
10_1101-2020_01_28_923532	239	47	of	of	IN
10_1101-2020_01_28_923532	239	48	targets	target	NNS
10_1101-2020_01_28_923532	239	49	needed	need	VBN
10_1101-2020_01_28_923532	239	50	to	to	TO
10_1101-2020_01_28_923532	239	51	treat	treat	VB
10_1101-2020_01_28_923532	239	52	the	the	DT
10_1101-2020_01_28_923532	239	53	whole	whole	JJ
10_1101-2020_01_28_923532	239	54	cohort	cohort	NN
10_1101-2020_01_28_923532	239	55	and	and	CC
10_1101-2020_01_28_923532	239	56	the	the	DT
10_1101-2020_01_28_923532	239	57	number	number	NN
10_1101-2020_01_28_923532	239	58	of	of	IN
10_1101-2020_01_28_923532	239	59	extra	extra	JJ
10_1101-2020_01_28_923532	239	60	targets	target	NNS
10_1101-2020_01_28_923532	239	61	above	above	IN
10_1101-2020_01_28_923532	239	62	the	the	DT
10_1101-2020_01_28_923532	239	63	ITS	ITS	NNP
10_1101-2020_01_28_923532	239	64	minimum	minimum	NN
10_1101-2020_01_28_923532	239	65	that	that	IN
10_1101-2020_01_28_923532	239	66	any	any	DT
10_1101-2020_01_28_923532	239	67	patient	patient	NN
10_1101-2020_01_28_923532	239	68	might	may	MD
10_1101-2020_01_28_923532	239	69	need	need	VB
10_1101-2020_01_28_923532	239	70	to	to	TO
10_1101-2020_01_28_923532	239	71	receive	receive	VB
10_1101-2020_01_28_923532	239	72	.	.	.
10_1101-2020_01_28_923532	240	1	For	for	IN
10_1101-2020_01_28_923532	240	2	8	8	CD
10_1101-2020_01_28_923532	240	3	out	out	IN
10_1101-2020_01_28_923532	240	4	of	of	IN
10_1101-2020_01_28_923532	240	5	9	9	CD
10_1101-2020_01_28_923532	240	6	data	data	NN
10_1101-2020_01_28_923532	240	7	sets	set	NNS
10_1101-2020_01_28_923532	240	8	,	,	,
10_1101-2020_01_28_923532	240	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	240	10	encouragingly	encouragingly	RB
10_1101-2020_01_28_923532	240	11	find	find	VBP
10_1101-2020_01_28_923532	240	12	that	that	IN
10_1101-2020_01_28_923532	240	13	the	the	DT
10_1101-2020_01_28_923532	240	14	unfairness	unfairness	JJ
10_1101-2020_01_28_923532	240	15	cost	cost	NN
10_1101-2020_01_28_923532	240	16	parameter	parameter	NN
10_1101-2020_01_28_923532	240	17	𝛼	𝛼	-RRB-
10_1101-2020_01_28_923532	240	18	is	be	VBZ
10_1101-2020_01_28_923532	240	19	bounded	bound	VBN
10_1101-2020_01_28_923532	240	20	by	by	IN
10_1101-2020_01_28_923532	240	21	a	a	DT
10_1101-2020_01_28_923532	240	22	constant	constant	NN
10_1101-2020_01_28_923532	240	23	of	of	IN
10_1101-2020_01_28_923532	240	24	3	3	CD
10_1101-2020_01_28_923532	240	25	;	;	:
10_1101-2020_01_28_923532	240	26	i.e.	i.e.	FW
10_1101-2020_01_28_923532	240	27	,	,	,
10_1101-2020_01_28_923532	240	28	it	-PRON-	PRP
10_1101-2020_01_28_923532	240	29	is	be	VBZ
10_1101-2020_01_28_923532	240	30	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	240	31	to	to	TO
10_1101-2020_01_28_923532	240	32	increase	increase	VB
10_1101-2020_01_28_923532	240	33	𝛼	𝛼	NNS
10_1101-2020_01_28_923532	240	34	by	by	IN
10_1101-2020_01_28_923532	240	35	no	no	DT
10_1101-2020_01_28_923532	240	36	more	more	JJR
10_1101-2020_01_28_923532	240	37	than	than	IN
10_1101-2020_01_28_923532	240	38	3	3	CD
10_1101-2020_01_28_923532	240	39	to	to	TO
10_1101-2020_01_28_923532	240	40	obtain	obtain	VB
10_1101-2020_01_28_923532	240	41	the	the	DT
10_1101-2020_01_28_923532	240	42	smallest	small	JJS
10_1101-2020_01_28_923532	240	43	CTS	CTS	NNP
10_1101-2020_01_28_923532	240	44	sizes	size	NNS
10_1101-2020_01_28_923532	240	45	in	in	IN
10_1101-2020_01_28_923532	240	46	the	the	DT
10_1101-2020_01_28_923532	240	47	optimally	optimally	RB
10_1101-2020_01_28_923532	240	48	fair	fair	JJ
10_1101-2020_01_28_923532	240	49	solutions	solution	NNS
10_1101-2020_01_28_923532	240	50	.	.	.
10_1101-2020_01_28_923532	241	1	For	for	IN
10_1101-2020_01_28_923532	241	2	the	the	DT
10_1101-2020_01_28_923532	241	3	largest	large	JJS
10_1101-2020_01_28_923532	241	4	data	data	NN
10_1101-2020_01_28_923532	241	5	set	set	NN
10_1101-2020_01_28_923532	241	6	(	(	-LRB-
10_1101-2020_01_28_923532	241	7	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	241	8	)	)	-RRB-
10_1101-2020_01_28_923532	241	9	,	,	,
10_1101-2020_01_28_923532	241	10	𝛼	𝛼	NN
10_1101-2020_01_28_923532	241	11	=	=	SYM
10_1101-2020_01_28_923532	241	12	4	4	CD
10_1101-2020_01_28_923532	241	13	.	.	.
10_1101-2020_01_28_923532	242	1	As	as	IN
10_1101-2020_01_28_923532	242	2	we	-PRON-	PRP
10_1101-2020_01_28_923532	242	3	show	show	VBP
10_1101-2020_01_28_923532	242	4	in	in	IN
10_1101-2020_01_28_923532	242	5	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	242	6	Materials	Materials	NNP
10_1101-2020_01_28_923532	242	7	10	10	CD
10_1101-2020_01_28_923532	242	8	,	,	,
10_1101-2020_01_28_923532	242	9	empirically	empirically	RB
10_1101-2020_01_28_923532	242	10	,	,	,
10_1101-2020_01_28_923532	242	11	even	even	RB
10_1101-2020_01_28_923532	242	12	if	if	IN
10_1101-2020_01_28_923532	242	13	one	one	PRP
10_1101-2020_01_28_923532	242	14	requires	require	VBZ
10_1101-2020_01_28_923532	242	15	lower	low	JJR
10_1101-2020_01_28_923532	242	16	α	α	DT
10_1101-2020_01_28_923532	242	17	values	value	NNS
10_1101-2020_01_28_923532	242	18	,	,	,
10_1101-2020_01_28_923532	242	19	then	then	RB
10_1101-2020_01_28_923532	242	20	as	as	IN
10_1101-2020_01_28_923532	242	21	those	those	DT
10_1101-2020_01_28_923532	242	22	approach	approach	NN
10_1101-2020_01_28_923532	242	23	0	0	CD
10_1101-2020_01_28_923532	242	24	,	,	,
10_1101-2020_01_28_923532	242	25	the	the	DT
10_1101-2020_01_28_923532	242	26	size	size	NN
10_1101-2020_01_28_923532	242	27	of	of	IN
10_1101-2020_01_28_923532	242	28	the	the	DT
10_1101-2020_01_28_923532	242	29	fairness	fairness	NN
10_1101-2020_01_28_923532	242	30	-	-	HYPH
10_1101-2020_01_28_923532	242	31	based	base	VBN
10_1101-2020_01_28_923532	242	32	CTS	CTS	NNP
10_1101-2020_01_28_923532	242	33	grows	grow	VBZ
10_1101-2020_01_28_923532	242	34	fairly	fairly	RB
10_1101-2020_01_28_923532	242	35	moderately	moderately	RB
10_1101-2020_01_28_923532	242	36	and	and	CC
10_1101-2020_01_28_923532	242	37	remains	remain	VBZ
10_1101-2020_01_28_923532	242	38	in	in	IN
10_1101-2020_01_28_923532	242	39	the	the	DT
10_1101-2020_01_28_923532	242	40	lower	low	JJR
10_1101-2020_01_28_923532	242	41	double	double	JJ
10_1101-2020_01_28_923532	242	42	digits	digit	NNS
10_1101-2020_01_28_923532	242	43	,	,	,
10_1101-2020_01_28_923532	242	44	and	and	CC
10_1101-2020_01_28_923532	242	45	the	the	DT
10_1101-2020_01_28_923532	242	46	mean	mean	JJ
10_1101-2020_01_28_923532	242	47	size	size	NN
10_1101-2020_01_28_923532	242	48	of	of	IN
10_1101-2020_01_28_923532	242	49	the	the	DT
10_1101-2020_01_28_923532	242	50	number	number	NN
10_1101-2020_01_28_923532	242	51	of	of	IN
10_1101-2020_01_28_923532	242	52	treatments	treatment	NNS
10_1101-2020_01_28_923532	242	53	given	give	VBN
10_1101-2020_01_28_923532	242	54	to	to	IN
10_1101-2020_01_28_923532	242	55	each	each	DT
10_1101-2020_01_28_923532	242	56	patient	patient	NN
10_1101-2020_01_28_923532	242	57	(	(	-LRB-
10_1101-2020_01_28_923532	242	58	their	-PRON-	PRP$
10_1101-2020_01_28_923532	242	59	ITS	ITS	NNP
10_1101-2020_01_28_923532	242	60	)	)	-RRB-
10_1101-2020_01_28_923532	242	61	is	be	VBZ
10_1101-2020_01_28_923532	242	62	overall	overall	JJ
10_1101-2020_01_28_923532	242	63	<	<	XX
10_1101-2020_01_28_923532	242	64	5	5	CD
10_1101-2020_01_28_923532	242	65	.	.	.
10_1101-2020_01_28_923532	243	1	Theoretically	theoretically	RB
10_1101-2020_01_28_923532	243	2	,	,	,
10_1101-2020_01_28_923532	243	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	243	4	show	show	VBP
10_1101-2020_01_28_923532	243	5	that	that	IN
10_1101-2020_01_28_923532	243	6	one	one	PRP
10_1101-2020_01_28_923532	243	7	can	can	MD
10_1101-2020_01_28_923532	243	8	design	design	VB
10_1101-2020_01_28_923532	243	9	instances	instance	NNS
10_1101-2020_01_28_923532	243	10	for	for	IN
10_1101-2020_01_28_923532	243	11	which	which	WDT
10_1101-2020_01_28_923532	243	12	𝛼	𝛼	NN
10_1101-2020_01_28_923532	243	13	would	would	MD
10_1101-2020_01_28_923532	243	14	need	need	VB
10_1101-2020_01_28_923532	243	15	to	to	TO
10_1101-2020_01_28_923532	243	16	be	be	VB
10_1101-2020_01_28_923532	243	17	at	at	IN
10_1101-2020_01_28_923532	243	18	least	least	JJS
10_1101-2020_01_28_923532	243	19	√𝑛	√𝑛	NN
10_1101-2020_01_28_923532	243	20	−	−	NNP
10_1101-2020_01_28_923532	243	21	1	1	CD
10_1101-2020_01_28_923532	243	22	to	to	TO
10_1101-2020_01_28_923532	243	23	get	get	VB
10_1101-2020_01_28_923532	243	24	a	a	DT
10_1101-2020_01_28_923532	243	25	CTS	CTS	NNP
10_1101-2020_01_28_923532	243	26	of	of	IN
10_1101-2020_01_28_923532	243	27	size	size	NN
10_1101-2020_01_28_923532	243	28	less	less	JJR
10_1101-2020_01_28_923532	243	29	than	than	IN
10_1101-2020_01_28_923532	243	30	the	the	DT
10_1101-2020_01_28_923532	243	31	overall	overall	JJ
10_1101-2020_01_28_923532	243	32	number	number	NN
10_1101-2020_01_28_923532	243	33	of	of	IN
10_1101-2020_01_28_923532	243	34	targets	target	NNS
10_1101-2020_01_28_923532	243	35	𝑛	𝑛	XX
10_1101-2020_01_28_923532	243	36	(	(	-LRB-
10_1101-2020_01_28_923532	243	37	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	243	38	Materials	Materials	NNP
10_1101-2020_01_28_923532	243	39	10	10	CD
10_1101-2020_01_28_923532	243	40	)	)	-RRB-
10_1101-2020_01_28_923532	243	41	.	.	.
10_1101-2020_01_28_923532	244	1	However	however	RB
10_1101-2020_01_28_923532	244	2	,	,	,
10_1101-2020_01_28_923532	244	3	in	in	IN
10_1101-2020_01_28_923532	244	4	practice	practice	NN
10_1101-2020_01_28_923532	244	5	,	,	,
10_1101-2020_01_28_923532	244	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	244	7	find	find	VBP
10_1101-2020_01_28_923532	244	8	that	that	IN
10_1101-2020_01_28_923532	244	9	given	give	VBN
10_1101-2020_01_28_923532	244	10	the	the	DT
10_1101-2020_01_28_923532	244	11	current	current	JJ
10_1101-2020_01_28_923532	244	12	tumor	tumor	NN
10_1101-2020_01_28_923532	244	13	single	single	JJ
10_1101-2020_01_28_923532	244	14	-	-	HYPH
10_1101-2020_01_28_923532	244	15	cell	cell	NN
10_1101-2020_01_28_923532	244	16	expression	expression	NN
10_1101-2020_01_28_923532	244	17	data	datum	NNS
10_1101-2020_01_28_923532	244	18	,	,	,
10_1101-2020_01_28_923532	244	19	fairness	fairness	NN
10_1101-2020_01_28_923532	244	20	-	-	HYPH
10_1101-2020_01_28_923532	244	21	based	base	VBN
10_1101-2020_01_28_923532	244	22	treatment	treatment	NN
10_1101-2020_01_28_923532	244	23	strategies	strategy	NNS
10_1101-2020_01_28_923532	244	24	are	be	VBP
10_1101-2020_01_28_923532	244	25	likely	likely	JJ
10_1101-2020_01_28_923532	244	26	to	to	TO
10_1101-2020_01_28_923532	244	27	be	be	VB
10_1101-2020_01_28_923532	244	28	a	a	DT
10_1101-2020_01_28_923532	244	29	reasonable	reasonable	JJ
10_1101-2020_01_28_923532	244	30	economic	economic	JJ
10_1101-2020_01_28_923532	244	31	option	option	NN
10_1101-2020_01_28_923532	244	32	in	in	IN
10_1101-2020_01_28_923532	244	33	the	the	DT
10_1101-2020_01_28_923532	244	34	future	future	NN
10_1101-2020_01_28_923532	244	35	.	.	.
10_1101-2020_01_28_923532	245	1	The	the	DT
10_1101-2020_01_28_923532	245	2	Landscape	Landscape	NNP
10_1101-2020_01_28_923532	245	3	of	of	IN
10_1101-2020_01_28_923532	245	4	Optimal	Optimal	NNP
10_1101-2020_01_28_923532	245	5	Solutions	Solutions	NNPS
10_1101-2020_01_28_923532	245	6	Targeting	Targeting	NNP
10_1101-2020_01_28_923532	245	7	Receptors	Receptors	NNPS
10_1101-2020_01_28_923532	245	8	that	that	WDT
10_1101-2020_01_28_923532	245	9	are	be	VBP
10_1101-2020_01_28_923532	245	10	Lowly	lowly	JJ
10_1101-2020_01_28_923532	245	11	Expressed	express	VBN
10_1101-2020_01_28_923532	245	12	Across	across	IN
10_1101-2020_01_28_923532	245	13	Many	many	JJ
10_1101-2020_01_28_923532	245	14	Healthy	healthy	JJ
10_1101-2020_01_28_923532	245	15	Tissues	tissue	NNS
10_1101-2020_01_28_923532	245	16	We	-PRON-	PRP
10_1101-2020_01_28_923532	245	17	turn	turn	VBP
10_1101-2020_01_28_923532	245	18	to	to	TO
10_1101-2020_01_28_923532	245	19	examine	examine	VB
10_1101-2020_01_28_923532	245	20	the	the	DT
10_1101-2020_01_28_923532	245	21	space	space	NN
10_1101-2020_01_28_923532	245	22	of	of	IN
10_1101-2020_01_28_923532	245	23	optimal	optimal	JJ
10_1101-2020_01_28_923532	245	24	solutions	solution	NNS
10_1101-2020_01_28_923532	245	25	when	when	WRB
10_1101-2020_01_28_923532	245	26	restricting	restrict	VBG
10_1101-2020_01_28_923532	245	27	the	the	DT
10_1101-2020_01_28_923532	245	28	set	set	NN
10_1101-2020_01_28_923532	245	29	of	of	IN
10_1101-2020_01_28_923532	245	30	eligible	eligible	JJ
10_1101-2020_01_28_923532	245	31	surface	surface	NN
10_1101-2020_01_28_923532	245	32	receptor	receptor	NN
10_1101-2020_01_28_923532	245	33	gene	gene	NN
10_1101-2020_01_28_923532	245	34	targets	target	NNS
10_1101-2020_01_28_923532	245	35	to	to	IN
10_1101-2020_01_28_923532	245	36	those	those	DT
10_1101-2020_01_28_923532	245	37	that	that	WDT
10_1101-2020_01_28_923532	245	38	have	have	VBP
10_1101-2020_01_28_923532	245	39	lower	low	JJR
10_1101-2020_01_28_923532	245	40	expression	expression	NN
10_1101-2020_01_28_923532	245	41	across	across	IN
10_1101-2020_01_28_923532	245	42	many	many	JJ
10_1101-2020_01_28_923532	245	43	noncancerous	noncancerous	JJ
10_1101-2020_01_28_923532	245	44	human	human	JJ
10_1101-2020_01_28_923532	245	45	tissues	tissue	NNS
10_1101-2020_01_28_923532	245	46	(	(	-LRB-
10_1101-2020_01_28_923532	245	47	Methods	Methods	NNP
10_1101-2020_01_28_923532	245	48	)	)	-RRB-
10_1101-2020_01_28_923532	245	49	,	,	,
10_1101-2020_01_28_923532	245	50	aiming	aim	VBG
10_1101-2020_01_28_923532	245	51	to	to	TO
10_1101-2020_01_28_923532	245	52	mitigate	mitigate	VB
10_1101-2020_01_28_923532	245	53	potential	potential	JJ
10_1101-2020_01_28_923532	245	54	damage	damage	NN
10_1101-2020_01_28_923532	245	55	to	to	IN
10_1101-2020_01_28_923532	245	56	tissues	tissue	NNS
10_1101-2020_01_28_923532	245	57	unrelated	unrelated	JJ
10_1101-2020_01_28_923532	245	58	to	to	IN
10_1101-2020_01_28_923532	245	59	the	the	DT
10_1101-2020_01_28_923532	245	60	tumor	tumor	NN
10_1101-2020_01_28_923532	245	61	site	site	NN
10_1101-2020_01_28_923532	245	62	.	.	.
10_1101-2020_01_28_923532	246	1	To	to	IN
10_1101-2020_01_28_923532	246	2	this	this	DT
10_1101-2020_01_28_923532	246	3	end	end	NN
10_1101-2020_01_28_923532	246	4	,	,	,
10_1101-2020_01_28_923532	246	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	246	6	selected	select	VBD
10_1101-2020_01_28_923532	246	7	subsets	subset	NNS
10_1101-2020_01_28_923532	246	8	of	of	IN
10_1101-2020_01_28_923532	246	9	the	the	DT
10_1101-2020_01_28_923532	246	10	1269	1269	CD
10_1101-2020_01_28_923532	246	11	cell	cell	NN
10_1101-2020_01_28_923532	246	12	surface	surface	NN
10_1101-2020_01_28_923532	246	13	receptor	receptor	NN
10_1101-2020_01_28_923532	246	14	targets	target	NNS
10_1101-2020_01_28_923532	246	15	in	in	IN
10_1101-2020_01_28_923532	246	16	which	which	WDT
10_1101-2020_01_28_923532	246	17	the	the	DT
10_1101-2020_01_28_923532	246	18	genes	gene	NNS
10_1101-2020_01_28_923532	246	19	have	have	VBP
10_1101-2020_01_28_923532	246	20	overall	overall	RB
10_1101-2020_01_28_923532	246	21	lower	low	JJR
10_1101-2020_01_28_923532	246	22	expression	expression	NN
10_1101-2020_01_28_923532	246	23	across	across	IN
10_1101-2020_01_28_923532	246	24	multiple	multiple	JJ
10_1101-2020_01_28_923532	246	25	normal	normal	JJ
10_1101-2020_01_28_923532	246	26	tissues	tissue	NNS
10_1101-2020_01_28_923532	246	27	,	,	,
10_1101-2020_01_28_923532	246	28	by	by	IN
10_1101-2020_01_28_923532	246	29	mining	mine	VBG
10_1101-2020_01_28_923532	246	30	GTEx	GTEx	NNS
10_1101-2020_01_28_923532	246	31	and	and	CC
10_1101-2020_01_28_923532	246	32	the	the	DT
10_1101-2020_01_28_923532	246	33	Human	Human	NNP
10_1101-2020_01_28_923532	246	34	Protein	Protein	NNP
10_1101-2020_01_28_923532	246	35	Atlas	Atlas	NNP
10_1101-2020_01_28_923532	246	36	(	(	-LRB-
10_1101-2020_01_28_923532	246	37	HPA	HPA	NNP
10_1101-2020_01_28_923532	246	38	)	)	-RRB-
10_1101-2020_01_28_923532	246	39	(	(	-LRB-
10_1101-2020_01_28_923532	246	40	Methods	Methods	NNP
10_1101-2020_01_28_923532	246	41	)	)	-RRB-
10_1101-2020_01_28_923532	246	42	.	.	.
10_1101-2020_01_28_923532	247	1	Varying	vary	VBG
10_1101-2020_01_28_923532	247	2	the	the	DT
10_1101-2020_01_28_923532	247	3	selectivity	selectivity	NN
10_1101-2020_01_28_923532	247	4	expression	expression	NN
10_1101-2020_01_28_923532	247	5	thresholds	threshold	NNS
10_1101-2020_01_28_923532	247	6	(	(	-LRB-
10_1101-2020_01_28_923532	247	7	expressed	express	VBN
10_1101-2020_01_28_923532	247	8	in	in	IN
10_1101-2020_01_28_923532	247	9	transcripts	transcript	NNS
10_1101-2020_01_28_923532	247	10	per	per	IN
10_1101-2020_01_28_923532	247	11	million	million	CD
10_1101-2020_01_28_923532	247	12	(	(	-LRB-
10_1101-2020_01_28_923532	247	13	TPM	TPM	NNP
10_1101-2020_01_28_923532	247	14	)	)	-RRB-
10_1101-2020_01_28_923532	247	15	)	)	-RRB-
10_1101-2020_01_28_923532	247	16	used	use	VBN
10_1101-2020_01_28_923532	247	17	to	to	TO
10_1101-2020_01_28_923532	247	18	filter	filter	VB
10_1101-2020_01_28_923532	247	19	out	out	RP
10_1101-2020_01_28_923532	247	20	genes	gene	NNS
10_1101-2020_01_28_923532	247	21	whose	whose	WP$
10_1101-2020_01_28_923532	247	22	mean	mean	VBP
10_1101-2020_01_28_923532	247	23	expression	expression	NN
10_1101-2020_01_28_923532	247	24	across	across	IN
10_1101-2020_01_28_923532	247	25	the	the	DT
10_1101-2020_01_28_923532	247	26	normal	normal	JJ
10_1101-2020_01_28_923532	247	27	adult	adult	NN
10_1101-2020_01_28_923532	247	28	tissues	tissue	NNS
10_1101-2020_01_28_923532	247	29	is	be	VBZ
10_1101-2020_01_28_923532	247	30	above	above	IN
10_1101-2020_01_28_923532	247	31	values	value	NNS
10_1101-2020_01_28_923532	247	32	of	of	IN
10_1101-2020_01_28_923532	247	33	10	10	CD
10_1101-2020_01_28_923532	247	34	,	,	,
10_1101-2020_01_28_923532	247	35	5	5	CD
10_1101-2020_01_28_923532	247	36	,	,	,
10_1101-2020_01_28_923532	247	37	2	2	CD
10_1101-2020_01_28_923532	247	38	,	,	,
10_1101-2020_01_28_923532	247	39	1	1	CD
10_1101-2020_01_28_923532	247	40	,	,	,
10_1101-2020_01_28_923532	247	41	0.5	0.5	CD
10_1101-2020_01_28_923532	247	42	,	,	,
10_1101-2020_01_28_923532	247	43	and	and	CC
10_1101-2020_01_28_923532	247	44	0.25	0.25	CD
10_1101-2020_01_28_923532	247	45	(	(	-LRB-
10_1101-2020_01_28_923532	247	46	i.e.	i.e.	FW
10_1101-2020_01_28_923532	247	47	,	,	,
10_1101-2020_01_28_923532	247	48	employing	employ	VBG
10_1101-2020_01_28_923532	247	49	more	more	JJR
10_1101-2020_01_28_923532	247	50	and	and	CC
10_1101-2020_01_28_923532	247	51	more	more	RBR
10_1101-2020_01_28_923532	247	52	extensive	extensive	JJ
10_1101-2020_01_28_923532	247	53	105	105	CD
10_1101-2020_01_28_923532	247	54	and	and	CC
10_1101-2020_01_28_923532	247	55	is	be	VBZ
10_1101-2020_01_28_923532	247	56	also	also	RB
10_1101-2020_01_28_923532	247	57	made	make	VBN
10_1101-2020_01_28_923532	247	58	available	available	JJ
10_1101-2020_01_28_923532	247	59	for	for	IN
10_1101-2020_01_28_923532	247	60	use	use	NN
10_1101-2020_01_28_923532	247	61	under	under	IN
10_1101-2020_01_28_923532	247	62	a	a	DT
10_1101-2020_01_28_923532	247	63	CC0	CC0	NNP
10_1101-2020_01_28_923532	247	64	license	license	NN
10_1101-2020_01_28_923532	247	65	.	.	.
10_1101-2020_01_28_923532	248	1	(	(	-LRB-
10_1101-2020_01_28_923532	248	2	which	which	WDT
10_1101-2020_01_28_923532	248	3	was	be	VBD
10_1101-2020_01_28_923532	248	4	not	not	RB
10_1101-2020_01_28_923532	248	5	certified	certify	VBN
10_1101-2020_01_28_923532	248	6	by	by	IN
10_1101-2020_01_28_923532	248	7	peer	peer	NN
10_1101-2020_01_28_923532	248	8	review	review	NN
10_1101-2020_01_28_923532	248	9	)	)	-RRB-
10_1101-2020_01_28_923532	248	10	is	be	VBZ
10_1101-2020_01_28_923532	248	11	the	the	DT
10_1101-2020_01_28_923532	248	12	author	author	NN
10_1101-2020_01_28_923532	248	13	/	/	SYM
10_1101-2020_01_28_923532	248	14	funder	funder	NN
10_1101-2020_01_28_923532	248	15	.	.	.
10_1101-2020_01_28_923532	249	1	This	this	DT
10_1101-2020_01_28_923532	249	2	article	article	NN
10_1101-2020_01_28_923532	249	3	is	be	VBZ
10_1101-2020_01_28_923532	249	4	a	a	DT
10_1101-2020_01_28_923532	249	5	US	US	NNP
10_1101-2020_01_28_923532	249	6	Government	Government	NNP
10_1101-2020_01_28_923532	249	7	work	work	NN
10_1101-2020_01_28_923532	249	8	.	.	.
10_1101-2020_01_28_923532	250	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	250	2	is	be	VBZ
10_1101-2020_01_28_923532	250	3	not	not	RB
10_1101-2020_01_28_923532	250	4	subject	subject	JJ
10_1101-2020_01_28_923532	250	5	to	to	IN
10_1101-2020_01_28_923532	250	6	copyright	copyright	NN
10_1101-2020_01_28_923532	250	7	under	under	IN
10_1101-2020_01_28_923532	250	8	17	17	CD
10_1101-2020_01_28_923532	250	9	USC	usc	NN
10_1101-2020_01_28_923532	250	10	The	the	DT
10_1101-2020_01_28_923532	250	11	copyright	copyright	NN
10_1101-2020_01_28_923532	250	12	holder	holder	NN
10_1101-2020_01_28_923532	250	13	for	for	IN
10_1101-2020_01_28_923532	250	14	this	this	DT
10_1101-2020_01_28_923532	250	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	250	16	version	version	NN
10_1101-2020_01_28_923532	250	17	posted	post	VBD
10_1101-2020_01_28_923532	250	18	February	February	NNP
10_1101-2020_01_28_923532	250	19	12	12	CD
10_1101-2020_01_28_923532	250	20	,	,	,
10_1101-2020_01_28_923532	250	21	2021	2021	CD
10_1101-2020_01_28_923532	250	22	.	.	.
10_1101-2020_01_28_923532	250	23	;	;	:
10_1101-2020_01_28_923532	250	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	250	25	:	:	:
10_1101-2020_01_28_923532	250	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	250	27	preprint	preprint	NN
10_1101-2020_01_28_923532	250	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	250	29	21	21	CD
10_1101-2020_01_28_923532	250	30	filtering	filter	VBG
10_1101-2020_01_28_923532	250	31	as	as	IN
10_1101-2020_01_28_923532	250	32	this	this	DT
10_1101-2020_01_28_923532	250	33	threshold	threshold	NN
10_1101-2020_01_28_923532	250	34	is	be	VBZ
10_1101-2020_01_28_923532	250	35	decreased	decrease	VBN
10_1101-2020_01_28_923532	250	36	)	)	-RRB-
10_1101-2020_01_28_923532	250	37	,	,	,
10_1101-2020_01_28_923532	250	38	decreases	decrease	VBZ
10_1101-2020_01_28_923532	250	39	the	the	DT
10_1101-2020_01_28_923532	250	40	size	size	NN
10_1101-2020_01_28_923532	250	41	of	of	IN
10_1101-2020_01_28_923532	250	42	the	the	DT
10_1101-2020_01_28_923532	250	43	target	target	NN
10_1101-2020_01_28_923532	250	44	cell	cell	NN
10_1101-2020_01_28_923532	250	45	surface	surface	NN
10_1101-2020_01_28_923532	250	46	receptor	receptor	NN
10_1101-2020_01_28_923532	250	47	gene	gene	NN
10_1101-2020_01_28_923532	250	48	list	list	NN
10_1101-2020_01_28_923532	250	49	by	by	IN
10_1101-2020_01_28_923532	250	50	more	more	JJR
10_1101-2020_01_28_923532	250	51	than	than	IN
10_1101-2020_01_28_923532	250	52	half	half	NN
10_1101-2020_01_28_923532	250	53	(	(	-LRB-
10_1101-2020_01_28_923532	250	54	Table	table	NN
10_1101-2020_01_28_923532	250	55	2	2	CD
10_1101-2020_01_28_923532	250	56	)	)	-RRB-
10_1101-2020_01_28_923532	250	57	.	.	.
10_1101-2020_01_28_923532	251	1	As	as	IN
10_1101-2020_01_28_923532	251	2	shown	show	VBN
10_1101-2020_01_28_923532	251	3	in	in	IN
10_1101-2020_01_28_923532	251	4	Figures	figure	NNS
10_1101-2020_01_28_923532	251	5	7A	7a	NN
10_1101-2020_01_28_923532	251	6	,	,	,
10_1101-2020_01_28_923532	251	7	B	b	NN
10_1101-2020_01_28_923532	251	8	(	(	-LRB-
10_1101-2020_01_28_923532	251	9	and	and	CC
10_1101-2020_01_28_923532	251	10	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	251	11	Figures	Figures	NNPS
10_1101-2020_01_28_923532	251	12	S24-S26	S24-S26	NNP
10_1101-2020_01_28_923532	251	13	)	)	-RRB-
10_1101-2020_01_28_923532	251	14	,	,	,
10_1101-2020_01_28_923532	251	15	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	251	16	identifies	identify	VBZ
10_1101-2020_01_28_923532	251	17	very	very	RB
10_1101-2020_01_28_923532	251	18	different	different	JJ
10_1101-2020_01_28_923532	251	19	cohort	cohort	NN
10_1101-2020_01_28_923532	251	20	target	target	NN
10_1101-2020_01_28_923532	251	21	sets	set	NNS
10_1101-2020_01_28_923532	251	22	(	(	-LRB-
10_1101-2020_01_28_923532	251	23	which	which	WDT
10_1101-2020_01_28_923532	251	24	are	be	VBP
10_1101-2020_01_28_923532	251	25	larger	large	JJR
10_1101-2020_01_28_923532	251	26	than	than	IN
10_1101-2020_01_28_923532	251	27	the	the	DT
10_1101-2020_01_28_923532	251	28	original	original	JJ
10_1101-2020_01_28_923532	251	29	optimal	optimal	JJ
10_1101-2020_01_28_923532	251	30	solutions	solution	NNS
10_1101-2020_01_28_923532	251	31	,	,	,
10_1101-2020_01_28_923532	251	32	as	as	IN
10_1101-2020_01_28_923532	251	33	expected	expect	VBN
10_1101-2020_01_28_923532	251	34	)	)	-RRB-
10_1101-2020_01_28_923532	251	35	as	as	IN
10_1101-2020_01_28_923532	251	36	the	the	DT
10_1101-2020_01_28_923532	251	37	TPM	TPM	NNP
10_1101-2020_01_28_923532	251	38	selectivity	selectivity	NN
10_1101-2020_01_28_923532	251	39	threshold	threshold	NN
10_1101-2020_01_28_923532	251	40	value	value	NN
10_1101-2020_01_28_923532	251	41	is	be	VBZ
10_1101-2020_01_28_923532	251	42	decreased	decrease	VBN
10_1101-2020_01_28_923532	251	43	.	.	.
10_1101-2020_01_28_923532	252	1	Furthermore	furthermore	RB
10_1101-2020_01_28_923532	252	2	,	,	,
10_1101-2020_01_28_923532	252	3	different	different	JJ
10_1101-2020_01_28_923532	252	4	ITS	its	PRP$
10_1101-2020_01_28_923532	252	5	instances	instance	NNS
10_1101-2020_01_28_923532	252	6	may	may	MD
10_1101-2020_01_28_923532	252	7	become	become	VB
10_1101-2020_01_28_923532	252	8	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	252	9	(	(	-LRB-
10_1101-2020_01_28_923532	252	10	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	252	11	Figure	Figure	NNP
10_1101-2020_01_28_923532	252	12	S27	S27	NNP
10_1101-2020_01_28_923532	252	13	)	)	-RRB-
10_1101-2020_01_28_923532	252	14	.	.	.
10_1101-2020_01_28_923532	253	1	At	at	IN
10_1101-2020_01_28_923532	253	2	an	an	DT
10_1101-2020_01_28_923532	253	3	individual	individual	JJ
10_1101-2020_01_28_923532	253	4	patient	patient	JJ
10_1101-2020_01_28_923532	253	5	level	level	NN
10_1101-2020_01_28_923532	253	6	,	,	,
10_1101-2020_01_28_923532	253	7	using	use	VBG
10_1101-2020_01_28_923532	253	8	lower	low	JJR
10_1101-2020_01_28_923532	253	9	selectivity	selectivity	NN
10_1101-2020_01_28_923532	253	10	threshold	threshold	NN
10_1101-2020_01_28_923532	253	11	levels	level	NNS
10_1101-2020_01_28_923532	253	12	,	,	,
10_1101-2020_01_28_923532	253	13	which	which	WDT
10_1101-2020_01_28_923532	253	14	leads	lead	VBZ
10_1101-2020_01_28_923532	253	15	to	to	IN
10_1101-2020_01_28_923532	253	16	a	a	DT
10_1101-2020_01_28_923532	253	17	smaller	small	JJR
10_1101-2020_01_28_923532	253	18	space	space	NN
10_1101-2020_01_28_923532	253	19	of	of	IN
10_1101-2020_01_28_923532	253	20	membrane	membrane	NN
10_1101-2020_01_28_923532	253	21	receptors	receptor	NNS
10_1101-2020_01_28_923532	253	22	to	to	TO
10_1101-2020_01_28_923532	253	23	choose	choose	VB
10_1101-2020_01_28_923532	253	24	from	from	IN
10_1101-2020_01_28_923532	253	25	,	,	,
10_1101-2020_01_28_923532	253	26	also	also	RB
10_1101-2020_01_28_923532	253	27	leads	lead	VBZ
10_1101-2020_01_28_923532	253	28	to	to	IN
10_1101-2020_01_28_923532	253	29	increased	increase	VBN
10_1101-2020_01_28_923532	253	30	mean	mean	VB
10_1101-2020_01_28_923532	253	31	ITS	its	PRP$
10_1101-2020_01_28_923532	253	32	sizes	size	NNS
10_1101-2020_01_28_923532	253	33	(	(	-LRB-
10_1101-2020_01_28_923532	253	34	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	253	35	Figures	Figures	NNPS
10_1101-2020_01_28_923532	253	36	S28	S28	NNP
10_1101-2020_01_28_923532	253	37	,	,	,
10_1101-2020_01_28_923532	253	38	S29	S29	NNP
10_1101-2020_01_28_923532	253	39	)	)	-RRB-
10_1101-2020_01_28_923532	253	40	.	.	.
10_1101-2020_01_28_923532	254	1	Across	across	IN
10_1101-2020_01_28_923532	254	2	the	the	DT
10_1101-2020_01_28_923532	254	3	nine	nine	CD
10_1101-2020_01_28_923532	254	4	data	data	NN
10_1101-2020_01_28_923532	254	5	sets	set	NNS
10_1101-2020_01_28_923532	254	6	,	,	,
10_1101-2020_01_28_923532	254	7	the	the	DT
10_1101-2020_01_28_923532	254	8	selectivity	selectivity	NN
10_1101-2020_01_28_923532	254	9	threshold	threshold	NN
10_1101-2020_01_28_923532	254	10	at	at	IN
10_1101-2020_01_28_923532	254	11	which	which	WDT
10_1101-2020_01_28_923532	254	12	the	the	DT
10_1101-2020_01_28_923532	254	13	CTS	CTS	NNP
10_1101-2020_01_28_923532	254	14	problem	problem	NN
10_1101-2020_01_28_923532	254	15	became	become	VBD
10_1101-2020_01_28_923532	254	16	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	254	17	varied	varied	JJ
10_1101-2020_01_28_923532	254	18	(	(	-LRB-
10_1101-2020_01_28_923532	254	19	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	254	20	Figure	Figure	NNP
10_1101-2020_01_28_923532	254	21	S27	S27	NNP
10_1101-2020_01_28_923532	254	22	)	)	-RRB-
10_1101-2020_01_28_923532	254	23	.	.	.
10_1101-2020_01_28_923532	255	1	The	the	DT
10_1101-2020_01_28_923532	255	2	differences	difference	NNS
10_1101-2020_01_28_923532	255	3	observed	observe	VBN
10_1101-2020_01_28_923532	255	4	could	could	MD
10_1101-2020_01_28_923532	255	5	be	be	VB
10_1101-2020_01_28_923532	255	6	the	the	DT
10_1101-2020_01_28_923532	255	7	result	result	NN
10_1101-2020_01_28_923532	255	8	of	of	IN
10_1101-2020_01_28_923532	255	9	expression	expression	NN
10_1101-2020_01_28_923532	255	10	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	255	11	of	of	IN
10_1101-2020_01_28_923532	255	12	the	the	DT
10_1101-2020_01_28_923532	255	13	cancer	cancer	NN
10_1101-2020_01_28_923532	255	14	,	,	,
10_1101-2020_01_28_923532	255	15	number	number	NN
10_1101-2020_01_28_923532	255	16	of	of	IN
10_1101-2020_01_28_923532	255	17	patients	patient	NNS
10_1101-2020_01_28_923532	255	18	within	within	IN
10_1101-2020_01_28_923532	255	19	the	the	DT
10_1101-2020_01_28_923532	255	20	data	data	NN
10_1101-2020_01_28_923532	255	21	set	set	NN
10_1101-2020_01_28_923532	255	22	,	,	,
10_1101-2020_01_28_923532	255	23	size	size	NN
10_1101-2020_01_28_923532	255	24	of	of	IN
10_1101-2020_01_28_923532	255	25	target	target	NN
10_1101-2020_01_28_923532	255	26	gene	gene	NN
10_1101-2020_01_28_923532	255	27	set	set	NN
10_1101-2020_01_28_923532	255	28	,	,	,
10_1101-2020_01_28_923532	255	29	lack	lack	NN
10_1101-2020_01_28_923532	255	30	of	of	IN
10_1101-2020_01_28_923532	255	31	expression	expression	NN
10_1101-2020_01_28_923532	255	32	of	of	IN
10_1101-2020_01_28_923532	255	33	available	available	JJ
10_1101-2020_01_28_923532	255	34	gene	gene	NN
10_1101-2020_01_28_923532	255	35	targets	target	NNS
10_1101-2020_01_28_923532	255	36	and	and	CC
10_1101-2020_01_28_923532	255	37	other	other	JJ
10_1101-2020_01_28_923532	255	38	unknown	unknown	JJ
10_1101-2020_01_28_923532	255	39	factors	factor	NNS
10_1101-2020_01_28_923532	255	40	.	.	.
10_1101-2020_01_28_923532	256	1	In	in	IN
10_1101-2020_01_28_923532	256	2	the	the	DT
10_1101-2020_01_28_923532	256	3	future	future	NN
10_1101-2020_01_28_923532	256	4	,	,	,
10_1101-2020_01_28_923532	256	5	further	further	JJ
10_1101-2020_01_28_923532	256	6	experimentation	experimentation	NN
10_1101-2020_01_28_923532	256	7	is	be	VBZ
10_1101-2020_01_28_923532	256	8	required	require	VBN
10_1101-2020_01_28_923532	256	9	to	to	TO
10_1101-2020_01_28_923532	256	10	identify	identify	VB
10_1101-2020_01_28_923532	256	11	tissue	tissue	NN
10_1101-2020_01_28_923532	256	12	-	-	HYPH
10_1101-2020_01_28_923532	256	13	specific	specific	JJ
10_1101-2020_01_28_923532	256	14	optimal	optimal	JJ
10_1101-2020_01_28_923532	256	15	gene	gene	NN
10_1101-2020_01_28_923532	256	16	expression	expression	NN
10_1101-2020_01_28_923532	256	17	thresholds	threshold	NNS
10_1101-2020_01_28_923532	256	18	that	that	WDT
10_1101-2020_01_28_923532	256	19	will	will	MD
10_1101-2020_01_28_923532	256	20	minimize	minimize	VB
10_1101-2020_01_28_923532	256	21	side	side	NN
10_1101-2020_01_28_923532	256	22	effects	effect	NNS
10_1101-2020_01_28_923532	256	23	while	while	IN
10_1101-2020_01_28_923532	256	24	allowing	allow	VBG
10_1101-2020_01_28_923532	256	25	cancer	cancer	NN
10_1101-2020_01_28_923532	256	26	cells	cell	NNS
10_1101-2020_01_28_923532	256	27	to	to	TO
10_1101-2020_01_28_923532	256	28	be	be	VB
10_1101-2020_01_28_923532	256	29	killed	kill	VBN
10_1101-2020_01_28_923532	256	30	by	by	IN
10_1101-2020_01_28_923532	256	31	combinations	combination	NNS
10_1101-2020_01_28_923532	256	32	of	of	IN
10_1101-2020_01_28_923532	256	33	targeted	target	VBN
10_1101-2020_01_28_923532	256	34	therapies	therapy	NNS
10_1101-2020_01_28_923532	256	35	.	.	.
10_1101-2020_01_28_923532	257	1	Finally	finally	RB
10_1101-2020_01_28_923532	257	2	,	,	,
10_1101-2020_01_28_923532	257	3	for	for	IN
10_1101-2020_01_28_923532	257	4	completeness	completeness	NN
10_1101-2020_01_28_923532	257	5	,	,	,
10_1101-2020_01_28_923532	257	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	257	7	also	also	RB
10_1101-2020_01_28_923532	257	8	tested	test	VBD
10_1101-2020_01_28_923532	257	9	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	257	10	on	on	IN
10_1101-2020_01_28_923532	257	11	the	the	DT
10_1101-2020_01_28_923532	257	12	set	set	NN
10_1101-2020_01_28_923532	257	13	of	of	IN
10_1101-2020_01_28_923532	257	14	533	533	CD
10_1101-2020_01_28_923532	257	15	lowly	lowly	JJ
10_1101-2020_01_28_923532	257	16	expressed	express	VBN
10_1101-2020_01_28_923532	257	17	genes	gene	NNS
10_1101-2020_01_28_923532	257	18	suggested	suggest	VBN
10_1101-2020_01_28_923532	257	19	by	by	IN
10_1101-2020_01_28_923532	257	20	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	257	21	et	et	NNP
10_1101-2020_01_28_923532	257	22	al.25	al.25	IN
10_1101-2020_01_28_923532	257	23	All	all	DT
10_1101-2020_01_28_923532	257	24	instances	instance	NNS
10_1101-2020_01_28_923532	257	25	with	with	IN
10_1101-2020_01_28_923532	257	26	default	default	NN
10_1101-2020_01_28_923532	257	27	setting	setting	NN
10_1101-2020_01_28_923532	257	28	of	of	IN
10_1101-2020_01_28_923532	257	29	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	257	30	,	,	,
10_1101-2020_01_28_923532	257	31	𝑙𝑏	𝑙𝑏	NNP
10_1101-2020_01_28_923532	257	32	,	,	,
10_1101-2020_01_28_923532	257	33	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	257	34	have	have	VBP
10_1101-2020_01_28_923532	257	35	feasible	feasible	JJ
10_1101-2020_01_28_923532	257	36	solutions	solution	NNS
10_1101-2020_01_28_923532	257	37	for	for	IN
10_1101-2020_01_28_923532	257	38	all	all	DT
10_1101-2020_01_28_923532	257	39	patients	patient	NNS
10_1101-2020_01_28_923532	257	40	.	.	.
10_1101-2020_01_28_923532	258	1	Mean	mean	VB
10_1101-2020_01_28_923532	258	2	ITS	its	PRP$
10_1101-2020_01_28_923532	258	3	sizes	size	NNS
10_1101-2020_01_28_923532	258	4	are	be	VBP
10_1101-2020_01_28_923532	258	5	below	below	IN
10_1101-2020_01_28_923532	258	6	4	4	CD
10_1101-2020_01_28_923532	258	7	for	for	IN
10_1101-2020_01_28_923532	258	8	eight	eight	CD
10_1101-2020_01_28_923532	258	9	of	of	IN
10_1101-2020_01_28_923532	258	10	nine	nine	CD
10_1101-2020_01_28_923532	258	11	data	data	NN
10_1101-2020_01_28_923532	258	12	sets	set	NNS
10_1101-2020_01_28_923532	258	13	,	,	,
10_1101-2020_01_28_923532	258	14	but	but	CC
10_1101-2020_01_28_923532	258	15	close	close	RB
10_1101-2020_01_28_923532	258	16	to	to	TO
10_1101-2020_01_28_923532	258	17	10	10	CD
10_1101-2020_01_28_923532	258	18	for	for	IN
10_1101-2020_01_28_923532	258	19	the	the	DT
10_1101-2020_01_28_923532	258	20	brain	brain	NN
10_1101-2020_01_28_923532	258	21	cancer	cancer	NN
10_1101-2020_01_28_923532	258	22	data	datum	NNS
10_1101-2020_01_28_923532	258	23	set	set	VBD
10_1101-2020_01_28_923532	258	24	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	258	25	.	.	.
10_1101-2020_01_28_923532	259	1	More	More	JJR
10_1101-2020_01_28_923532	259	2	details	detail	NNS
10_1101-2020_01_28_923532	259	3	can	can	MD
10_1101-2020_01_28_923532	259	4	be	be	VB
10_1101-2020_01_28_923532	259	5	found	find	VBN
10_1101-2020_01_28_923532	259	6	in	in	IN
10_1101-2020_01_28_923532	259	7	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	259	8	Materials	Materials	NNP
10_1101-2020_01_28_923532	259	9	11	11	CD
10_1101-2020_01_28_923532	259	10	and	and	CC
10_1101-2020_01_28_923532	259	11	Table	Table	NNP
10_1101-2020_01_28_923532	259	12	S3	S3	NNP
10_1101-2020_01_28_923532	259	13	.	.	.
10_1101-2020_01_28_923532	260	1	105	105	CD
10_1101-2020_01_28_923532	260	2	and	and	CC
10_1101-2020_01_28_923532	260	3	is	be	VBZ
10_1101-2020_01_28_923532	260	4	also	also	RB
10_1101-2020_01_28_923532	260	5	made	make	VBN
10_1101-2020_01_28_923532	260	6	available	available	JJ
10_1101-2020_01_28_923532	260	7	for	for	IN
10_1101-2020_01_28_923532	260	8	use	use	NN
10_1101-2020_01_28_923532	260	9	under	under	IN
10_1101-2020_01_28_923532	260	10	a	a	DT
10_1101-2020_01_28_923532	260	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	260	12	license	license	NN
10_1101-2020_01_28_923532	260	13	.	.	.
10_1101-2020_01_28_923532	261	1	(	(	-LRB-
10_1101-2020_01_28_923532	261	2	which	which	WDT
10_1101-2020_01_28_923532	261	3	was	be	VBD
10_1101-2020_01_28_923532	261	4	not	not	RB
10_1101-2020_01_28_923532	261	5	certified	certify	VBN
10_1101-2020_01_28_923532	261	6	by	by	IN
10_1101-2020_01_28_923532	261	7	peer	peer	NN
10_1101-2020_01_28_923532	261	8	review	review	NN
10_1101-2020_01_28_923532	261	9	)	)	-RRB-
10_1101-2020_01_28_923532	261	10	is	be	VBZ
10_1101-2020_01_28_923532	261	11	the	the	DT
10_1101-2020_01_28_923532	261	12	author	author	NN
10_1101-2020_01_28_923532	261	13	/	/	SYM
10_1101-2020_01_28_923532	261	14	funder	funder	NN
10_1101-2020_01_28_923532	261	15	.	.	.
10_1101-2020_01_28_923532	262	1	This	this	DT
10_1101-2020_01_28_923532	262	2	article	article	NN
10_1101-2020_01_28_923532	262	3	is	be	VBZ
10_1101-2020_01_28_923532	262	4	a	a	DT
10_1101-2020_01_28_923532	262	5	US	US	NNP
10_1101-2020_01_28_923532	262	6	Government	Government	NNP
10_1101-2020_01_28_923532	262	7	work	work	NN
10_1101-2020_01_28_923532	262	8	.	.	.
10_1101-2020_01_28_923532	263	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	263	2	is	be	VBZ
10_1101-2020_01_28_923532	263	3	not	not	RB
10_1101-2020_01_28_923532	263	4	subject	subject	JJ
10_1101-2020_01_28_923532	263	5	to	to	IN
10_1101-2020_01_28_923532	263	6	copyright	copyright	NN
10_1101-2020_01_28_923532	263	7	under	under	IN
10_1101-2020_01_28_923532	263	8	17	17	CD
10_1101-2020_01_28_923532	263	9	USC	usc	NN
10_1101-2020_01_28_923532	263	10	The	the	DT
10_1101-2020_01_28_923532	263	11	copyright	copyright	NN
10_1101-2020_01_28_923532	263	12	holder	holder	NN
10_1101-2020_01_28_923532	263	13	for	for	IN
10_1101-2020_01_28_923532	263	14	this	this	DT
10_1101-2020_01_28_923532	263	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	263	16	version	version	NN
10_1101-2020_01_28_923532	263	17	posted	post	VBD
10_1101-2020_01_28_923532	263	18	February	February	NNP
10_1101-2020_01_28_923532	263	19	12	12	CD
10_1101-2020_01_28_923532	263	20	,	,	,
10_1101-2020_01_28_923532	263	21	2021	2021	CD
10_1101-2020_01_28_923532	263	22	.	.	.
10_1101-2020_01_28_923532	263	23	;	;	:
10_1101-2020_01_28_923532	263	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	263	25	:	:	:
10_1101-2020_01_28_923532	263	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	263	27	preprint	preprint	NN
10_1101-2020_01_28_923532	263	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	263	29	22	22	CD
10_1101-2020_01_28_923532	263	30	Figure	figure	NN
10_1101-2020_01_28_923532	263	31	7	7	CD
10_1101-2020_01_28_923532	263	32	.	.	.
10_1101-2020_01_28_923532	264	1	Variation	variation	NN
10_1101-2020_01_28_923532	264	2	in	in	IN
10_1101-2020_01_28_923532	264	3	the	the	DT
10_1101-2020_01_28_923532	264	4	CTS	CTS	NNP
10_1101-2020_01_28_923532	264	5	size	size	NN
10_1101-2020_01_28_923532	264	6	and	and	CC
10_1101-2020_01_28_923532	264	7	composition	composition	NN
10_1101-2020_01_28_923532	264	8	as	as	IN
10_1101-2020_01_28_923532	264	9	function	function	NN
10_1101-2020_01_28_923532	264	10	of	of	IN
10_1101-2020_01_28_923532	264	11	the	the	DT
10_1101-2020_01_28_923532	264	12	magnitude	magnitude	NN
10_1101-2020_01_28_923532	264	13	of	of	IN
10_1101-2020_01_28_923532	264	14	filtering	filtering	NN
10_1101-2020_01_28_923532	264	15	of	of	IN
10_1101-2020_01_28_923532	264	16	genes	gene	NNS
10_1101-2020_01_28_923532	264	17	expressed	express	VBN
10_1101-2020_01_28_923532	264	18	in	in	IN
10_1101-2020_01_28_923532	264	19	noncancerous	noncancerous	JJ
10_1101-2020_01_28_923532	264	20	human	human	JJ
10_1101-2020_01_28_923532	264	21	tissues	tissue	NNS
10_1101-2020_01_28_923532	264	22	,	,	,
10_1101-2020_01_28_923532	264	23	for	for	IN
10_1101-2020_01_28_923532	264	24	different	different	JJ
10_1101-2020_01_28_923532	264	25	tumor	tumor	NN
10_1101-2020_01_28_923532	264	26	types	type	NNS
10_1101-2020_01_28_923532	264	27	.	.	.
10_1101-2020_01_28_923532	265	1	(	(	-LRB-
10_1101-2020_01_28_923532	265	2	A-	A-	NNP
10_1101-2020_01_28_923532	265	3	B	B	NNP
10_1101-2020_01_28_923532	265	4	)	)	-RRB-
10_1101-2020_01_28_923532	265	5	The	the	DT
10_1101-2020_01_28_923532	265	6	number	number	NN
10_1101-2020_01_28_923532	265	7	of	of	IN
10_1101-2020_01_28_923532	265	8	times	time	NNS
10_1101-2020_01_28_923532	265	9	a	a	DT
10_1101-2020_01_28_923532	265	10	gene	gene	NN
10_1101-2020_01_28_923532	265	11	(	(	-LRB-
10_1101-2020_01_28_923532	265	12	cell	cell	NN
10_1101-2020_01_28_923532	265	13	-	-	HYPH
10_1101-2020_01_28_923532	265	14	surface	surface	NN
10_1101-2020_01_28_923532	265	15	receptor	receptor	NN
10_1101-2020_01_28_923532	265	16	)	)	-RRB-
10_1101-2020_01_28_923532	265	17	is	be	VBZ
10_1101-2020_01_28_923532	265	18	included	include	VBN
10_1101-2020_01_28_923532	265	19	in	in	IN
10_1101-2020_01_28_923532	265	20	the	the	DT
10_1101-2020_01_28_923532	265	21	CTS	CTS	NNP
10_1101-2020_01_28_923532	265	22	(	(	-LRB-
10_1101-2020_01_28_923532	265	23	out	out	IN
10_1101-2020_01_28_923532	265	24	of	of	IN
10_1101-2020_01_28_923532	265	25	20	20	CD
10_1101-2020_01_28_923532	265	26	replicates	replicate	NNS
10_1101-2020_01_28_923532	265	27	,	,	,
10_1101-2020_01_28_923532	265	28	which	which	WDT
10_1101-2020_01_28_923532	265	29	is	be	VBZ
10_1101-2020_01_28_923532	265	30	therefore	therefore	RB
10_1101-2020_01_28_923532	265	31	the	the	DT
10_1101-2020_01_28_923532	265	32	Max	Max	NNP
10_1101-2020_01_28_923532	265	33	count	count	NN
10_1101-2020_01_28_923532	265	34	in	in	IN
10_1101-2020_01_28_923532	265	35	panels	panel	NNS
10_1101-2020_01_28_923532	265	36	A	A	NNP
10_1101-2020_01_28_923532	265	37	-	-	HYPH
10_1101-2020_01_28_923532	265	38	B	b	NN
10_1101-2020_01_28_923532	265	39	)	)	-RRB-
10_1101-2020_01_28_923532	265	40	,	,	,
10_1101-2020_01_28_923532	265	41	where	where	WRB
10_1101-2020_01_28_923532	265	42	each	each	DT
10_1101-2020_01_28_923532	265	43	column	column	NN
10_1101-2020_01_28_923532	265	44	presents	present	VBZ
10_1101-2020_01_28_923532	265	45	the	the	DT
10_1101-2020_01_28_923532	265	46	CTS	CTS	NNP
10_1101-2020_01_28_923532	265	47	solutions	solution	NNS
10_1101-2020_01_28_923532	265	48	when	when	WRB
10_1101-2020_01_28_923532	265	49	the	the	DT
10_1101-2020_01_28_923532	265	50	input	input	NN
10_1101-2020_01_28_923532	265	51	target	target	NN
10_1101-2020_01_28_923532	265	52	genes	gene	NNS
10_1101-2020_01_28_923532	265	53	sets	set	NNS
10_1101-2020_01_28_923532	265	54	are	be	VBP
10_1101-2020_01_28_923532	265	55	filtered	filter	VBN
10_1101-2020_01_28_923532	265	56	using	use	VBG
10_1101-2020_01_28_923532	265	57	a	a	DT
10_1101-2020_01_28_923532	265	58	specific	specific	JJ
10_1101-2020_01_28_923532	265	59	TPM	tpm	JJ
10_1101-2020_01_28_923532	265	60	filtering	filtering	NN
10_1101-2020_01_28_923532	265	61	threshold	threshold	NN
10_1101-2020_01_28_923532	265	62	(	(	-LRB-
10_1101-2020_01_28_923532	265	63	Methods	Methods	NNP
10_1101-2020_01_28_923532	265	64	)	)	-RRB-
10_1101-2020_01_28_923532	265	65	,	,	,
10_1101-2020_01_28_923532	265	66	for	for	IN
10_1101-2020_01_28_923532	265	67	(	(	-LRB-
10_1101-2020_01_28_923532	265	68	A	a	NN
10_1101-2020_01_28_923532	265	69	)	)	-RRB-
10_1101-2020_01_28_923532	265	70	a	a	DT
10_1101-2020_01_28_923532	265	71	breast	breast	NN
10_1101-2020_01_28_923532	265	72	cancer	cancer	NN
10_1101-2020_01_28_923532	265	73	and	and	CC
10_1101-2020_01_28_923532	265	74	(	(	-LRB-
10_1101-2020_01_28_923532	265	75	B	b	NN
10_1101-2020_01_28_923532	265	76	)	)	-RRB-
10_1101-2020_01_28_923532	265	77	brain	brain	NN
10_1101-2020_01_28_923532	265	78	cancer	cancer	NN
10_1101-2020_01_28_923532	265	79	.	.	.
10_1101-2020_01_28_923532	266	1	These	these	DT
10_1101-2020_01_28_923532	266	2	data	datum	NNS
10_1101-2020_01_28_923532	266	3	sets	set	NNS
10_1101-2020_01_28_923532	266	4	were	be	VBD
10_1101-2020_01_28_923532	266	5	selected	select	VBN
10_1101-2020_01_28_923532	266	6	due	due	JJ
10_1101-2020_01_28_923532	266	7	to	to	IN
10_1101-2020_01_28_923532	266	8	their	-PRON-	PRP$
10_1101-2020_01_28_923532	266	9	relatively	relatively	RB
10_1101-2020_01_28_923532	266	10	small	small	JJ
10_1101-2020_01_28_923532	266	11	cohort	cohort	NN
10_1101-2020_01_28_923532	266	12	target	target	NN
10_1101-2020_01_28_923532	266	13	set	set	NN
10_1101-2020_01_28_923532	266	14	sizes	size	NNS
10_1101-2020_01_28_923532	266	15	,	,	,
10_1101-2020_01_28_923532	266	16	permitting	permit	VBG
10_1101-2020_01_28_923532	266	17	their	-PRON-	PRP$
10_1101-2020_01_28_923532	266	18	visualization	visualization	NN
10_1101-2020_01_28_923532	266	19	.	.	.
10_1101-2020_01_28_923532	267	1	(	(	-LRB-
10_1101-2020_01_28_923532	267	2	C	C	NNP
10_1101-2020_01_28_923532	267	3	-	-	HYPH
10_1101-2020_01_28_923532	267	4	F	F	NNP
10_1101-2020_01_28_923532	267	5	)	)	-RRB-
10_1101-2020_01_28_923532	267	6	CircOs	CircOs	:
10_1101-2020_01_28_923532	267	7	plots	plot	NNS
10_1101-2020_01_28_923532	267	8	of	of	IN
10_1101-2020_01_28_923532	267	9	the	the	DT
10_1101-2020_01_28_923532	267	10	genes	gene	NNS
10_1101-2020_01_28_923532	267	11	occurring	occur	VBG
10_1101-2020_01_28_923532	267	12	most	most	RBS
10_1101-2020_01_28_923532	267	13	frequently	frequently	RB
10_1101-2020_01_28_923532	267	14	in	in	IN
10_1101-2020_01_28_923532	267	15	optimal	optimal	JJ
10_1101-2020_01_28_923532	267	16	CTS	CTS	NNP
10_1101-2020_01_28_923532	267	17	solutions	solution	NNS
10_1101-2020_01_28_923532	267	18	(	(	-LRB-
10_1101-2020_01_28_923532	267	19	length	length	NN
10_1101-2020_01_28_923532	267	20	of	of	IN
10_1101-2020_01_28_923532	267	21	arc	arc	NN
10_1101-2020_01_28_923532	267	22	along	along	IN
10_1101-2020_01_28_923532	267	23	the	the	DT
10_1101-2020_01_28_923532	267	24	circumference	circumference	NN
10_1101-2020_01_28_923532	267	25	)	)	-RRB-
10_1101-2020_01_28_923532	267	26	and	and	CC
10_1101-2020_01_28_923532	267	27	their	-PRON-	PRP$
10_1101-2020_01_28_923532	267	28	pairwise	pairwise	NN
10_1101-2020_01_28_923532	267	29	co	co	NN
10_1101-2020_01_28_923532	267	30	-	-	NN
10_1101-2020_01_28_923532	267	31	occurrence	occurrence	NN
10_1101-2020_01_28_923532	267	32	(	(	-LRB-
10_1101-2020_01_28_923532	267	33	thickness	thickness	NN
10_1101-2020_01_28_923532	267	34	of	of	IN
10_1101-2020_01_28_923532	267	35	the	the	DT
10_1101-2020_01_28_923532	267	36	connecting	connect	VBG
10_1101-2020_01_28_923532	267	37	edge	edge	NN
10_1101-2020_01_28_923532	267	38	)	)	-RRB-
10_1101-2020_01_28_923532	267	39	for	for	IN
10_1101-2020_01_28_923532	267	40	the	the	DT
10_1101-2020_01_28_923532	267	41	four	four	CD
10_1101-2020_01_28_923532	267	42	main	main	JJ
10_1101-2020_01_28_923532	267	43	cancer	cancer	NN
10_1101-2020_01_28_923532	267	44	types	type	NNS
10_1101-2020_01_28_923532	267	45	,	,	,
10_1101-2020_01_28_923532	267	46	in	in	IN
10_1101-2020_01_28_923532	267	47	our	-PRON-	PRP$
10_1101-2020_01_28_923532	267	48	original	original	JJ
10_1101-2020_01_28_923532	267	49	target	target	NN
10_1101-2020_01_28_923532	267	50	space	space	NN
10_1101-2020_01_28_923532	267	51	of	of	IN
10_1101-2020_01_28_923532	267	52	1269	1269	CD
10_1101-2020_01_28_923532	267	53	encoding	encode	VBG
10_1101-2020_01_28_923532	267	54	cell	cell	NN
10_1101-2020_01_28_923532	267	55	-	-	HYPH
10_1101-2020_01_28_923532	267	56	surface	surface	NN
10_1101-2020_01_28_923532	267	57	receptors	receptor	NNS
10_1101-2020_01_28_923532	267	58	.	.	.
10_1101-2020_01_28_923532	268	1	For	for	IN
10_1101-2020_01_28_923532	268	2	each	each	DT
10_1101-2020_01_28_923532	268	3	data	data	NN
10_1101-2020_01_28_923532	268	4	set	set	NN
10_1101-2020_01_28_923532	268	5	,	,	,
10_1101-2020_01_28_923532	268	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	268	7	sampled	sample	VBD
10_1101-2020_01_28_923532	268	8	up	up	RP
10_1101-2020_01_28_923532	268	9	to	to	TO
10_1101-2020_01_28_923532	268	10	50	50	CD
10_1101-2020_01_28_923532	268	11	optimal	optimal	JJ
10_1101-2020_01_28_923532	268	12	CTS	CTS	NNP
10_1101-2020_01_28_923532	268	13	solutions	solution	NNS
10_1101-2020_01_28_923532	268	14	.	.	.
10_1101-2020_01_28_923532	269	1	Network	network	NN
10_1101-2020_01_28_923532	269	2	representations	representation	NNS
10_1101-2020_01_28_923532	269	3	of	of	IN
10_1101-2020_01_28_923532	269	4	the	the	DT
10_1101-2020_01_28_923532	269	5	12	12	CD
10_1101-2020_01_28_923532	269	6	most	most	RBS
10_1101-2020_01_28_923532	269	7	common	common	JJ
10_1101-2020_01_28_923532	269	8	target	target	NN
10_1101-2020_01_28_923532	269	9	genes	gene	NNS
10_1101-2020_01_28_923532	269	10	out	out	IN
10_1101-2020_01_28_923532	269	11	of	of	IN
10_1101-2020_01_28_923532	269	12	1269	1269	CD
10_1101-2020_01_28_923532	269	13	encoding	encode	VBG
10_1101-2020_01_28_923532	269	14	cell	cell	NN
10_1101-2020_01_28_923532	269	15	-	-	HYPH
10_1101-2020_01_28_923532	269	16	surface	surface	NN
10_1101-2020_01_28_923532	269	17	receptors	receptor	NNS
10_1101-2020_01_28_923532	269	18	(	(	-LRB-
10_1101-2020_01_28_923532	269	19	with	with	IN
10_1101-2020_01_28_923532	269	20	greater	great	JJR
10_1101-2020_01_28_923532	269	21	than	than	IN
10_1101-2020_01_28_923532	269	22	5	5	CD
10_1101-2020_01_28_923532	269	23	%	%	NN
10_1101-2020_01_28_923532	269	24	frequency	frequency	NN
10_1101-2020_01_28_923532	269	25	of	of	IN
10_1101-2020_01_28_923532	269	26	occurrence	occurrence	NN
10_1101-2020_01_28_923532	269	27	)	)	-RRB-
10_1101-2020_01_28_923532	269	28	are	be	VBP
10_1101-2020_01_28_923532	269	29	represented	represent	VBN
10_1101-2020_01_28_923532	269	30	in	in	IN
10_1101-2020_01_28_923532	269	31	a	a	DT
10_1101-2020_01_28_923532	269	32	cancer	cancer	NN
10_1101-2020_01_28_923532	269	33	specific	specific	JJ
10_1101-2020_01_28_923532	269	34	manner	manner	NN
10_1101-2020_01_28_923532	269	35	for	for	IN
10_1101-2020_01_28_923532	269	36	(	(	-LRB-
10_1101-2020_01_28_923532	269	37	C	C	NNP
10_1101-2020_01_28_923532	269	38	)	)	-RRB-
10_1101-2020_01_28_923532	269	39	brain	brain	NN
10_1101-2020_01_28_923532	269	40	cancer	cancer	NN
10_1101-2020_01_28_923532	269	41	,	,	,
10_1101-2020_01_28_923532	269	42	(	(	-LRB-
10_1101-2020_01_28_923532	269	43	D	d	NN
10_1101-2020_01_28_923532	269	44	)	)	-RRB-
10_1101-2020_01_28_923532	269	45	head	head	NN
10_1101-2020_01_28_923532	269	46	and	and	CC
10_1101-2020_01_28_923532	269	47	neck	neck	NN
10_1101-2020_01_28_923532	269	48	cancer	cancer	NN
10_1101-2020_01_28_923532	269	49	,	,	,
10_1101-2020_01_28_923532	269	50	(	(	-LRB-
10_1101-2020_01_28_923532	269	51	only	only	RB
10_1101-2020_01_28_923532	269	52	seven	seven	CD
10_1101-2020_01_28_923532	269	53	genes	gene	NNS
10_1101-2020_01_28_923532	269	54	have	have	VBP
10_1101-2020_01_28_923532	269	55	a	a	DT
10_1101-2020_01_28_923532	269	56	frequency	frequency	NN
10_1101-2020_01_28_923532	269	57	of	of	IN
10_1101-2020_01_28_923532	269	58	5	5	CD
10_1101-2020_01_28_923532	269	59	%	%	NN
10_1101-2020_01_28_923532	269	60	or	or	CC
10_1101-2020_01_28_923532	269	61	more	more	JJR
10_1101-2020_01_28_923532	269	62	across	across	IN
10_1101-2020_01_28_923532	269	63	optimal	optimal	JJ
10_1101-2020_01_28_923532	269	64	105	105	CD
10_1101-2020_01_28_923532	269	65	and	and	CC
10_1101-2020_01_28_923532	269	66	is	be	VBZ
10_1101-2020_01_28_923532	269	67	also	also	RB
10_1101-2020_01_28_923532	269	68	made	make	VBN
10_1101-2020_01_28_923532	269	69	available	available	JJ
10_1101-2020_01_28_923532	269	70	for	for	IN
10_1101-2020_01_28_923532	269	71	use	use	NN
10_1101-2020_01_28_923532	269	72	under	under	IN
10_1101-2020_01_28_923532	269	73	a	a	DT
10_1101-2020_01_28_923532	269	74	CC0	CC0	NNP
10_1101-2020_01_28_923532	269	75	license	license	NN
10_1101-2020_01_28_923532	269	76	.	.	.
10_1101-2020_01_28_923532	270	1	(	(	-LRB-
10_1101-2020_01_28_923532	270	2	which	which	WDT
10_1101-2020_01_28_923532	270	3	was	be	VBD
10_1101-2020_01_28_923532	270	4	not	not	RB
10_1101-2020_01_28_923532	270	5	certified	certify	VBN
10_1101-2020_01_28_923532	270	6	by	by	IN
10_1101-2020_01_28_923532	270	7	peer	peer	NN
10_1101-2020_01_28_923532	270	8	review	review	NN
10_1101-2020_01_28_923532	270	9	)	)	-RRB-
10_1101-2020_01_28_923532	270	10	is	be	VBZ
10_1101-2020_01_28_923532	270	11	the	the	DT
10_1101-2020_01_28_923532	270	12	author	author	NN
10_1101-2020_01_28_923532	270	13	/	/	SYM
10_1101-2020_01_28_923532	270	14	funder	funder	NN
10_1101-2020_01_28_923532	270	15	.	.	.
10_1101-2020_01_28_923532	271	1	This	this	DT
10_1101-2020_01_28_923532	271	2	article	article	NN
10_1101-2020_01_28_923532	271	3	is	be	VBZ
10_1101-2020_01_28_923532	271	4	a	a	DT
10_1101-2020_01_28_923532	271	5	US	US	NNP
10_1101-2020_01_28_923532	271	6	Government	Government	NNP
10_1101-2020_01_28_923532	271	7	work	work	NN
10_1101-2020_01_28_923532	271	8	.	.	.
10_1101-2020_01_28_923532	272	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	272	2	is	be	VBZ
10_1101-2020_01_28_923532	272	3	not	not	RB
10_1101-2020_01_28_923532	272	4	subject	subject	JJ
10_1101-2020_01_28_923532	272	5	to	to	IN
10_1101-2020_01_28_923532	272	6	copyright	copyright	NN
10_1101-2020_01_28_923532	272	7	under	under	IN
10_1101-2020_01_28_923532	272	8	17	17	CD
10_1101-2020_01_28_923532	272	9	USC	usc	NN
10_1101-2020_01_28_923532	272	10	The	the	DT
10_1101-2020_01_28_923532	272	11	copyright	copyright	NN
10_1101-2020_01_28_923532	272	12	holder	holder	NN
10_1101-2020_01_28_923532	272	13	for	for	IN
10_1101-2020_01_28_923532	272	14	this	this	DT
10_1101-2020_01_28_923532	272	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	272	16	version	version	NN
10_1101-2020_01_28_923532	272	17	posted	post	VBD
10_1101-2020_01_28_923532	272	18	February	February	NNP
10_1101-2020_01_28_923532	272	19	12	12	CD
10_1101-2020_01_28_923532	272	20	,	,	,
10_1101-2020_01_28_923532	272	21	2021	2021	CD
10_1101-2020_01_28_923532	272	22	.	.	.
10_1101-2020_01_28_923532	272	23	;	;	:
10_1101-2020_01_28_923532	272	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	272	25	:	:	:
10_1101-2020_01_28_923532	272	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	272	27	preprint	preprint	NN
10_1101-2020_01_28_923532	272	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	272	29	23	23	CD
10_1101-2020_01_28_923532	272	30	solutions	solution	NNS
10_1101-2020_01_28_923532	272	31	)	)	-RRB-
10_1101-2020_01_28_923532	272	32	,	,	,
10_1101-2020_01_28_923532	272	33	(	(	-LRB-
10_1101-2020_01_28_923532	272	34	E	e	NN
10_1101-2020_01_28_923532	272	35	)	)	-RRB-
10_1101-2020_01_28_923532	272	36	melanoma	melanoma	NN
10_1101-2020_01_28_923532	272	37	,	,	,
10_1101-2020_01_28_923532	272	38	and	and	CC
10_1101-2020_01_28_923532	272	39	(	(	-LRB-
10_1101-2020_01_28_923532	272	40	F	f	NN
10_1101-2020_01_28_923532	272	41	)	)	-RRB-
10_1101-2020_01_28_923532	272	42	lung	lung	NN
10_1101-2020_01_28_923532	272	43	cancer	cancer	NN
10_1101-2020_01_28_923532	272	44	.	.	.
10_1101-2020_01_28_923532	273	1	Genes	gene	NNS
10_1101-2020_01_28_923532	273	2	and	and	CC
10_1101-2020_01_28_923532	273	3	connections	connection	NNS
10_1101-2020_01_28_923532	273	4	have	have	VBP
10_1101-2020_01_28_923532	273	5	distinct	distinct	JJ
10_1101-2020_01_28_923532	273	6	colors	color	NNS
10_1101-2020_01_28_923532	273	7	for	for	IN
10_1101-2020_01_28_923532	273	8	improved	improved	JJ
10_1101-2020_01_28_923532	273	9	visibility	visibility	NN
10_1101-2020_01_28_923532	273	10	.	.	.
10_1101-2020_01_28_923532	274	1	Key	Key	NNP
10_1101-2020_01_28_923532	274	2	Targets	Targets	NNPS
10_1101-2020_01_28_923532	274	3	Composing	Composing	NNP
10_1101-2020_01_28_923532	274	4	Optimal	Optimal	NNP
10_1101-2020_01_28_923532	274	5	Solutions	Solutions	NNPS
10_1101-2020_01_28_923532	274	6	Across	across	IN
10_1101-2020_01_28_923532	274	7	the	the	DT
10_1101-2020_01_28_923532	274	8	Space	Space	NNP
10_1101-2020_01_28_923532	274	9	of	of	IN
10_1101-2020_01_28_923532	274	10	1269	1269	CD
10_1101-2020_01_28_923532	274	11	membrane	membrane	NN
10_1101-2020_01_28_923532	274	12	receptors	receptor	NNS
10_1101-2020_01_28_923532	274	13	To	to	TO
10_1101-2020_01_28_923532	274	14	identify	identify	VB
10_1101-2020_01_28_923532	274	15	the	the	DT
10_1101-2020_01_28_923532	274	16	genes	gene	NNS
10_1101-2020_01_28_923532	274	17	that	that	WDT
10_1101-2020_01_28_923532	274	18	occur	occur	VBP
10_1101-2020_01_28_923532	274	19	most	most	RBS
10_1101-2020_01_28_923532	274	20	often	often	RB
10_1101-2020_01_28_923532	274	21	in	in	IN
10_1101-2020_01_28_923532	274	22	optimal	optimal	JJ
10_1101-2020_01_28_923532	274	23	solutions	solution	NNS
10_1101-2020_01_28_923532	274	24	for	for	IN
10_1101-2020_01_28_923532	274	25	our	-PRON-	PRP$
10_1101-2020_01_28_923532	274	26	baseline	baseline	JJ
10_1101-2020_01_28_923532	274	27	settings	setting	NNS
10_1101-2020_01_28_923532	274	28	,	,	,
10_1101-2020_01_28_923532	274	29	since	since	IN
10_1101-2020_01_28_923532	274	30	there	there	EX
10_1101-2020_01_28_923532	274	31	may	may	MD
10_1101-2020_01_28_923532	274	32	be	be	VB
10_1101-2020_01_28_923532	274	33	multiple	multiple	JJ
10_1101-2020_01_28_923532	274	34	distinct	distinct	JJ
10_1101-2020_01_28_923532	274	35	optimal	optimal	JJ
10_1101-2020_01_28_923532	274	36	solutions	solution	NNS
10_1101-2020_01_28_923532	274	37	composed	compose	VBN
10_1101-2020_01_28_923532	274	38	of	of	IN
10_1101-2020_01_28_923532	274	39	different	different	JJ
10_1101-2020_01_28_923532	274	40	target	target	NN
10_1101-2020_01_28_923532	274	41	genes	gene	NNS
10_1101-2020_01_28_923532	274	42	,	,	,
10_1101-2020_01_28_923532	274	43	we	-PRON-	PRP
10_1101-2020_01_28_923532	274	44	sampled	sample	VBD
10_1101-2020_01_28_923532	274	45	up	up	RP
10_1101-2020_01_28_923532	274	46	to	to	TO
10_1101-2020_01_28_923532	274	47	50	50	CD
10_1101-2020_01_28_923532	274	48	optimal	optimal	JJ
10_1101-2020_01_28_923532	274	49	solutions	solution	NNS
10_1101-2020_01_28_923532	274	50	for	for	IN
10_1101-2020_01_28_923532	274	51	each	each	DT
10_1101-2020_01_28_923532	274	52	optimization	optimization	NN
10_1101-2020_01_28_923532	274	53	instance	instance	NN
10_1101-2020_01_28_923532	274	54	solved	solve	VBD
10_1101-2020_01_28_923532	274	55	and	and	CC
10_1101-2020_01_28_923532	274	56	recorded	record	VBD
10_1101-2020_01_28_923532	274	57	how	how	WRB
10_1101-2020_01_28_923532	274	58	often	often	RB
10_1101-2020_01_28_923532	274	59	each	each	DT
10_1101-2020_01_28_923532	274	60	gene	gene	NN
10_1101-2020_01_28_923532	274	61	occurs	occur	VBZ
10_1101-2020_01_28_923532	274	62	and	and	CC
10_1101-2020_01_28_923532	274	63	how	how	WRB
10_1101-2020_01_28_923532	274	64	often	often	RB
10_1101-2020_01_28_923532	274	65	each	each	DT
10_1101-2020_01_28_923532	274	66	pair	pair	NN
10_1101-2020_01_28_923532	274	67	of	of	IN
10_1101-2020_01_28_923532	274	68	genes	gene	NNS
10_1101-2020_01_28_923532	274	69	occur	occur	VBP
10_1101-2020_01_28_923532	274	70	together	together	RB
10_1101-2020_01_28_923532	274	71	(	(	-LRB-
10_1101-2020_01_28_923532	274	72	Methods	Methods	NNP
10_1101-2020_01_28_923532	274	73	)	)	-RRB-
10_1101-2020_01_28_923532	274	74	.	.	.
10_1101-2020_01_28_923532	275	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	275	2	analyzed	analyze	VBD
10_1101-2020_01_28_923532	275	3	and	and	CC
10_1101-2020_01_28_923532	275	4	visualized	visualize	VBD
10_1101-2020_01_28_923532	275	5	these	these	DT
10_1101-2020_01_28_923532	275	6	gene	gene	NN
10_1101-2020_01_28_923532	275	7	(	(	-LRB-
10_1101-2020_01_28_923532	275	8	co-)occurrences	co-)occurrence	NNS
10_1101-2020_01_28_923532	275	9	in	in	IN
10_1101-2020_01_28_923532	275	10	three	three	CD
10_1101-2020_01_28_923532	275	11	ways	way	NNS
10_1101-2020_01_28_923532	275	12	.	.	.
10_1101-2020_01_28_923532	276	1	First	first	RB
10_1101-2020_01_28_923532	276	2	,	,	,
10_1101-2020_01_28_923532	276	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	276	4	constructed	construct	VBD
10_1101-2020_01_28_923532	276	5	co	co	NN
10_1101-2020_01_28_923532	276	6	-	-	NN
10_1101-2020_01_28_923532	276	7	occurrence	occurrence	JJ
10_1101-2020_01_28_923532	276	8	circus	circus	NN
10_1101-2020_01_28_923532	276	9	plots	plot	NNS
10_1101-2020_01_28_923532	276	10	in	in	IN
10_1101-2020_01_28_923532	276	11	which	which	WDT
10_1101-2020_01_28_923532	276	12	arcs	arc	NNS
10_1101-2020_01_28_923532	276	13	around	around	IN
10_1101-2020_01_28_923532	276	14	the	the	DT
10_1101-2020_01_28_923532	276	15	circle	circle	NN
10_1101-2020_01_28_923532	276	16	represent	represent	VBP
10_1101-2020_01_28_923532	276	17	frequently	frequently	RB
10_1101-2020_01_28_923532	276	18	occurring	occur	VBG
10_1101-2020_01_28_923532	276	19	genes	gene	NNS
10_1101-2020_01_28_923532	276	20	and	and	CC
10_1101-2020_01_28_923532	276	21	edges	edge	VBZ
10_1101-2020_01_28_923532	276	22	connect	connect	VBP
10_1101-2020_01_28_923532	276	23	targets	target	NNS
10_1101-2020_01_28_923532	276	24	that	that	WDT
10_1101-2020_01_28_923532	276	25	frequently	frequently	RB
10_1101-2020_01_28_923532	276	26	co	co	VBP
10_1101-2020_01_28_923532	276	27	-	-	NN
10_1101-2020_01_28_923532	276	28	occur	occur	VB
10_1101-2020_01_28_923532	276	29	in	in	IN
10_1101-2020_01_28_923532	276	30	optimal	optimal	JJ
10_1101-2020_01_28_923532	276	31	CTS	CTS	NNP
10_1101-2020_01_28_923532	276	32	solutions	solution	NNS
10_1101-2020_01_28_923532	276	33	.	.	.
10_1101-2020_01_28_923532	277	1	Figure	Figure	NNP
10_1101-2020_01_28_923532	277	2	7C	7C	NNP
10_1101-2020_01_28_923532	277	3	-	-	HYPH
10_1101-2020_01_28_923532	277	4	F	F	NNP
10_1101-2020_01_28_923532	277	5	shows	show	VBZ
10_1101-2020_01_28_923532	277	6	the	the	DT
10_1101-2020_01_28_923532	277	7	co	co	NN
10_1101-2020_01_28_923532	277	8	-	-	NN
10_1101-2020_01_28_923532	277	9	occurrence	occurrence	JJ
10_1101-2020_01_28_923532	277	10	visualizations	visualization	NNS
10_1101-2020_01_28_923532	277	11	for	for	IN
10_1101-2020_01_28_923532	277	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	277	13	CTS	CTS	NNP
10_1101-2020_01_28_923532	277	14	solutions	solution	NNS
10_1101-2020_01_28_923532	277	15	obtained	obtain	VBN
10_1101-2020_01_28_923532	277	16	with	with	IN
10_1101-2020_01_28_923532	277	17	the	the	DT
10_1101-2020_01_28_923532	277	18	original	original	JJ
10_1101-2020_01_28_923532	277	19	,	,	,
10_1101-2020_01_28_923532	277	20	unfiltered	unfiltered	JJ
10_1101-2020_01_28_923532	277	21	target	target	NN
10_1101-2020_01_28_923532	277	22	space	space	NN
10_1101-2020_01_28_923532	277	23	of	of	IN
10_1101-2020_01_28_923532	277	24	1269	1269	CD
10_1101-2020_01_28_923532	277	25	genes	gene	NNS
10_1101-2020_01_28_923532	277	26	and	and	CC
10_1101-2020_01_28_923532	277	27	in	in	IN
10_1101-2020_01_28_923532	277	28	baseline	baseline	JJ
10_1101-2020_01_28_923532	277	29	parameter	parameter	NN
10_1101-2020_01_28_923532	277	30	settings	setting	NNS
10_1101-2020_01_28_923532	277	31	.	.	.
10_1101-2020_01_28_923532	278	1	The	the	DT
10_1101-2020_01_28_923532	278	2	genes	gene	NNS
10_1101-2020_01_28_923532	278	3	frequently	frequently	RB
10_1101-2020_01_28_923532	278	4	occurring	occur	VBG
10_1101-2020_01_28_923532	278	5	in	in	IN
10_1101-2020_01_28_923532	278	6	optimal	optimal	JJ
10_1101-2020_01_28_923532	278	7	solutions	solution	NNS
10_1101-2020_01_28_923532	278	8	are	be	VBP
10_1101-2020_01_28_923532	278	9	quite	quite	RB
10_1101-2020_01_28_923532	278	10	specific	specific	JJ
10_1101-2020_01_28_923532	278	11	and	and	CC
10_1101-2020_01_28_923532	278	12	distinct	distinct	JJ
10_1101-2020_01_28_923532	278	13	between	between	IN
10_1101-2020_01_28_923532	278	14	different	different	JJ
10_1101-2020_01_28_923532	278	15	cancer	cancer	NN
10_1101-2020_01_28_923532	278	16	types	type	NNS
10_1101-2020_01_28_923532	278	17	.	.	.
10_1101-2020_01_28_923532	279	1	In	in	IN
10_1101-2020_01_28_923532	279	2	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	279	3	,	,	,
10_1101-2020_01_28_923532	279	4	the	the	DT
10_1101-2020_01_28_923532	279	5	edges	edge	NNS
10_1101-2020_01_28_923532	279	6	form	form	VBP
10_1101-2020_01_28_923532	279	7	a	a	DT
10_1101-2020_01_28_923532	279	8	clique	clique	NN
10_1101-2020_01_28_923532	279	9	-	-	HYPH
10_1101-2020_01_28_923532	279	10	like	like	JJ
10_1101-2020_01_28_923532	279	11	network	network	NN
10_1101-2020_01_28_923532	279	12	because	because	IN
10_1101-2020_01_28_923532	279	13	virtually	virtually	RB
10_1101-2020_01_28_923532	279	14	all	all	DT
10_1101-2020_01_28_923532	279	15	optimal	optimal	JJ
10_1101-2020_01_28_923532	279	16	solutions	solution	NNS
10_1101-2020_01_28_923532	279	17	include	include	VBP
10_1101-2020_01_28_923532	279	18	the	the	DT
10_1101-2020_01_28_923532	279	19	same	same	JJ
10_1101-2020_01_28_923532	279	20	clique	clique	NN
10_1101-2020_01_28_923532	279	21	of	of	IN
10_1101-2020_01_28_923532	279	22	12	12	CD
10_1101-2020_01_28_923532	279	23	genes	gene	NNS
10_1101-2020_01_28_923532	279	24	(	(	-LRB-
10_1101-2020_01_28_923532	279	25	Figure	figure	NN
10_1101-2020_01_28_923532	279	26	7E	7e	NN
10_1101-2020_01_28_923532	279	27	)	)	-RRB-
10_1101-2020_01_28_923532	279	28	.	.	.
10_1101-2020_01_28_923532	280	1	The	the	DT
10_1101-2020_01_28_923532	280	2	head	head	NN
10_1101-2020_01_28_923532	280	3	and	and	CC
10_1101-2020_01_28_923532	280	4	neck	neck	NN
10_1101-2020_01_28_923532	280	5	cancer	cancer	NN
10_1101-2020_01_28_923532	280	6	data	datum	NNS
10_1101-2020_01_28_923532	280	7	set	set	NN
10_1101-2020_01_28_923532	280	8	has	have	VBZ
10_1101-2020_01_28_923532	280	9	only	only	RB
10_1101-2020_01_28_923532	280	10	one	one	CD
10_1101-2020_01_28_923532	280	11	commonly	commonly	RB
10_1101-2020_01_28_923532	280	12	co	co	JJ
10_1101-2020_01_28_923532	280	13	-	-	JJ
10_1101-2020_01_28_923532	280	14	occurring	occurring	JJ
10_1101-2020_01_28_923532	280	15	pair	pair	NN
10_1101-2020_01_28_923532	280	16	{	{	-LRB-
10_1101-2020_01_28_923532	280	17	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	280	18	,	,	,
10_1101-2020_01_28_923532	280	19	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	280	20	}	}	-RRB-
10_1101-2020_01_28_923532	280	21	(	(	-LRB-
10_1101-2020_01_28_923532	280	22	Figure	figure	NN
10_1101-2020_01_28_923532	280	23	7D	7d	NN
10_1101-2020_01_28_923532	280	24	)	)	-RRB-
10_1101-2020_01_28_923532	280	25	.	.	.
10_1101-2020_01_28_923532	281	1	Of	of	IN
10_1101-2020_01_28_923532	281	2	the	the	DT
10_1101-2020_01_28_923532	281	3	cancer	cancer	NN
10_1101-2020_01_28_923532	281	4	types	type	NNS
10_1101-2020_01_28_923532	281	5	not	not	RB
10_1101-2020_01_28_923532	281	6	depicted	depict	VBN
10_1101-2020_01_28_923532	281	7	in	in	IN
10_1101-2020_01_28_923532	281	8	Figure	Figure	NNP
10_1101-2020_01_28_923532	281	9	7	7	CD
10_1101-2020_01_28_923532	281	10	,	,	,
10_1101-2020_01_28_923532	281	11	the	the	DT
10_1101-2020_01_28_923532	281	12	breast	breast	NN
10_1101-2020_01_28_923532	281	13	cancer	cancer	NN
10_1101-2020_01_28_923532	281	14	data	datum	NNS
10_1101-2020_01_28_923532	281	15	set	set	NN
10_1101-2020_01_28_923532	281	16	has	have	VBZ
10_1101-2020_01_28_923532	281	17	a	a	DT
10_1101-2020_01_28_923532	281	18	commonly	commonly	RB
10_1101-2020_01_28_923532	281	19	co	co	JJ
10_1101-2020_01_28_923532	281	20	-	-	JJ
10_1101-2020_01_28_923532	281	21	occurring	occurring	JJ
10_1101-2020_01_28_923532	281	22	set	set	NN
10_1101-2020_01_28_923532	281	23	of	of	IN
10_1101-2020_01_28_923532	281	24	size	size	NN
10_1101-2020_01_28_923532	281	25	4	4	CD
10_1101-2020_01_28_923532	281	26	,	,	,
10_1101-2020_01_28_923532	281	27	{	{	-LRB-
10_1101-2020_01_28_923532	281	28	CLDN4	CLDN4	NNP
10_1101-2020_01_28_923532	281	29	,	,	,
10_1101-2020_01_28_923532	281	30	INSR	INSR	NNP
10_1101-2020_01_28_923532	281	31	,	,	,
10_1101-2020_01_28_923532	281	32	P2RY8	P2RY8	NNP
10_1101-2020_01_28_923532	281	33	,	,	,
10_1101-2020_01_28_923532	281	34	SORL	SORL	NNP
10_1101-2020_01_28_923532	281	35	}	}	-RRB-
10_1101-2020_01_28_923532	281	36	,	,	,
10_1101-2020_01_28_923532	281	37	and	and	CC
10_1101-2020_01_28_923532	281	38	the	the	DT
10_1101-2020_01_28_923532	281	39	colorectal	colorectal	JJ
10_1101-2020_01_28_923532	281	40	cancer	cancer	NN
10_1101-2020_01_28_923532	281	41	data	datum	NNS
10_1101-2020_01_28_923532	281	42	set	set	NN
10_1101-2020_01_28_923532	281	43	has	have	VBZ
10_1101-2020_01_28_923532	281	44	a	a	DT
10_1101-2020_01_28_923532	281	45	different	different	JJ
10_1101-2020_01_28_923532	281	46	commonly	commonly	RB
10_1101-2020_01_28_923532	281	47	co	co	JJ
10_1101-2020_01_28_923532	281	48	-	-	JJ
10_1101-2020_01_28_923532	281	49	occurring	occurring	JJ
10_1101-2020_01_28_923532	281	50	set	set	NN
10_1101-2020_01_28_923532	281	51	of	of	IN
10_1101-2020_01_28_923532	281	52	size	size	NN
10_1101-2020_01_28_923532	281	53	4	4	CD
10_1101-2020_01_28_923532	281	54	,	,	,
10_1101-2020_01_28_923532	281	55	{	{	-LRB-
10_1101-2020_01_28_923532	281	56	GABRE	GABRE	NNP
10_1101-2020_01_28_923532	281	57	,	,	,
10_1101-2020_01_28_923532	281	58	GPRR	GPRR	NNP
10_1101-2020_01_28_923532	281	59	,	,	,
10_1101-2020_01_28_923532	281	60	LGR5	LGR5	NNP
10_1101-2020_01_28_923532	281	61	,	,	,
10_1101-2020_01_28_923532	281	62	PTPRJ	PTPRJ	NNP
10_1101-2020_01_28_923532	281	63	}	}	-RRB-
10_1101-2020_01_28_923532	281	64	(	(	-LRB-
10_1101-2020_01_28_923532	281	65	data	datum	NNS
10_1101-2020_01_28_923532	281	66	not	not	RB
10_1101-2020_01_28_923532	281	67	shown	show	VBN
10_1101-2020_01_28_923532	281	68	)	)	-RRB-
10_1101-2020_01_28_923532	281	69	.	.	.
10_1101-2020_01_28_923532	282	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	282	2	next	next	RB
10_1101-2020_01_28_923532	282	3	tabulated	tabulate	VBN
10_1101-2020_01_28_923532	282	4	sums	sum	NNS
10_1101-2020_01_28_923532	282	5	of	of	IN
10_1101-2020_01_28_923532	282	6	how	how	WRB
10_1101-2020_01_28_923532	282	7	often	often	RB
10_1101-2020_01_28_923532	282	8	each	each	DT
10_1101-2020_01_28_923532	282	9	gene	gene	NN
10_1101-2020_01_28_923532	282	10	occurred	occur	VBD
10_1101-2020_01_28_923532	282	11	in	in	IN
10_1101-2020_01_28_923532	282	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	282	13	solutions	solution	NNS
10_1101-2020_01_28_923532	282	14	for	for	IN
10_1101-2020_01_28_923532	282	15	all	all	DT
10_1101-2020_01_28_923532	282	16	nine	nine	CD
10_1101-2020_01_28_923532	282	17	data	data	NN
10_1101-2020_01_28_923532	282	18	sets	set	NNS
10_1101-2020_01_28_923532	282	19	(	(	-LRB-
10_1101-2020_01_28_923532	282	20	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	282	21	Materials	Materials	NNP
10_1101-2020_01_28_923532	282	22	12	12	CD
10_1101-2020_01_28_923532	282	23	,	,	,
10_1101-2020_01_28_923532	282	24	Tables	Tables	NNPS
10_1101-2020_01_28_923532	282	25	S4	S4	NNP
10_1101-2020_01_28_923532	282	26	,	,	,
10_1101-2020_01_28_923532	282	27	S5	s5	NN
10_1101-2020_01_28_923532	282	28	and	and	CC
10_1101-2020_01_28_923532	282	29	S6	S6	NNP
10_1101-2020_01_28_923532	282	30	)	)	-RRB-
10_1101-2020_01_28_923532	282	31	,	,	,
10_1101-2020_01_28_923532	282	32	obtained	obtain	VBN
10_1101-2020_01_28_923532	282	33	when	when	WRB
10_1101-2020_01_28_923532	282	34	solving	solve	VBG
10_1101-2020_01_28_923532	282	35	for	for	IN
10_1101-2020_01_28_923532	282	36	either	either	DT
10_1101-2020_01_28_923532	282	37	58	58	CD
10_1101-2020_01_28_923532	282	38	gene	gene	NN
10_1101-2020_01_28_923532	282	39	targets	target	NNS
10_1101-2020_01_28_923532	282	40	or	or	CC
10_1101-2020_01_28_923532	282	41	1269	1269	CD
10_1101-2020_01_28_923532	282	42	gene	gene	NN
10_1101-2020_01_28_923532	282	43	targets	target	NNS
10_1101-2020_01_28_923532	282	44	.	.	.
10_1101-2020_01_28_923532	283	1	Strikingly	strikingly	RB
10_1101-2020_01_28_923532	283	2	,	,	,
10_1101-2020_01_28_923532	283	3	one	one	CD
10_1101-2020_01_28_923532	283	4	gene	gene	NN
10_1101-2020_01_28_923532	283	5	,	,	,
10_1101-2020_01_28_923532	283	6	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	283	7	(	(	-LRB-
10_1101-2020_01_28_923532	283	8	protein	protein	NN
10_1101-2020_01_28_923532	283	9	tyrosine	tyrosine	NNP
10_1101-2020_01_28_923532	283	10	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	283	11	receptor	receptor	NNP
10_1101-2020_01_28_923532	283	12	zeta	zeta	NNP
10_1101-2020_01_28_923532	283	13	1	1	CD
10_1101-2020_01_28_923532	283	14	)	)	-RRB-
10_1101-2020_01_28_923532	283	15	,	,	,
10_1101-2020_01_28_923532	283	16	appears	appear	VBZ
10_1101-2020_01_28_923532	283	17	far	far	RB
10_1101-2020_01_28_923532	283	18	more	more	RBR
10_1101-2020_01_28_923532	283	19	frequently	frequently	RB
10_1101-2020_01_28_923532	283	20	than	than	IN
10_1101-2020_01_28_923532	283	21	others	other	NNS
10_1101-2020_01_28_923532	283	22	,	,	,
10_1101-2020_01_28_923532	283	23	especially	especially	RB
10_1101-2020_01_28_923532	283	24	in	in	IN
10_1101-2020_01_28_923532	283	25	three	three	CD
10_1101-2020_01_28_923532	283	26	brain	brain	NN
10_1101-2020_01_28_923532	283	27	cancer	cancer	NN
10_1101-2020_01_28_923532	283	28	data	datum	NNS
10_1101-2020_01_28_923532	283	29	sets	set	NNS
10_1101-2020_01_28_923532	283	30	(	(	-LRB-
10_1101-2020_01_28_923532	283	31	GSE70630	GSE70630	NNP
10_1101-2020_01_28_923532	283	32	,	,	,
10_1101-2020_01_28_923532	283	33	GSE89567	GSE89567	NNP
10_1101-2020_01_28_923532	283	34	,	,	,
10_1101-2020_01_28_923532	283	35	GSE102130	GSE102130	NNP
10_1101-2020_01_28_923532	283	36	,	,	,
10_1101-2020_01_28_923532	283	37	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	283	38	Table	Table	NNP
10_1101-2020_01_28_923532	283	39	S6	S6	NNP
10_1101-2020_01_28_923532	283	40	)	)	-RRB-
10_1101-2020_01_28_923532	283	41	.	.	.
10_1101-2020_01_28_923532	284	1	PTPRZ1	PTPRZ1	NNP
10_1101-2020_01_28_923532	284	2	also	also	RB
10_1101-2020_01_28_923532	284	3	occurs	occur	VBZ
10_1101-2020_01_28_923532	284	4	commonly	commonly	RB
10_1101-2020_01_28_923532	284	5	in	in	IN
10_1101-2020_01_28_923532	284	6	optimal	optimal	JJ
10_1101-2020_01_28_923532	284	7	solutions	solution	NNS
10_1101-2020_01_28_923532	284	8	for	for	IN
10_1101-2020_01_28_923532	284	9	the	the	DT
10_1101-2020_01_28_923532	284	10	head	head	NN
10_1101-2020_01_28_923532	284	11	and	and	CC
10_1101-2020_01_28_923532	284	12	neck	neck	NN
10_1101-2020_01_28_923532	284	13	cancer	cancer	NN
10_1101-2020_01_28_923532	284	14	data	datum	NNS
10_1101-2020_01_28_923532	284	15	set	set	NN
10_1101-2020_01_28_923532	284	16	(	(	-LRB-
10_1101-2020_01_28_923532	284	17	Figure	Figure	NNP
10_1101-2020_01_28_923532	284	18	7D	7d	NN
10_1101-2020_01_28_923532	284	19	)	)	-RRB-
10_1101-2020_01_28_923532	284	20	.	.	.
10_1101-2020_01_28_923532	285	1	The	the	DT
10_1101-2020_01_28_923532	285	2	brain	brain	NN
10_1101-2020_01_28_923532	285	3	cancer	cancer	NN
10_1101-2020_01_28_923532	285	4	finding	find	VBG
10_1101-2020_01_28_923532	285	5	coincides	coincide	NNS
10_1101-2020_01_28_923532	285	6	with	with	IN
10_1101-2020_01_28_923532	285	7	previous	previous	JJ
10_1101-2020_01_28_923532	285	8	reports	report	NNS
10_1101-2020_01_28_923532	285	9	that	that	IN
10_1101-2020_01_28_923532	285	10	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	285	11	is	be	VBZ
10_1101-2020_01_28_923532	285	12	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	285	13	in	in	IN
10_1101-2020_01_28_923532	285	14	glioblastoma	glioblastoma	NNP
10_1101-2020_01_28_923532	285	15	(	(	-LRB-
10_1101-2020_01_28_923532	285	16	GBM)39,40	gbm)39,40	NN
10_1101-2020_01_28_923532	285	17	.	.	.
10_1101-2020_01_28_923532	286	1	PTPRZ1	PTPRZ1	NNP
10_1101-2020_01_28_923532	286	2	also	also	RB
10_1101-2020_01_28_923532	286	3	forms	form	VBZ
10_1101-2020_01_28_923532	286	4	a	a	DT
10_1101-2020_01_28_923532	286	5	fusion	fusion	NN
10_1101-2020_01_28_923532	286	6	with	with	IN
10_1101-2020_01_28_923532	286	7	the	the	DT
10_1101-2020_01_28_923532	286	8	nearby	nearby	JJ
10_1101-2020_01_28_923532	286	9	oncogene	oncogene	NN
10_1101-2020_01_28_923532	286	10	MET	MET	NNP
10_1101-2020_01_28_923532	286	11	in	in	IN
10_1101-2020_01_28_923532	286	12	some	some	DT
10_1101-2020_01_28_923532	286	13	brain	brain	NN
10_1101-2020_01_28_923532	286	14	tumors	tumor	NNS
10_1101-2020_01_28_923532	286	15	that	that	WDT
10_1101-2020_01_28_923532	286	16	have	have	VBP
10_1101-2020_01_28_923532	286	17	an	an	DT
10_1101-2020_01_28_923532	286	18	overexpression	overexpression	NN
10_1101-2020_01_28_923532	286	19	of	of	IN
10_1101-2020_01_28_923532	286	20	the	the	DT
10_1101-2020_01_28_923532	286	21	fused	fuse	VBN
10_1101-2020_01_28_923532	286	22	MET41	MET41	NNP
10_1101-2020_01_28_923532	286	23	.	.	.
10_1101-2020_01_28_923532	287	1	Notably	notably	RB
10_1101-2020_01_28_923532	287	2	,	,	,
10_1101-2020_01_28_923532	287	3	various	various	JJ
10_1101-2020_01_28_923532	287	4	cell	cell	NN
10_1101-2020_01_28_923532	287	5	line	line	NN
10_1101-2020_01_28_923532	287	6	studies	study	VBZ
10_1101-2020_01_28_923532	287	7	105	105	CD
10_1101-2020_01_28_923532	287	8	and	and	CC
10_1101-2020_01_28_923532	287	9	is	be	VBZ
10_1101-2020_01_28_923532	287	10	also	also	RB
10_1101-2020_01_28_923532	287	11	made	make	VBN
10_1101-2020_01_28_923532	287	12	available	available	JJ
10_1101-2020_01_28_923532	287	13	for	for	IN
10_1101-2020_01_28_923532	287	14	use	use	NN
10_1101-2020_01_28_923532	287	15	under	under	IN
10_1101-2020_01_28_923532	287	16	a	a	DT
10_1101-2020_01_28_923532	287	17	CC0	CC0	NNP
10_1101-2020_01_28_923532	287	18	license	license	NN
10_1101-2020_01_28_923532	287	19	.	.	.
10_1101-2020_01_28_923532	288	1	(	(	-LRB-
10_1101-2020_01_28_923532	288	2	which	which	WDT
10_1101-2020_01_28_923532	288	3	was	be	VBD
10_1101-2020_01_28_923532	288	4	not	not	RB
10_1101-2020_01_28_923532	288	5	certified	certify	VBN
10_1101-2020_01_28_923532	288	6	by	by	IN
10_1101-2020_01_28_923532	288	7	peer	peer	NN
10_1101-2020_01_28_923532	288	8	review	review	NN
10_1101-2020_01_28_923532	288	9	)	)	-RRB-
10_1101-2020_01_28_923532	288	10	is	be	VBZ
10_1101-2020_01_28_923532	288	11	the	the	DT
10_1101-2020_01_28_923532	288	12	author	author	NN
10_1101-2020_01_28_923532	288	13	/	/	SYM
10_1101-2020_01_28_923532	288	14	funder	funder	NN
10_1101-2020_01_28_923532	288	15	.	.	.
10_1101-2020_01_28_923532	289	1	This	this	DT
10_1101-2020_01_28_923532	289	2	article	article	NN
10_1101-2020_01_28_923532	289	3	is	be	VBZ
10_1101-2020_01_28_923532	289	4	a	a	DT
10_1101-2020_01_28_923532	289	5	US	US	NNP
10_1101-2020_01_28_923532	289	6	Government	Government	NNP
10_1101-2020_01_28_923532	289	7	work	work	NN
10_1101-2020_01_28_923532	289	8	.	.	.
10_1101-2020_01_28_923532	290	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	290	2	is	be	VBZ
10_1101-2020_01_28_923532	290	3	not	not	RB
10_1101-2020_01_28_923532	290	4	subject	subject	JJ
10_1101-2020_01_28_923532	290	5	to	to	IN
10_1101-2020_01_28_923532	290	6	copyright	copyright	NN
10_1101-2020_01_28_923532	290	7	under	under	IN
10_1101-2020_01_28_923532	290	8	17	17	CD
10_1101-2020_01_28_923532	290	9	USC	usc	NN
10_1101-2020_01_28_923532	290	10	The	the	DT
10_1101-2020_01_28_923532	290	11	copyright	copyright	NN
10_1101-2020_01_28_923532	290	12	holder	holder	NN
10_1101-2020_01_28_923532	290	13	for	for	IN
10_1101-2020_01_28_923532	290	14	this	this	DT
10_1101-2020_01_28_923532	290	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	290	16	version	version	NN
10_1101-2020_01_28_923532	290	17	posted	post	VBD
10_1101-2020_01_28_923532	290	18	February	February	NNP
10_1101-2020_01_28_923532	290	19	12	12	CD
10_1101-2020_01_28_923532	290	20	,	,	,
10_1101-2020_01_28_923532	290	21	2021	2021	CD
10_1101-2020_01_28_923532	290	22	.	.	.
10_1101-2020_01_28_923532	290	23	;	;	:
10_1101-2020_01_28_923532	290	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	290	25	:	:	:
10_1101-2020_01_28_923532	290	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	290	27	preprint	preprint	NN
10_1101-2020_01_28_923532	290	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	290	29	24	24	CD
10_1101-2020_01_28_923532	290	30	and	and	CC
10_1101-2020_01_28_923532	290	31	mouse	mouse	NN
10_1101-2020_01_28_923532	290	32	studies	study	NNS
10_1101-2020_01_28_923532	290	33	have	have	VBP
10_1101-2020_01_28_923532	290	34	shown	show	VBN
10_1101-2020_01_28_923532	290	35	that	that	IN
10_1101-2020_01_28_923532	290	36	inhibiting	inhibit	VBG
10_1101-2020_01_28_923532	290	37	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	290	38	,	,	,
10_1101-2020_01_28_923532	290	39	for	for	IN
10_1101-2020_01_28_923532	290	40	example	example	NN
10_1101-2020_01_28_923532	290	41	by	by	IN
10_1101-2020_01_28_923532	290	42	shRNAs	shRNAs	NNP
10_1101-2020_01_28_923532	290	43	,	,	,
10_1101-2020_01_28_923532	290	44	can	can	MD
10_1101-2020_01_28_923532	290	45	slow	slow	VB
10_1101-2020_01_28_923532	290	46	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	290	47	tumor	tumor	NN
10_1101-2020_01_28_923532	290	48	growth	growth	NN
10_1101-2020_01_28_923532	290	49	and	and	CC
10_1101-2020_01_28_923532	290	50	migration42,43	migration42,43	NNP
10_1101-2020_01_28_923532	290	51	.	.	.
10_1101-2020_01_28_923532	291	1	There	there	EX
10_1101-2020_01_28_923532	291	2	have	have	VBP
10_1101-2020_01_28_923532	291	3	been	be	VBN
10_1101-2020_01_28_923532	291	4	some	some	DT
10_1101-2020_01_28_923532	291	5	attempts	attempt	NNS
10_1101-2020_01_28_923532	291	6	to	to	TO
10_1101-2020_01_28_923532	291	7	inhibit	inhibit	VB
10_1101-2020_01_28_923532	291	8	PTPRZ1	ptprz1	CC
10_1101-2020_01_28_923532	291	9	pharmacologically	pharmacologically	RB
10_1101-2020_01_28_923532	291	10	in	in	IN
10_1101-2020_01_28_923532	291	11	brain	brain	NN
10_1101-2020_01_28_923532	291	12	cancer	cancer	NN
10_1101-2020_01_28_923532	291	13	and	and	CC
10_1101-2020_01_28_923532	291	14	other	other	JJ
10_1101-2020_01_28_923532	291	15	brain	brain	NN
10_1101-2020_01_28_923532	291	16	disorders44,45	disorders44,45	NNP
10_1101-2020_01_28_923532	291	17	.	.	.
10_1101-2020_01_28_923532	292	1	In	in	IN
10_1101-2020_01_28_923532	292	2	the	the	DT
10_1101-2020_01_28_923532	292	3	four	four	CD
10_1101-2020_01_28_923532	292	4	brain	brain	NN
10_1101-2020_01_28_923532	292	5	cancer	cancer	NN
10_1101-2020_01_28_923532	292	6	data	datum	NNS
10_1101-2020_01_28_923532	292	7	sets	set	NNS
10_1101-2020_01_28_923532	292	8	,	,	,
10_1101-2020_01_28_923532	292	9	PTPRZ1	PTPRZ1	NNP
10_1101-2020_01_28_923532	292	10	is	be	VBZ
10_1101-2020_01_28_923532	292	11	expressed	express	VBN
10_1101-2020_01_28_923532	292	12	selectively	selectively	RB
10_1101-2020_01_28_923532	292	13	above	above	IN
10_1101-2020_01_28_923532	292	14	the	the	DT
10_1101-2020_01_28_923532	292	15	baseline	baseline	NN
10_1101-2020_01_28_923532	292	16	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	292	17	=	=	SYM
10_1101-2020_01_28_923532	292	18	2.0	2.0	CD
10_1101-2020_01_28_923532	292	19	in	in	IN
10_1101-2020_01_28_923532	292	20	0.99	0.99	CD
10_1101-2020_01_28_923532	292	21	(	(	-LRB-
10_1101-2020_01_28_923532	292	22	GSE89567	GSE89567	NNP
10_1101-2020_01_28_923532	292	23	)	)	-RRB-
10_1101-2020_01_28_923532	292	24	,	,	,
10_1101-2020_01_28_923532	292	25	0.84	0.84	CD
10_1101-2020_01_28_923532	292	26	(	(	-LRB-
10_1101-2020_01_28_923532	292	27	GSE70630	GSE70630	NNP
10_1101-2020_01_28_923532	292	28	)	)	-RRB-
10_1101-2020_01_28_923532	292	29	,	,	,
10_1101-2020_01_28_923532	292	30	0.96	0.96	CD
10_1101-2020_01_28_923532	292	31	(	(	-LRB-
10_1101-2020_01_28_923532	292	32	GSE102130	GSE102130	NNP
10_1101-2020_01_28_923532	292	33	)	)	-RRB-
10_1101-2020_01_28_923532	292	34	and	and	CC
10_1101-2020_01_28_923532	292	35	0.27	0.27	CD
10_1101-2020_01_28_923532	292	36	(	(	-LRB-
10_1101-2020_01_28_923532	292	37	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	292	38	)	)	-RRB-
10_1101-2020_01_28_923532	292	39	proportion	proportion	NN
10_1101-2020_01_28_923532	292	40	of	of	IN
10_1101-2020_01_28_923532	292	41	cells	cell	NNS
10_1101-2020_01_28_923532	292	42	in	in	IN
10_1101-2020_01_28_923532	292	43	each	each	DT
10_1101-2020_01_28_923532	292	44	cohort	cohort	NN
10_1101-2020_01_28_923532	292	45	.	.	.
10_1101-2020_01_28_923532	293	1	The	the	DT
10_1101-2020_01_28_923532	293	2	much	much	RB
10_1101-2020_01_28_923532	293	3	lower	low	JJR
10_1101-2020_01_28_923532	293	4	relative	relative	JJ
10_1101-2020_01_28_923532	293	5	level	level	NN
10_1101-2020_01_28_923532	293	6	of	of	IN
10_1101-2020_01_28_923532	293	7	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	293	8	expression	expression	NN
10_1101-2020_01_28_923532	293	9	in	in	IN
10_1101-2020_01_28_923532	293	10	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	293	11	is	be	VBZ
10_1101-2020_01_28_923532	293	12	likely	likely	RB
10_1101-2020_01_28_923532	293	13	due	due	IN
10_1101-2020_01_28_923532	293	14	to	to	IN
10_1101-2020_01_28_923532	293	15	the	the	DT
10_1101-2020_01_28_923532	293	16	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	293	17	of	of	IN
10_1101-2020_01_28_923532	293	18	brain	brain	NN
10_1101-2020_01_28_923532	293	19	cancer	cancer	NN
10_1101-2020_01_28_923532	293	20	types	type	NNS
10_1101-2020_01_28_923532	293	21	in	in	IN
10_1101-2020_01_28_923532	293	22	this	this	DT
10_1101-2020_01_28_923532	293	23	data	datum	NNS
10_1101-2020_01_28_923532	293	24	set46	set46	NNS
10_1101-2020_01_28_923532	293	25	.	.	.
10_1101-2020_01_28_923532	294	1	Among	among	IN
10_1101-2020_01_28_923532	294	2	the	the	DT
10_1101-2020_01_28_923532	294	3	58	58	CD
10_1101-2020_01_28_923532	294	4	genes	gene	NNS
10_1101-2020_01_28_923532	294	5	with	with	IN
10_1101-2020_01_28_923532	294	6	known	know	VBN
10_1101-2020_01_28_923532	294	7	ligand	ligand	NN
10_1101-2020_01_28_923532	294	8	-	-	HYPH
10_1101-2020_01_28_923532	294	9	mimicking	mimicking	NN
10_1101-2020_01_28_923532	294	10	peptides	peptide	NNS
10_1101-2020_01_28_923532	294	11	,	,	,
10_1101-2020_01_28_923532	294	12	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	294	13	stands	stand	VBZ
10_1101-2020_01_28_923532	294	14	out	out	RP
10_1101-2020_01_28_923532	294	15	as	as	IN
10_1101-2020_01_28_923532	294	16	most	most	RBS
10_1101-2020_01_28_923532	294	17	common	common	JJ
10_1101-2020_01_28_923532	294	18	in	in	IN
10_1101-2020_01_28_923532	294	19	optimal	optimal	JJ
10_1101-2020_01_28_923532	294	20	solutions	solution	NNS
10_1101-2020_01_28_923532	294	21	(	(	-LRB-
10_1101-2020_01_28_923532	294	22	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	294	23	Table	Table	NNP
10_1101-2020_01_28_923532	294	24	S4	S4	NNP
10_1101-2020_01_28_923532	294	25	)	)	-RRB-
10_1101-2020_01_28_923532	294	26	.	.	.
10_1101-2020_01_28_923532	295	1	Even	even	RB
10_1101-2020_01_28_923532	295	2	when	when	WRB
10_1101-2020_01_28_923532	295	3	all	all	DT
10_1101-2020_01_28_923532	295	4	1269	1269	CD
10_1101-2020_01_28_923532	295	5	genes	gene	NNS
10_1101-2020_01_28_923532	295	6	are	be	VBP
10_1101-2020_01_28_923532	295	7	available	available	JJ
10_1101-2020_01_28_923532	295	8	,	,	,
10_1101-2020_01_28_923532	295	9	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	295	10	is	be	VBZ
10_1101-2020_01_28_923532	295	11	most	most	RBS
10_1101-2020_01_28_923532	295	12	commonly	commonly	RB
10_1101-2020_01_28_923532	295	13	selected	select	VBN
10_1101-2020_01_28_923532	295	14	for	for	IN
10_1101-2020_01_28_923532	295	15	the	the	DT
10_1101-2020_01_28_923532	295	16	brain	brain	NN
10_1101-2020_01_28_923532	295	17	cancer	cancer	NN
10_1101-2020_01_28_923532	295	18	data	datum	NNS
10_1101-2020_01_28_923532	295	19	set	set	NN
10_1101-2020_01_28_923532	295	20	(	(	-LRB-
10_1101-2020_01_28_923532	295	21	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	295	22	)	)	-RRB-
10_1101-2020_01_28_923532	295	23	in	in	IN
10_1101-2020_01_28_923532	295	24	which	which	WDT
10_1101-2020_01_28_923532	295	25	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	295	26	is	be	VBZ
10_1101-2020_01_28_923532	295	27	not	not	RB
10_1101-2020_01_28_923532	295	28	as	as	RB
10_1101-2020_01_28_923532	295	29	highly	highly	RB
10_1101-2020_01_28_923532	295	30	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	295	31	(	(	-LRB-
10_1101-2020_01_28_923532	295	32	Figure	Figure	NNP
10_1101-2020_01_28_923532	295	33	7C	7c	NN
10_1101-2020_01_28_923532	295	34	)	)	-RRB-
10_1101-2020_01_28_923532	295	35	.	.	.
10_1101-2020_01_28_923532	296	1	PTPRZ1	PTPRZ1	NNP
10_1101-2020_01_28_923532	296	2	was	be	VBD
10_1101-2020_01_28_923532	296	3	the	the	DT
10_1101-2020_01_28_923532	296	4	fifth	fifth	JJ
10_1101-2020_01_28_923532	296	5	most	most	RBS
10_1101-2020_01_28_923532	296	6	frequently	frequently	RB
10_1101-2020_01_28_923532	296	7	occurring	occur	VBG
10_1101-2020_01_28_923532	296	8	gene	gene	NN
10_1101-2020_01_28_923532	296	9	in	in	IN
10_1101-2020_01_28_923532	296	10	optimal	optimal	JJ
10_1101-2020_01_28_923532	296	11	solutions	solution	NNS
10_1101-2020_01_28_923532	296	12	for	for	IN
10_1101-2020_01_28_923532	296	13	the	the	DT
10_1101-2020_01_28_923532	296	14	head	head	NN
10_1101-2020_01_28_923532	296	15	and	and	CC
10_1101-2020_01_28_923532	296	16	neck	neck	NN
10_1101-2020_01_28_923532	296	17	cancer	cancer	NN
10_1101-2020_01_28_923532	296	18	data	datum	NNS
10_1101-2020_01_28_923532	296	19	set	set	NN
10_1101-2020_01_28_923532	296	20	(	(	-LRB-
10_1101-2020_01_28_923532	296	21	GSE103322	GSE103322	NNP
10_1101-2020_01_28_923532	296	22	)	)	-RRB-
10_1101-2020_01_28_923532	296	23	.	.	.
10_1101-2020_01_28_923532	297	1	The	the	DT
10_1101-2020_01_28_923532	297	2	two	two	CD
10_1101-2020_01_28_923532	297	3	most	most	RBS
10_1101-2020_01_28_923532	297	4	common	common	JJ
10_1101-2020_01_28_923532	297	5	genes	gene	NNS
10_1101-2020_01_28_923532	297	6	by	by	IN
10_1101-2020_01_28_923532	297	7	a	a	DT
10_1101-2020_01_28_923532	297	8	large	large	JJ
10_1101-2020_01_28_923532	297	9	margin	margin	NN
10_1101-2020_01_28_923532	297	10	are	be	VBP
10_1101-2020_01_28_923532	297	11	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	297	12	and	and	CC
10_1101-2020_01_28_923532	297	13	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	297	14	.	.	.
10_1101-2020_01_28_923532	298	1	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	298	2	has	have	VBZ
10_1101-2020_01_28_923532	298	3	been	be	VBN
10_1101-2020_01_28_923532	298	4	studied	study	VBN
10_1101-2020_01_28_923532	298	5	primarily	primarily	RB
10_1101-2020_01_28_923532	298	6	by	by	IN
10_1101-2020_01_28_923532	298	7	virologists	virologist	NNS
10_1101-2020_01_28_923532	298	8	and	and	CC
10_1101-2020_01_28_923532	298	9	immunologists	immunologist	NNS
10_1101-2020_01_28_923532	298	10	because	because	IN
10_1101-2020_01_28_923532	298	11	it	-PRON-	PRP
10_1101-2020_01_28_923532	298	12	encodes	encode	VBZ
10_1101-2020_01_28_923532	298	13	a	a	DT
10_1101-2020_01_28_923532	298	14	receptor	receptor	NN
10_1101-2020_01_28_923532	298	15	for	for	IN
10_1101-2020_01_28_923532	298	16	cocksackieviruses	cocksackieviruse	NNS
10_1101-2020_01_28_923532	298	17	and	and	CC
10_1101-2020_01_28_923532	298	18	adenoviruses47	adenoviruses47	NNS
10_1101-2020_01_28_923532	298	19	.	.	.
10_1101-2020_01_28_923532	299	1	In	in	IN
10_1101-2020_01_28_923532	299	2	one	one	CD
10_1101-2020_01_28_923532	299	3	breast	breast	NN
10_1101-2020_01_28_923532	299	4	cancer	cancer	NN
10_1101-2020_01_28_923532	299	5	study	study	NN
10_1101-2020_01_28_923532	299	6	,	,	,
10_1101-2020_01_28_923532	299	7	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	299	8	was	be	VBD
10_1101-2020_01_28_923532	299	9	found	find	VBN
10_1101-2020_01_28_923532	299	10	to	to	TO
10_1101-2020_01_28_923532	299	11	play	play	VB
10_1101-2020_01_28_923532	299	12	a	a	DT
10_1101-2020_01_28_923532	299	13	role	role	NN
10_1101-2020_01_28_923532	299	14	in	in	IN
10_1101-2020_01_28_923532	299	15	regulating	regulate	VBG
10_1101-2020_01_28_923532	299	16	PTEN	PTEN	NNP
10_1101-2020_01_28_923532	299	17	in	in	IN
10_1101-2020_01_28_923532	299	18	the	the	DT
10_1101-2020_01_28_923532	299	19	AKT	AKT	NNP
10_1101-2020_01_28_923532	299	20	pathway	pathway	NN
10_1101-2020_01_28_923532	299	21	,	,	,
10_1101-2020_01_28_923532	299	22	but	but	CC
10_1101-2020_01_28_923532	299	23	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	299	24	was	be	VBD
10_1101-2020_01_28_923532	299	25	underexpressed	underexpresse	VBN
10_1101-2020_01_28_923532	299	26	in	in	IN
10_1101-2020_01_28_923532	299	27	breast	breast	NN
10_1101-2020_01_28_923532	299	28	cancer48	cancer48	NN
10_1101-2020_01_28_923532	299	29	whereas	whereas	IN
10_1101-2020_01_28_923532	299	30	it	-PRON-	PRP
10_1101-2020_01_28_923532	299	31	is	be	VBZ
10_1101-2020_01_28_923532	299	32	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	299	33	in	in	IN
10_1101-2020_01_28_923532	299	34	the	the	DT
10_1101-2020_01_28_923532	299	35	head	head	NN
10_1101-2020_01_28_923532	299	36	and	and	CC
10_1101-2020_01_28_923532	299	37	neck	neck	NN
10_1101-2020_01_28_923532	299	38	cancer	cancer	NN
10_1101-2020_01_28_923532	299	39	data	datum	NNS
10_1101-2020_01_28_923532	299	40	we	-PRON-	PRP
10_1101-2020_01_28_923532	299	41	analyzed	analyze	VBD
10_1101-2020_01_28_923532	299	42	.	.	.
10_1101-2020_01_28_923532	300	1	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	300	2	is	be	VBZ
10_1101-2020_01_28_923532	300	3	a	a	DT
10_1101-2020_01_28_923532	300	4	rarely	rarely	RB
10_1101-2020_01_28_923532	300	5	studied	study	VBN
10_1101-2020_01_28_923532	300	6	G	g	NN
10_1101-2020_01_28_923532	300	7	protein	protein	NN
10_1101-2020_01_28_923532	300	8	-	-	HYPH
10_1101-2020_01_28_923532	300	9	coupled	couple	VBN
10_1101-2020_01_28_923532	300	10	receptor	receptor	NN
10_1101-2020_01_28_923532	300	11	with	with	IN
10_1101-2020_01_28_923532	300	12	an	an	DT
10_1101-2020_01_28_923532	300	13	unknown	unknown	JJ
10_1101-2020_01_28_923532	300	14	natural	natural	JJ
10_1101-2020_01_28_923532	300	15	ligand49	ligand49	NN
10_1101-2020_01_28_923532	300	16	.	.	.
10_1101-2020_01_28_923532	301	1	In	in	IN
10_1101-2020_01_28_923532	301	2	the	the	DT
10_1101-2020_01_28_923532	301	3	context	context	NN
10_1101-2020_01_28_923532	301	4	of	of	IN
10_1101-2020_01_28_923532	301	5	cancer	cancer	NN
10_1101-2020_01_28_923532	301	6	,	,	,
10_1101-2020_01_28_923532	301	7	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	301	8	has	have	VBZ
10_1101-2020_01_28_923532	301	9	previously	previously	RB
10_1101-2020_01_28_923532	301	10	been	be	VBN
10_1101-2020_01_28_923532	301	11	reported	report	VBN
10_1101-2020_01_28_923532	301	12	as	as	IN
10_1101-2020_01_28_923532	301	13	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	301	14	in	in	IN
10_1101-2020_01_28_923532	301	15	several	several	JJ
10_1101-2020_01_28_923532	301	16	tumor	tumor	NN
10_1101-2020_01_28_923532	301	17	types	type	NNS
10_1101-2020_01_28_923532	301	18	including	include	VBG
10_1101-2020_01_28_923532	301	19	lung	lung	NN
10_1101-2020_01_28_923532	301	20	and	and	CC
10_1101-2020_01_28_923532	301	21	liver49	liver49	NNP
10_1101-2020_01_28_923532	301	22	and	and	CC
10_1101-2020_01_28_923532	301	23	its	-PRON-	PRP$
10_1101-2020_01_28_923532	301	24	overexpression	overexpression	NN
10_1101-2020_01_28_923532	301	25	may	may	MD
10_1101-2020_01_28_923532	301	26	play	play	VB
10_1101-2020_01_28_923532	301	27	an	an	DT
10_1101-2020_01_28_923532	301	28	oncogenic	oncogenic	JJ
10_1101-2020_01_28_923532	301	29	role	role	NN
10_1101-2020_01_28_923532	301	30	via	via	IN
10_1101-2020_01_28_923532	301	31	either	either	CC
10_1101-2020_01_28_923532	301	32	the	the	DT
10_1101-2020_01_28_923532	301	33	p53	p53	NN
10_1101-2020_01_28_923532	301	34	pathway50	pathway50	NN
10_1101-2020_01_28_923532	301	35	the	the	DT
10_1101-2020_01_28_923532	301	36	NFκB	NFκB	NNP
10_1101-2020_01_28_923532	301	37	pathway51	pathway51	NNS
10_1101-2020_01_28_923532	301	38	or	or	CC
10_1101-2020_01_28_923532	301	39	other	other	JJ
10_1101-2020_01_28_923532	301	40	pathways	pathway	NNS
10_1101-2020_01_28_923532	301	41	.	.	.
10_1101-2020_01_28_923532	302	1	Finally	finally	RB
10_1101-2020_01_28_923532	302	2	,	,	,
10_1101-2020_01_28_923532	302	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	302	4	analyzed	analyze	VBD
10_1101-2020_01_28_923532	302	5	the	the	DT
10_1101-2020_01_28_923532	302	6	set	set	NN
10_1101-2020_01_28_923532	302	7	of	of	IN
10_1101-2020_01_28_923532	302	8	genes	gene	NNS
10_1101-2020_01_28_923532	302	9	in	in	IN
10_1101-2020_01_28_923532	302	10	optimal	optimal	JJ
10_1101-2020_01_28_923532	302	11	solutions	solution	NNS
10_1101-2020_01_28_923532	302	12	via	via	IN
10_1101-2020_01_28_923532	302	13	the	the	DT
10_1101-2020_01_28_923532	302	14	STRING	string	NN
10_1101-2020_01_28_923532	302	15	database	database	NN
10_1101-2020_01_28_923532	302	16	and	and	CC
10_1101-2020_01_28_923532	302	17	associated	associate	VBD
10_1101-2020_01_28_923532	302	18	tools52	tools52	VBZ
10_1101-2020_01_28_923532	302	19	to	to	TO
10_1101-2020_01_28_923532	302	20	perform	perform	VB
10_1101-2020_01_28_923532	302	21	several	several	JJ
10_1101-2020_01_28_923532	302	22	types	type	NNS
10_1101-2020_01_28_923532	302	23	of	of	IN
10_1101-2020_01_28_923532	302	24	gene	gene	NN
10_1101-2020_01_28_923532	302	25	set	set	NN
10_1101-2020_01_28_923532	302	26	and	and	CC
10_1101-2020_01_28_923532	302	27	pathway	pathway	JJ
10_1101-2020_01_28_923532	302	28	enrichment	enrichment	NN
10_1101-2020_01_28_923532	302	29	analyses	analysis	NNS
10_1101-2020_01_28_923532	302	30	.	.	.
10_1101-2020_01_28_923532	303	1	Figures	figure	NNS
10_1101-2020_01_28_923532	303	2	S30-S33	S30-S33	NNP
10_1101-2020_01_28_923532	303	3	(	(	-LRB-
10_1101-2020_01_28_923532	303	4	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	303	5	Materials	Materials	NNP
10_1101-2020_01_28_923532	303	6	12	12	CD
10_1101-2020_01_28_923532	303	7	)	)	-RRB-
10_1101-2020_01_28_923532	303	8	show	show	VBP
10_1101-2020_01_28_923532	303	9	STRING	string	NN
10_1101-2020_01_28_923532	303	10	-	-	HYPH
10_1101-2020_01_28_923532	303	11	derived	derive	VBN
10_1101-2020_01_28_923532	303	12	protein	protein	NN
10_1101-2020_01_28_923532	303	13	-	-	HYPH
10_1101-2020_01_28_923532	303	14	protein	protein	NN
10_1101-2020_01_28_923532	303	15	interaction	interaction	NN
10_1101-2020_01_28_923532	303	16	networks	network	NNS
10_1101-2020_01_28_923532	303	17	for	for	IN
10_1101-2020_01_28_923532	303	18	the	the	DT
10_1101-2020_01_28_923532	303	19	25	25	CD
10_1101-2020_01_28_923532	303	20	most	most	RBS
10_1101-2020_01_28_923532	303	21	common	common	JJ
10_1101-2020_01_28_923532	303	22	genes	gene	NNS
10_1101-2020_01_28_923532	303	23	in	in	IN
10_1101-2020_01_28_923532	303	24	the	the	DT
10_1101-2020_01_28_923532	303	25	same	same	JJ
10_1101-2020_01_28_923532	303	26	four	four	CD
10_1101-2020_01_28_923532	303	27	data	datum	NNS
10_1101-2020_01_28_923532	303	28	for	for	IN
10_1101-2020_01_28_923532	303	29	which	which	WDT
10_1101-2020_01_28_923532	303	30	we	-PRON-	PRP
10_1101-2020_01_28_923532	303	31	showed	show	VBD
10_1101-2020_01_28_923532	303	32	co-	co-	IN
10_1101-2020_01_28_923532	303	33	occurrence	occurrence	NN
10_1101-2020_01_28_923532	303	34	graphs	graphs	NN
10_1101-2020_01_28_923532	303	35	in	in	IN
10_1101-2020_01_28_923532	303	36	Figure	Figure	NNP
10_1101-2020_01_28_923532	303	37	7C	7C	NNP
10_1101-2020_01_28_923532	303	38	-	-	HYPH
10_1101-2020_01_28_923532	303	39	F.	F.	NNP
10_1101-2020_01_28_923532	303	40	Again	Again	NNP
10_1101-2020_01_28_923532	303	41	,	,	,
10_1101-2020_01_28_923532	303	42	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	303	43	stands	stand	VBZ
10_1101-2020_01_28_923532	303	44	out	out	RP
10_1101-2020_01_28_923532	303	45	as	as	IN
10_1101-2020_01_28_923532	303	46	being	be	VBG
10_1101-2020_01_28_923532	303	47	a	a	DT
10_1101-2020_01_28_923532	303	48	highly	highly	RB
10_1101-2020_01_28_923532	303	49	connected	connected	JJ
10_1101-2020_01_28_923532	303	50	protein	protein	NN
10_1101-2020_01_28_923532	303	51	node	node	RB
10_1101-2020_01_28_923532	303	52	in	in	IN
10_1101-2020_01_28_923532	303	53	the	the	DT
10_1101-2020_01_28_923532	303	54	solution	solution	NN
10_1101-2020_01_28_923532	303	55	networks	network	NNS
10_1101-2020_01_28_923532	303	56	for	for	IN
10_1101-2020_01_28_923532	303	57	both	both	CC
10_1101-2020_01_28_923532	303	58	the	the	DT
10_1101-2020_01_28_923532	303	59	brain	brain	NN
10_1101-2020_01_28_923532	303	60	cancer	cancer	NN
10_1101-2020_01_28_923532	303	61	and	and	CC
10_1101-2020_01_28_923532	303	62	head	head	NN
10_1101-2020_01_28_923532	303	63	and	and	CC
10_1101-2020_01_28_923532	303	64	neck	neck	NN
10_1101-2020_01_28_923532	303	65	cancer	cancer	NN
10_1101-2020_01_28_923532	303	66	data	datum	NNS
10_1101-2020_01_28_923532	303	67	sets	set	NNS
10_1101-2020_01_28_923532	303	68	.	.	.
10_1101-2020_01_28_923532	304	1	Among	among	IN
10_1101-2020_01_28_923532	304	2	the	the	DT
10_1101-2020_01_28_923532	304	3	30	30	CD
10_1101-2020_01_28_923532	304	4	genes	gene	NNS
10_1101-2020_01_28_923532	304	5	in	in	IN
10_1101-2020_01_28_923532	304	6	the	the	DT
10_1101-2020_01_28_923532	304	7	1269-gene	1269-gene	CD
10_1101-2020_01_28_923532	304	8	set	set	NN
10_1101-2020_01_28_923532	304	9	most	most	RBS
10_1101-2020_01_28_923532	304	10	commonly	commonly	RB
10_1101-2020_01_28_923532	304	11	in	in	IN
10_1101-2020_01_28_923532	304	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	304	13	solutions	solution	NNS
10_1101-2020_01_28_923532	304	14	(	(	-LRB-
10_1101-2020_01_28_923532	304	15	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	304	16	Table	Table	NNP
10_1101-2020_01_28_923532	304	17	S5	s5	NN
10_1101-2020_01_28_923532	304	18	)	)	-RRB-
10_1101-2020_01_28_923532	304	19	,	,	,
10_1101-2020_01_28_923532	304	20	there	there	EX
10_1101-2020_01_28_923532	304	21	are	be	VBP
10_1101-2020_01_28_923532	304	22	six	six	CD
10_1101-2020_01_28_923532	304	23	kinases	kinase	NNS
10_1101-2020_01_28_923532	304	24	(	(	-LRB-
10_1101-2020_01_28_923532	304	25	out	out	IN
10_1101-2020_01_28_923532	304	26	of	of	IN
10_1101-2020_01_28_923532	304	27	88	88	CD
10_1101-2020_01_28_923532	304	28	total	total	JJ
10_1101-2020_01_28_923532	304	29	human	human	JJ
10_1101-2020_01_28_923532	304	30	transmembrane	transmembrane	NNP
10_1101-2020_01_28_923532	304	31	kinases	kinase	NNS
10_1101-2020_01_28_923532	304	32	with	with	IN
10_1101-2020_01_28_923532	304	33	a	a	DT
10_1101-2020_01_28_923532	304	34	catalytic	catalytic	JJ
10_1101-2020_01_28_923532	304	35	domain	domain	NN
10_1101-2020_01_28_923532	304	36	,	,	,
10_1101-2020_01_28_923532	304	37	STRING	string	NN
10_1101-2020_01_28_923532	304	38	gene	gene	NN
10_1101-2020_01_28_923532	304	39	set	set	VBP
10_1101-2020_01_28_923532	304	40	enrichment	enrichment	NN
10_1101-2020_01_28_923532	304	41	𝑝	𝑝	NNP
10_1101-2020_01_28_923532	304	42	<	<	XX
10_1101-2020_01_28_923532	304	43	1𝑒	1𝑒	NNP
10_1101-2020_01_28_923532	304	44	−	−	NNP
10_1101-2020_01_28_923532	304	45	6	6	CD
10_1101-2020_01_28_923532	304	46	)	)	-RRB-
10_1101-2020_01_28_923532	304	47	,	,	,
10_1101-2020_01_28_923532	304	48	namely	namely	RB
10_1101-2020_01_28_923532	304	49	{	{	-LRB-
10_1101-2020_01_28_923532	304	50	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	304	51	,	,	,
10_1101-2020_01_28_923532	304	52	EPHB4	EPHB4	NNP
10_1101-2020_01_28_923532	304	53	,	,	,
10_1101-2020_01_28_923532	304	54	ERBB3	ERBB3	NNS
10_1101-2020_01_28_923532	304	55	,	,	,
10_1101-2020_01_28_923532	304	56	FGFR1	FGFR1	NNP
10_1101-2020_01_28_923532	304	57	,	,	,
10_1101-2020_01_28_923532	304	58	INSR	INSR	NNP
10_1101-2020_01_28_923532	304	59	,	,	,
10_1101-2020_01_28_923532	304	60	NTRK2	NTRK2	.
10_1101-2020_01_28_923532	304	61	}	}	-RRB-
10_1101-2020_01_28_923532	304	62	and	and	CC
10_1101-2020_01_28_923532	304	63	two	two	CD
10_1101-2020_01_28_923532	304	64	phosphatases	phosphatase	NNS
10_1101-2020_01_28_923532	304	65	{	{	-LRB-
10_1101-2020_01_28_923532	304	66	PTPRJ	ptprj	NN
10_1101-2020_01_28_923532	304	67	,	,	,
10_1101-2020_01_28_923532	304	68	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	304	69	}	}	-RRB-
10_1101-2020_01_28_923532	304	70	.	.	.
10_1101-2020_01_28_923532	305	1	The	the	DT
10_1101-2020_01_28_923532	305	2	KEGG	KEGG	NNP
10_1101-2020_01_28_923532	305	3	pathways	pathway	VBZ
10_1101-2020_01_28_923532	305	4	most	most	JJS
10_1101-2020_01_28_923532	305	5	105	105	CD
10_1101-2020_01_28_923532	305	6	and	and	CC
10_1101-2020_01_28_923532	305	7	is	be	VBZ
10_1101-2020_01_28_923532	305	8	also	also	RB
10_1101-2020_01_28_923532	305	9	made	make	VBN
10_1101-2020_01_28_923532	305	10	available	available	JJ
10_1101-2020_01_28_923532	305	11	for	for	IN
10_1101-2020_01_28_923532	305	12	use	use	NN
10_1101-2020_01_28_923532	305	13	under	under	IN
10_1101-2020_01_28_923532	305	14	a	a	DT
10_1101-2020_01_28_923532	305	15	CC0	CC0	NNP
10_1101-2020_01_28_923532	305	16	license	license	NN
10_1101-2020_01_28_923532	305	17	.	.	.
10_1101-2020_01_28_923532	306	1	(	(	-LRB-
10_1101-2020_01_28_923532	306	2	which	which	WDT
10_1101-2020_01_28_923532	306	3	was	be	VBD
10_1101-2020_01_28_923532	306	4	not	not	RB
10_1101-2020_01_28_923532	306	5	certified	certify	VBN
10_1101-2020_01_28_923532	306	6	by	by	IN
10_1101-2020_01_28_923532	306	7	peer	peer	NN
10_1101-2020_01_28_923532	306	8	review	review	NN
10_1101-2020_01_28_923532	306	9	)	)	-RRB-
10_1101-2020_01_28_923532	306	10	is	be	VBZ
10_1101-2020_01_28_923532	306	11	the	the	DT
10_1101-2020_01_28_923532	306	12	author	author	NN
10_1101-2020_01_28_923532	306	13	/	/	SYM
10_1101-2020_01_28_923532	306	14	funder	funder	NN
10_1101-2020_01_28_923532	306	15	.	.	.
10_1101-2020_01_28_923532	307	1	This	this	DT
10_1101-2020_01_28_923532	307	2	article	article	NN
10_1101-2020_01_28_923532	307	3	is	be	VBZ
10_1101-2020_01_28_923532	307	4	a	a	DT
10_1101-2020_01_28_923532	307	5	US	US	NNP
10_1101-2020_01_28_923532	307	6	Government	Government	NNP
10_1101-2020_01_28_923532	307	7	work	work	NN
10_1101-2020_01_28_923532	307	8	.	.	.
10_1101-2020_01_28_923532	308	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	308	2	is	be	VBZ
10_1101-2020_01_28_923532	308	3	not	not	RB
10_1101-2020_01_28_923532	308	4	subject	subject	JJ
10_1101-2020_01_28_923532	308	5	to	to	IN
10_1101-2020_01_28_923532	308	6	copyright	copyright	NN
10_1101-2020_01_28_923532	308	7	under	under	IN
10_1101-2020_01_28_923532	308	8	17	17	CD
10_1101-2020_01_28_923532	308	9	USC	usc	NN
10_1101-2020_01_28_923532	308	10	The	the	DT
10_1101-2020_01_28_923532	308	11	copyright	copyright	NN
10_1101-2020_01_28_923532	308	12	holder	holder	NN
10_1101-2020_01_28_923532	308	13	for	for	IN
10_1101-2020_01_28_923532	308	14	this	this	DT
10_1101-2020_01_28_923532	308	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	308	16	version	version	NN
10_1101-2020_01_28_923532	308	17	posted	post	VBD
10_1101-2020_01_28_923532	308	18	February	February	NNP
10_1101-2020_01_28_923532	308	19	12	12	CD
10_1101-2020_01_28_923532	308	20	,	,	,
10_1101-2020_01_28_923532	308	21	2021	2021	CD
10_1101-2020_01_28_923532	308	22	.	.	.
10_1101-2020_01_28_923532	308	23	;	;	:
10_1101-2020_01_28_923532	308	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	308	25	:	:	:
10_1101-2020_01_28_923532	308	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	308	27	preprint	preprint	NN
10_1101-2020_01_28_923532	308	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	308	29	25	25	CD
10_1101-2020_01_28_923532	308	30	significantly	significantly	RB
10_1101-2020_01_28_923532	308	31	enriched	enrich	VBN
10_1101-2020_01_28_923532	308	32	,	,	,
10_1101-2020_01_28_923532	308	33	all	all	RB
10_1101-2020_01_28_923532	308	34	at	at	IN
10_1101-2020_01_28_923532	308	35	𝐹𝐷𝑅	𝐹𝐷𝑅	NNP
10_1101-2020_01_28_923532	308	36	<	<	XX
10_1101-2020_01_28_923532	308	37	0.005	0.005	XX
10_1101-2020_01_28_923532	308	38	,	,	,
10_1101-2020_01_28_923532	308	39	are	be	VBP
10_1101-2020_01_28_923532	308	40	(	(	-LRB-
10_1101-2020_01_28_923532	308	41	“	"	``
10_1101-2020_01_28_923532	308	42	proteoglycans	proteoglycans	NNPS
10_1101-2020_01_28_923532	308	43	in	in	IN
10_1101-2020_01_28_923532	308	44	cancer	cancer	NN
10_1101-2020_01_28_923532	308	45	”	"	''
10_1101-2020_01_28_923532	308	46	)	)	-RRB-
10_1101-2020_01_28_923532	308	47	represented	represent	VBN
10_1101-2020_01_28_923532	308	48	by	by	IN
10_1101-2020_01_28_923532	308	49	{	{	-LRB-
10_1101-2020_01_28_923532	308	50	CD44	CD44	NNP
10_1101-2020_01_28_923532	308	51	,	,	,
10_1101-2020_01_28_923532	308	52	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	308	53	,	,	,
10_1101-2020_01_28_923532	308	54	ERBB3	ERBB3	NNS
10_1101-2020_01_28_923532	308	55	,	,	,
10_1101-2020_01_28_923532	308	56	FGFR1	fgfr1	CD
10_1101-2020_01_28_923532	308	57	,	,	,
10_1101-2020_01_28_923532	308	58	PLAUR	PLAUR	NNP
10_1101-2020_01_28_923532	308	59	}	}	-RRB-
10_1101-2020_01_28_923532	308	60	,	,	,
10_1101-2020_01_28_923532	308	61	(	(	-LRB-
10_1101-2020_01_28_923532	308	62	“	"	``
10_1101-2020_01_28_923532	308	63	adherens	adherens	NNPS
10_1101-2020_01_28_923532	308	64	junction	junction	NNP
10_1101-2020_01_28_923532	308	65	”	"	''
10_1101-2020_01_28_923532	308	66	)	)	-RRB-
10_1101-2020_01_28_923532	308	67	represented	represent	VBN
10_1101-2020_01_28_923532	308	68	by	by	IN
10_1101-2020_01_28_923532	308	69	{	{	-LRB-
10_1101-2020_01_28_923532	308	70	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	308	71	,	,	,
10_1101-2020_01_28_923532	308	72	FGFR1	FGFR1	NNS
10_1101-2020_01_28_923532	308	73	,	,	,
10_1101-2020_01_28_923532	308	74	INSR	INSR	NNP
10_1101-2020_01_28_923532	308	75	,	,	,
10_1101-2020_01_28_923532	308	76	PTPRJ	PTPRJ	NNP
10_1101-2020_01_28_923532	308	77	}	}	-RRB-
10_1101-2020_01_28_923532	308	78	,	,	,
10_1101-2020_01_28_923532	308	79	and	and	CC
10_1101-2020_01_28_923532	308	80	(	(	-LRB-
10_1101-2020_01_28_923532	308	81	“	"	``
10_1101-2020_01_28_923532	308	82	calcium	calcium	NN
10_1101-2020_01_28_923532	308	83	signaling	signal	VBG
10_1101-2020_01_28_923532	308	84	pathway	pathway	NN
10_1101-2020_01_28_923532	308	85	”	"	''
10_1101-2020_01_28_923532	308	86	)	)	-RRB-
10_1101-2020_01_28_923532	308	87	represented	represent	VBN
10_1101-2020_01_28_923532	308	88	by	by	IN
10_1101-2020_01_28_923532	308	89	{	{	-LRB-
10_1101-2020_01_28_923532	308	90	EDNRB	EDNRB	NNP
10_1101-2020_01_28_923532	308	91	,	,	,
10_1101-2020_01_28_923532	308	92	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	308	93	,	,	,
10_1101-2020_01_28_923532	308	94	ERBB3	ERBB3	NNS
10_1101-2020_01_28_923532	308	95	,	,	,
10_1101-2020_01_28_923532	308	96	GRPR	GRPR	NNP
10_1101-2020_01_28_923532	308	97	,	,	,
10_1101-2020_01_28_923532	308	98	P2RX6	P2RX6	NNP
10_1101-2020_01_28_923532	308	99	}	}	-RRB-
10_1101-2020_01_28_923532	308	100	.	.	.
10_1101-2020_01_28_923532	309	1	The	the	DT
10_1101-2020_01_28_923532	309	2	one	one	CD
10_1101-2020_01_28_923532	309	3	gene	gene	NN
10_1101-2020_01_28_923532	309	4	in	in	IN
10_1101-2020_01_28_923532	309	5	the	the	DT
10_1101-2020_01_28_923532	309	6	intersection	intersection	NN
10_1101-2020_01_28_923532	309	7	of	of	IN
10_1101-2020_01_28_923532	309	8	all	all	PDT
10_1101-2020_01_28_923532	309	9	these	these	DT
10_1101-2020_01_28_923532	309	10	pathways	pathway	NNS
10_1101-2020_01_28_923532	309	11	and	and	CC
10_1101-2020_01_28_923532	309	12	functions	function	NNS
10_1101-2020_01_28_923532	309	13	is	be	VBZ
10_1101-2020_01_28_923532	309	14	EGFR	EGFR	VBN
10_1101-2020_01_28_923532	309	15	.	.	.
10_1101-2020_01_28_923532	310	1	Discussion	discussion	NN
10_1101-2020_01_28_923532	310	2	In	in	IN
10_1101-2020_01_28_923532	310	3	this	this	DT
10_1101-2020_01_28_923532	310	4	multi	multi	JJ
10_1101-2020_01_28_923532	310	5	-	-	JJ
10_1101-2020_01_28_923532	310	6	disciplinary	disciplinary	JJ
10_1101-2020_01_28_923532	310	7	study	study	NN
10_1101-2020_01_28_923532	310	8	,	,	,
10_1101-2020_01_28_923532	310	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	310	10	harnessed	harness	VBD
10_1101-2020_01_28_923532	310	11	techniques	technique	NNS
10_1101-2020_01_28_923532	310	12	from	from	IN
10_1101-2020_01_28_923532	310	13	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	310	14	optimization	optimization	NN
10_1101-2020_01_28_923532	310	15	to	to	TO
10_1101-2020_01_28_923532	310	16	analyze	analyze	VB
10_1101-2020_01_28_923532	310	17	publicly	publicly	RB
10_1101-2020_01_28_923532	310	18	available	available	JJ
10_1101-2020_01_28_923532	310	19	single	single	JJ
10_1101-2020_01_28_923532	310	20	-	-	HYPH
10_1101-2020_01_28_923532	310	21	cell	cell	NN
10_1101-2020_01_28_923532	310	22	tumor	tumor	NN
10_1101-2020_01_28_923532	310	23	transcriptomics	transcriptomic	NNS
10_1101-2020_01_28_923532	310	24	data	datum	NNS
10_1101-2020_01_28_923532	310	25	to	to	TO
10_1101-2020_01_28_923532	310	26	chart	chart	VB
10_1101-2020_01_28_923532	310	27	the	the	DT
10_1101-2020_01_28_923532	310	28	landscape	landscape	NN
10_1101-2020_01_28_923532	310	29	of	of	IN
10_1101-2020_01_28_923532	310	30	future	future	JJ
10_1101-2020_01_28_923532	310	31	personalized	personalize	VBN
10_1101-2020_01_28_923532	310	32	combinations	combination	NNS
10_1101-2020_01_28_923532	310	33	that	that	WDT
10_1101-2020_01_28_923532	310	34	are	be	VBP
10_1101-2020_01_28_923532	310	35	based	base	VBN
10_1101-2020_01_28_923532	310	36	on	on	IN
10_1101-2020_01_28_923532	310	37	‘	'	``
10_1101-2020_01_28_923532	310	38	modular	modular	JJ
10_1101-2020_01_28_923532	310	39	’	'	''
10_1101-2020_01_28_923532	310	40	therapies	therapy	NNS
10_1101-2020_01_28_923532	310	41	,	,	,
10_1101-2020_01_28_923532	310	42	including	include	VBG
10_1101-2020_01_28_923532	310	43	CAR	CAR	NNP
10_1101-2020_01_28_923532	310	44	-	-	HYPH
10_1101-2020_01_28_923532	310	45	T	t	NN
10_1101-2020_01_28_923532	310	46	therapy	therapy	NN
10_1101-2020_01_28_923532	310	47	.	.	.
10_1101-2020_01_28_923532	311	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	311	2	showed	show	VBD
10_1101-2020_01_28_923532	311	3	that	that	IN
10_1101-2020_01_28_923532	311	4	,	,	,
10_1101-2020_01_28_923532	311	5	for	for	IN
10_1101-2020_01_28_923532	311	6	most	most	JJS
10_1101-2020_01_28_923532	311	7	tumors	tumor	NNS
10_1101-2020_01_28_923532	311	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	311	9	studied	study	VBD
10_1101-2020_01_28_923532	311	10	,	,	,
10_1101-2020_01_28_923532	311	11	four	four	CD
10_1101-2020_01_28_923532	311	12	modular	modular	JJ
10_1101-2020_01_28_923532	311	13	medications	medication	NNS
10_1101-2020_01_28_923532	311	14	targeting	target	VBG
10_1101-2020_01_28_923532	311	15	different	different	JJ
10_1101-2020_01_28_923532	311	16	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	311	17	receptors	receptor	NNS
10_1101-2020_01_28_923532	311	18	may	may	MD
10_1101-2020_01_28_923532	311	19	suffice	suffice	VB
10_1101-2020_01_28_923532	311	20	to	to	TO
10_1101-2020_01_28_923532	311	21	selectively	selectively	RB
10_1101-2020_01_28_923532	311	22	kill	kill	VB
10_1101-2020_01_28_923532	311	23	most	most	JJS
10_1101-2020_01_28_923532	311	24	tumor	tumor	NN
10_1101-2020_01_28_923532	311	25	cells	cell	NNS
10_1101-2020_01_28_923532	311	26	,	,	,
10_1101-2020_01_28_923532	311	27	while	while	IN
10_1101-2020_01_28_923532	311	28	sparing	spare	VBG
10_1101-2020_01_28_923532	311	29	most	most	JJS
10_1101-2020_01_28_923532	311	30	of	of	IN
10_1101-2020_01_28_923532	311	31	the	the	DT
10_1101-2020_01_28_923532	311	32	non	non	JJ
10_1101-2020_01_28_923532	311	33	-	-	JJ
10_1101-2020_01_28_923532	311	34	cancerous	cancerous	JJ
10_1101-2020_01_28_923532	311	35	cells	cell	NNS
10_1101-2020_01_28_923532	311	36	(	(	-LRB-
10_1101-2020_01_28_923532	311	37	Figures	figure	NNS
10_1101-2020_01_28_923532	311	38	3	3	CD
10_1101-2020_01_28_923532	311	39	and	and	CC
10_1101-2020_01_28_923532	311	40	4	4	CD
10_1101-2020_01_28_923532	311	41	and	and	CC
10_1101-2020_01_28_923532	311	42	Table	Table	NNP
10_1101-2020_01_28_923532	311	43	S2	S2	NNP
10_1101-2020_01_28_923532	311	44	)	)	-RRB-
10_1101-2020_01_28_923532	311	45	.	.	.
10_1101-2020_01_28_923532	312	1	For	for	IN
10_1101-2020_01_28_923532	312	2	the	the	DT
10_1101-2020_01_28_923532	312	3	more	more	RBR
10_1101-2020_01_28_923532	312	4	restricted	restricted	JJ
10_1101-2020_01_28_923532	312	5	sets	set	NNS
10_1101-2020_01_28_923532	312	6	of	of	IN
10_1101-2020_01_28_923532	312	7	low-	low-	NN
10_1101-2020_01_28_923532	312	8	expression	expression	NN
10_1101-2020_01_28_923532	312	9	genes25	genes25	NNPS
10_1101-2020_01_28_923532	312	10	or	or	CC
10_1101-2020_01_28_923532	312	11	the	the	DT
10_1101-2020_01_28_923532	312	12	58	58	CD
10_1101-2020_01_28_923532	312	13	receptors	receptor	NNS
10_1101-2020_01_28_923532	312	14	with	with	IN
10_1101-2020_01_28_923532	312	15	validated	validate	VBN
10_1101-2020_01_28_923532	312	16	ligand	ligand	NN
10_1101-2020_01_28_923532	312	17	-	-	HYPH
10_1101-2020_01_28_923532	312	18	mimicking	mimicking	NN
10_1101-2020_01_28_923532	312	19	peptides	peptide	NNS
10_1101-2020_01_28_923532	312	20	(	(	-LRB-
10_1101-2020_01_28_923532	312	21	Tables	tables	NN
10_1101-2020_01_28_923532	312	22	3	3	CD
10_1101-2020_01_28_923532	312	23	and	and	CC
10_1101-2020_01_28_923532	312	24	4	4	CD
10_1101-2020_01_28_923532	312	25	)	)	-RRB-
10_1101-2020_01_28_923532	312	26	,	,	,
10_1101-2020_01_28_923532	312	27	some	some	DT
10_1101-2020_01_28_923532	312	28	patients	patient	NNS
10_1101-2020_01_28_923532	312	29	do	do	VBP
10_1101-2020_01_28_923532	312	30	not	not	RB
10_1101-2020_01_28_923532	312	31	have	have	VB
10_1101-2020_01_28_923532	312	32	feasible	feasible	JJ
10_1101-2020_01_28_923532	312	33	solutions	solution	NNS
10_1101-2020_01_28_923532	312	34	,	,	,
10_1101-2020_01_28_923532	312	35	especially	especially	RB
10_1101-2020_01_28_923532	312	36	as	as	IN
10_1101-2020_01_28_923532	312	37	we	-PRON-	PRP
10_1101-2020_01_28_923532	312	38	reduce	reduce	VBP
10_1101-2020_01_28_923532	312	39	the	the	DT
10_1101-2020_01_28_923532	312	40	TPM	TPM	NNP
10_1101-2020_01_28_923532	312	41	expression	expression	NN
10_1101-2020_01_28_923532	312	42	used	use	VBN
10_1101-2020_01_28_923532	312	43	for	for	IN
10_1101-2020_01_28_923532	312	44	filtering	filter	VBG
10_1101-2020_01_28_923532	312	45	the	the	DT
10_1101-2020_01_28_923532	312	46	gene	gene	NN
10_1101-2020_01_28_923532	312	47	set	set	VBN
10_1101-2020_01_28_923532	312	48	to	to	TO
10_1101-2020_01_28_923532	312	49	avoid	avoid	VB
10_1101-2020_01_28_923532	312	50	targeting	target	VBG
10_1101-2020_01_28_923532	312	51	non	non	JJ
10_1101-2020_01_28_923532	312	52	-	-	JJ
10_1101-2020_01_28_923532	312	53	cancerous	cancerous	JJ
10_1101-2020_01_28_923532	312	54	tissues	tissue	NNS
10_1101-2020_01_28_923532	312	55	.	.	.
10_1101-2020_01_28_923532	313	1	These	these	DT
10_1101-2020_01_28_923532	313	2	findings	finding	NNS
10_1101-2020_01_28_923532	313	3	indicate	indicate	VBP
10_1101-2020_01_28_923532	313	4	,	,	,
10_1101-2020_01_28_923532	313	5	on	on	IN
10_1101-2020_01_28_923532	313	6	one	one	CD
10_1101-2020_01_28_923532	313	7	hand	hand	NN
10_1101-2020_01_28_923532	313	8	,	,	,
10_1101-2020_01_28_923532	313	9	that	that	WDT
10_1101-2020_01_28_923532	313	10	researchers	researcher	NNS
10_1101-2020_01_28_923532	313	11	designing	design	VBG
10_1101-2020_01_28_923532	313	12	ligand	ligand	NN
10_1101-2020_01_28_923532	313	13	-	-	HYPH
10_1101-2020_01_28_923532	313	14	mimicking	mimicking	NN
10_1101-2020_01_28_923532	313	15	peptides	peptide	NNS
10_1101-2020_01_28_923532	313	16	have	have	VBP
10_1101-2020_01_28_923532	313	17	been	be	VBN
10_1101-2020_01_28_923532	313	18	astute	astute	JJ
10_1101-2020_01_28_923532	313	19	in	in	IN
10_1101-2020_01_28_923532	313	20	choosing	choose	VBG
10_1101-2020_01_28_923532	313	21	targets	target	NNS
10_1101-2020_01_28_923532	313	22	relevant	relevant	JJ
10_1101-2020_01_28_923532	313	23	to	to	IN
10_1101-2020_01_28_923532	313	24	cancer	cancer	NN
10_1101-2020_01_28_923532	313	25	.	.	.
10_1101-2020_01_28_923532	314	1	On	on	IN
10_1101-2020_01_28_923532	314	2	the	the	DT
10_1101-2020_01_28_923532	314	3	other	other	JJ
10_1101-2020_01_28_923532	314	4	hand	hand	NN
10_1101-2020_01_28_923532	314	5	,	,	,
10_1101-2020_01_28_923532	314	6	these	these	DT
10_1101-2020_01_28_923532	314	7	results	result	NNS
10_1101-2020_01_28_923532	314	8	suggest	suggest	VBP
10_1101-2020_01_28_923532	314	9	that	that	IN
10_1101-2020_01_28_923532	314	10	there	there	EX
10_1101-2020_01_28_923532	314	11	is	be	VBZ
10_1101-2020_01_28_923532	314	12	a	a	DT
10_1101-2020_01_28_923532	314	13	need	need	NN
10_1101-2020_01_28_923532	314	14	for	for	IN
10_1101-2020_01_28_923532	314	15	extending	extend	VBG
10_1101-2020_01_28_923532	314	16	the	the	DT
10_1101-2020_01_28_923532	314	17	set	set	NN
10_1101-2020_01_28_923532	314	18	of	of	IN
10_1101-2020_01_28_923532	314	19	cell	cell	NN
10_1101-2020_01_28_923532	314	20	surface	surface	NN
10_1101-2020_01_28_923532	314	21	receptors	receptor	NNS
10_1101-2020_01_28_923532	314	22	that	that	WDT
10_1101-2020_01_28_923532	314	23	can	can	MD
10_1101-2020_01_28_923532	314	24	be	be	VB
10_1101-2020_01_28_923532	314	25	targeted	target	VBN
10_1101-2020_01_28_923532	314	26	to	to	TO
10_1101-2020_01_28_923532	314	27	enter	enter	VB
10_1101-2020_01_28_923532	314	28	tumor	tumor	NN
10_1101-2020_01_28_923532	314	29	cells	cell	NNS
10_1101-2020_01_28_923532	314	30	with	with	IN
10_1101-2020_01_28_923532	314	31	ligated	ligate	VBN
10_1101-2020_01_28_923532	314	32	chemotherapy	chemotherapy	NN
10_1101-2020_01_28_923532	314	33	agents	agent	NNS
10_1101-2020_01_28_923532	314	34	.	.	.
10_1101-2020_01_28_923532	315	1	Remarkably	remarkably	RB
10_1101-2020_01_28_923532	315	2	,	,	,
10_1101-2020_01_28_923532	315	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	315	4	found	find	VBD
10_1101-2020_01_28_923532	315	5	that	that	IN
10_1101-2020_01_28_923532	315	6	if	if	IN
10_1101-2020_01_28_923532	315	7	one	one	NN
10_1101-2020_01_28_923532	315	8	designs	design	VBZ
10_1101-2020_01_28_923532	315	9	the	the	DT
10_1101-2020_01_28_923532	315	10	optimal	optimal	JJ
10_1101-2020_01_28_923532	315	11	set	set	NN
10_1101-2020_01_28_923532	315	12	of	of	IN
10_1101-2020_01_28_923532	315	13	treatments	treatment	NNS
10_1101-2020_01_28_923532	315	14	for	for	IN
10_1101-2020_01_28_923532	315	15	an	an	DT
10_1101-2020_01_28_923532	315	16	entire	entire	JJ
10_1101-2020_01_28_923532	315	17	cohort	cohort	NN
10_1101-2020_01_28_923532	315	18	adopting	adopt	VBG
10_1101-2020_01_28_923532	315	19	a	a	DT
10_1101-2020_01_28_923532	315	20	fairness	fairness	NN
10_1101-2020_01_28_923532	315	21	-	-	HYPH
10_1101-2020_01_28_923532	315	22	based	base	VBN
10_1101-2020_01_28_923532	315	23	policy	policy	NN
10_1101-2020_01_28_923532	315	24	,	,	,
10_1101-2020_01_28_923532	315	25	then	then	RB
10_1101-2020_01_28_923532	315	26	the	the	DT
10_1101-2020_01_28_923532	315	27	size	size	NN
10_1101-2020_01_28_923532	315	28	of	of	IN
10_1101-2020_01_28_923532	315	29	the	the	DT
10_1101-2020_01_28_923532	315	30	projected	project	VBN
10_1101-2020_01_28_923532	315	31	treatment	treatment	NN
10_1101-2020_01_28_923532	315	32	combinations	combination	NNS
10_1101-2020_01_28_923532	315	33	for	for	IN
10_1101-2020_01_28_923532	315	34	individual	individual	JJ
10_1101-2020_01_28_923532	315	35	patients	patient	NNS
10_1101-2020_01_28_923532	315	36	are	be	VBP
10_1101-2020_01_28_923532	315	37	at	at	IN
10_1101-2020_01_28_923532	315	38	most	most	RBS
10_1101-2020_01_28_923532	315	39	3	3	CD
10_1101-2020_01_28_923532	315	40	targets	target	NNS
10_1101-2020_01_28_923532	315	41	larger	large	JJR
10_1101-2020_01_28_923532	315	42	,	,	,
10_1101-2020_01_28_923532	315	43	and	and	CC
10_1101-2020_01_28_923532	315	44	in	in	IN
10_1101-2020_01_28_923532	315	45	most	most	JJS
10_1101-2020_01_28_923532	315	46	data	data	NN
10_1101-2020_01_28_923532	315	47	sets	set	NNS
10_1101-2020_01_28_923532	315	48	at	at	IN
10_1101-2020_01_28_923532	315	49	most	most	JJS
10_1101-2020_01_28_923532	315	50	1	1	CD
10_1101-2020_01_28_923532	315	51	target	target	NN
10_1101-2020_01_28_923532	315	52	receptor	receptor	NN
10_1101-2020_01_28_923532	315	53	larger	large	JJR
10_1101-2020_01_28_923532	315	54	than	than	IN
10_1101-2020_01_28_923532	315	55	the	the	DT
10_1101-2020_01_28_923532	315	56	optimal	optimal	JJ
10_1101-2020_01_28_923532	315	57	solutions	solution	NNS
10_1101-2020_01_28_923532	315	58	that	that	WDT
10_1101-2020_01_28_923532	315	59	would	would	MD
10_1101-2020_01_28_923532	315	60	have	have	VB
10_1101-2020_01_28_923532	315	61	been	be	VBN
10_1101-2020_01_28_923532	315	62	assigned	assign	VBN
10_1101-2020_01_28_923532	315	63	for	for	IN
10_1101-2020_01_28_923532	315	64	these	these	DT
10_1101-2020_01_28_923532	315	65	patients	patient	NNS
10_1101-2020_01_28_923532	315	66	based	base	VBN
10_1101-2020_01_28_923532	315	67	on	on	IN
10_1101-2020_01_28_923532	315	68	an	an	DT
10_1101-2020_01_28_923532	315	69	individual	individual	JJ
10_1101-2020_01_28_923532	315	70	-	-	HYPH
10_1101-2020_01_28_923532	315	71	centric	centric	NN
10_1101-2020_01_28_923532	315	72	policy	policy	NN
10_1101-2020_01_28_923532	315	73	(	(	-LRB-
10_1101-2020_01_28_923532	315	74	Figure	Figure	NNP
10_1101-2020_01_28_923532	315	75	6	6	CD
10_1101-2020_01_28_923532	315	76	,	,	,
10_1101-2020_01_28_923532	315	77	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	315	78	Materials	Materials	NNP
10_1101-2020_01_28_923532	315	79	10	10	CD
10_1101-2020_01_28_923532	315	80	)	)	-RRB-
10_1101-2020_01_28_923532	315	81	.	.	.
10_1101-2020_01_28_923532	316	1	This	this	DT
10_1101-2020_01_28_923532	316	2	suggests	suggest	VBZ
10_1101-2020_01_28_923532	316	3	that	that	IN
10_1101-2020_01_28_923532	316	4	the	the	DT
10_1101-2020_01_28_923532	316	5	concern	concern	NN
10_1101-2020_01_28_923532	316	6	that	that	IN
10_1101-2020_01_28_923532	316	7	the	the	DT
10_1101-2020_01_28_923532	316	8	personalized	personalized	JJ
10_1101-2020_01_28_923532	316	9	treatment	treatment	NN
10_1101-2020_01_28_923532	316	10	for	for	IN
10_1101-2020_01_28_923532	316	11	any	any	DT
10_1101-2020_01_28_923532	316	12	individual	individual	NN
10_1101-2020_01_28_923532	316	13	will	will	MD
10_1101-2020_01_28_923532	316	14	be	be	VB
10_1101-2020_01_28_923532	316	15	suboptimal	suboptimal	VBN
10_1101-2020_01_28_923532	316	16	solely	solely	RB
10_1101-2020_01_28_923532	316	17	because	because	IN
10_1101-2020_01_28_923532	316	18	that	that	DT
10_1101-2020_01_28_923532	316	19	individual	individual	NN
10_1101-2020_01_28_923532	316	20	happens	happen	VBZ
10_1101-2020_01_28_923532	316	21	to	to	TO
10_1101-2020_01_28_923532	316	22	have	have	VB
10_1101-2020_01_28_923532	316	23	registered	register	VBN
10_1101-2020_01_28_923532	316	24	for	for	IN
10_1101-2020_01_28_923532	316	25	a	a	DT
10_1101-2020_01_28_923532	316	26	cohort	cohort	NN
10_1101-2020_01_28_923532	316	27	trial	trial	NN
10_1101-2020_01_28_923532	316	28	appears	appear	VBZ
10_1101-2020_01_28_923532	316	29	to	to	TO
10_1101-2020_01_28_923532	316	30	be	be	VB
10_1101-2020_01_28_923532	316	31	tightly	tightly	RB
10_1101-2020_01_28_923532	316	32	bounded	bound	VBN
10_1101-2020_01_28_923532	316	33	.	.	.
10_1101-2020_01_28_923532	317	1	Like	like	IN
10_1101-2020_01_28_923532	317	2	the	the	DT
10_1101-2020_01_28_923532	317	3	study	study	NN
10_1101-2020_01_28_923532	317	4	of	of	IN
10_1101-2020_01_28_923532	317	5	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	317	6	et	et	NNP
10_1101-2020_01_28_923532	317	7	al.25	al.25	RB
10_1101-2020_01_28_923532	317	8	,	,	,
10_1101-2020_01_28_923532	317	9	our	-PRON-	PRP$
10_1101-2020_01_28_923532	317	10	study	study	NN
10_1101-2020_01_28_923532	317	11	is	be	VBZ
10_1101-2020_01_28_923532	317	12	a	a	DT
10_1101-2020_01_28_923532	317	13	conceptual	conceptual	JJ
10_1101-2020_01_28_923532	317	14	computational	computational	JJ
10_1101-2020_01_28_923532	317	15	investigation	investigation	NN
10_1101-2020_01_28_923532	317	16	.	.	.
10_1101-2020_01_28_923532	318	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	318	2	studied	study	VBD
10_1101-2020_01_28_923532	318	3	nine	nine	CD
10_1101-2020_01_28_923532	318	4	data	datum	NNS
10_1101-2020_01_28_923532	318	5	single	single	JJ
10_1101-2020_01_28_923532	318	6	-	-	HYPH
10_1101-2020_01_28_923532	318	7	cell	cell	NN
10_1101-2020_01_28_923532	318	8	expression	expression	NN
10_1101-2020_01_28_923532	318	9	data	data	NN
10_1101-2020_01_28_923532	318	10	sets	set	NNS
10_1101-2020_01_28_923532	318	11	for	for	IN
10_1101-2020_01_28_923532	318	12	the	the	DT
10_1101-2020_01_28_923532	318	13	first	first	JJ
10_1101-2020_01_28_923532	318	14	time	time	NN
10_1101-2020_01_28_923532	318	15	,	,	,
10_1101-2020_01_28_923532	318	16	but	but	CC
10_1101-2020_01_28_923532	318	17	it	-PRON-	PRP
10_1101-2020_01_28_923532	318	18	would	would	MD
10_1101-2020_01_28_923532	318	19	be	be	VB
10_1101-2020_01_28_923532	318	20	helpful	helpful	JJ
10_1101-2020_01_28_923532	318	21	to	to	IN
10_1101-2020_01_28_923532	318	22	105	105	CD
10_1101-2020_01_28_923532	318	23	and	and	CC
10_1101-2020_01_28_923532	318	24	is	be	VBZ
10_1101-2020_01_28_923532	318	25	also	also	RB
10_1101-2020_01_28_923532	318	26	made	make	VBN
10_1101-2020_01_28_923532	318	27	available	available	JJ
10_1101-2020_01_28_923532	318	28	for	for	IN
10_1101-2020_01_28_923532	318	29	use	use	NN
10_1101-2020_01_28_923532	318	30	under	under	IN
10_1101-2020_01_28_923532	318	31	a	a	DT
10_1101-2020_01_28_923532	318	32	CC0	CC0	NNP
10_1101-2020_01_28_923532	318	33	license	license	NN
10_1101-2020_01_28_923532	318	34	.	.	.
10_1101-2020_01_28_923532	319	1	(	(	-LRB-
10_1101-2020_01_28_923532	319	2	which	which	WDT
10_1101-2020_01_28_923532	319	3	was	be	VBD
10_1101-2020_01_28_923532	319	4	not	not	RB
10_1101-2020_01_28_923532	319	5	certified	certify	VBN
10_1101-2020_01_28_923532	319	6	by	by	IN
10_1101-2020_01_28_923532	319	7	peer	peer	NN
10_1101-2020_01_28_923532	319	8	review	review	NN
10_1101-2020_01_28_923532	319	9	)	)	-RRB-
10_1101-2020_01_28_923532	319	10	is	be	VBZ
10_1101-2020_01_28_923532	319	11	the	the	DT
10_1101-2020_01_28_923532	319	12	author	author	NN
10_1101-2020_01_28_923532	319	13	/	/	SYM
10_1101-2020_01_28_923532	319	14	funder	funder	NN
10_1101-2020_01_28_923532	319	15	.	.	.
10_1101-2020_01_28_923532	320	1	This	this	DT
10_1101-2020_01_28_923532	320	2	article	article	NN
10_1101-2020_01_28_923532	320	3	is	be	VBZ
10_1101-2020_01_28_923532	320	4	a	a	DT
10_1101-2020_01_28_923532	320	5	US	US	NNP
10_1101-2020_01_28_923532	320	6	Government	Government	NNP
10_1101-2020_01_28_923532	320	7	work	work	NN
10_1101-2020_01_28_923532	320	8	.	.	.
10_1101-2020_01_28_923532	321	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	321	2	is	be	VBZ
10_1101-2020_01_28_923532	321	3	not	not	RB
10_1101-2020_01_28_923532	321	4	subject	subject	JJ
10_1101-2020_01_28_923532	321	5	to	to	IN
10_1101-2020_01_28_923532	321	6	copyright	copyright	NN
10_1101-2020_01_28_923532	321	7	under	under	IN
10_1101-2020_01_28_923532	321	8	17	17	CD
10_1101-2020_01_28_923532	321	9	USC	usc	NN
10_1101-2020_01_28_923532	321	10	The	the	DT
10_1101-2020_01_28_923532	321	11	copyright	copyright	NN
10_1101-2020_01_28_923532	321	12	holder	holder	NN
10_1101-2020_01_28_923532	321	13	for	for	IN
10_1101-2020_01_28_923532	321	14	this	this	DT
10_1101-2020_01_28_923532	321	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	321	16	version	version	NN
10_1101-2020_01_28_923532	321	17	posted	post	VBD
10_1101-2020_01_28_923532	321	18	February	February	NNP
10_1101-2020_01_28_923532	321	19	12	12	CD
10_1101-2020_01_28_923532	321	20	,	,	,
10_1101-2020_01_28_923532	321	21	2021	2021	CD
10_1101-2020_01_28_923532	321	22	.	.	.
10_1101-2020_01_28_923532	321	23	;	;	:
10_1101-2020_01_28_923532	321	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	321	25	:	:	:
10_1101-2020_01_28_923532	321	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	321	27	preprint	preprint	NN
10_1101-2020_01_28_923532	321	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	321	29	26	26	CD
10_1101-2020_01_28_923532	321	30	analyze	analyze	VBP
10_1101-2020_01_28_923532	321	31	more	more	JJR
10_1101-2020_01_28_923532	321	32	and	and	CC
10_1101-2020_01_28_923532	321	33	larger	large	JJR
10_1101-2020_01_28_923532	321	34	data	data	NN
10_1101-2020_01_28_923532	321	35	sets	set	NNS
10_1101-2020_01_28_923532	321	36	in	in	IN
10_1101-2020_01_28_923532	321	37	the	the	DT
10_1101-2020_01_28_923532	321	38	future	future	NN
10_1101-2020_01_28_923532	321	39	.	.	.
10_1101-2020_01_28_923532	322	1	Even	even	RB
10_1101-2020_01_28_923532	322	2	among	among	IN
10_1101-2020_01_28_923532	322	3	four	four	CD
10_1101-2020_01_28_923532	322	4	data	data	NN
10_1101-2020_01_28_923532	322	5	sets	set	NNS
10_1101-2020_01_28_923532	322	6	of	of	IN
10_1101-2020_01_28_923532	322	7	the	the	DT
10_1101-2020_01_28_923532	322	8	same	same	JJ
10_1101-2020_01_28_923532	322	9	(	(	-LRB-
10_1101-2020_01_28_923532	322	10	brain	brain	NN
10_1101-2020_01_28_923532	322	11	)	)	-RRB-
10_1101-2020_01_28_923532	322	12	cancer	cancer	NN
10_1101-2020_01_28_923532	322	13	type	type	NN
10_1101-2020_01_28_923532	322	14	,	,	,
10_1101-2020_01_28_923532	322	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	322	16	observed	observe	VBD
10_1101-2020_01_28_923532	322	17	considerable	considerable	JJ
10_1101-2020_01_28_923532	322	18	variability	variability	NN
10_1101-2020_01_28_923532	322	19	in	in	IN
10_1101-2020_01_28_923532	322	20	CTS	CTS	NNP
10_1101-2020_01_28_923532	322	21	and	and	CC
10_1101-2020_01_28_923532	322	22	ITS	its	PRP$
10_1101-2020_01_28_923532	322	23	sizes	size	NNS
10_1101-2020_01_28_923532	322	24	.	.	.
10_1101-2020_01_28_923532	323	1	Since	since	IN
10_1101-2020_01_28_923532	323	2	our	-PRON-	PRP$
10_1101-2020_01_28_923532	323	3	approach	approach	NN
10_1101-2020_01_28_923532	323	4	is	be	VBZ
10_1101-2020_01_28_923532	323	5	general	general	JJ
10_1101-2020_01_28_923532	323	6	and	and	CC
10_1101-2020_01_28_923532	323	7	the	the	DT
10_1101-2020_01_28_923532	323	8	software	software	NN
10_1101-2020_01_28_923532	323	9	is	be	VBZ
10_1101-2020_01_28_923532	323	10	freely	freely	RB
10_1101-2020_01_28_923532	323	11	available	available	JJ
10_1101-2020_01_28_923532	323	12	as	as	IN
10_1101-2020_01_28_923532	323	13	source	source	NN
10_1101-2020_01_28_923532	323	14	code	code	NN
10_1101-2020_01_28_923532	323	15	,	,	,
10_1101-2020_01_28_923532	323	16	other	other	JJ
10_1101-2020_01_28_923532	323	17	researchers	researcher	NNS
10_1101-2020_01_28_923532	323	18	can	can	MD
10_1101-2020_01_28_923532	323	19	test	test	VB
10_1101-2020_01_28_923532	323	20	the	the	DT
10_1101-2020_01_28_923532	323	21	method	method	NN
10_1101-2020_01_28_923532	323	22	on	on	IN
10_1101-2020_01_28_923532	323	23	new	new	JJ
10_1101-2020_01_28_923532	323	24	data	data	NN
10_1101-2020_01_28_923532	323	25	sets	set	NNS
10_1101-2020_01_28_923532	323	26	or	or	CC
10_1101-2020_01_28_923532	323	27	add	add	VB
10_1101-2020_01_28_923532	323	28	new	new	JJ
10_1101-2020_01_28_923532	323	29	variables	variable	NNS
10_1101-2020_01_28_923532	323	30	,	,	,
10_1101-2020_01_28_923532	323	31	constraints	constraint	NNS
10_1101-2020_01_28_923532	323	32	,	,	,
10_1101-2020_01_28_923532	323	33	and	and	CC
10_1101-2020_01_28_923532	323	34	optimality	optimality	NN
10_1101-2020_01_28_923532	323	35	criteria	criterion	NNS
10_1101-2020_01_28_923532	323	36	.	.	.
10_1101-2020_01_28_923532	324	1	These	these	DT
10_1101-2020_01_28_923532	324	2	investigations	investigation	NNS
10_1101-2020_01_28_923532	324	3	may	may	MD
10_1101-2020_01_28_923532	324	4	of	of	IN
10_1101-2020_01_28_923532	324	5	course	course	NN
10_1101-2020_01_28_923532	324	6	lead	lead	VB
10_1101-2020_01_28_923532	324	7	other	other	JJ
10_1101-2020_01_28_923532	324	8	to	to	TO
10_1101-2020_01_28_923532	324	9	further	further	RB
10_1101-2020_01_28_923532	324	10	improve	improve	VB
10_1101-2020_01_28_923532	324	11	our	-PRON-	PRP$
10_1101-2020_01_28_923532	324	12	method	method	NN
10_1101-2020_01_28_923532	324	13	and	and	CC
10_1101-2020_01_28_923532	324	14	broaden	broaden	VB
10_1101-2020_01_28_923532	324	15	its	-PRON-	PRP$
10_1101-2020_01_28_923532	324	16	applicability	applicability	NN
10_1101-2020_01_28_923532	324	17	.	.	.
10_1101-2020_01_28_923532	325	1	In	in	IN
10_1101-2020_01_28_923532	325	2	future	future	JJ
10_1101-2020_01_28_923532	325	3	work	work	NN
10_1101-2020_01_28_923532	325	4	,	,	,
10_1101-2020_01_28_923532	325	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	325	6	plan	plan	VBP
10_1101-2020_01_28_923532	325	7	to	to	TO
10_1101-2020_01_28_923532	325	8	apply	apply	VB
10_1101-2020_01_28_923532	325	9	our	-PRON-	PRP$
10_1101-2020_01_28_923532	325	10	approach	approach	NN
10_1101-2020_01_28_923532	325	11	to	to	TO
10_1101-2020_01_28_923532	325	12	study	study	VB
10_1101-2020_01_28_923532	325	13	ways	way	NNS
10_1101-2020_01_28_923532	325	14	for	for	IN
10_1101-2020_01_28_923532	325	15	selectively	selectively	RB
10_1101-2020_01_28_923532	325	16	killing	kill	VBG
10_1101-2020_01_28_923532	325	17	specific	specific	JJ
10_1101-2020_01_28_923532	325	18	populations	population	NNS
10_1101-2020_01_28_923532	325	19	of	of	IN
10_1101-2020_01_28_923532	325	20	immune	immune	JJ
10_1101-2020_01_28_923532	325	21	cells	cell	NNS
10_1101-2020_01_28_923532	325	22	,	,	,
10_1101-2020_01_28_923532	325	23	such	such	JJ
10_1101-2020_01_28_923532	325	24	as	as	IN
10_1101-2020_01_28_923532	325	25	myeloid	myeloid	JJ
10_1101-2020_01_28_923532	325	26	-	-	HYPH
10_1101-2020_01_28_923532	325	27	derived	derive	VBN
10_1101-2020_01_28_923532	325	28	suppressor	suppressor	NN
10_1101-2020_01_28_923532	325	29	cells	cell	NNS
10_1101-2020_01_28_923532	325	30	,	,	,
10_1101-2020_01_28_923532	325	31	because	because	IN
10_1101-2020_01_28_923532	325	32	they	-PRON-	PRP
10_1101-2020_01_28_923532	325	33	inhibit	inhibit	VBP
10_1101-2020_01_28_923532	325	34	tumor	tumor	NN
10_1101-2020_01_28_923532	325	35	killing	killing	NN
10_1101-2020_01_28_923532	325	36	,	,	,
10_1101-2020_01_28_923532	325	37	while	while	IN
10_1101-2020_01_28_923532	325	38	sparing	spare	VBG
10_1101-2020_01_28_923532	325	39	most	most	JJS
10_1101-2020_01_28_923532	325	40	other	other	JJ
10_1101-2020_01_28_923532	325	41	non	non	JJ
10_1101-2020_01_28_923532	325	42	-	-	JJ
10_1101-2020_01_28_923532	325	43	cancer	cancer	JJ
10_1101-2020_01_28_923532	325	44	cells	cell	NNS
10_1101-2020_01_28_923532	325	45	.	.	.
10_1101-2020_01_28_923532	326	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	326	2	compared	compare	VBD
10_1101-2020_01_28_923532	326	3	gene	gene	NN
10_1101-2020_01_28_923532	326	4	expression	expression	NN
10_1101-2020_01_28_923532	326	5	levels	level	NNS
10_1101-2020_01_28_923532	326	6	between	between	IN
10_1101-2020_01_28_923532	326	7	non	non	JJ
10_1101-2020_01_28_923532	326	8	-	-	JJ
10_1101-2020_01_28_923532	326	9	cancer	cancer	JJ
10_1101-2020_01_28_923532	326	10	cells	cell	NNS
10_1101-2020_01_28_923532	326	11	and	and	CC
10_1101-2020_01_28_923532	326	12	cancer	cancer	NN
10_1101-2020_01_28_923532	326	13	cells	cell	NNS
10_1101-2020_01_28_923532	326	14	sampled	sample	VBN
10_1101-2020_01_28_923532	326	15	from	from	IN
10_1101-2020_01_28_923532	326	16	the	the	DT
10_1101-2020_01_28_923532	326	17	same	same	JJ
10_1101-2020_01_28_923532	326	18	patient	patient	NN
10_1101-2020_01_28_923532	326	19	,	,	,
10_1101-2020_01_28_923532	326	20	which	which	WDT
10_1101-2020_01_28_923532	326	21	avoids	avoid	VBZ
10_1101-2020_01_28_923532	326	22	inter	inter	JJ
10_1101-2020_01_28_923532	326	23	-	-	JJ
10_1101-2020_01_28_923532	326	24	patient	patient	JJ
10_1101-2020_01_28_923532	326	25	expression	expression	NN
10_1101-2020_01_28_923532	326	26	variability53	variability53	NN
10_1101-2020_01_28_923532	326	27	.	.	.
10_1101-2020_01_28_923532	327	1	However	however	RB
10_1101-2020_01_28_923532	327	2	,	,	,
10_1101-2020_01_28_923532	327	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	327	4	did	do	VBD
10_1101-2020_01_28_923532	327	5	little	little	JJ
10_1101-2020_01_28_923532	327	6	to	to	TO
10_1101-2020_01_28_923532	327	7	account	account	VB
10_1101-2020_01_28_923532	327	8	for	for	IN
10_1101-2020_01_28_923532	327	9	“	"	``
10_1101-2020_01_28_923532	327	10	expression	expression	NN
10_1101-2020_01_28_923532	327	11	dropout	dropout	NN
10_1101-2020_01_28_923532	327	12	”	"	''
10_1101-2020_01_28_923532	327	13	beyond	beyond	IN
10_1101-2020_01_28_923532	327	14	the	the	DT
10_1101-2020_01_28_923532	327	15	normalization	normalization	NN
10_1101-2020_01_28_923532	327	16	performed	perform	VBN
10_1101-2020_01_28_923532	327	17	by	by	IN
10_1101-2020_01_28_923532	327	18	the	the	DT
10_1101-2020_01_28_923532	327	19	providers	provider	NNS
10_1101-2020_01_28_923532	327	20	of	of	IN
10_1101-2020_01_28_923532	327	21	the	the	DT
10_1101-2020_01_28_923532	327	22	data	data	NN
10_1101-2020_01_28_923532	327	23	sets	set	NNS
10_1101-2020_01_28_923532	327	24	,	,	,
10_1101-2020_01_28_923532	327	25	aiming	aim	VBG
10_1101-2020_01_28_923532	327	26	to	to	TO
10_1101-2020_01_28_923532	327	27	preserve	preserve	VB
10_1101-2020_01_28_923532	327	28	the	the	DT
10_1101-2020_01_28_923532	327	29	public	public	JJ
10_1101-2020_01_28_923532	327	30	data	datum	NNS
10_1101-2020_01_28_923532	327	31	as	as	IN
10_1101-2020_01_28_923532	327	32	it	-PRON-	PRP
10_1101-2020_01_28_923532	327	33	was	be	VBD
10_1101-2020_01_28_923532	327	34	submitted	submit	VBN
10_1101-2020_01_28_923532	327	35	to	to	IN
10_1101-2020_01_28_923532	327	36	GEO	GEO	NNP
10_1101-2020_01_28_923532	327	37	or	or	CC
10_1101-2020_01_28_923532	327	38	Array	Array	NNP
10_1101-2020_01_28_923532	327	39	Express	Express	NNP
10_1101-2020_01_28_923532	327	40	.	.	.
10_1101-2020_01_28_923532	328	1	To	to	TO
10_1101-2020_01_28_923532	328	2	achieve	achieve	VB
10_1101-2020_01_28_923532	328	3	some	some	DT
10_1101-2020_01_28_923532	328	4	uniformity	uniformity	NN
10_1101-2020_01_28_923532	328	5	and	and	CC
10_1101-2020_01_28_923532	328	6	also	also	RB
10_1101-2020_01_28_923532	328	7	to	to	TO
10_1101-2020_01_28_923532	328	8	take	take	VB
10_1101-2020_01_28_923532	328	9	as	as	RB
10_1101-2020_01_28_923532	328	10	cautious	cautious	JJ
10_1101-2020_01_28_923532	328	11	an	an	DT
10_1101-2020_01_28_923532	328	12	approach	approach	NN
10_1101-2020_01_28_923532	328	13	as	as	IN
10_1101-2020_01_28_923532	328	14	possible	possible	JJ
10_1101-2020_01_28_923532	328	15	,	,	,
10_1101-2020_01_28_923532	328	16	we	-PRON-	PRP
10_1101-2020_01_28_923532	328	17	added	add	VBD
10_1101-2020_01_28_923532	328	18	a	a	DT
10_1101-2020_01_28_923532	328	19	step	step	NN
10_1101-2020_01_28_923532	328	20	to	to	TO
10_1101-2020_01_28_923532	328	21	filter	filter	VB
10_1101-2020_01_28_923532	328	22	low	low	JJ
10_1101-2020_01_28_923532	328	23	expressing	express	VBG
10_1101-2020_01_28_923532	328	24	cells	cell	NNS
10_1101-2020_01_28_923532	328	25	because	because	IN
10_1101-2020_01_28_923532	328	26	some	some	DT
10_1101-2020_01_28_923532	328	27	data	data	NN
10_1101-2020_01_28_923532	328	28	sets	set	NNS
10_1101-2020_01_28_923532	328	29	had	have	VBD
10_1101-2020_01_28_923532	328	30	already	already	RB
10_1101-2020_01_28_923532	328	31	been	be	VBN
10_1101-2020_01_28_923532	328	32	filtered	filter	VBN
10_1101-2020_01_28_923532	328	33	in	in	IN
10_1101-2020_01_28_923532	328	34	this	this	DT
10_1101-2020_01_28_923532	328	35	way	way	NN
10_1101-2020_01_28_923532	328	36	.	.	.
10_1101-2020_01_28_923532	329	1	One	one	PRP
10_1101-2020_01_28_923532	329	2	could	could	MD
10_1101-2020_01_28_923532	329	3	instead	instead	RB
10_1101-2020_01_28_923532	329	4	apply	apply	VB
10_1101-2020_01_28_923532	329	5	imputation	imputation	NN
10_1101-2020_01_28_923532	329	6	methods	method	NNS
10_1101-2020_01_28_923532	329	7	such	such	JJ
10_1101-2020_01_28_923532	329	8	as	as	IN
10_1101-2020_01_28_923532	329	9	MAGIC54	MAGIC54	NNP
10_1101-2020_01_28_923532	329	10	or	or	CC
10_1101-2020_01_28_923532	329	11	scImpute55	scImpute55	NNP
10_1101-2020_01_28_923532	329	12	to	to	TO
10_1101-2020_01_28_923532	329	13	infer	infer	VB
10_1101-2020_01_28_923532	329	14	denser	denser	NN
10_1101-2020_01_28_923532	329	15	gene	gene	NNP
10_1101-2020_01_28_923532	329	16	expression	expression	NN
10_1101-2020_01_28_923532	329	17	matrices	matrix	NNS
10_1101-2020_01_28_923532	329	18	and	and	CC
10_1101-2020_01_28_923532	329	19	then	then	RB
10_1101-2020_01_28_923532	329	20	apply	apply	VB
10_1101-2020_01_28_923532	329	21	our	-PRON-	PRP$
10_1101-2020_01_28_923532	329	22	method	method	NN
10_1101-2020_01_28_923532	329	23	to	to	IN
10_1101-2020_01_28_923532	329	24	the	the	DT
10_1101-2020_01_28_923532	329	25	adjusted	adjust	VBN
10_1101-2020_01_28_923532	329	26	input	input	NN
10_1101-2020_01_28_923532	329	27	data	datum	NNS
10_1101-2020_01_28_923532	329	28	.	.	.
10_1101-2020_01_28_923532	330	1	Therefore	therefore	RB
10_1101-2020_01_28_923532	330	2	,	,	,
10_1101-2020_01_28_923532	330	3	our	-PRON-	PRP$
10_1101-2020_01_28_923532	330	4	results	result	NNS
10_1101-2020_01_28_923532	330	5	about	about	IN
10_1101-2020_01_28_923532	330	6	the	the	DT
10_1101-2020_01_28_923532	330	7	sizes	size	NNS
10_1101-2020_01_28_923532	330	8	of	of	IN
10_1101-2020_01_28_923532	330	9	optimal	optimal	JJ
10_1101-2020_01_28_923532	330	10	ITS	its	PRP$
10_1101-2020_01_28_923532	330	11	should	should	MD
10_1101-2020_01_28_923532	330	12	be	be	VB
10_1101-2020_01_28_923532	330	13	viewed	view	VBN
10_1101-2020_01_28_923532	330	14	as	as	IN
10_1101-2020_01_28_923532	330	15	estimated	estimate	VBN
10_1101-2020_01_28_923532	330	16	upper	upper	JJ
10_1101-2020_01_28_923532	330	17	bounds	bound	NNS
10_1101-2020_01_28_923532	330	18	that	that	WDT
10_1101-2020_01_28_923532	330	19	are	be	VBP
10_1101-2020_01_28_923532	330	20	likely	likely	JJ
10_1101-2020_01_28_923532	330	21	to	to	TO
10_1101-2020_01_28_923532	330	22	decrease	decrease	VB
10_1101-2020_01_28_923532	330	23	if	if	IN
10_1101-2020_01_28_923532	330	24	the	the	DT
10_1101-2020_01_28_923532	330	25	dropout	dropout	NN
10_1101-2020_01_28_923532	330	26	rate	rate	NN
10_1101-2020_01_28_923532	330	27	decreases	decrease	VBZ
10_1101-2020_01_28_923532	330	28	or	or	CC
10_1101-2020_01_28_923532	330	29	if	if	IN
10_1101-2020_01_28_923532	330	30	cells	cell	NNS
10_1101-2020_01_28_923532	330	31	expressing	express	VBG
10_1101-2020_01_28_923532	330	32	few	few	JJ
10_1101-2020_01_28_923532	330	33	genes	gene	NNS
10_1101-2020_01_28_923532	330	34	are	be	VBP
10_1101-2020_01_28_923532	330	35	eliminated	eliminate	VBN
10_1101-2020_01_28_923532	330	36	from	from	IN
10_1101-2020_01_28_923532	330	37	the	the	DT
10_1101-2020_01_28_923532	330	38	analysis	analysis	NN
10_1101-2020_01_28_923532	330	39	more	more	RBR
10_1101-2020_01_28_923532	330	40	stringently	stringently	RB
10_1101-2020_01_28_923532	330	41	.	.	.
10_1101-2020_01_28_923532	331	1	Another	another	DT
10_1101-2020_01_28_923532	331	2	limitation	limitation	NN
10_1101-2020_01_28_923532	331	3	of	of	IN
10_1101-2020_01_28_923532	331	4	our	-PRON-	PRP$
10_1101-2020_01_28_923532	331	5	method	method	NN
10_1101-2020_01_28_923532	331	6	is	be	VBZ
10_1101-2020_01_28_923532	331	7	that	that	IN
10_1101-2020_01_28_923532	331	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	331	9	viewed	view	VBD
10_1101-2020_01_28_923532	331	10	the	the	DT
10_1101-2020_01_28_923532	331	11	measured	measure	VBN
10_1101-2020_01_28_923532	331	12	gene	gene	NN
10_1101-2020_01_28_923532	331	13	expression	expression	NN
10_1101-2020_01_28_923532	331	14	as	as	IN
10_1101-2020_01_28_923532	331	15	being	be	VBG
10_1101-2020_01_28_923532	331	16	valid	valid	JJ
10_1101-2020_01_28_923532	331	17	over	over	IN
10_1101-2020_01_28_923532	331	18	all	all	DT
10_1101-2020_01_28_923532	331	19	time	time	NN
10_1101-2020_01_28_923532	331	20	,	,	,
10_1101-2020_01_28_923532	331	21	even	even	RB
10_1101-2020_01_28_923532	331	22	though	though	IN
10_1101-2020_01_28_923532	331	23	gene	gene	NN
10_1101-2020_01_28_923532	331	24	expression	expression	NN
10_1101-2020_01_28_923532	331	25	is	be	VBZ
10_1101-2020_01_28_923532	331	26	known	know	VBN
10_1101-2020_01_28_923532	331	27	to	to	TO
10_1101-2020_01_28_923532	331	28	be	be	VB
10_1101-2020_01_28_923532	331	29	a	a	DT
10_1101-2020_01_28_923532	331	30	stochastic	stochastic	JJ
10_1101-2020_01_28_923532	331	31	process56	process56	NN
10_1101-2020_01_28_923532	331	32	.	.	.
10_1101-2020_01_28_923532	332	1	In	in	IN
10_1101-2020_01_28_923532	332	2	the	the	DT
10_1101-2020_01_28_923532	332	3	future	future	NN
10_1101-2020_01_28_923532	332	4	,	,	,
10_1101-2020_01_28_923532	332	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	332	6	would	would	MD
10_1101-2020_01_28_923532	332	7	like	like	VB
10_1101-2020_01_28_923532	332	8	to	to	TO
10_1101-2020_01_28_923532	332	9	extend	extend	VB
10_1101-2020_01_28_923532	332	10	our	-PRON-	PRP$
10_1101-2020_01_28_923532	332	11	approach	approach	NN
10_1101-2020_01_28_923532	332	12	to	to	TO
10_1101-2020_01_28_923532	332	13	use	use	VB
10_1101-2020_01_28_923532	332	14	the	the	DT
10_1101-2020_01_28_923532	332	15	single	single	JJ
10_1101-2020_01_28_923532	332	16	-	-	HYPH
10_1101-2020_01_28_923532	332	17	cell	cell	NN
10_1101-2020_01_28_923532	332	18	data	datum	NNS
10_1101-2020_01_28_923532	332	19	to	to	TO
10_1101-2020_01_28_923532	332	20	infer	infer	VB
10_1101-2020_01_28_923532	332	21	how	how	WRB
10_1101-2020_01_28_923532	332	22	stochastic	stochastic	JJ
10_1101-2020_01_28_923532	332	23	is	be	VBZ
10_1101-2020_01_28_923532	332	24	the	the	DT
10_1101-2020_01_28_923532	332	25	expression	expression	NN
10_1101-2020_01_28_923532	332	26	of	of	IN
10_1101-2020_01_28_923532	332	27	each	each	DT
10_1101-2020_01_28_923532	332	28	gene57	gene57	NN
10_1101-2020_01_28_923532	332	29	and	and	CC
10_1101-2020_01_28_923532	332	30	to	to	TO
10_1101-2020_01_28_923532	332	31	prefer	prefer	VB
10_1101-2020_01_28_923532	332	32	targets	target	NNS
10_1101-2020_01_28_923532	332	33	whose	whose	WP$
10_1101-2020_01_28_923532	332	34	expression	expression	NN
10_1101-2020_01_28_923532	332	35	is	be	VBZ
10_1101-2020_01_28_923532	332	36	more	more	RBR
10_1101-2020_01_28_923532	332	37	stable	stable	JJ
10_1101-2020_01_28_923532	332	38	.	.	.
10_1101-2020_01_28_923532	333	1	Even	even	RB
10_1101-2020_01_28_923532	333	2	though	though	IN
10_1101-2020_01_28_923532	333	3	the	the	DT
10_1101-2020_01_28_923532	333	4	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	333	5	optimization	optimization	NN
10_1101-2020_01_28_923532	333	6	problems	problem	NNS
10_1101-2020_01_28_923532	333	7	solved	solve	VBN
10_1101-2020_01_28_923532	333	8	here	here	RB
10_1101-2020_01_28_923532	333	9	are	be	VBP
10_1101-2020_01_28_923532	333	10	in	in	IN
10_1101-2020_01_28_923532	333	11	the	the	DT
10_1101-2020_01_28_923532	333	12	worst	bad	JJS
10_1101-2020_01_28_923532	333	13	-	-	HYPH
10_1101-2020_01_28_923532	333	14	case	case	NN
10_1101-2020_01_28_923532	333	15	exponentially	exponentially	RB
10_1101-2020_01_28_923532	333	16	hard	hard	RB
10_1101-2020_01_28_923532	333	17	(	(	-LRB-
10_1101-2020_01_28_923532	333	18	NP	NP	NNP
10_1101-2020_01_28_923532	333	19	-	-	HYPH
10_1101-2020_01_28_923532	333	20	complete36	complete36	RB
10_1101-2020_01_28_923532	333	21	in	in	IN
10_1101-2020_01_28_923532	333	22	computer	computer	NN
10_1101-2020_01_28_923532	333	23	science	science	NN
10_1101-2020_01_28_923532	333	24	terminology	terminology	NN
10_1101-2020_01_28_923532	333	25	)	)	-RRB-
10_1101-2020_01_28_923532	333	26	,	,	,
10_1101-2020_01_28_923532	333	27	the	the	DT
10_1101-2020_01_28_923532	333	28	actual	actual	JJ
10_1101-2020_01_28_923532	333	29	instances	instance	NNS
10_1101-2020_01_28_923532	333	30	that	that	WDT
10_1101-2020_01_28_923532	333	31	arise	arise	VBP
10_1101-2020_01_28_923532	333	32	from	from	IN
10_1101-2020_01_28_923532	333	33	the	the	DT
10_1101-2020_01_28_923532	333	34	single	single	JJ
10_1101-2020_01_28_923532	333	35	-	-	HYPH
10_1101-2020_01_28_923532	333	36	cell	cell	NN
10_1101-2020_01_28_923532	333	37	data	datum	NNS
10_1101-2020_01_28_923532	333	38	could	could	MD
10_1101-2020_01_28_923532	333	39	be	be	VB
10_1101-2020_01_28_923532	333	40	either	either	CC
10_1101-2020_01_28_923532	333	41	formally	formally	RB
10_1101-2020_01_28_923532	333	42	solved	solve	VBN
10_1101-2020_01_28_923532	333	43	to	to	IN
10_1101-2020_01_28_923532	333	44	optimality	optimality	NN
10_1101-2020_01_28_923532	333	45	or	or	CC
10_1101-2020_01_28_923532	333	46	shown	show	VBN
10_1101-2020_01_28_923532	333	47	to	to	TO
10_1101-2020_01_28_923532	333	48	be	be	VB
10_1101-2020_01_28_923532	333	49	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	333	50	with	with	IN
10_1101-2020_01_28_923532	333	51	modern	modern	JJ
10_1101-2020_01_28_923532	333	52	optimization	optimization	NN
10_1101-2020_01_28_923532	333	53	software	software	NN
10_1101-2020_01_28_923532	333	54	.	.	.
10_1101-2020_01_28_923532	334	1	Of	of	IN
10_1101-2020_01_28_923532	334	2	note	note	NN
10_1101-2020_01_28_923532	334	3	,	,	,
10_1101-2020_01_28_923532	334	4	Delaney	Delaney	NNP
10_1101-2020_01_28_923532	334	5	et	et	FW
10_1101-2020_01_28_923532	334	6	al	al	NNP
10_1101-2020_01_28_923532	334	7	.	.	NNP
10_1101-2020_01_28_923532	334	8	,	,	,
10_1101-2020_01_28_923532	334	9	have	have	VBP
10_1101-2020_01_28_923532	334	10	recently	recently	RB
10_1101-2020_01_28_923532	334	11	formalized	formalize	VBN
10_1101-2020_01_28_923532	334	12	a	a	DT
10_1101-2020_01_28_923532	334	13	related	related	JJ
10_1101-2020_01_28_923532	334	14	optimization	optimization	NN
10_1101-2020_01_28_923532	334	15	problem	problem	NN
10_1101-2020_01_28_923532	334	16	in	in	IN
10_1101-2020_01_28_923532	334	17	analysis	analysis	NN
10_1101-2020_01_28_923532	334	18	of	of	IN
10_1101-2020_01_28_923532	334	19	single	single	JJ
10_1101-2020_01_28_923532	334	20	-	-	HYPH
10_1101-2020_01_28_923532	334	21	cell	cell	NN
10_1101-2020_01_28_923532	334	22	clustered	cluster	VBN
10_1101-2020_01_28_923532	334	23	data	datum	NNS
10_1101-2020_01_28_923532	334	24	for	for	IN
10_1101-2020_01_28_923532	334	25	immunology38	immunology38	NN
10_1101-2020_01_28_923532	334	26	.	.	.
10_1101-2020_01_28_923532	335	1	Their	-PRON-	PRP$
10_1101-2020_01_28_923532	335	2	optimization	optimization	NN
10_1101-2020_01_28_923532	335	3	problem	problem	NN
10_1101-2020_01_28_923532	335	4	is	be	VBZ
10_1101-2020_01_28_923532	335	5	also	also	RB
10_1101-2020_01_28_923532	335	6	NP	NP	NNP
10_1101-2020_01_28_923532	335	7	-	-	HYPH
10_1101-2020_01_28_923532	335	8	complete	complete	JJ
10_1101-2020_01_28_923532	335	9	in	in	IN
10_1101-2020_01_28_923532	335	10	the	the	DT
10_1101-2020_01_28_923532	335	11	worst	bad	JJS
10_1101-2020_01_28_923532	335	12	case	case	NN
10_1101-2020_01_28_923532	335	13	and	and	CC
10_1101-2020_01_28_923532	335	14	they	-PRON-	PRP
10_1101-2020_01_28_923532	335	15	could	could	MD
10_1101-2020_01_28_923532	335	16	solve	solve	VB
10_1101-2020_01_28_923532	335	17	sets	set	NNS
10_1101-2020_01_28_923532	335	18	of	of	IN
10_1101-2020_01_28_923532	335	19	up	up	IN
10_1101-2020_01_28_923532	335	20	to	to	TO
10_1101-2020_01_28_923532	335	21	size	size	VB
10_1101-2020_01_28_923532	335	22	four	four	CD
10_1101-2020_01_28_923532	335	23	using	use	VBG
10_1101-2020_01_28_923532	335	24	heuristic	heuristic	JJ
10_1101-2020_01_28_923532	335	25	methods38	methods38	NN
10_1101-2020_01_28_923532	335	26	.	.	.
10_1101-2020_01_28_923532	336	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	336	2	have	have	VBP
10_1101-2020_01_28_923532	336	3	shown	show	VBN
10_1101-2020_01_28_923532	336	4	that	that	IN
10_1101-2020_01_28_923532	336	5	the	the	DT
10_1101-2020_01_28_923532	336	6	optimal	optimal	JJ
10_1101-2020_01_28_923532	336	7	ILP	ILP	NNP
10_1101-2020_01_28_923532	336	8	solutions	solution	NNS
10_1101-2020_01_28_923532	336	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	336	10	obtained	obtain	VBD
10_1101-2020_01_28_923532	336	11	105	105	CD
10_1101-2020_01_28_923532	336	12	and	and	CC
10_1101-2020_01_28_923532	336	13	is	be	VBZ
10_1101-2020_01_28_923532	336	14	also	also	RB
10_1101-2020_01_28_923532	336	15	made	make	VBN
10_1101-2020_01_28_923532	336	16	available	available	JJ
10_1101-2020_01_28_923532	336	17	for	for	IN
10_1101-2020_01_28_923532	336	18	use	use	NN
10_1101-2020_01_28_923532	336	19	under	under	IN
10_1101-2020_01_28_923532	336	20	a	a	DT
10_1101-2020_01_28_923532	336	21	CC0	CC0	NNP
10_1101-2020_01_28_923532	336	22	license	license	NN
10_1101-2020_01_28_923532	336	23	.	.	.
10_1101-2020_01_28_923532	337	1	(	(	-LRB-
10_1101-2020_01_28_923532	337	2	which	which	WDT
10_1101-2020_01_28_923532	337	3	was	be	VBD
10_1101-2020_01_28_923532	337	4	not	not	RB
10_1101-2020_01_28_923532	337	5	certified	certify	VBN
10_1101-2020_01_28_923532	337	6	by	by	IN
10_1101-2020_01_28_923532	337	7	peer	peer	NN
10_1101-2020_01_28_923532	337	8	review	review	NN
10_1101-2020_01_28_923532	337	9	)	)	-RRB-
10_1101-2020_01_28_923532	337	10	is	be	VBZ
10_1101-2020_01_28_923532	337	11	the	the	DT
10_1101-2020_01_28_923532	337	12	author	author	NN
10_1101-2020_01_28_923532	337	13	/	/	SYM
10_1101-2020_01_28_923532	337	14	funder	funder	NN
10_1101-2020_01_28_923532	337	15	.	.	.
10_1101-2020_01_28_923532	338	1	This	this	DT
10_1101-2020_01_28_923532	338	2	article	article	NN
10_1101-2020_01_28_923532	338	3	is	be	VBZ
10_1101-2020_01_28_923532	338	4	a	a	DT
10_1101-2020_01_28_923532	338	5	US	US	NNP
10_1101-2020_01_28_923532	338	6	Government	Government	NNP
10_1101-2020_01_28_923532	338	7	work	work	NN
10_1101-2020_01_28_923532	338	8	.	.	.
10_1101-2020_01_28_923532	339	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	339	2	is	be	VBZ
10_1101-2020_01_28_923532	339	3	not	not	RB
10_1101-2020_01_28_923532	339	4	subject	subject	JJ
10_1101-2020_01_28_923532	339	5	to	to	IN
10_1101-2020_01_28_923532	339	6	copyright	copyright	NN
10_1101-2020_01_28_923532	339	7	under	under	IN
10_1101-2020_01_28_923532	339	8	17	17	CD
10_1101-2020_01_28_923532	339	9	USC	usc	NN
10_1101-2020_01_28_923532	339	10	The	the	DT
10_1101-2020_01_28_923532	339	11	copyright	copyright	NN
10_1101-2020_01_28_923532	339	12	holder	holder	NN
10_1101-2020_01_28_923532	339	13	for	for	IN
10_1101-2020_01_28_923532	339	14	this	this	DT
10_1101-2020_01_28_923532	339	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	339	16	version	version	NN
10_1101-2020_01_28_923532	339	17	posted	post	VBD
10_1101-2020_01_28_923532	339	18	February	February	NNP
10_1101-2020_01_28_923532	339	19	12	12	CD
10_1101-2020_01_28_923532	339	20	,	,	,
10_1101-2020_01_28_923532	339	21	2021	2021	CD
10_1101-2020_01_28_923532	339	22	.	.	.
10_1101-2020_01_28_923532	339	23	;	;	:
10_1101-2020_01_28_923532	339	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	339	25	:	:	:
10_1101-2020_01_28_923532	339	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	339	27	preprint	preprint	NN
10_1101-2020_01_28_923532	339	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	339	29	27	27	CD
10_1101-2020_01_28_923532	339	30	are	be	VBP
10_1101-2020_01_28_923532	339	31	often	often	RB
10_1101-2020_01_28_923532	339	32	substantially	substantially	RB
10_1101-2020_01_28_923532	339	33	smaller	small	JJR
10_1101-2020_01_28_923532	339	34	than	than	IN
10_1101-2020_01_28_923532	339	35	solutions	solution	NNS
10_1101-2020_01_28_923532	339	36	obtained	obtain	VBN
10_1101-2020_01_28_923532	339	37	via	via	IN
10_1101-2020_01_28_923532	339	38	a	a	DT
10_1101-2020_01_28_923532	339	39	greedy	greedy	JJ
10_1101-2020_01_28_923532	339	40	heuristic	heuristic	JJ
10_1101-2020_01_28_923532	339	41	(	(	-LRB-
10_1101-2020_01_28_923532	339	42	Figure	figure	NN
10_1101-2020_01_28_923532	339	43	4	4	CD
10_1101-2020_01_28_923532	339	44	,	,	,
10_1101-2020_01_28_923532	339	45	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	339	46	Materials	Materials	NNP
10_1101-2020_01_28_923532	339	47	8	8	CD
10_1101-2020_01_28_923532	339	48	including	include	VBG
10_1101-2020_01_28_923532	339	49	Table	Table	NNP
10_1101-2020_01_28_923532	339	50	S2	S2	NNP
10_1101-2020_01_28_923532	339	51	)	)	-RRB-
10_1101-2020_01_28_923532	339	52	.	.	.
10_1101-2020_01_28_923532	340	1	On	on	IN
10_1101-2020_01_28_923532	340	2	the	the	DT
10_1101-2020_01_28_923532	340	3	cautionary	cautionary	JJ
10_1101-2020_01_28_923532	340	4	side	side	NN
10_1101-2020_01_28_923532	340	5	,	,	,
10_1101-2020_01_28_923532	340	6	experiments	experiment	NNS
10_1101-2020_01_28_923532	340	7	with	with	IN
10_1101-2020_01_28_923532	340	8	target	target	NN
10_1101-2020_01_28_923532	340	9	gene	gene	NN
10_1101-2020_01_28_923532	340	10	sets	set	NNS
10_1101-2020_01_28_923532	340	11	that	that	WDT
10_1101-2020_01_28_923532	340	12	were	be	VBD
10_1101-2020_01_28_923532	340	13	further	further	RB
10_1101-2020_01_28_923532	340	14	filtered	filter	VBN
10_1101-2020_01_28_923532	340	15	by	by	IN
10_1101-2020_01_28_923532	340	16	low	low	JJ
10_1101-2020_01_28_923532	340	17	expression	expression	NN
10_1101-2020_01_28_923532	340	18	in	in	IN
10_1101-2020_01_28_923532	340	19	normal	normal	JJ
10_1101-2020_01_28_923532	340	20	tissues	tissue	NNS
10_1101-2020_01_28_923532	340	21	showed	show	VBD
10_1101-2020_01_28_923532	340	22	that	that	IN
10_1101-2020_01_28_923532	340	23	the	the	DT
10_1101-2020_01_28_923532	340	24	individual	individual	JJ
10_1101-2020_01_28_923532	340	25	target	target	NN
10_1101-2020_01_28_923532	340	26	set	set	VBN
10_1101-2020_01_28_923532	340	27	problem	problem	NN
10_1101-2020_01_28_923532	340	28	can	can	MD
10_1101-2020_01_28_923532	340	29	become	become	VB
10_1101-2020_01_28_923532	340	30	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	340	31	in	in	IN
10_1101-2020_01_28_923532	340	32	many	many	JJ
10_1101-2020_01_28_923532	340	33	instances	instance	NNS
10_1101-2020_01_28_923532	340	34	.	.	.
10_1101-2020_01_28_923532	341	1	Even	even	RB
10_1101-2020_01_28_923532	341	2	when	when	WRB
10_1101-2020_01_28_923532	341	3	the	the	DT
10_1101-2020_01_28_923532	341	4	instance	instance	NN
10_1101-2020_01_28_923532	341	5	remained	remain	VBD
10_1101-2020_01_28_923532	341	6	feasible	feasible	JJ
10_1101-2020_01_28_923532	341	7	,	,	,
10_1101-2020_01_28_923532	341	8	optimal	optimal	JJ
10_1101-2020_01_28_923532	341	9	cohort	cohort	NN
10_1101-2020_01_28_923532	341	10	treatment	treatment	NN
10_1101-2020_01_28_923532	341	11	set	set	NN
10_1101-2020_01_28_923532	341	12	sizes	size	NNS
10_1101-2020_01_28_923532	341	13	increased	increase	VBD
10_1101-2020_01_28_923532	341	14	rapidly	rapidly	RB
10_1101-2020_01_28_923532	341	15	as	as	IN
10_1101-2020_01_28_923532	341	16	the	the	DT
10_1101-2020_01_28_923532	341	17	expression	expression	NN
10_1101-2020_01_28_923532	341	18	levels	level	NNS
10_1101-2020_01_28_923532	341	19	allowed	allow	VBN
10_1101-2020_01_28_923532	341	20	decreased	decreased	JJ
10_1101-2020_01_28_923532	341	21	(	(	-LRB-
10_1101-2020_01_28_923532	341	22	Figure	Figure	NNP
10_1101-2020_01_28_923532	341	23	7	7	CD
10_1101-2020_01_28_923532	341	24	)	)	-RRB-
10_1101-2020_01_28_923532	341	25	,	,	,
10_1101-2020_01_28_923532	341	26	pointing	point	VBG
10_1101-2020_01_28_923532	341	27	to	to	IN
10_1101-2020_01_28_923532	341	28	potential	potential	JJ
10_1101-2020_01_28_923532	341	29	inherent	inherent	JJ
10_1101-2020_01_28_923532	341	30	limitations	limitation	NNS
10_1101-2020_01_28_923532	341	31	of	of	IN
10_1101-2020_01_28_923532	341	32	applying	apply	VBG
10_1101-2020_01_28_923532	341	33	such	such	JJ
10_1101-2020_01_28_923532	341	34	combination	combination	NN
10_1101-2020_01_28_923532	341	35	approaches	approach	NNS
10_1101-2020_01_28_923532	341	36	to	to	IN
10_1101-2020_01_28_923532	341	37	patients	patient	NNS
10_1101-2020_01_28_923532	341	38	in	in	IN
10_1101-2020_01_28_923532	341	39	the	the	DT
10_1101-2020_01_28_923532	341	40	clinic	clinic	NN
10_1101-2020_01_28_923532	341	41	and	and	CC
10_1101-2020_01_28_923532	341	42	the	the	DT
10_1101-2020_01_28_923532	341	43	need	need	NN
10_1101-2020_01_28_923532	341	44	to	to	TO
10_1101-2020_01_28_923532	341	45	carefully	carefully	RB
10_1101-2020_01_28_923532	341	46	monitor	monitor	VB
10_1101-2020_01_28_923532	341	47	their	-PRON-	PRP$
10_1101-2020_01_28_923532	341	48	putative	putative	JJ
10_1101-2020_01_28_923532	341	49	safety	safety	NN
10_1101-2020_01_28_923532	341	50	and	and	CC
10_1101-2020_01_28_923532	341	51	toxicity	toxicity	NN
10_1101-2020_01_28_923532	341	52	in	in	IN
10_1101-2020_01_28_923532	341	53	future	future	JJ
10_1101-2020_01_28_923532	341	54	applications	application	NNS
10_1101-2020_01_28_923532	341	55	.	.	.
10_1101-2020_01_28_923532	342	1	Finally	finally	RB
10_1101-2020_01_28_923532	342	2	,	,	,
10_1101-2020_01_28_923532	342	3	functional	functional	JJ
10_1101-2020_01_28_923532	342	4	enrichment	enrichment	NN
10_1101-2020_01_28_923532	342	5	analysis	analysis	NN
10_1101-2020_01_28_923532	342	6	of	of	IN
10_1101-2020_01_28_923532	342	7	genes	gene	NNS
10_1101-2020_01_28_923532	342	8	commonly	commonly	RB
10_1101-2020_01_28_923532	342	9	occurring	occur	VBG
10_1101-2020_01_28_923532	342	10	in	in	IN
10_1101-2020_01_28_923532	342	11	the	the	DT
10_1101-2020_01_28_923532	342	12	optimal	optimal	JJ
10_1101-2020_01_28_923532	342	13	target	target	NN
10_1101-2020_01_28_923532	342	14	sets	set	NNS
10_1101-2020_01_28_923532	342	15	reinforced	reinforce	VBD
10_1101-2020_01_28_923532	342	16	the	the	DT
10_1101-2020_01_28_923532	342	17	central	central	JJ
10_1101-2020_01_28_923532	342	18	role	role	NN
10_1101-2020_01_28_923532	342	19	of	of	IN
10_1101-2020_01_28_923532	342	20	the	the	DT
10_1101-2020_01_28_923532	342	21	widely	widely	RB
10_1101-2020_01_28_923532	342	22	studied	studied	JJ
10_1101-2020_01_28_923532	342	23	oncogene	oncogene	NN
10_1101-2020_01_28_923532	342	24	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	342	25	and	and	CC
10_1101-2020_01_28_923532	342	26	other	other	JJ
10_1101-2020_01_28_923532	342	27	transmembrane	transmembrane	JJ
10_1101-2020_01_28_923532	342	28	kinases	kinase	NNS
10_1101-2020_01_28_923532	342	29	.	.	.
10_1101-2020_01_28_923532	343	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	343	2	also	also	RB
10_1101-2020_01_28_923532	343	3	found	find	VBD
10_1101-2020_01_28_923532	343	4	that	that	IN
10_1101-2020_01_28_923532	343	5	that	that	IN
10_1101-2020_01_28_923532	343	6	the	the	DT
10_1101-2020_01_28_923532	343	7	less	less	RBR
10_1101-2020_01_28_923532	343	8	-	-	HYPH
10_1101-2020_01_28_923532	343	9	studied	study	VBN
10_1101-2020_01_28_923532	343	10	phosphatase	phosphatase	NN
10_1101-2020_01_28_923532	343	11	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	343	12	is	be	VBZ
10_1101-2020_01_28_923532	343	13	a	a	DT
10_1101-2020_01_28_923532	343	14	useful	useful	JJ
10_1101-2020_01_28_923532	343	15	target	target	NN
10_1101-2020_01_28_923532	343	16	,	,	,
10_1101-2020_01_28_923532	343	17	especially	especially	RB
10_1101-2020_01_28_923532	343	18	in	in	IN
10_1101-2020_01_28_923532	343	19	brain	brain	NN
10_1101-2020_01_28_923532	343	20	cancer	cancer	NN
10_1101-2020_01_28_923532	343	21	.	.	.
10_1101-2020_01_28_923532	344	1	In	in	IN
10_1101-2020_01_28_923532	344	2	summary	summary	NN
10_1101-2020_01_28_923532	344	3	,	,	,
10_1101-2020_01_28_923532	344	4	this	this	DT
10_1101-2020_01_28_923532	344	5	study	study	NN
10_1101-2020_01_28_923532	344	6	is	be	VBZ
10_1101-2020_01_28_923532	344	7	the	the	DT
10_1101-2020_01_28_923532	344	8	first	first	JJ
10_1101-2020_01_28_923532	344	9	to	to	IN
10_1101-2020_01_28_923532	344	10	harness	harness	JJ
10_1101-2020_01_28_923532	344	11	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	344	12	optimization	optimization	NN
10_1101-2020_01_28_923532	344	13	tools	tool	NNS
10_1101-2020_01_28_923532	344	14	to	to	TO
10_1101-2020_01_28_923532	344	15	analyze	analyze	VB
10_1101-2020_01_28_923532	344	16	emerging	emerge	VBG
10_1101-2020_01_28_923532	344	17	single	single	JJ
10_1101-2020_01_28_923532	344	18	-	-	HYPH
10_1101-2020_01_28_923532	344	19	cell	cell	NN
10_1101-2020_01_28_923532	344	20	data	datum	NNS
10_1101-2020_01_28_923532	344	21	to	to	TO
10_1101-2020_01_28_923532	344	22	portray	portray	VB
10_1101-2020_01_28_923532	344	23	the	the	DT
10_1101-2020_01_28_923532	344	24	landscape	landscape	NN
10_1101-2020_01_28_923532	344	25	of	of	IN
10_1101-2020_01_28_923532	344	26	feasible	feasible	JJ
10_1101-2020_01_28_923532	344	27	personalized	personalize	VBN
10_1101-2020_01_28_923532	344	28	combinations	combination	NNS
10_1101-2020_01_28_923532	344	29	in	in	IN
10_1101-2020_01_28_923532	344	30	cancer	cancer	NN
10_1101-2020_01_28_923532	344	31	medicine	medicine	NN
10_1101-2020_01_28_923532	344	32	.	.	.
10_1101-2020_01_28_923532	345	1	Our	-PRON-	PRP$
10_1101-2020_01_28_923532	345	2	findings	finding	NNS
10_1101-2020_01_28_923532	345	3	uncover	uncover	VBP
10_1101-2020_01_28_923532	345	4	promising	promise	VBG
10_1101-2020_01_28_923532	345	5	membranal	membranal	JJ
10_1101-2020_01_28_923532	345	6	targets	target	NNS
10_1101-2020_01_28_923532	345	7	for	for	IN
10_1101-2020_01_28_923532	345	8	the	the	DT
10_1101-2020_01_28_923532	345	9	development	development	NN
10_1101-2020_01_28_923532	345	10	of	of	IN
10_1101-2020_01_28_923532	345	11	future	future	JJ
10_1101-2020_01_28_923532	345	12	oncology	oncology	NN
10_1101-2020_01_28_923532	345	13	medicines	medicine	NNS
10_1101-2020_01_28_923532	345	14	that	that	WDT
10_1101-2020_01_28_923532	345	15	may	may	MD
10_1101-2020_01_28_923532	345	16	serve	serve	VB
10_1101-2020_01_28_923532	345	17	to	to	TO
10_1101-2020_01_28_923532	345	18	optimize	optimize	VB
10_1101-2020_01_28_923532	345	19	the	the	DT
10_1101-2020_01_28_923532	345	20	treatment	treatment	NN
10_1101-2020_01_28_923532	345	21	of	of	IN
10_1101-2020_01_28_923532	345	22	cancer	cancer	NN
10_1101-2020_01_28_923532	345	23	patient	patient	NN
10_1101-2020_01_28_923532	345	24	cohorts	cohort	NNS
10_1101-2020_01_28_923532	345	25	in	in	IN
10_1101-2020_01_28_923532	345	26	several	several	JJ
10_1101-2020_01_28_923532	345	27	cancer	cancer	NN
10_1101-2020_01_28_923532	345	28	types	type	NNS
10_1101-2020_01_28_923532	345	29	.	.	.
10_1101-2020_01_28_923532	346	1	The	the	DT
10_1101-2020_01_28_923532	346	2	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	346	3	approach	approach	NN
10_1101-2020_01_28_923532	346	4	presented	present	VBD
10_1101-2020_01_28_923532	346	5	and	and	CC
10_1101-2020_01_28_923532	346	6	the	the	DT
10_1101-2020_01_28_923532	346	7	accompanying	accompany	VBG
10_1101-2020_01_28_923532	346	8	software	software	NN
10_1101-2020_01_28_923532	346	9	made	make	VBD
10_1101-2020_01_28_923532	346	10	public	public	JJ
10_1101-2020_01_28_923532	346	11	can	can	MD
10_1101-2020_01_28_923532	346	12	be	be	VB
10_1101-2020_01_28_923532	346	13	readily	readily	RB
10_1101-2020_01_28_923532	346	14	applied	apply	VBN
10_1101-2020_01_28_923532	346	15	to	to	TO
10_1101-2020_01_28_923532	346	16	address	address	VB
10_1101-2020_01_28_923532	346	17	additional	additional	JJ
10_1101-2020_01_28_923532	346	18	fundamental	fundamental	JJ
10_1101-2020_01_28_923532	346	19	related	related	JJ
10_1101-2020_01_28_923532	346	20	research	research	NN
10_1101-2020_01_28_923532	346	21	questions	question	NNS
10_1101-2020_01_28_923532	346	22	and	and	CC
10_1101-2020_01_28_923532	346	23	analyze	analyze	VB
10_1101-2020_01_28_923532	346	24	additional	additional	JJ
10_1101-2020_01_28_923532	346	25	cancer	cancer	NN
10_1101-2020_01_28_923532	346	26	data	datum	NNS
10_1101-2020_01_28_923532	346	27	sets	set	NNS
10_1101-2020_01_28_923532	346	28	as	as	IN
10_1101-2020_01_28_923532	346	29	they	-PRON-	PRP
10_1101-2020_01_28_923532	346	30	become	become	VBP
10_1101-2020_01_28_923532	346	31	available	available	JJ
10_1101-2020_01_28_923532	346	32	.	.	.
10_1101-2020_01_28_923532	347	1	Methods	Methods	NNP
10_1101-2020_01_28_923532	347	2	Data	data	NN
10_1101-2020_01_28_923532	347	3	Sets	set	NNS
10_1101-2020_01_28_923532	347	4	We	-PRON-	PRP
10_1101-2020_01_28_923532	347	5	retrieved	retrieve	VBD
10_1101-2020_01_28_923532	347	6	and	and	CC
10_1101-2020_01_28_923532	347	7	organized	organize	VBN
10_1101-2020_01_28_923532	347	8	data	data	NN
10_1101-2020_01_28_923532	347	9	sets	set	NNS
10_1101-2020_01_28_923532	347	10	from	from	IN
10_1101-2020_01_28_923532	347	11	NCBI	NCBI	NNP
10_1101-2020_01_28_923532	347	12	’s	’s	POS
10_1101-2020_01_28_923532	347	13	Gene	Gene	NNP
10_1101-2020_01_28_923532	347	14	Expression	Expression	NNP
10_1101-2020_01_28_923532	347	15	Omnibus	Omnibus	NNP
10_1101-2020_01_28_923532	347	16	(	(	-LRB-
10_1101-2020_01_28_923532	347	17	GEO)58	geo)58	DT
10_1101-2020_01_28_923532	347	18	and	and	CC
10_1101-2020_01_28_923532	347	19	Ensembl	Ensembl	NNP
10_1101-2020_01_28_923532	347	20	’s	’s	,
10_1101-2020_01_28_923532	347	21	ArrayExpess59	ArrayExpess59	NNP
10_1101-2020_01_28_923532	347	22	and	and	CC
10_1101-2020_01_28_923532	347	23	the	the	DT
10_1101-2020_01_28_923532	347	24	Broad	Broad	NNP
10_1101-2020_01_28_923532	347	25	Institute	Institute	NNP
10_1101-2020_01_28_923532	347	26	’s	’s	POS
10_1101-2020_01_28_923532	347	27	Single	Single	NNP
10_1101-2020_01_28_923532	347	28	Cell	Cell	NNP
10_1101-2020_01_28_923532	347	29	Portal	Portal	NNP
10_1101-2020_01_28_923532	347	30	(	(	-LRB-
10_1101-2020_01_28_923532	347	31	https://portals.broadinstitute.org/single_cell	https://portals.broadinstitute.org/single_cell	UH
10_1101-2020_01_28_923532	347	32	)	)	-RRB-
10_1101-2020_01_28_923532	347	33	.	.	.
10_1101-2020_01_28_923532	348	1	Nine	nine	CD
10_1101-2020_01_28_923532	348	2	data	data	NN
10_1101-2020_01_28_923532	348	3	sets	set	NNS
10_1101-2020_01_28_923532	348	4	had	have	VBD
10_1101-2020_01_28_923532	348	5	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	348	6	tumor	tumor	NN
10_1101-2020_01_28_923532	348	7	and	and	CC
10_1101-2020_01_28_923532	348	8	non	non	JJ
10_1101-2020_01_28_923532	348	9	-	-	JJ
10_1101-2020_01_28_923532	348	10	tumor	tumor	JJ
10_1101-2020_01_28_923532	348	11	cells	cell	NNS
10_1101-2020_01_28_923532	348	12	and	and	CC
10_1101-2020_01_28_923532	348	13	were	be	VBD
10_1101-2020_01_28_923532	348	14	used	use	VBN
10_1101-2020_01_28_923532	348	15	in	in	IN
10_1101-2020_01_28_923532	348	16	this	this	DT
10_1101-2020_01_28_923532	348	17	study	study	NN
10_1101-2020_01_28_923532	348	18	;	;	:
10_1101-2020_01_28_923532	348	19	an	an	DT
10_1101-2020_01_28_923532	348	20	additional	additional	JJ
10_1101-2020_01_28_923532	348	21	five	five	CD
10_1101-2020_01_28_923532	348	22	data	datum	NNS
10_1101-2020_01_28_923532	348	23	sets	set	NNS
10_1101-2020_01_28_923532	348	24	had	have	VBD
10_1101-2020_01_28_923532	348	25	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	348	26	tumor	tumor	NN
10_1101-2020_01_28_923532	348	27	cells	cell	NNS
10_1101-2020_01_28_923532	348	28	only	only	RB
10_1101-2020_01_28_923532	348	29	and	and	CC
10_1101-2020_01_28_923532	348	30	were	be	VBD
10_1101-2020_01_28_923532	348	31	used	use	VBN
10_1101-2020_01_28_923532	348	32	in	in	IN
10_1101-2020_01_28_923532	348	33	testing	test	VBG
10_1101-2020_01_28_923532	348	34	early	early	JJ
10_1101-2020_01_28_923532	348	35	versions	version	NNS
10_1101-2020_01_28_923532	348	36	of	of	IN
10_1101-2020_01_28_923532	348	37	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	348	38	.	.	.
10_1101-2020_01_28_923532	349	1	Suitable	suitable	JJ
10_1101-2020_01_28_923532	349	2	data	data	NN
10_1101-2020_01_28_923532	349	3	sets	set	NNS
10_1101-2020_01_28_923532	349	4	were	be	VBD
10_1101-2020_01_28_923532	349	5	identified	identify	VBN
10_1101-2020_01_28_923532	349	6	by	by	IN
10_1101-2020_01_28_923532	349	7	searching	search	VBG
10_1101-2020_01_28_923532	349	8	scRNASeqDB60	scRNASeqDB60	NNP
10_1101-2020_01_28_923532	349	9	,	,	,
10_1101-2020_01_28_923532	349	10	CancerSea61	CancerSea61	NNP
10_1101-2020_01_28_923532	349	11	,	,	,
10_1101-2020_01_28_923532	349	12	GEO	GEO	NNP
10_1101-2020_01_28_923532	349	13	,	,	,
10_1101-2020_01_28_923532	349	14	ArrayExpress	ArrayExpress	NNP
10_1101-2020_01_28_923532	349	15	,	,	,
10_1101-2020_01_28_923532	349	16	Google	Google	NNP
10_1101-2020_01_28_923532	349	17	Scholar	Scholar	NNP
10_1101-2020_01_28_923532	349	18	,	,	,
10_1101-2020_01_28_923532	349	19	and	and	CC
10_1101-2020_01_28_923532	349	20	the	the	DT
10_1101-2020_01_28_923532	349	21	10x	10x	NNPS
10_1101-2020_01_28_923532	349	22	Genomics	Genomics	NNP
10_1101-2020_01_28_923532	349	23	list	list	NN
10_1101-2020_01_28_923532	349	24	of	of	IN
10_1101-2020_01_28_923532	349	25	publications	publication	NNS
10_1101-2020_01_28_923532	349	26	(	(	-LRB-
10_1101-2020_01_28_923532	349	27	https://www.10xgenomics.com/resources/publications/	https://www.10xgenomics.com/resources/publications/	NNP
10_1101-2020_01_28_923532	349	28	)	)	-RRB-
10_1101-2020_01_28_923532	349	29	.	.	.
10_1101-2020_01_28_923532	350	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	350	2	required	require	VBD
10_1101-2020_01_28_923532	350	3	that	that	IN
10_1101-2020_01_28_923532	350	4	each	each	DT
10_1101-2020_01_28_923532	350	5	105	105	CD
10_1101-2020_01_28_923532	350	6	and	and	CC
10_1101-2020_01_28_923532	350	7	is	be	VBZ
10_1101-2020_01_28_923532	350	8	also	also	RB
10_1101-2020_01_28_923532	350	9	made	make	VBN
10_1101-2020_01_28_923532	350	10	available	available	JJ
10_1101-2020_01_28_923532	350	11	for	for	IN
10_1101-2020_01_28_923532	350	12	use	use	NN
10_1101-2020_01_28_923532	350	13	under	under	IN
10_1101-2020_01_28_923532	350	14	a	a	DT
10_1101-2020_01_28_923532	350	15	CC0	CC0	NNP
10_1101-2020_01_28_923532	350	16	license	license	NN
10_1101-2020_01_28_923532	350	17	.	.	.
10_1101-2020_01_28_923532	351	1	(	(	-LRB-
10_1101-2020_01_28_923532	351	2	which	which	WDT
10_1101-2020_01_28_923532	351	3	was	be	VBD
10_1101-2020_01_28_923532	351	4	not	not	RB
10_1101-2020_01_28_923532	351	5	certified	certify	VBN
10_1101-2020_01_28_923532	351	6	by	by	IN
10_1101-2020_01_28_923532	351	7	peer	peer	NN
10_1101-2020_01_28_923532	351	8	review	review	NN
10_1101-2020_01_28_923532	351	9	)	)	-RRB-
10_1101-2020_01_28_923532	351	10	is	be	VBZ
10_1101-2020_01_28_923532	351	11	the	the	DT
10_1101-2020_01_28_923532	351	12	author	author	NN
10_1101-2020_01_28_923532	351	13	/	/	SYM
10_1101-2020_01_28_923532	351	14	funder	funder	NN
10_1101-2020_01_28_923532	351	15	.	.	.
10_1101-2020_01_28_923532	352	1	This	this	DT
10_1101-2020_01_28_923532	352	2	article	article	NN
10_1101-2020_01_28_923532	352	3	is	be	VBZ
10_1101-2020_01_28_923532	352	4	a	a	DT
10_1101-2020_01_28_923532	352	5	US	US	NNP
10_1101-2020_01_28_923532	352	6	Government	Government	NNP
10_1101-2020_01_28_923532	352	7	work	work	NN
10_1101-2020_01_28_923532	352	8	.	.	.
10_1101-2020_01_28_923532	353	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	353	2	is	be	VBZ
10_1101-2020_01_28_923532	353	3	not	not	RB
10_1101-2020_01_28_923532	353	4	subject	subject	JJ
10_1101-2020_01_28_923532	353	5	to	to	IN
10_1101-2020_01_28_923532	353	6	copyright	copyright	NN
10_1101-2020_01_28_923532	353	7	under	under	IN
10_1101-2020_01_28_923532	353	8	17	17	CD
10_1101-2020_01_28_923532	353	9	USC	usc	NN
10_1101-2020_01_28_923532	353	10	The	the	DT
10_1101-2020_01_28_923532	353	11	copyright	copyright	NN
10_1101-2020_01_28_923532	353	12	holder	holder	NN
10_1101-2020_01_28_923532	353	13	for	for	IN
10_1101-2020_01_28_923532	353	14	this	this	DT
10_1101-2020_01_28_923532	353	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	353	16	version	version	NN
10_1101-2020_01_28_923532	353	17	posted	post	VBD
10_1101-2020_01_28_923532	353	18	February	February	NNP
10_1101-2020_01_28_923532	353	19	12	12	CD
10_1101-2020_01_28_923532	353	20	,	,	,
10_1101-2020_01_28_923532	353	21	2021	2021	CD
10_1101-2020_01_28_923532	353	22	.	.	.
10_1101-2020_01_28_923532	353	23	;	;	:
10_1101-2020_01_28_923532	353	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	353	25	:	:	:
10_1101-2020_01_28_923532	353	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	353	27	preprint	preprint	NN
10_1101-2020_01_28_923532	353	28	https://portals.broadinstitute.org/single_cell	https://portals.broadinstitute.org/single_cell	ADD
10_1101-2020_01_28_923532	353	29	https://www.10xgenomics.com/resources/publications/	https://www.10xgenomics.com/resources/publications/	PRP
10_1101-2020_01_28_923532	353	30	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	353	31	28	28	CD
10_1101-2020_01_28_923532	353	32	data	datum	NNS
10_1101-2020_01_28_923532	353	33	set	set	NN
10_1101-2020_01_28_923532	353	34	contain	contain	NN
10_1101-2020_01_28_923532	353	35	measurements	measurement	NNS
10_1101-2020_01_28_923532	353	36	of	of	IN
10_1101-2020_01_28_923532	353	37	RNA	RNA	NNP
10_1101-2020_01_28_923532	353	38	expression	expression	NN
10_1101-2020_01_28_923532	353	39	on	on	IN
10_1101-2020_01_28_923532	353	40	single	single	JJ
10_1101-2020_01_28_923532	353	41	cells	cell	NNS
10_1101-2020_01_28_923532	353	42	from	from	IN
10_1101-2020_01_28_923532	353	43	human	human	JJ
10_1101-2020_01_28_923532	353	44	primary	primary	JJ
10_1101-2020_01_28_923532	353	45	solid	solid	JJ
10_1101-2020_01_28_923532	353	46	tumors	tumor	NNS
10_1101-2020_01_28_923532	353	47	of	of	IN
10_1101-2020_01_28_923532	353	48	at	at	RB
10_1101-2020_01_28_923532	353	49	least	least	RBS
10_1101-2020_01_28_923532	353	50	two	two	CD
10_1101-2020_01_28_923532	353	51	patients	patient	NNS
10_1101-2020_01_28_923532	353	52	and	and	CC
10_1101-2020_01_28_923532	353	53	the	the	DT
10_1101-2020_01_28_923532	353	54	metadata	metadata	NN
10_1101-2020_01_28_923532	353	55	are	be	VBP
10_1101-2020_01_28_923532	353	56	consistent	consistent	JJ
10_1101-2020_01_28_923532	353	57	with	with	IN
10_1101-2020_01_28_923532	353	58	the	the	DT
10_1101-2020_01_28_923532	353	59	primary	primary	JJ
10_1101-2020_01_28_923532	353	60	data	datum	NNS
10_1101-2020_01_28_923532	353	61	.	.	.
10_1101-2020_01_28_923532	354	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	354	2	are	be	VBP
10_1101-2020_01_28_923532	354	3	grateful	grateful	JJ
10_1101-2020_01_28_923532	354	4	to	to	IN
10_1101-2020_01_28_923532	354	5	several	several	JJ
10_1101-2020_01_28_923532	354	6	of	of	IN
10_1101-2020_01_28_923532	354	7	the	the	DT
10_1101-2020_01_28_923532	354	8	data	datum	NNS
10_1101-2020_01_28_923532	354	9	depositing	deposit	VBG
10_1101-2020_01_28_923532	354	10	authors	author	NNS
10_1101-2020_01_28_923532	354	11	of	of	IN
10_1101-2020_01_28_923532	354	12	data	datum	NNS
10_1101-2020_01_28_923532	354	13	sets	set	NNS
10_1101-2020_01_28_923532	354	14	for	for	IN
10_1101-2020_01_28_923532	354	15	resolving	resolve	VBG
10_1101-2020_01_28_923532	354	16	metadata	metadata	NN
10_1101-2020_01_28_923532	354	17	inconsistencies	inconsistency	NNS
10_1101-2020_01_28_923532	354	18	by	by	IN
10_1101-2020_01_28_923532	354	19	e	e	NN
10_1101-2020_01_28_923532	354	20	-	-	NN
10_1101-2020_01_28_923532	354	21	mail	mail	NN
10_1101-2020_01_28_923532	354	22	correspondence	correspondence	NN
10_1101-2020_01_28_923532	354	23	and	and	CC
10_1101-2020_01_28_923532	354	24	by	by	IN
10_1101-2020_01_28_923532	354	25	sending	send	VBG
10_1101-2020_01_28_923532	354	26	additional	additional	JJ
10_1101-2020_01_28_923532	354	27	files	file	NNS
10_1101-2020_01_28_923532	354	28	not	not	RB
10_1101-2020_01_28_923532	354	29	available	available	JJ
10_1101-2020_01_28_923532	354	30	at	at	IN
10_1101-2020_01_28_923532	354	31	GEO	GEO	NNP
10_1101-2020_01_28_923532	354	32	or	or	CC
10_1101-2020_01_28_923532	354	33	ArrayExpress	ArrayExpress	NNP
10_1101-2020_01_28_923532	354	34	.	.	.
10_1101-2020_01_28_923532	355	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	355	2	excluded	exclude	VBD
10_1101-2020_01_28_923532	355	3	blood	blood	NN
10_1101-2020_01_28_923532	355	4	cancers	cancer	NNS
10_1101-2020_01_28_923532	355	5	and	and	CC
10_1101-2020_01_28_923532	355	6	data	data	NN
10_1101-2020_01_28_923532	355	7	sets	set	NNS
10_1101-2020_01_28_923532	355	8	with	with	IN
10_1101-2020_01_28_923532	355	9	single	single	JJ
10_1101-2020_01_28_923532	355	10	patients	patient	NNS
10_1101-2020_01_28_923532	355	11	.	.	.
10_1101-2020_01_28_923532	356	1	When	when	WRB
10_1101-2020_01_28_923532	356	2	it	-PRON-	PRP
10_1101-2020_01_28_923532	356	3	was	be	VBD
10_1101-2020_01_28_923532	356	4	easily	easily	RB
10_1101-2020_01_28_923532	356	5	possible	possible	JJ
10_1101-2020_01_28_923532	356	6	to	to	TO
10_1101-2020_01_28_923532	356	7	separate	separate	VB
10_1101-2020_01_28_923532	356	8	cancer	cancer	NN
10_1101-2020_01_28_923532	356	9	cells	cell	NNS
10_1101-2020_01_28_923532	356	10	from	from	IN
10_1101-2020_01_28_923532	356	11	non	non	JJ
10_1101-2020_01_28_923532	356	12	-	-	JJ
10_1101-2020_01_28_923532	356	13	cancer	cancer	JJ
10_1101-2020_01_28_923532	356	14	cells	cell	NNS
10_1101-2020_01_28_923532	356	15	of	of	IN
10_1101-2020_01_28_923532	356	16	a	a	DT
10_1101-2020_01_28_923532	356	17	similar	similar	JJ
10_1101-2020_01_28_923532	356	18	type	type	NN
10_1101-2020_01_28_923532	356	19	,	,	,
10_1101-2020_01_28_923532	356	20	we	-PRON-	PRP
10_1101-2020_01_28_923532	356	21	did	do	VBD
10_1101-2020_01_28_923532	356	22	so	so	RB
10_1101-2020_01_28_923532	356	23	.	.	.
10_1101-2020_01_28_923532	357	1	The	the	DT
10_1101-2020_01_28_923532	357	2	main	main	JJ
10_1101-2020_01_28_923532	357	3	task	task	NN
10_1101-2020_01_28_923532	357	4	in	in	IN
10_1101-2020_01_28_923532	357	5	organizing	organize	VBG
10_1101-2020_01_28_923532	357	6	each	each	DT
10_1101-2020_01_28_923532	357	7	data	data	NN
10_1101-2020_01_28_923532	357	8	set	set	NN
10_1101-2020_01_28_923532	357	9	was	be	VBD
10_1101-2020_01_28_923532	357	10	to	to	TO
10_1101-2020_01_28_923532	357	11	separate	separate	VB
10_1101-2020_01_28_923532	357	12	the	the	DT
10_1101-2020_01_28_923532	357	13	cells	cell	NNS
10_1101-2020_01_28_923532	357	14	from	from	IN
10_1101-2020_01_28_923532	357	15	each	each	DT
10_1101-2020_01_28_923532	357	16	sample	sample	NN
10_1101-2020_01_28_923532	357	17	or	or	CC
10_1101-2020_01_28_923532	357	18	each	each	DT
10_1101-2020_01_28_923532	357	19	patient	patient	NN
10_1101-2020_01_28_923532	357	20	into	into	IN
10_1101-2020_01_28_923532	357	21	one	one	CD
10_1101-2020_01_28_923532	357	22	or	or	CC
10_1101-2020_01_28_923532	357	23	more	more	JJR
10_1101-2020_01_28_923532	357	24	single	single	JJ
10_1101-2020_01_28_923532	357	25	files	file	NNS
10_1101-2020_01_28_923532	357	26	.	.	.
10_1101-2020_01_28_923532	358	1	Representations	representation	NNS
10_1101-2020_01_28_923532	358	2	of	of	IN
10_1101-2020_01_28_923532	358	3	the	the	DT
10_1101-2020_01_28_923532	358	4	expression	expression	NN
10_1101-2020_01_28_923532	358	5	as	as	IN
10_1101-2020_01_28_923532	358	6	binary	binary	JJ
10_1101-2020_01_28_923532	358	7	,	,	,
10_1101-2020_01_28_923532	358	8	as	as	IN
10_1101-2020_01_28_923532	358	9	read	read	VBN
10_1101-2020_01_28_923532	358	10	counts	count	NNS
10_1101-2020_01_28_923532	358	11	,	,	,
10_1101-2020_01_28_923532	358	12	or	or	CC
10_1101-2020_01_28_923532	358	13	as	as	IN
10_1101-2020_01_28_923532	358	14	normalized	normalized	JJ
10_1101-2020_01_28_923532	358	15	quantities	quantity	NNS
10_1101-2020_01_28_923532	358	16	such	such	JJ
10_1101-2020_01_28_923532	358	17	as	as	IN
10_1101-2020_01_28_923532	358	18	transcripts	transcript	NNS
10_1101-2020_01_28_923532	358	19	per	per	IN
10_1101-2020_01_28_923532	358	20	million	million	CD
10_1101-2020_01_28_923532	358	21	(	(	-LRB-
10_1101-2020_01_28_923532	358	22	TPM	TPM	NNP
10_1101-2020_01_28_923532	358	23	)	)	-RRB-
10_1101-2020_01_28_923532	358	24	were	be	VBD
10_1101-2020_01_28_923532	358	25	retained	retain	VBN
10_1101-2020_01_28_923532	358	26	from	from	IN
10_1101-2020_01_28_923532	358	27	the	the	DT
10_1101-2020_01_28_923532	358	28	original	original	JJ
10_1101-2020_01_28_923532	358	29	data	datum	NNS
10_1101-2020_01_28_923532	358	30	.	.	.
10_1101-2020_01_28_923532	359	1	When	when	WRB
10_1101-2020_01_28_923532	359	2	the	the	DT
10_1101-2020_01_28_923532	359	3	data	data	NN
10_1101-2020_01_28_923532	359	4	set	set	NN
10_1101-2020_01_28_923532	359	5	included	include	VBD
10_1101-2020_01_28_923532	359	6	cell	cell	NN
10_1101-2020_01_28_923532	359	7	type	type	NN
10_1101-2020_01_28_923532	359	8	assignments	assignment	NNS
10_1101-2020_01_28_923532	359	9	,	,	,
10_1101-2020_01_28_923532	359	10	we	-PRON-	PRP
10_1101-2020_01_28_923532	359	11	retained	retain	VBD
10_1101-2020_01_28_923532	359	12	those	those	DT
10_1101-2020_01_28_923532	359	13	to	to	TO
10_1101-2020_01_28_923532	359	14	classify	classify	VB
10_1101-2020_01_28_923532	359	15	cells	cell	NNS
10_1101-2020_01_28_923532	359	16	as	as	IN
10_1101-2020_01_28_923532	359	17	“	"	``
10_1101-2020_01_28_923532	359	18	cancer	cancer	NN
10_1101-2020_01_28_923532	359	19	”	"	''
10_1101-2020_01_28_923532	359	20	or	or	CC
10_1101-2020_01_28_923532	359	21	“	"	``
10_1101-2020_01_28_923532	359	22	non	non	JJ
10_1101-2020_01_28_923532	359	23	-	-	JJ
10_1101-2020_01_28_923532	359	24	cancer	cancer	JJ
10_1101-2020_01_28_923532	359	25	”	"	''
10_1101-2020_01_28_923532	359	26	,	,	,
10_1101-2020_01_28_923532	359	27	except	except	IN
10_1101-2020_01_28_923532	359	28	in	in	IN
10_1101-2020_01_28_923532	359	29	the	the	DT
10_1101-2020_01_28_923532	359	30	data	data	NN
10_1101-2020_01_28_923532	359	31	set	set	NN
10_1101-2020_01_28_923532	359	32	of	of	IN
10_1101-2020_01_28_923532	359	33	Karaayvaz	Karaayvaz	NNP
10_1101-2020_01_28_923532	359	34	et	et	NNP
10_1101-2020_01_28_923532	359	35	al.62	al.62	NNP
10_1101-2020_01_28_923532	359	36	where	where	WRB
10_1101-2020_01_28_923532	359	37	it	-PRON-	PRP
10_1101-2020_01_28_923532	359	38	was	be	VBD
10_1101-2020_01_28_923532	359	39	necessary	necessary	JJ
10_1101-2020_01_28_923532	359	40	to	to	TO
10_1101-2020_01_28_923532	359	41	reapply	reapply	VB
10_1101-2020_01_28_923532	359	42	filters	filter	NNS
10_1101-2020_01_28_923532	359	43	described	describe	VBN
10_1101-2020_01_28_923532	359	44	in	in	IN
10_1101-2020_01_28_923532	359	45	the	the	DT
10_1101-2020_01_28_923532	359	46	paper	paper	NN
10_1101-2020_01_28_923532	359	47	to	to	TO
10_1101-2020_01_28_923532	359	48	exclude	exclude	VB
10_1101-2020_01_28_923532	359	49	cells	cell	NNS
10_1101-2020_01_28_923532	359	50	expressing	express	VBG
10_1101-2020_01_28_923532	359	51	few	few	JJ
10_1101-2020_01_28_923532	359	52	genes	gene	NNS
10_1101-2020_01_28_923532	359	53	and	and	CC
10_1101-2020_01_28_923532	359	54	to	to	TO
10_1101-2020_01_28_923532	359	55	identify	identify	VB
10_1101-2020_01_28_923532	359	56	likely	likely	JJ
10_1101-2020_01_28_923532	359	57	cancer	cancer	NN
10_1101-2020_01_28_923532	359	58	and	and	CC
10_1101-2020_01_28_923532	359	59	likely	likely	JJ
10_1101-2020_01_28_923532	359	60	non	non	JJ
10_1101-2020_01_28_923532	359	61	-	-	JJ
10_1101-2020_01_28_923532	359	62	cancer	cancer	JJ
10_1101-2020_01_28_923532	359	63	cells	cell	NNS
10_1101-2020_01_28_923532	359	64	.	.	.
10_1101-2020_01_28_923532	360	1	If	if	IN
10_1101-2020_01_28_923532	360	2	cell	cell	NN
10_1101-2020_01_28_923532	360	3	types	type	NNS
10_1101-2020_01_28_923532	360	4	were	be	VBD
10_1101-2020_01_28_923532	360	5	not	not	RB
10_1101-2020_01_28_923532	360	6	distinguished	distinguish	VBN
10_1101-2020_01_28_923532	360	7	,	,	,
10_1101-2020_01_28_923532	360	8	all	all	DT
10_1101-2020_01_28_923532	360	9	cells	cell	NNS
10_1101-2020_01_28_923532	360	10	were	be	VBD
10_1101-2020_01_28_923532	360	11	treated	treat	VBN
10_1101-2020_01_28_923532	360	12	as	as	IN
10_1101-2020_01_28_923532	360	13	cancer	cancer	NN
10_1101-2020_01_28_923532	360	14	cells	cell	NNS
10_1101-2020_01_28_923532	360	15	.	.	.
10_1101-2020_01_28_923532	361	1	To	to	TO
10_1101-2020_01_28_923532	361	2	achieve	achieve	VB
10_1101-2020_01_28_923532	361	3	partial	partial	JJ
10_1101-2020_01_28_923532	361	4	consistency	consistency	NN
10_1101-2020_01_28_923532	361	5	in	in	IN
10_1101-2020_01_28_923532	361	6	the	the	DT
10_1101-2020_01_28_923532	361	7	genes	gene	NNS
10_1101-2020_01_28_923532	361	8	included	include	VBN
10_1101-2020_01_28_923532	361	9	,	,	,
10_1101-2020_01_28_923532	361	10	we	-PRON-	PRP
10_1101-2020_01_28_923532	361	11	filtered	filter	VBD
10_1101-2020_01_28_923532	361	12	data	data	NN
10_1101-2020_01_28_923532	361	13	sets	set	NNS
10_1101-2020_01_28_923532	361	14	to	to	TO
10_1101-2020_01_28_923532	361	15	include	include	VB
10_1101-2020_01_28_923532	361	16	only	only	RB
10_1101-2020_01_28_923532	361	17	those	those	DT
10_1101-2020_01_28_923532	361	18	gene	gene	NN
10_1101-2020_01_28_923532	361	19	labels	label	NNS
10_1101-2020_01_28_923532	361	20	recognized	recognize	VBD
10_1101-2020_01_28_923532	361	21	as	as	IN
10_1101-2020_01_28_923532	361	22	valid	valid	JJ
10_1101-2020_01_28_923532	361	23	by	by	IN
10_1101-2020_01_28_923532	361	24	the	the	DT
10_1101-2020_01_28_923532	361	25	HUGO	HUGO	NNP
10_1101-2020_01_28_923532	361	26	Gene	Gene	NNP
10_1101-2020_01_28_923532	361	27	Nomenclature	Nomenclature	NNP
10_1101-2020_01_28_923532	361	28	Committee	Committee	NNP
10_1101-2020_01_28_923532	361	29	(	(	-LRB-
10_1101-2020_01_28_923532	361	30	http://genenames.org	http://genenames.org	NNP
10_1101-2020_01_28_923532	361	31	)	)	-RRB-
10_1101-2020_01_28_923532	361	32	,	,	,
10_1101-2020_01_28_923532	361	33	but	but	CC
10_1101-2020_01_28_923532	361	34	otherwise	otherwise	RB
10_1101-2020_01_28_923532	361	35	we	-PRON-	PRP
10_1101-2020_01_28_923532	361	36	retained	retain	VBD
10_1101-2020_01_28_923532	361	37	whatever	whatever	WDT
10_1101-2020_01_28_923532	361	38	recognized	recognize	VBN
10_1101-2020_01_28_923532	361	39	genes	gene	NNS
10_1101-2020_01_28_923532	361	40	that	that	WDT
10_1101-2020_01_28_923532	361	41	the	the	DT
10_1101-2020_01_28_923532	361	42	data	datum	NNS
10_1101-2020_01_28_923532	361	43	submitters	submitter	NNS
10_1101-2020_01_28_923532	361	44	chose	choose	VBD
10_1101-2020_01_28_923532	361	45	to	to	TO
10_1101-2020_01_28_923532	361	46	include	include	VB
10_1101-2020_01_28_923532	361	47	.	.	.
10_1101-2020_01_28_923532	362	1	After	after	IN
10_1101-2020_01_28_923532	362	2	filtering	filter	VBG
10_1101-2020_01_28_923532	362	3	out	out	RP
10_1101-2020_01_28_923532	362	4	the	the	DT
10_1101-2020_01_28_923532	362	5	non	non	JJ
10_1101-2020_01_28_923532	362	6	-	-	JJ
10_1101-2020_01_28_923532	362	7	HUGO	hugo	JJ
10_1101-2020_01_28_923532	362	8	genes	gene	NNS
10_1101-2020_01_28_923532	362	9	,	,	,
10_1101-2020_01_28_923532	362	10	but	but	CC
10_1101-2020_01_28_923532	362	11	before	before	IN
10_1101-2020_01_28_923532	362	12	reducing	reduce	VBG
10_1101-2020_01_28_923532	362	13	the	the	DT
10_1101-2020_01_28_923532	362	14	set	set	NN
10_1101-2020_01_28_923532	362	15	of	of	IN
10_1101-2020_01_28_923532	362	16	genes	gene	NNS
10_1101-2020_01_28_923532	362	17	to	to	IN
10_1101-2020_01_28_923532	362	18	1269	1269	CD
10_1101-2020_01_28_923532	362	19	or	or	CC
10_1101-2020_01_28_923532	362	20	900	900	CD
10_1101-2020_01_28_923532	362	21	or	or	CC
10_1101-2020_01_28_923532	362	22	424	424	CD
10_1101-2020_01_28_923532	362	23	or	or	CC
10_1101-2020_01_28_923532	362	24	58	58	CD
10_1101-2020_01_28_923532	362	25	,	,	,
10_1101-2020_01_28_923532	362	26	we	-PRON-	PRP
10_1101-2020_01_28_923532	362	27	filtered	filter	VBD
10_1101-2020_01_28_923532	362	28	out	out	RP
10_1101-2020_01_28_923532	362	29	cells	cell	NNS
10_1101-2020_01_28_923532	362	30	as	as	IN
10_1101-2020_01_28_923532	362	31	follows	follow	VBZ
10_1101-2020_01_28_923532	362	32	.	.	.
10_1101-2020_01_28_923532	363	1	Some	some	DT
10_1101-2020_01_28_923532	363	2	data	data	NN
10_1101-2020_01_28_923532	363	3	sets	set	NNS
10_1101-2020_01_28_923532	363	4	came	come	VBD
10_1101-2020_01_28_923532	363	5	with	with	IN
10_1101-2020_01_28_923532	363	6	low	low	JJ
10_1101-2020_01_28_923532	363	7	expressing	express	VBG
10_1101-2020_01_28_923532	363	8	cells	cell	NNS
10_1101-2020_01_28_923532	363	9	filtered	filter	VBN
10_1101-2020_01_28_923532	363	10	out	out	RP
10_1101-2020_01_28_923532	363	11	.	.	.
10_1101-2020_01_28_923532	364	1	To	to	TO
10_1101-2020_01_28_923532	364	2	achieve	achieve	VB
10_1101-2020_01_28_923532	364	3	some	some	DT
10_1101-2020_01_28_923532	364	4	homogeneity	homogeneity	NN
10_1101-2020_01_28_923532	364	5	,	,	,
10_1101-2020_01_28_923532	364	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	364	7	filtered	filter	VBD
10_1101-2020_01_28_923532	364	8	out	out	RP
10_1101-2020_01_28_923532	364	9	any	any	DT
10_1101-2020_01_28_923532	364	10	cells	cell	NNS
10_1101-2020_01_28_923532	364	11	expressing	express	VBG
10_1101-2020_01_28_923532	364	12	fewer	few	JJR
10_1101-2020_01_28_923532	364	13	than	than	IN
10_1101-2020_01_28_923532	364	14	10	10	CD
10_1101-2020_01_28_923532	364	15	%	%	NN
10_1101-2020_01_28_923532	364	16	of	of	IN
10_1101-2020_01_28_923532	364	17	all	all	DT
10_1101-2020_01_28_923532	364	18	genes	gene	NNS
10_1101-2020_01_28_923532	364	19	before	before	IN
10_1101-2020_01_28_923532	364	20	we	-PRON-	PRP
10_1101-2020_01_28_923532	364	21	reduced	reduce	VBD
10_1101-2020_01_28_923532	364	22	the	the	DT
10_1101-2020_01_28_923532	364	23	number	number	NN
10_1101-2020_01_28_923532	364	24	of	of	IN
10_1101-2020_01_28_923532	364	25	genes	gene	NNS
10_1101-2020_01_28_923532	364	26	.	.	.
10_1101-2020_01_28_923532	365	1	In	in	IN
10_1101-2020_01_28_923532	365	2	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	365	3	Materials	Materials	NNP
10_1101-2020_01_28_923532	365	4	4	4	CD
10_1101-2020_01_28_923532	365	5	,	,	,
10_1101-2020_01_28_923532	365	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	365	7	tested	test	VBD
10_1101-2020_01_28_923532	365	8	the	the	DT
10_1101-2020_01_28_923532	365	9	robustness	robustness	NN
10_1101-2020_01_28_923532	365	10	of	of	IN
10_1101-2020_01_28_923532	365	11	this	this	DT
10_1101-2020_01_28_923532	365	12	10	10	CD
10_1101-2020_01_28_923532	365	13	%	%	NN
10_1101-2020_01_28_923532	365	14	threshold	threshold	NN
10_1101-2020_01_28_923532	365	15	.	.	.
10_1101-2020_01_28_923532	366	1	Finally	finally	RB
10_1101-2020_01_28_923532	366	2	,	,	,
10_1101-2020_01_28_923532	366	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	366	4	retained	retain	VBD
10_1101-2020_01_28_923532	366	5	either	either	CC
10_1101-2020_01_28_923532	366	6	all	all	DT
10_1101-2020_01_28_923532	366	7	available	available	JJ
10_1101-2020_01_28_923532	366	8	genes	gene	NNS
10_1101-2020_01_28_923532	366	9	from	from	IN
10_1101-2020_01_28_923532	366	10	among	among	IN
10_1101-2020_01_28_923532	366	11	either	either	CC
10_1101-2020_01_28_923532	366	12	our	-PRON-	PRP$
10_1101-2020_01_28_923532	366	13	set	set	NN
10_1101-2020_01_28_923532	366	14	of	of	IN
10_1101-2020_01_28_923532	366	15	1269	1269	CD
10_1101-2020_01_28_923532	366	16	genes	gene	NNS
10_1101-2020_01_28_923532	366	17	encoding	encode	VBG
10_1101-2020_01_28_923532	366	18	cell	cell	NN
10_1101-2020_01_28_923532	366	19	-	-	HYPH
10_1101-2020_01_28_923532	366	20	surface	surface	NN
10_1101-2020_01_28_923532	366	21	receptors	receptor	NNS
10_1101-2020_01_28_923532	366	22	that	that	WDT
10_1101-2020_01_28_923532	366	23	met	meet	VBD
10_1101-2020_01_28_923532	366	24	additional	additional	JJ
10_1101-2020_01_28_923532	366	25	criteria	criterion	NNS
10_1101-2020_01_28_923532	366	26	on	on	IN
10_1101-2020_01_28_923532	366	27	low	low	JJ
10_1101-2020_01_28_923532	366	28	expression	expression	NN
10_1101-2020_01_28_923532	366	29	or	or	CC
10_1101-2020_01_28_923532	366	30	available	available	JJ
10_1101-2020_01_28_923532	366	31	ligand	ligand	NN
10_1101-2020_01_28_923532	366	32	-	-	HYPH
10_1101-2020_01_28_923532	366	33	mimicking	mimicking	NN
10_1101-2020_01_28_923532	366	34	peptides	peptide	NNS
10_1101-2020_01_28_923532	366	35	.	.	.
10_1101-2020_01_28_923532	367	1	Table	table	NN
10_1101-2020_01_28_923532	367	2	1	1	CD
10_1101-2020_01_28_923532	367	3	.	.	.
10_1101-2020_01_28_923532	368	1	Summary	summary	JJ
10_1101-2020_01_28_923532	368	2	descriptions	description	NNS
10_1101-2020_01_28_923532	368	3	of	of	IN
10_1101-2020_01_28_923532	368	4	single	single	JJ
10_1101-2020_01_28_923532	368	5	-	-	HYPH
10_1101-2020_01_28_923532	368	6	cell	cell	NN
10_1101-2020_01_28_923532	368	7	data	data	NN
10_1101-2020_01_28_923532	368	8	sets	set	NNS
10_1101-2020_01_28_923532	368	9	from	from	IN
10_1101-2020_01_28_923532	368	10	solid	solid	JJ
10_1101-2020_01_28_923532	368	11	tumors	tumor	NNS
10_1101-2020_01_28_923532	368	12	used	use	VBN
10_1101-2020_01_28_923532	368	13	either	either	CC
10_1101-2020_01_28_923532	368	14	for	for	IN
10_1101-2020_01_28_923532	368	15	analysis	analysis	NN
10_1101-2020_01_28_923532	368	16	(	(	-LRB-
10_1101-2020_01_28_923532	368	17	9	9	CD
10_1101-2020_01_28_923532	368	18	)	)	-RRB-
10_1101-2020_01_28_923532	368	19	or	or	CC
10_1101-2020_01_28_923532	368	20	preliminary	preliminary	JJ
10_1101-2020_01_28_923532	368	21	testing	testing	NN
10_1101-2020_01_28_923532	368	22	(	(	-LRB-
10_1101-2020_01_28_923532	368	23	5	5	CD
10_1101-2020_01_28_923532	368	24	additional	additional	JJ
10_1101-2020_01_28_923532	368	25	)	)	-RRB-
10_1101-2020_01_28_923532	368	26	.	.	.
10_1101-2020_01_28_923532	369	1	Data	data	NN
10_1101-2020_01_28_923532	369	2	sets	set	NNS
10_1101-2020_01_28_923532	369	3	are	be	VBP
10_1101-2020_01_28_923532	369	4	ordered	order	VBN
10_1101-2020_01_28_923532	369	5	so	so	IN
10_1101-2020_01_28_923532	369	6	that	that	IN
10_1101-2020_01_28_923532	369	7	those	those	DT
10_1101-2020_01_28_923532	369	8	from	from	IN
10_1101-2020_01_28_923532	369	9	the	the	DT
10_1101-2020_01_28_923532	369	10	same	same	JJ
10_1101-2020_01_28_923532	369	11	or	or	CC
10_1101-2020_01_28_923532	369	12	similar	similar	JJ
10_1101-2020_01_28_923532	369	13	tumor	tumor	NN
10_1101-2020_01_28_923532	369	14	types	type	NNS
10_1101-2020_01_28_923532	369	15	are	be	VBP
10_1101-2020_01_28_923532	369	16	on	on	IN
10_1101-2020_01_28_923532	369	17	consecutive	consecutive	JJ
10_1101-2020_01_28_923532	369	18	rows	row	NNS
10_1101-2020_01_28_923532	369	19	.	.	.
10_1101-2020_01_28_923532	370	1	The	the	DT
10_1101-2020_01_28_923532	370	2	first	first	JJ
10_1101-2020_01_28_923532	370	3	13	13	CD
10_1101-2020_01_28_923532	370	4	data	datum	NNS
10_1101-2020_01_28_923532	370	5	sets	set	NNS
10_1101-2020_01_28_923532	370	6	were	be	VBD
10_1101-2020_01_28_923532	370	7	obtained	obtain	VBN
10_1101-2020_01_28_923532	370	8	either	either	CC
10_1101-2020_01_28_923532	370	9	from	from	IN
10_1101-2020_01_28_923532	370	10	GEO	GEO	NNP
10_1101-2020_01_28_923532	370	11	or	or	CC
10_1101-2020_01_28_923532	370	12	the	the	DT
10_1101-2020_01_28_923532	370	13	Broad	Broad	NNP
10_1101-2020_01_28_923532	370	14	Institute	Institute	NNP
10_1101-2020_01_28_923532	370	15	Single	Single	NNP
10_1101-2020_01_28_923532	370	16	Cell	Cell	NNP
10_1101-2020_01_28_923532	370	17	Portal	Portal	NNP
10_1101-2020_01_28_923532	370	18	,	,	,
10_1101-2020_01_28_923532	370	19	but	but	CC
10_1101-2020_01_28_923532	370	20	the	the	DT
10_1101-2020_01_28_923532	370	21	GEO	GEO	NNP
10_1101-2020_01_28_923532	370	22	code	code	NN
10_1101-2020_01_28_923532	370	23	is	be	VBZ
10_1101-2020_01_28_923532	370	24	shown	show	VBN
10_1101-2020_01_28_923532	370	25	.	.	.
10_1101-2020_01_28_923532	371	1	The	the	DT
10_1101-2020_01_28_923532	371	2	data	datum	NNS
10_1101-2020_01_28_923532	371	3	set	set	VBN
10_1101-2020_01_28_923532	371	4	on	on	IN
10_1101-2020_01_28_923532	371	5	the	the	DT
10_1101-2020_01_28_923532	371	6	last	last	JJ
10_1101-2020_01_28_923532	371	7	row	row	NN
10_1101-2020_01_28_923532	371	8	was	be	VBD
10_1101-2020_01_28_923532	371	9	obtained	obtain	VBN
10_1101-2020_01_28_923532	371	10	from	from	IN
10_1101-2020_01_28_923532	371	11	ArrayExpress	ArrayExpress	NNP
10_1101-2020_01_28_923532	371	12	.	.	.
10_1101-2020_01_28_923532	372	1	In	in	IN
10_1101-2020_01_28_923532	372	2	some	some	DT
10_1101-2020_01_28_923532	372	3	data	data	NN
10_1101-2020_01_28_923532	372	4	sets	set	NNS
10_1101-2020_01_28_923532	372	5	that	that	WDT
10_1101-2020_01_28_923532	372	6	have	have	VBP
10_1101-2020_01_28_923532	372	7	both	both	DT
10_1101-2020_01_28_923532	372	8	cancer	cancer	NN
10_1101-2020_01_28_923532	372	9	and	and	CC
10_1101-2020_01_28_923532	372	10	non-	non-	NN
10_1101-2020_01_28_923532	372	11	cancer	cancer	NN
10_1101-2020_01_28_923532	372	12	cells	cell	NNS
10_1101-2020_01_28_923532	372	13	,	,	,
10_1101-2020_01_28_923532	372	14	there	there	EX
10_1101-2020_01_28_923532	372	15	may	may	MD
10_1101-2020_01_28_923532	372	16	be	be	VB
10_1101-2020_01_28_923532	372	17	samples	sample	NNS
10_1101-2020_01_28_923532	372	18	for	for	IN
10_1101-2020_01_28_923532	372	19	which	which	WDT
10_1101-2020_01_28_923532	372	20	only	only	RB
10_1101-2020_01_28_923532	372	21	one	one	CD
10_1101-2020_01_28_923532	372	22	type	type	NN
10_1101-2020_01_28_923532	372	23	or	or	CC
10_1101-2020_01_28_923532	372	24	the	the	DT
10_1101-2020_01_28_923532	372	25	other	other	JJ
10_1101-2020_01_28_923532	372	26	is	be	VBZ
10_1101-2020_01_28_923532	372	27	provided	provide	VBN
10_1101-2020_01_28_923532	372	28	.	.	.
10_1101-2020_01_28_923532	373	1	Hence	hence	RB
10_1101-2020_01_28_923532	373	2	,	,	,
10_1101-2020_01_28_923532	373	3	the	the	DT
10_1101-2020_01_28_923532	373	4	105	105	CD
10_1101-2020_01_28_923532	373	5	and	and	CC
10_1101-2020_01_28_923532	373	6	is	be	VBZ
10_1101-2020_01_28_923532	373	7	also	also	RB
10_1101-2020_01_28_923532	373	8	made	make	VBN
10_1101-2020_01_28_923532	373	9	available	available	JJ
10_1101-2020_01_28_923532	373	10	for	for	IN
10_1101-2020_01_28_923532	373	11	use	use	NN
10_1101-2020_01_28_923532	373	12	under	under	IN
10_1101-2020_01_28_923532	373	13	a	a	DT
10_1101-2020_01_28_923532	373	14	CC0	CC0	NNP
10_1101-2020_01_28_923532	373	15	license	license	NN
10_1101-2020_01_28_923532	373	16	.	.	.
10_1101-2020_01_28_923532	374	1	(	(	-LRB-
10_1101-2020_01_28_923532	374	2	which	which	WDT
10_1101-2020_01_28_923532	374	3	was	be	VBD
10_1101-2020_01_28_923532	374	4	not	not	RB
10_1101-2020_01_28_923532	374	5	certified	certify	VBN
10_1101-2020_01_28_923532	374	6	by	by	IN
10_1101-2020_01_28_923532	374	7	peer	peer	NN
10_1101-2020_01_28_923532	374	8	review	review	NN
10_1101-2020_01_28_923532	374	9	)	)	-RRB-
10_1101-2020_01_28_923532	374	10	is	be	VBZ
10_1101-2020_01_28_923532	374	11	the	the	DT
10_1101-2020_01_28_923532	374	12	author	author	NN
10_1101-2020_01_28_923532	374	13	/	/	SYM
10_1101-2020_01_28_923532	374	14	funder	funder	NN
10_1101-2020_01_28_923532	374	15	.	.	.
10_1101-2020_01_28_923532	375	1	This	this	DT
10_1101-2020_01_28_923532	375	2	article	article	NN
10_1101-2020_01_28_923532	375	3	is	be	VBZ
10_1101-2020_01_28_923532	375	4	a	a	DT
10_1101-2020_01_28_923532	375	5	US	US	NNP
10_1101-2020_01_28_923532	375	6	Government	Government	NNP
10_1101-2020_01_28_923532	375	7	work	work	NN
10_1101-2020_01_28_923532	375	8	.	.	.
10_1101-2020_01_28_923532	376	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	376	2	is	be	VBZ
10_1101-2020_01_28_923532	376	3	not	not	RB
10_1101-2020_01_28_923532	376	4	subject	subject	JJ
10_1101-2020_01_28_923532	376	5	to	to	IN
10_1101-2020_01_28_923532	376	6	copyright	copyright	NN
10_1101-2020_01_28_923532	376	7	under	under	IN
10_1101-2020_01_28_923532	376	8	17	17	CD
10_1101-2020_01_28_923532	376	9	USC	usc	NN
10_1101-2020_01_28_923532	376	10	The	the	DT
10_1101-2020_01_28_923532	376	11	copyright	copyright	NN
10_1101-2020_01_28_923532	376	12	holder	holder	NN
10_1101-2020_01_28_923532	376	13	for	for	IN
10_1101-2020_01_28_923532	376	14	this	this	DT
10_1101-2020_01_28_923532	376	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	376	16	version	version	NN
10_1101-2020_01_28_923532	376	17	posted	post	VBD
10_1101-2020_01_28_923532	376	18	February	February	NNP
10_1101-2020_01_28_923532	376	19	12	12	CD
10_1101-2020_01_28_923532	376	20	,	,	,
10_1101-2020_01_28_923532	376	21	2021	2021	CD
10_1101-2020_01_28_923532	376	22	.	.	.
10_1101-2020_01_28_923532	376	23	;	;	:
10_1101-2020_01_28_923532	376	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	376	25	:	:	:
10_1101-2020_01_28_923532	376	26	bioRxiv	biorxiv	NN
10_1101-2020_01_28_923532	376	27	preprint	preprint	NN
10_1101-2020_01_28_923532	376	28	http://genenames.org/	http://genenames.org/	NN
10_1101-2020_01_28_923532	376	29	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	376	30	29	29	CD
10_1101-2020_01_28_923532	376	31	numbers	number	NNS
10_1101-2020_01_28_923532	376	32	in	in	IN
10_1101-2020_01_28_923532	376	33	parentheses	parenthesis	NNS
10_1101-2020_01_28_923532	376	34	in	in	IN
10_1101-2020_01_28_923532	376	35	the	the	DT
10_1101-2020_01_28_923532	376	36	third	third	JJ
10_1101-2020_01_28_923532	376	37	and	and	CC
10_1101-2020_01_28_923532	376	38	fourth	fourth	JJ
10_1101-2020_01_28_923532	376	39	columns	column	NNS
10_1101-2020_01_28_923532	376	40	may	may	MD
10_1101-2020_01_28_923532	376	41	differ	differ	VB
10_1101-2020_01_28_923532	376	42	.	.	.
10_1101-2020_01_28_923532	377	1	Data	datum	NNS
10_1101-2020_01_28_923532	377	2	set	set	NN
10_1101-2020_01_28_923532	377	3	GSE11597863	gse11597863	NN
10_1101-2020_01_28_923532	377	4	supersedes	supersede	NNS
10_1101-2020_01_28_923532	377	5	and	and	CC
10_1101-2020_01_28_923532	377	6	partly	partly	RB
10_1101-2020_01_28_923532	377	7	subsumes	subsume	VBZ
10_1101-2020_01_28_923532	377	8	GSE725664	GSE725664	NNP
10_1101-2020_01_28_923532	377	9	.	.	.
10_1101-2020_01_28_923532	378	1	Data	datum	NNS
10_1101-2020_01_28_923532	378	2	set	set	VBD
10_1101-2020_01_28_923532	378	3	code	code	NN
10_1101-2020_01_28_923532	378	4	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	378	5	type(s	type(s	NNP
10_1101-2020_01_28_923532	378	6	)	)	-RRB-
10_1101-2020_01_28_923532	378	7	Cancer	cancer	NN
10_1101-2020_01_28_923532	378	8	cells(samples	cells(sample	VBZ
10_1101-2020_01_28_923532	378	9	)	)	-RRB-
10_1101-2020_01_28_923532	378	10	Non-	Non-	NNP
10_1101-2020_01_28_923532	378	11	cancer	cancer	NN
10_1101-2020_01_28_923532	378	12	cells	cell	NNS
10_1101-2020_01_28_923532	378	13	(	(	-LRB-
10_1101-2020_01_28_923532	378	14	samples	sample	NNS
10_1101-2020_01_28_923532	378	15	)	)	-RRB-
10_1101-2020_01_28_923532	378	16	Clinical	clinical	JJ
10_1101-2020_01_28_923532	378	17	follow	follow	NN
10_1101-2020_01_28_923532	378	18	-	-	HYPH
10_1101-2020_01_28_923532	378	19	up	up	NN
10_1101-2020_01_28_923532	378	20	Reference(s	reference(s	CD
10_1101-2020_01_28_923532	378	21	)	)	-RRB-
10_1101-2020_01_28_923532	378	22	GSE75688	GSE75688	NNP
10_1101-2020_01_28_923532	378	23	Breast	Breast	NNP
10_1101-2020_01_28_923532	378	24	441(11	441(11	CD
10_1101-2020_01_28_923532	378	25	)	)	-RRB-
10_1101-2020_01_28_923532	378	26	--	--	:
10_1101-2020_01_28_923532	378	27	Metastasis	metastasis	NN
10_1101-2020_01_28_923532	378	28	or	or	CC
10_1101-2020_01_28_923532	378	29	not	not	RB
10_1101-2020_01_28_923532	378	30	65	65	CD
10_1101-2020_01_28_923532	378	31	GSE118389	GSE118389	NNP
10_1101-2020_01_28_923532	378	32	Breast	Breast	NNP
10_1101-2020_01_28_923532	378	33	804(6	804(6	CD
10_1101-2020_01_28_923532	378	34	)	)	-RRB-
10_1101-2020_01_28_923532	378	35	314(6	314(6	CD
10_1101-2020_01_28_923532	378	36	)	)	-RRB-
10_1101-2020_01_28_923532	378	37	Metastasis	metastasis	NN
10_1101-2020_01_28_923532	378	38	or	or	CC
10_1101-2020_01_28_923532	378	39	not	not	RB
10_1101-2020_01_28_923532	378	40	62	62	CD
10_1101-2020_01_28_923532	378	41	GSE89567	GSE89567	NNP
10_1101-2020_01_28_923532	378	42	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	43	(	(	-LRB-
10_1101-2020_01_28_923532	378	44	glioma	glioma	NNP
10_1101-2020_01_28_923532	378	45	)	)	-RRB-
10_1101-2020_01_28_923532	378	46	5097(10	5097(10	CD
10_1101-2020_01_28_923532	378	47	)	)	-RRB-
10_1101-2020_01_28_923532	378	48	1146(9	1146(9	CD
10_1101-2020_01_28_923532	378	49	)	)	-RRB-
10_1101-2020_01_28_923532	378	50	No	no	DT
10_1101-2020_01_28_923532	378	51	66	66	CD
10_1101-2020_01_28_923532	378	52	GSE103224	GSE103224	NNP
10_1101-2020_01_28_923532	378	53	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	54	(	(	-LRB-
10_1101-2020_01_28_923532	378	55	glioma	glioma	NNP
10_1101-2020_01_28_923532	378	56	)	)	-RRB-
10_1101-2020_01_28_923532	378	57	23793(8	23793(8	CD
10_1101-2020_01_28_923532	378	58	)	)	-RRB-
10_1101-2020_01_28_923532	378	59	--	--	:
10_1101-2020_01_28_923532	378	60	No	no	DT
10_1101-2020_01_28_923532	378	61	61	61	CD
10_1101-2020_01_28_923532	378	62	GSE70630	GSE70630	NNP
10_1101-2020_01_28_923532	378	63	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	64	(	(	-LRB-
10_1101-2020_01_28_923532	378	65	glioma	glioma	NNP
10_1101-2020_01_28_923532	378	66	)	)	-RRB-
10_1101-2020_01_28_923532	378	67	4044(6	4044(6	CD
10_1101-2020_01_28_923532	378	68	)	)	-RRB-
10_1101-2020_01_28_923532	378	69	303(6	303(6	CD
10_1101-2020_01_28_923532	378	70	)	)	-RRB-
10_1101-2020_01_28_923532	378	71	No	no	DT
10_1101-2020_01_28_923532	378	72	67	67	CD
10_1101-2020_01_28_923532	378	73	GSE57872	GSE57872	NNP
10_1101-2020_01_28_923532	378	74	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	75	(	(	-LRB-
10_1101-2020_01_28_923532	378	76	glioma	glioma	NNP
10_1101-2020_01_28_923532	378	77	)	)	-RRB-
10_1101-2020_01_28_923532	378	78	440(6	440(6	CD
10_1101-2020_01_28_923532	378	79	)	)	-RRB-
10_1101-2020_01_28_923532	378	80	--	--	:
10_1101-2020_01_28_923532	378	81	No	no	DT
10_1101-2020_01_28_923532	378	82	68	68	CD
10_1101-2020_01_28_923532	378	83	GSE102130	GSE102130	NNP
10_1101-2020_01_28_923532	378	84	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	85	(	(	-LRB-
10_1101-2020_01_28_923532	378	86	6	6	CD
10_1101-2020_01_28_923532	378	87	glioma	glioma	NNS
10_1101-2020_01_28_923532	378	88	and	and	CC
10_1101-2020_01_28_923532	378	89	3	3	CD
10_1101-2020_01_28_923532	378	90	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	378	91	)	)	-RRB-
10_1101-2020_01_28_923532	378	92	2858(9	2858(9	CD
10_1101-2020_01_28_923532	378	93	)	)	-RRB-
10_1101-2020_01_28_923532	378	94	94(5	94(5	CD
10_1101-2020_01_28_923532	378	95	)	)	-RRB-
10_1101-2020_01_28_923532	378	96	No	no	DT
10_1101-2020_01_28_923532	378	97	69	69	CD
10_1101-2020_01_28_923532	378	98	GSE84465	GSE84465	NNP
10_1101-2020_01_28_923532	378	99	Brain	Brain	NNP
10_1101-2020_01_28_923532	378	100	(	(	-LRB-
10_1101-2020_01_28_923532	378	101	glioblastoma	glioblastoma	NNP
10_1101-2020_01_28_923532	378	102	)	)	-RRB-
10_1101-2020_01_28_923532	378	103	1091(4	1091(4	CD
10_1101-2020_01_28_923532	378	104	)	)	-RRB-
10_1101-2020_01_28_923532	378	105	651(4	651(4	CD
10_1101-2020_01_28_923532	378	106	)	)	-RRB-
10_1101-2020_01_28_923532	378	107	No	no	DT
10_1101-2020_01_28_923532	378	108	46	46	CD
10_1101-2020_01_28_923532	378	109	GSE81861	GSE81861	NNP
10_1101-2020_01_28_923532	378	110	Colorectal	Colorectal	NNP
10_1101-2020_01_28_923532	378	111	272(10	272(10	CD
10_1101-2020_01_28_923532	378	112	)	)	-RRB-
10_1101-2020_01_28_923532	378	113	160(6	160(6	CD
10_1101-2020_01_28_923532	378	114	)	)	-RRB-
10_1101-2020_01_28_923532	378	115	No	no	DT
10_1101-2020_01_28_923532	378	116	70	70	CD
10_1101-2020_01_28_923532	378	117	GSE103322	GSE103322	NNP
10_1101-2020_01_28_923532	378	118	Head	Head	NNP
10_1101-2020_01_28_923532	378	119	and	and	CC
10_1101-2020_01_28_923532	378	120	Neck	Neck	NNP
10_1101-2020_01_28_923532	378	121	2093(13	2093(13	CD
10_1101-2020_01_28_923532	378	122	)	)	-RRB-
10_1101-2020_01_28_923532	378	123	3197(15	3197(15	CD
10_1101-2020_01_28_923532	378	124	)	)	-RRB-
10_1101-2020_01_28_923532	378	125	No	no	DT
10_1101-2020_01_28_923532	378	126	71	71	CD
10_1101-2020_01_28_923532	378	127	GSE115978	GSE115978	NNP
10_1101-2020_01_28_923532	378	128	Melanoma	Melanoma	NNP
10_1101-2020_01_28_923532	378	129	2018(23	2018(23	CD
10_1101-2020_01_28_923532	378	130	)	)	-RRB-
10_1101-2020_01_28_923532	378	131	4334(32	4334(32	CD
10_1101-2020_01_28_923532	378	132	)	)	-RRB-
10_1101-2020_01_28_923532	378	133	Yes	yes	UH
10_1101-2020_01_28_923532	378	134	,	,	,
10_1101-2020_01_28_923532	378	135	immuno-	immuno-	NN
10_1101-2020_01_28_923532	378	136	therapy	therapy	NN
10_1101-2020_01_28_923532	378	137	63,64	63,64	CD
10_1101-2020_01_28_923532	378	138	GSE118828	GSE118828	NNP
10_1101-2020_01_28_923532	378	139	Ovarian	Ovarian	NNP
10_1101-2020_01_28_923532	378	140	1415(11	1415(11	CD
10_1101-2020_01_28_923532	378	141	primary	primary	NN
10_1101-2020_01_28_923532	378	142	)	)	-RRB-
10_1101-2020_01_28_923532	378	143	973	973	CD
10_1101-2020_01_28_923532	378	144	(	(	-LRB-
10_1101-2020_01_28_923532	378	145	5	5	CD
10_1101-2020_01_28_923532	378	146	metastasis	metastasis	NN
10_1101-2020_01_28_923532	378	147	)	)	-RRB-
10_1101-2020_01_28_923532	378	148	578(2	578(2	NN
10_1101-2020_01_28_923532	378	149	)	)	-RRB-
10_1101-2020_01_28_923532	378	150	No	no	DT
10_1101-2020_01_28_923532	378	151	72	72	CD
10_1101-2020_01_28_923532	378	152	GSE67980	GSE67980	NNP
10_1101-2020_01_28_923532	378	153	Prostate	Prostate	NNP
10_1101-2020_01_28_923532	378	154	124(21	124(21	CD
10_1101-2020_01_28_923532	378	155	)	)	-RRB-
10_1101-2020_01_28_923532	378	156	--	--	:
10_1101-2020_01_28_923532	378	157	Metastasis	metastasis	NN
10_1101-2020_01_28_923532	378	158	or	or	CC
10_1101-2020_01_28_923532	378	159	not	not	RB
10_1101-2020_01_28_923532	378	160	73	73	CD
10_1101-2020_01_28_923532	378	161	E	E	NNP
10_1101-2020_01_28_923532	378	162	-	-	NNP
10_1101-2020_01_28_923532	378	163	MTAB-	MTAB-	NNP
10_1101-2020_01_28_923532	378	164	6149	6149	CD
10_1101-2020_01_28_923532	378	165	Lung	Lung	NNP
10_1101-2020_01_28_923532	378	166	7351(5	7351(5	CD
10_1101-2020_01_28_923532	378	167	)	)	-RRB-
10_1101-2020_01_28_923532	378	168	2730(5	2730(5	CD
10_1101-2020_01_28_923532	378	169	)	)	-RRB-
10_1101-2020_01_28_923532	378	170	No	no	DT
10_1101-2020_01_28_923532	378	171	74	74	CD
10_1101-2020_01_28_923532	378	172	105	105	CD
10_1101-2020_01_28_923532	378	173	and	and	CC
10_1101-2020_01_28_923532	378	174	is	be	VBZ
10_1101-2020_01_28_923532	378	175	also	also	RB
10_1101-2020_01_28_923532	378	176	made	make	VBN
10_1101-2020_01_28_923532	378	177	available	available	JJ
10_1101-2020_01_28_923532	378	178	for	for	IN
10_1101-2020_01_28_923532	378	179	use	use	NN
10_1101-2020_01_28_923532	378	180	under	under	IN
10_1101-2020_01_28_923532	378	181	a	a	DT
10_1101-2020_01_28_923532	378	182	CC0	CC0	NNP
10_1101-2020_01_28_923532	378	183	license	license	NN
10_1101-2020_01_28_923532	378	184	.	.	.
10_1101-2020_01_28_923532	379	1	(	(	-LRB-
10_1101-2020_01_28_923532	379	2	which	which	WDT
10_1101-2020_01_28_923532	379	3	was	be	VBD
10_1101-2020_01_28_923532	379	4	not	not	RB
10_1101-2020_01_28_923532	379	5	certified	certify	VBN
10_1101-2020_01_28_923532	379	6	by	by	IN
10_1101-2020_01_28_923532	379	7	peer	peer	NN
10_1101-2020_01_28_923532	379	8	review	review	NN
10_1101-2020_01_28_923532	379	9	)	)	-RRB-
10_1101-2020_01_28_923532	379	10	is	be	VBZ
10_1101-2020_01_28_923532	379	11	the	the	DT
10_1101-2020_01_28_923532	379	12	author	author	NN
10_1101-2020_01_28_923532	379	13	/	/	SYM
10_1101-2020_01_28_923532	379	14	funder	funder	NN
10_1101-2020_01_28_923532	379	15	.	.	.
10_1101-2020_01_28_923532	380	1	This	this	DT
10_1101-2020_01_28_923532	380	2	article	article	NN
10_1101-2020_01_28_923532	380	3	is	be	VBZ
10_1101-2020_01_28_923532	380	4	a	a	DT
10_1101-2020_01_28_923532	380	5	US	US	NNP
10_1101-2020_01_28_923532	380	6	Government	Government	NNP
10_1101-2020_01_28_923532	380	7	work	work	NN
10_1101-2020_01_28_923532	380	8	.	.	.
10_1101-2020_01_28_923532	381	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	381	2	is	be	VBZ
10_1101-2020_01_28_923532	381	3	not	not	RB
10_1101-2020_01_28_923532	381	4	subject	subject	JJ
10_1101-2020_01_28_923532	381	5	to	to	IN
10_1101-2020_01_28_923532	381	6	copyright	copyright	NN
10_1101-2020_01_28_923532	381	7	under	under	IN
10_1101-2020_01_28_923532	381	8	17	17	CD
10_1101-2020_01_28_923532	381	9	USC	usc	NN
10_1101-2020_01_28_923532	381	10	The	the	DT
10_1101-2020_01_28_923532	381	11	copyright	copyright	NN
10_1101-2020_01_28_923532	381	12	holder	holder	NN
10_1101-2020_01_28_923532	381	13	for	for	IN
10_1101-2020_01_28_923532	381	14	this	this	DT
10_1101-2020_01_28_923532	381	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	381	16	version	version	NN
10_1101-2020_01_28_923532	381	17	posted	post	VBD
10_1101-2020_01_28_923532	381	18	February	February	NNP
10_1101-2020_01_28_923532	381	19	12	12	CD
10_1101-2020_01_28_923532	381	20	,	,	,
10_1101-2020_01_28_923532	381	21	2021	2021	CD
10_1101-2020_01_28_923532	381	22	.	.	.
10_1101-2020_01_28_923532	381	23	;	;	:
10_1101-2020_01_28_923532	381	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	381	25	:	:	:
10_1101-2020_01_28_923532	381	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	381	27	preprint	preprint	NN
10_1101-2020_01_28_923532	381	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	381	29	30	30	CD
10_1101-2020_01_28_923532	381	30	Sampling	Sampling	NNP
10_1101-2020_01_28_923532	381	31	Process	Process	NNP
10_1101-2020_01_28_923532	381	32	to	to	IN
10_1101-2020_01_28_923532	381	33	Generate	Generate	NNP
10_1101-2020_01_28_923532	381	34	Replicates	Replicates	NNPS
10_1101-2020_01_28_923532	381	35	of	of	IN
10_1101-2020_01_28_923532	381	36	Data	Data	NNP
10_1101-2020_01_28_923532	381	37	Sets	Sets	NNPS
10_1101-2020_01_28_923532	381	38	As	as	IN
10_1101-2020_01_28_923532	381	39	shown	show	VBN
10_1101-2020_01_28_923532	381	40	in	in	IN
10_1101-2020_01_28_923532	381	41	Table	table	NN
10_1101-2020_01_28_923532	381	42	1	1	CD
10_1101-2020_01_28_923532	381	43	,	,	,
10_1101-2020_01_28_923532	381	44	the	the	DT
10_1101-2020_01_28_923532	381	45	number	number	NN
10_1101-2020_01_28_923532	381	46	of	of	IN
10_1101-2020_01_28_923532	381	47	cells	cell	NNS
10_1101-2020_01_28_923532	381	48	available	available	JJ
10_1101-2020_01_28_923532	381	49	in	in	IN
10_1101-2020_01_28_923532	381	50	the	the	DT
10_1101-2020_01_28_923532	381	51	different	different	JJ
10_1101-2020_01_28_923532	381	52	single	single	JJ
10_1101-2020_01_28_923532	381	53	-	-	HYPH
10_1101-2020_01_28_923532	381	54	cell	cell	NN
10_1101-2020_01_28_923532	381	55	data	data	NN
10_1101-2020_01_28_923532	381	56	sets	set	NNS
10_1101-2020_01_28_923532	381	57	varies	vary	VBZ
10_1101-2020_01_28_923532	381	58	by	by	IN
10_1101-2020_01_28_923532	381	59	three	three	CD
10_1101-2020_01_28_923532	381	60	orders	order	NNS
10_1101-2020_01_28_923532	381	61	of	of	IN
10_1101-2020_01_28_923532	381	62	magnitude	magnitude	NN
10_1101-2020_01_28_923532	381	63	;	;	:
10_1101-2020_01_28_923532	381	64	to	to	TO
10_1101-2020_01_28_923532	381	65	enable	enable	VB
10_1101-2020_01_28_923532	381	66	us	-PRON-	PRP
10_1101-2020_01_28_923532	381	67	to	to	TO
10_1101-2020_01_28_923532	381	68	compare	compare	VB
10_1101-2020_01_28_923532	381	69	the	the	DT
10_1101-2020_01_28_923532	381	70	findings	finding	NNS
10_1101-2020_01_28_923532	381	71	across	across	IN
10_1101-2020_01_28_923532	381	72	different	different	JJ
10_1101-2020_01_28_923532	381	73	data	data	NN
10_1101-2020_01_28_923532	381	74	sets	set	NNS
10_1101-2020_01_28_923532	381	75	and	and	CC
10_1101-2020_01_28_923532	381	76	cancer	cancer	NN
10_1101-2020_01_28_923532	381	77	types	type	NNS
10_1101-2020_01_28_923532	381	78	on	on	IN
10_1101-2020_01_28_923532	381	79	more	more	RBR
10_1101-2020_01_28_923532	381	80	equal	equal	JJ
10_1101-2020_01_28_923532	381	81	footing	footing	NN
10_1101-2020_01_28_923532	381	82	,	,	,
10_1101-2020_01_28_923532	381	83	we	-PRON-	PRP
10_1101-2020_01_28_923532	381	84	employed	employ	VBD
10_1101-2020_01_28_923532	381	85	sampling	sampling	NN
10_1101-2020_01_28_923532	381	86	from	from	IN
10_1101-2020_01_28_923532	381	87	the	the	DT
10_1101-2020_01_28_923532	381	88	larger	large	JJR
10_1101-2020_01_28_923532	381	89	sets	set	NNS
10_1101-2020_01_28_923532	381	90	to	to	TO
10_1101-2020_01_28_923532	381	91	reduce	reduce	VB
10_1101-2020_01_28_923532	381	92	this	this	DT
10_1101-2020_01_28_923532	381	93	difference	difference	NN
10_1101-2020_01_28_923532	381	94	to	to	IN
10_1101-2020_01_28_923532	381	95	one	one	CD
10_1101-2020_01_28_923532	381	96	order	order	NN
10_1101-2020_01_28_923532	381	97	of	of	IN
10_1101-2020_01_28_923532	381	98	magnitude	magnitude	NN
10_1101-2020_01_28_923532	381	99	.	.	.
10_1101-2020_01_28_923532	382	1	This	this	DT
10_1101-2020_01_28_923532	382	2	goes	go	VBZ
10_1101-2020_01_28_923532	382	3	along	along	RP
10_1101-2020_01_28_923532	382	4	with	with	IN
10_1101-2020_01_28_923532	382	5	the	the	DT
10_1101-2020_01_28_923532	382	6	data	datum	NNS
10_1101-2020_01_28_923532	382	7	collection	collection	NN
10_1101-2020_01_28_923532	382	8	process	process	NN
10_1101-2020_01_28_923532	382	9	in	in	IN
10_1101-2020_01_28_923532	382	10	the	the	DT
10_1101-2020_01_28_923532	382	11	real	real	JJ
10_1101-2020_01_28_923532	382	12	world	world	NN
10_1101-2020_01_28_923532	382	13	as	as	IN
10_1101-2020_01_28_923532	382	14	we	-PRON-	PRP
10_1101-2020_01_28_923532	382	15	might	may	MD
10_1101-2020_01_28_923532	382	16	get	get	VB
10_1101-2020_01_28_923532	382	17	measurements	measurement	NNS
10_1101-2020_01_28_923532	382	18	from	from	IN
10_1101-2020_01_28_923532	382	19	different	different	JJ
10_1101-2020_01_28_923532	382	20	samples	sample	NNS
10_1101-2020_01_28_923532	382	21	at	at	IN
10_1101-2020_01_28_923532	382	22	different	different	JJ
10_1101-2020_01_28_923532	382	23	times	time	NNS
10_1101-2020_01_28_923532	382	24	.	.	.
10_1101-2020_01_28_923532	383	1	Suppose	suppose	VB
10_1101-2020_01_28_923532	383	2	for	for	IN
10_1101-2020_01_28_923532	383	3	a	a	DT
10_1101-2020_01_28_923532	383	4	data	data	NN
10_1101-2020_01_28_923532	383	5	set	set	NN
10_1101-2020_01_28_923532	383	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	383	7	have	have	VBP
10_1101-2020_01_28_923532	383	8	𝑛	𝑛	NN
10_1101-2020_01_28_923532	383	9	genes	gene	NNS
10_1101-2020_01_28_923532	383	10	,	,	,
10_1101-2020_01_28_923532	383	11	and	and	CC
10_1101-2020_01_28_923532	383	12	𝑚	𝑚	DT
10_1101-2020_01_28_923532	383	13	cells	cell	NNS
10_1101-2020_01_28_923532	383	14	comprising	comprise	VBG
10_1101-2020_01_28_923532	383	15	tumor	tumor	NN
10_1101-2020_01_28_923532	383	16	cells	cell	NNS
10_1101-2020_01_28_923532	383	17	and	and	CC
10_1101-2020_01_28_923532	383	18	non	non	JJ
10_1101-2020_01_28_923532	383	19	-	-	JJ
10_1101-2020_01_28_923532	383	20	tumor	tumor	JJ
10_1101-2020_01_28_923532	383	21	cells	cell	NNS
10_1101-2020_01_28_923532	383	22	.	.	.
10_1101-2020_01_28_923532	384	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	384	2	want	want	VBP
10_1101-2020_01_28_923532	384	3	to	to	TO
10_1101-2020_01_28_923532	384	4	select	select	VB
10_1101-2020_01_28_923532	384	5	a	a	DT
10_1101-2020_01_28_923532	384	6	subset	subset	NN
10_1101-2020_01_28_923532	384	7	of	of	IN
10_1101-2020_01_28_923532	384	8	𝑚	𝑚	DT
10_1101-2020_01_28_923532	384	9	′	′	XX
10_1101-2020_01_28_923532	384	10	<	<	XX
10_1101-2020_01_28_923532	384	11	𝑚	𝑚	NN
10_1101-2020_01_28_923532	384	12	cells	cell	NNS
10_1101-2020_01_28_923532	384	13	.	.	.
10_1101-2020_01_28_923532	385	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	385	2	select	select	VBP
10_1101-2020_01_28_923532	385	3	a	a	DT
10_1101-2020_01_28_923532	385	4	set	set	NN
10_1101-2020_01_28_923532	385	5	of	of	IN
10_1101-2020_01_28_923532	385	6	𝑚′	𝑚′	NN
10_1101-2020_01_28_923532	385	7	cells	cell	NNS
10_1101-2020_01_28_923532	385	8	uniformly	uniformly	RB
10_1101-2020_01_28_923532	385	9	at	at	IN
10_1101-2020_01_28_923532	385	10	random	random	JJ
10_1101-2020_01_28_923532	385	11	without	without	IN
10_1101-2020_01_28_923532	385	12	replacement	replacement	NN
10_1101-2020_01_28_923532	385	13	from	from	IN
10_1101-2020_01_28_923532	385	14	among	among	IN
10_1101-2020_01_28_923532	385	15	all	all	DT
10_1101-2020_01_28_923532	385	16	cells	cell	NNS
10_1101-2020_01_28_923532	385	17	.	.	.
10_1101-2020_01_28_923532	386	1	Then	then	RB
10_1101-2020_01_28_923532	386	2	we	-PRON-	PRP
10_1101-2020_01_28_923532	386	3	partition	partition	VBP
10_1101-2020_01_28_923532	386	4	the	the	DT
10_1101-2020_01_28_923532	386	5	selected	select	VBN
10_1101-2020_01_28_923532	386	6	cells	cell	NNS
10_1101-2020_01_28_923532	386	7	into	into	IN
10_1101-2020_01_28_923532	386	8	𝑚𝑡	𝑚𝑡	NNP
10_1101-2020_01_28_923532	386	9	′	′	CD
10_1101-2020_01_28_923532	386	10	tumor	tumor	NN
10_1101-2020_01_28_923532	386	11	cells	cell	NNS
10_1101-2020_01_28_923532	386	12	and	and	CC
10_1101-2020_01_28_923532	386	13	𝑚𝑛	𝑚𝑛	NNP
10_1101-2020_01_28_923532	386	14	′	′	NFP
10_1101-2020_01_28_923532	386	15	non	non	JJ
10_1101-2020_01_28_923532	386	16	-	-	JJ
10_1101-2020_01_28_923532	386	17	tumor	tumor	JJ
10_1101-2020_01_28_923532	386	18	cells	cell	NNS
10_1101-2020_01_28_923532	386	19	to	to	TO
10_1101-2020_01_28_923532	386	20	define	define	VB
10_1101-2020_01_28_923532	386	21	one	one	CD
10_1101-2020_01_28_923532	386	22	replicate	replicate	NN
10_1101-2020_01_28_923532	386	23	.	.	.
10_1101-2020_01_28_923532	387	1	In	in	IN
10_1101-2020_01_28_923532	387	2	most	most	JJS
10_1101-2020_01_28_923532	387	3	of	of	IN
10_1101-2020_01_28_923532	387	4	the	the	DT
10_1101-2020_01_28_923532	387	5	computational	computational	JJ
10_1101-2020_01_28_923532	387	6	experiments	experiment	NNS
10_1101-2020_01_28_923532	387	7	shown	show	VBN
10_1101-2020_01_28_923532	387	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	387	9	used	use	VBD
10_1101-2020_01_28_923532	387	10	20	20	CD
10_1101-2020_01_28_923532	387	11	replicates	replicate	NNS
10_1101-2020_01_28_923532	387	12	and	and	CC
10_1101-2020_01_28_923532	387	13	we	-PRON-	PRP
10_1101-2020_01_28_923532	387	14	report	report	VBP
10_1101-2020_01_28_923532	387	15	either	either	CC
10_1101-2020_01_28_923532	387	16	the	the	DT
10_1101-2020_01_28_923532	387	17	arithmetic	arithmetic	JJ
10_1101-2020_01_28_923532	387	18	mean	mean	NN
10_1101-2020_01_28_923532	387	19	or	or	CC
10_1101-2020_01_28_923532	387	20	entire	entire	JJ
10_1101-2020_01_28_923532	387	21	distribution	distribution	NN
10_1101-2020_01_28_923532	387	22	of	of	IN
10_1101-2020_01_28_923532	387	23	quantities	quantity	NNS
10_1101-2020_01_28_923532	387	24	such	such	JJ
10_1101-2020_01_28_923532	387	25	as	as	IN
10_1101-2020_01_28_923532	387	26	the	the	DT
10_1101-2020_01_28_923532	387	27	CTS	CTS	NNP
10_1101-2020_01_28_923532	387	28	size	size	NN
10_1101-2020_01_28_923532	387	29	.	.	.
10_1101-2020_01_28_923532	388	1	Considering	consider	VBG
10_1101-2020_01_28_923532	388	2	a	a	DT
10_1101-2020_01_28_923532	388	3	previously	previously	RB
10_1101-2020_01_28_923532	388	4	defined	define	VBN
10_1101-2020_01_28_923532	388	5	set	set	NN
10_1101-2020_01_28_923532	388	6	of	of	IN
10_1101-2020_01_28_923532	388	7	target	target	NN
10_1101-2020_01_28_923532	388	8	genes	gene	NNS
10_1101-2020_01_28_923532	388	9	and	and	CC
10_1101-2020_01_28_923532	388	10	of	of	IN
10_1101-2020_01_28_923532	388	11	HPA	HPA	NNP
10_1101-2020_01_28_923532	388	12	gene	gene	NN
10_1101-2020_01_28_923532	388	13	expression	expression	NN
10_1101-2020_01_28_923532	388	14	across	across	IN
10_1101-2020_01_28_923532	388	15	different	different	JJ
10_1101-2020_01_28_923532	388	16	normal	normal	JJ
10_1101-2020_01_28_923532	388	17	tissues	tissue	NNS
10_1101-2020_01_28_923532	388	18	The	the	DT
10_1101-2020_01_28_923532	388	19	general	general	JJ
10_1101-2020_01_28_923532	388	20	aim	aim	NN
10_1101-2020_01_28_923532	388	21	of	of	IN
10_1101-2020_01_28_923532	388	22	our	-PRON-	PRP$
10_1101-2020_01_28_923532	388	23	methods	method	NNS
10_1101-2020_01_28_923532	388	24	is	be	VBZ
10_1101-2020_01_28_923532	388	25	to	to	TO
10_1101-2020_01_28_923532	388	26	target	target	VB
10_1101-2020_01_28_923532	388	27	the	the	DT
10_1101-2020_01_28_923532	388	28	cancer	cancer	NN
10_1101-2020_01_28_923532	388	29	cells	cell	NNS
10_1101-2020_01_28_923532	388	30	while	while	IN
10_1101-2020_01_28_923532	388	31	sparing	spare	VBG
10_1101-2020_01_28_923532	388	32	the	the	DT
10_1101-2020_01_28_923532	388	33	adjacent	adjacent	JJ
10_1101-2020_01_28_923532	388	34	non-	non-	NN
10_1101-2020_01_28_923532	388	35	cancer	cancer	NN
10_1101-2020_01_28_923532	388	36	cells	cell	NNS
10_1101-2020_01_28_923532	388	37	as	as	RB
10_1101-2020_01_28_923532	388	38	much	much	RB
10_1101-2020_01_28_923532	388	39	as	as	IN
10_1101-2020_01_28_923532	388	40	possible	possible	JJ
10_1101-2020_01_28_923532	388	41	.	.	.
10_1101-2020_01_28_923532	389	1	A	a	DT
10_1101-2020_01_28_923532	389	2	related	related	JJ
10_1101-2020_01_28_923532	389	3	concern	concern	NN
10_1101-2020_01_28_923532	389	4	is	be	VBZ
10_1101-2020_01_28_923532	389	5	that	that	IN
10_1101-2020_01_28_923532	389	6	genes	gene	NNS
10_1101-2020_01_28_923532	389	7	within	within	IN
10_1101-2020_01_28_923532	389	8	the	the	DT
10_1101-2020_01_28_923532	389	9	target	target	NN
10_1101-2020_01_28_923532	389	10	set	set	VBN
10_1101-2020_01_28_923532	389	11	could	could	MD
10_1101-2020_01_28_923532	389	12	be	be	VB
10_1101-2020_01_28_923532	389	13	expressed	express	VBN
10_1101-2020_01_28_923532	389	14	at	at	IN
10_1101-2020_01_28_923532	389	15	high	high	JJ
10_1101-2020_01_28_923532	389	16	levels	level	NNS
10_1101-2020_01_28_923532	389	17	in	in	IN
10_1101-2020_01_28_923532	389	18	other	other	JJ
10_1101-2020_01_28_923532	389	19	normal	normal	JJ
10_1101-2020_01_28_923532	389	20	tissues	tissue	NNS
10_1101-2020_01_28_923532	389	21	that	that	WDT
10_1101-2020_01_28_923532	389	22	are	be	VBP
10_1101-2020_01_28_923532	389	23	not	not	RB
10_1101-2020_01_28_923532	389	24	part	part	NN
10_1101-2020_01_28_923532	389	25	of	of	IN
10_1101-2020_01_28_923532	389	26	the	the	DT
10_1101-2020_01_28_923532	389	27	non	non	JJ
10_1101-2020_01_28_923532	389	28	-	-	JJ
10_1101-2020_01_28_923532	389	29	cancer	cancer	JJ
10_1101-2020_01_28_923532	389	30	cells	cell	NNS
10_1101-2020_01_28_923532	389	31	from	from	IN
10_1101-2020_01_28_923532	389	32	the	the	DT
10_1101-2020_01_28_923532	389	33	tumor	tumor	NN
10_1101-2020_01_28_923532	389	34	microenvironment	microenvironment	NN
10_1101-2020_01_28_923532	389	35	included	include	VBN
10_1101-2020_01_28_923532	389	36	in	in	IN
10_1101-2020_01_28_923532	389	37	the	the	DT
10_1101-2020_01_28_923532	389	38	input	input	NN
10_1101-2020_01_28_923532	389	39	data	datum	NNS
10_1101-2020_01_28_923532	389	40	sets	set	NNS
10_1101-2020_01_28_923532	389	41	.	.	.
10_1101-2020_01_28_923532	390	1	One	one	CD
10_1101-2020_01_28_923532	390	2	way	way	NN
10_1101-2020_01_28_923532	390	3	to	to	TO
10_1101-2020_01_28_923532	390	4	address	address	VB
10_1101-2020_01_28_923532	390	5	this	this	DT
10_1101-2020_01_28_923532	390	6	problem	problem	NN
10_1101-2020_01_28_923532	390	7	is	be	VBZ
10_1101-2020_01_28_923532	390	8	to	to	TO
10_1101-2020_01_28_923532	390	9	identify	identify	VB
10_1101-2020_01_28_923532	390	10	genes	gene	NNS
10_1101-2020_01_28_923532	390	11	that	that	WDT
10_1101-2020_01_28_923532	390	12	have	have	VBP
10_1101-2020_01_28_923532	390	13	low	low	JJ
10_1101-2020_01_28_923532	390	14	expression	expression	NN
10_1101-2020_01_28_923532	390	15	in	in	IN
10_1101-2020_01_28_923532	390	16	the	the	DT
10_1101-2020_01_28_923532	390	17	majority	majority	NN
10_1101-2020_01_28_923532	390	18	of	of	IN
10_1101-2020_01_28_923532	390	19	the	the	DT
10_1101-2020_01_28_923532	390	20	tissues	tissue	NNS
10_1101-2020_01_28_923532	390	21	and	and	CC
10_1101-2020_01_28_923532	390	22	to	to	TO
10_1101-2020_01_28_923532	390	23	use	use	VB
10_1101-2020_01_28_923532	390	24	them	-PRON-	PRP
10_1101-2020_01_28_923532	390	25	to	to	TO
10_1101-2020_01_28_923532	390	26	obtain	obtain	VB
10_1101-2020_01_28_923532	390	27	a	a	DT
10_1101-2020_01_28_923532	390	28	target	target	NN
10_1101-2020_01_28_923532	390	29	set	set	VBN
10_1101-2020_01_28_923532	390	30	.	.	.
10_1101-2020_01_28_923532	391	1	This	this	DT
10_1101-2020_01_28_923532	391	2	approach	approach	NN
10_1101-2020_01_28_923532	391	3	has	have	VBZ
10_1101-2020_01_28_923532	391	4	been	be	VBN
10_1101-2020_01_28_923532	391	5	pioneered	pioneer	VBN
10_1101-2020_01_28_923532	391	6	in	in	IN
10_1101-2020_01_28_923532	391	7	a	a	DT
10_1101-2020_01_28_923532	391	8	recent	recent	JJ
10_1101-2020_01_28_923532	391	9	paper	paper	NN
10_1101-2020_01_28_923532	391	10	on	on	IN
10_1101-2020_01_28_923532	391	11	selecting	select	VBG
10_1101-2020_01_28_923532	391	12	gene	gene	NN
10_1101-2020_01_28_923532	391	13	targets	target	NNS
10_1101-2020_01_28_923532	391	14	suitable	suitable	JJ
10_1101-2020_01_28_923532	391	15	for	for	IN
10_1101-2020_01_28_923532	391	16	CAR	CAR	NNP
10_1101-2020_01_28_923532	391	17	-	-	HYPH
10_1101-2020_01_28_923532	391	18	T	t	NN
10_1101-2020_01_28_923532	391	19	therapy25	therapy25	NN
10_1101-2020_01_28_923532	391	20	.	.	.
10_1101-2020_01_28_923532	392	1	The	the	DT
10_1101-2020_01_28_923532	392	2	authors	author	NNS
10_1101-2020_01_28_923532	392	3	selected	select	VBD
10_1101-2020_01_28_923532	392	4	533	533	CD
10_1101-2020_01_28_923532	392	5	candidate	candidate	NN
10_1101-2020_01_28_923532	392	6	genes	gene	NNS
10_1101-2020_01_28_923532	392	7	that	that	WDT
10_1101-2020_01_28_923532	392	8	they	-PRON-	PRP
10_1101-2020_01_28_923532	392	9	judged	judge	VBD
10_1101-2020_01_28_923532	392	10	could	could	MD
10_1101-2020_01_28_923532	392	11	be	be	VB
10_1101-2020_01_28_923532	392	12	reasonable	reasonable	JJ
10_1101-2020_01_28_923532	392	13	targets	target	NNS
10_1101-2020_01_28_923532	392	14	for	for	IN
10_1101-2020_01_28_923532	392	15	CAR	car	NN
10_1101-2020_01_28_923532	392	16	-	-	HYPH
10_1101-2020_01_28_923532	392	17	T.	t.	NN
10_1101-2020_01_28_923532	393	1	They	-PRON-	PRP
10_1101-2020_01_28_923532	393	2	made	make	VBD
10_1101-2020_01_28_923532	393	3	this	this	DT
10_1101-2020_01_28_923532	393	4	selection	selection	NN
10_1101-2020_01_28_923532	393	5	based	base	VBN
10_1101-2020_01_28_923532	393	6	on	on	IN
10_1101-2020_01_28_923532	393	7	expression	expression	NN
10_1101-2020_01_28_923532	393	8	data	datum	NNS
10_1101-2020_01_28_923532	393	9	from	from	IN
10_1101-2020_01_28_923532	393	10	the	the	DT
10_1101-2020_01_28_923532	393	11	Human	Human	NNP
10_1101-2020_01_28_923532	393	12	Protein	Protein	NNP
10_1101-2020_01_28_923532	393	13	Atlas75	Atlas75	NNP
10_1101-2020_01_28_923532	393	14	and	and	CC
10_1101-2020_01_28_923532	393	15	the	the	DT
10_1101-2020_01_28_923532	393	16	Genotype	Genotype	NNP
10_1101-2020_01_28_923532	393	17	-	-	HYPH
10_1101-2020_01_28_923532	393	18	Tissue	Tissue	NNP
10_1101-2020_01_28_923532	393	19	Expression	Expression	NNP
10_1101-2020_01_28_923532	393	20	consortium	consortium	NN
10_1101-2020_01_28_923532	393	21	(	(	-LRB-
10_1101-2020_01_28_923532	393	22	GTEx)76	GTEx)76	NNP
10_1101-2020_01_28_923532	393	23	,	,	,
10_1101-2020_01_28_923532	393	24	which	which	WDT
10_1101-2020_01_28_923532	393	25	have	have	VBP
10_1101-2020_01_28_923532	393	26	expression	expression	NN
10_1101-2020_01_28_923532	393	27	information	information	NN
10_1101-2020_01_28_923532	393	28	from	from	IN
10_1101-2020_01_28_923532	393	29	multiple	multiple	JJ
10_1101-2020_01_28_923532	393	30	tissues	tissue	NNS
10_1101-2020_01_28_923532	393	31	which	which	WDT
10_1101-2020_01_28_923532	393	32	was	be	VBD
10_1101-2020_01_28_923532	393	33	used	use	VBN
10_1101-2020_01_28_923532	393	34	to	to	TO
10_1101-2020_01_28_923532	393	35	identify	identify	VB
10_1101-2020_01_28_923532	393	36	low	low	JJ
10_1101-2020_01_28_923532	393	37	expressed	express	VBN
10_1101-2020_01_28_923532	393	38	target	target	NN
10_1101-2020_01_28_923532	393	39	genes	gene	NNS
10_1101-2020_01_28_923532	393	40	.	.	.
10_1101-2020_01_28_923532	394	1	McKay	McKay	NNP
10_1101-2020_01_28_923532	394	2	et	et	NNP
10_1101-2020_01_28_923532	394	3	al.25	al.25	IN
10_1101-2020_01_28_923532	394	4	used	use	VBD
10_1101-2020_01_28_923532	394	5	a	a	DT
10_1101-2020_01_28_923532	394	6	threshold	threshold	NN
10_1101-2020_01_28_923532	394	7	of	of	IN
10_1101-2020_01_28_923532	394	8	15	15	CD
10_1101-2020_01_28_923532	394	9	TPM	TPM	NNP
10_1101-2020_01_28_923532	394	10	units	unit	NNS
10_1101-2020_01_28_923532	394	11	of	of	IN
10_1101-2020_01_28_923532	394	12	expression	expression	NN
10_1101-2020_01_28_923532	394	13	(	(	-LRB-
10_1101-2020_01_28_923532	394	14	written	write	VBN
10_1101-2020_01_28_923532	394	15	in	in	IN
10_1101-2020_01_28_923532	394	16	their	-PRON-	PRP$
10_1101-2020_01_28_923532	394	17	work	work	NN
10_1101-2020_01_28_923532	394	18	as	as	IN
10_1101-2020_01_28_923532	394	19	log2(TPM+1	log2(TPM+1	NNP
10_1101-2020_01_28_923532	394	20	)	)	-RRB-
10_1101-2020_01_28_923532	394	21	≤	≤	NNP
10_1101-2020_01_28_923532	394	22	4	4	CD
10_1101-2020_01_28_923532	394	23	)	)	-RRB-
10_1101-2020_01_28_923532	394	24	,	,	,
10_1101-2020_01_28_923532	394	25	but	but	CC
10_1101-2020_01_28_923532	394	26	they	-PRON-	PRP
10_1101-2020_01_28_923532	394	27	allowed	allow	VBD
10_1101-2020_01_28_923532	394	28	a	a	DT
10_1101-2020_01_28_923532	394	29	small	small	JJ
10_1101-2020_01_28_923532	394	30	number	number	NN
10_1101-2020_01_28_923532	394	31	of	of	IN
10_1101-2020_01_28_923532	394	32	tissues	tissue	NNS
10_1101-2020_01_28_923532	394	33	to	to	TO
10_1101-2020_01_28_923532	394	34	exceed	exceed	VB
10_1101-2020_01_28_923532	394	35	this	this	DT
10_1101-2020_01_28_923532	394	36	threshold	threshold	NN
10_1101-2020_01_28_923532	394	37	.	.	.
10_1101-2020_01_28_923532	395	1	Instead	instead	RB
10_1101-2020_01_28_923532	395	2	,	,	,
10_1101-2020_01_28_923532	395	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	395	4	used	use	VBD
10_1101-2020_01_28_923532	395	5	quantitative	quantitative	JJ
10_1101-2020_01_28_923532	395	6	levels	level	NNS
10_1101-2020_01_28_923532	395	7	of	of	IN
10_1101-2020_01_28_923532	395	8	expression	expression	NN
10_1101-2020_01_28_923532	395	9	for	for	IN
10_1101-2020_01_28_923532	395	10	finer	fine	JJR
10_1101-2020_01_28_923532	395	11	granularity	granularity	NN
10_1101-2020_01_28_923532	395	12	in	in	IN
10_1101-2020_01_28_923532	395	13	analysis	analysis	NN
10_1101-2020_01_28_923532	395	14	,	,	,
10_1101-2020_01_28_923532	395	15	as	as	IN
10_1101-2020_01_28_923532	395	16	described	describe	VBN
10_1101-2020_01_28_923532	395	17	in	in	IN
10_1101-2020_01_28_923532	395	18	the	the	DT
10_1101-2020_01_28_923532	395	19	next	next	JJ
10_1101-2020_01_28_923532	395	20	subsection	subsection	NN
10_1101-2020_01_28_923532	395	21	.	.	.
10_1101-2020_01_28_923532	396	1	One	one	CD
10_1101-2020_01_28_923532	396	2	clinical	clinical	JJ
10_1101-2020_01_28_923532	396	3	difference	difference	NN
10_1101-2020_01_28_923532	396	4	is	be	VBZ
10_1101-2020_01_28_923532	396	5	that	that	IN
10_1101-2020_01_28_923532	396	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	396	7	looked	look	VBD
10_1101-2020_01_28_923532	396	8	only	only	RB
10_1101-2020_01_28_923532	396	9	at	at	IN
10_1101-2020_01_28_923532	396	10	adult	adult	NN
10_1101-2020_01_28_923532	396	11	tissues	tissue	NNS
10_1101-2020_01_28_923532	396	12	because	because	IN
10_1101-2020_01_28_923532	396	13	we	-PRON-	PRP
10_1101-2020_01_28_923532	396	14	are	be	VBP
10_1101-2020_01_28_923532	396	15	105	105	CD
10_1101-2020_01_28_923532	396	16	and	and	CC
10_1101-2020_01_28_923532	396	17	is	be	VBZ
10_1101-2020_01_28_923532	396	18	also	also	RB
10_1101-2020_01_28_923532	396	19	made	make	VBN
10_1101-2020_01_28_923532	396	20	available	available	JJ
10_1101-2020_01_28_923532	396	21	for	for	IN
10_1101-2020_01_28_923532	396	22	use	use	NN
10_1101-2020_01_28_923532	396	23	under	under	IN
10_1101-2020_01_28_923532	396	24	a	a	DT
10_1101-2020_01_28_923532	396	25	CC0	CC0	NNP
10_1101-2020_01_28_923532	396	26	license	license	NN
10_1101-2020_01_28_923532	396	27	.	.	.
10_1101-2020_01_28_923532	397	1	(	(	-LRB-
10_1101-2020_01_28_923532	397	2	which	which	WDT
10_1101-2020_01_28_923532	397	3	was	be	VBD
10_1101-2020_01_28_923532	397	4	not	not	RB
10_1101-2020_01_28_923532	397	5	certified	certify	VBN
10_1101-2020_01_28_923532	397	6	by	by	IN
10_1101-2020_01_28_923532	397	7	peer	peer	NN
10_1101-2020_01_28_923532	397	8	review	review	NN
10_1101-2020_01_28_923532	397	9	)	)	-RRB-
10_1101-2020_01_28_923532	397	10	is	be	VBZ
10_1101-2020_01_28_923532	397	11	the	the	DT
10_1101-2020_01_28_923532	397	12	author	author	NN
10_1101-2020_01_28_923532	397	13	/	/	SYM
10_1101-2020_01_28_923532	397	14	funder	funder	NN
10_1101-2020_01_28_923532	397	15	.	.	.
10_1101-2020_01_28_923532	398	1	This	this	DT
10_1101-2020_01_28_923532	398	2	article	article	NN
10_1101-2020_01_28_923532	398	3	is	be	VBZ
10_1101-2020_01_28_923532	398	4	a	a	DT
10_1101-2020_01_28_923532	398	5	US	US	NNP
10_1101-2020_01_28_923532	398	6	Government	Government	NNP
10_1101-2020_01_28_923532	398	7	work	work	NN
10_1101-2020_01_28_923532	398	8	.	.	.
10_1101-2020_01_28_923532	399	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	399	2	is	be	VBZ
10_1101-2020_01_28_923532	399	3	not	not	RB
10_1101-2020_01_28_923532	399	4	subject	subject	JJ
10_1101-2020_01_28_923532	399	5	to	to	IN
10_1101-2020_01_28_923532	399	6	copyright	copyright	NN
10_1101-2020_01_28_923532	399	7	under	under	IN
10_1101-2020_01_28_923532	399	8	17	17	CD
10_1101-2020_01_28_923532	399	9	USC	usc	NN
10_1101-2020_01_28_923532	399	10	The	the	DT
10_1101-2020_01_28_923532	399	11	copyright	copyright	NN
10_1101-2020_01_28_923532	399	12	holder	holder	NN
10_1101-2020_01_28_923532	399	13	for	for	IN
10_1101-2020_01_28_923532	399	14	this	this	DT
10_1101-2020_01_28_923532	399	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	399	16	version	version	NN
10_1101-2020_01_28_923532	399	17	posted	post	VBD
10_1101-2020_01_28_923532	399	18	February	February	NNP
10_1101-2020_01_28_923532	399	19	12	12	CD
10_1101-2020_01_28_923532	399	20	,	,	,
10_1101-2020_01_28_923532	399	21	2021	2021	CD
10_1101-2020_01_28_923532	399	22	.	.	.
10_1101-2020_01_28_923532	399	23	;	;	:
10_1101-2020_01_28_923532	399	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	399	25	:	:	:
10_1101-2020_01_28_923532	399	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	399	27	preprint	preprint	NN
10_1101-2020_01_28_923532	399	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	399	29	31	31	CD
10_1101-2020_01_28_923532	399	30	analyzing	analyze	VBG
10_1101-2020_01_28_923532	399	31	adult	adult	NN
10_1101-2020_01_28_923532	399	32	tumors	tumor	NNS
10_1101-2020_01_28_923532	399	33	,	,	,
10_1101-2020_01_28_923532	399	34	while	while	IN
10_1101-2020_01_28_923532	399	35	CAR	CAR	NNP
10_1101-2020_01_28_923532	399	36	-	-	HYPH
10_1101-2020_01_28_923532	399	37	T	t	NN
10_1101-2020_01_28_923532	399	38	therapy	therapy	NN
10_1101-2020_01_28_923532	399	39	can	can	MD
10_1101-2020_01_28_923532	399	40	be	be	VB
10_1101-2020_01_28_923532	399	41	used	use	VBN
10_1101-2020_01_28_923532	399	42	for	for	IN
10_1101-2020_01_28_923532	399	43	either	either	DT
10_1101-2020_01_28_923532	399	44	childhood	childhood	NN
10_1101-2020_01_28_923532	399	45	or	or	CC
10_1101-2020_01_28_923532	399	46	adult	adult	NN
10_1101-2020_01_28_923532	399	47	tumors	tumor	NNS
10_1101-2020_01_28_923532	399	48	.	.	.
10_1101-2020_01_28_923532	400	1	The	the	DT
10_1101-2020_01_28_923532	400	2	reason	reason	NN
10_1101-2020_01_28_923532	400	3	to	to	TO
10_1101-2020_01_28_923532	400	4	focus	focus	VB
10_1101-2020_01_28_923532	400	5	on	on	IN
10_1101-2020_01_28_923532	400	6	cell	cell	NN
10_1101-2020_01_28_923532	400	7	-	-	HYPH
10_1101-2020_01_28_923532	400	8	surface	surface	NN
10_1101-2020_01_28_923532	400	9	receptors	receptor	NNS
10_1101-2020_01_28_923532	400	10	,	,	,
10_1101-2020_01_28_923532	400	11	as	as	IN
10_1101-2020_01_28_923532	400	12	suggested	suggest	VBN
10_1101-2020_01_28_923532	400	13	by	by	IN
10_1101-2020_01_28_923532	400	14	Dannenfelser	Dannenfelser	NNP
10_1101-2020_01_28_923532	400	15	et	et	NNP
10_1101-2020_01_28_923532	400	16	al.24	al.24	NNP
10_1101-2020_01_28_923532	400	17	,	,	,
10_1101-2020_01_28_923532	400	18	is	be	VBZ
10_1101-2020_01_28_923532	400	19	that	that	IN
10_1101-2020_01_28_923532	400	20	CAR-	CAR-	NNP
10_1101-2020_01_28_923532	400	21	T	T	NNP
10_1101-2020_01_28_923532	400	22	therapy	therapy	NN
10_1101-2020_01_28_923532	400	23	requires	require	VBZ
10_1101-2020_01_28_923532	400	24	a	a	DT
10_1101-2020_01_28_923532	400	25	cell	cell	NN
10_1101-2020_01_28_923532	400	26	-	-	HYPH
10_1101-2020_01_28_923532	400	27	surface	surface	NN
10_1101-2020_01_28_923532	400	28	target	target	NN
10_1101-2020_01_28_923532	400	29	that	that	WDT
10_1101-2020_01_28_923532	400	30	may	may	MD
10_1101-2020_01_28_923532	400	31	or	or	CC
10_1101-2020_01_28_923532	400	32	may	may	MD
10_1101-2020_01_28_923532	400	33	not	not	RB
10_1101-2020_01_28_923532	400	34	be	be	VB
10_1101-2020_01_28_923532	400	35	a	a	DT
10_1101-2020_01_28_923532	400	36	receptor	receptor	NN
10_1101-2020_01_28_923532	400	37	,	,	,
10_1101-2020_01_28_923532	400	38	antibody	antibody	NN
10_1101-2020_01_28_923532	400	39	technologies	technology	NNS
10_1101-2020_01_28_923532	400	40	require	require	VBP
10_1101-2020_01_28_923532	400	41	a	a	DT
10_1101-2020_01_28_923532	400	42	cell	cell	NN
10_1101-2020_01_28_923532	400	43	surface	surface	NN
10_1101-2020_01_28_923532	400	44	receptor	receptor	NN
10_1101-2020_01_28_923532	400	45	,	,	,
10_1101-2020_01_28_923532	400	46	and	and	CC
10_1101-2020_01_28_923532	400	47	the	the	DT
10_1101-2020_01_28_923532	400	48	ligand	ligand	NN
10_1101-2020_01_28_923532	400	49	-	-	HYPH
10_1101-2020_01_28_923532	400	50	mimicking	mimic	VBG
10_1101-2020_01_28_923532	400	51	peptide	peptide	NN
10_1101-2020_01_28_923532	400	52	nanotechnology	nanotechnology	NN
10_1101-2020_01_28_923532	400	53	that	that	IN
10_1101-2020_01_28_923532	400	54	we	-PRON-	PRP
10_1101-2020_01_28_923532	400	55	summarized	summarize	VBD
10_1101-2020_01_28_923532	400	56	in	in	IN
10_1101-2020_01_28_923532	400	57	the	the	DT
10_1101-2020_01_28_923532	400	58	Introduction	introduction	NN
10_1101-2020_01_28_923532	400	59	also	also	RB
10_1101-2020_01_28_923532	400	60	requires	require	VBZ
10_1101-2020_01_28_923532	400	61	cell	cell	NN
10_1101-2020_01_28_923532	400	62	surface	surface	NN
10_1101-2020_01_28_923532	400	63	receptor	receptor	NN
10_1101-2020_01_28_923532	400	64	targets	target	NNS
10_1101-2020_01_28_923532	400	65	.	.	.
10_1101-2020_01_28_923532	401	1	Construction	construction	NN
10_1101-2020_01_28_923532	401	2	of	of	IN
10_1101-2020_01_28_923532	401	3	target	target	NN
10_1101-2020_01_28_923532	401	4	gene	gene	NN
10_1101-2020_01_28_923532	401	5	sets	set	NNS
10_1101-2020_01_28_923532	401	6	that	that	WDT
10_1101-2020_01_28_923532	401	7	are	be	VBP
10_1101-2020_01_28_923532	401	8	lowly	lowly	RB
10_1101-2020_01_28_923532	401	9	expressed	express	VBN
10_1101-2020_01_28_923532	401	10	in	in	IN
10_1101-2020_01_28_923532	401	11	normal	normal	JJ
10_1101-2020_01_28_923532	401	12	tissues	tissue	NNS
10_1101-2020_01_28_923532	401	13	To	to	TO
10_1101-2020_01_28_923532	401	14	analyze	analyze	VB
10_1101-2020_01_28_923532	401	15	the	the	DT
10_1101-2020_01_28_923532	401	16	tissue	tissue	NN
10_1101-2020_01_28_923532	401	17	specificity	specificity	NN
10_1101-2020_01_28_923532	401	18	of	of	IN
10_1101-2020_01_28_923532	401	19	the	the	DT
10_1101-2020_01_28_923532	401	20	1269	1269	CD
10_1101-2020_01_28_923532	401	21	candidate	candidate	NN
10_1101-2020_01_28_923532	401	22	target	target	NN
10_1101-2020_01_28_923532	401	23	genes	gene	NNS
10_1101-2020_01_28_923532	401	24	,	,	,
10_1101-2020_01_28_923532	401	25	the	the	DT
10_1101-2020_01_28_923532	401	26	RNAseq	RNAseq	NNP
10_1101-2020_01_28_923532	401	27	based	base	VBN
10_1101-2020_01_28_923532	401	28	multiple	multiple	JJ
10_1101-2020_01_28_923532	401	29	tissue	tissue	NN
10_1101-2020_01_28_923532	401	30	expression	expression	NN
10_1101-2020_01_28_923532	401	31	data	datum	NNS
10_1101-2020_01_28_923532	401	32	was	be	VBD
10_1101-2020_01_28_923532	401	33	obtained	obtain	VBN
10_1101-2020_01_28_923532	401	34	from	from	IN
10_1101-2020_01_28_923532	401	35	the	the	DT
10_1101-2020_01_28_923532	401	36	Human	Human	NNP
10_1101-2020_01_28_923532	401	37	Protein	Protein	NNP
10_1101-2020_01_28_923532	401	38	Atlas	Atlas	NNP
10_1101-2020_01_28_923532	401	39	(	(	-LRB-
10_1101-2020_01_28_923532	401	40	HPA	HPA	NNP
10_1101-2020_01_28_923532	401	41	)	)	-RRB-
10_1101-2020_01_28_923532	401	42	database	database	NN
10_1101-2020_01_28_923532	401	43	(	(	-LRB-
10_1101-2020_01_28_923532	401	44	https://www.proteinatlas.org/about/download	https://www.proteinatlas.org/about/download	NN
10_1101-2020_01_28_923532	401	45	;	;	:
10_1101-2020_01_28_923532	401	46	Date	date	NN
10_1101-2020_01_28_923532	401	47	:	:	:
10_1101-2020_01_28_923532	401	48	May	May	NNP
10_1101-2020_01_28_923532	401	49	29	29	CD
10_1101-2020_01_28_923532	401	50	,	,	,
10_1101-2020_01_28_923532	401	51	2020	2020	CD
10_1101-2020_01_28_923532	401	52	)	)	-RRB-
10_1101-2020_01_28_923532	401	53	.	.	.
10_1101-2020_01_28_923532	402	1	The	the	DT
10_1101-2020_01_28_923532	402	2	HPA	HPA	NNP
10_1101-2020_01_28_923532	402	3	database	database	NN
10_1101-2020_01_28_923532	402	4	includes	include	VBZ
10_1101-2020_01_28_923532	402	5	expression	expression	NN
10_1101-2020_01_28_923532	402	6	values	value	NNS
10_1101-2020_01_28_923532	402	7	(	(	-LRB-
10_1101-2020_01_28_923532	402	8	in	in	IN
10_1101-2020_01_28_923532	402	9	units	unit	NNS
10_1101-2020_01_28_923532	402	10	of	of	IN
10_1101-2020_01_28_923532	402	11	transcripts	transcript	NNS
10_1101-2020_01_28_923532	402	12	per	per	IN
10_1101-2020_01_28_923532	402	13	million	million	CD
10_1101-2020_01_28_923532	402	14	(	(	-LRB-
10_1101-2020_01_28_923532	402	15	TPM	TPM	NNP
10_1101-2020_01_28_923532	402	16	)	)	-RRB-
10_1101-2020_01_28_923532	402	17	)	)	-RRB-
10_1101-2020_01_28_923532	402	18	for	for	IN
10_1101-2020_01_28_923532	402	19	37	37	CD
10_1101-2020_01_28_923532	402	20	tissues	tissue	NNS
10_1101-2020_01_28_923532	402	21	from	from	IN
10_1101-2020_01_28_923532	402	22	HPA	HPA	NNP
10_1101-2020_01_28_923532	402	23	(	(	-LRB-
10_1101-2020_01_28_923532	402	24	rna_tissue_hpa.tsv.zip)75	rna_tissue_hpa.tsv.zip)75	NNP
10_1101-2020_01_28_923532	402	25	and	and	CC
10_1101-2020_01_28_923532	402	26	36	36	CD
10_1101-2020_01_28_923532	402	27	tissues	tissue	NNS
10_1101-2020_01_28_923532	402	28	from	from	IN
10_1101-2020_01_28_923532	402	29	the	the	DT
10_1101-2020_01_28_923532	402	30	Genotype	Genotype	NNP
10_1101-2020_01_28_923532	402	31	-	-	HYPH
10_1101-2020_01_28_923532	402	32	Tissue	Tissue	NNP
10_1101-2020_01_28_923532	402	33	Expression	Expression	NNP
10_1101-2020_01_28_923532	402	34	consortium	consortium	NN
10_1101-2020_01_28_923532	402	35	(	(	-LRB-
10_1101-2020_01_28_923532	402	36	rna_tissue_gtex.tsv.zip)76	rna_tissue_gtex.tsv.zip)76	NNP
10_1101-2020_01_28_923532	402	37	.	.	.
10_1101-2020_01_28_923532	403	1	Next	next	RB
10_1101-2020_01_28_923532	403	2	,	,	,
10_1101-2020_01_28_923532	403	3	to	to	TO
10_1101-2020_01_28_923532	403	4	identify	identify	VB
10_1101-2020_01_28_923532	403	5	target	target	NN
10_1101-2020_01_28_923532	403	6	genes	gene	NNS
10_1101-2020_01_28_923532	403	7	with	with	IN
10_1101-2020_01_28_923532	403	8	low	low	JJ
10_1101-2020_01_28_923532	403	9	or	or	CC
10_1101-2020_01_28_923532	403	10	no	no	DT
10_1101-2020_01_28_923532	403	11	expression	expression	NN
10_1101-2020_01_28_923532	403	12	within	within	IN
10_1101-2020_01_28_923532	403	13	majority	majority	NN
10_1101-2020_01_28_923532	403	14	of	of	IN
10_1101-2020_01_28_923532	403	15	adult	adult	NN
10_1101-2020_01_28_923532	403	16	human	human	JJ
10_1101-2020_01_28_923532	403	17	tissues	tissue	NNS
10_1101-2020_01_28_923532	403	18	,	,	,
10_1101-2020_01_28_923532	403	19	for	for	IN
10_1101-2020_01_28_923532	403	20	the	the	DT
10_1101-2020_01_28_923532	403	21	1269	1269	CD
10_1101-2020_01_28_923532	403	22	candidate	candidate	NN
10_1101-2020_01_28_923532	403	23	genes	gene	NNS
10_1101-2020_01_28_923532	403	24	we	-PRON-	PRP
10_1101-2020_01_28_923532	403	25	identified	identify	VBD
10_1101-2020_01_28_923532	403	26	genes	gene	NNS
10_1101-2020_01_28_923532	403	27	whose	whose	WP$
10_1101-2020_01_28_923532	403	28	average	average	JJ
10_1101-2020_01_28_923532	403	29	expression	expression	NN
10_1101-2020_01_28_923532	403	30	across	across	IN
10_1101-2020_01_28_923532	403	31	tissues	tissue	NNS
10_1101-2020_01_28_923532	403	32	is	be	VBZ
10_1101-2020_01_28_923532	403	33	below	below	IN
10_1101-2020_01_28_923532	403	34	certain	certain	JJ
10_1101-2020_01_28_923532	403	35	threshold	threshold	NN
10_1101-2020_01_28_923532	403	36	value	value	NN
10_1101-2020_01_28_923532	403	37	(	(	-LRB-
10_1101-2020_01_28_923532	403	38	0.25	0.25	CD
10_1101-2020_01_28_923532	403	39	,	,	,
10_1101-2020_01_28_923532	403	40	0.5	0.5	CD
10_1101-2020_01_28_923532	403	41	,	,	,
10_1101-2020_01_28_923532	403	42	1	1	CD
10_1101-2020_01_28_923532	403	43	,	,	,
10_1101-2020_01_28_923532	403	44	2	2	CD
10_1101-2020_01_28_923532	403	45	,	,	,
10_1101-2020_01_28_923532	403	46	5	5	CD
10_1101-2020_01_28_923532	403	47	,	,	,
10_1101-2020_01_28_923532	403	48	and	and	CC
10_1101-2020_01_28_923532	403	49	10	10	CD
10_1101-2020_01_28_923532	403	50	TPM	TPM	NNP
10_1101-2020_01_28_923532	403	51	)	)	-RRB-
10_1101-2020_01_28_923532	403	52	in	in	IN
10_1101-2020_01_28_923532	403	53	both	both	DT
10_1101-2020_01_28_923532	403	54	HPA	HPA	NNP
10_1101-2020_01_28_923532	403	55	and	and	CC
10_1101-2020_01_28_923532	403	56	GTEx	GTEx	NNP
10_1101-2020_01_28_923532	403	57	data	datum	NNS
10_1101-2020_01_28_923532	403	58	sets	set	NNS
10_1101-2020_01_28_923532	403	59	.	.	.
10_1101-2020_01_28_923532	404	1	Using	use	VBG
10_1101-2020_01_28_923532	404	2	the	the	DT
10_1101-2020_01_28_923532	404	3	intersection	intersection	NN
10_1101-2020_01_28_923532	404	4	of	of	IN
10_1101-2020_01_28_923532	404	5	low	low	JJ
10_1101-2020_01_28_923532	404	6	expression	expression	NN
10_1101-2020_01_28_923532	404	7	candidate	candidate	NN
10_1101-2020_01_28_923532	404	8	genes	gene	NNS
10_1101-2020_01_28_923532	404	9	from	from	IN
10_1101-2020_01_28_923532	404	10	HPA	HPA	NNP
10_1101-2020_01_28_923532	404	11	and	and	CC
10_1101-2020_01_28_923532	404	12	GTEx	GTEx	NNP
10_1101-2020_01_28_923532	404	13	data	data	NN
10_1101-2020_01_28_923532	404	14	sets	set	NNS
10_1101-2020_01_28_923532	404	15	,	,	,
10_1101-2020_01_28_923532	404	16	we	-PRON-	PRP
10_1101-2020_01_28_923532	404	17	generated	generate	VBD
10_1101-2020_01_28_923532	404	18	lists	list	NNS
10_1101-2020_01_28_923532	404	19	of	of	IN
10_1101-2020_01_28_923532	404	20	high	high	JJ
10_1101-2020_01_28_923532	404	21	confidence	confidence	NN
10_1101-2020_01_28_923532	404	22	targets	target	NNS
10_1101-2020_01_28_923532	404	23	.	.	.
10_1101-2020_01_28_923532	405	1	The	the	DT
10_1101-2020_01_28_923532	405	2	size	size	NN
10_1101-2020_01_28_923532	405	3	of	of	IN
10_1101-2020_01_28_923532	405	4	the	the	DT
10_1101-2020_01_28_923532	405	5	resulting	result	VBG
10_1101-2020_01_28_923532	405	6	high	high	JJ
10_1101-2020_01_28_923532	405	7	confidence	confidence	NN
10_1101-2020_01_28_923532	405	8	target	target	NN
10_1101-2020_01_28_923532	405	9	genes	gene	NNS
10_1101-2020_01_28_923532	405	10	varied	vary	VBN
10_1101-2020_01_28_923532	405	11	from	from	IN
10_1101-2020_01_28_923532	405	12	424	424	CD
10_1101-2020_01_28_923532	405	13	(	(	-LRB-
10_1101-2020_01_28_923532	405	14	average	average	JJ
10_1101-2020_01_28_923532	405	15	expression	expression	NN
10_1101-2020_01_28_923532	405	16	less	less	JJR
10_1101-2020_01_28_923532	405	17	than	than	IN
10_1101-2020_01_28_923532	405	18	0.25	0.25	CD
10_1101-2020_01_28_923532	405	19	TPM	TPM	NNP
10_1101-2020_01_28_923532	405	20	)	)	-RRB-
10_1101-2020_01_28_923532	405	21	to	to	IN
10_1101-2020_01_28_923532	405	22	900	900	CD
10_1101-2020_01_28_923532	405	23	(	(	-LRB-
10_1101-2020_01_28_923532	405	24	average	average	JJ
10_1101-2020_01_28_923532	405	25	expression	expression	NN
10_1101-2020_01_28_923532	405	26	across	across	IN
10_1101-2020_01_28_923532	405	27	tissue	tissue	NN
10_1101-2020_01_28_923532	405	28	less	less	JJR
10_1101-2020_01_28_923532	405	29	than	than	IN
10_1101-2020_01_28_923532	405	30	10	10	CD
10_1101-2020_01_28_923532	405	31	TPM	TPM	NNP
10_1101-2020_01_28_923532	405	32	)	)	-RRB-
10_1101-2020_01_28_923532	405	33	genes	gene	NNS
10_1101-2020_01_28_923532	405	34	(	(	-LRB-
10_1101-2020_01_28_923532	405	35	Table	table	NN
10_1101-2020_01_28_923532	405	36	2	2	CD
10_1101-2020_01_28_923532	405	37	)	)	-RRB-
10_1101-2020_01_28_923532	405	38	.	.	.
10_1101-2020_01_28_923532	406	1	While	while	IN
10_1101-2020_01_28_923532	406	2	the	the	DT
10_1101-2020_01_28_923532	406	3	total	total	JJ
10_1101-2020_01_28_923532	406	4	number	number	NN
10_1101-2020_01_28_923532	406	5	of	of	IN
10_1101-2020_01_28_923532	406	6	genes	gene	NNS
10_1101-2020_01_28_923532	406	7	decreases	decrease	VBZ
10_1101-2020_01_28_923532	406	8	slowly	slowly	RB
10_1101-2020_01_28_923532	406	9	,	,	,
10_1101-2020_01_28_923532	406	10	the	the	DT
10_1101-2020_01_28_923532	406	11	decrease	decrease	NN
10_1101-2020_01_28_923532	406	12	is	be	VBZ
10_1101-2020_01_28_923532	406	13	much	much	RB
10_1101-2020_01_28_923532	406	14	steeper	steep	JJR
10_1101-2020_01_28_923532	406	15	if	if	IN
10_1101-2020_01_28_923532	406	16	one	one	CD
10_1101-2020_01_28_923532	406	17	excludes	exclude	VBZ
10_1101-2020_01_28_923532	406	18	olfactory	olfactory	JJ
10_1101-2020_01_28_923532	406	19	receptors	receptor	NNS
10_1101-2020_01_28_923532	406	20	and	and	CC
10_1101-2020_01_28_923532	406	21	taste	taste	NN
10_1101-2020_01_28_923532	406	22	receptors	receptor	NNS
10_1101-2020_01_28_923532	406	23	(	(	-LRB-
10_1101-2020_01_28_923532	406	24	Table	table	NN
10_1101-2020_01_28_923532	406	25	2	2	CD
10_1101-2020_01_28_923532	406	26	)	)	-RRB-
10_1101-2020_01_28_923532	406	27	.	.	.
10_1101-2020_01_28_923532	407	1	These	these	DT
10_1101-2020_01_28_923532	407	2	sensory	sensory	JJ
10_1101-2020_01_28_923532	407	3	receptors	receptor	NNS
10_1101-2020_01_28_923532	407	4	are	be	VBP
10_1101-2020_01_28_923532	407	5	not	not	RB
10_1101-2020_01_28_923532	407	6	typically	typically	RB
10_1101-2020_01_28_923532	407	7	considered	consider	VBN
10_1101-2020_01_28_923532	407	8	as	as	IN
10_1101-2020_01_28_923532	407	9	cancer	cancer	NN
10_1101-2020_01_28_923532	407	10	targets	target	NNS
10_1101-2020_01_28_923532	407	11	,	,	,
10_1101-2020_01_28_923532	407	12	although	although	IN
10_1101-2020_01_28_923532	407	13	a	a	DT
10_1101-2020_01_28_923532	407	14	few	few	JJ
10_1101-2020_01_28_923532	407	15	of	of	IN
10_1101-2020_01_28_923532	407	16	these	these	DT
10_1101-2020_01_28_923532	407	17	receptors	receptor	NNS
10_1101-2020_01_28_923532	407	18	are	be	VBP
10_1101-2020_01_28_923532	407	19	selected	select	VBN
10_1101-2020_01_28_923532	407	20	in	in	IN
10_1101-2020_01_28_923532	407	21	optimal	optimal	JJ
10_1101-2020_01_28_923532	407	22	target	target	NN
10_1101-2020_01_28_923532	407	23	sets	set	NNS
10_1101-2020_01_28_923532	407	24	when	when	WRB
10_1101-2020_01_28_923532	407	25	there	there	EX
10_1101-2020_01_28_923532	407	26	are	be	VBP
10_1101-2020_01_28_923532	407	27	few	few	JJ
10_1101-2020_01_28_923532	407	28	alternatives	alternative	NNS
10_1101-2020_01_28_923532	407	29	(	(	-LRB-
10_1101-2020_01_28_923532	407	30	Figure	Figure	NNP
10_1101-2020_01_28_923532	407	31	7	7	CD
10_1101-2020_01_28_923532	407	32	)	)	-RRB-
10_1101-2020_01_28_923532	407	33	.	.	.
10_1101-2020_01_28_923532	408	1	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	408	2	was	be	VBD
10_1101-2020_01_28_923532	408	3	run	run	VBN
10_1101-2020_01_28_923532	408	4	on	on	IN
10_1101-2020_01_28_923532	408	5	all	all	DT
10_1101-2020_01_28_923532	408	6	nine	nine	CD
10_1101-2020_01_28_923532	408	7	data	data	NN
10_1101-2020_01_28_923532	408	8	sets	set	NNS
10_1101-2020_01_28_923532	408	9	using	use	VBG
10_1101-2020_01_28_923532	408	10	the	the	DT
10_1101-2020_01_28_923532	408	11	expression	expression	NN
10_1101-2020_01_28_923532	408	12	information	information	NN
10_1101-2020_01_28_923532	408	13	from	from	IN
10_1101-2020_01_28_923532	408	14	the	the	DT
10_1101-2020_01_28_923532	408	15	high	high	JJ
10_1101-2020_01_28_923532	408	16	confidence	confidence	NN
10_1101-2020_01_28_923532	408	17	gene	gene	NN
10_1101-2020_01_28_923532	408	18	lists	list	NNS
10_1101-2020_01_28_923532	408	19	.	.	.
10_1101-2020_01_28_923532	409	1	Table	table	NN
10_1101-2020_01_28_923532	409	2	2	2	CD
10_1101-2020_01_28_923532	409	3	:	:	:
10_1101-2020_01_28_923532	409	4	Size	size	NN
10_1101-2020_01_28_923532	409	5	of	of	IN
10_1101-2020_01_28_923532	409	6	high	high	JJ
10_1101-2020_01_28_923532	409	7	confidence	confidence	NN
10_1101-2020_01_28_923532	409	8	target	target	NN
10_1101-2020_01_28_923532	409	9	gene	gene	NN
10_1101-2020_01_28_923532	409	10	sets	set	NNS
10_1101-2020_01_28_923532	409	11	for	for	IN
10_1101-2020_01_28_923532	409	12	different	different	JJ
10_1101-2020_01_28_923532	409	13	thresholds	threshold	NNS
10_1101-2020_01_28_923532	409	14	.	.	.
10_1101-2020_01_28_923532	410	1	Thresholds	threshold	NNS
10_1101-2020_01_28_923532	410	2	expression	expression	NN
10_1101-2020_01_28_923532	410	3	across	across	IN
10_1101-2020_01_28_923532	410	4	Size	size	NN
10_1101-2020_01_28_923532	410	5	of	of	IN
10_1101-2020_01_28_923532	410	6	gene	gene	NN
10_1101-2020_01_28_923532	410	7	set	set	VBN
10_1101-2020_01_28_923532	410	8	No	no	NN
10_1101-2020_01_28_923532	410	9	of	of	IN
10_1101-2020_01_28_923532	410	10	genes	gene	NNS
10_1101-2020_01_28_923532	410	11	which	which	WDT
10_1101-2020_01_28_923532	410	12	are	be	VBP
10_1101-2020_01_28_923532	410	13	NOT	not	RB
10_1101-2020_01_28_923532	410	14	olfactory	olfactory	JJ
10_1101-2020_01_28_923532	410	15	No	no	NN
10_1101-2020_01_28_923532	410	16	of	of	IN
10_1101-2020_01_28_923532	410	17	genes	gene	NNS
10_1101-2020_01_28_923532	410	18	with	with	IN
10_1101-2020_01_28_923532	410	19	ligand	ligand	NNP
10_1101-2020_01_28_923532	410	20	mimicking	mimic	VBG
10_1101-2020_01_28_923532	410	21	105	105	CD
10_1101-2020_01_28_923532	410	22	and	and	CC
10_1101-2020_01_28_923532	410	23	is	be	VBZ
10_1101-2020_01_28_923532	410	24	also	also	RB
10_1101-2020_01_28_923532	410	25	made	make	VBN
10_1101-2020_01_28_923532	410	26	available	available	JJ
10_1101-2020_01_28_923532	410	27	for	for	IN
10_1101-2020_01_28_923532	410	28	use	use	NN
10_1101-2020_01_28_923532	410	29	under	under	IN
10_1101-2020_01_28_923532	410	30	a	a	DT
10_1101-2020_01_28_923532	410	31	CC0	CC0	NNP
10_1101-2020_01_28_923532	410	32	license	license	NN
10_1101-2020_01_28_923532	410	33	.	.	.
10_1101-2020_01_28_923532	411	1	(	(	-LRB-
10_1101-2020_01_28_923532	411	2	which	which	WDT
10_1101-2020_01_28_923532	411	3	was	be	VBD
10_1101-2020_01_28_923532	411	4	not	not	RB
10_1101-2020_01_28_923532	411	5	certified	certify	VBN
10_1101-2020_01_28_923532	411	6	by	by	IN
10_1101-2020_01_28_923532	411	7	peer	peer	NN
10_1101-2020_01_28_923532	411	8	review	review	NN
10_1101-2020_01_28_923532	411	9	)	)	-RRB-
10_1101-2020_01_28_923532	411	10	is	be	VBZ
10_1101-2020_01_28_923532	411	11	the	the	DT
10_1101-2020_01_28_923532	411	12	author	author	NN
10_1101-2020_01_28_923532	411	13	/	/	SYM
10_1101-2020_01_28_923532	411	14	funder	funder	NN
10_1101-2020_01_28_923532	411	15	.	.	.
10_1101-2020_01_28_923532	412	1	This	this	DT
10_1101-2020_01_28_923532	412	2	article	article	NN
10_1101-2020_01_28_923532	412	3	is	be	VBZ
10_1101-2020_01_28_923532	412	4	a	a	DT
10_1101-2020_01_28_923532	412	5	US	US	NNP
10_1101-2020_01_28_923532	412	6	Government	Government	NNP
10_1101-2020_01_28_923532	412	7	work	work	NN
10_1101-2020_01_28_923532	412	8	.	.	.
10_1101-2020_01_28_923532	413	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	413	2	is	be	VBZ
10_1101-2020_01_28_923532	413	3	not	not	RB
10_1101-2020_01_28_923532	413	4	subject	subject	JJ
10_1101-2020_01_28_923532	413	5	to	to	IN
10_1101-2020_01_28_923532	413	6	copyright	copyright	NN
10_1101-2020_01_28_923532	413	7	under	under	IN
10_1101-2020_01_28_923532	413	8	17	17	CD
10_1101-2020_01_28_923532	413	9	USC	usc	NN
10_1101-2020_01_28_923532	413	10	The	the	DT
10_1101-2020_01_28_923532	413	11	copyright	copyright	NN
10_1101-2020_01_28_923532	413	12	holder	holder	NN
10_1101-2020_01_28_923532	413	13	for	for	IN
10_1101-2020_01_28_923532	413	14	this	this	DT
10_1101-2020_01_28_923532	413	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	413	16	version	version	NN
10_1101-2020_01_28_923532	413	17	posted	post	VBD
10_1101-2020_01_28_923532	413	18	February	February	NNP
10_1101-2020_01_28_923532	413	19	12	12	CD
10_1101-2020_01_28_923532	413	20	,	,	,
10_1101-2020_01_28_923532	413	21	2021	2021	CD
10_1101-2020_01_28_923532	413	22	.	.	.
10_1101-2020_01_28_923532	413	23	;	;	:
10_1101-2020_01_28_923532	413	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	413	25	:	:	:
10_1101-2020_01_28_923532	413	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	413	27	preprint	preprint	NN
10_1101-2020_01_28_923532	413	28	https://www.proteinatlas.org/about/download	https://www.proteinatlas.org/about/download	NN
10_1101-2020_01_28_923532	413	29	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	413	30	32	32	CD
10_1101-2020_01_28_923532	413	31	tissues	tissue	NNS
10_1101-2020_01_28_923532	413	32	(	(	-LRB-
10_1101-2020_01_28_923532	413	33	TPM	TPM	NNP
10_1101-2020_01_28_923532	413	34	)	)	-RRB-
10_1101-2020_01_28_923532	413	35	(	(	-LRB-
10_1101-2020_01_28_923532	413	36	OR	or	CC
10_1101-2020_01_28_923532	413	37	*	*	NFP
10_1101-2020_01_28_923532	413	38	)	)	-RRB-
10_1101-2020_01_28_923532	413	39	and	and	CC
10_1101-2020_01_28_923532	413	40	taste	taste	NN
10_1101-2020_01_28_923532	413	41	receptors	receptor	NNS
10_1101-2020_01_28_923532	413	42	(	(	-LRB-
10_1101-2020_01_28_923532	413	43	TAS	TAS	NNP
10_1101-2020_01_28_923532	413	44	*	*	NFP
10_1101-2020_01_28_923532	413	45	)	)	-RRB-
10_1101-2020_01_28_923532	413	46	peptides	peptide	NNS
10_1101-2020_01_28_923532	413	47	(	(	-LRB-
10_1101-2020_01_28_923532	413	48	intersection	intersection	NN
10_1101-2020_01_28_923532	413	49	with	with	IN
10_1101-2020_01_28_923532	413	50	Tables	Tables	NNP
10_1101-2020_01_28_923532	413	51	3	3	CD
10_1101-2020_01_28_923532	413	52	and	and	CC
10_1101-2020_01_28_923532	413	53	4	4	CD
10_1101-2020_01_28_923532	413	54	)	)	-RRB-
10_1101-2020_01_28_923532	413	55	0.25	0.25	CD
10_1101-2020_01_28_923532	413	56	424	424	CD
10_1101-2020_01_28_923532	413	57	97	97	CD
10_1101-2020_01_28_923532	413	58	1	1	CD
10_1101-2020_01_28_923532	413	59	0.5	0.5	CD
10_1101-2020_01_28_923532	413	60	494	494	CD
10_1101-2020_01_28_923532	413	61	141	141	CD
10_1101-2020_01_28_923532	413	62	3	3	CD
10_1101-2020_01_28_923532	413	63	1	1	CD
10_1101-2020_01_28_923532	413	64	547	547	CD
10_1101-2020_01_28_923532	413	65	187	187	CD
10_1101-2020_01_28_923532	413	66	3	3	CD
10_1101-2020_01_28_923532	413	67	2	2	CD
10_1101-2020_01_28_923532	413	68	632	632	CD
10_1101-2020_01_28_923532	413	69	269	269	CD
10_1101-2020_01_28_923532	413	70	6	6	CD
10_1101-2020_01_28_923532	413	71	5	5	CD
10_1101-2020_01_28_923532	413	72	762	762	CD
10_1101-2020_01_28_923532	413	73	398	398	CD
10_1101-2020_01_28_923532	413	74	10	10	CD
10_1101-2020_01_28_923532	413	75	10	10	CD
10_1101-2020_01_28_923532	413	76	900	900	CD
10_1101-2020_01_28_923532	413	77	536	536	CD
10_1101-2020_01_28_923532	413	78	19	19	CD
10_1101-2020_01_28_923532	413	79	Assembling	assemble	VBG
10_1101-2020_01_28_923532	413	80	Lists	Lists	NNPS
10_1101-2020_01_28_923532	413	81	of	of	IN
10_1101-2020_01_28_923532	413	82	Membrane	Membrane	NNP
10_1101-2020_01_28_923532	413	83	Target	Target	NNP
10_1101-2020_01_28_923532	413	84	Genes	Genes	NNPS
10_1101-2020_01_28_923532	413	85	We	-PRON-	PRP
10_1101-2020_01_28_923532	413	86	are	be	VBP
10_1101-2020_01_28_923532	413	87	interested	interested	JJ
10_1101-2020_01_28_923532	413	88	in	in	IN
10_1101-2020_01_28_923532	413	89	the	the	DT
10_1101-2020_01_28_923532	413	90	set	set	NN
10_1101-2020_01_28_923532	413	91	of	of	IN
10_1101-2020_01_28_923532	413	92	genes	gene	NNS
10_1101-2020_01_28_923532	413	93	𝐺	𝐺	NN
10_1101-2020_01_28_923532	413	94	that	that	WDT
10_1101-2020_01_28_923532	413	95	i	i	PRP
10_1101-2020_01_28_923532	413	96	)	)	-RRB-
10_1101-2020_01_28_923532	413	97	have	have	VBP
10_1101-2020_01_28_923532	413	98	the	the	DT
10_1101-2020_01_28_923532	413	99	encoded	encoded	JJ
10_1101-2020_01_28_923532	413	100	protein	protein	NN
10_1101-2020_01_28_923532	413	101	expressed	express	VBD
10_1101-2020_01_28_923532	413	102	on	on	IN
10_1101-2020_01_28_923532	413	103	the	the	DT
10_1101-2020_01_28_923532	413	104	cell	cell	NN
10_1101-2020_01_28_923532	413	105	surface	surface	NN
10_1101-2020_01_28_923532	413	106	and	and	CC
10_1101-2020_01_28_923532	413	107	ii	ii	NN
10_1101-2020_01_28_923532	413	108	)	)	-RRB-
10_1101-2020_01_28_923532	413	109	for	for	IN
10_1101-2020_01_28_923532	413	110	which	which	WDT
10_1101-2020_01_28_923532	413	111	some	some	DT
10_1101-2020_01_28_923532	413	112	biochemistry	biochemistry	NN
10_1101-2020_01_28_923532	413	113	lab	lab	NN
10_1101-2020_01_28_923532	413	114	has	have	VBZ
10_1101-2020_01_28_923532	413	115	found	find	VBN
10_1101-2020_01_28_923532	413	116	a	a	DT
10_1101-2020_01_28_923532	413	117	small	small	JJ
10_1101-2020_01_28_923532	413	118	peptide	peptide	NN
10_1101-2020_01_28_923532	413	119	(	(	-LRB-
10_1101-2020_01_28_923532	413	120	i.e.	i.e.	FW
10_1101-2020_01_28_923532	414	1	amino	amino	NNP
10_1101-2020_01_28_923532	414	2	acid	acid	NNP
10_1101-2020_01_28_923532	414	3	sequences	sequence	NNS
10_1101-2020_01_28_923532	414	4	of	of	IN
10_1101-2020_01_28_923532	414	5	5	5	CD
10_1101-2020_01_28_923532	414	6	-	-	SYM
10_1101-2020_01_28_923532	414	7	30	30	CD
10_1101-2020_01_28_923532	414	8	amino	amino	JJ
10_1101-2020_01_28_923532	414	9	acids	acid	NNS
10_1101-2020_01_28_923532	414	10	)	)	-RRB-
10_1101-2020_01_28_923532	414	11	that	that	WDT
10_1101-2020_01_28_923532	414	12	can	can	MD
10_1101-2020_01_28_923532	414	13	attach	attach	VB
10_1101-2020_01_28_923532	414	14	itself	-PRON-	PRP
10_1101-2020_01_28_923532	414	15	to	to	IN
10_1101-2020_01_28_923532	414	16	the	the	DT
10_1101-2020_01_28_923532	414	17	target	target	NN
10_1101-2020_01_28_923532	414	18	protein	protein	NN
10_1101-2020_01_28_923532	414	19	and	and	CC
10_1101-2020_01_28_923532	414	20	get	get	VB
10_1101-2020_01_28_923532	414	21	inside	inside	IN
10_1101-2020_01_28_923532	414	22	the	the	DT
10_1101-2020_01_28_923532	414	23	cell	cell	NN
10_1101-2020_01_28_923532	414	24	carrying	carry	VBG
10_1101-2020_01_28_923532	414	25	a	a	DT
10_1101-2020_01_28_923532	414	26	tiny	tiny	JJ
10_1101-2020_01_28_923532	414	27	cargo	cargo	NN
10_1101-2020_01_28_923532	414	28	of	of	IN
10_1101-2020_01_28_923532	414	29	a	a	DT
10_1101-2020_01_28_923532	414	30	toxic	toxic	JJ
10_1101-2020_01_28_923532	414	31	drug	drug	NN
10_1101-2020_01_28_923532	414	32	that	that	WDT
10_1101-2020_01_28_923532	414	33	will	will	MD
10_1101-2020_01_28_923532	414	34	kill	kill	VB
10_1101-2020_01_28_923532	414	35	the	the	DT
10_1101-2020_01_28_923532	414	36	cell	cell	NN
10_1101-2020_01_28_923532	414	37	and	and	CC
10_1101-2020_01_28_923532	414	38	iii	iii	NNP
10_1101-2020_01_28_923532	414	39	)	)	-RRB-
10_1101-2020_01_28_923532	414	40	encode	encode	VBP
10_1101-2020_01_28_923532	414	41	proteins	protein	NNS
10_1101-2020_01_28_923532	414	42	that	that	WDT
10_1101-2020_01_28_923532	414	43	are	be	VBP
10_1101-2020_01_28_923532	414	44	receptors	receptor	NNS
10_1101-2020_01_28_923532	414	45	.	.	.
10_1101-2020_01_28_923532	415	1	The	the	DT
10_1101-2020_01_28_923532	415	2	third	third	JJ
10_1101-2020_01_28_923532	415	3	condition	condition	NN
10_1101-2020_01_28_923532	415	4	is	be	VBZ
10_1101-2020_01_28_923532	415	5	needed	need	VBN
10_1101-2020_01_28_923532	415	6	because	because	IN
10_1101-2020_01_28_923532	415	7	many	many	JJ
10_1101-2020_01_28_923532	415	8	proteins	protein	NNS
10_1101-2020_01_28_923532	415	9	that	that	WDT
10_1101-2020_01_28_923532	415	10	reside	reside	VBP
10_1101-2020_01_28_923532	415	11	on	on	IN
10_1101-2020_01_28_923532	415	12	the	the	DT
10_1101-2020_01_28_923532	415	13	cell	cell	NN
10_1101-2020_01_28_923532	415	14	surface	surface	NN
10_1101-2020_01_28_923532	415	15	are	be	VBP
10_1101-2020_01_28_923532	415	16	not	not	RB
10_1101-2020_01_28_923532	415	17	receptors	receptor	NNS
10_1101-2020_01_28_923532	415	18	that	that	WDT
10_1101-2020_01_28_923532	415	19	can	can	MD
10_1101-2020_01_28_923532	415	20	undergo	undergo	VB
10_1101-2020_01_28_923532	415	21	RME	rme	NN
10_1101-2020_01_28_923532	415	22	.	.	.
10_1101-2020_01_28_923532	416	1	The	the	DT
10_1101-2020_01_28_923532	416	2	first	first	JJ
10_1101-2020_01_28_923532	416	3	condition	condition	NN
10_1101-2020_01_28_923532	416	4	can	can	MD
10_1101-2020_01_28_923532	416	5	be	be	VB
10_1101-2020_01_28_923532	416	6	reliably	reliably	RB
10_1101-2020_01_28_923532	416	7	tested	test	VBN
10_1101-2020_01_28_923532	416	8	using	use	VBG
10_1101-2020_01_28_923532	416	9	a	a	DT
10_1101-2020_01_28_923532	416	10	recently	recently	RB
10_1101-2020_01_28_923532	416	11	published	publish	VBN
10_1101-2020_01_28_923532	416	12	list	list	NN
10_1101-2020_01_28_923532	416	13	of	of	IN
10_1101-2020_01_28_923532	416	14	2799	2799	CD
10_1101-2020_01_28_923532	416	15	genes	gene	NNS
10_1101-2020_01_28_923532	416	16	encoding	encode	VBG
10_1101-2020_01_28_923532	416	17	human	human	JJ
10_1101-2020_01_28_923532	416	18	predicted	predict	VBD
10_1101-2020_01_28_923532	416	19	cell	cell	NN
10_1101-2020_01_28_923532	416	20	surface	surface	NN
10_1101-2020_01_28_923532	416	21	proteins77	proteins77	NNP
10_1101-2020_01_28_923532	416	22	;	;	:
10_1101-2020_01_28_923532	416	23	we	-PRON-	PRP
10_1101-2020_01_28_923532	416	24	reduced	reduce	VBD
10_1101-2020_01_28_923532	416	25	the	the	DT
10_1101-2020_01_28_923532	416	26	list	list	NN
10_1101-2020_01_28_923532	416	27	to	to	IN
10_1101-2020_01_28_923532	416	28	1269	1269	CD
10_1101-2020_01_28_923532	416	29	by	by	IN
10_1101-2020_01_28_923532	416	30	requiring	require	VBG
10_1101-2020_01_28_923532	416	31	that	that	IN
10_1101-2020_01_28_923532	416	32	the	the	DT
10_1101-2020_01_28_923532	416	33	proteins	protein	NNS
10_1101-2020_01_28_923532	416	34	be	be	VB
10_1101-2020_01_28_923532	416	35	receptors	receptor	NNS
10_1101-2020_01_28_923532	416	36	,	,	,
10_1101-2020_01_28_923532	416	37	which	which	WDT
10_1101-2020_01_28_923532	416	38	is	be	VBZ
10_1101-2020_01_28_923532	416	39	necessary	necessary	JJ
10_1101-2020_01_28_923532	416	40	for	for	IN
10_1101-2020_01_28_923532	416	41	RME	rme	NN
10_1101-2020_01_28_923532	416	42	-	-	HYPH
10_1101-2020_01_28_923532	416	43	based	base	VBN
10_1101-2020_01_28_923532	416	44	therapies	therapy	NNS
10_1101-2020_01_28_923532	416	45	but	but	CC
10_1101-2020_01_28_923532	416	46	not	not	RB
10_1101-2020_01_28_923532	416	47	for	for	IN
10_1101-2020_01_28_923532	416	48	CAR	CAR	NNP
10_1101-2020_01_28_923532	416	49	-	-	HYPH
10_1101-2020_01_28_923532	416	50	T	T	NNP
10_1101-2020_01_28_923532	416	51	therpy24	therpy24	NNS
10_1101-2020_01_28_923532	416	52	.	.	.
10_1101-2020_01_28_923532	417	1	For	for	IN
10_1101-2020_01_28_923532	417	2	condition	condition	NN
10_1101-2020_01_28_923532	417	3	ii	ii	NNP
10_1101-2020_01_28_923532	417	4	)	)	-RRB-
10_1101-2020_01_28_923532	417	5	,	,	,
10_1101-2020_01_28_923532	417	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	417	7	found	find	VBD
10_1101-2020_01_28_923532	417	8	two	two	CD
10_1101-2020_01_28_923532	417	9	review	review	NN
10_1101-2020_01_28_923532	417	10	articles	article	NNS
10_1101-2020_01_28_923532	417	11	in	in	IN
10_1101-2020_01_28_923532	417	12	the	the	DT
10_1101-2020_01_28_923532	417	13	chemistry	chemistry	NN
10_1101-2020_01_28_923532	417	14	literature19	literature19	NNP
10_1101-2020_01_28_923532	417	15	-	-	:
10_1101-2020_01_28_923532	417	16	20	20	CD
10_1101-2020_01_28_923532	417	17	that	that	DT
10_1101-2020_01_28_923532	417	18	list	list	NN
10_1101-2020_01_28_923532	417	19	targets	target	NNS
10_1101-2020_01_28_923532	417	20	effectively	effectively	RB
10_1101-2020_01_28_923532	417	21	meeting	meet	VBG
10_1101-2020_01_28_923532	417	22	this	this	DT
10_1101-2020_01_28_923532	417	23	condition	condition	NN
10_1101-2020_01_28_923532	417	24	.	.	.
10_1101-2020_01_28_923532	418	1	Intersecting	intersect	VBG
10_1101-2020_01_28_923532	418	2	the	the	DT
10_1101-2020_01_28_923532	418	3	lists	list	NNS
10_1101-2020_01_28_923532	418	4	meeting	meet	VBG
10_1101-2020_01_28_923532	418	5	conditions	condition	NNS
10_1101-2020_01_28_923532	418	6	i	i	PRP
10_1101-2020_01_28_923532	418	7	)	)	-RRB-
10_1101-2020_01_28_923532	418	8	and	and	CC
10_1101-2020_01_28_923532	418	9	ii	ii	NNP
10_1101-2020_01_28_923532	418	10	)	)	-RRB-
10_1101-2020_01_28_923532	418	11	gave	give	VBD
10_1101-2020_01_28_923532	418	12	us	-PRON-	PRP
10_1101-2020_01_28_923532	418	13	38	38	CD
10_1101-2020_01_28_923532	418	14	genes	gene	NNS
10_1101-2020_01_28_923532	418	15	/	/	SYM
10_1101-2020_01_28_923532	418	16	proteins	protein	NNS
10_1101-2020_01_28_923532	418	17	that	that	WDT
10_1101-2020_01_28_923532	418	18	could	could	MD
10_1101-2020_01_28_923532	418	19	be	be	VB
10_1101-2020_01_28_923532	418	20	targeted	target	VBN
10_1101-2020_01_28_923532	418	21	(	(	-LRB-
10_1101-2020_01_28_923532	418	22	Table	table	NN
10_1101-2020_01_28_923532	418	23	3	3	CD
10_1101-2020_01_28_923532	418	24	)	)	-RRB-
10_1101-2020_01_28_923532	418	25	.	.	.
10_1101-2020_01_28_923532	419	1	Most	Most	JJS
10_1101-2020_01_28_923532	419	2	of	of	IN
10_1101-2020_01_28_923532	419	3	the	the	DT
10_1101-2020_01_28_923532	419	4	data	data	NN
10_1101-2020_01_28_923532	419	5	sets	set	NNS
10_1101-2020_01_28_923532	419	6	listed	list	VBN
10_1101-2020_01_28_923532	419	7	in	in	IN
10_1101-2020_01_28_923532	419	8	Table	table	NN
10_1101-2020_01_28_923532	419	9	1	1	CD
10_1101-2020_01_28_923532	419	10	had	have	VBD
10_1101-2020_01_28_923532	419	11	expression	expression	NN
10_1101-2020_01_28_923532	419	12	data	datum	NNS
10_1101-2020_01_28_923532	419	13	on	on	IN
10_1101-2020_01_28_923532	419	14	1200	1200	CD
10_1101-2020_01_28_923532	419	15	-	-	SYM
10_1101-2020_01_28_923532	419	16	1220	1220	CD
10_1101-2020_01_28_923532	419	17	of	of	IN
10_1101-2020_01_28_923532	419	18	these	these	DT
10_1101-2020_01_28_923532	419	19	genes	gene	NNS
10_1101-2020_01_28_923532	419	20	because	because	IN
10_1101-2020_01_28_923532	419	21	the	the	DT
10_1101-2020_01_28_923532	419	22	list	list	NN
10_1101-2020_01_28_923532	419	23	of	of	IN
10_1101-2020_01_28_923532	419	24	1269	1269	CD
10_1101-2020_01_28_923532	419	25	includes	include	VBZ
10_1101-2020_01_28_923532	419	26	many	many	JJ
10_1101-2020_01_28_923532	419	27	olfactory	olfactory	JJ
10_1101-2020_01_28_923532	419	28	receptor	receptor	NN
10_1101-2020_01_28_923532	419	29	genes	gene	NNS
10_1101-2020_01_28_923532	419	30	that	that	WDT
10_1101-2020_01_28_923532	419	31	may	may	MD
10_1101-2020_01_28_923532	419	32	be	be	VB
10_1101-2020_01_28_923532	419	33	omitted	omit	VBN
10_1101-2020_01_28_923532	419	34	from	from	IN
10_1101-2020_01_28_923532	419	35	standard	standard	JJ
10_1101-2020_01_28_923532	419	36	genome	genome	NN
10_1101-2020_01_28_923532	419	37	-	-	HYPH
10_1101-2020_01_28_923532	419	38	wide	wide	JJ
10_1101-2020_01_28_923532	419	39	expression	expression	NN
10_1101-2020_01_28_923532	419	40	experiments	experiment	NNS
10_1101-2020_01_28_923532	419	41	.	.	.
10_1101-2020_01_28_923532	420	1	Among	among	IN
10_1101-2020_01_28_923532	420	2	the	the	DT
10_1101-2020_01_28_923532	420	3	38	38	CD
10_1101-2020_01_28_923532	420	4	genes	gene	NNS
10_1101-2020_01_28_923532	420	5	in	in	IN
10_1101-2020_01_28_923532	420	6	Table	table	NN
10_1101-2020_01_28_923532	420	7	3	3	CD
10_1101-2020_01_28_923532	420	8	,	,	,
10_1101-2020_01_28_923532	420	9	13/14	13/14	CD
10_1101-2020_01_28_923532	420	10	data	data	NN
10_1101-2020_01_28_923532	420	11	sets	set	NNS
10_1101-2020_01_28_923532	420	12	have	have	VBP
10_1101-2020_01_28_923532	420	13	all	all	DT
10_1101-2020_01_28_923532	420	14	38	38	CD
10_1101-2020_01_28_923532	420	15	genes	gene	NNS
10_1101-2020_01_28_923532	420	16	,	,	,
10_1101-2020_01_28_923532	420	17	but	but	CC
10_1101-2020_01_28_923532	420	18	GSE57872	GSE57872	NNP
10_1101-2020_01_28_923532	420	19	was	be	VBD
10_1101-2020_01_28_923532	420	20	substantially	substantially	RB
10_1101-2020_01_28_923532	420	21	filtered	filter	VBN
10_1101-2020_01_28_923532	420	22	and	and	CC
10_1101-2020_01_28_923532	420	23	has	have	VBZ
10_1101-2020_01_28_923532	420	24	only	only	RB
10_1101-2020_01_28_923532	420	25	10/38	10/38	CD
10_1101-2020_01_28_923532	420	26	genes	gene	NNS
10_1101-2020_01_28_923532	420	27	;	;	:
10_1101-2020_01_28_923532	420	28	since	since	IN
10_1101-2020_01_28_923532	420	29	GSE57872	GSE57872	NNP
10_1101-2020_01_28_923532	420	30	lacks	lack	VBZ
10_1101-2020_01_28_923532	420	31	non	non	JJ
10_1101-2020_01_28_923532	420	32	-	-	JJ
10_1101-2020_01_28_923532	420	33	tumor	tumor	JJ
10_1101-2020_01_28_923532	420	34	cells	cell	NNS
10_1101-2020_01_28_923532	420	35	,	,	,
10_1101-2020_01_28_923532	420	36	we	-PRON-	PRP
10_1101-2020_01_28_923532	420	37	did	do	VBD
10_1101-2020_01_28_923532	420	38	not	not	RB
10_1101-2020_01_28_923532	420	39	use	use	VB
10_1101-2020_01_28_923532	420	40	this	this	DT
10_1101-2020_01_28_923532	420	41	data	data	NN
10_1101-2020_01_28_923532	420	42	set	set	VBN
10_1101-2020_01_28_923532	420	43	in	in	IN
10_1101-2020_01_28_923532	420	44	any	any	DT
10_1101-2020_01_28_923532	420	45	analyses	analysis	NNS
10_1101-2020_01_28_923532	420	46	shown	show	VBN
10_1101-2020_01_28_923532	420	47	.	.	.
10_1101-2020_01_28_923532	421	1	105	105	CD
10_1101-2020_01_28_923532	421	2	and	and	CC
10_1101-2020_01_28_923532	421	3	is	be	VBZ
10_1101-2020_01_28_923532	421	4	also	also	RB
10_1101-2020_01_28_923532	421	5	made	make	VBN
10_1101-2020_01_28_923532	421	6	available	available	JJ
10_1101-2020_01_28_923532	421	7	for	for	IN
10_1101-2020_01_28_923532	421	8	use	use	NN
10_1101-2020_01_28_923532	421	9	under	under	IN
10_1101-2020_01_28_923532	421	10	a	a	DT
10_1101-2020_01_28_923532	421	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	421	12	license	license	NN
10_1101-2020_01_28_923532	421	13	.	.	.
10_1101-2020_01_28_923532	422	1	(	(	-LRB-
10_1101-2020_01_28_923532	422	2	which	which	WDT
10_1101-2020_01_28_923532	422	3	was	be	VBD
10_1101-2020_01_28_923532	422	4	not	not	RB
10_1101-2020_01_28_923532	422	5	certified	certify	VBN
10_1101-2020_01_28_923532	422	6	by	by	IN
10_1101-2020_01_28_923532	422	7	peer	peer	NN
10_1101-2020_01_28_923532	422	8	review	review	NN
10_1101-2020_01_28_923532	422	9	)	)	-RRB-
10_1101-2020_01_28_923532	422	10	is	be	VBZ
10_1101-2020_01_28_923532	422	11	the	the	DT
10_1101-2020_01_28_923532	422	12	author	author	NN
10_1101-2020_01_28_923532	422	13	/	/	SYM
10_1101-2020_01_28_923532	422	14	funder	funder	NN
10_1101-2020_01_28_923532	422	15	.	.	.
10_1101-2020_01_28_923532	423	1	This	this	DT
10_1101-2020_01_28_923532	423	2	article	article	NN
10_1101-2020_01_28_923532	423	3	is	be	VBZ
10_1101-2020_01_28_923532	423	4	a	a	DT
10_1101-2020_01_28_923532	423	5	US	US	NNP
10_1101-2020_01_28_923532	423	6	Government	Government	NNP
10_1101-2020_01_28_923532	423	7	work	work	NN
10_1101-2020_01_28_923532	423	8	.	.	.
10_1101-2020_01_28_923532	424	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	424	2	is	be	VBZ
10_1101-2020_01_28_923532	424	3	not	not	RB
10_1101-2020_01_28_923532	424	4	subject	subject	JJ
10_1101-2020_01_28_923532	424	5	to	to	IN
10_1101-2020_01_28_923532	424	6	copyright	copyright	NN
10_1101-2020_01_28_923532	424	7	under	under	IN
10_1101-2020_01_28_923532	424	8	17	17	CD
10_1101-2020_01_28_923532	424	9	USC	usc	NN
10_1101-2020_01_28_923532	424	10	The	the	DT
10_1101-2020_01_28_923532	424	11	copyright	copyright	NN
10_1101-2020_01_28_923532	424	12	holder	holder	NN
10_1101-2020_01_28_923532	424	13	for	for	IN
10_1101-2020_01_28_923532	424	14	this	this	DT
10_1101-2020_01_28_923532	424	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	424	16	version	version	NN
10_1101-2020_01_28_923532	424	17	posted	post	VBD
10_1101-2020_01_28_923532	424	18	February	February	NNP
10_1101-2020_01_28_923532	424	19	12	12	CD
10_1101-2020_01_28_923532	424	20	,	,	,
10_1101-2020_01_28_923532	424	21	2021	2021	CD
10_1101-2020_01_28_923532	424	22	.	.	.
10_1101-2020_01_28_923532	424	23	;	;	:
10_1101-2020_01_28_923532	424	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	424	25	:	:	:
10_1101-2020_01_28_923532	424	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	424	27	preprint	preprint	NN
10_1101-2020_01_28_923532	424	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	424	29	33	33	CD
10_1101-2020_01_28_923532	424	30	Because	because	IN
10_1101-2020_01_28_923532	424	31	the	the	DT
10_1101-2020_01_28_923532	424	32	latter	latter	JJ
10_1101-2020_01_28_923532	424	33	review20	review20	NNP
10_1101-2020_01_28_923532	424	34	was	be	VBD
10_1101-2020_01_28_923532	424	35	published	publish	VBN
10_1101-2020_01_28_923532	424	36	in	in	IN
10_1101-2020_01_28_923532	424	37	2017	2017	CD
10_1101-2020_01_28_923532	424	38	,	,	,
10_1101-2020_01_28_923532	424	39	we	-PRON-	PRP
10_1101-2020_01_28_923532	424	40	expected	expect	VBD
10_1101-2020_01_28_923532	424	41	that	that	IN
10_1101-2020_01_28_923532	424	42	there	there	EX
10_1101-2020_01_28_923532	424	43	are	be	VBP
10_1101-2020_01_28_923532	424	44	now	now	RB
10_1101-2020_01_28_923532	424	45	additional	additional	JJ
10_1101-2020_01_28_923532	424	46	genes	gene	NNS
10_1101-2020_01_28_923532	424	47	for	for	IN
10_1101-2020_01_28_923532	424	48	which	which	WDT
10_1101-2020_01_28_923532	424	49	ligand	ligand	NN
10_1101-2020_01_28_923532	424	50	-	-	HYPH
10_1101-2020_01_28_923532	424	51	mimicking	mimicking	NN
10_1101-2020_01_28_923532	424	52	peptides	peptide	NNS
10_1101-2020_01_28_923532	424	53	are	be	VBP
10_1101-2020_01_28_923532	424	54	known	know	VBN
10_1101-2020_01_28_923532	424	55	.	.	.
10_1101-2020_01_28_923532	425	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	425	2	found	find	VBD
10_1101-2020_01_28_923532	425	3	20	20	CD
10_1101-2020_01_28_923532	425	4	additional	additional	JJ
10_1101-2020_01_28_923532	425	5	genes	gene	NNS
10_1101-2020_01_28_923532	425	6	and	and	CC
10_1101-2020_01_28_923532	425	7	those	those	DT
10_1101-2020_01_28_923532	425	8	are	be	VBP
10_1101-2020_01_28_923532	425	9	listed	list	VBN
10_1101-2020_01_28_923532	425	10	in	in	IN
10_1101-2020_01_28_923532	425	11	Table	table	NN
10_1101-2020_01_28_923532	425	12	4	4	CD
10_1101-2020_01_28_923532	425	13	.	.	.
10_1101-2020_01_28_923532	426	1	Thus	thus	RB
10_1101-2020_01_28_923532	426	2	,	,	,
10_1101-2020_01_28_923532	426	3	our	-PRON-	PRP$
10_1101-2020_01_28_923532	426	4	target	target	NN
10_1101-2020_01_28_923532	426	5	set	set	VBN
10_1101-2020_01_28_923532	426	6	analyses	analysis	NNS
10_1101-2020_01_28_923532	426	7	restricted	restrict	VBN
10_1101-2020_01_28_923532	426	8	to	to	IN
10_1101-2020_01_28_923532	426	9	genes	gene	NNS
10_1101-2020_01_28_923532	426	10	with	with	IN
10_1101-2020_01_28_923532	426	11	known	know	VBN
10_1101-2020_01_28_923532	426	12	ligand	ligand	NN
10_1101-2020_01_28_923532	426	13	-	-	HYPH
10_1101-2020_01_28_923532	426	14	mimicking	mimicking	NN
10_1101-2020_01_28_923532	426	15	peptides	peptide	NNS
10_1101-2020_01_28_923532	426	16	use	use	VBP
10_1101-2020_01_28_923532	426	17	58	58	CD
10_1101-2020_01_28_923532	426	18	=	=	SYM
10_1101-2020_01_28_923532	426	19	38	38	CD
10_1101-2020_01_28_923532	426	20	+	+	SYM
10_1101-2020_01_28_923532	426	21	20	20	CD
10_1101-2020_01_28_923532	426	22	targets	target	NNS
10_1101-2020_01_28_923532	426	23	.	.	.
10_1101-2020_01_28_923532	427	1	Table	table	NN
10_1101-2020_01_28_923532	427	2	3	3	CD
10_1101-2020_01_28_923532	427	3	.	.	.
10_1101-2020_01_28_923532	428	1	Single	single	JJ
10_1101-2020_01_28_923532	428	2	proteins	protein	NNS
10_1101-2020_01_28_923532	428	3	that	that	WDT
10_1101-2020_01_28_923532	428	4	can	can	MD
10_1101-2020_01_28_923532	428	5	be	be	VB
10_1101-2020_01_28_923532	428	6	targeted	target	VBN
10_1101-2020_01_28_923532	428	7	by	by	IN
10_1101-2020_01_28_923532	428	8	peptides	peptide	NNS
10_1101-2020_01_28_923532	428	9	based	base	VBN
10_1101-2020_01_28_923532	428	10	on	on	IN
10_1101-2020_01_28_923532	428	11	references	reference	NNS
10_1101-2020_01_28_923532	428	12	18	18	CD
10_1101-2020_01_28_923532	428	13	,	,	,
10_1101-2020_01_28_923532	428	14	19	19	CD
10_1101-2020_01_28_923532	428	15	and	and	CC
10_1101-2020_01_28_923532	428	16	are	be	VBP
10_1101-2020_01_28_923532	428	17	expressed	express	VBN
10_1101-2020_01_28_923532	428	18	on	on	IN
10_1101-2020_01_28_923532	428	19	the	the	DT
10_1101-2020_01_28_923532	428	20	cell	cell	NN
10_1101-2020_01_28_923532	428	21	surface77	surface77	NN
10_1101-2020_01_28_923532	428	22	.	.	.
10_1101-2020_01_28_923532	429	1	For	for	IN
10_1101-2020_01_28_923532	429	2	easier	easy	JJR
10_1101-2020_01_28_923532	429	3	correspondence	correspondence	NN
10_1101-2020_01_28_923532	429	4	with	with	IN
10_1101-2020_01_28_923532	429	5	the	the	DT
10_1101-2020_01_28_923532	429	6	gene	gene	NN
10_1101-2020_01_28_923532	429	7	expression	expression	NN
10_1101-2020_01_28_923532	429	8	data	datum	NNS
10_1101-2020_01_28_923532	429	9	,	,	,
10_1101-2020_01_28_923532	429	10	the	the	DT
10_1101-2020_01_28_923532	429	11	entries	entry	NNS
10_1101-2020_01_28_923532	429	12	are	be	VBP
10_1101-2020_01_28_923532	429	13	listed	list	VBN
10_1101-2020_01_28_923532	429	14	in	in	IN
10_1101-2020_01_28_923532	429	15	alphabetical	alphabetical	JJ
10_1101-2020_01_28_923532	429	16	order	order	NN
10_1101-2020_01_28_923532	429	17	by	by	IN
10_1101-2020_01_28_923532	429	18	gene	gene	NN
10_1101-2020_01_28_923532	429	19	symbol	symbol	NN
10_1101-2020_01_28_923532	429	20	.	.	.
10_1101-2020_01_28_923532	430	1	In	in	IN
10_1101-2020_01_28_923532	430	2	this	this	DT
10_1101-2020_01_28_923532	430	3	table	table	NN
10_1101-2020_01_28_923532	430	4	,	,	,
10_1101-2020_01_28_923532	430	5	we	-PRON-	PRP
10_1101-2020_01_28_923532	430	6	follow	follow	VBP
10_1101-2020_01_28_923532	430	7	the	the	DT
10_1101-2020_01_28_923532	430	8	clinical	clinical	JJ
10_1101-2020_01_28_923532	430	9	genetics	genetic	NNS
10_1101-2020_01_28_923532	430	10	formatting	format	VBG
10_1101-2020_01_28_923532	430	11	convention	convention	NN
10_1101-2020_01_28_923532	430	12	that	that	WDT
10_1101-2020_01_28_923532	430	13	proteins	protein	NNS
10_1101-2020_01_28_923532	430	14	are	be	VBP
10_1101-2020_01_28_923532	430	15	in	in	IN
10_1101-2020_01_28_923532	430	16	Roman	roman	JJ
10_1101-2020_01_28_923532	430	17	and	and	CC
10_1101-2020_01_28_923532	430	18	gene	gene	NN
10_1101-2020_01_28_923532	430	19	symbols	symbol	NNS
10_1101-2020_01_28_923532	430	20	are	be	VBP
10_1101-2020_01_28_923532	430	21	in	in	IN
10_1101-2020_01_28_923532	430	22	italics	italic	NNS
10_1101-2020_01_28_923532	430	23	.	.	.
10_1101-2020_01_28_923532	431	1	Protein	Protein	NNP
10_1101-2020_01_28_923532	431	2	Gene	Gene	NNP
10_1101-2020_01_28_923532	431	3	Symbol	Symbol	NNP
10_1101-2020_01_28_923532	431	4	APN	APN	NNP
10_1101-2020_01_28_923532	431	5	/	/	SYM
10_1101-2020_01_28_923532	431	6	CD13	CD13	NNP
10_1101-2020_01_28_923532	431	7	ANPEP	ANPEP	NNP
10_1101-2020_01_28_923532	431	8	APP	APP	NNP
10_1101-2020_01_28_923532	431	9	APP	APP	NNP
10_1101-2020_01_28_923532	431	10	PD	PD	NNP
10_1101-2020_01_28_923532	431	11	-	-	HYPH
10_1101-2020_01_28_923532	431	12	L1	L1	NNP
10_1101-2020_01_28_923532	431	13	CD274	CD274	NNP
10_1101-2020_01_28_923532	431	14	CD44	CD44	NNP
10_1101-2020_01_28_923532	431	15	CD44	CD44	NNP
10_1101-2020_01_28_923532	431	16	P32	P32	NNP
10_1101-2020_01_28_923532	431	17	/	/	SYM
10_1101-2020_01_28_923532	431	18	gC1qR	gC1qR	NNP
10_1101-2020_01_28_923532	431	19	CD93	CD93	NNP
10_1101-2020_01_28_923532	431	20	E	E	NNP
10_1101-2020_01_28_923532	431	21	-	-	HYPH
10_1101-2020_01_28_923532	431	22	cadherin	cadherin	NNP
10_1101-2020_01_28_923532	431	23	CDH1	CDH1	NNP
10_1101-2020_01_28_923532	431	24	N	N	NNP
10_1101-2020_01_28_923532	431	25	-	-	HYPH
10_1101-2020_01_28_923532	431	26	cadherin	cadherin	NN
10_1101-2020_01_28_923532	431	27	CDH2	CDH2	NNP
10_1101-2020_01_28_923532	431	28	CD21	CD21	NNP
10_1101-2020_01_28_923532	431	29	CR2	CR2	NNP
10_1101-2020_01_28_923532	431	30	EGFR	EGFR	NNP
10_1101-2020_01_28_923532	431	31	EGFR	egfr	NN
10_1101-2020_01_28_923532	431	32	Epha2	epha2	NN
10_1101-2020_01_28_923532	431	33	EPHA2	epha2	XX
10_1101-2020_01_28_923532	431	34	EphB4	EphB4	NNP
10_1101-2020_01_28_923532	431	35	EPHB4	EPHB4	NNP
10_1101-2020_01_28_923532	431	36	HER2	HER2	NNP
10_1101-2020_01_28_923532	431	37	ERBB2	ERBB2	NNS
10_1101-2020_01_28_923532	431	38	FGFR1	fgfr1	CD
10_1101-2020_01_28_923532	431	39	FGFR1	fgfr1	CD
10_1101-2020_01_28_923532	431	40	FGFR2	fgfr2	NN
10_1101-2020_01_28_923532	431	41	FGFR2	FGFR2	NNP
10_1101-2020_01_28_923532	431	42	FGFR3	FGFR3	NNP
10_1101-2020_01_28_923532	431	43	FGFR3	FGFR3	NNP
10_1101-2020_01_28_923532	431	44	105	105	CD
10_1101-2020_01_28_923532	431	45	and	and	CC
10_1101-2020_01_28_923532	431	46	is	be	VBZ
10_1101-2020_01_28_923532	431	47	also	also	RB
10_1101-2020_01_28_923532	431	48	made	make	VBN
10_1101-2020_01_28_923532	431	49	available	available	JJ
10_1101-2020_01_28_923532	431	50	for	for	IN
10_1101-2020_01_28_923532	431	51	use	use	NN
10_1101-2020_01_28_923532	431	52	under	under	IN
10_1101-2020_01_28_923532	431	53	a	a	DT
10_1101-2020_01_28_923532	431	54	CC0	CC0	NNP
10_1101-2020_01_28_923532	431	55	license	license	NN
10_1101-2020_01_28_923532	431	56	.	.	.
10_1101-2020_01_28_923532	432	1	(	(	-LRB-
10_1101-2020_01_28_923532	432	2	which	which	WDT
10_1101-2020_01_28_923532	432	3	was	be	VBD
10_1101-2020_01_28_923532	432	4	not	not	RB
10_1101-2020_01_28_923532	432	5	certified	certify	VBN
10_1101-2020_01_28_923532	432	6	by	by	IN
10_1101-2020_01_28_923532	432	7	peer	peer	NN
10_1101-2020_01_28_923532	432	8	review	review	NN
10_1101-2020_01_28_923532	432	9	)	)	-RRB-
10_1101-2020_01_28_923532	432	10	is	be	VBZ
10_1101-2020_01_28_923532	432	11	the	the	DT
10_1101-2020_01_28_923532	432	12	author	author	NN
10_1101-2020_01_28_923532	432	13	/	/	SYM
10_1101-2020_01_28_923532	432	14	funder	funder	NN
10_1101-2020_01_28_923532	432	15	.	.	.
10_1101-2020_01_28_923532	433	1	This	this	DT
10_1101-2020_01_28_923532	433	2	article	article	NN
10_1101-2020_01_28_923532	433	3	is	be	VBZ
10_1101-2020_01_28_923532	433	4	a	a	DT
10_1101-2020_01_28_923532	433	5	US	US	NNP
10_1101-2020_01_28_923532	433	6	Government	Government	NNP
10_1101-2020_01_28_923532	433	7	work	work	NN
10_1101-2020_01_28_923532	433	8	.	.	.
10_1101-2020_01_28_923532	434	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	434	2	is	be	VBZ
10_1101-2020_01_28_923532	434	3	not	not	RB
10_1101-2020_01_28_923532	434	4	subject	subject	JJ
10_1101-2020_01_28_923532	434	5	to	to	IN
10_1101-2020_01_28_923532	434	6	copyright	copyright	NN
10_1101-2020_01_28_923532	434	7	under	under	IN
10_1101-2020_01_28_923532	434	8	17	17	CD
10_1101-2020_01_28_923532	434	9	USC	usc	NN
10_1101-2020_01_28_923532	434	10	The	the	DT
10_1101-2020_01_28_923532	434	11	copyright	copyright	NN
10_1101-2020_01_28_923532	434	12	holder	holder	NN
10_1101-2020_01_28_923532	434	13	for	for	IN
10_1101-2020_01_28_923532	434	14	this	this	DT
10_1101-2020_01_28_923532	434	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	434	16	version	version	NN
10_1101-2020_01_28_923532	434	17	posted	post	VBD
10_1101-2020_01_28_923532	434	18	February	February	NNP
10_1101-2020_01_28_923532	434	19	12	12	CD
10_1101-2020_01_28_923532	434	20	,	,	,
10_1101-2020_01_28_923532	434	21	2021	2021	CD
10_1101-2020_01_28_923532	434	22	.	.	.
10_1101-2020_01_28_923532	434	23	;	;	:
10_1101-2020_01_28_923532	434	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	434	25	:	:	:
10_1101-2020_01_28_923532	434	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	434	27	preprint	preprint	NN
10_1101-2020_01_28_923532	434	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	434	29	34	34	CD
10_1101-2020_01_28_923532	434	30	FGFR4	FGFR4	NNS
10_1101-2020_01_28_923532	434	31	FGFR4	fgfr4	NN
10_1101-2020_01_28_923532	434	32	VEGFR1	VEGFR1	NNP
10_1101-2020_01_28_923532	434	33	FLT1	FLT1	NNP
10_1101-2020_01_28_923532	434	34	VEGFR3	VEGFR3	NNP
10_1101-2020_01_28_923532	434	35	FLT4	FLT4	NNP
10_1101-2020_01_28_923532	434	36	PSMA	PSMA	NNP
10_1101-2020_01_28_923532	434	37	FOLH1	folh1	NN
10_1101-2020_01_28_923532	434	38	GPC3	GPC3	NNP
10_1101-2020_01_28_923532	434	39	GPC3	GPC3	NNP
10_1101-2020_01_28_923532	434	40	IL-10RA	IL-10RA	NNP
10_1101-2020_01_28_923532	434	41	IL10RA	IL10RA	NNP
10_1101-2020_01_28_923532	434	42	IL-11Rα	IL-11Rα	NNP
10_1101-2020_01_28_923532	434	43	IL11RA	IL11RA	NNP
10_1101-2020_01_28_923532	434	44	IL-13Rα2	IL-13Rα2	NNP
10_1101-2020_01_28_923532	434	45	IL13RA2	IL13RA2	NNP
10_1101-2020_01_28_923532	434	46	IL-6Rα	IL-6Rα	NNP
10_1101-2020_01_28_923532	434	47	IL6R	il6r	NN
10_1101-2020_01_28_923532	434	48	GP130	GP130	NNP
10_1101-2020_01_28_923532	434	49	IL6ST	IL6ST	NNP
10_1101-2020_01_28_923532	434	50	VEGFR2	VEGFR2	VBD
10_1101-2020_01_28_923532	434	51	KDR	KDR	NNP
10_1101-2020_01_28_923532	434	52	MUC18	muc18	NN
10_1101-2020_01_28_923532	434	53	MCAM	MCAM	NNS
10_1101-2020_01_28_923532	434	54	Met	Met	NNP
10_1101-2020_01_28_923532	434	55	MET	MET	NNP
10_1101-2020_01_28_923532	434	56	MMP9	MMP9	NNP
10_1101-2020_01_28_923532	434	57	MMP9	MMP9	NNP
10_1101-2020_01_28_923532	434	58	Thomsen	Thomsen	NNP
10_1101-2020_01_28_923532	434	59	-	-	HYPH
10_1101-2020_01_28_923532	434	60	Friedenreich	Friedenreich	NNP
10_1101-2020_01_28_923532	434	61	carbohydrate	carbohydrate	NN
10_1101-2020_01_28_923532	434	62	antigen	antigen	NN
10_1101-2020_01_28_923532	434	63	MUC1	MUC1	NNP
10_1101-2020_01_28_923532	434	64	NRP-1	NRP-1	NNP
10_1101-2020_01_28_923532	434	65	NRP1	NRP1	NNP
10_1101-2020_01_28_923532	434	66	PDGFRβ	PDGFRβ	VBZ
10_1101-2020_01_28_923532	434	67	PDGFRB	pdgfrb	NN
10_1101-2020_01_28_923532	434	68	CD133	cd133	DT
10_1101-2020_01_28_923532	434	69	PROM1	prom1	NN
10_1101-2020_01_28_923532	434	70	PTPRJ	PTPRJ	NNP
10_1101-2020_01_28_923532	434	71	PTPRJ	ptprj	NN
10_1101-2020_01_28_923532	434	72	HSPG	HSPG	NNS
10_1101-2020_01_28_923532	434	73	SDC2	SDC2	NNP
10_1101-2020_01_28_923532	434	74	E	e	NN
10_1101-2020_01_28_923532	434	75	-	-	NN
10_1101-2020_01_28_923532	434	76	selectin	selectin	JJ
10_1101-2020_01_28_923532	434	77	SELE	SELE	NNP
10_1101-2020_01_28_923532	434	78	Tie2	Tie2	NNP
10_1101-2020_01_28_923532	434	79	TEK	tek	FW
10_1101-2020_01_28_923532	434	80	VPAC1	vpac1	FW
10_1101-2020_01_28_923532	434	81	VIPR1	VIPR1	NNP
10_1101-2020_01_28_923532	434	82	Table	table	NN
10_1101-2020_01_28_923532	434	83	4	4	CD
10_1101-2020_01_28_923532	434	84	.	.	.
10_1101-2020_01_28_923532	435	1	Single	single	JJ
10_1101-2020_01_28_923532	435	2	proteins	protein	NNS
10_1101-2020_01_28_923532	435	3	that	that	WDT
10_1101-2020_01_28_923532	435	4	can	can	MD
10_1101-2020_01_28_923532	435	5	be	be	VB
10_1101-2020_01_28_923532	435	6	targeted	target	VBN
10_1101-2020_01_28_923532	435	7	by	by	IN
10_1101-2020_01_28_923532	435	8	ligand	ligand	NN
10_1101-2020_01_28_923532	435	9	-	-	HYPH
10_1101-2020_01_28_923532	435	10	mimicking	mimic	VBG
10_1101-2020_01_28_923532	435	11	peptides	peptide	NNS
10_1101-2020_01_28_923532	435	12	but	but	CC
10_1101-2020_01_28_923532	435	13	are	be	VBP
10_1101-2020_01_28_923532	435	14	not	not	RB
10_1101-2020_01_28_923532	435	15	included	include	VBN
10_1101-2020_01_28_923532	435	16	in	in	IN
10_1101-2020_01_28_923532	435	17	the	the	DT
10_1101-2020_01_28_923532	435	18	two	two	CD
10_1101-2020_01_28_923532	435	19	principal	principal	JJ
10_1101-2020_01_28_923532	435	20	reviews	review	NNS
10_1101-2020_01_28_923532	435	21	that	that	WDT
10_1101-2020_01_28_923532	435	22	we	-PRON-	PRP
10_1101-2020_01_28_923532	435	23	consulted19	consulted19	NNP
10_1101-2020_01_28_923532	435	24	-	-	:
10_1101-2020_01_28_923532	435	25	20	20	CD
10_1101-2020_01_28_923532	435	26	and	and	CC
10_1101-2020_01_28_923532	435	27	are	be	VBP
10_1101-2020_01_28_923532	435	28	among	among	IN
10_1101-2020_01_28_923532	435	29	1269	1269	CD
10_1101-2020_01_28_923532	435	30	cell	cell	NN
10_1101-2020_01_28_923532	435	31	surface	surface	NN
10_1101-2020_01_28_923532	435	32	receptors77	receptors77	NNP
10_1101-2020_01_28_923532	435	33	.	.	.
10_1101-2020_01_28_923532	436	1	105	105	CD
10_1101-2020_01_28_923532	436	2	and	and	CC
10_1101-2020_01_28_923532	436	3	is	be	VBZ
10_1101-2020_01_28_923532	436	4	also	also	RB
10_1101-2020_01_28_923532	436	5	made	make	VBN
10_1101-2020_01_28_923532	436	6	available	available	JJ
10_1101-2020_01_28_923532	436	7	for	for	IN
10_1101-2020_01_28_923532	436	8	use	use	NN
10_1101-2020_01_28_923532	436	9	under	under	IN
10_1101-2020_01_28_923532	436	10	a	a	DT
10_1101-2020_01_28_923532	436	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	436	12	license	license	NN
10_1101-2020_01_28_923532	436	13	.	.	.
10_1101-2020_01_28_923532	437	1	(	(	-LRB-
10_1101-2020_01_28_923532	437	2	which	which	WDT
10_1101-2020_01_28_923532	437	3	was	be	VBD
10_1101-2020_01_28_923532	437	4	not	not	RB
10_1101-2020_01_28_923532	437	5	certified	certify	VBN
10_1101-2020_01_28_923532	437	6	by	by	IN
10_1101-2020_01_28_923532	437	7	peer	peer	NN
10_1101-2020_01_28_923532	437	8	review	review	NN
10_1101-2020_01_28_923532	437	9	)	)	-RRB-
10_1101-2020_01_28_923532	437	10	is	be	VBZ
10_1101-2020_01_28_923532	437	11	the	the	DT
10_1101-2020_01_28_923532	437	12	author	author	NN
10_1101-2020_01_28_923532	437	13	/	/	SYM
10_1101-2020_01_28_923532	437	14	funder	funder	NN
10_1101-2020_01_28_923532	437	15	.	.	.
10_1101-2020_01_28_923532	438	1	This	this	DT
10_1101-2020_01_28_923532	438	2	article	article	NN
10_1101-2020_01_28_923532	438	3	is	be	VBZ
10_1101-2020_01_28_923532	438	4	a	a	DT
10_1101-2020_01_28_923532	438	5	US	US	NNP
10_1101-2020_01_28_923532	438	6	Government	Government	NNP
10_1101-2020_01_28_923532	438	7	work	work	NN
10_1101-2020_01_28_923532	438	8	.	.	.
10_1101-2020_01_28_923532	439	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	439	2	is	be	VBZ
10_1101-2020_01_28_923532	439	3	not	not	RB
10_1101-2020_01_28_923532	439	4	subject	subject	JJ
10_1101-2020_01_28_923532	439	5	to	to	IN
10_1101-2020_01_28_923532	439	6	copyright	copyright	NN
10_1101-2020_01_28_923532	439	7	under	under	IN
10_1101-2020_01_28_923532	439	8	17	17	CD
10_1101-2020_01_28_923532	439	9	USC	usc	NN
10_1101-2020_01_28_923532	439	10	The	the	DT
10_1101-2020_01_28_923532	439	11	copyright	copyright	NN
10_1101-2020_01_28_923532	439	12	holder	holder	NN
10_1101-2020_01_28_923532	439	13	for	for	IN
10_1101-2020_01_28_923532	439	14	this	this	DT
10_1101-2020_01_28_923532	439	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	439	16	version	version	NN
10_1101-2020_01_28_923532	439	17	posted	post	VBD
10_1101-2020_01_28_923532	439	18	February	February	NNP
10_1101-2020_01_28_923532	439	19	12	12	CD
10_1101-2020_01_28_923532	439	20	,	,	,
10_1101-2020_01_28_923532	439	21	2021	2021	CD
10_1101-2020_01_28_923532	439	22	.	.	.
10_1101-2020_01_28_923532	439	23	;	;	:
10_1101-2020_01_28_923532	439	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	439	25	:	:	:
10_1101-2020_01_28_923532	439	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	439	27	preprint	preprint	NN
10_1101-2020_01_28_923532	439	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	439	29	35	35	CD
10_1101-2020_01_28_923532	439	30	Since	since	IN
10_1101-2020_01_28_923532	439	31	the	the	DT
10_1101-2020_01_28_923532	439	32	evidence	evidence	NN
10_1101-2020_01_28_923532	439	33	that	that	IN
10_1101-2020_01_28_923532	439	34	these	these	DT
10_1101-2020_01_28_923532	439	35	20	20	CD
10_1101-2020_01_28_923532	439	36	genes	gene	NNS
10_1101-2020_01_28_923532	439	37	have	have	VBP
10_1101-2020_01_28_923532	439	38	ligand	ligand	NN
10_1101-2020_01_28_923532	439	39	-	-	HYPH
10_1101-2020_01_28_923532	439	40	mimicking	mimicking	NN
10_1101-2020_01_28_923532	439	41	peptides	peptide	NNS
10_1101-2020_01_28_923532	439	42	is	be	VBZ
10_1101-2020_01_28_923532	439	43	scattered	scatter	VBN
10_1101-2020_01_28_923532	439	44	in	in	IN
10_1101-2020_01_28_923532	439	45	the	the	DT
10_1101-2020_01_28_923532	439	46	literature	literature	NN
10_1101-2020_01_28_923532	439	47	,	,	,
10_1101-2020_01_28_923532	439	48	we	-PRON-	PRP
10_1101-2020_01_28_923532	439	49	include	include	VBP
10_1101-2020_01_28_923532	439	50	at	at	IN
10_1101-2020_01_28_923532	439	51	least	least	JJS
10_1101-2020_01_28_923532	439	52	one	one	CD
10_1101-2020_01_28_923532	439	53	PubMed	PubMed	NNP
10_1101-2020_01_28_923532	439	54	ID	ID	NNP
10_1101-2020_01_28_923532	439	55	of	of	IN
10_1101-2020_01_28_923532	439	56	a	a	DT
10_1101-2020_01_28_923532	439	57	paper	paper	NN
10_1101-2020_01_28_923532	439	58	describing	describe	VBG
10_1101-2020_01_28_923532	439	59	a	a	DT
10_1101-2020_01_28_923532	439	60	suitable	suitable	JJ
10_1101-2020_01_28_923532	439	61	peptide	peptide	NN
10_1101-2020_01_28_923532	439	62	.	.	.
10_1101-2020_01_28_923532	440	1	Protein	protein	NN
10_1101-2020_01_28_923532	440	2	Gene	Gene	NNP
10_1101-2020_01_28_923532	440	3	Symbol	Symbol	NNP
10_1101-2020_01_28_923532	440	4	At	at	IN
10_1101-2020_01_28_923532	440	5	Least	Least	JJS
10_1101-2020_01_28_923532	440	6	One	one	CD
10_1101-2020_01_28_923532	440	7	PubMed	PubMed	NNP
10_1101-2020_01_28_923532	440	8	ID	ID	NNP
10_1101-2020_01_28_923532	440	9	ActRIIB	ActRIIB	NNP
10_1101-2020_01_28_923532	440	10	ACVR2B	ACVR2B	NNP
10_1101-2020_01_28_923532	440	11	28955765	28955765	CD
10_1101-2020_01_28_923532	440	12	CD163	CD163	NNP
10_1101-2020_01_28_923532	440	13	CD163	CD163	NNP
10_1101-2020_01_28_923532	440	14	27563889	27563889	CD
10_1101-2020_01_28_923532	440	15	CXCR4	CXCR4	NNS
10_1101-2020_01_28_923532	440	16	CXCR4	CXCR4	NNS
10_1101-2020_01_28_923532	440	17	19482312	19482312	CD
10_1101-2020_01_28_923532	440	18	,	,	,
10_1101-2020_01_28_923532	440	19	22523575	22523575	CD
10_1101-2020_01_28_923532	440	20	ephrin	ephrin	NN
10_1101-2020_01_28_923532	440	21	A4	A4	NNP
10_1101-2020_01_28_923532	440	22	EPHA4	EPHA4	NNP
10_1101-2020_01_28_923532	440	23	15681844	15681844	CD
10_1101-2020_01_28_923532	440	24	,	,	,
10_1101-2020_01_28_923532	440	25	22523575	22523575	CD
10_1101-2020_01_28_923532	440	26	ephrin	ephrin	NN
10_1101-2020_01_28_923532	440	27	B1	B1	NNP
10_1101-2020_01_28_923532	440	28	EPHB1	EPHB1	NNP
10_1101-2020_01_28_923532	440	29	15722342	15722342	CD
10_1101-2020_01_28_923532	440	30	,	,	,
10_1101-2020_01_28_923532	440	31	22523575	22523575	CD
10_1101-2020_01_28_923532	440	32	ephrin	ephrin	NN
10_1101-2020_01_28_923532	440	33	B2	B2	NNP
10_1101-2020_01_28_923532	440	34	EPHB2	EPHB2	NNP
10_1101-2020_01_28_923532	440	35	15722342	15722342	CD
10_1101-2020_01_28_923532	440	36	,	,	,
10_1101-2020_01_28_923532	440	37	22523575	22523575	CD
10_1101-2020_01_28_923532	440	38	ephrin	ephrin	NNP
10_1101-2020_01_28_923532	440	39	B3	B3	NNP
10_1101-2020_01_28_923532	440	40	EPHB3	EPHB3	NNS
10_1101-2020_01_28_923532	440	41	15722342	15722342	CD
10_1101-2020_01_28_923532	440	42	,	,	,
10_1101-2020_01_28_923532	440	43	22523575	22523575	CD
10_1101-2020_01_28_923532	440	44	gonadotrophin	gonadotrophin	NN
10_1101-2020_01_28_923532	440	45	releasing	release	VBG
10_1101-2020_01_28_923532	440	46	hormone	hormone	NN
10_1101-2020_01_28_923532	440	47	receptor	receptor	NN
10_1101-2020_01_28_923532	440	48	GNRHR	GNRHR	NNP
10_1101-2020_01_28_923532	440	49	20814857	20814857	CD
10_1101-2020_01_28_923532	440	50	,	,	,
10_1101-2020_01_28_923532	440	51	22523575	22523575	CD
10_1101-2020_01_28_923532	440	52	G	G	NNP
10_1101-2020_01_28_923532	440	53	Protein	Protein	NNP
10_1101-2020_01_28_923532	440	54	coupled	couple	VBN
10_1101-2020_01_28_923532	440	55	receptor	receptor	NN
10_1101-2020_01_28_923532	440	56	55	55	CD
10_1101-2020_01_28_923532	440	57	GPR55	gpr55	CD
10_1101-2020_01_28_923532	440	58	28029647	28029647	CD
10_1101-2020_01_28_923532	440	59	bombesin	bombesin	NNP
10_1101-2020_01_28_923532	440	60	receptor	receptor	NN
10_1101-2020_01_28_923532	440	61	2	2	CD
10_1101-2020_01_28_923532	440	62	GRPR	GRPR	NNP
10_1101-2020_01_28_923532	440	63	20814857	20814857	CD
10_1101-2020_01_28_923532	440	64	,	,	,
10_1101-2020_01_28_923532	440	65	22523575	22523575	CD
10_1101-2020_01_28_923532	440	66	IL4	IL4	NNP
10_1101-2020_01_28_923532	440	67	receptor	receptor	NN
10_1101-2020_01_28_923532	440	68	IL4R	il4r	POS
10_1101-2020_01_28_923532	440	69	19012727	19012727	CD
10_1101-2020_01_28_923532	440	70	low	low	JJ
10_1101-2020_01_28_923532	440	71	density	density	NN
10_1101-2020_01_28_923532	440	72	lipoprotein	lipoprotein	NNP
10_1101-2020_01_28_923532	440	73	receptor	receptor	NN
10_1101-2020_01_28_923532	440	74	LDLR	LDLR	NNP
10_1101-2020_01_28_923532	440	75	27656777	27656777	CD
10_1101-2020_01_28_923532	440	76	leptin	leptin	NNP
10_1101-2020_01_28_923532	440	77	receptor	receptor	NNP
10_1101-2020_01_28_923532	440	78	LEPR	LEPR	NNP
10_1101-2020_01_28_923532	440	79	19233229	19233229	CD
10_1101-2020_01_28_923532	440	80	,	,	,
10_1101-2020_01_28_923532	440	81	26265355	26265355	CD
10_1101-2020_01_28_923532	440	82	LRP1	LRP1	NNP
10_1101-2020_01_28_923532	440	83	LRP1	LRP1	NNP
10_1101-2020_01_28_923532	440	84	29090274	29090274	CD
10_1101-2020_01_28_923532	440	85	melanocortin	melanocortin	NNP
10_1101-2020_01_28_923532	440	86	1	1	CD
10_1101-2020_01_28_923532	440	87	receptor	receptor	NN
10_1101-2020_01_28_923532	440	88	MC1R	MC1R	NNP
10_1101-2020_01_28_923532	440	89	22964391	22964391	CD
10_1101-2020_01_28_923532	440	90	melanocortin	melanocortin	NNP
10_1101-2020_01_28_923532	440	91	4	4	CD
10_1101-2020_01_28_923532	440	92	receptor	receptor	NN
10_1101-2020_01_28_923532	440	93	MC4R	MC4R	NNP
10_1101-2020_01_28_923532	440	94	17591746	17591746	CD
10_1101-2020_01_28_923532	440	95	CD206	CD206	NNP
10_1101-2020_01_28_923532	440	96	MRC1	MRC1	NNP
10_1101-2020_01_28_923532	440	97	30768279	30768279	CD
10_1101-2020_01_28_923532	440	98	urokinase	urokinase	NNP
10_1101-2020_01_28_923532	440	99	plasminogen	plasminogen	NN
10_1101-2020_01_28_923532	440	100	activator	activator	NN
10_1101-2020_01_28_923532	440	101	receptor	receptor	NN
10_1101-2020_01_28_923532	440	102	PLAUR	PLAUR	NNP
10_1101-2020_01_28_923532	440	103	25080049	25080049	CD
10_1101-2020_01_28_923532	440	104	neurokinin-1	neurokinin-1	NNP
10_1101-2020_01_28_923532	440	105	receptor	receptor	NN
10_1101-2020_01_28_923532	440	106	TACR1	TACR1	NFP
10_1101-2020_01_28_923532	440	107	29498264	29498264	CD
10_1101-2020_01_28_923532	440	108	VPAC2	vpac2	NN
10_1101-2020_01_28_923532	440	109	VIPR2	VIPR2	NNP
10_1101-2020_01_28_923532	440	110	30077368	30077368	CD
10_1101-2020_01_28_923532	440	111	105	105	CD
10_1101-2020_01_28_923532	440	112	and	and	CC
10_1101-2020_01_28_923532	440	113	is	be	VBZ
10_1101-2020_01_28_923532	440	114	also	also	RB
10_1101-2020_01_28_923532	440	115	made	make	VBN
10_1101-2020_01_28_923532	440	116	available	available	JJ
10_1101-2020_01_28_923532	440	117	for	for	IN
10_1101-2020_01_28_923532	440	118	use	use	NN
10_1101-2020_01_28_923532	440	119	under	under	IN
10_1101-2020_01_28_923532	440	120	a	a	DT
10_1101-2020_01_28_923532	440	121	CC0	CC0	NNP
10_1101-2020_01_28_923532	440	122	license	license	NN
10_1101-2020_01_28_923532	440	123	.	.	.
10_1101-2020_01_28_923532	441	1	(	(	-LRB-
10_1101-2020_01_28_923532	441	2	which	which	WDT
10_1101-2020_01_28_923532	441	3	was	be	VBD
10_1101-2020_01_28_923532	441	4	not	not	RB
10_1101-2020_01_28_923532	441	5	certified	certify	VBN
10_1101-2020_01_28_923532	441	6	by	by	IN
10_1101-2020_01_28_923532	441	7	peer	peer	NN
10_1101-2020_01_28_923532	441	8	review	review	NN
10_1101-2020_01_28_923532	441	9	)	)	-RRB-
10_1101-2020_01_28_923532	441	10	is	be	VBZ
10_1101-2020_01_28_923532	441	11	the	the	DT
10_1101-2020_01_28_923532	441	12	author	author	NN
10_1101-2020_01_28_923532	441	13	/	/	SYM
10_1101-2020_01_28_923532	441	14	funder	funder	NN
10_1101-2020_01_28_923532	441	15	.	.	.
10_1101-2020_01_28_923532	442	1	This	this	DT
10_1101-2020_01_28_923532	442	2	article	article	NN
10_1101-2020_01_28_923532	442	3	is	be	VBZ
10_1101-2020_01_28_923532	442	4	a	a	DT
10_1101-2020_01_28_923532	442	5	US	US	NNP
10_1101-2020_01_28_923532	442	6	Government	Government	NNP
10_1101-2020_01_28_923532	442	7	work	work	NN
10_1101-2020_01_28_923532	442	8	.	.	.
10_1101-2020_01_28_923532	443	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	443	2	is	be	VBZ
10_1101-2020_01_28_923532	443	3	not	not	RB
10_1101-2020_01_28_923532	443	4	subject	subject	JJ
10_1101-2020_01_28_923532	443	5	to	to	IN
10_1101-2020_01_28_923532	443	6	copyright	copyright	NN
10_1101-2020_01_28_923532	443	7	under	under	IN
10_1101-2020_01_28_923532	443	8	17	17	CD
10_1101-2020_01_28_923532	443	9	USC	usc	NN
10_1101-2020_01_28_923532	443	10	The	the	DT
10_1101-2020_01_28_923532	443	11	copyright	copyright	NN
10_1101-2020_01_28_923532	443	12	holder	holder	NN
10_1101-2020_01_28_923532	443	13	for	for	IN
10_1101-2020_01_28_923532	443	14	this	this	DT
10_1101-2020_01_28_923532	443	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	443	16	version	version	NN
10_1101-2020_01_28_923532	443	17	posted	post	VBD
10_1101-2020_01_28_923532	443	18	February	February	NNP
10_1101-2020_01_28_923532	443	19	12	12	CD
10_1101-2020_01_28_923532	443	20	,	,	,
10_1101-2020_01_28_923532	443	21	2021	2021	CD
10_1101-2020_01_28_923532	443	22	.	.	.
10_1101-2020_01_28_923532	443	23	;	;	:
10_1101-2020_01_28_923532	443	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	443	25	:	:	:
10_1101-2020_01_28_923532	443	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	443	27	preprint	preprint	NN
10_1101-2020_01_28_923532	443	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	ADD
10_1101-2020_01_28_923532	443	29	36	36	CD
10_1101-2020_01_28_923532	443	30	Definition	definition	NN
10_1101-2020_01_28_923532	443	31	of	of	IN
10_1101-2020_01_28_923532	443	32	the	the	DT
10_1101-2020_01_28_923532	443	33	Minimum	Minimum	NNP
10_1101-2020_01_28_923532	443	34	Hitting	Hitting	NNP
10_1101-2020_01_28_923532	443	35	Set	Set	NNP
10_1101-2020_01_28_923532	443	36	Problem	Problem	NNP
10_1101-2020_01_28_923532	443	37	and	and	CC
10_1101-2020_01_28_923532	443	38	Solution	Solution	NNP
10_1101-2020_01_28_923532	443	39	Feasibility	Feasibility	NNP
10_1101-2020_01_28_923532	443	40	One	one	CD
10_1101-2020_01_28_923532	443	41	of	of	IN
10_1101-2020_01_28_923532	443	42	Karp	Karp	NNP
10_1101-2020_01_28_923532	443	43	’s	’s	POS
10_1101-2020_01_28_923532	443	44	original	original	JJ
10_1101-2020_01_28_923532	443	45	NP	np	NN
10_1101-2020_01_28_923532	443	46	-	-	HYPH
10_1101-2020_01_28_923532	443	47	complete	complete	JJ
10_1101-2020_01_28_923532	443	48	problems	problem	NNS
10_1101-2020_01_28_923532	443	49	is	be	VBZ
10_1101-2020_01_28_923532	443	50	called	call	VBN
10_1101-2020_01_28_923532	443	51	“	"	``
10_1101-2020_01_28_923532	443	52	hitting	hit	VBG
10_1101-2020_01_28_923532	443	53	set	set	NN
10_1101-2020_01_28_923532	443	54	”	"	''
10_1101-2020_01_28_923532	443	55	and	and	CC
10_1101-2020_01_28_923532	443	56	is	be	VBZ
10_1101-2020_01_28_923532	443	57	defined	define	VBN
10_1101-2020_01_28_923532	443	58	as	as	IN
10_1101-2020_01_28_923532	443	59	follows36	follows36	NNP
10_1101-2020_01_28_923532	443	60	.	.	.
10_1101-2020_01_28_923532	444	1	Let	let	VB
10_1101-2020_01_28_923532	444	2	𝑈	𝑈	NNP
10_1101-2020_01_28_923532	444	3	be	be	VB
10_1101-2020_01_28_923532	444	4	a	a	DT
10_1101-2020_01_28_923532	444	5	finite	finite	JJ
10_1101-2020_01_28_923532	444	6	universal	universal	JJ
10_1101-2020_01_28_923532	444	7	set	set	NN
10_1101-2020_01_28_923532	444	8	of	of	IN
10_1101-2020_01_28_923532	444	9	elements	element	NNS
10_1101-2020_01_28_923532	444	10	.	.	.
10_1101-2020_01_28_923532	445	1	Let	let	VB
10_1101-2020_01_28_923532	445	2	𝑆1	𝑆1	NNP
10_1101-2020_01_28_923532	445	3	,	,	,
10_1101-2020_01_28_923532	445	4	𝑆2	𝑆2	NN
10_1101-2020_01_28_923532	445	5	,	,	,
10_1101-2020_01_28_923532	445	6	𝑆3	𝑆3	NNP
10_1101-2020_01_28_923532	445	7	,	,	,
10_1101-2020_01_28_923532	445	8	.	.	.
10_1101-2020_01_28_923532	446	1	.	.	.
10_1101-2020_01_28_923532	447	1	.	.	.
10_1101-2020_01_28_923532	448	1	,	,	,
10_1101-2020_01_28_923532	448	2	𝑆𝑘	𝑆𝑘	NNP
10_1101-2020_01_28_923532	448	3	be	be	VB
10_1101-2020_01_28_923532	448	4	subsets	subset	NNS
10_1101-2020_01_28_923532	448	5	of	of	IN
10_1101-2020_01_28_923532	448	6	𝑈.	𝑈.	NNP
10_1101-2020_01_28_923532	449	1	Is	be	VBZ
10_1101-2020_01_28_923532	449	2	there	there	EX
10_1101-2020_01_28_923532	449	3	a	a	DT
10_1101-2020_01_28_923532	449	4	small	small	JJ
10_1101-2020_01_28_923532	449	5	subset	subset	NN
10_1101-2020_01_28_923532	449	6	𝐻	𝐻	NNP
10_1101-2020_01_28_923532	449	7	⊆	⊆	ADD
10_1101-2020_01_28_923532	449	8	𝑈	𝑈	NNP
10_1101-2020_01_28_923532	449	9	such	such	JJ
10_1101-2020_01_28_923532	449	10	that	that	IN
10_1101-2020_01_28_923532	449	11	for	for	IN
10_1101-2020_01_28_923532	449	12	𝑖	𝑖	NNP
10_1101-2020_01_28_923532	449	13	=	=	SYM
10_1101-2020_01_28_923532	449	14	1	1	CD
10_1101-2020_01_28_923532	449	15	,	,	,
10_1101-2020_01_28_923532	449	16	2	2	CD
10_1101-2020_01_28_923532	449	17	,	,	,
10_1101-2020_01_28_923532	449	18	3	3	CD
10_1101-2020_01_28_923532	449	19	,	,	,
10_1101-2020_01_28_923532	449	20	.	.	.
10_1101-2020_01_28_923532	450	1	.	.	.
10_1101-2020_01_28_923532	451	1	.	.	.
10_1101-2020_01_28_923532	452	1	,	,	,
10_1101-2020_01_28_923532	452	2	𝑘	𝑘	NNP
10_1101-2020_01_28_923532	452	3	,	,	,
10_1101-2020_01_28_923532	452	4	𝑆𝑖	𝑆𝑖	NNP
10_1101-2020_01_28_923532	452	5	∩	∩	NN
10_1101-2020_01_28_923532	452	6	𝐻	𝐻	NNP
10_1101-2020_01_28_923532	452	7	is	be	VBZ
10_1101-2020_01_28_923532	452	8	non	non	JJ
10_1101-2020_01_28_923532	452	9	-	-	JJ
10_1101-2020_01_28_923532	452	10	empty	empty	JJ
10_1101-2020_01_28_923532	452	11	.	.	.
10_1101-2020_01_28_923532	453	1	In	in	IN
10_1101-2020_01_28_923532	453	2	our	-PRON-	PRP$
10_1101-2020_01_28_923532	453	3	setting	setting	NN
10_1101-2020_01_28_923532	453	4	,	,	,
10_1101-2020_01_28_923532	453	5	U	u	NN
10_1101-2020_01_28_923532	453	6	is	be	VBZ
10_1101-2020_01_28_923532	453	7	the	the	DT
10_1101-2020_01_28_923532	453	8	set	set	NN
10_1101-2020_01_28_923532	453	9	of	of	IN
10_1101-2020_01_28_923532	453	10	target	target	NN
10_1101-2020_01_28_923532	453	11	genes	gene	NNS
10_1101-2020_01_28_923532	453	12	and	and	CC
10_1101-2020_01_28_923532	453	13	the	the	DT
10_1101-2020_01_28_923532	453	14	subsets	subset	NNS
10_1101-2020_01_28_923532	453	15	𝑆𝑖are	𝑆𝑖are	NNP
10_1101-2020_01_28_923532	453	16	the	the	DT
10_1101-2020_01_28_923532	453	17	single	single	JJ
10_1101-2020_01_28_923532	453	18	cells	cell	NNS
10_1101-2020_01_28_923532	453	19	.	.	.
10_1101-2020_01_28_923532	454	1	In	in	IN
10_1101-2020_01_28_923532	454	2	reference	reference	NN
10_1101-2020_01_28_923532	454	3	78	78	CD
10_1101-2020_01_28_923532	454	4	,	,	,
10_1101-2020_01_28_923532	454	5	numerous	numerous	JJ
10_1101-2020_01_28_923532	454	6	applications	application	NNS
10_1101-2020_01_28_923532	454	7	for	for	IN
10_1101-2020_01_28_923532	454	8	hitting	hit	VBG
10_1101-2020_01_28_923532	454	9	set	set	VBN
10_1101-2020_01_28_923532	454	10	and	and	CC
10_1101-2020_01_28_923532	454	11	the	the	DT
10_1101-2020_01_28_923532	454	12	closely	closely	RB
10_1101-2020_01_28_923532	454	13	related	related	JJ
10_1101-2020_01_28_923532	454	14	problems	problem	NNS
10_1101-2020_01_28_923532	454	15	of	of	IN
10_1101-2020_01_28_923532	454	16	subset	subset	NN
10_1101-2020_01_28_923532	454	17	cover	cover	NN
10_1101-2020_01_28_923532	454	18	and	and	CC
10_1101-2020_01_28_923532	454	19	dominating	dominating	JJ
10_1101-2020_01_28_923532	454	20	set	set	NN
10_1101-2020_01_28_923532	454	21	are	be	VBP
10_1101-2020_01_28_923532	454	22	described	describe	VBN
10_1101-2020_01_28_923532	454	23	;	;	:
10_1101-2020_01_28_923532	454	24	in	in	IN
10_1101-2020_01_28_923532	454	25	addition	addition	NN
10_1101-2020_01_28_923532	454	26	,	,	,
10_1101-2020_01_28_923532	454	27	practical	practical	JJ
10_1101-2020_01_28_923532	454	28	algorithms	algorithm	NNS
10_1101-2020_01_28_923532	454	29	for	for	IN
10_1101-2020_01_28_923532	454	30	hitting	hit	VBG
10_1101-2020_01_28_923532	454	31	set	set	NN
10_1101-2020_01_28_923532	454	32	are	be	VBP
10_1101-2020_01_28_923532	454	33	compared	compare	VBN
10_1101-2020_01_28_923532	454	34	on	on	IN
10_1101-2020_01_28_923532	454	35	real	real	JJ
10_1101-2020_01_28_923532	454	36	and	and	CC
10_1101-2020_01_28_923532	454	37	synthetic	synthetic	JJ
10_1101-2020_01_28_923532	454	38	data	datum	NNS
10_1101-2020_01_28_923532	454	39	.	.	.
10_1101-2020_01_28_923532	455	1	Among	among	IN
10_1101-2020_01_28_923532	455	2	the	the	DT
10_1101-2020_01_28_923532	455	3	applications	application	NNS
10_1101-2020_01_28_923532	455	4	of	of	IN
10_1101-2020_01_28_923532	455	5	hitting	hit	VBG
10_1101-2020_01_28_923532	455	6	set	set	VBN
10_1101-2020_01_28_923532	455	7	and	and	CC
10_1101-2020_01_28_923532	455	8	closely	closely	RB
10_1101-2020_01_28_923532	455	9	related	related	JJ
10_1101-2020_01_28_923532	455	10	NP	NP	NNP
10_1101-2020_01_28_923532	455	11	-	-	HYPH
10_1101-2020_01_28_923532	455	12	complete	complete	JJ
10_1101-2020_01_28_923532	455	13	problems	problem	NNS
10_1101-2020_01_28_923532	455	14	in	in	IN
10_1101-2020_01_28_923532	455	15	biology	biology	NN
10_1101-2020_01_28_923532	455	16	and	and	CC
10_1101-2020_01_28_923532	455	17	biochemistry	biochemistry	NN
10_1101-2020_01_28_923532	455	18	are	be	VBP
10_1101-2020_01_28_923532	455	19	stability	stability	NN
10_1101-2020_01_28_923532	455	20	analysis	analysis	NN
10_1101-2020_01_28_923532	455	21	of	of	IN
10_1101-2020_01_28_923532	455	22	metabolic	metabolic	NNP
10_1101-2020_01_28_923532	455	23	networks79	networks79	NNP
10_1101-2020_01_28_923532	455	24	-	-	HYPH
10_1101-2020_01_28_923532	455	25	83	83	CD
10_1101-2020_01_28_923532	455	26	,	,	,
10_1101-2020_01_28_923532	455	27	identification	identification	NN
10_1101-2020_01_28_923532	455	28	of	of	IN
10_1101-2020_01_28_923532	455	29	critical	critical	JJ
10_1101-2020_01_28_923532	455	30	paths	path	NNS
10_1101-2020_01_28_923532	455	31	in	in	IN
10_1101-2020_01_28_923532	455	32	gene	gene	NN
10_1101-2020_01_28_923532	455	33	signaling	signaling	NN
10_1101-2020_01_28_923532	455	34	and	and	CC
10_1101-2020_01_28_923532	455	35	regulatory	regulatory	JJ
10_1101-2020_01_28_923532	455	36	networks84	networks84	NNP
10_1101-2020_01_28_923532	455	37	-	-	HYPH
10_1101-2020_01_28_923532	455	38	86	86	CD
10_1101-2020_01_28_923532	455	39	and	and	CC
10_1101-2020_01_28_923532	455	40	selection	selection	NN
10_1101-2020_01_28_923532	455	41	of	of	IN
10_1101-2020_01_28_923532	455	42	a	a	DT
10_1101-2020_01_28_923532	455	43	set	set	NN
10_1101-2020_01_28_923532	455	44	of	of	IN
10_1101-2020_01_28_923532	455	45	drugs	drug	NNS
10_1101-2020_01_28_923532	455	46	to	to	TO
10_1101-2020_01_28_923532	455	47	treat	treat	VB
10_1101-2020_01_28_923532	455	48	cell	cell	NN
10_1101-2020_01_28_923532	455	49	lines87	lines87	NNP
10_1101-2020_01_28_923532	455	50	-	-	HYPH
10_1101-2020_01_28_923532	455	51	88	88	CD
10_1101-2020_01_28_923532	455	52	or	or	CC
10_1101-2020_01_28_923532	455	53	single	single	JJ
10_1101-2020_01_28_923532	455	54	patients89	patients89	NNP
10_1101-2020_01_28_923532	455	55	-	-	SYM
10_1101-2020_01_28_923532	455	56	90	90	CD
10_1101-2020_01_28_923532	455	57	.	.	.
10_1101-2020_01_28_923532	456	1	More	More	JJR
10_1101-2020_01_28_923532	456	2	information	information	NN
10_1101-2020_01_28_923532	456	3	about	about	IN
10_1101-2020_01_28_923532	456	4	related	related	JJ
10_1101-2020_01_28_923532	456	5	work	work	NN
10_1101-2020_01_28_923532	456	6	can	can	MD
10_1101-2020_01_28_923532	456	7	be	be	VB
10_1101-2020_01_28_923532	456	8	found	find	VBN
10_1101-2020_01_28_923532	456	9	in	in	IN
10_1101-2020_01_28_923532	456	10	Supplementary	Supplementary	NNP
10_1101-2020_01_28_923532	456	11	Materials	Materials	NNP
10_1101-2020_01_28_923532	456	12	1	1	CD
10_1101-2020_01_28_923532	456	13	.	.	.
10_1101-2020_01_28_923532	457	1	Two	two	CD
10_1101-2020_01_28_923532	457	2	different	different	JJ
10_1101-2020_01_28_923532	457	3	difficulties	difficulty	NNS
10_1101-2020_01_28_923532	457	4	arising	arise	VBG
10_1101-2020_01_28_923532	457	5	in	in	IN
10_1101-2020_01_28_923532	457	6	problems	problem	NNS
10_1101-2020_01_28_923532	457	7	such	such	JJ
10_1101-2020_01_28_923532	457	8	as	as	IN
10_1101-2020_01_28_923532	457	9	hitting	hit	VBG
10_1101-2020_01_28_923532	457	10	set	set	VBN
10_1101-2020_01_28_923532	457	11	are	be	VBP
10_1101-2020_01_28_923532	457	12	that	that	IN
10_1101-2020_01_28_923532	457	13	1	1	LS
10_1101-2020_01_28_923532	457	14	)	)	-RRB-
10_1101-2020_01_28_923532	457	15	an	an	DT
10_1101-2020_01_28_923532	457	16	instance	instance	NN
10_1101-2020_01_28_923532	457	17	may	may	MD
10_1101-2020_01_28_923532	457	18	be	be	VB
10_1101-2020_01_28_923532	457	19	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	457	20	meaning	meaning	NN
10_1101-2020_01_28_923532	457	21	that	that	IN
10_1101-2020_01_28_923532	457	22	there	there	EX
10_1101-2020_01_28_923532	457	23	does	do	VBZ
10_1101-2020_01_28_923532	457	24	not	not	RB
10_1101-2020_01_28_923532	457	25	exist	exist	VB
10_1101-2020_01_28_923532	457	26	a	a	DT
10_1101-2020_01_28_923532	457	27	solution	solution	NN
10_1101-2020_01_28_923532	457	28	satisfying	satisfy	VBG
10_1101-2020_01_28_923532	457	29	all	all	DT
10_1101-2020_01_28_923532	457	30	constraints	constraint	NNS
10_1101-2020_01_28_923532	457	31	and	and	CC
10_1101-2020_01_28_923532	457	32	2	2	LS
10_1101-2020_01_28_923532	457	33	)	)	-RRB-
10_1101-2020_01_28_923532	457	34	an	an	DT
10_1101-2020_01_28_923532	457	35	instance	instance	NN
10_1101-2020_01_28_923532	457	36	may	may	MD
10_1101-2020_01_28_923532	457	37	be	be	VB
10_1101-2020_01_28_923532	457	38	intractable	intractable	JJ
10_1101-2020_01_28_923532	457	39	meaning	meaning	NN
10_1101-2020_01_28_923532	457	40	that	that	IN
10_1101-2020_01_28_923532	457	41	in	in	IN
10_1101-2020_01_28_923532	457	42	the	the	DT
10_1101-2020_01_28_923532	457	43	time	time	NN
10_1101-2020_01_28_923532	457	44	available	available	JJ
10_1101-2020_01_28_923532	457	45	,	,	,
10_1101-2020_01_28_923532	457	46	one	one	PRP
10_1101-2020_01_28_923532	457	47	can	can	MD
10_1101-2020_01_28_923532	457	48	not	not	RB
10_1101-2020_01_28_923532	457	49	either	either	RB
10_1101-2020_01_28_923532	457	50	i	i	PRP
10_1101-2020_01_28_923532	457	51	)	)	-RRB-
10_1101-2020_01_28_923532	457	52	prove	prove	VBP
10_1101-2020_01_28_923532	457	53	that	that	IN
10_1101-2020_01_28_923532	457	54	the	the	DT
10_1101-2020_01_28_923532	457	55	instance	instance	NN
10_1101-2020_01_28_923532	457	56	is	be	VBZ
10_1101-2020_01_28_923532	457	57	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	457	58	or	or	CC
10_1101-2020_01_28_923532	457	59	ii	ii	LS
10_1101-2020_01_28_923532	457	60	)	)	-RRB-
10_1101-2020_01_28_923532	457	61	find	find	VBP
10_1101-2020_01_28_923532	457	62	an	an	DT
10_1101-2020_01_28_923532	457	63	optimal	optimal	JJ
10_1101-2020_01_28_923532	457	64	feasible	feasible	JJ
10_1101-2020_01_28_923532	457	65	solution	solution	NN
10_1101-2020_01_28_923532	457	66	.	.	.
10_1101-2020_01_28_923532	458	1	All	all	DT
10_1101-2020_01_28_923532	458	2	instances	instance	NNS
10_1101-2020_01_28_923532	458	3	of	of	IN
10_1101-2020_01_28_923532	458	4	minimum	minimum	JJ
10_1101-2020_01_28_923532	458	5	hitting	hitting	NN
10_1101-2020_01_28_923532	458	6	set	set	NN
10_1101-2020_01_28_923532	458	7	that	that	IN
10_1101-2020_01_28_923532	458	8	we	-PRON-	PRP
10_1101-2020_01_28_923532	458	9	considered	consider	VBD
10_1101-2020_01_28_923532	458	10	were	be	VBD
10_1101-2020_01_28_923532	458	11	tractable	tractable	JJ
10_1101-2020_01_28_923532	458	12	on	on	IN
10_1101-2020_01_28_923532	458	13	the	the	DT
10_1101-2020_01_28_923532	458	14	NIH	NIH	NNP
10_1101-2020_01_28_923532	458	15	Biowulf	Biowulf	NNP
10_1101-2020_01_28_923532	458	16	system	system	NN
10_1101-2020_01_28_923532	458	17	.	.	.
10_1101-2020_01_28_923532	459	1	Many	many	JJ
10_1101-2020_01_28_923532	459	2	instances	instance	NNS
10_1101-2020_01_28_923532	459	3	were	be	VBD
10_1101-2020_01_28_923532	459	4	provably	provably	RB
10_1101-2020_01_28_923532	459	5	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	459	6	;	;	:
10_1101-2020_01_28_923532	459	7	in	in	IN
10_1101-2020_01_28_923532	459	8	almost	almost	RB
10_1101-2020_01_28_923532	459	9	all	all	DT
10_1101-2020_01_28_923532	459	10	cases	case	NNS
10_1101-2020_01_28_923532	459	11	.	.	.
10_1101-2020_01_28_923532	460	1	we	-PRON-	PRP
10_1101-2020_01_28_923532	460	2	did	do	VBD
10_1101-2020_01_28_923532	460	3	not	not	RB
10_1101-2020_01_28_923532	460	4	plot	plot	VB
10_1101-2020_01_28_923532	460	5	the	the	DT
10_1101-2020_01_28_923532	460	6	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	460	7	parameter	parameter	NN
10_1101-2020_01_28_923532	460	8	combinations	combination	NNS
10_1101-2020_01_28_923532	460	9	.	.	.
10_1101-2020_01_28_923532	461	1	However	however	RB
10_1101-2020_01_28_923532	461	2	,	,	,
10_1101-2020_01_28_923532	461	3	in	in	IN
10_1101-2020_01_28_923532	461	4	Figure	figure	NN
10_1101-2020_01_28_923532	461	5	4	4	CD
10_1101-2020_01_28_923532	461	6	,	,	,
10_1101-2020_01_28_923532	461	7	the	the	DT
10_1101-2020_01_28_923532	461	8	instance	instance	NN
10_1101-2020_01_28_923532	461	9	for	for	IN
10_1101-2020_01_28_923532	461	10	the	the	DT
10_1101-2020_01_28_923532	461	11	melanoma	melanoma	NNP
10_1101-2020_01_28_923532	461	12	data	datum	NNS
10_1101-2020_01_28_923532	461	13	set	set	VBN
10_1101-2020_01_28_923532	461	14	with	with	IN
10_1101-2020_01_28_923532	461	15	the	the	DT
10_1101-2020_01_28_923532	461	16	more	more	RBR
10_1101-2020_01_28_923532	461	17	stringent	stringent	JJ
10_1101-2020_01_28_923532	461	18	parameters	parameter	NNS
10_1101-2020_01_28_923532	461	19	was	be	VBD
10_1101-2020_01_28_923532	461	20	infeasible	infeasible	JJ
10_1101-2020_01_28_923532	461	21	because	because	IN
10_1101-2020_01_28_923532	461	22	of	of	IN
10_1101-2020_01_28_923532	461	23	only	only	RB
10_1101-2020_01_28_923532	461	24	one	one	CD
10_1101-2020_01_28_923532	461	25	patient	patient	JJ
10_1101-2020_01_28_923532	461	26	sample	sample	NN
10_1101-2020_01_28_923532	461	27	,	,	,
10_1101-2020_01_28_923532	461	28	so	so	RB
10_1101-2020_01_28_923532	461	29	we	-PRON-	PRP
10_1101-2020_01_28_923532	461	30	omitted	omit	VBD
10_1101-2020_01_28_923532	461	31	that	that	DT
10_1101-2020_01_28_923532	461	32	patient	patient	NN
10_1101-2020_01_28_923532	461	33	for	for	IN
10_1101-2020_01_28_923532	461	34	both	both	DT
10_1101-2020_01_28_923532	461	35	parameter	parameter	NN
10_1101-2020_01_28_923532	461	36	settings	setting	NNS
10_1101-2020_01_28_923532	461	37	in	in	IN
10_1101-2020_01_28_923532	461	38	Figure	Figure	NNP
10_1101-2020_01_28_923532	461	39	4	4	CD
10_1101-2020_01_28_923532	461	40	.	.	.
10_1101-2020_01_28_923532	462	1	Basic	Basic	NNP
10_1101-2020_01_28_923532	462	2	Optimal	Optimal	NNP
10_1101-2020_01_28_923532	462	3	Target	target	NN
10_1101-2020_01_28_923532	462	4	Set	Set	NNP
10_1101-2020_01_28_923532	462	5	Formulation	Formulation	NNP
10_1101-2020_01_28_923532	462	6	Given	give	VBN
10_1101-2020_01_28_923532	462	7	a	a	DT
10_1101-2020_01_28_923532	462	8	collection	collection	NN
10_1101-2020_01_28_923532	462	9	𝑆	𝑆	NN
10_1101-2020_01_28_923532	462	10	=	=	SYM
10_1101-2020_01_28_923532	462	11	{	{	-LRB-
10_1101-2020_01_28_923532	462	12	𝑆1	𝑆1	NNP
10_1101-2020_01_28_923532	462	13	,	,	,
10_1101-2020_01_28_923532	462	14	𝑆2	𝑆2	NN
10_1101-2020_01_28_923532	462	15	,	,	,
10_1101-2020_01_28_923532	462	16	𝑆3	𝑆3	NNP
10_1101-2020_01_28_923532	462	17	,	,	,
10_1101-2020_01_28_923532	462	18	.	.	.
10_1101-2020_01_28_923532	463	1	.	.	.
10_1101-2020_01_28_923532	464	1	.	.	.
10_1101-2020_01_28_923532	464	2	}	}	-RRB-
10_1101-2020_01_28_923532	465	1	of	of	IN
10_1101-2020_01_28_923532	465	2	subsets	subset	NNS
10_1101-2020_01_28_923532	465	3	of	of	IN
10_1101-2020_01_28_923532	465	4	a	a	DT
10_1101-2020_01_28_923532	465	5	set	set	VBN
10_1101-2020_01_28_923532	465	6	𝑈	𝑈	NN
10_1101-2020_01_28_923532	465	7	,	,	,
10_1101-2020_01_28_923532	465	8	the	the	DT
10_1101-2020_01_28_923532	465	9	hitting	hitting	NN
10_1101-2020_01_28_923532	465	10	set	set	NN
10_1101-2020_01_28_923532	465	11	problem	problem	NN
10_1101-2020_01_28_923532	465	12	is	be	VBZ
10_1101-2020_01_28_923532	465	13	to	to	TO
10_1101-2020_01_28_923532	465	14	find	find	VB
10_1101-2020_01_28_923532	465	15	the	the	DT
10_1101-2020_01_28_923532	465	16	smallest	small	JJS
10_1101-2020_01_28_923532	465	17	subset	subset	NN
10_1101-2020_01_28_923532	465	18	𝐻	𝐻	NNP
10_1101-2020_01_28_923532	465	19	⊆	⊆	ADD
10_1101-2020_01_28_923532	465	20	𝑈	𝑈	NN
10_1101-2020_01_28_923532	465	21	that	that	WDT
10_1101-2020_01_28_923532	465	22	intersects	intersect	VBZ
10_1101-2020_01_28_923532	465	23	every	every	DT
10_1101-2020_01_28_923532	465	24	set	set	NN
10_1101-2020_01_28_923532	465	25	in	in	IN
10_1101-2020_01_28_923532	465	26	𝑆.	𝑆.	NN
10_1101-2020_01_28_923532	466	1	The	the	DT
10_1101-2020_01_28_923532	466	2	hitting	hit	VBG
10_1101-2020_01_28_923532	466	3	set	set	NN
10_1101-2020_01_28_923532	466	4	problem	problem	NN
10_1101-2020_01_28_923532	466	5	is	be	VBZ
10_1101-2020_01_28_923532	466	6	equivalent	equivalent	JJ
10_1101-2020_01_28_923532	466	7	to	to	IN
10_1101-2020_01_28_923532	466	8	the	the	DT
10_1101-2020_01_28_923532	466	9	set	set	VBN
10_1101-2020_01_28_923532	466	10	cover	cover	NN
10_1101-2020_01_28_923532	466	11	problem	problem	NN
10_1101-2020_01_28_923532	466	12	and	and	CC
10_1101-2020_01_28_923532	466	13	hence	hence	RB
10_1101-2020_01_28_923532	466	14	is	be	VBZ
10_1101-2020_01_28_923532	466	15	NP	np	NN
10_1101-2020_01_28_923532	466	16	-	-	HYPH
10_1101-2020_01_28_923532	466	17	complete	complete	JJ
10_1101-2020_01_28_923532	466	18	.	.	.
10_1101-2020_01_28_923532	467	1	The	the	DT
10_1101-2020_01_28_923532	467	2	following	following	JJ
10_1101-2020_01_28_923532	467	3	ILP	ILP	NNP
10_1101-2020_01_28_923532	467	4	formulates	formulate	VBZ
10_1101-2020_01_28_923532	467	5	this	this	DT
10_1101-2020_01_28_923532	467	6	target	target	NN
10_1101-2020_01_28_923532	467	7	set	set	NN
10_1101-2020_01_28_923532	467	8	problem	problem	NN
10_1101-2020_01_28_923532	467	9	:	:	:
10_1101-2020_01_28_923532	467	10	105	105	CD
10_1101-2020_01_28_923532	467	11	and	and	CC
10_1101-2020_01_28_923532	467	12	is	be	VBZ
10_1101-2020_01_28_923532	467	13	also	also	RB
10_1101-2020_01_28_923532	467	14	made	make	VBN
10_1101-2020_01_28_923532	467	15	available	available	JJ
10_1101-2020_01_28_923532	467	16	for	for	IN
10_1101-2020_01_28_923532	467	17	use	use	NN
10_1101-2020_01_28_923532	467	18	under	under	IN
10_1101-2020_01_28_923532	467	19	a	a	DT
10_1101-2020_01_28_923532	467	20	CC0	CC0	NNP
10_1101-2020_01_28_923532	467	21	license	license	NN
10_1101-2020_01_28_923532	467	22	.	.	.
10_1101-2020_01_28_923532	468	1	(	(	-LRB-
10_1101-2020_01_28_923532	468	2	which	which	WDT
10_1101-2020_01_28_923532	468	3	was	be	VBD
10_1101-2020_01_28_923532	468	4	not	not	RB
10_1101-2020_01_28_923532	468	5	certified	certify	VBN
10_1101-2020_01_28_923532	468	6	by	by	IN
10_1101-2020_01_28_923532	468	7	peer	peer	NN
10_1101-2020_01_28_923532	468	8	review	review	NN
10_1101-2020_01_28_923532	468	9	)	)	-RRB-
10_1101-2020_01_28_923532	468	10	is	be	VBZ
10_1101-2020_01_28_923532	468	11	the	the	DT
10_1101-2020_01_28_923532	468	12	author	author	NN
10_1101-2020_01_28_923532	468	13	/	/	SYM
10_1101-2020_01_28_923532	468	14	funder	funder	NN
10_1101-2020_01_28_923532	468	15	.	.	.
10_1101-2020_01_28_923532	469	1	This	this	DT
10_1101-2020_01_28_923532	469	2	article	article	NN
10_1101-2020_01_28_923532	469	3	is	be	VBZ
10_1101-2020_01_28_923532	469	4	a	a	DT
10_1101-2020_01_28_923532	469	5	US	US	NNP
10_1101-2020_01_28_923532	469	6	Government	Government	NNP
10_1101-2020_01_28_923532	469	7	work	work	NN
10_1101-2020_01_28_923532	469	8	.	.	.
10_1101-2020_01_28_923532	470	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	470	2	is	be	VBZ
10_1101-2020_01_28_923532	470	3	not	not	RB
10_1101-2020_01_28_923532	470	4	subject	subject	JJ
10_1101-2020_01_28_923532	470	5	to	to	IN
10_1101-2020_01_28_923532	470	6	copyright	copyright	NN
10_1101-2020_01_28_923532	470	7	under	under	IN
10_1101-2020_01_28_923532	470	8	17	17	CD
10_1101-2020_01_28_923532	470	9	USC	usc	NN
10_1101-2020_01_28_923532	470	10	The	the	DT
10_1101-2020_01_28_923532	470	11	copyright	copyright	NN
10_1101-2020_01_28_923532	470	12	holder	holder	NN
10_1101-2020_01_28_923532	470	13	for	for	IN
10_1101-2020_01_28_923532	470	14	this	this	DT
10_1101-2020_01_28_923532	470	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	470	16	version	version	NN
10_1101-2020_01_28_923532	470	17	posted	post	VBD
10_1101-2020_01_28_923532	470	18	February	February	NNP
10_1101-2020_01_28_923532	470	19	12	12	CD
10_1101-2020_01_28_923532	470	20	,	,	,
10_1101-2020_01_28_923532	470	21	2021	2021	CD
10_1101-2020_01_28_923532	470	22	.	.	.
10_1101-2020_01_28_923532	470	23	;	;	:
10_1101-2020_01_28_923532	470	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	470	25	:	:	:
10_1101-2020_01_28_923532	470	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	470	27	preprint	preprint	NN
10_1101-2020_01_28_923532	470	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	470	29	37	37	CD
10_1101-2020_01_28_923532	470	30	𝑚𝑖𝑛	𝑚𝑖𝑛	NN
10_1101-2020_01_28_923532	470	31	∑	∑	XX
10_1101-2020_01_28_923532	470	32	𝑔∈𝑈	𝑔∈𝑈	NFP
10_1101-2020_01_28_923532	470	33	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	470	34	)	)	-RRB-
10_1101-2020_01_28_923532	470	35	∑	∑	.
10_1101-2020_01_28_923532	470	36	𝑔∈𝐶	𝑔∈𝐶	NN
10_1101-2020_01_28_923532	470	37	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	470	38	)	)	-RRB-
10_1101-2020_01_28_923532	470	39	≥	≥	UH
10_1101-2020_01_28_923532	470	40	1	1	CD
10_1101-2020_01_28_923532	470	41	∀𝑆𝑖	∀𝑆𝑖	NN
10_1101-2020_01_28_923532	470	42	∈	∈	NNP
10_1101-2020_01_28_923532	470	43	𝑆	𝑆	NN
10_1101-2020_01_28_923532	470	44	(	(	-LRB-
10_1101-2020_01_28_923532	470	45	1	1	CD
10_1101-2020_01_28_923532	470	46	)	)	-RRB-
10_1101-2020_01_28_923532	470	47	In	in	IN
10_1101-2020_01_28_923532	470	48	this	this	DT
10_1101-2020_01_28_923532	470	49	formulation	formulation	NN
10_1101-2020_01_28_923532	470	50	,	,	,
10_1101-2020_01_28_923532	470	51	there	there	EX
10_1101-2020_01_28_923532	470	52	is	be	VBZ
10_1101-2020_01_28_923532	470	53	a	a	DT
10_1101-2020_01_28_923532	470	54	binary	binary	JJ
10_1101-2020_01_28_923532	470	55	variable	variable	JJ
10_1101-2020_01_28_923532	470	56	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	470	57	)	)	-RRB-
10_1101-2020_01_28_923532	470	58	for	for	IN
10_1101-2020_01_28_923532	470	59	each	each	DT
10_1101-2020_01_28_923532	470	60	element	element	NN
10_1101-2020_01_28_923532	470	61	𝑔	𝑔	XX
10_1101-2020_01_28_923532	470	62	∈	∈	JJ
10_1101-2020_01_28_923532	470	63	𝑈that	𝑈that	NNP
10_1101-2020_01_28_923532	470	64	denotes	denote	NNS
10_1101-2020_01_28_923532	470	65	whether	whether	IN
10_1101-2020_01_28_923532	470	66	the	the	DT
10_1101-2020_01_28_923532	470	67	element	element	NN
10_1101-2020_01_28_923532	470	68	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	470	69	is	be	VBZ
10_1101-2020_01_28_923532	470	70	selected	select	VBN
10_1101-2020_01_28_923532	470	71	or	or	CC
10_1101-2020_01_28_923532	470	72	not	not	RB
10_1101-2020_01_28_923532	470	73	.	.	.
10_1101-2020_01_28_923532	471	1	Constraint	constraint	NN
10_1101-2020_01_28_923532	471	2	(	(	-LRB-
10_1101-2020_01_28_923532	471	3	1	1	LS
10_1101-2020_01_28_923532	471	4	)	)	-RRB-
10_1101-2020_01_28_923532	471	5	makes	make	VBZ
10_1101-2020_01_28_923532	471	6	sure	sure	JJ
10_1101-2020_01_28_923532	471	7	that	that	IN
10_1101-2020_01_28_923532	471	8	from	from	IN
10_1101-2020_01_28_923532	471	9	each	each	DT
10_1101-2020_01_28_923532	471	10	set	set	VBN
10_1101-2020_01_28_923532	471	11	𝑆𝑖	𝑆𝑖	NNP
10_1101-2020_01_28_923532	471	12	in	in	IN
10_1101-2020_01_28_923532	471	13	S	S	NNP
10_1101-2020_01_28_923532	471	14	,	,	,
10_1101-2020_01_28_923532	471	15	at	at	RB
10_1101-2020_01_28_923532	471	16	least	least	RBS
10_1101-2020_01_28_923532	471	17	one	one	CD
10_1101-2020_01_28_923532	471	18	element	element	NN
10_1101-2020_01_28_923532	471	19	is	be	VBZ
10_1101-2020_01_28_923532	471	20	selected	select	VBN
10_1101-2020_01_28_923532	471	21	.	.	.
10_1101-2020_01_28_923532	472	1	For	for	IN
10_1101-2020_01_28_923532	472	2	any	any	DT
10_1101-2020_01_28_923532	472	3	data	datum	NNS
10_1101-2020_01_28_923532	472	4	set	set	NN
10_1101-2020_01_28_923532	472	5	of	of	IN
10_1101-2020_01_28_923532	472	6	tumor	tumor	NN
10_1101-2020_01_28_923532	472	7	cells	cell	NNS
10_1101-2020_01_28_923532	472	8	,	,	,
10_1101-2020_01_28_923532	472	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	472	10	begin	begin	VBP
10_1101-2020_01_28_923532	472	11	with	with	IN
10_1101-2020_01_28_923532	472	12	the	the	DT
10_1101-2020_01_28_923532	472	13	model	model	NN
10_1101-2020_01_28_923532	472	14	that	that	WDT
10_1101-2020_01_28_923532	472	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	472	16	specify	specify	VBP
10_1101-2020_01_28_923532	472	17	a	a	DT
10_1101-2020_01_28_923532	472	18	set	set	NN
10_1101-2020_01_28_923532	472	19	of	of	IN
10_1101-2020_01_28_923532	472	20	genes	gene	NNS
10_1101-2020_01_28_923532	472	21	that	that	WDT
10_1101-2020_01_28_923532	472	22	can	can	MD
10_1101-2020_01_28_923532	472	23	be	be	VB
10_1101-2020_01_28_923532	472	24	targeted	target	VBN
10_1101-2020_01_28_923532	472	25	,	,	,
10_1101-2020_01_28_923532	472	26	and	and	CC
10_1101-2020_01_28_923532	472	27	that	that	DT
10_1101-2020_01_28_923532	472	28	is	be	VBZ
10_1101-2020_01_28_923532	472	29	𝑈.	𝑈.	NNP
10_1101-2020_01_28_923532	473	1	Each	each	DT
10_1101-2020_01_28_923532	473	2	cell	cell	NN
10_1101-2020_01_28_923532	473	3	is	be	VBZ
10_1101-2020_01_28_923532	473	4	represented	represent	VBN
10_1101-2020_01_28_923532	473	5	by	by	IN
10_1101-2020_01_28_923532	473	6	the	the	DT
10_1101-2020_01_28_923532	473	7	subset	subset	NN
10_1101-2020_01_28_923532	473	8	of	of	IN
10_1101-2020_01_28_923532	473	9	genes	gene	NNS
10_1101-2020_01_28_923532	473	10	in	in	IN
10_1101-2020_01_28_923532	473	11	𝑈	𝑈	NN
10_1101-2020_01_28_923532	473	12	whose	whose	WP$
10_1101-2020_01_28_923532	473	13	expression	expression	NN
10_1101-2020_01_28_923532	473	14	is	be	VBZ
10_1101-2020_01_28_923532	473	15	greater	great	JJR
10_1101-2020_01_28_923532	473	16	than	than	IN
10_1101-2020_01_28_923532	473	17	zero	zero	CD
10_1101-2020_01_28_923532	473	18	.	.	.
10_1101-2020_01_28_923532	474	1	In	in	IN
10_1101-2020_01_28_923532	474	2	biological	biological	JJ
10_1101-2020_01_28_923532	474	3	terms	term	NNS
10_1101-2020_01_28_923532	474	4	,	,	,
10_1101-2020_01_28_923532	474	5	a	a	DT
10_1101-2020_01_28_923532	474	6	cell	cell	NN
10_1101-2020_01_28_923532	474	7	is	be	VBZ
10_1101-2020_01_28_923532	474	8	killed	kill	VBN
10_1101-2020_01_28_923532	474	9	(	(	-LRB-
10_1101-2020_01_28_923532	474	10	hit	hit	VBN
10_1101-2020_01_28_923532	474	11	)	)	-RRB-
10_1101-2020_01_28_923532	474	12	if	if	IN
10_1101-2020_01_28_923532	474	13	it	-PRON-	PRP
10_1101-2020_01_28_923532	474	14	expresses	express	VBZ
10_1101-2020_01_28_923532	474	15	at	at	IN
10_1101-2020_01_28_923532	474	16	any	any	DT
10_1101-2020_01_28_923532	474	17	level	level	NN
10_1101-2020_01_28_923532	474	18	on	on	IN
10_1101-2020_01_28_923532	474	19	one	one	CD
10_1101-2020_01_28_923532	474	20	of	of	IN
10_1101-2020_01_28_923532	474	21	the	the	DT
10_1101-2020_01_28_923532	474	22	genes	gene	NNS
10_1101-2020_01_28_923532	474	23	that	that	WDT
10_1101-2020_01_28_923532	474	24	is	be	VBZ
10_1101-2020_01_28_923532	474	25	selected	select	VBN
10_1101-2020_01_28_923532	474	26	to	to	TO
10_1101-2020_01_28_923532	474	27	be	be	VB
10_1101-2020_01_28_923532	474	28	a	a	DT
10_1101-2020_01_28_923532	474	29	target	target	NN
10_1101-2020_01_28_923532	474	30	(	(	-LRB-
10_1101-2020_01_28_923532	474	31	i.e.	i.e.	FW
10_1101-2020_01_28_923532	474	32	,	,	,
10_1101-2020_01_28_923532	474	33	in	in	IN
10_1101-2020_01_28_923532	474	34	the	the	DT
10_1101-2020_01_28_923532	474	35	optimal	optimal	JJ
10_1101-2020_01_28_923532	474	36	target	target	NN
10_1101-2020_01_28_923532	474	37	set	set	VBN
10_1101-2020_01_28_923532	474	38	)	)	-RRB-
10_1101-2020_01_28_923532	474	39	in	in	IN
10_1101-2020_01_28_923532	474	40	the	the	DT
10_1101-2020_01_28_923532	474	41	treatment	treatment	NN
10_1101-2020_01_28_923532	474	42	.	.	.
10_1101-2020_01_28_923532	475	1	In	in	IN
10_1101-2020_01_28_923532	475	2	this	this	DT
10_1101-2020_01_28_923532	475	3	initial	initial	JJ
10_1101-2020_01_28_923532	475	4	formulation	formulation	NN
10_1101-2020_01_28_923532	475	5	,	,	,
10_1101-2020_01_28_923532	475	6	all	all	DT
10_1101-2020_01_28_923532	475	7	tumor	tumor	NN
10_1101-2020_01_28_923532	475	8	cells	cell	NNS
10_1101-2020_01_28_923532	475	9	are	be	VBP
10_1101-2020_01_28_923532	475	10	combined	combine	VBN
10_1101-2020_01_28_923532	475	11	as	as	IN
10_1101-2020_01_28_923532	475	12	if	if	IN
10_1101-2020_01_28_923532	475	13	they	-PRON-	PRP
10_1101-2020_01_28_923532	475	14	come	come	VBP
10_1101-2020_01_28_923532	475	15	from	from	IN
10_1101-2020_01_28_923532	475	16	one	one	CD
10_1101-2020_01_28_923532	475	17	patient	patient	NN
10_1101-2020_01_28_923532	475	18	because	because	IN
10_1101-2020_01_28_923532	475	19	we	-PRON-	PRP
10_1101-2020_01_28_923532	475	20	model	model	VBP
10_1101-2020_01_28_923532	475	21	that	that	IN
10_1101-2020_01_28_923532	475	22	the	the	DT
10_1101-2020_01_28_923532	475	23	treatment	treatment	NN
10_1101-2020_01_28_923532	475	24	goal	goal	NN
10_1101-2020_01_28_923532	475	25	is	be	VBZ
10_1101-2020_01_28_923532	475	26	to	to	TO
10_1101-2020_01_28_923532	475	27	kill	kill	VB
10_1101-2020_01_28_923532	475	28	(	(	-LRB-
10_1101-2020_01_28_923532	475	29	hit	hit	VB
10_1101-2020_01_28_923532	475	30	)	)	-RRB-
10_1101-2020_01_28_923532	475	31	all	all	DT
10_1101-2020_01_28_923532	475	32	tumor	tumor	NN
10_1101-2020_01_28_923532	475	33	cells	cell	NNS
10_1101-2020_01_28_923532	475	34	(	(	-LRB-
10_1101-2020_01_28_923532	475	35	all	all	DT
10_1101-2020_01_28_923532	475	36	subsets	subset	NNS
10_1101-2020_01_28_923532	475	37	)	)	-RRB-
10_1101-2020_01_28_923532	475	38	.	.	.
10_1101-2020_01_28_923532	476	1	In	in	IN
10_1101-2020_01_28_923532	476	2	a	a	DT
10_1101-2020_01_28_923532	476	3	later	later	JJ
10_1101-2020_01_28_923532	476	4	subsection	subsection	NN
10_1101-2020_01_28_923532	476	5	,	,	,
10_1101-2020_01_28_923532	476	6	we	-PRON-	PRP
10_1101-2020_01_28_923532	476	7	consider	consider	VBP
10_1101-2020_01_28_923532	476	8	a	a	DT
10_1101-2020_01_28_923532	476	9	fair	fair	JJ
10_1101-2020_01_28_923532	476	10	version	version	NN
10_1101-2020_01_28_923532	476	11	of	of	IN
10_1101-2020_01_28_923532	476	12	this	this	DT
10_1101-2020_01_28_923532	476	13	problem	problem	NN
10_1101-2020_01_28_923532	476	14	,	,	,
10_1101-2020_01_28_923532	476	15	taking	take	VBG
10_1101-2020_01_28_923532	476	16	into	into	IN
10_1101-2020_01_28_923532	476	17	account	account	NN
10_1101-2020_01_28_923532	476	18	that	that	IN
10_1101-2020_01_28_923532	476	19	each	each	DT
10_1101-2020_01_28_923532	476	20	patient	patient	NN
10_1101-2020_01_28_923532	476	21	is	be	VBZ
10_1101-2020_01_28_923532	476	22	part	part	NN
10_1101-2020_01_28_923532	476	23	of	of	IN
10_1101-2020_01_28_923532	476	24	a	a	DT
10_1101-2020_01_28_923532	476	25	cohort	cohort	NN
10_1101-2020_01_28_923532	476	26	.	.	.
10_1101-2020_01_28_923532	477	1	Before	before	IN
10_1101-2020_01_28_923532	477	2	that	that	DT
10_1101-2020_01_28_923532	477	3	,	,	,
10_1101-2020_01_28_923532	477	4	we	-PRON-	PRP
10_1101-2020_01_28_923532	477	5	model	model	VBP
10_1101-2020_01_28_923532	477	6	the	the	DT
10_1101-2020_01_28_923532	477	7	oncologist	oncologist	NN
10_1101-2020_01_28_923532	477	8	’s	’s	POS
10_1101-2020_01_28_923532	477	9	intuition	intuition	NN
10_1101-2020_01_28_923532	477	10	that	that	IN
10_1101-2020_01_28_923532	477	11	we	-PRON-	PRP
10_1101-2020_01_28_923532	477	12	want	want	VBP
10_1101-2020_01_28_923532	477	13	to	to	TO
10_1101-2020_01_28_923532	477	14	target	target	VB
10_1101-2020_01_28_923532	477	15	genes	gene	NNS
10_1101-2020_01_28_923532	477	16	that	that	WDT
10_1101-2020_01_28_923532	477	17	are	be	VBP
10_1101-2020_01_28_923532	477	18	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	477	19	in	in	IN
10_1101-2020_01_28_923532	477	20	the	the	DT
10_1101-2020_01_28_923532	477	21	tumor	tumor	NN
10_1101-2020_01_28_923532	477	22	.	.	.
10_1101-2020_01_28_923532	478	1	Combining	combine	VBG
10_1101-2020_01_28_923532	478	2	Data	Data	NNPS
10_1101-2020_01_28_923532	478	3	on	on	IN
10_1101-2020_01_28_923532	478	4	Tumor	Tumor	NNP
10_1101-2020_01_28_923532	478	5	Cells	Cells	NNPS
10_1101-2020_01_28_923532	478	6	and	and	CC
10_1101-2020_01_28_923532	478	7	Non	non	JJ
10_1101-2020_01_28_923532	478	8	-	-	JJ
10_1101-2020_01_28_923532	478	9	Tumor	tumor	JJ
10_1101-2020_01_28_923532	478	10	Cells	cell	NNS
10_1101-2020_01_28_923532	478	11	To	to	TO
10_1101-2020_01_28_923532	478	12	make	make	VB
10_1101-2020_01_28_923532	478	13	the	the	DT
10_1101-2020_01_28_923532	478	14	hitting	hit	VBG
10_1101-2020_01_28_923532	478	15	set	set	NN
10_1101-2020_01_28_923532	478	16	formulation	formulation	NN
10_1101-2020_01_28_923532	478	17	more	more	RBR
10_1101-2020_01_28_923532	478	18	realistic	realistic	JJ
10_1101-2020_01_28_923532	478	19	,	,	,
10_1101-2020_01_28_923532	478	20	we	-PRON-	PRP
10_1101-2020_01_28_923532	478	21	would	would	MD
10_1101-2020_01_28_923532	478	22	likely	likely	RB
10_1101-2020_01_28_923532	478	23	model	model	VB
10_1101-2020_01_28_923532	478	24	that	that	IN
10_1101-2020_01_28_923532	478	25	a	a	DT
10_1101-2020_01_28_923532	478	26	cell	cell	NN
10_1101-2020_01_28_923532	478	27	(	(	-LRB-
10_1101-2020_01_28_923532	478	28	set	set	NN
10_1101-2020_01_28_923532	478	29	)	)	-RRB-
10_1101-2020_01_28_923532	478	30	is	be	VBZ
10_1101-2020_01_28_923532	478	31	killed	kill	VBN
10_1101-2020_01_28_923532	478	32	(	(	-LRB-
10_1101-2020_01_28_923532	478	33	hit	hit	VBN
10_1101-2020_01_28_923532	478	34	)	)	-RRB-
10_1101-2020_01_28_923532	478	35	only	only	RB
10_1101-2020_01_28_923532	478	36	if	if	IN
10_1101-2020_01_28_923532	478	37	one	one	CD
10_1101-2020_01_28_923532	478	38	of	of	IN
10_1101-2020_01_28_923532	478	39	its	-PRON-	PRP$
10_1101-2020_01_28_923532	478	40	targets	target	NNS
10_1101-2020_01_28_923532	478	41	is	be	VBZ
10_1101-2020_01_28_923532	478	42	overexpressed	overexpresse	VBN
10_1101-2020_01_28_923532	478	43	compared	compare	VBN
10_1101-2020_01_28_923532	478	44	to	to	IN
10_1101-2020_01_28_923532	478	45	typical	typical	JJ
10_1101-2020_01_28_923532	478	46	expression	expression	NN
10_1101-2020_01_28_923532	478	47	in	in	IN
10_1101-2020_01_28_923532	478	48	non-	non-	NNP
10_1101-2020_01_28_923532	478	49	cancer	cancer	NN
10_1101-2020_01_28_923532	478	50	cells	cell	NNS
10_1101-2020_01_28_923532	478	51	.	.	.
10_1101-2020_01_28_923532	479	1	Such	such	JJ
10_1101-2020_01_28_923532	479	2	modeling	modeling	NN
10_1101-2020_01_28_923532	479	3	can	can	MD
10_1101-2020_01_28_923532	479	4	be	be	VB
10_1101-2020_01_28_923532	479	5	applied	apply	VBN
10_1101-2020_01_28_923532	479	6	in	in	IN
10_1101-2020_01_28_923532	479	7	the	the	DT
10_1101-2020_01_28_923532	479	8	nine	nine	CD
10_1101-2020_01_28_923532	479	9	single	single	JJ
10_1101-2020_01_28_923532	479	10	-	-	HYPH
10_1101-2020_01_28_923532	479	11	cell	cell	NN
10_1101-2020_01_28_923532	479	12	data	data	NN
10_1101-2020_01_28_923532	479	13	sets	set	NNS
10_1101-2020_01_28_923532	479	14	that	that	WDT
10_1101-2020_01_28_923532	479	15	have	have	VBP
10_1101-2020_01_28_923532	479	16	data	datum	NNS
10_1101-2020_01_28_923532	479	17	on	on	IN
10_1101-2020_01_28_923532	479	18	non-	non-	NNP
10_1101-2020_01_28_923532	479	19	cancer	cancer	NN
10_1101-2020_01_28_923532	479	20	cells	cell	NNS
10_1101-2020_01_28_923532	479	21	to	to	TO
10_1101-2020_01_28_923532	479	22	reflect	reflect	VB
10_1101-2020_01_28_923532	479	23	the	the	DT
10_1101-2020_01_28_923532	479	24	principle	principle	NN
10_1101-2020_01_28_923532	479	25	that	that	IN
10_1101-2020_01_28_923532	479	26	we	-PRON-	PRP
10_1101-2020_01_28_923532	479	27	would	would	MD
10_1101-2020_01_28_923532	479	28	like	like	VB
10_1101-2020_01_28_923532	479	29	the	the	DT
10_1101-2020_01_28_923532	479	30	treatment	treatment	NN
10_1101-2020_01_28_923532	479	31	to	to	TO
10_1101-2020_01_28_923532	479	32	kill	kill	VB
10_1101-2020_01_28_923532	479	33	the	the	DT
10_1101-2020_01_28_923532	479	34	tumor	tumor	NN
10_1101-2020_01_28_923532	479	35	cells	cell	NNS
10_1101-2020_01_28_923532	479	36	and	and	CC
10_1101-2020_01_28_923532	479	37	spare	spare	VB
10_1101-2020_01_28_923532	479	38	the	the	DT
10_1101-2020_01_28_923532	479	39	non	non	JJ
10_1101-2020_01_28_923532	479	40	-	-	JJ
10_1101-2020_01_28_923532	479	41	tumor	tumor	JJ
10_1101-2020_01_28_923532	479	42	cells	cell	NNS
10_1101-2020_01_28_923532	479	43	.	.	.
10_1101-2020_01_28_923532	480	1	Let	let	VB
10_1101-2020_01_28_923532	480	2	𝑁𝑇	𝑁𝑇	NNP
10_1101-2020_01_28_923532	480	3	be	be	VB
10_1101-2020_01_28_923532	480	4	the	the	DT
10_1101-2020_01_28_923532	480	5	set	set	NN
10_1101-2020_01_28_923532	480	6	of	of	IN
10_1101-2020_01_28_923532	480	7	non	non	JJ
10_1101-2020_01_28_923532	480	8	-	-	JJ
10_1101-2020_01_28_923532	480	9	tumor	tumor	JJ
10_1101-2020_01_28_923532	480	10	cells	cell	NNS
10_1101-2020_01_28_923532	480	11	.	.	.
10_1101-2020_01_28_923532	481	1	For	for	IN
10_1101-2020_01_28_923532	481	2	each	each	DT
10_1101-2020_01_28_923532	481	3	gene	gene	NN
10_1101-2020_01_28_923532	481	4	𝑔	𝑔	NN
10_1101-2020_01_28_923532	481	5	,	,	,
10_1101-2020_01_28_923532	481	6	define	define	VB
10_1101-2020_01_28_923532	481	7	its	-PRON-	PRP$
10_1101-2020_01_28_923532	481	8	average	average	JJ
10_1101-2020_01_28_923532	481	9	expression	expression	NN
10_1101-2020_01_28_923532	481	10	𝐸(𝑔	𝐸(𝑔	NNP
10_1101-2020_01_28_923532	481	11	)	)	-RRB-
10_1101-2020_01_28_923532	481	12	as	as	IN
10_1101-2020_01_28_923532	481	13	the	the	DT
10_1101-2020_01_28_923532	481	14	arithmetic	arithmetic	JJ
10_1101-2020_01_28_923532	481	15	mean	mean	NN
10_1101-2020_01_28_923532	481	16	among	among	IN
10_1101-2020_01_28_923532	481	17	all	all	PDT
10_1101-2020_01_28_923532	481	18	the	the	DT
10_1101-2020_01_28_923532	481	19	non	non	JJ
10_1101-2020_01_28_923532	481	20	-	-	JJ
10_1101-2020_01_28_923532	481	21	zero	zero	JJ
10_1101-2020_01_28_923532	481	22	values	value	NNS
10_1101-2020_01_28_923532	481	23	of	of	IN
10_1101-2020_01_28_923532	481	24	the	the	DT
10_1101-2020_01_28_923532	481	25	expression	expression	NN
10_1101-2020_01_28_923532	481	26	level	level	NN
10_1101-2020_01_28_923532	481	27	of	of	IN
10_1101-2020_01_28_923532	481	28	𝑔	𝑔	NN
10_1101-2020_01_28_923532	481	29	and	and	CC
10_1101-2020_01_28_923532	481	30	cells	cell	NNS
10_1101-2020_01_28_923532	481	31	in	in	IN
10_1101-2020_01_28_923532	481	32	𝑁𝑇.	𝑁𝑇.	CD
10_1101-2020_01_28_923532	482	1	The	the	DT
10_1101-2020_01_28_923532	482	2	zeroes	zero	NNS
10_1101-2020_01_28_923532	482	3	are	be	VBP
10_1101-2020_01_28_923532	482	4	ignored	ignore	VBN
10_1101-2020_01_28_923532	482	5	because	because	IN
10_1101-2020_01_28_923532	482	6	many	many	JJ
10_1101-2020_01_28_923532	482	7	of	of	IN
10_1101-2020_01_28_923532	482	8	these	these	DT
10_1101-2020_01_28_923532	482	9	likely	likely	JJ
10_1101-2020_01_28_923532	482	10	represent	represent	VBP
10_1101-2020_01_28_923532	482	11	dropouts	dropout	NNS
10_1101-2020_01_28_923532	482	12	in	in	IN
10_1101-2020_01_28_923532	482	13	the	the	DT
10_1101-2020_01_28_923532	482	14	expression	expression	NN
10_1101-2020_01_28_923532	482	15	measurement	measurement	NN
10_1101-2020_01_28_923532	482	16	.	.	.
10_1101-2020_01_28_923532	483	1	Following	follow	VBG
10_1101-2020_01_28_923532	483	2	the	the	DT
10_1101-2020_01_28_923532	483	3	design	design	NN
10_1101-2020_01_28_923532	483	4	of	of	IN
10_1101-2020_01_28_923532	483	5	experiments	experiment	NNS
10_1101-2020_01_28_923532	483	6	in	in	IN
10_1101-2020_01_28_923532	483	7	the	the	DT
10_1101-2020_01_28_923532	483	8	lab	lab	NN
10_1101-2020_01_28_923532	483	9	of	of	IN
10_1101-2020_01_28_923532	483	10	N.	N.	NNP
10_1101-2020_01_28_923532	483	11	A.	A.	NNP
10_1101-2020_01_28_923532	483	12	,	,	,
10_1101-2020_01_28_923532	483	13	we	-PRON-	PRP
10_1101-2020_01_28_923532	483	14	define	define	VBP
10_1101-2020_01_28_923532	483	15	an	an	DT
10_1101-2020_01_28_923532	483	16	expression	expression	NN
10_1101-2020_01_28_923532	483	17	ratio	ratio	NN
10_1101-2020_01_28_923532	483	18	threshold	threshold	NN
10_1101-2020_01_28_923532	483	19	factor	factor	NN
10_1101-2020_01_28_923532	483	20	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	483	21	whose	whose	WP$
10_1101-2020_01_28_923532	483	22	baseline	baseline	NN
10_1101-2020_01_28_923532	483	23	value	value	NN
10_1101-2020_01_28_923532	483	24	is	be	VBZ
10_1101-2020_01_28_923532	483	25	2.0	2.0	CD
10_1101-2020_01_28_923532	483	26	.	.	.
10_1101-2020_01_28_923532	484	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	484	2	adjust	adjust	VBP
10_1101-2020_01_28_923532	484	3	the	the	DT
10_1101-2020_01_28_923532	484	4	formulation	formulation	NN
10_1101-2020_01_28_923532	484	5	of	of	IN
10_1101-2020_01_28_923532	484	6	the	the	DT
10_1101-2020_01_28_923532	484	7	previous	previous	JJ
10_1101-2020_01_28_923532	484	8	subsection	subsection	NN
10_1101-2020_01_28_923532	484	9	,	,	,
10_1101-2020_01_28_923532	484	10	so	so	IN
10_1101-2020_01_28_923532	484	11	that	that	IN
10_1101-2020_01_28_923532	484	12	the	the	DT
10_1101-2020_01_28_923532	484	13	set	set	NN
10_1101-2020_01_28_923532	484	14	representing	represent	VBG
10_1101-2020_01_28_923532	484	15	a	a	DT
10_1101-2020_01_28_923532	484	16	cell	cell	NN
10_1101-2020_01_28_923532	484	17	(	(	-LRB-
10_1101-2020_01_28_923532	484	18	in	in	IN
10_1101-2020_01_28_923532	484	19	the	the	DT
10_1101-2020_01_28_923532	484	20	tumor	tumor	NN
10_1101-2020_01_28_923532	484	21	cell	cell	NN
10_1101-2020_01_28_923532	484	22	set	set	NN
10_1101-2020_01_28_923532	484	23	)	)	-RRB-
10_1101-2020_01_28_923532	484	24	contains	contain	VBZ
10_1101-2020_01_28_923532	484	25	only	only	RB
10_1101-2020_01_28_923532	484	26	those	those	DT
10_1101-2020_01_28_923532	484	27	genes	gene	NNS
10_1101-2020_01_28_923532	484	28	𝑔	𝑔	VBP
10_1101-2020_01_28_923532	484	29	such	such	JJ
10_1101-2020_01_28_923532	484	30	that	that	IN
10_1101-2020_01_28_923532	484	31	the	the	DT
10_1101-2020_01_28_923532	484	32	expression	expression	NN
10_1101-2020_01_28_923532	484	33	of	of	IN
10_1101-2020_01_28_923532	484	34	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	484	35	is	be	VBZ
10_1101-2020_01_28_923532	484	36	greater	great	JJR
10_1101-2020_01_28_923532	484	37	than	than	IN
10_1101-2020_01_28_923532	484	38	𝑟	𝑟	NN
10_1101-2020_01_28_923532	484	39	×	×	NN
10_1101-2020_01_28_923532	484	40	𝐸(𝑔	𝐸(𝑔	NNP
10_1101-2020_01_28_923532	484	41	)	)	-RRB-
10_1101-2020_01_28_923532	484	42	instead	instead	RB
10_1101-2020_01_28_923532	484	43	of	of	IN
10_1101-2020_01_28_923532	484	44	greater	great	JJR
10_1101-2020_01_28_923532	484	45	than	than	IN
10_1101-2020_01_28_923532	484	46	zero	zero	CD
10_1101-2020_01_28_923532	484	47	.	.	.
10_1101-2020_01_28_923532	485	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	485	2	keep	keep	VBP
10_1101-2020_01_28_923532	485	3	the	the	DT
10_1101-2020_01_28_923532	485	4	105	105	CD
10_1101-2020_01_28_923532	485	5	and	and	CC
10_1101-2020_01_28_923532	485	6	is	be	VBZ
10_1101-2020_01_28_923532	485	7	also	also	RB
10_1101-2020_01_28_923532	485	8	made	make	VBN
10_1101-2020_01_28_923532	485	9	available	available	JJ
10_1101-2020_01_28_923532	485	10	for	for	IN
10_1101-2020_01_28_923532	485	11	use	use	NN
10_1101-2020_01_28_923532	485	12	under	under	IN
10_1101-2020_01_28_923532	485	13	a	a	DT
10_1101-2020_01_28_923532	485	14	CC0	CC0	NNP
10_1101-2020_01_28_923532	485	15	license	license	NN
10_1101-2020_01_28_923532	485	16	.	.	.
10_1101-2020_01_28_923532	486	1	(	(	-LRB-
10_1101-2020_01_28_923532	486	2	which	which	WDT
10_1101-2020_01_28_923532	486	3	was	be	VBD
10_1101-2020_01_28_923532	486	4	not	not	RB
10_1101-2020_01_28_923532	486	5	certified	certify	VBN
10_1101-2020_01_28_923532	486	6	by	by	IN
10_1101-2020_01_28_923532	486	7	peer	peer	NN
10_1101-2020_01_28_923532	486	8	review	review	NN
10_1101-2020_01_28_923532	486	9	)	)	-RRB-
10_1101-2020_01_28_923532	486	10	is	be	VBZ
10_1101-2020_01_28_923532	486	11	the	the	DT
10_1101-2020_01_28_923532	486	12	author	author	NN
10_1101-2020_01_28_923532	486	13	/	/	SYM
10_1101-2020_01_28_923532	486	14	funder	funder	NN
10_1101-2020_01_28_923532	486	15	.	.	.
10_1101-2020_01_28_923532	487	1	This	this	DT
10_1101-2020_01_28_923532	487	2	article	article	NN
10_1101-2020_01_28_923532	487	3	is	be	VBZ
10_1101-2020_01_28_923532	487	4	a	a	DT
10_1101-2020_01_28_923532	487	5	US	US	NNP
10_1101-2020_01_28_923532	487	6	Government	Government	NNP
10_1101-2020_01_28_923532	487	7	work	work	NN
10_1101-2020_01_28_923532	487	8	.	.	.
10_1101-2020_01_28_923532	488	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	488	2	is	be	VBZ
10_1101-2020_01_28_923532	488	3	not	not	RB
10_1101-2020_01_28_923532	488	4	subject	subject	JJ
10_1101-2020_01_28_923532	488	5	to	to	IN
10_1101-2020_01_28_923532	488	6	copyright	copyright	NN
10_1101-2020_01_28_923532	488	7	under	under	IN
10_1101-2020_01_28_923532	488	8	17	17	CD
10_1101-2020_01_28_923532	488	9	USC	usc	NN
10_1101-2020_01_28_923532	488	10	The	the	DT
10_1101-2020_01_28_923532	488	11	copyright	copyright	NN
10_1101-2020_01_28_923532	488	12	holder	holder	NN
10_1101-2020_01_28_923532	488	13	for	for	IN
10_1101-2020_01_28_923532	488	14	this	this	DT
10_1101-2020_01_28_923532	488	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	488	16	version	version	NN
10_1101-2020_01_28_923532	488	17	posted	post	VBD
10_1101-2020_01_28_923532	488	18	February	February	NNP
10_1101-2020_01_28_923532	488	19	12	12	CD
10_1101-2020_01_28_923532	488	20	,	,	,
10_1101-2020_01_28_923532	488	21	2021	2021	CD
10_1101-2020_01_28_923532	488	22	.	.	.
10_1101-2020_01_28_923532	488	23	;	;	:
10_1101-2020_01_28_923532	488	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	488	25	:	:	:
10_1101-2020_01_28_923532	488	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	488	27	preprint	preprint	NN
10_1101-2020_01_28_923532	488	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	488	29	38	38	CD
10_1101-2020_01_28_923532	488	30	objective	objective	JJ
10_1101-2020_01_28_923532	488	31	function	function	NN
10_1101-2020_01_28_923532	488	32	limited	limit	VBN
10_1101-2020_01_28_923532	488	33	to	to	IN
10_1101-2020_01_28_923532	488	34	the	the	DT
10_1101-2020_01_28_923532	488	35	tumor	tumor	NN
10_1101-2020_01_28_923532	488	36	cells	cell	NNS
10_1101-2020_01_28_923532	488	37	,	,	,
10_1101-2020_01_28_923532	488	38	but	but	CC
10_1101-2020_01_28_923532	488	39	we	-PRON-	PRP
10_1101-2020_01_28_923532	488	40	also	also	RB
10_1101-2020_01_28_923532	488	41	store	store	VBP
10_1101-2020_01_28_923532	488	42	a	a	DT
10_1101-2020_01_28_923532	488	43	set	set	NN
10_1101-2020_01_28_923532	488	44	to	to	TO
10_1101-2020_01_28_923532	488	45	represent	represent	VB
10_1101-2020_01_28_923532	488	46	each	each	DT
10_1101-2020_01_28_923532	488	47	non	non	JJ
10_1101-2020_01_28_923532	488	48	-	-	JJ
10_1101-2020_01_28_923532	488	49	tumor	tumor	JJ
10_1101-2020_01_28_923532	488	50	cell	cell	NN
10_1101-2020_01_28_923532	488	51	,	,	,
10_1101-2020_01_28_923532	488	52	and	and	CC
10_1101-2020_01_28_923532	488	53	we	-PRON-	PRP
10_1101-2020_01_28_923532	488	54	tabulate	tabulate	VBP
10_1101-2020_01_28_923532	488	55	which	which	WDT
10_1101-2020_01_28_923532	488	56	non	non	JJ
10_1101-2020_01_28_923532	488	57	-	-	JJ
10_1101-2020_01_28_923532	488	58	tumor	tumor	JJ
10_1101-2020_01_28_923532	488	59	cells	cell	NNS
10_1101-2020_01_28_923532	488	60	(	(	-LRB-
10_1101-2020_01_28_923532	488	61	sets	set	NNS
10_1101-2020_01_28_923532	488	62	)	)	-RRB-
10_1101-2020_01_28_923532	488	63	would	would	MD
10_1101-2020_01_28_923532	488	64	be	be	VB
10_1101-2020_01_28_923532	488	65	killed	kill	VBN
10_1101-2020_01_28_923532	488	66	(	(	-LRB-
10_1101-2020_01_28_923532	488	67	hit	hit	VBN
10_1101-2020_01_28_923532	488	68	)	)	-RRB-
10_1101-2020_01_28_923532	488	69	because	because	IN
10_1101-2020_01_28_923532	488	70	for	for	IN
10_1101-2020_01_28_923532	488	71	at	at	RB
10_1101-2020_01_28_923532	488	72	least	least	RBS
10_1101-2020_01_28_923532	488	73	one	one	CD
10_1101-2020_01_28_923532	488	74	of	of	IN
10_1101-2020_01_28_923532	488	75	the	the	DT
10_1101-2020_01_28_923532	488	76	genes	gene	NNS
10_1101-2020_01_28_923532	488	77	in	in	IN
10_1101-2020_01_28_923532	488	78	the	the	DT
10_1101-2020_01_28_923532	488	79	optimal	optimal	JJ
10_1101-2020_01_28_923532	488	80	target	target	NN
10_1101-2020_01_28_923532	488	81	set	set	VBN
10_1101-2020_01_28_923532	488	82	,	,	,
10_1101-2020_01_28_923532	488	83	the	the	DT
10_1101-2020_01_28_923532	488	84	expression	expression	NN
10_1101-2020_01_28_923532	488	85	of	of	IN
10_1101-2020_01_28_923532	488	86	that	that	DT
10_1101-2020_01_28_923532	488	87	gene	gene	NN
10_1101-2020_01_28_923532	488	88	in	in	IN
10_1101-2020_01_28_923532	488	89	that	that	DT
10_1101-2020_01_28_923532	488	90	non	non	JJ
10_1101-2020_01_28_923532	488	91	-	-	JJ
10_1101-2020_01_28_923532	488	92	tumor	tumor	JJ
10_1101-2020_01_28_923532	488	93	cell	cell	NN
10_1101-2020_01_28_923532	488	94	exceeds	exceed	VBZ
10_1101-2020_01_28_923532	488	95	the	the	DT
10_1101-2020_01_28_923532	488	96	threshold	threshold	NN
10_1101-2020_01_28_923532	488	97	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	488	98	×	×	NNP
10_1101-2020_01_28_923532	488	99	𝐸(𝑔	𝐸(𝑔	NNP
10_1101-2020_01_28_923532	488	100	)	)	-RRB-
10_1101-2020_01_28_923532	488	101	.	.	.
10_1101-2020_01_28_923532	489	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	489	2	add	add	VBP
10_1101-2020_01_28_923532	489	3	parameters	parameter	NNS
10_1101-2020_01_28_923532	489	4	𝑙𝑏	𝑙𝑏	VBP
10_1101-2020_01_28_923532	489	5	and	and	CC
10_1101-2020_01_28_923532	489	6	𝑢𝑏	𝑢𝑏	VB
10_1101-2020_01_28_923532	489	7	each	each	DT
10_1101-2020_01_28_923532	489	8	in	in	IN
10_1101-2020_01_28_923532	489	9	the	the	DT
10_1101-2020_01_28_923532	489	10	range	range	NN
10_1101-2020_01_28_923532	489	11	[	[	-LRB-
10_1101-2020_01_28_923532	489	12	0,1	0,1	NFP
10_1101-2020_01_28_923532	489	13	]	]	-RRB-
10_1101-2020_01_28_923532	489	14	and	and	CC
10_1101-2020_01_28_923532	489	15	representing	represent	VBG
10_1101-2020_01_28_923532	489	16	respectively	respectively	RB
10_1101-2020_01_28_923532	489	17	a	a	DT
10_1101-2020_01_28_923532	489	18	lower	low	JJR
10_1101-2020_01_28_923532	489	19	bound	bind	VBN
10_1101-2020_01_28_923532	489	20	on	on	IN
10_1101-2020_01_28_923532	489	21	the	the	DT
10_1101-2020_01_28_923532	489	22	proportion	proportion	NN
10_1101-2020_01_28_923532	489	23	of	of	IN
10_1101-2020_01_28_923532	489	24	tumor	tumor	NN
10_1101-2020_01_28_923532	489	25	cells	cell	NNS
10_1101-2020_01_28_923532	489	26	killed	kill	VBN
10_1101-2020_01_28_923532	489	27	and	and	CC
10_1101-2020_01_28_923532	489	28	an	an	DT
10_1101-2020_01_28_923532	489	29	upper	upper	JJ
10_1101-2020_01_28_923532	489	30	bound	bind	VBN
10_1101-2020_01_28_923532	489	31	on	on	IN
10_1101-2020_01_28_923532	489	32	the	the	DT
10_1101-2020_01_28_923532	489	33	proportion	proportion	NN
10_1101-2020_01_28_923532	489	34	of	of	IN
10_1101-2020_01_28_923532	489	35	non	non	JJ
10_1101-2020_01_28_923532	489	36	-	-	JJ
10_1101-2020_01_28_923532	489	37	tumor	tumor	JJ
10_1101-2020_01_28_923532	489	38	cells	cell	NNS
10_1101-2020_01_28_923532	489	39	killed	kill	VBN
10_1101-2020_01_28_923532	489	40	.	.	.
10_1101-2020_01_28_923532	490	1	The	the	DT
10_1101-2020_01_28_923532	490	2	parameters	parameter	NNS
10_1101-2020_01_28_923532	490	3	𝑙𝑏	𝑙𝑏	VBP
10_1101-2020_01_28_923532	490	4	,	,	,
10_1101-2020_01_28_923532	490	5	ub	ub	PRP
10_1101-2020_01_28_923532	490	6	are	be	VBP
10_1101-2020_01_28_923532	490	7	used	use	VBN
10_1101-2020_01_28_923532	490	8	only	only	RB
10_1101-2020_01_28_923532	490	9	in	in	IN
10_1101-2020_01_28_923532	490	10	two	two	CD
10_1101-2020_01_28_923532	490	11	constraints	constraint	NNS
10_1101-2020_01_28_923532	490	12	,	,	,
10_1101-2020_01_28_923532	490	13	and	and	CC
10_1101-2020_01_28_923532	490	14	we	-PRON-	PRP
10_1101-2020_01_28_923532	490	15	do	do	VBP
10_1101-2020_01_28_923532	490	16	not	not	RB
10_1101-2020_01_28_923532	490	17	favor	favor	VB
10_1101-2020_01_28_923532	490	18	optimal	optimal	JJ
10_1101-2020_01_28_923532	490	19	solutions	solution	NNS
10_1101-2020_01_28_923532	490	20	that	that	WDT
10_1101-2020_01_28_923532	490	21	kill	kill	VBP
10_1101-2020_01_28_923532	490	22	more	more	JJR
10_1101-2020_01_28_923532	490	23	tumor	tumor	NN
10_1101-2020_01_28_923532	490	24	cells	cell	NNS
10_1101-2020_01_28_923532	490	25	or	or	CC
10_1101-2020_01_28_923532	490	26	fewer	few	JJR
10_1101-2020_01_28_923532	490	27	non	non	JJ
10_1101-2020_01_28_923532	490	28	-	-	JJ
10_1101-2020_01_28_923532	490	29	tumor	tumor	JJ
10_1101-2020_01_28_923532	490	30	cells	cell	NNS
10_1101-2020_01_28_923532	490	31	,	,	,
10_1101-2020_01_28_923532	490	32	so	so	RB
10_1101-2020_01_28_923532	490	33	long	long	RB
10_1101-2020_01_28_923532	490	34	as	as	IN
10_1101-2020_01_28_923532	490	35	the	the	DT
10_1101-2020_01_28_923532	490	36	solutions	solution	NNS
10_1101-2020_01_28_923532	490	37	obey	obey	VBP
10_1101-2020_01_28_923532	490	38	the	the	DT
10_1101-2020_01_28_923532	490	39	constraints	constraint	NNS
10_1101-2020_01_28_923532	490	40	.	.	.
10_1101-2020_01_28_923532	491	1	The	the	DT
10_1101-2020_01_28_923532	491	2	Fair	Fair	NNP
10_1101-2020_01_28_923532	491	3	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	491	4	Target	Target	NNP
10_1101-2020_01_28_923532	491	5	Set	Set	VBD
10_1101-2020_01_28_923532	491	6	Problem	problem	NN
10_1101-2020_01_28_923532	491	7	for	for	IN
10_1101-2020_01_28_923532	491	8	a	a	DT
10_1101-2020_01_28_923532	491	9	Multi	multi	JJ
10_1101-2020_01_28_923532	491	10	-	-	JJ
10_1101-2020_01_28_923532	491	11	Patient	patient	JJ
10_1101-2020_01_28_923532	491	12	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	491	13	We	-PRON-	PRP
10_1101-2020_01_28_923532	491	14	want	want	VBP
10_1101-2020_01_28_923532	491	15	to	to	TO
10_1101-2020_01_28_923532	491	16	formulate	formulate	VB
10_1101-2020_01_28_923532	491	17	an	an	DT
10_1101-2020_01_28_923532	491	18	integer	integer	NN
10_1101-2020_01_28_923532	491	19	linear	linear	NN
10_1101-2020_01_28_923532	491	20	program	program	NN
10_1101-2020_01_28_923532	491	21	that	that	WDT
10_1101-2020_01_28_923532	491	22	selects	select	VBZ
10_1101-2020_01_28_923532	491	23	a	a	DT
10_1101-2020_01_28_923532	491	24	set	set	NN
10_1101-2020_01_28_923532	491	25	of	of	IN
10_1101-2020_01_28_923532	491	26	genes	gene	NNS
10_1101-2020_01_28_923532	491	27	𝑆∗	𝑆∗	NNS
10_1101-2020_01_28_923532	491	28	from	from	IN
10_1101-2020_01_28_923532	491	29	available	available	JJ
10_1101-2020_01_28_923532	491	30	genes	gene	NNS
10_1101-2020_01_28_923532	491	31	in	in	IN
10_1101-2020_01_28_923532	491	32	such	such	PDT
10_1101-2020_01_28_923532	491	33	a	a	DT
10_1101-2020_01_28_923532	491	34	way	way	NN
10_1101-2020_01_28_923532	491	35	that	that	IN
10_1101-2020_01_28_923532	491	36	,	,	,
10_1101-2020_01_28_923532	491	37	for	for	IN
10_1101-2020_01_28_923532	491	38	each	each	DT
10_1101-2020_01_28_923532	491	39	patient	patient	NN
10_1101-2020_01_28_923532	491	40	,	,	,
10_1101-2020_01_28_923532	491	41	there	there	EX
10_1101-2020_01_28_923532	491	42	exists	exist	VBZ
10_1101-2020_01_28_923532	491	43	an	an	DT
10_1101-2020_01_28_923532	491	44	individual	individual	JJ
10_1101-2020_01_28_923532	491	45	target	target	NN
10_1101-2020_01_28_923532	491	46	set	set	VBN
10_1101-2020_01_28_923532	491	47	𝐻𝑖	𝐻𝑖	NNP
10_1101-2020_01_28_923532	491	48	𝑆∗	𝑆∗	ADD
10_1101-2020_01_28_923532	491	49	⊆	⊆	:
10_1101-2020_01_28_923532	491	50	𝑆∗of	𝑆∗of	PRP
10_1101-2020_01_28_923532	491	51	a	a	DT
10_1101-2020_01_28_923532	491	52	relative	relative	JJ
10_1101-2020_01_28_923532	491	53	small	small	JJ
10_1101-2020_01_28_923532	491	54	size	size	NN
10_1101-2020_01_28_923532	491	55	(	(	-LRB-
10_1101-2020_01_28_923532	491	56	compared	compare	VBN
10_1101-2020_01_28_923532	491	57	to	to	IN
10_1101-2020_01_28_923532	491	58	the	the	DT
10_1101-2020_01_28_923532	491	59	optimal	optimal	JJ
10_1101-2020_01_28_923532	491	60	ITS	ITS	NNP
10_1101-2020_01_28_923532	491	61	of	of	IN
10_1101-2020_01_28_923532	491	62	that	that	DT
10_1101-2020_01_28_923532	491	63	patient	patient	NN
10_1101-2020_01_28_923532	491	64	alone	alone	RB
10_1101-2020_01_28_923532	491	65	which	which	WDT
10_1101-2020_01_28_923532	491	66	is	be	VBZ
10_1101-2020_01_28_923532	491	67	denoted	denote	VBN
10_1101-2020_01_28_923532	491	68	by	by	IN
10_1101-2020_01_28_923532	491	69	𝐻(𝑖	𝐻(𝑖	CD
10_1101-2020_01_28_923532	491	70	)	)	-RRB-
10_1101-2020_01_28_923532	491	71	)	)	-RRB-
10_1101-2020_01_28_923532	491	72	.	.	.
10_1101-2020_01_28_923532	492	1	Let	let	VB
10_1101-2020_01_28_923532	492	2	U	u	PRP
10_1101-2020_01_28_923532	492	3	=	=	NFP
10_1101-2020_01_28_923532	492	4	{	{	-LRB-
10_1101-2020_01_28_923532	492	5	g1	g1	NN
10_1101-2020_01_28_923532	492	6	,	,	,
10_1101-2020_01_28_923532	492	7	g2	g2	NNP
10_1101-2020_01_28_923532	492	8	,	,	,
10_1101-2020_01_28_923532	492	9	...	...	:
10_1101-2020_01_28_923532	492	10	,	,	,
10_1101-2020_01_28_923532	492	11	g|U|	g|U|	NNP
10_1101-2020_01_28_923532	492	12	}	}	-RRB-
10_1101-2020_01_28_923532	492	13	be	be	VB
10_1101-2020_01_28_923532	492	14	the	the	DT
10_1101-2020_01_28_923532	492	15	set	set	NN
10_1101-2020_01_28_923532	492	16	of	of	IN
10_1101-2020_01_28_923532	492	17	genes	gene	NNS
10_1101-2020_01_28_923532	492	18	.	.	.
10_1101-2020_01_28_923532	493	1	There	there	EX
10_1101-2020_01_28_923532	493	2	are	be	VBP
10_1101-2020_01_28_923532	493	3	𝑛	𝑛	NN
10_1101-2020_01_28_923532	493	4	patients	patient	NNS
10_1101-2020_01_28_923532	493	5	.	.	.
10_1101-2020_01_28_923532	494	1	For	for	IN
10_1101-2020_01_28_923532	494	2	the	the	DT
10_1101-2020_01_28_923532	494	3	i	i	PRP
10_1101-2020_01_28_923532	494	4	th	th	XX
10_1101-2020_01_28_923532	494	5	patient	patient	NN
10_1101-2020_01_28_923532	494	6	,	,	,
10_1101-2020_01_28_923532	494	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	494	8	denote	denote	VBP
10_1101-2020_01_28_923532	494	9	by	by	IN
10_1101-2020_01_28_923532	494	10	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NNP
10_1101-2020_01_28_923532	494	11	)	)	-RRB-
10_1101-2020_01_28_923532	494	12	,	,	,
10_1101-2020_01_28_923532	494	13	the	the	DT
10_1101-2020_01_28_923532	494	14	set	set	NN
10_1101-2020_01_28_923532	494	15	of	of	IN
10_1101-2020_01_28_923532	494	16	tumor	tumor	NN
10_1101-2020_01_28_923532	494	17	cells	cell	NNS
10_1101-2020_01_28_923532	494	18	related	relate	VBN
10_1101-2020_01_28_923532	494	19	to	to	IN
10_1101-2020_01_28_923532	494	20	patient	patient	NN
10_1101-2020_01_28_923532	494	21	i.	i.	NNP
10_1101-2020_01_28_923532	495	1	For	for	IN
10_1101-2020_01_28_923532	495	2	each	each	DT
10_1101-2020_01_28_923532	495	3	tumor	tumor	NN
10_1101-2020_01_28_923532	495	4	cell	cell	NN
10_1101-2020_01_28_923532	495	5	𝐶	𝐶	NNP
10_1101-2020_01_28_923532	495	6	∈	∈	NNP
10_1101-2020_01_28_923532	495	7	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	495	8	)	)	-RRB-
10_1101-2020_01_28_923532	495	9	,	,	,
10_1101-2020_01_28_923532	495	10	we	-PRON-	PRP
10_1101-2020_01_28_923532	495	11	describe	describe	VBP
10_1101-2020_01_28_923532	495	12	it	-PRON-	PRP
10_1101-2020_01_28_923532	495	13	as	as	IN
10_1101-2020_01_28_923532	495	14	a	a	DT
10_1101-2020_01_28_923532	495	15	set	set	NN
10_1101-2020_01_28_923532	495	16	of	of	IN
10_1101-2020_01_28_923532	495	17	genes	gene	NNS
10_1101-2020_01_28_923532	495	18	which	which	WDT
10_1101-2020_01_28_923532	495	19	is	be	VBZ
10_1101-2020_01_28_923532	495	20	known	know	VBN
10_1101-2020_01_28_923532	495	21	to	to	TO
10_1101-2020_01_28_923532	495	22	be	be	VB
10_1101-2020_01_28_923532	495	23	targetable	targetable	JJ
10_1101-2020_01_28_923532	495	24	to	to	TO
10_1101-2020_01_28_923532	495	25	cell	cell	NN
10_1101-2020_01_28_923532	495	26	𝐶.	𝐶.	NNP
10_1101-2020_01_28_923532	496	1	That	that	RB
10_1101-2020_01_28_923532	496	2	is	is	RB
10_1101-2020_01_28_923532	496	3	,	,	,
10_1101-2020_01_28_923532	496	4	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	496	5	∈	∈	NNP
10_1101-2020_01_28_923532	496	6	𝐶	𝐶	NNP
10_1101-2020_01_28_923532	496	7	if	if	IN
10_1101-2020_01_28_923532	496	8	and	and	CC
10_1101-2020_01_28_923532	496	9	only	only	RB
10_1101-2020_01_28_923532	496	10	if	if	IN
10_1101-2020_01_28_923532	496	11	a	a	DT
10_1101-2020_01_28_923532	496	12	drug	drug	NN
10_1101-2020_01_28_923532	496	13	containing	contain	VBG
10_1101-2020_01_28_923532	496	14	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	496	15	can	can	MD
10_1101-2020_01_28_923532	496	16	target	target	VB
10_1101-2020_01_28_923532	496	17	the	the	DT
10_1101-2020_01_28_923532	496	18	cell	cell	NN
10_1101-2020_01_28_923532	496	19	𝐶.	𝐶.	NN
10_1101-2020_01_28_923532	497	1	In	in	IN
10_1101-2020_01_28_923532	497	2	the	the	DT
10_1101-2020_01_28_923532	497	3	ILP	ILP	NNP
10_1101-2020_01_28_923532	497	4	,	,	,
10_1101-2020_01_28_923532	497	5	there	there	EX
10_1101-2020_01_28_923532	497	6	is	be	VBZ
10_1101-2020_01_28_923532	497	7	a	a	DT
10_1101-2020_01_28_923532	497	8	variable	variable	JJ
10_1101-2020_01_28_923532	497	9	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	497	10	)	)	-RRB-
10_1101-2020_01_28_923532	497	11	corresponding	correspond	VBG
10_1101-2020_01_28_923532	497	12	to	to	IN
10_1101-2020_01_28_923532	497	13	each	each	DT
10_1101-2020_01_28_923532	497	14	gene	gene	NN
10_1101-2020_01_28_923532	497	15	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	497	16	∈	∈	NNP
10_1101-2020_01_28_923532	497	17	𝑈	𝑈	NN
10_1101-2020_01_28_923532	497	18	that	that	WDT
10_1101-2020_01_28_923532	497	19	shows	show	VBZ
10_1101-2020_01_28_923532	497	20	whether	whether	IN
10_1101-2020_01_28_923532	497	21	the	the	DT
10_1101-2020_01_28_923532	497	22	gene	gene	NN
10_1101-2020_01_28_923532	497	23	g	g	NN
10_1101-2020_01_28_923532	497	24	is	be	VBZ
10_1101-2020_01_28_923532	497	25	selected	select	VBN
10_1101-2020_01_28_923532	497	26	or	or	CC
10_1101-2020_01_28_923532	497	27	not	not	RB
10_1101-2020_01_28_923532	497	28	.	.	.
10_1101-2020_01_28_923532	498	1	There	there	EX
10_1101-2020_01_28_923532	498	2	is	be	VBZ
10_1101-2020_01_28_923532	498	3	a	a	DT
10_1101-2020_01_28_923532	498	4	variable	variable	JJ
10_1101-2020_01_28_923532	498	5	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	498	6	,	,	,
10_1101-2020_01_28_923532	498	7	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	498	8	)	)	-RRB-
10_1101-2020_01_28_923532	498	9	)	)	-RRB-
10_1101-2020_01_28_923532	498	10	which	which	WDT
10_1101-2020_01_28_923532	498	11	shows	show	VBZ
10_1101-2020_01_28_923532	498	12	whether	whether	IN
10_1101-2020_01_28_923532	498	13	a	a	DT
10_1101-2020_01_28_923532	498	14	gene	gene	NN
10_1101-2020_01_28_923532	498	15	g	g	NN
10_1101-2020_01_28_923532	498	16	is	be	VBZ
10_1101-2020_01_28_923532	498	17	selected	select	VBN
10_1101-2020_01_28_923532	498	18	in	in	IN
10_1101-2020_01_28_923532	498	19	the	the	DT
10_1101-2020_01_28_923532	498	20	target	target	NN
10_1101-2020_01_28_923532	498	21	set	set	VBN
10_1101-2020_01_28_923532	498	22	of	of	IN
10_1101-2020_01_28_923532	498	23	patient	patient	JJ
10_1101-2020_01_28_923532	498	24	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	498	25	)	)	-RRB-
10_1101-2020_01_28_923532	498	26	.	.	.
10_1101-2020_01_28_923532	499	1	The	the	DT
10_1101-2020_01_28_923532	499	2	objective	objective	JJ
10_1101-2020_01_28_923532	499	3	function	function	NN
10_1101-2020_01_28_923532	499	4	is	be	VBZ
10_1101-2020_01_28_923532	499	5	to	to	TO
10_1101-2020_01_28_923532	499	6	minimize	minimize	VB
10_1101-2020_01_28_923532	499	7	the	the	DT
10_1101-2020_01_28_923532	499	8	total	total	JJ
10_1101-2020_01_28_923532	499	9	number	number	NN
10_1101-2020_01_28_923532	499	10	of	of	IN
10_1101-2020_01_28_923532	499	11	genes	gene	NNS
10_1101-2020_01_28_923532	499	12	selected	select	VBN
10_1101-2020_01_28_923532	499	13	,	,	,
10_1101-2020_01_28_923532	499	14	subject	subject	JJ
10_1101-2020_01_28_923532	499	15	to	to	IN
10_1101-2020_01_28_923532	499	16	having	have	VBG
10_1101-2020_01_28_923532	499	17	a	a	DT
10_1101-2020_01_28_923532	499	18	target	target	NN
10_1101-2020_01_28_923532	499	19	set	set	VBN
10_1101-2020_01_28_923532	499	20	of	of	IN
10_1101-2020_01_28_923532	499	21	size	size	NN
10_1101-2020_01_28_923532	499	22	at	at	IN
10_1101-2020_01_28_923532	499	23	most	most	JJS
10_1101-2020_01_28_923532	499	24	𝐻(𝑖	𝐻(𝑖	CD
10_1101-2020_01_28_923532	499	25	)	)	-RRB-
10_1101-2020_01_28_923532	499	26	+	+	CC
10_1101-2020_01_28_923532	499	27	𝛼	𝛼	NN
10_1101-2020_01_28_923532	499	28	for	for	IN
10_1101-2020_01_28_923532	499	29	patient	patient	NNP
10_1101-2020_01_28_923532	499	30	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	499	31	)	)	-RRB-
10_1101-2020_01_28_923532	499	32	where	where	WRB
10_1101-2020_01_28_923532	499	33	1	1	CD
10_1101-2020_01_28_923532	499	34	≤	≤	NNP
10_1101-2020_01_28_923532	499	35	𝑖	𝑖	NNP
10_1101-2020_01_28_923532	499	36	≤	≤	NN
10_1101-2020_01_28_923532	499	37	𝑛.	𝑛.	NNP
10_1101-2020_01_28_923532	499	38	Constraint	Constraint	NNP
10_1101-2020_01_28_923532	499	39	(	(	-LRB-
10_1101-2020_01_28_923532	499	40	3	3	LS
10_1101-2020_01_28_923532	499	41	)	)	-RRB-
10_1101-2020_01_28_923532	499	42	ensures	ensure	VBZ
10_1101-2020_01_28_923532	499	43	that	that	IN
10_1101-2020_01_28_923532	499	44	,	,	,
10_1101-2020_01_28_923532	499	45	for	for	IN
10_1101-2020_01_28_923532	499	46	patient	patient	JJ
10_1101-2020_01_28_923532	499	47	𝑃(𝑖),we	𝑃(𝑖),we	NNP
10_1101-2020_01_28_923532	499	48	do	do	VBP
10_1101-2020_01_28_923532	499	49	not	not	RB
10_1101-2020_01_28_923532	499	50	select	select	VB
10_1101-2020_01_28_923532	499	51	any	any	DT
10_1101-2020_01_28_923532	499	52	gene	gene	NN
10_1101-2020_01_28_923532	499	53	𝑔	𝑔	NN
10_1101-2020_01_28_923532	499	54	that	that	WDT
10_1101-2020_01_28_923532	499	55	are	be	VBP
10_1101-2020_01_28_923532	499	56	not	not	RB
10_1101-2020_01_28_923532	499	57	selected	select	VBN
10_1101-2020_01_28_923532	499	58	in	in	IN
10_1101-2020_01_28_923532	499	59	the	the	DT
10_1101-2020_01_28_923532	499	60	global	global	JJ
10_1101-2020_01_28_923532	499	61	set	set	NN
10_1101-2020_01_28_923532	499	62	.	.	.
10_1101-2020_01_28_923532	500	1	Constraint	constraint	NN
10_1101-2020_01_28_923532	500	2	(	(	-LRB-
10_1101-2020_01_28_923532	500	3	4	4	CD
10_1101-2020_01_28_923532	500	4	)	)	-RRB-
10_1101-2020_01_28_923532	500	5	ensures	ensure	VBZ
10_1101-2020_01_28_923532	500	6	all	all	PDT
10_1101-2020_01_28_923532	500	7	the	the	DT
10_1101-2020_01_28_923532	500	8	sets	set	NNS
10_1101-2020_01_28_923532	500	9	corresponding	correspond	VBG
10_1101-2020_01_28_923532	500	10	to	to	IN
10_1101-2020_01_28_923532	500	11	tumor	tumor	NN
10_1101-2020_01_28_923532	500	12	cells	cell	NNS
10_1101-2020_01_28_923532	500	13	of	of	IN
10_1101-2020_01_28_923532	500	14	patient	patient	JJ
10_1101-2020_01_28_923532	500	15	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	500	16	)	)	-RRB-
10_1101-2020_01_28_923532	500	17	are	be	VBP
10_1101-2020_01_28_923532	500	18	hit	hit	VBN
10_1101-2020_01_28_923532	500	19	.	.	.
10_1101-2020_01_28_923532	501	1	𝑚𝑖𝑛	𝑚𝑖𝑛	NNP
10_1101-2020_01_28_923532	501	2	∑	∑	XX
10_1101-2020_01_28_923532	501	3	𝑔∈𝑈	𝑔∈𝑈	NNP
10_1101-2020_01_28_923532	501	4	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	501	5	)	)	-RRB-
10_1101-2020_01_28_923532	501	6	(	(	-LRB-
10_1101-2020_01_28_923532	501	7	1	1	CD
10_1101-2020_01_28_923532	501	8	)	)	-RRB-
10_1101-2020_01_28_923532	501	9	∑	∑	.
10_1101-2020_01_28_923532	501	10	𝑔∈𝑆𝑃(𝑖	𝑔∈𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	501	11	)	)	-RRB-
10_1101-2020_01_28_923532	501	12	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	501	13	,	,	,
10_1101-2020_01_28_923532	501	14	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	501	15	)	)	-RRB-
10_1101-2020_01_28_923532	501	16	)	)	-RRB-
10_1101-2020_01_28_923532	501	17	≤	≤	NNP
10_1101-2020_01_28_923532	501	18	𝐻(𝑖	𝐻(𝑖	CD
10_1101-2020_01_28_923532	501	19	)	)	-RRB-
10_1101-2020_01_28_923532	501	20	+	+	CC
10_1101-2020_01_28_923532	501	21	𝛼	𝛼	NN
10_1101-2020_01_28_923532	501	22	∀𝑖	∀𝑖	NNP
10_1101-2020_01_28_923532	501	23	(	(	-LRB-
10_1101-2020_01_28_923532	501	24	2	2	CD
10_1101-2020_01_28_923532	501	25	)	)	-RRB-
10_1101-2020_01_28_923532	501	26	105	105	CD
10_1101-2020_01_28_923532	501	27	and	and	CC
10_1101-2020_01_28_923532	501	28	is	be	VBZ
10_1101-2020_01_28_923532	501	29	also	also	RB
10_1101-2020_01_28_923532	501	30	made	make	VBN
10_1101-2020_01_28_923532	501	31	available	available	JJ
10_1101-2020_01_28_923532	501	32	for	for	IN
10_1101-2020_01_28_923532	501	33	use	use	NN
10_1101-2020_01_28_923532	501	34	under	under	IN
10_1101-2020_01_28_923532	501	35	a	a	DT
10_1101-2020_01_28_923532	501	36	CC0	CC0	NNP
10_1101-2020_01_28_923532	501	37	license	license	NN
10_1101-2020_01_28_923532	501	38	.	.	.
10_1101-2020_01_28_923532	502	1	(	(	-LRB-
10_1101-2020_01_28_923532	502	2	which	which	WDT
10_1101-2020_01_28_923532	502	3	was	be	VBD
10_1101-2020_01_28_923532	502	4	not	not	RB
10_1101-2020_01_28_923532	502	5	certified	certify	VBN
10_1101-2020_01_28_923532	502	6	by	by	IN
10_1101-2020_01_28_923532	502	7	peer	peer	NN
10_1101-2020_01_28_923532	502	8	review	review	NN
10_1101-2020_01_28_923532	502	9	)	)	-RRB-
10_1101-2020_01_28_923532	502	10	is	be	VBZ
10_1101-2020_01_28_923532	502	11	the	the	DT
10_1101-2020_01_28_923532	502	12	author	author	NN
10_1101-2020_01_28_923532	502	13	/	/	SYM
10_1101-2020_01_28_923532	502	14	funder	funder	NN
10_1101-2020_01_28_923532	502	15	.	.	.
10_1101-2020_01_28_923532	503	1	This	this	DT
10_1101-2020_01_28_923532	503	2	article	article	NN
10_1101-2020_01_28_923532	503	3	is	be	VBZ
10_1101-2020_01_28_923532	503	4	a	a	DT
10_1101-2020_01_28_923532	503	5	US	US	NNP
10_1101-2020_01_28_923532	503	6	Government	Government	NNP
10_1101-2020_01_28_923532	503	7	work	work	NN
10_1101-2020_01_28_923532	503	8	.	.	.
10_1101-2020_01_28_923532	504	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	504	2	is	be	VBZ
10_1101-2020_01_28_923532	504	3	not	not	RB
10_1101-2020_01_28_923532	504	4	subject	subject	JJ
10_1101-2020_01_28_923532	504	5	to	to	IN
10_1101-2020_01_28_923532	504	6	copyright	copyright	NN
10_1101-2020_01_28_923532	504	7	under	under	IN
10_1101-2020_01_28_923532	504	8	17	17	CD
10_1101-2020_01_28_923532	504	9	USC	usc	NN
10_1101-2020_01_28_923532	504	10	The	the	DT
10_1101-2020_01_28_923532	504	11	copyright	copyright	NN
10_1101-2020_01_28_923532	504	12	holder	holder	NN
10_1101-2020_01_28_923532	504	13	for	for	IN
10_1101-2020_01_28_923532	504	14	this	this	DT
10_1101-2020_01_28_923532	504	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	504	16	version	version	NN
10_1101-2020_01_28_923532	504	17	posted	post	VBD
10_1101-2020_01_28_923532	504	18	February	February	NNP
10_1101-2020_01_28_923532	504	19	12	12	CD
10_1101-2020_01_28_923532	504	20	,	,	,
10_1101-2020_01_28_923532	504	21	2021	2021	CD
10_1101-2020_01_28_923532	504	22	.	.	.
10_1101-2020_01_28_923532	504	23	;	;	:
10_1101-2020_01_28_923532	504	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	504	25	:	:	:
10_1101-2020_01_28_923532	504	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	504	27	preprint	preprint	NN
10_1101-2020_01_28_923532	504	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	504	29	39	39	CD
10_1101-2020_01_28_923532	504	30	𝑥(𝑔	𝑥(𝑔	CD
10_1101-2020_01_28_923532	504	31	,	,	,
10_1101-2020_01_28_923532	504	32	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	504	33	)	)	-RRB-
10_1101-2020_01_28_923532	504	34	)	)	-RRB-
10_1101-2020_01_28_923532	504	35	≤	≤	NNP
10_1101-2020_01_28_923532	504	36	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	504	37	)	)	-RRB-
10_1101-2020_01_28_923532	504	38	∀𝑖∀𝑔	∀𝑖∀𝑔	CD
10_1101-2020_01_28_923532	504	39	∈	∈	NNP
10_1101-2020_01_28_923532	504	40	𝑈	𝑈	NNP
10_1101-2020_01_28_923532	504	41	(	(	-LRB-
10_1101-2020_01_28_923532	504	42	3	3	CD
10_1101-2020_01_28_923532	504	43	)	)	-RRB-
10_1101-2020_01_28_923532	504	44	∑	∑	.
10_1101-2020_01_28_923532	504	45	𝑔∈𝐶	𝑔∈𝐶	NN
10_1101-2020_01_28_923532	504	46	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	504	47	,	,	,
10_1101-2020_01_28_923532	504	48	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	504	49	)	)	-RRB-
10_1101-2020_01_28_923532	504	50	)	)	-RRB-
10_1101-2020_01_28_923532	504	51	≥	≥	UH
10_1101-2020_01_28_923532	504	52	1	1	CD
10_1101-2020_01_28_923532	504	53	∀𝑖∀𝐶	∀𝑖∀𝐶	NNS
10_1101-2020_01_28_923532	504	54	∈	∈	NNP
10_1101-2020_01_28_923532	504	55	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	504	56	)	)	-RRB-
10_1101-2020_01_28_923532	504	57	(	(	-LRB-
10_1101-2020_01_28_923532	504	58	4	4	LS
10_1101-2020_01_28_923532	504	59	)	)	-RRB-
10_1101-2020_01_28_923532	504	60	Parameterization	parameterization	NN
10_1101-2020_01_28_923532	504	61	of	of	IN
10_1101-2020_01_28_923532	504	62	the	the	DT
10_1101-2020_01_28_923532	504	63	Fair	Fair	NNP
10_1101-2020_01_28_923532	504	64	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	504	65	Target	Target	NNP
10_1101-2020_01_28_923532	504	66	Set	Set	VBD
10_1101-2020_01_28_923532	504	67	Problem	problem	NN
10_1101-2020_01_28_923532	504	68	In	in	IN
10_1101-2020_01_28_923532	504	69	the	the	DT
10_1101-2020_01_28_923532	504	70	Fair	Fair	NNP
10_1101-2020_01_28_923532	504	71	Cohort	Cohort	NNP
10_1101-2020_01_28_923532	504	72	Target	Target	NNP
10_1101-2020_01_28_923532	504	73	Set	Set	NNP
10_1101-2020_01_28_923532	504	74	ILP	ILP	NNP
10_1101-2020_01_28_923532	504	75	shown	show	VBN
10_1101-2020_01_28_923532	504	76	above	above	RB
10_1101-2020_01_28_923532	504	77	,	,	,
10_1101-2020_01_28_923532	504	78	we	-PRON-	PRP
10_1101-2020_01_28_923532	504	79	give	give	VBP
10_1101-2020_01_28_923532	504	80	more	more	JJR
10_1101-2020_01_28_923532	504	81	preference	preference	NN
10_1101-2020_01_28_923532	504	82	towards	towards	IN
10_1101-2020_01_28_923532	504	83	minimizing	minimize	VBG
10_1101-2020_01_28_923532	504	84	number	number	NN
10_1101-2020_01_28_923532	504	85	of	of	IN
10_1101-2020_01_28_923532	504	86	genes	gene	NNS
10_1101-2020_01_28_923532	504	87	needed	need	VBN
10_1101-2020_01_28_923532	504	88	in	in	IN
10_1101-2020_01_28_923532	504	89	the	the	DT
10_1101-2020_01_28_923532	504	90	CTS	CTS	NNP
10_1101-2020_01_28_923532	504	91	.	.	.
10_1101-2020_01_28_923532	505	1	However	however	RB
10_1101-2020_01_28_923532	505	2	,	,	,
10_1101-2020_01_28_923532	505	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	505	4	do	do	VBP
10_1101-2020_01_28_923532	505	5	not	not	RB
10_1101-2020_01_28_923532	505	6	take	take	VB
10_1101-2020_01_28_923532	505	7	into	into	IN
10_1101-2020_01_28_923532	505	8	account	account	NN
10_1101-2020_01_28_923532	505	9	the	the	DT
10_1101-2020_01_28_923532	505	10	number	number	NN
10_1101-2020_01_28_923532	505	11	of	of	IN
10_1101-2020_01_28_923532	505	12	non-	non-	NNP
10_1101-2020_01_28_923532	505	13	tumor	tumor	NN
10_1101-2020_01_28_923532	505	14	cells	cell	NNS
10_1101-2020_01_28_923532	505	15	killed	kill	VBN
10_1101-2020_01_28_923532	505	16	.	.	.
10_1101-2020_01_28_923532	506	1	Killing	kill	VBG
10_1101-2020_01_28_923532	506	2	(	(	-LRB-
10_1101-2020_01_28_923532	506	3	covering	cover	VBG
10_1101-2020_01_28_923532	506	4	)	)	-RRB-
10_1101-2020_01_28_923532	506	5	too	too	RB
10_1101-2020_01_28_923532	506	6	many	many	JJ
10_1101-2020_01_28_923532	506	7	non	non	JJ
10_1101-2020_01_28_923532	506	8	-	-	JJ
10_1101-2020_01_28_923532	506	9	tumor	tumor	JJ
10_1101-2020_01_28_923532	506	10	cells	cell	NNS
10_1101-2020_01_28_923532	506	11	potentially	potentially	RB
10_1101-2020_01_28_923532	506	12	hurts	hurt	VBZ
10_1101-2020_01_28_923532	506	13	patients	patient	NNS
10_1101-2020_01_28_923532	506	14	.	.	.
10_1101-2020_01_28_923532	507	1	In	in	IN
10_1101-2020_01_28_923532	507	2	order	order	NN
10_1101-2020_01_28_923532	507	3	to	to	TO
10_1101-2020_01_28_923532	507	4	avoid	avoid	VB
10_1101-2020_01_28_923532	507	5	that	that	DT
10_1101-2020_01_28_923532	507	6	,	,	,
10_1101-2020_01_28_923532	507	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	507	8	add	add	VBP
10_1101-2020_01_28_923532	507	9	an	an	DT
10_1101-2020_01_28_923532	507	10	additional	additional	JJ
10_1101-2020_01_28_923532	507	11	constraint	constraint	NN
10_1101-2020_01_28_923532	507	12	to	to	IN
10_1101-2020_01_28_923532	507	13	both	both	PDT
10_1101-2020_01_28_923532	507	14	the	the	DT
10_1101-2020_01_28_923532	507	15	ILP	ILP	NNP
10_1101-2020_01_28_923532	507	16	for	for	IN
10_1101-2020_01_28_923532	507	17	the	the	DT
10_1101-2020_01_28_923532	507	18	local	local	JJ
10_1101-2020_01_28_923532	507	19	instances	instance	NNS
10_1101-2020_01_28_923532	507	20	and	and	CC
10_1101-2020_01_28_923532	507	21	the	the	DT
10_1101-2020_01_28_923532	507	22	global	global	JJ
10_1101-2020_01_28_923532	507	23	instance	instance	NN
10_1101-2020_01_28_923532	507	24	.	.	.
10_1101-2020_01_28_923532	508	1	Intuitively	intuitively	RB
10_1101-2020_01_28_923532	508	2	,	,	,
10_1101-2020_01_28_923532	508	3	for	for	IN
10_1101-2020_01_28_923532	508	4	patient	patient	JJ
10_1101-2020_01_28_923532	508	5	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	508	6	)	)	-RRB-
10_1101-2020_01_28_923532	508	7	,	,	,
10_1101-2020_01_28_923532	508	8	given	give	VBN
10_1101-2020_01_28_923532	508	9	an	an	DT
10_1101-2020_01_28_923532	508	10	upper	upper	JJ
10_1101-2020_01_28_923532	508	11	bound	bound	NN
10_1101-2020_01_28_923532	508	12	of	of	IN
10_1101-2020_01_28_923532	508	13	the	the	DT
10_1101-2020_01_28_923532	508	14	portion	portion	NN
10_1101-2020_01_28_923532	508	15	of	of	IN
10_1101-2020_01_28_923532	508	16	the	the	DT
10_1101-2020_01_28_923532	508	17	non-	non-	NNP
10_1101-2020_01_28_923532	508	18	tumor	tumor	NNP
10_1101-2020_01_28_923532	508	19	cell	cell	NN
10_1101-2020_01_28_923532	508	20	killed	kill	VBD
10_1101-2020_01_28_923532	508	21	𝑈𝐵	𝑈𝐵	NN
10_1101-2020_01_28_923532	508	22	,	,	,
10_1101-2020_01_28_923532	508	23	we	-PRON-	PRP
10_1101-2020_01_28_923532	508	24	want	want	VBP
10_1101-2020_01_28_923532	508	25	to	to	TO
10_1101-2020_01_28_923532	508	26	find	find	VB
10_1101-2020_01_28_923532	508	27	the	the	DT
10_1101-2020_01_28_923532	508	28	smallest	small	JJS
10_1101-2020_01_28_923532	508	29	cohort	cohort	NN
10_1101-2020_01_28_923532	508	30	target	target	NN
10_1101-2020_01_28_923532	508	31	set	set	VBD
10_1101-2020_01_28_923532	508	32	𝐻(𝑖	𝐻(𝑖	CD
10_1101-2020_01_28_923532	508	33	)	)	-RRB-
10_1101-2020_01_28_923532	508	34	with	with	IN
10_1101-2020_01_28_923532	508	35	the	the	DT
10_1101-2020_01_28_923532	508	36	following	follow	VBG
10_1101-2020_01_28_923532	508	37	properties	property	NNS
10_1101-2020_01_28_923532	508	38	:	:	:
10_1101-2020_01_28_923532	508	39	1	1	CD
10_1101-2020_01_28_923532	508	40	.	.	.
10_1101-2020_01_28_923532	509	1	𝐻(𝑖	𝐻(𝑖	ADD
10_1101-2020_01_28_923532	509	2	)	)	-RRB-
10_1101-2020_01_28_923532	509	3	covers	cover	VBZ
10_1101-2020_01_28_923532	509	4	all	all	PDT
10_1101-2020_01_28_923532	509	5	the	the	DT
10_1101-2020_01_28_923532	509	6	tumor	tumor	NN
10_1101-2020_01_28_923532	509	7	cells	cell	NNS
10_1101-2020_01_28_923532	509	8	of	of	IN
10_1101-2020_01_28_923532	509	9	patient	patient	JJ
10_1101-2020_01_28_923532	509	10	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	509	11	)	)	-RRB-
10_1101-2020_01_28_923532	509	12	.	.	.
10_1101-2020_01_28_923532	510	1	2	2	LS
10_1101-2020_01_28_923532	510	2	.	.	.
10_1101-2020_01_28_923532	511	1	𝐻(𝑖	𝐻(𝑖	ADD
10_1101-2020_01_28_923532	511	2	)	)	-RRB-
10_1101-2020_01_28_923532	511	3	covers	cover	VBZ
10_1101-2020_01_28_923532	511	4	at	at	IN
10_1101-2020_01_28_923532	511	5	most	most	JJS
10_1101-2020_01_28_923532	511	6	𝑈𝐵	𝑈𝐵	NN
10_1101-2020_01_28_923532	511	7	∗	∗	NNP
10_1101-2020_01_28_923532	511	8	|𝑁𝑇𝑃(𝑖)|	|𝑁𝑇𝑃(𝑖)|	NN
10_1101-2020_01_28_923532	511	9	where	where	WRB
10_1101-2020_01_28_923532	511	10	𝑁𝑇𝑃(𝑖	𝑁𝑇𝑃(𝑖	JJ
10_1101-2020_01_28_923532	511	11	)	)	-RRB-
10_1101-2020_01_28_923532	511	12	is	be	VBZ
10_1101-2020_01_28_923532	511	13	the	the	DT
10_1101-2020_01_28_923532	511	14	set	set	NN
10_1101-2020_01_28_923532	511	15	of	of	IN
10_1101-2020_01_28_923532	511	16	non	non	JJ
10_1101-2020_01_28_923532	511	17	-	-	JJ
10_1101-2020_01_28_923532	511	18	tumor	tumor	JJ
10_1101-2020_01_28_923532	511	19	cells	cell	NNS
10_1101-2020_01_28_923532	511	20	known	know	VBN
10_1101-2020_01_28_923532	511	21	for	for	IN
10_1101-2020_01_28_923532	511	22	patient	patient	JJ
10_1101-2020_01_28_923532	511	23	𝑃(𝑖	𝑃(𝑖	NNP
10_1101-2020_01_28_923532	511	24	)	)	-RRB-
10_1101-2020_01_28_923532	511	25	;	;	:
10_1101-2020_01_28_923532	511	26	the	the	DT
10_1101-2020_01_28_923532	511	27	number	number	NN
10_1101-2020_01_28_923532	511	28	of	of	IN
10_1101-2020_01_28_923532	511	29	non	non	JJ
10_1101-2020_01_28_923532	511	30	-	-	JJ
10_1101-2020_01_28_923532	511	31	tumor	tumor	JJ
10_1101-2020_01_28_923532	511	32	cells	cell	NNS
10_1101-2020_01_28_923532	511	33	killed	kill	VBN
10_1101-2020_01_28_923532	511	34	is	be	VBZ
10_1101-2020_01_28_923532	511	35	represented	represent	VBN
10_1101-2020_01_28_923532	511	36	by	by	IN
10_1101-2020_01_28_923532	511	37	the	the	DT
10_1101-2020_01_28_923532	511	38	variable	variable	JJ
10_1101-2020_01_28_923532	511	39	𝑦.	𝑦.	NNP
10_1101-2020_01_28_923532	512	1	The	the	DT
10_1101-2020_01_28_923532	512	2	ILP	ILP	NNP
10_1101-2020_01_28_923532	512	3	can	can	MD
10_1101-2020_01_28_923532	512	4	be	be	VB
10_1101-2020_01_28_923532	512	5	formulated	formulate	VBN
10_1101-2020_01_28_923532	512	6	as	as	IN
10_1101-2020_01_28_923532	512	7	follows	follow	VBZ
10_1101-2020_01_28_923532	512	8	:	:	:
10_1101-2020_01_28_923532	512	9	𝑚𝑖𝑛	𝑚𝑖𝑛	NN
10_1101-2020_01_28_923532	512	10	∑	∑	XX
10_1101-2020_01_28_923532	512	11	𝑔∈𝑈	𝑔∈𝑈	NFP
10_1101-2020_01_28_923532	512	12	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	512	13	)	)	-RRB-
10_1101-2020_01_28_923532	512	14	(	(	-LRB-
10_1101-2020_01_28_923532	512	15	1	1	CD
10_1101-2020_01_28_923532	512	16	)	)	-RRB-
10_1101-2020_01_28_923532	512	17	∑	∑	.
10_1101-2020_01_28_923532	512	18	𝑔∈𝐶	𝑔∈𝐶	VBZ
10_1101-2020_01_28_923532	512	19	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	512	20	)	)	-RRB-
10_1101-2020_01_28_923532	512	21	≥	≥	NN
10_1101-2020_01_28_923532	512	22	1	1	CD
10_1101-2020_01_28_923532	512	23	∀𝐶	∀𝐶	NN
10_1101-2020_01_28_923532	512	24	∈	∈	NNP
10_1101-2020_01_28_923532	512	25	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	512	26	)	)	-RRB-
10_1101-2020_01_28_923532	512	27	(	(	-LRB-
10_1101-2020_01_28_923532	512	28	2	2	LS
10_1101-2020_01_28_923532	512	29	)	)	-RRB-
10_1101-2020_01_28_923532	512	30	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	512	31	)	)	-RRB-
10_1101-2020_01_28_923532	512	32	≥	≥	UH
10_1101-2020_01_28_923532	512	33	𝑚𝑎𝑥	𝑚𝑎𝑥	FW
10_1101-2020_01_28_923532	512	34	𝑔∈𝐶	𝑔∈𝐶	NNP
10_1101-2020_01_28_923532	512	35	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	512	36	)	)	-RRB-
10_1101-2020_01_28_923532	512	37	∀𝐶	∀𝐶	CD
10_1101-2020_01_28_923532	512	38	∈	∈	UH
10_1101-2020_01_28_923532	512	39	𝑁𝑇𝑃(𝑖	𝑁𝑇𝑃(𝑖	NN
10_1101-2020_01_28_923532	512	40	)	)	-RRB-
10_1101-2020_01_28_923532	512	41	(	(	-LRB-
10_1101-2020_01_28_923532	512	42	3	3	LS
10_1101-2020_01_28_923532	512	43	)	)	-RRB-
10_1101-2020_01_28_923532	512	44	∑	∑	.
10_1101-2020_01_28_923532	512	45	𝐶	𝐶	NN
10_1101-2020_01_28_923532	512	46	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	512	47	)	)	-RRB-
10_1101-2020_01_28_923532	512	48	≤	≤	NNP
10_1101-2020_01_28_923532	512	49	𝑈𝐵	𝑈𝐵	NNP
10_1101-2020_01_28_923532	512	50	∗	∗	NNP
10_1101-2020_01_28_923532	512	51	|𝑁𝑇𝑃(𝑖)|	|𝑁𝑇𝑃(𝑖)|	NNP
10_1101-2020_01_28_923532	512	52	∀𝐶	∀𝐶	NNP
10_1101-2020_01_28_923532	512	53	∈	∈	UH
10_1101-2020_01_28_923532	512	54	𝑁𝑇𝑃(𝑖	𝑁𝑇𝑃(𝑖	NN
10_1101-2020_01_28_923532	512	55	)	)	-RRB-
10_1101-2020_01_28_923532	512	56	(	(	-LRB-
10_1101-2020_01_28_923532	512	57	4	4	LS
10_1101-2020_01_28_923532	512	58	)	)	-RRB-
10_1101-2020_01_28_923532	512	59	With	with	IN
10_1101-2020_01_28_923532	512	60	this	this	DT
10_1101-2020_01_28_923532	512	61	formulation	formulation	NN
10_1101-2020_01_28_923532	512	62	,	,	,
10_1101-2020_01_28_923532	512	63	the	the	DT
10_1101-2020_01_28_923532	512	64	existence	existence	NN
10_1101-2020_01_28_923532	512	65	of	of	IN
10_1101-2020_01_28_923532	512	66	a	a	DT
10_1101-2020_01_28_923532	512	67	feasible	feasible	JJ
10_1101-2020_01_28_923532	512	68	solution	solution	NN
10_1101-2020_01_28_923532	512	69	is	be	VBZ
10_1101-2020_01_28_923532	512	70	not	not	RB
10_1101-2020_01_28_923532	512	71	guaranteed	guarantee	VBN
10_1101-2020_01_28_923532	512	72	.	.	.
10_1101-2020_01_28_923532	513	1	However	however	RB
10_1101-2020_01_28_923532	513	2	,	,	,
10_1101-2020_01_28_923532	513	3	covering	cover	VBG
10_1101-2020_01_28_923532	513	4	all	all	DT
10_1101-2020_01_28_923532	513	5	tumor	tumor	NN
10_1101-2020_01_28_923532	513	6	cells	cell	NNS
10_1101-2020_01_28_923532	513	7	might	may	MD
10_1101-2020_01_28_923532	513	8	not	not	RB
10_1101-2020_01_28_923532	513	9	always	always	RB
10_1101-2020_01_28_923532	513	10	be	be	VB
10_1101-2020_01_28_923532	513	11	necessary	necessary	JJ
10_1101-2020_01_28_923532	513	12	either	either	RB
10_1101-2020_01_28_923532	513	13	.	.	.
10_1101-2020_01_28_923532	514	1	This	this	DT
10_1101-2020_01_28_923532	514	2	statement	statement	NN
10_1101-2020_01_28_923532	514	3	can	can	MD
10_1101-2020_01_28_923532	514	4	be	be	VB
10_1101-2020_01_28_923532	514	5	justified	justify	VBN
10_1101-2020_01_28_923532	514	6	as	as	IN
10_1101-2020_01_28_923532	514	7	(	(	-LRB-
10_1101-2020_01_28_923532	514	8	1	1	CD
10_1101-2020_01_28_923532	514	9	)	)	-RRB-
10_1101-2020_01_28_923532	514	10	measuring	measure	VBG
10_1101-2020_01_28_923532	514	11	data	datum	NNS
10_1101-2020_01_28_923532	514	12	is	be	VBZ
10_1101-2020_01_28_923532	514	13	not	not	RB
10_1101-2020_01_28_923532	514	14	always	always	RB
10_1101-2020_01_28_923532	514	15	accurate	accurate	JJ
10_1101-2020_01_28_923532	514	16	,	,	,
10_1101-2020_01_28_923532	514	17	and	and	CC
10_1101-2020_01_28_923532	514	18	some	some	DT
10_1101-2020_01_28_923532	514	19	tumor	tumor	NN
10_1101-2020_01_28_923532	514	20	cells	cell	NNS
10_1101-2020_01_28_923532	514	21	could	could	MD
10_1101-2020_01_28_923532	514	22	be	be	VB
10_1101-2020_01_28_923532	514	23	missing	miss	VBG
10_1101-2020_01_28_923532	514	24	and	and	CC
10_1101-2020_01_28_923532	514	25	(	(	-LRB-
10_1101-2020_01_28_923532	514	26	2	2	LS
10_1101-2020_01_28_923532	514	27	)	)	-RRB-
10_1101-2020_01_28_923532	514	28	in	in	IN
10_1101-2020_01_28_923532	514	29	some	some	DT
10_1101-2020_01_28_923532	514	30	cases	case	NNS
10_1101-2020_01_28_923532	514	31	,	,	,
10_1101-2020_01_28_923532	514	32	it	-PRON-	PRP
10_1101-2020_01_28_923532	514	33	might	may	MD
10_1101-2020_01_28_923532	514	34	be	be	VB
10_1101-2020_01_28_923532	514	35	possible	possible	JJ
10_1101-2020_01_28_923532	514	36	to	to	TO
10_1101-2020_01_28_923532	514	37	handle	handle	VB
10_1101-2020_01_28_923532	514	38	uncovered	uncovered	JJ
10_1101-2020_01_28_923532	514	39	tumor	tumor	NN
10_1101-2020_01_28_923532	514	40	cells	cell	NNS
10_1101-2020_01_28_923532	514	41	using	use	VBG
10_1101-2020_01_28_923532	514	42	different	different	JJ
10_1101-2020_01_28_923532	514	43	methods	method	NNS
10_1101-2020_01_28_923532	514	44	.	.	.
10_1101-2020_01_28_923532	515	1	Hence	hence	RB
10_1101-2020_01_28_923532	515	2	,	,	,
10_1101-2020_01_28_923532	515	3	we	-PRON-	PRP
10_1101-2020_01_28_923532	515	4	add	add	VBP
10_1101-2020_01_28_923532	515	5	another	another	DT
10_1101-2020_01_28_923532	515	6	parameter	parameter	NN
10_1101-2020_01_28_923532	515	7	𝐿𝐵	𝐿𝐵	NN
10_1101-2020_01_28_923532	515	8	to	to	TO
10_1101-2020_01_28_923532	515	9	let	let	VB
10_1101-2020_01_28_923532	515	10	us	-PRON-	PRP
10_1101-2020_01_28_923532	515	11	model	model	VB
10_1101-2020_01_28_923532	515	12	this	this	DT
10_1101-2020_01_28_923532	515	13	scenario	scenario	NN
10_1101-2020_01_28_923532	515	14	.	.	.
10_1101-2020_01_28_923532	516	1	In	in	IN
10_1101-2020_01_28_923532	516	2	the	the	DT
10_1101-2020_01_28_923532	516	3	high	high	JJ
10_1101-2020_01_28_923532	516	4	-	-	HYPH
10_1101-2020_01_28_923532	516	5	level	level	NN
10_1101-2020_01_28_923532	516	6	,	,	,
10_1101-2020_01_28_923532	516	7	this	this	DT
10_1101-2020_01_28_923532	516	8	is	be	VBZ
10_1101-2020_01_28_923532	516	9	the	the	DT
10_1101-2020_01_28_923532	516	10	ratio	ratio	NN
10_1101-2020_01_28_923532	516	11	of	of	IN
10_1101-2020_01_28_923532	516	12	the	the	DT
10_1101-2020_01_28_923532	516	13	tumor	tumor	NN
10_1101-2020_01_28_923532	516	14	cells	cell	NNS
10_1101-2020_01_28_923532	516	15	we	-PRON-	PRP
10_1101-2020_01_28_923532	516	16	want	want	VBP
10_1101-2020_01_28_923532	516	17	to	to	TO
10_1101-2020_01_28_923532	516	18	cover	cover	VB
10_1101-2020_01_28_923532	516	19	.	.	.
10_1101-2020_01_28_923532	517	1	The	the	DT
10_1101-2020_01_28_923532	517	2	ILP	ILP	NNP
10_1101-2020_01_28_923532	517	3	can	can	MD
10_1101-2020_01_28_923532	517	4	be	be	VB
10_1101-2020_01_28_923532	517	5	formulated	formulate	VBN
10_1101-2020_01_28_923532	517	6	as	as	IN
10_1101-2020_01_28_923532	517	7	follows	follow	VBZ
10_1101-2020_01_28_923532	517	8	:	:	:
10_1101-2020_01_28_923532	517	9	𝑚𝑖𝑛	𝑚𝑖𝑛	NN
10_1101-2020_01_28_923532	517	10	∑	∑	XX
10_1101-2020_01_28_923532	517	11	𝑔∈𝑈	𝑔∈𝑈	NFP
10_1101-2020_01_28_923532	517	12	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	517	13	)	)	-RRB-
10_1101-2020_01_28_923532	517	14	(	(	-LRB-
10_1101-2020_01_28_923532	517	15	1	1	CD
10_1101-2020_01_28_923532	517	16	)	)	-RRB-
10_1101-2020_01_28_923532	517	17	105	105	CD
10_1101-2020_01_28_923532	517	18	and	and	CC
10_1101-2020_01_28_923532	517	19	is	be	VBZ
10_1101-2020_01_28_923532	517	20	also	also	RB
10_1101-2020_01_28_923532	517	21	made	make	VBN
10_1101-2020_01_28_923532	517	22	available	available	JJ
10_1101-2020_01_28_923532	517	23	for	for	IN
10_1101-2020_01_28_923532	517	24	use	use	NN
10_1101-2020_01_28_923532	517	25	under	under	IN
10_1101-2020_01_28_923532	517	26	a	a	DT
10_1101-2020_01_28_923532	517	27	CC0	CC0	NNP
10_1101-2020_01_28_923532	517	28	license	license	NN
10_1101-2020_01_28_923532	517	29	.	.	.
10_1101-2020_01_28_923532	518	1	(	(	-LRB-
10_1101-2020_01_28_923532	518	2	which	which	WDT
10_1101-2020_01_28_923532	518	3	was	be	VBD
10_1101-2020_01_28_923532	518	4	not	not	RB
10_1101-2020_01_28_923532	518	5	certified	certify	VBN
10_1101-2020_01_28_923532	518	6	by	by	IN
10_1101-2020_01_28_923532	518	7	peer	peer	NN
10_1101-2020_01_28_923532	518	8	review	review	NN
10_1101-2020_01_28_923532	518	9	)	)	-RRB-
10_1101-2020_01_28_923532	518	10	is	be	VBZ
10_1101-2020_01_28_923532	518	11	the	the	DT
10_1101-2020_01_28_923532	518	12	author	author	NN
10_1101-2020_01_28_923532	518	13	/	/	SYM
10_1101-2020_01_28_923532	518	14	funder	funder	NN
10_1101-2020_01_28_923532	518	15	.	.	.
10_1101-2020_01_28_923532	519	1	This	this	DT
10_1101-2020_01_28_923532	519	2	article	article	NN
10_1101-2020_01_28_923532	519	3	is	be	VBZ
10_1101-2020_01_28_923532	519	4	a	a	DT
10_1101-2020_01_28_923532	519	5	US	US	NNP
10_1101-2020_01_28_923532	519	6	Government	Government	NNP
10_1101-2020_01_28_923532	519	7	work	work	NN
10_1101-2020_01_28_923532	519	8	.	.	.
10_1101-2020_01_28_923532	520	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	520	2	is	be	VBZ
10_1101-2020_01_28_923532	520	3	not	not	RB
10_1101-2020_01_28_923532	520	4	subject	subject	JJ
10_1101-2020_01_28_923532	520	5	to	to	IN
10_1101-2020_01_28_923532	520	6	copyright	copyright	NN
10_1101-2020_01_28_923532	520	7	under	under	IN
10_1101-2020_01_28_923532	520	8	17	17	CD
10_1101-2020_01_28_923532	520	9	USC	usc	NN
10_1101-2020_01_28_923532	520	10	The	the	DT
10_1101-2020_01_28_923532	520	11	copyright	copyright	NN
10_1101-2020_01_28_923532	520	12	holder	holder	NN
10_1101-2020_01_28_923532	520	13	for	for	IN
10_1101-2020_01_28_923532	520	14	this	this	DT
10_1101-2020_01_28_923532	520	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	520	16	version	version	NN
10_1101-2020_01_28_923532	520	17	posted	post	VBD
10_1101-2020_01_28_923532	520	18	February	February	NNP
10_1101-2020_01_28_923532	520	19	12	12	CD
10_1101-2020_01_28_923532	520	20	,	,	,
10_1101-2020_01_28_923532	520	21	2021	2021	CD
10_1101-2020_01_28_923532	520	22	.	.	.
10_1101-2020_01_28_923532	520	23	;	;	:
10_1101-2020_01_28_923532	520	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	520	25	:	:	:
10_1101-2020_01_28_923532	520	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	520	27	preprint	preprint	NN
10_1101-2020_01_28_923532	520	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	520	29	40	40	CD
10_1101-2020_01_28_923532	520	30	∑	∑	CD
10_1101-2020_01_28_923532	520	31	𝐶	𝐶	NN
10_1101-2020_01_28_923532	520	32	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	520	33	)	)	-RRB-
10_1101-2020_01_28_923532	520	34	≥	≥	UH
10_1101-2020_01_28_923532	520	35	𝐿𝐵	𝐿𝐵	NNP
10_1101-2020_01_28_923532	520	36	∗	∗	NNP
10_1101-2020_01_28_923532	520	37	|𝑆𝑃(𝑖)|	|𝑆𝑃(𝑖)|	NNP
10_1101-2020_01_28_923532	520	38	∀𝐶	∀𝐶	CD
10_1101-2020_01_28_923532	520	39	∈	∈	NNP
10_1101-2020_01_28_923532	520	40	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	520	41	)	)	-RRB-
10_1101-2020_01_28_923532	520	42	(	(	-LRB-
10_1101-2020_01_28_923532	520	43	2	2	LS
10_1101-2020_01_28_923532	520	44	)	)	-RRB-
10_1101-2020_01_28_923532	520	45	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	520	46	)	)	-RRB-
10_1101-2020_01_28_923532	520	47	≥	≥	UH
10_1101-2020_01_28_923532	520	48	𝑚𝑎𝑥	𝑚𝑎𝑥	FW
10_1101-2020_01_28_923532	520	49	𝑔∈𝐶	𝑔∈𝐶	NNP
10_1101-2020_01_28_923532	520	50	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	520	51	)	)	-RRB-
10_1101-2020_01_28_923532	520	52	∀𝐶	∀𝐶	ADD
10_1101-2020_01_28_923532	520	53	∈	∈	NNP
10_1101-2020_01_28_923532	520	54	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	520	55	)	)	-RRB-
10_1101-2020_01_28_923532	520	56	∪	∪	NNP
10_1101-2020_01_28_923532	520	57	𝑁𝑇𝑃(𝑖	𝑁𝑇𝑃(𝑖	NN
10_1101-2020_01_28_923532	520	58	)	)	-RRB-
10_1101-2020_01_28_923532	520	59	(	(	-LRB-
10_1101-2020_01_28_923532	520	60	3	3	LS
10_1101-2020_01_28_923532	520	61	)	)	-RRB-
10_1101-2020_01_28_923532	520	62	∑	∑	.
10_1101-2020_01_28_923532	520	63	𝐶	𝐶	NN
10_1101-2020_01_28_923532	520	64	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	520	65	)	)	-RRB-
10_1101-2020_01_28_923532	520	66	≤	≤	NNP
10_1101-2020_01_28_923532	520	67	𝑈𝐵	𝑈𝐵	NNP
10_1101-2020_01_28_923532	520	68	∗	∗	NNP
10_1101-2020_01_28_923532	520	69	|𝑁𝑇𝑃(𝑖)|	|𝑁𝑇𝑃(𝑖)|	NNP
10_1101-2020_01_28_923532	520	70	∀𝐶	∀𝐶	NNP
10_1101-2020_01_28_923532	520	71	∈	∈	UH
10_1101-2020_01_28_923532	520	72	𝑁𝑇𝑃(𝑖	𝑁𝑇𝑃(𝑖	NN
10_1101-2020_01_28_923532	520	73	)	)	-RRB-
10_1101-2020_01_28_923532	520	74	(	(	-LRB-
10_1101-2020_01_28_923532	520	75	4	4	LS
10_1101-2020_01_28_923532	520	76	)	)	-RRB-
10_1101-2020_01_28_923532	520	77	Notice	notice	VB
10_1101-2020_01_28_923532	520	78	that	that	IN
10_1101-2020_01_28_923532	520	79	the	the	DT
10_1101-2020_01_28_923532	520	80	constraint	constraint	NN
10_1101-2020_01_28_923532	520	81	(	(	-LRB-
10_1101-2020_01_28_923532	520	82	2	2	LS
10_1101-2020_01_28_923532	520	83	)	)	-RRB-
10_1101-2020_01_28_923532	520	84	here	here	RB
10_1101-2020_01_28_923532	520	85	is	be	VBZ
10_1101-2020_01_28_923532	520	86	different	different	JJ
10_1101-2020_01_28_923532	520	87	from	from	IN
10_1101-2020_01_28_923532	520	88	the	the	DT
10_1101-2020_01_28_923532	520	89	one	one	NN
10_1101-2020_01_28_923532	520	90	above	above	IN
10_1101-2020_01_28_923532	520	91	as	as	IN
10_1101-2020_01_28_923532	520	92	we	-PRON-	PRP
10_1101-2020_01_28_923532	520	93	only	only	RB
10_1101-2020_01_28_923532	520	94	care	care	VBP
10_1101-2020_01_28_923532	520	95	about	about	IN
10_1101-2020_01_28_923532	520	96	the	the	DT
10_1101-2020_01_28_923532	520	97	total	total	JJ
10_1101-2020_01_28_923532	520	98	number	number	NN
10_1101-2020_01_28_923532	520	99	of	of	IN
10_1101-2020_01_28_923532	520	100	tumor	tumor	NN
10_1101-2020_01_28_923532	520	101	cells	cell	NNS
10_1101-2020_01_28_923532	520	102	covered	cover	VBN
10_1101-2020_01_28_923532	520	103	.	.	.
10_1101-2020_01_28_923532	521	1	Even	even	RB
10_1101-2020_01_28_923532	521	2	with	with	IN
10_1101-2020_01_28_923532	521	3	both	both	CC
10_1101-2020_01_28_923532	521	4	𝑈𝐵	𝑈𝐵	NN
10_1101-2020_01_28_923532	521	5	and	and	CC
10_1101-2020_01_28_923532	521	6	𝐿𝐵	𝐿𝐵	NNP
10_1101-2020_01_28_923532	521	7	,	,	,
10_1101-2020_01_28_923532	521	8	the	the	DT
10_1101-2020_01_28_923532	521	9	feasibility	feasibility	NN
10_1101-2020_01_28_923532	521	10	of	of	IN
10_1101-2020_01_28_923532	521	11	the	the	DT
10_1101-2020_01_28_923532	521	12	ILP	ILP	NNP
10_1101-2020_01_28_923532	521	13	is	be	VBZ
10_1101-2020_01_28_923532	521	14	still	still	RB
10_1101-2020_01_28_923532	521	15	not	not	RB
10_1101-2020_01_28_923532	521	16	guaranteed	guarantee	VBN
10_1101-2020_01_28_923532	521	17	.	.	.
10_1101-2020_01_28_923532	522	1	However	however	RB
10_1101-2020_01_28_923532	522	2	,	,	,
10_1101-2020_01_28_923532	522	3	modeling	model	VBG
10_1101-2020_01_28_923532	522	4	the	the	DT
10_1101-2020_01_28_923532	522	5	ILP	ILP	NNP
10_1101-2020_01_28_923532	522	6	in	in	IN
10_1101-2020_01_28_923532	522	7	this	this	DT
10_1101-2020_01_28_923532	522	8	way	way	NN
10_1101-2020_01_28_923532	522	9	allows	allow	VBZ
10_1101-2020_01_28_923532	522	10	us	-PRON-	PRP
10_1101-2020_01_28_923532	522	11	to	to	TO
10_1101-2020_01_28_923532	522	12	parameterize	parameterize	VB
10_1101-2020_01_28_923532	522	13	the	the	DT
10_1101-2020_01_28_923532	522	14	ILP	ILP	NNP
10_1101-2020_01_28_923532	522	15	for	for	IN
10_1101-2020_01_28_923532	522	16	various	various	JJ
10_1101-2020_01_28_923532	522	17	other	other	JJ
10_1101-2020_01_28_923532	522	18	scenarios	scenario	NNS
10_1101-2020_01_28_923532	522	19	of	of	IN
10_1101-2020_01_28_923532	522	20	interest	interest	NN
10_1101-2020_01_28_923532	522	21	.	.	.
10_1101-2020_01_28_923532	523	1	While	while	IN
10_1101-2020_01_28_923532	523	2	the	the	DT
10_1101-2020_01_28_923532	523	3	two	two	CD
10_1101-2020_01_28_923532	523	4	ILPs	ilp	NNS
10_1101-2020_01_28_923532	523	5	above	above	RB
10_1101-2020_01_28_923532	523	6	are	be	VBP
10_1101-2020_01_28_923532	523	7	designed	design	VBN
10_1101-2020_01_28_923532	523	8	for	for	IN
10_1101-2020_01_28_923532	523	9	one	one	CD
10_1101-2020_01_28_923532	523	10	patient	patient	NN
10_1101-2020_01_28_923532	523	11	,	,	,
10_1101-2020_01_28_923532	523	12	one	one	PRP
10_1101-2020_01_28_923532	523	13	can	can	MD
10_1101-2020_01_28_923532	523	14	extend	extend	VB
10_1101-2020_01_28_923532	523	15	these	these	DT
10_1101-2020_01_28_923532	523	16	ILPs	ilp	NNS
10_1101-2020_01_28_923532	523	17	for	for	IN
10_1101-2020_01_28_923532	523	18	multi	multi	JJ
10_1101-2020_01_28_923532	523	19	-	-	JJ
10_1101-2020_01_28_923532	523	20	patient	patient	JJ
10_1101-2020_01_28_923532	523	21	cohort	cohort	NN
10_1101-2020_01_28_923532	523	22	.	.	.
10_1101-2020_01_28_923532	524	1	𝑚𝑖𝑛	𝑚𝑖𝑛	NNP
10_1101-2020_01_28_923532	524	2	∑	∑	XX
10_1101-2020_01_28_923532	524	3	𝑔∈𝑈	𝑔∈𝑈	NNP
10_1101-2020_01_28_923532	524	4	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	524	5	)	)	-RRB-
10_1101-2020_01_28_923532	524	6	(	(	-LRB-
10_1101-2020_01_28_923532	524	7	1	1	CD
10_1101-2020_01_28_923532	524	8	)	)	-RRB-
10_1101-2020_01_28_923532	524	9	∑	∑	.
10_1101-2020_01_28_923532	524	10	𝑔∈𝐶	𝑔∈𝐶	NN
10_1101-2020_01_28_923532	524	11	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	524	12	,	,	,
10_1101-2020_01_28_923532	524	13	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	524	14	)	)	-RRB-
10_1101-2020_01_28_923532	524	15	)	)	-RRB-
10_1101-2020_01_28_923532	524	16	≤	≤	NNP
10_1101-2020_01_28_923532	524	17	𝐻(𝑖	𝐻(𝑖	CD
10_1101-2020_01_28_923532	524	18	)	)	-RRB-
10_1101-2020_01_28_923532	524	19	+	+	CC
10_1101-2020_01_28_923532	524	20	𝛼	𝛼	LS
10_1101-2020_01_28_923532	524	21	∀𝑖∀𝐶	∀𝑖∀𝐶	NNS
10_1101-2020_01_28_923532	524	22	∈	∈	NNP
10_1101-2020_01_28_923532	524	23	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	524	24	)	)	-RRB-
10_1101-2020_01_28_923532	524	25	(	(	-LRB-
10_1101-2020_01_28_923532	524	26	2	2	LS
10_1101-2020_01_28_923532	524	27	)	)	-RRB-
10_1101-2020_01_28_923532	524	28	𝑥(𝑔	𝑥(𝑔	NN
10_1101-2020_01_28_923532	524	29	,	,	,
10_1101-2020_01_28_923532	524	30	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	524	31	)	)	-RRB-
10_1101-2020_01_28_923532	524	32	)	)	-RRB-
10_1101-2020_01_28_923532	524	33	≤	≤	NNP
10_1101-2020_01_28_923532	524	34	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	524	35	)	)	-RRB-
10_1101-2020_01_28_923532	524	36	∀𝑖	∀𝑖	CD
10_1101-2020_01_28_923532	524	37	,	,	,
10_1101-2020_01_28_923532	524	38	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	524	39	∈	∈	NNP
10_1101-2020_01_28_923532	524	40	𝑈	𝑈	NNP
10_1101-2020_01_28_923532	524	41	(	(	-LRB-
10_1101-2020_01_28_923532	524	42	3	3	CD
10_1101-2020_01_28_923532	524	43	)	)	-RRB-
10_1101-2020_01_28_923532	524	44	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	524	45	,	,	,
10_1101-2020_01_28_923532	524	46	𝑃𝑃(𝑖	𝑃𝑃(𝑖	NNP
10_1101-2020_01_28_923532	524	47	)	)	-RRB-
10_1101-2020_01_28_923532	524	48	)	)	-RRB-
10_1101-2020_01_28_923532	524	49	≥	≥	UH
10_1101-2020_01_28_923532	524	50	𝑚𝑎𝑥	𝑚𝑎𝑥	FW
10_1101-2020_01_28_923532	524	51	𝑔	𝑔	NNP
10_1101-2020_01_28_923532	524	52	∈𝐶	∈𝐶	NN
10_1101-2020_01_28_923532	524	53	𝑥(𝑔	𝑥(𝑔	NNP
10_1101-2020_01_28_923532	524	54	,	,	,
10_1101-2020_01_28_923532	524	55	𝑃(𝑖	𝑃(𝑖	CD
10_1101-2020_01_28_923532	524	56	)	)	-RRB-
10_1101-2020_01_28_923532	524	57	)	)	-RRB-
10_1101-2020_01_28_923532	524	58	∀𝑖∀𝐶	∀𝑖∀𝐶	VB
10_1101-2020_01_28_923532	524	59	∈	∈	VB
10_1101-2020_01_28_923532	524	60	𝑆𝑃(𝑖	𝑆𝑃(𝑖	NN
10_1101-2020_01_28_923532	524	61	)	)	-RRB-
10_1101-2020_01_28_923532	524	62	(	(	-LRB-
10_1101-2020_01_28_923532	524	63	4	4	CD
10_1101-2020_01_28_923532	524	64	)	)	-RRB-
10_1101-2020_01_28_923532	524	65	∑	∑	.
10_1101-2020_01_28_923532	524	66	𝐶	𝐶	NN
10_1101-2020_01_28_923532	524	67	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	524	68	,	,	,
10_1101-2020_01_28_923532	524	69	𝑃𝑃(𝑖	𝑃𝑃(𝑖	NNP
10_1101-2020_01_28_923532	524	70	)	)	-RRB-
10_1101-2020_01_28_923532	524	71	)	)	-RRB-
10_1101-2020_01_28_923532	524	72	≥	≥	NN
10_1101-2020_01_28_923532	524	73	𝐿𝐵	𝐿𝐵	NNP
10_1101-2020_01_28_923532	524	74	∗	∗	NNP
10_1101-2020_01_28_923532	524	75	|𝑆𝑃(𝑖)|	|𝑆𝑃(𝑖)|	NNP
10_1101-2020_01_28_923532	524	76	∀𝑖	∀𝑖	NNP
10_1101-2020_01_28_923532	524	77	(	(	-LRB-
10_1101-2020_01_28_923532	524	78	5	5	CD
10_1101-2020_01_28_923532	524	79	)	)	-RRB-
10_1101-2020_01_28_923532	524	80	∑	∑	.
10_1101-2020_01_28_923532	524	81	𝐶	𝐶	NN
10_1101-2020_01_28_923532	524	82	𝑦(𝐶	𝑦(𝐶	NN
10_1101-2020_01_28_923532	524	83	,	,	,
10_1101-2020_01_28_923532	524	84	𝑃𝑃(𝑖	𝑃𝑃(𝑖	NNP
10_1101-2020_01_28_923532	524	85	)	)	-RRB-
10_1101-2020_01_28_923532	524	86	)	)	-RRB-
10_1101-2020_01_28_923532	524	87	≤	≤	JJ
10_1101-2020_01_28_923532	524	88	𝑈𝐵	𝑈𝐵	NNP
10_1101-2020_01_28_923532	524	89	∗	∗	NNP
10_1101-2020_01_28_923532	524	90	|𝑁𝑇𝑃(𝑖)|	|𝑁𝑇𝑃(𝑖)|	NNP
10_1101-2020_01_28_923532	524	91	∀𝑖	∀𝑖	NNP
10_1101-2020_01_28_923532	524	92	(	(	-LRB-
10_1101-2020_01_28_923532	524	93	6	6	CD
10_1101-2020_01_28_923532	524	94	)	)	-RRB-
10_1101-2020_01_28_923532	524	95	Implementation	implementation	NN
10_1101-2020_01_28_923532	524	96	Note	note	NN
10_1101-2020_01_28_923532	524	97	,	,	,
10_1101-2020_01_28_923532	524	98	Accounting	account	VBG
10_1101-2020_01_28_923532	524	99	for	for	IN
10_1101-2020_01_28_923532	524	100	Multiple	Multiple	NNP
10_1101-2020_01_28_923532	524	101	Optima	Optima	NNP
10_1101-2020_01_28_923532	524	102	and	and	CC
10_1101-2020_01_28_923532	524	103	Software	Software	NNP
10_1101-2020_01_28_923532	524	104	Availability	Availability	NNP
10_1101-2020_01_28_923532	524	105	We	-PRON-	PRP
10_1101-2020_01_28_923532	524	106	implemented	implement	VBD
10_1101-2020_01_28_923532	524	107	in	in	IN
10_1101-2020_01_28_923532	524	108	Python	Python	NNP
10_1101-2020_01_28_923532	524	109	3	3	CD
10_1101-2020_01_28_923532	524	110	the	the	DT
10_1101-2020_01_28_923532	524	111	above	above	JJ
10_1101-2020_01_28_923532	524	112	fair	fair	JJ
10_1101-2020_01_28_923532	524	113	cohort	cohort	NN
10_1101-2020_01_28_923532	524	114	target	target	NN
10_1101-2020_01_28_923532	524	115	set	set	VBN
10_1101-2020_01_28_923532	524	116	formulations	formulation	NNS
10_1101-2020_01_28_923532	524	117	,	,	,
10_1101-2020_01_28_923532	524	118	with	with	IN
10_1101-2020_01_28_923532	524	119	the	the	DT
10_1101-2020_01_28_923532	524	120	expression	expression	NN
10_1101-2020_01_28_923532	524	121	ratio	ratio	NN
10_1101-2020_01_28_923532	524	122	𝑟	𝑟	NNP
10_1101-2020_01_28_923532	524	123	as	as	IN
10_1101-2020_01_28_923532	524	124	an	an	DT
10_1101-2020_01_28_923532	524	125	option	option	NN
10_1101-2020_01_28_923532	524	126	when	when	WRB
10_1101-2020_01_28_923532	524	127	non	non	JJ
10_1101-2020_01_28_923532	524	128	-	-	JJ
10_1101-2020_01_28_923532	524	129	tumor	tumor	JJ
10_1101-2020_01_28_923532	524	130	cells	cell	NNS
10_1101-2020_01_28_923532	524	131	are	be	VBP
10_1101-2020_01_28_923532	524	132	available	available	JJ
10_1101-2020_01_28_923532	524	133	.	.	.
10_1101-2020_01_28_923532	525	1	The	the	DT
10_1101-2020_01_28_923532	525	2	parameters	parameter	NNS
10_1101-2020_01_28_923532	525	3	𝛼	𝛼	LS
10_1101-2020_01_28_923532	525	4	,	,	,
10_1101-2020_01_28_923532	525	5	𝑙𝑏	𝑙𝑏	UH
10_1101-2020_01_28_923532	525	6	,	,	,
10_1101-2020_01_28_923532	525	7	𝑢𝑏	𝑢𝑏	NNP
10_1101-2020_01_28_923532	525	8	can	can	MD
10_1101-2020_01_28_923532	525	9	be	be	VB
10_1101-2020_01_28_923532	525	10	set	set	VBN
10_1101-2020_01_28_923532	525	11	by	by	IN
10_1101-2020_01_28_923532	525	12	the	the	DT
10_1101-2020_01_28_923532	525	13	user	user	NN
10_1101-2020_01_28_923532	525	14	in	in	IN
10_1101-2020_01_28_923532	525	15	the	the	DT
10_1101-2020_01_28_923532	525	16	command	command	NN
10_1101-2020_01_28_923532	525	17	line	line	NN
10_1101-2020_01_28_923532	525	18	.	.	.
10_1101-2020_01_28_923532	526	1	To	to	TO
10_1101-2020_01_28_923532	526	2	solve	solve	VB
10_1101-2020_01_28_923532	526	3	the	the	DT
10_1101-2020_01_28_923532	526	4	ILPs	ilp	NNS
10_1101-2020_01_28_923532	526	5	to	to	TO
10_1101-2020_01_28_923532	526	6	optimality	optimality	NN
10_1101-2020_01_28_923532	526	7	we	-PRON-	PRP
10_1101-2020_01_28_923532	526	8	usually	usually	RB
10_1101-2020_01_28_923532	526	9	used	use	VBD
10_1101-2020_01_28_923532	526	10	the	the	DT
10_1101-2020_01_28_923532	526	11	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	526	12	library	library	NN
10_1101-2020_01_28_923532	526	13	and	and	CC
10_1101-2020_01_28_923532	526	14	its	-PRON-	PRP$
10_1101-2020_01_28_923532	526	15	Python	Python	NNP
10_1101-2020_01_28_923532	526	16	interface891	interface891	NNP
10_1101-2020_01_28_923532	526	17	.	.	.
10_1101-2020_01_28_923532	527	1	To	to	TO
10_1101-2020_01_28_923532	527	2	obtain	obtain	VB
10_1101-2020_01_28_923532	527	3	multiple	multiple	JJ
10_1101-2020_01_28_923532	527	4	optimal	optimal	JJ
10_1101-2020_01_28_923532	527	5	solutions	solution	NNS
10_1101-2020_01_28_923532	527	6	of	of	IN
10_1101-2020_01_28_923532	527	7	equal	equal	JJ
10_1101-2020_01_28_923532	527	8	size	size	NN
10_1101-2020_01_28_923532	527	9	we	-PRON-	PRP
10_1101-2020_01_28_923532	527	10	used	use	VBD
10_1101-2020_01_28_923532	527	11	the	the	DT
10_1101-2020_01_28_923532	527	12	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	527	13	library	library	NN
10_1101-2020_01_28_923532	527	14	(	(	-LRB-
10_1101-2020_01_28_923532	527	15	https://www.gurobi.com	https://www.gurobi.com	ADD
10_1101-2020_01_28_923532	527	16	)	)	-RRB-
10_1101-2020_01_28_923532	527	17	and	and	CC
10_1101-2020_01_28_923532	527	18	its	-PRON-	PRP$
10_1101-2020_01_28_923532	527	19	python	python	JJ
10_1101-2020_01_28_923532	527	20	interface	interface	NN
10_1101-2020_01_28_923532	527	21	.	.	.
10_1101-2020_01_28_923532	528	1	When	when	WRB
10_1101-2020_01_28_923532	528	2	evaluating	evaluate	VBG
10_1101-2020_01_28_923532	528	3	multiple	multiple	JJ
10_1101-2020_01_28_923532	528	4	optima	optima	NN
10_1101-2020_01_28_923532	528	5	,	,	,
10_1101-2020_01_28_923532	528	6	for	for	IN
10_1101-2020_01_28_923532	528	7	all	all	DT
10_1101-2020_01_28_923532	528	8	feasible	feasible	JJ
10_1101-2020_01_28_923532	528	9	instances	instance	NNS
10_1101-2020_01_28_923532	528	10	,	,	,
10_1101-2020_01_28_923532	528	11	we	-PRON-	PRP
10_1101-2020_01_28_923532	528	12	sampled	sample	VBD
10_1101-2020_01_28_923532	528	13	50	50	CD
10_1101-2020_01_28_923532	528	14	optimal	optimal	JJ
10_1101-2020_01_28_923532	528	15	solutions	solution	NNS
10_1101-2020_01_28_923532	528	16	that	that	WDT
10_1101-2020_01_28_923532	528	17	may	may	MD
10_1101-2020_01_28_923532	528	18	or	or	CC
10_1101-2020_01_28_923532	528	19	may	may	MD
10_1101-2020_01_28_923532	528	20	not	not	RB
10_1101-2020_01_28_923532	528	21	be	be	VB
10_1101-2020_01_28_923532	528	22	distinct	distinct	JJ
10_1101-2020_01_28_923532	528	23	,	,	,
10_1101-2020_01_28_923532	528	24	using	use	VBG
10_1101-2020_01_28_923532	528	25	the	the	DT
10_1101-2020_01_28_923532	528	26	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	528	27	function	function	NN
10_1101-2020_01_28_923532	528	28	select_solution	select_solution	NNP
10_1101-2020_01_28_923532	528	29	(	(	-LRB-
10_1101-2020_01_28_923532	528	30	)	)	-RRB-
10_1101-2020_01_28_923532	528	31	.	.	.
10_1101-2020_01_28_923532	529	1	To	to	TO
10_1101-2020_01_28_923532	529	2	determine	determine	VB
10_1101-2020_01_28_923532	529	3	how	how	WRB
10_1101-2020_01_28_923532	529	4	often	often	RB
10_1101-2020_01_28_923532	529	5	each	each	DT
10_1101-2020_01_28_923532	529	6	gene	gene	NN
10_1101-2020_01_28_923532	529	7	or	or	CC
10_1101-2020_01_28_923532	529	8	pair	pair	NN
10_1101-2020_01_28_923532	529	9	of	of	IN
10_1101-2020_01_28_923532	529	10	genes	gene	NNS
10_1101-2020_01_28_923532	529	11	occur	occur	VBP
10_1101-2020_01_28_923532	529	12	in	in	IN
10_1101-2020_01_28_923532	529	13	105	105	CD
10_1101-2020_01_28_923532	529	14	and	and	CC
10_1101-2020_01_28_923532	529	15	is	be	VBZ
10_1101-2020_01_28_923532	529	16	also	also	RB
10_1101-2020_01_28_923532	529	17	made	make	VBN
10_1101-2020_01_28_923532	529	18	available	available	JJ
10_1101-2020_01_28_923532	529	19	for	for	IN
10_1101-2020_01_28_923532	529	20	use	use	NN
10_1101-2020_01_28_923532	529	21	under	under	IN
10_1101-2020_01_28_923532	529	22	a	a	DT
10_1101-2020_01_28_923532	529	23	CC0	CC0	NNP
10_1101-2020_01_28_923532	529	24	license	license	NN
10_1101-2020_01_28_923532	529	25	.	.	.
10_1101-2020_01_28_923532	530	1	(	(	-LRB-
10_1101-2020_01_28_923532	530	2	which	which	WDT
10_1101-2020_01_28_923532	530	3	was	be	VBD
10_1101-2020_01_28_923532	530	4	not	not	RB
10_1101-2020_01_28_923532	530	5	certified	certify	VBN
10_1101-2020_01_28_923532	530	6	by	by	IN
10_1101-2020_01_28_923532	530	7	peer	peer	NN
10_1101-2020_01_28_923532	530	8	review	review	NN
10_1101-2020_01_28_923532	530	9	)	)	-RRB-
10_1101-2020_01_28_923532	530	10	is	be	VBZ
10_1101-2020_01_28_923532	530	11	the	the	DT
10_1101-2020_01_28_923532	530	12	author	author	NN
10_1101-2020_01_28_923532	530	13	/	/	SYM
10_1101-2020_01_28_923532	530	14	funder	funder	NN
10_1101-2020_01_28_923532	530	15	.	.	.
10_1101-2020_01_28_923532	531	1	This	this	DT
10_1101-2020_01_28_923532	531	2	article	article	NN
10_1101-2020_01_28_923532	531	3	is	be	VBZ
10_1101-2020_01_28_923532	531	4	a	a	DT
10_1101-2020_01_28_923532	531	5	US	US	NNP
10_1101-2020_01_28_923532	531	6	Government	Government	NNP
10_1101-2020_01_28_923532	531	7	work	work	NN
10_1101-2020_01_28_923532	531	8	.	.	.
10_1101-2020_01_28_923532	532	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	532	2	is	be	VBZ
10_1101-2020_01_28_923532	532	3	not	not	RB
10_1101-2020_01_28_923532	532	4	subject	subject	JJ
10_1101-2020_01_28_923532	532	5	to	to	IN
10_1101-2020_01_28_923532	532	6	copyright	copyright	NN
10_1101-2020_01_28_923532	532	7	under	under	IN
10_1101-2020_01_28_923532	532	8	17	17	CD
10_1101-2020_01_28_923532	532	9	USC	usc	NN
10_1101-2020_01_28_923532	532	10	The	the	DT
10_1101-2020_01_28_923532	532	11	copyright	copyright	NN
10_1101-2020_01_28_923532	532	12	holder	holder	NN
10_1101-2020_01_28_923532	532	13	for	for	IN
10_1101-2020_01_28_923532	532	14	this	this	DT
10_1101-2020_01_28_923532	532	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	532	16	version	version	NN
10_1101-2020_01_28_923532	532	17	posted	post	VBD
10_1101-2020_01_28_923532	532	18	February	February	NNP
10_1101-2020_01_28_923532	532	19	12	12	CD
10_1101-2020_01_28_923532	532	20	,	,	,
10_1101-2020_01_28_923532	532	21	2021	2021	CD
10_1101-2020_01_28_923532	532	22	.	.	.
10_1101-2020_01_28_923532	532	23	;	;	:
10_1101-2020_01_28_923532	532	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	532	25	:	:	:
10_1101-2020_01_28_923532	532	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	532	27	preprint	preprint	NN
10_1101-2020_01_28_923532	532	28	https://www.gurobi.com/	https://www.gurobi.com/	NN
10_1101-2020_01_28_923532	532	29	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	532	30	41	41	CD
10_1101-2020_01_28_923532	532	31	optimal	optimal	JJ
10_1101-2020_01_28_923532	532	32	solutions	solution	NNS
10_1101-2020_01_28_923532	532	33	,	,	,
10_1101-2020_01_28_923532	532	34	we	-PRON-	PRP
10_1101-2020_01_28_923532	532	35	computed	compute	VBD
10_1101-2020_01_28_923532	532	36	the	the	DT
10_1101-2020_01_28_923532	532	37	arithmetic	arithmetic	JJ
10_1101-2020_01_28_923532	532	38	mean	mean	NN
10_1101-2020_01_28_923532	532	39	of	of	IN
10_1101-2020_01_28_923532	532	40	gene	gene	NN
10_1101-2020_01_28_923532	532	41	frequencies	frequency	NNS
10_1101-2020_01_28_923532	532	42	and	and	CC
10_1101-2020_01_28_923532	532	43	gene	gene	NN
10_1101-2020_01_28_923532	532	44	pair	pair	NN
10_1101-2020_01_28_923532	532	45	frequencies	frequency	NNS
10_1101-2020_01_28_923532	532	46	over	over	IN
10_1101-2020_01_28_923532	532	47	all	all	DT
10_1101-2020_01_28_923532	532	48	sampled	sample	VBN
10_1101-2020_01_28_923532	532	49	optimal	optimal	JJ
10_1101-2020_01_28_923532	532	50	solutions	solution	NNS
10_1101-2020_01_28_923532	532	51	.	.	.
10_1101-2020_01_28_923532	533	1	The	the	DT
10_1101-2020_01_28_923532	533	2	software	software	NN
10_1101-2020_01_28_923532	533	3	package	package	NN
10_1101-2020_01_28_923532	533	4	is	be	VBZ
10_1101-2020_01_28_923532	533	5	called	call	VBN
10_1101-2020_01_28_923532	533	6	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	533	7	.	.	.
10_1101-2020_01_28_923532	534	1	The	the	DT
10_1101-2020_01_28_923532	534	2	main	main	JJ
10_1101-2020_01_28_923532	534	3	program	program	NN
10_1101-2020_01_28_923532	534	4	is	be	VBZ
10_1101-2020_01_28_923532	534	5	called	call	VBN
10_1101-2020_01_28_923532	534	6	hitting_set.py	hitting_set.py	NN
10_1101-2020_01_28_923532	534	7	.	.	.
10_1101-2020_01_28_923532	535	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	535	2	include	include	VBP
10_1101-2020_01_28_923532	535	3	in	in	IN
10_1101-2020_01_28_923532	535	4	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	535	5	a	a	DT
10_1101-2020_01_28_923532	535	6	separate	separate	JJ
10_1101-2020_01_28_923532	535	7	program	program	NN
10_1101-2020_01_28_923532	535	8	to	to	TO
10_1101-2020_01_28_923532	535	9	sample	sample	VB
10_1101-2020_01_28_923532	535	10	cells	cell	NNS
10_1101-2020_01_28_923532	535	11	and	and	CC
10_1101-2020_01_28_923532	535	12	generate	generate	VB
10_1101-2020_01_28_923532	535	13	replicates	replicate	NNS
10_1101-2020_01_28_923532	535	14	,	,	,
10_1101-2020_01_28_923532	535	15	called	call	VBN
10_1101-2020_01_28_923532	535	16	sample_columns.py	sample_columns.py	CD
10_1101-2020_01_28_923532	535	17	.	.	.
10_1101-2020_01_28_923532	536	1	So	so	RB
10_1101-2020_01_28_923532	536	2	long	long	RB
10_1101-2020_01_28_923532	536	3	as	as	IN
10_1101-2020_01_28_923532	536	4	one	one	NN
10_1101-2020_01_28_923532	536	5	seeks	seek	VBZ
10_1101-2020_01_28_923532	536	6	only	only	RB
10_1101-2020_01_28_923532	536	7	single	single	JJ
10_1101-2020_01_28_923532	536	8	optimal	optimal	JJ
10_1101-2020_01_28_923532	536	9	solutions	solution	NNS
10_1101-2020_01_28_923532	536	10	for	for	IN
10_1101-2020_01_28_923532	536	11	each	each	DT
10_1101-2020_01_28_923532	536	12	instance	instance	NN
10_1101-2020_01_28_923532	536	13	,	,	,
10_1101-2020_01_28_923532	536	14	exactly	exactly	RB
10_1101-2020_01_28_923532	536	15	one	one	CD
10_1101-2020_01_28_923532	536	16	of	of	IN
10_1101-2020_01_28_923532	536	17	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	536	18	and	and	CC
10_1101-2020_01_28_923532	536	19	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	536	20	is	be	VBZ
10_1101-2020_01_28_923532	536	21	sufficient	sufficient	JJ
10_1101-2020_01_28_923532	536	22	to	to	TO
10_1101-2020_01_28_923532	536	23	use	use	VB
10_1101-2020_01_28_923532	536	24	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	536	25	.	.	.
10_1101-2020_01_28_923532	537	1	We	-PRON-	PRP
10_1101-2020_01_28_923532	537	2	verified	verify	VBD
10_1101-2020_01_28_923532	537	3	that	that	IN
10_1101-2020_01_28_923532	537	4	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	537	5	and	and	CC
10_1101-2020_01_28_923532	537	6	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	537	7	give	give	VBP
10_1101-2020_01_28_923532	537	8	optimal	optimal	JJ
10_1101-2020_01_28_923532	537	9	solutions	solution	NNS
10_1101-2020_01_28_923532	537	10	of	of	IN
10_1101-2020_01_28_923532	537	11	the	the	DT
10_1101-2020_01_28_923532	537	12	same	same	JJ
10_1101-2020_01_28_923532	537	13	size	size	NN
10_1101-2020_01_28_923532	537	14	.	.	.
10_1101-2020_01_28_923532	538	1	If	if	IN
10_1101-2020_01_28_923532	538	2	one	one	PRP
10_1101-2020_01_28_923532	538	3	wants	want	VBZ
10_1101-2020_01_28_923532	538	4	to	to	TO
10_1101-2020_01_28_923532	538	5	sample	sample	VB
10_1101-2020_01_28_923532	538	6	multiple	multiple	JJ
10_1101-2020_01_28_923532	538	7	optima	optimum	NNS
10_1101-2020_01_28_923532	538	8	,	,	,
10_1101-2020_01_28_923532	538	9	this	this	DT
10_1101-2020_01_28_923532	538	10	can	can	MD
10_1101-2020_01_28_923532	538	11	be	be	VB
10_1101-2020_01_28_923532	538	12	done	do	VBN
10_1101-2020_01_28_923532	538	13	only	only	RB
10_1101-2020_01_28_923532	538	14	with	with	IN
10_1101-2020_01_28_923532	538	15	the	the	DT
10_1101-2020_01_28_923532	538	16	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	538	17	library	library	NN
10_1101-2020_01_28_923532	538	18	.	.	.
10_1101-2020_01_28_923532	539	1	The	the	DT
10_1101-2020_01_28_923532	539	2	choice	choice	NN
10_1101-2020_01_28_923532	539	3	between	between	IN
10_1101-2020_01_28_923532	539	4	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	539	5	and	and	CC
10_1101-2020_01_28_923532	539	6	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	539	7	and	and	CC
10_1101-2020_01_28_923532	539	8	the	the	DT
10_1101-2020_01_28_923532	539	9	number	number	NN
10_1101-2020_01_28_923532	539	10	of	of	IN
10_1101-2020_01_28_923532	539	11	optima	optima	NNP
10_1101-2020_01_28_923532	539	12	to	to	TO
10_1101-2020_01_28_923532	539	13	sample	sample	NN
10_1101-2020_01_28_923532	539	14	are	be	VBP
10_1101-2020_01_28_923532	539	15	controlled	control	VBN
10_1101-2020_01_28_923532	539	16	by	by	IN
10_1101-2020_01_28_923532	539	17	command	command	NN
10_1101-2020_01_28_923532	539	18	-	-	HYPH
10_1101-2020_01_28_923532	539	19	line	line	NN
10_1101-2020_01_28_923532	539	20	parameters	parameter	NNS
10_1101-2020_01_28_923532	539	21	use_gurobi	use_gurobi	NNP
10_1101-2020_01_28_923532	539	22	and	and	CC
10_1101-2020_01_28_923532	539	23	num_sol	num_sol	NNP
10_1101-2020_01_28_923532	539	24	,	,	,
10_1101-2020_01_28_923532	539	25	respectively	respectively	RB
10_1101-2020_01_28_923532	539	26	.	.	.
10_1101-2020_01_28_923532	540	1	The	the	DT
10_1101-2020_01_28_923532	540	2	MadHitter	MadHitter	NNP
10_1101-2020_01_28_923532	540	3	software	software	NN
10_1101-2020_01_28_923532	540	4	is	be	VBZ
10_1101-2020_01_28_923532	540	5	available	available	JJ
10_1101-2020_01_28_923532	540	6	on	on	IN
10_1101-2020_01_28_923532	540	7	GitHub	GitHub	NNP
10_1101-2020_01_28_923532	540	8	at	at	IN
10_1101-2020_01_28_923532	540	9	https://github.com/ruppinlab/madhitter	https://github.com/ruppinlab/madhitter	NN
10_1101-2020_01_28_923532	540	10	Acknowledgements	acknowledgement	NNS
10_1101-2020_01_28_923532	540	11	This	this	DT
10_1101-2020_01_28_923532	540	12	research	research	NN
10_1101-2020_01_28_923532	540	13	is	be	VBZ
10_1101-2020_01_28_923532	540	14	supported	support	VBN
10_1101-2020_01_28_923532	540	15	in	in	IN
10_1101-2020_01_28_923532	540	16	part	part	NN
10_1101-2020_01_28_923532	540	17	by	by	IN
10_1101-2020_01_28_923532	540	18	the	the	DT
10_1101-2020_01_28_923532	540	19	Intramural	Intramural	NNP
10_1101-2020_01_28_923532	540	20	Research	Research	NNP
10_1101-2020_01_28_923532	540	21	program	program	NN
10_1101-2020_01_28_923532	540	22	of	of	IN
10_1101-2020_01_28_923532	540	23	the	the	DT
10_1101-2020_01_28_923532	540	24	National	National	NNP
10_1101-2020_01_28_923532	540	25	Institutes	Institutes	NNPS
10_1101-2020_01_28_923532	540	26	of	of	IN
10_1101-2020_01_28_923532	540	27	Health	Health	NNP
10_1101-2020_01_28_923532	540	28	,	,	,
10_1101-2020_01_28_923532	540	29	National	National	NNP
10_1101-2020_01_28_923532	540	30	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	540	31	Institute	Institute	NNP
10_1101-2020_01_28_923532	540	32	.	.	.
10_1101-2020_01_28_923532	541	1	This	this	DT
10_1101-2020_01_28_923532	541	2	research	research	NN
10_1101-2020_01_28_923532	541	3	is	be	VBZ
10_1101-2020_01_28_923532	541	4	supported	support	VBN
10_1101-2020_01_28_923532	541	5	in	in	IN
10_1101-2020_01_28_923532	541	6	part	part	NN
10_1101-2020_01_28_923532	541	7	by	by	IN
10_1101-2020_01_28_923532	541	8	the	the	DT
10_1101-2020_01_28_923532	541	9	University	University	NNP
10_1101-2020_01_28_923532	541	10	of	of	IN
10_1101-2020_01_28_923532	541	11	Maryland	Maryland	NNP
10_1101-2020_01_28_923532	541	12	Year	Year	NNP
10_1101-2020_01_28_923532	541	13	of	of	IN
10_1101-2020_01_28_923532	541	14	Data	Data	NNP
10_1101-2020_01_28_923532	541	15	Science	Science	NNP
10_1101-2020_01_28_923532	541	16	Program	Program	NNP
10_1101-2020_01_28_923532	541	17	.	.	.
10_1101-2020_01_28_923532	542	1	This	this	DT
10_1101-2020_01_28_923532	542	2	research	research	NN
10_1101-2020_01_28_923532	542	3	is	be	VBZ
10_1101-2020_01_28_923532	542	4	supported	support	VBN
10_1101-2020_01_28_923532	542	5	in	in	IN
10_1101-2020_01_28_923532	542	6	part	part	NN
10_1101-2020_01_28_923532	542	7	by	by	IN
10_1101-2020_01_28_923532	542	8	start	start	VB
10_1101-2020_01_28_923532	542	9	-	-	HYPH
10_1101-2020_01_28_923532	542	10	up	up	RP
10_1101-2020_01_28_923532	542	11	funds	fund	NNS
10_1101-2020_01_28_923532	542	12	from	from	IN
10_1101-2020_01_28_923532	542	13	Northwestern	Northwestern	NNP
10_1101-2020_01_28_923532	542	14	University	University	NNP
10_1101-2020_01_28_923532	542	15	and	and	CC
10_1101-2020_01_28_923532	542	16	a	a	DT
10_1101-2020_01_28_923532	542	17	research	research	NN
10_1101-2020_01_28_923532	542	18	award	award	NN
10_1101-2020_01_28_923532	542	19	from	from	IN
10_1101-2020_01_28_923532	542	20	Amazon	Amazon	NNP
10_1101-2020_01_28_923532	542	21	to	to	TO
10_1101-2020_01_28_923532	542	22	support	support	VB
10_1101-2020_01_28_923532	542	23	the	the	DT
10_1101-2020_01_28_923532	542	24	research	research	NN
10_1101-2020_01_28_923532	542	25	of	of	IN
10_1101-2020_01_28_923532	542	26	S.K.	S.K.	NNP
10_1101-2020_01_28_923532	543	1	This	this	DT
10_1101-2020_01_28_923532	543	2	work	work	NN
10_1101-2020_01_28_923532	543	3	utilized	utilize	VBD
10_1101-2020_01_28_923532	543	4	the	the	DT
10_1101-2020_01_28_923532	543	5	computational	computational	JJ
10_1101-2020_01_28_923532	543	6	resources	resource	NNS
10_1101-2020_01_28_923532	543	7	of	of	IN
10_1101-2020_01_28_923532	543	8	the	the	DT
10_1101-2020_01_28_923532	543	9	NIH	NIH	NNP
10_1101-2020_01_28_923532	543	10	HPC	HPC	NNP
10_1101-2020_01_28_923532	543	11	Biowulf	Biowulf	NNP
10_1101-2020_01_28_923532	543	12	cluster	cluster	NN
10_1101-2020_01_28_923532	543	13	.	.	.
10_1101-2020_01_28_923532	544	1	(	(	-LRB-
10_1101-2020_01_28_923532	544	2	http://hpc.nih.gov	http://hpc.nih.gov	NNP
10_1101-2020_01_28_923532	544	3	)	)	-RRB-
10_1101-2020_01_28_923532	544	4	.	.	.
10_1101-2020_01_28_923532	545	1	Thanks	thank	NNS
10_1101-2020_01_28_923532	545	2	to	to	IN
10_1101-2020_01_28_923532	545	3	E.	E.	NNP
10_1101-2020_01_28_923532	545	4	Michael	Michael	NNP
10_1101-2020_01_28_923532	545	5	Gertz	Gertz	NNP
10_1101-2020_01_28_923532	545	6	for	for	IN
10_1101-2020_01_28_923532	545	7	technical	technical	JJ
10_1101-2020_01_28_923532	545	8	assistance	assistance	NN
10_1101-2020_01_28_923532	545	9	with	with	IN
10_1101-2020_01_28_923532	545	10	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	545	11	,	,	,
10_1101-2020_01_28_923532	545	12	Gurobi	Gurobi	NNP
10_1101-2020_01_28_923532	545	13	,	,	,
10_1101-2020_01_28_923532	545	14	and	and	CC
10_1101-2020_01_28_923532	545	15	Biowulf	Biowulf	NNP
10_1101-2020_01_28_923532	545	16	.	.	.
10_1101-2020_01_28_923532	546	1	Thanks	thank	NNS
10_1101-2020_01_28_923532	546	2	to	to	IN
10_1101-2020_01_28_923532	546	3	Allon	Allon	NNP
10_1101-2020_01_28_923532	546	4	Wagner	Wagner	NNP
10_1101-2020_01_28_923532	546	5	,	,	,
10_1101-2020_01_28_923532	546	6	Keren	Keren	NNP
10_1101-2020_01_28_923532	546	7	Yizhak	Yizhak	NNP
10_1101-2020_01_28_923532	546	8	and	and	CC
10_1101-2020_01_28_923532	546	9	Sushant	Sushant	NNP
10_1101-2020_01_28_923532	546	10	Patkar	Patkar	NNP
10_1101-2020_01_28_923532	546	11	for	for	IN
10_1101-2020_01_28_923532	546	12	assistance	assistance	NN
10_1101-2020_01_28_923532	546	13	in	in	IN
10_1101-2020_01_28_923532	546	14	identifying	identify	VBG
10_1101-2020_01_28_923532	546	15	and	and	CC
10_1101-2020_01_28_923532	546	16	retrieving	retrieve	VBG
10_1101-2020_01_28_923532	546	17	suitable	suitable	JJ
10_1101-2020_01_28_923532	546	18	single	single	JJ
10_1101-2020_01_28_923532	546	19	-	-	HYPH
10_1101-2020_01_28_923532	546	20	cell	cell	NN
10_1101-2020_01_28_923532	546	21	RNAseq	RNAseq	NNP
10_1101-2020_01_28_923532	546	22	data	datum	NNS
10_1101-2020_01_28_923532	546	23	sets	set	NNS
10_1101-2020_01_28_923532	546	24	.	.	.
10_1101-2020_01_28_923532	547	1	Thanks	thank	NNS
10_1101-2020_01_28_923532	547	2	to	to	IN
10_1101-2020_01_28_923532	547	3	Leandro	Leandro	NNP
10_1101-2020_01_28_923532	547	4	Hermida	Hermida	NNP
10_1101-2020_01_28_923532	547	5	for	for	IN
10_1101-2020_01_28_923532	547	6	technical	technical	JJ
10_1101-2020_01_28_923532	547	7	advice	advice	NN
10_1101-2020_01_28_923532	547	8	.	.	.
10_1101-2020_01_28_923532	548	1	Competing	compete	VBG
10_1101-2020_01_28_923532	548	2	Interests	interest	NNS
10_1101-2020_01_28_923532	548	3	The	the	DT
10_1101-2020_01_28_923532	548	4	authors	author	NNS
10_1101-2020_01_28_923532	548	5	declare	declare	VBP
10_1101-2020_01_28_923532	548	6	that	that	IN
10_1101-2020_01_28_923532	548	7	they	-PRON-	PRP
10_1101-2020_01_28_923532	548	8	have	have	VBP
10_1101-2020_01_28_923532	548	9	no	no	DT
10_1101-2020_01_28_923532	548	10	competing	compete	VBG
10_1101-2020_01_28_923532	548	11	interests	interest	NNS
10_1101-2020_01_28_923532	548	12	.	.	.
10_1101-2020_01_28_923532	549	1	References	reference	NNS
10_1101-2020_01_28_923532	549	2	1	1	CD
10_1101-2020_01_28_923532	549	3	.	.	.
10_1101-2020_01_28_923532	550	1	Von	Von	NNP
10_1101-2020_01_28_923532	550	2	Hoff	Hoff	NNP
10_1101-2020_01_28_923532	550	3	D.D.	D.D.	NNP
10_1101-2020_01_28_923532	550	4	,	,	,
10_1101-2020_01_28_923532	550	5	et	et	NNP
10_1101-2020_01_28_923532	550	6	al	al	NNP
10_1101-2020_01_28_923532	550	7	.	.	.
10_1101-2020_01_28_923532	551	1	Pilot	pilot	NN
10_1101-2020_01_28_923532	551	2	study	study	NN
10_1101-2020_01_28_923532	551	3	using	use	VBG
10_1101-2020_01_28_923532	551	4	molecular	molecular	JJ
10_1101-2020_01_28_923532	551	5	profiling	profiling	NN
10_1101-2020_01_28_923532	551	6	of	of	IN
10_1101-2020_01_28_923532	551	7	patients	patient	NNS
10_1101-2020_01_28_923532	551	8	’	’	POS
10_1101-2020_01_28_923532	551	9	tumors	tumor	NNS
10_1101-2020_01_28_923532	551	10	to	to	TO
10_1101-2020_01_28_923532	551	11	find	find	VB
10_1101-2020_01_28_923532	551	12	potential	potential	JJ
10_1101-2020_01_28_923532	551	13	targets	target	NNS
10_1101-2020_01_28_923532	551	14	and	and	CC
10_1101-2020_01_28_923532	551	15	select	select	VB
10_1101-2020_01_28_923532	551	16	treatments	treatment	NNS
10_1101-2020_01_28_923532	551	17	for	for	IN
10_1101-2020_01_28_923532	551	18	their	-PRON-	PRP$
10_1101-2020_01_28_923532	551	19	refractory	refractory	JJ
10_1101-2020_01_28_923532	551	20	cancers	cancer	NNS
10_1101-2020_01_28_923532	551	21	.	.	.
10_1101-2020_01_28_923532	552	1	J.	J.	NNP
10_1101-2020_01_28_923532	552	2	Clin	Clin	NNP
10_1101-2020_01_28_923532	552	3	.	.	.
10_1101-2020_01_28_923532	553	1	Oncol	Oncol	NNP
10_1101-2020_01_28_923532	553	2	.	.	.
10_1101-2020_01_28_923532	554	1	28(33	28(33	CD
10_1101-2020_01_28_923532	554	2	)	)	-RRB-
10_1101-2020_01_28_923532	554	3	,	,	,
10_1101-2020_01_28_923532	554	4	4877	4877	CD
10_1101-2020_01_28_923532	554	5	-	-	SYM
10_1101-2020_01_28_923532	554	6	4883	4883	CD
10_1101-2020_01_28_923532	554	7	(	(	-LRB-
10_1101-2020_01_28_923532	554	8	2010	2010	CD
10_1101-2020_01_28_923532	554	9	)	)	-RRB-
10_1101-2020_01_28_923532	554	10	.	.	.
10_1101-2020_01_28_923532	555	1	105	105	CD
10_1101-2020_01_28_923532	555	2	and	and	CC
10_1101-2020_01_28_923532	555	3	is	be	VBZ
10_1101-2020_01_28_923532	555	4	also	also	RB
10_1101-2020_01_28_923532	555	5	made	make	VBN
10_1101-2020_01_28_923532	555	6	available	available	JJ
10_1101-2020_01_28_923532	555	7	for	for	IN
10_1101-2020_01_28_923532	555	8	use	use	NN
10_1101-2020_01_28_923532	555	9	under	under	IN
10_1101-2020_01_28_923532	555	10	a	a	DT
10_1101-2020_01_28_923532	555	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	555	12	license	license	NN
10_1101-2020_01_28_923532	555	13	.	.	.
10_1101-2020_01_28_923532	556	1	(	(	-LRB-
10_1101-2020_01_28_923532	556	2	which	which	WDT
10_1101-2020_01_28_923532	556	3	was	be	VBD
10_1101-2020_01_28_923532	556	4	not	not	RB
10_1101-2020_01_28_923532	556	5	certified	certify	VBN
10_1101-2020_01_28_923532	556	6	by	by	IN
10_1101-2020_01_28_923532	556	7	peer	peer	NN
10_1101-2020_01_28_923532	556	8	review	review	NN
10_1101-2020_01_28_923532	556	9	)	)	-RRB-
10_1101-2020_01_28_923532	556	10	is	be	VBZ
10_1101-2020_01_28_923532	556	11	the	the	DT
10_1101-2020_01_28_923532	556	12	author	author	NN
10_1101-2020_01_28_923532	556	13	/	/	SYM
10_1101-2020_01_28_923532	556	14	funder	funder	NN
10_1101-2020_01_28_923532	556	15	.	.	.
10_1101-2020_01_28_923532	557	1	This	this	DT
10_1101-2020_01_28_923532	557	2	article	article	NN
10_1101-2020_01_28_923532	557	3	is	be	VBZ
10_1101-2020_01_28_923532	557	4	a	a	DT
10_1101-2020_01_28_923532	557	5	US	US	NNP
10_1101-2020_01_28_923532	557	6	Government	Government	NNP
10_1101-2020_01_28_923532	557	7	work	work	NN
10_1101-2020_01_28_923532	557	8	.	.	.
10_1101-2020_01_28_923532	558	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	558	2	is	be	VBZ
10_1101-2020_01_28_923532	558	3	not	not	RB
10_1101-2020_01_28_923532	558	4	subject	subject	JJ
10_1101-2020_01_28_923532	558	5	to	to	IN
10_1101-2020_01_28_923532	558	6	copyright	copyright	NN
10_1101-2020_01_28_923532	558	7	under	under	IN
10_1101-2020_01_28_923532	558	8	17	17	CD
10_1101-2020_01_28_923532	558	9	USC	usc	NN
10_1101-2020_01_28_923532	558	10	The	the	DT
10_1101-2020_01_28_923532	558	11	copyright	copyright	NN
10_1101-2020_01_28_923532	558	12	holder	holder	NN
10_1101-2020_01_28_923532	558	13	for	for	IN
10_1101-2020_01_28_923532	558	14	this	this	DT
10_1101-2020_01_28_923532	558	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	558	16	version	version	NN
10_1101-2020_01_28_923532	558	17	posted	post	VBD
10_1101-2020_01_28_923532	558	18	February	February	NNP
10_1101-2020_01_28_923532	558	19	12	12	CD
10_1101-2020_01_28_923532	558	20	,	,	,
10_1101-2020_01_28_923532	558	21	2021	2021	CD
10_1101-2020_01_28_923532	558	22	.	.	.
10_1101-2020_01_28_923532	558	23	;	;	:
10_1101-2020_01_28_923532	558	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	558	25	:	:	:
10_1101-2020_01_28_923532	558	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	558	27	preprint	preprint	NN
10_1101-2020_01_28_923532	558	28	https://github.com/ruppinlab/madhitter	https://github.com/ruppinlab/madhitter	NN
10_1101-2020_01_28_923532	558	29	http://hpc.nih.gov/	http://hpc.nih.gov/	NNP
10_1101-2020_01_28_923532	558	30	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	ADD
10_1101-2020_01_28_923532	558	31	42	42	CD
10_1101-2020_01_28_923532	558	32	2	2	CD
10_1101-2020_01_28_923532	558	33	.	.	.
10_1101-2020_01_28_923532	559	1	Schütte	Schütte	NNP
10_1101-2020_01_28_923532	559	2	M.	M.	NNP
10_1101-2020_01_28_923532	559	3	,	,	,
10_1101-2020_01_28_923532	559	4	et	et	NNP
10_1101-2020_01_28_923532	559	5	al	al	NNP
10_1101-2020_01_28_923532	559	6	.	.	.
10_1101-2020_01_28_923532	560	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	560	2	precision	precision	NN
10_1101-2020_01_28_923532	560	3	medicine	medicine	NN
10_1101-2020_01_28_923532	560	4	:	:	:
10_1101-2020_01_28_923532	560	5	Why	why	WRB
10_1101-2020_01_28_923532	560	6	more	more	JJR
10_1101-2020_01_28_923532	560	7	is	be	VBZ
10_1101-2020_01_28_923532	560	8	more	more	JJR
10_1101-2020_01_28_923532	560	9	and	and	CC
10_1101-2020_01_28_923532	560	10	DNA	DNA	NNP
10_1101-2020_01_28_923532	560	11	is	be	VBZ
10_1101-2020_01_28_923532	560	12	not	not	RB
10_1101-2020_01_28_923532	560	13	enough	enough	JJ
10_1101-2020_01_28_923532	560	14	.	.	.
10_1101-2020_01_28_923532	561	1	Pub	pub	RB
10_1101-2020_01_28_923532	561	2	.	.	.
10_1101-2020_01_28_923532	562	1	Health	Health	NNP
10_1101-2020_01_28_923532	562	2	Genomics	Genomics	NNPS
10_1101-2020_01_28_923532	562	3	20(2):70	20(2):70	NNP
10_1101-2020_01_28_923532	562	4	-	-	HYPH
10_1101-2020_01_28_923532	562	5	80	80	CD
10_1101-2020_01_28_923532	562	6	(	(	-LRB-
10_1101-2020_01_28_923532	562	7	2017	2017	CD
10_1101-2020_01_28_923532	562	8	)	)	-RRB-
10_1101-2020_01_28_923532	562	9	.	.	.
10_1101-2020_01_28_923532	563	1	3	3	LS
10_1101-2020_01_28_923532	563	2	.	.	.
10_1101-2020_01_28_923532	564	1	Jameson	Jameson	NNP
10_1101-2020_01_28_923532	564	2	,	,	,
10_1101-2020_01_28_923532	564	3	G.S.	G.S.	NNP
10_1101-2020_01_28_923532	564	4	,	,	,
10_1101-2020_01_28_923532	564	5	et	et	NNP
10_1101-2020_01_28_923532	564	6	al	al	NNP
10_1101-2020_01_28_923532	564	7	.	.	.
10_1101-2020_01_28_923532	565	1	A	a	DT
10_1101-2020_01_28_923532	565	2	pilot	pilot	NN
10_1101-2020_01_28_923532	565	3	study	study	NN
10_1101-2020_01_28_923532	565	4	utilizing	utilize	VBG
10_1101-2020_01_28_923532	565	5	multi	multi	JJ
10_1101-2020_01_28_923532	565	6	-	-	JJ
10_1101-2020_01_28_923532	565	7	omic	omic	JJ
10_1101-2020_01_28_923532	565	8	molecular	molecular	JJ
10_1101-2020_01_28_923532	565	9	profiling	profiling	NN
10_1101-2020_01_28_923532	565	10	to	to	TO
10_1101-2020_01_28_923532	565	11	find	find	VB
10_1101-2020_01_28_923532	565	12	potential	potential	JJ
10_1101-2020_01_28_923532	565	13	targets	target	NNS
10_1101-2020_01_28_923532	565	14	and	and	CC
10_1101-2020_01_28_923532	565	15	select	select	VB
10_1101-2020_01_28_923532	565	16	individualized	individualized	JJ
10_1101-2020_01_28_923532	565	17	treatments	treatment	NNS
10_1101-2020_01_28_923532	565	18	for	for	IN
10_1101-2020_01_28_923532	565	19	patients	patient	NNS
10_1101-2020_01_28_923532	565	20	with	with	IN
10_1101-2020_01_28_923532	565	21	previously	previously	RB
10_1101-2020_01_28_923532	565	22	treated	treat	VBN
10_1101-2020_01_28_923532	565	23	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	565	24	breast	breast	NN
10_1101-2020_01_28_923532	565	25	cancer	cancer	NN
10_1101-2020_01_28_923532	565	26	.	.	.
10_1101-2020_01_28_923532	566	1	Breast	Breast	NNP
10_1101-2020_01_28_923532	566	2	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	566	3	Res	Res	NNP
10_1101-2020_01_28_923532	566	4	.	.	.
10_1101-2020_01_28_923532	567	1	Treat	treat	VB
10_1101-2020_01_28_923532	567	2	.	.	.
10_1101-2020_01_28_923532	568	1	147(3	147(3	CD
10_1101-2020_01_28_923532	568	2	)	)	-RRB-
10_1101-2020_01_28_923532	568	3	,	,	,
10_1101-2020_01_28_923532	568	4	579	579	CD
10_1101-2020_01_28_923532	568	5	-	-	SYM
10_1101-2020_01_28_923532	568	6	588	588	CD
10_1101-2020_01_28_923532	568	7	(	(	-LRB-
10_1101-2020_01_28_923532	568	8	2014	2014	CD
10_1101-2020_01_28_923532	568	9	)	)	-RRB-
10_1101-2020_01_28_923532	568	10	.	.	.
10_1101-2020_01_28_923532	569	1	4	4	LS
10_1101-2020_01_28_923532	569	2	.	.	.
10_1101-2020_01_28_923532	570	1	Saulnier	Saulnier	NNP
10_1101-2020_01_28_923532	570	2	Sholler	Sholler	NNP
10_1101-2020_01_28_923532	570	3	,	,	,
10_1101-2020_01_28_923532	570	4	G.L.	G.L.	NNP
10_1101-2020_01_28_923532	570	5	,	,	,
10_1101-2020_01_28_923532	570	6	et	et	NNP
10_1101-2020_01_28_923532	570	7	al	al	NNP
10_1101-2020_01_28_923532	570	8	.	.	.
10_1101-2020_01_28_923532	571	1	Feasibility	feasibility	NN
10_1101-2020_01_28_923532	571	2	of	of	IN
10_1101-2020_01_28_923532	571	3	implementing	implement	VBG
10_1101-2020_01_28_923532	571	4	molecular	molecular	NN
10_1101-2020_01_28_923532	571	5	-	-	HYPH
10_1101-2020_01_28_923532	571	6	guided	guide	VBN
10_1101-2020_01_28_923532	571	7	therapy	therapy	NN
10_1101-2020_01_28_923532	571	8	for	for	IN
10_1101-2020_01_28_923532	571	9	the	the	DT
10_1101-2020_01_28_923532	571	10	treatment	treatment	NN
10_1101-2020_01_28_923532	571	11	of	of	IN
10_1101-2020_01_28_923532	571	12	patients	patient	NNS
10_1101-2020_01_28_923532	571	13	with	with	IN
10_1101-2020_01_28_923532	571	14	relapsed	relapsed	JJ
10_1101-2020_01_28_923532	571	15	or	or	CC
10_1101-2020_01_28_923532	571	16	refractory	refractory	JJ
10_1101-2020_01_28_923532	571	17	neuroblastoma	neuroblastoma	NN
10_1101-2020_01_28_923532	571	18	.	.	.
10_1101-2020_01_28_923532	572	1	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	572	2	Med	Med	NNP
10_1101-2020_01_28_923532	572	3	.	.	.
10_1101-2020_01_28_923532	573	1	4(6):871	4(6):871	CD
10_1101-2020_01_28_923532	573	2	-	-	HYPH
10_1101-2020_01_28_923532	573	3	886	886	CD
10_1101-2020_01_28_923532	573	4	(	(	-LRB-
10_1101-2020_01_28_923532	573	5	2015	2015	CD
10_1101-2020_01_28_923532	573	6	)	)	-RRB-
10_1101-2020_01_28_923532	573	7	.	.	.
10_1101-2020_01_28_923532	574	1	5	5	CD
10_1101-2020_01_28_923532	574	2	.	.	.
10_1101-2020_01_28_923532	575	1	Byron	Byron	NNP
10_1101-2020_01_28_923532	575	2	,	,	,
10_1101-2020_01_28_923532	575	3	S.A.	S.A.	NNP
10_1101-2020_01_28_923532	575	4	,	,	,
10_1101-2020_01_28_923532	575	5	et	et	NNP
10_1101-2020_01_28_923532	575	6	al	al	NNP
10_1101-2020_01_28_923532	575	7	.	.	.
10_1101-2020_01_28_923532	576	1	Prospective	prospective	JJ
10_1101-2020_01_28_923532	576	2	feasibility	feasibility	NN
10_1101-2020_01_28_923532	576	3	trial	trial	NN
10_1101-2020_01_28_923532	576	4	for	for	IN
10_1101-2020_01_28_923532	576	5	genomics	genomic	NNS
10_1101-2020_01_28_923532	576	6	-	-	HYPH
10_1101-2020_01_28_923532	576	7	informed	inform	VBN
10_1101-2020_01_28_923532	576	8	treatment	treatment	NN
10_1101-2020_01_28_923532	576	9	in	in	IN
10_1101-2020_01_28_923532	576	10	recurrent	recurrent	JJ
10_1101-2020_01_28_923532	576	11	and	and	CC
10_1101-2020_01_28_923532	576	12	progressive	progressive	JJ
10_1101-2020_01_28_923532	576	13	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	576	14	.	.	.
10_1101-2020_01_28_923532	577	1	Clin	Clin	NNP
10_1101-2020_01_28_923532	577	2	.	.	.
10_1101-2020_01_28_923532	578	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	578	2	Res	Res	NNP
10_1101-2020_01_28_923532	578	3	.	.	.
10_1101-2020_01_28_923532	579	1	24(2	24(2	LS
10_1101-2020_01_28_923532	579	2	)	)	-RRB-
10_1101-2020_01_28_923532	579	3	,	,	,
10_1101-2020_01_28_923532	579	4	295	295	CD
10_1101-2020_01_28_923532	579	5	-	-	SYM
10_1101-2020_01_28_923532	579	6	305	305	CD
10_1101-2020_01_28_923532	579	7	(	(	-LRB-
10_1101-2020_01_28_923532	579	8	2018	2018	CD
10_1101-2020_01_28_923532	579	9	)	)	-RRB-
10_1101-2020_01_28_923532	579	10	.	.	.
10_1101-2020_01_28_923532	580	1	6	6	CD
10_1101-2020_01_28_923532	580	2	.	.	.
10_1101-2020_01_28_923532	581	1	Schwaederle	Schwaederle	NNP
10_1101-2020_01_28_923532	581	2	,	,	,
10_1101-2020_01_28_923532	581	3	M.	M.	NNP
10_1101-2020_01_28_923532	581	4	,	,	,
10_1101-2020_01_28_923532	581	5	et	et	NNP
10_1101-2020_01_28_923532	581	6	al	al	NNP
10_1101-2020_01_28_923532	581	7	.	.	.
10_1101-2020_01_28_923532	582	1	Association	Association	NNP
10_1101-2020_01_28_923532	582	2	of	of	IN
10_1101-2020_01_28_923532	582	3	biomarker	biomarker	NN
10_1101-2020_01_28_923532	582	4	-	-	HYPH
10_1101-2020_01_28_923532	582	5	based	base	VBN
10_1101-2020_01_28_923532	582	6	treatment	treatment	NN
10_1101-2020_01_28_923532	582	7	strategies	strategy	NNS
10_1101-2020_01_28_923532	582	8	with	with	IN
10_1101-2020_01_28_923532	582	9	response	response	NN
10_1101-2020_01_28_923532	582	10	rates	rate	NNS
10_1101-2020_01_28_923532	582	11	and	and	CC
10_1101-2020_01_28_923532	582	12	progression	progression	NN
10_1101-2020_01_28_923532	582	13	-	-	HYPH
10_1101-2020_01_28_923532	582	14	free	free	JJ
10_1101-2020_01_28_923532	582	15	survival	survival	NN
10_1101-2020_01_28_923532	582	16	in	in	IN
10_1101-2020_01_28_923532	582	17	refractory	refractory	JJ
10_1101-2020_01_28_923532	582	18	malignant	malignant	JJ
10_1101-2020_01_28_923532	582	19	neoplasms	neoplasm	NNS
10_1101-2020_01_28_923532	582	20	:	:	:
10_1101-2020_01_28_923532	582	21	A	a	DT
10_1101-2020_01_28_923532	582	22	meta	meta	JJ
10_1101-2020_01_28_923532	582	23	-	-	HYPH
10_1101-2020_01_28_923532	582	24	analysis	analysis	NN
10_1101-2020_01_28_923532	582	25	.	.	.
10_1101-2020_01_28_923532	583	1	JAMA	JAMA	NNP
10_1101-2020_01_28_923532	583	2	Oncology	Oncology	NNP
10_1101-2020_01_28_923532	583	3	2(11	2(11	NNP
10_1101-2020_01_28_923532	583	4	)	)	-RRB-
10_1101-2020_01_28_923532	583	5	,	,	,
10_1101-2020_01_28_923532	583	6	1452	1452	CD
10_1101-2020_01_28_923532	583	7	-	-	SYM
10_1101-2020_01_28_923532	583	8	1459	1459	CD
10_1101-2020_01_28_923532	583	9	(	(	-LRB-
10_1101-2020_01_28_923532	583	10	2016	2016	CD
10_1101-2020_01_28_923532	583	11	)	)	-RRB-
10_1101-2020_01_28_923532	583	12	.	.	.
10_1101-2020_01_28_923532	584	1	7	7	LS
10_1101-2020_01_28_923532	584	2	.	.	.
10_1101-2020_01_28_923532	585	1	Arnedos	Arnedos	NNP
10_1101-2020_01_28_923532	585	2	,	,	,
10_1101-2020_01_28_923532	585	3	M.	M.	NNP
10_1101-2020_01_28_923532	585	4	,	,	,
10_1101-2020_01_28_923532	585	5	Vielh	Vielh	NNP
10_1101-2020_01_28_923532	585	6	,	,	,
10_1101-2020_01_28_923532	585	7	P.	P.	NNP
10_1101-2020_01_28_923532	585	8	,	,	,
10_1101-2020_01_28_923532	585	9	Soria	Soria	NNP
10_1101-2020_01_28_923532	585	10	,	,	,
10_1101-2020_01_28_923532	585	11	J.C.	J.C.	NNP
10_1101-2020_01_28_923532	585	12	&	&	CC
10_1101-2020_01_28_923532	585	13	Andre	Andre	NNP
10_1101-2020_01_28_923532	585	14	,	,	,
10_1101-2020_01_28_923532	585	15	F.	F.	NNP
10_1101-2020_01_28_923532	585	16	The	the	DT
10_1101-2020_01_28_923532	585	17	genetic	genetic	JJ
10_1101-2020_01_28_923532	585	18	complexity	complexity	NN
10_1101-2020_01_28_923532	585	19	of	of	IN
10_1101-2020_01_28_923532	585	20	common	common	JJ
10_1101-2020_01_28_923532	585	21	cancers	cancer	NNS
10_1101-2020_01_28_923532	585	22	and	and	CC
10_1101-2020_01_28_923532	585	23	the	the	DT
10_1101-2020_01_28_923532	585	24	promise	promise	NN
10_1101-2020_01_28_923532	585	25	of	of	IN
10_1101-2020_01_28_923532	585	26	personalized	personalized	JJ
10_1101-2020_01_28_923532	585	27	medicine	medicine	NN
10_1101-2020_01_28_923532	585	28	:	:	:
10_1101-2020_01_28_923532	585	29	is	be	VBZ
10_1101-2020_01_28_923532	585	30	there	there	EX
10_1101-2020_01_28_923532	585	31	any	any	DT
10_1101-2020_01_28_923532	585	32	hope	hope	NN
10_1101-2020_01_28_923532	585	33	?	?	.
10_1101-2020_01_28_923532	586	1	J.	J.	NNP
10_1101-2020_01_28_923532	586	2	Pathol	Pathol	NNP
10_1101-2020_01_28_923532	586	3	.	.	.
10_1101-2020_01_28_923532	587	1	232(2	232(2	LS
10_1101-2020_01_28_923532	587	2	)	)	-RRB-
10_1101-2020_01_28_923532	587	3	:	:	:
10_1101-2020_01_28_923532	587	4	274	274	CD
10_1101-2020_01_28_923532	587	5	-	-	HYPH
10_1101-2020_01_28_923532	587	6	282	282	CD
10_1101-2020_01_28_923532	587	7	(	(	-LRB-
10_1101-2020_01_28_923532	587	8	2014	2014	CD
10_1101-2020_01_28_923532	587	9	)	)	-RRB-
10_1101-2020_01_28_923532	587	10	.	.	.
10_1101-2020_01_28_923532	588	1	8	8	LS
10_1101-2020_01_28_923532	588	2	.	.	.
10_1101-2020_01_28_923532	589	1	Nikanjam	Nikanjam	NNP
10_1101-2020_01_28_923532	589	2	,	,	,
10_1101-2020_01_28_923532	589	3	M.	M.	NNP
10_1101-2020_01_28_923532	589	4	,	,	,
10_1101-2020_01_28_923532	589	5	Liu	Liu	NNP
10_1101-2020_01_28_923532	589	6	,	,	,
10_1101-2020_01_28_923532	589	7	S.	S.	NNP
10_1101-2020_01_28_923532	589	8	,	,	,
10_1101-2020_01_28_923532	589	9	Yang	Yang	NNP
10_1101-2020_01_28_923532	589	10	,	,	,
10_1101-2020_01_28_923532	589	11	J.	J.	NNP
10_1101-2020_01_28_923532	590	1	&	&	CC
10_1101-2020_01_28_923532	590	2	Kurzrock	Kurzrock	NNP
10_1101-2020_01_28_923532	590	3	,	,	,
10_1101-2020_01_28_923532	590	4	R.	R.	NNP
10_1101-2020_01_28_923532	590	5	Dosing	Dosing	NNP
10_1101-2020_01_28_923532	590	6	three	three	CD
10_1101-2020_01_28_923532	590	7	-	-	HYPH
10_1101-2020_01_28_923532	590	8	drug	drug	NN
10_1101-2020_01_28_923532	590	9	combinations	combination	NNS
10_1101-2020_01_28_923532	590	10	that	that	WDT
10_1101-2020_01_28_923532	590	11	include	include	VBP
10_1101-2020_01_28_923532	590	12	targeted	target	VBN
10_1101-2020_01_28_923532	590	13	anti	anti	JJ
10_1101-2020_01_28_923532	590	14	-	-	JJ
10_1101-2020_01_28_923532	590	15	cancer	cancer	JJ
10_1101-2020_01_28_923532	590	16	agents	agent	NNS
10_1101-2020_01_28_923532	590	17	:	:	:
10_1101-2020_01_28_923532	590	18	Analysis	analysis	NN
10_1101-2020_01_28_923532	590	19	of	of	IN
10_1101-2020_01_28_923532	590	20	37,763	37,763	CD
10_1101-2020_01_28_923532	590	21	patients	patient	NNS
10_1101-2020_01_28_923532	590	22	.	.	.
10_1101-2020_01_28_923532	591	1	Oncologist	oncologist	JJ
10_1101-2020_01_28_923532	591	2	22(5	22(5	CD
10_1101-2020_01_28_923532	591	3	)	)	-RRB-
10_1101-2020_01_28_923532	591	4	,	,	,
10_1101-2020_01_28_923532	591	5	576	576	CD
10_1101-2020_01_28_923532	591	6	-	-	HYPH
10_1101-2020_01_28_923532	591	7	584	584	CD
10_1101-2020_01_28_923532	591	8	(	(	-LRB-
10_1101-2020_01_28_923532	591	9	2017	2017	CD
10_1101-2020_01_28_923532	591	10	)	)	-RRB-
10_1101-2020_01_28_923532	591	11	.	.	.
10_1101-2020_01_28_923532	592	1	9	9	CD
10_1101-2020_01_28_923532	592	2	.	.	.
10_1101-2020_01_28_923532	593	1	Rebollo	Rebollo	NNP
10_1101-2020_01_28_923532	593	2	,	,	,
10_1101-2020_01_28_923532	593	3	J.	J.	NNP
10_1101-2020_01_28_923532	593	4	et	et	NNP
10_1101-2020_01_28_923532	593	5	al	al	NNP
10_1101-2020_01_28_923532	593	6	.	.	.
10_1101-2020_01_28_923532	594	1	Gene	gene	NN
10_1101-2020_01_28_923532	594	2	expression	expression	NN
10_1101-2020_01_28_923532	594	3	profiling	profiling	NN
10_1101-2020_01_28_923532	594	4	of	of	IN
10_1101-2020_01_28_923532	594	5	tumors	tumor	NNS
10_1101-2020_01_28_923532	594	6	from	from	IN
10_1101-2020_01_28_923532	594	7	heavily	heavily	RB
10_1101-2020_01_28_923532	594	8	pretreated	pretreate	VBN
10_1101-2020_01_28_923532	594	9	patients	patient	NNS
10_1101-2020_01_28_923532	594	10	with	with	IN
10_1101-2020_01_28_923532	594	11	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	594	12	cancer	cancer	NN
10_1101-2020_01_28_923532	594	13	for	for	IN
10_1101-2020_01_28_923532	594	14	the	the	DT
10_1101-2020_01_28_923532	594	15	selection	selection	NN
10_1101-2020_01_28_923532	594	16	of	of	IN
10_1101-2020_01_28_923532	594	17	therapy	therapy	NN
10_1101-2020_01_28_923532	594	18	:	:	:
10_1101-2020_01_28_923532	594	19	A	a	DT
10_1101-2020_01_28_923532	594	20	pilot	pilot	NN
10_1101-2020_01_28_923532	594	21	study	study	NN
10_1101-2020_01_28_923532	594	22	.	.	.
10_1101-2020_01_28_923532	595	1	Am	Am	NNP
10_1101-2020_01_28_923532	595	2	.	.	.
10_1101-2020_01_28_923532	596	1	J.	J.	NNP
10_1101-2020_01_28_923532	596	2	Clin	Clin	NNP
10_1101-2020_01_28_923532	596	3	.	.	.
10_1101-2020_01_28_923532	597	1	Oncol	Oncol	NNP
10_1101-2020_01_28_923532	597	2	.	.	.
10_1101-2020_01_28_923532	598	1	40(2	40(2	LS
10_1101-2020_01_28_923532	598	2	)	)	-RRB-
10_1101-2020_01_28_923532	598	3	,	,	,
10_1101-2020_01_28_923532	598	4	140-	140-	VBZ
10_1101-2020_01_28_923532	598	5	145	145	CD
10_1101-2020_01_28_923532	598	6	(	(	-LRB-
10_1101-2020_01_28_923532	598	7	2017	2017	CD
10_1101-2020_01_28_923532	598	8	)	)	-RRB-
10_1101-2020_01_28_923532	598	9	.	.	.
10_1101-2020_01_28_923532	599	1	10	10	CD
10_1101-2020_01_28_923532	599	2	.	.	.
10_1101-2020_01_28_923532	600	1	Sureda	Sureda	NNP
10_1101-2020_01_28_923532	600	2	,	,	,
10_1101-2020_01_28_923532	600	3	M.	M.	NNP
10_1101-2020_01_28_923532	600	4	,	,	,
10_1101-2020_01_28_923532	600	5	et	et	NNP
10_1101-2020_01_28_923532	600	6	al	al	NNP
10_1101-2020_01_28_923532	600	7	.	.	.
10_1101-2020_01_28_923532	601	1	Determining	determine	VBG
10_1101-2020_01_28_923532	601	2	personalized	personalized	JJ
10_1101-2020_01_28_923532	601	3	treatment	treatment	NN
10_1101-2020_01_28_923532	601	4	by	by	IN
10_1101-2020_01_28_923532	601	5	gene	gene	NN
10_1101-2020_01_28_923532	601	6	expression	expression	NN
10_1101-2020_01_28_923532	601	7	profiling	profiling	NN
10_1101-2020_01_28_923532	601	8	in	in	IN
10_1101-2020_01_28_923532	601	9	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	601	10	breast	breast	NN
10_1101-2020_01_28_923532	601	11	carcinoma	carcinoma	NN
10_1101-2020_01_28_923532	601	12	patients	patient	NNS
10_1101-2020_01_28_923532	601	13	:	:	:
10_1101-2020_01_28_923532	601	14	a	a	DT
10_1101-2020_01_28_923532	601	15	pilot	pilot	NN
10_1101-2020_01_28_923532	601	16	study	study	NN
10_1101-2020_01_28_923532	601	17	.	.	.
10_1101-2020_01_28_923532	602	1	Clin	Clin	NNP
10_1101-2020_01_28_923532	602	2	.	.	.
10_1101-2020_01_28_923532	603	1	Trans	tran	NNS
10_1101-2020_01_28_923532	603	2	.	.	.
10_1101-2020_01_28_923532	604	1	Oncol	Oncol	NNP
10_1101-2020_01_28_923532	604	2	.	.	.
10_1101-2020_01_28_923532	605	1	20(6	20(6	LS
10_1101-2020_01_28_923532	605	2	)	)	-RRB-
10_1101-2020_01_28_923532	605	3	,	,	,
10_1101-2020_01_28_923532	605	4	785	785	CD
10_1101-2020_01_28_923532	605	5	-	-	SYM
10_1101-2020_01_28_923532	605	6	793	793	CD
10_1101-2020_01_28_923532	605	7	(	(	-LRB-
10_1101-2020_01_28_923532	605	8	2018	2018	CD
10_1101-2020_01_28_923532	605	9	)	)	-RRB-
10_1101-2020_01_28_923532	605	10	.	.	.
10_1101-2020_01_28_923532	606	1	11	11	CD
10_1101-2020_01_28_923532	606	2	.	.	.
10_1101-2020_01_28_923532	607	1	Sicklick	Sicklick	NNP
10_1101-2020_01_28_923532	607	2	,	,	,
10_1101-2020_01_28_923532	607	3	J.K.	J.K.	NNP
10_1101-2020_01_28_923532	607	4	,	,	,
10_1101-2020_01_28_923532	607	5	et	et	NNP
10_1101-2020_01_28_923532	607	6	al	al	NNP
10_1101-2020_01_28_923532	607	7	.	.	.
10_1101-2020_01_28_923532	608	1	Molecular	molecular	JJ
10_1101-2020_01_28_923532	608	2	profiling	profiling	NN
10_1101-2020_01_28_923532	608	3	of	of	IN
10_1101-2020_01_28_923532	608	4	cancer	cancer	NN
10_1101-2020_01_28_923532	608	5	patients	patient	NNS
10_1101-2020_01_28_923532	608	6	enables	enable	VBZ
10_1101-2020_01_28_923532	608	7	personalized	personalize	VBN
10_1101-2020_01_28_923532	608	8	combination	combination	NN
10_1101-2020_01_28_923532	608	9	therapy	therapy	NN
10_1101-2020_01_28_923532	608	10	:	:	:
10_1101-2020_01_28_923532	608	11	the	the	DT
10_1101-2020_01_28_923532	608	12	I	I	NNP
10_1101-2020_01_28_923532	608	13	-	-	HYPH
10_1101-2020_01_28_923532	608	14	PREDICT	PREDICT	NNP
10_1101-2020_01_28_923532	608	15	study	study	NN
10_1101-2020_01_28_923532	608	16	.	.	.
10_1101-2020_01_28_923532	609	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	609	2	.	.	.
10_1101-2020_01_28_923532	610	1	Med	Med	NNP
10_1101-2020_01_28_923532	610	2	.	.	.
10_1101-2020_01_28_923532	611	1	25(5	25(5	LS
10_1101-2020_01_28_923532	611	2	)	)	-RRB-
10_1101-2020_01_28_923532	611	3	,	,	,
10_1101-2020_01_28_923532	611	4	744	744	CD
10_1101-2020_01_28_923532	611	5	-	-	HYPH
10_1101-2020_01_28_923532	611	6	750	750	CD
10_1101-2020_01_28_923532	611	7	(	(	-LRB-
10_1101-2020_01_28_923532	611	8	2019	2019	CD
10_1101-2020_01_28_923532	611	9	)	)	-RRB-
10_1101-2020_01_28_923532	611	10	.	.	.
10_1101-2020_01_28_923532	612	1	12	12	CD
10_1101-2020_01_28_923532	612	2	.	.	.
10_1101-2020_01_28_923532	613	1	Joo	Joo	NNP
10_1101-2020_01_28_923532	613	2	,	,	,
10_1101-2020_01_28_923532	613	3	J.I.	J.I.	NNP
10_1101-2020_01_28_923532	613	4	,	,	,
10_1101-2020_01_28_923532	613	5	et	et	NNP
10_1101-2020_01_28_923532	613	6	al	al	NNP
10_1101-2020_01_28_923532	613	7	.	.	.
10_1101-2020_01_28_923532	614	1	Realizing	realize	VBG
10_1101-2020_01_28_923532	614	2	cancer	cancer	NN
10_1101-2020_01_28_923532	614	3	precision	precision	NN
10_1101-2020_01_28_923532	614	4	medicine	medicine	NN
10_1101-2020_01_28_923532	614	5	by	by	IN
10_1101-2020_01_28_923532	614	6	integrating	integrate	VBG
10_1101-2020_01_28_923532	614	7	systems	system	NNS
10_1101-2020_01_28_923532	614	8	biology	biology	NN
10_1101-2020_01_28_923532	614	9	and	and	CC
10_1101-2020_01_28_923532	614	10	nanomaterial	nanomaterial	JJ
10_1101-2020_01_28_923532	614	11	engineering	engineering	NN
10_1101-2020_01_28_923532	614	12	.	.	.
10_1101-2020_01_28_923532	615	1	Adv	Adv	NNP
10_1101-2020_01_28_923532	615	2	.	.	.
10_1101-2020_01_28_923532	616	1	Mater	Mater	NNP
10_1101-2020_01_28_923532	616	2	.	.	.
10_1101-2020_01_28_923532	617	1	32(35):e1906783	32(35):e1906783	CD
10_1101-2020_01_28_923532	617	2	(	(	-LRB-
10_1101-2020_01_28_923532	617	3	2020	2020	CD
10_1101-2020_01_28_923532	617	4	)	)	-RRB-
10_1101-2020_01_28_923532	617	5	.	.	.
10_1101-2020_01_28_923532	618	1	13	13	CD
10_1101-2020_01_28_923532	618	2	.	.	.
10_1101-2020_01_28_923532	619	1	Marusyk	Marusyk	NNP
10_1101-2020_01_28_923532	619	2	,	,	,
10_1101-2020_01_28_923532	619	3	A.	a.	NN
10_1101-2020_01_28_923532	620	1	&	&	CC
10_1101-2020_01_28_923532	620	2	Polyak	Polyak	NNP
10_1101-2020_01_28_923532	620	3	,	,	,
10_1101-2020_01_28_923532	620	4	K.	K.	NNP
10_1101-2020_01_28_923532	620	5	Tumor	Tumor	NNP
10_1101-2020_01_28_923532	620	6	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	620	7	:	:	:
10_1101-2020_01_28_923532	620	8	Causes	cause	NNS
10_1101-2020_01_28_923532	620	9	and	and	CC
10_1101-2020_01_28_923532	620	10	consequences	consequence	NNS
10_1101-2020_01_28_923532	620	11	.	.	.
10_1101-2020_01_28_923532	621	1	Biochimica	Biochimica	NNP
10_1101-2020_01_28_923532	621	2	et	et	NNP
10_1101-2020_01_28_923532	621	3	Biophysica	Biophysica	NNP
10_1101-2020_01_28_923532	621	4	Acta	Acta	NNP
10_1101-2020_01_28_923532	621	5	1805(1	1805(1	NNP
10_1101-2020_01_28_923532	621	6	)	)	-RRB-
10_1101-2020_01_28_923532	621	7	,	,	,
10_1101-2020_01_28_923532	621	8	105	105	CD
10_1101-2020_01_28_923532	621	9	-	-	SYM
10_1101-2020_01_28_923532	621	10	117	117	CD
10_1101-2020_01_28_923532	621	11	(	(	-LRB-
10_1101-2020_01_28_923532	621	12	2010	2010	CD
10_1101-2020_01_28_923532	621	13	)	)	-RRB-
10_1101-2020_01_28_923532	621	14	.	.	.
10_1101-2020_01_28_923532	622	1	14	14	CD
10_1101-2020_01_28_923532	622	2	.	.	.
10_1101-2020_01_28_923532	623	1	McGranahan	McGranahan	NNP
10_1101-2020_01_28_923532	623	2	,	,	,
10_1101-2020_01_28_923532	623	3	N.	N.	NNP
10_1101-2020_01_28_923532	623	4	&	&	CC
10_1101-2020_01_28_923532	623	5	Swanton	Swanton	NNP
10_1101-2020_01_28_923532	623	6	,	,	,
10_1101-2020_01_28_923532	623	7	C.	C.	NNP
10_1101-2020_01_28_923532	623	8	Biological	Biological	NNP
10_1101-2020_01_28_923532	623	9	and	and	CC
10_1101-2020_01_28_923532	623	10	therapeutic	therapeutic	JJ
10_1101-2020_01_28_923532	623	11	impact	impact	NN
10_1101-2020_01_28_923532	623	12	of	of	IN
10_1101-2020_01_28_923532	623	13	intratumor	intratumor	JJ
10_1101-2020_01_28_923532	623	14	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	623	15	in	in	IN
10_1101-2020_01_28_923532	623	16	cancer	cancer	NN
10_1101-2020_01_28_923532	623	17	evolution	evolution	NN
10_1101-2020_01_28_923532	623	18	.	.	.
10_1101-2020_01_28_923532	624	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	624	2	Cell	Cell	NNP
10_1101-2020_01_28_923532	624	3	27(1):15	27(1):15	NNP
10_1101-2020_01_28_923532	624	4	-	-	HYPH
10_1101-2020_01_28_923532	624	5	26	26	CD
10_1101-2020_01_28_923532	624	6	(	(	-LRB-
10_1101-2020_01_28_923532	624	7	2015	2015	CD
10_1101-2020_01_28_923532	624	8	)	)	-RRB-
10_1101-2020_01_28_923532	624	9	.	.	.
10_1101-2020_01_28_923532	625	1	15	15	CD
10_1101-2020_01_28_923532	625	2	.	.	.
10_1101-2020_01_28_923532	626	1	Yofe	Yofe	NNP
10_1101-2020_01_28_923532	626	2	,	,	,
10_1101-2020_01_28_923532	626	3	I.	I.	NNP
10_1101-2020_01_28_923532	626	4	,	,	,
10_1101-2020_01_28_923532	626	5	Dahan	Dahan	NNP
10_1101-2020_01_28_923532	626	6	,	,	,
10_1101-2020_01_28_923532	626	7	R.	R.	NNP
10_1101-2020_01_28_923532	626	8	&	&	CC
10_1101-2020_01_28_923532	626	9	Amit	Amit	NNP
10_1101-2020_01_28_923532	626	10	I.	I.	NNP
10_1101-2020_01_28_923532	626	11	Single	single	JJ
10_1101-2020_01_28_923532	626	12	-	-	HYPH
10_1101-2020_01_28_923532	626	13	cell	cell	NN
10_1101-2020_01_28_923532	626	14	genomic	genomic	JJ
10_1101-2020_01_28_923532	626	15	approaches	approach	NNS
10_1101-2020_01_28_923532	626	16	for	for	IN
10_1101-2020_01_28_923532	626	17	developing	develop	VBG
10_1101-2020_01_28_923532	626	18	the	the	DT
10_1101-2020_01_28_923532	626	19	next	next	JJ
10_1101-2020_01_28_923532	626	20	generation	generation	NN
10_1101-2020_01_28_923532	626	21	of	of	IN
10_1101-2020_01_28_923532	626	22	immunotherapies	immunotherapy	NNS
10_1101-2020_01_28_923532	626	23	.	.	.
10_1101-2020_01_28_923532	627	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	627	2	.	.	.
10_1101-2020_01_28_923532	628	1	Med	Med	NNP
10_1101-2020_01_28_923532	628	2	.	.	.
10_1101-2020_01_28_923532	629	1	26(2	26(2	LS
10_1101-2020_01_28_923532	629	2	)	)	-RRB-
10_1101-2020_01_28_923532	629	3	,	,	,
10_1101-2020_01_28_923532	629	4	171	171	CD
10_1101-2020_01_28_923532	629	5	-	-	SYM
10_1101-2020_01_28_923532	629	6	177	177	CD
10_1101-2020_01_28_923532	629	7	(	(	-LRB-
10_1101-2020_01_28_923532	629	8	2020	2020	CD
10_1101-2020_01_28_923532	629	9	)	)	-RRB-
10_1101-2020_01_28_923532	629	10	.	.	.
10_1101-2020_01_28_923532	630	1	16	16	CD
10_1101-2020_01_28_923532	630	2	.	.	.
10_1101-2020_01_28_923532	631	1	Neelapu	Neelapu	NNP
10_1101-2020_01_28_923532	631	2	,	,	,
10_1101-2020_01_28_923532	631	3	S.S.	S.S.	NNP
10_1101-2020_01_28_923532	631	4	,	,	,
10_1101-2020_01_28_923532	631	5	et	et	NNP
10_1101-2020_01_28_923532	631	6	al	al	NNP
10_1101-2020_01_28_923532	631	7	.	.	.
10_1101-2020_01_28_923532	632	1	Axicabatagene	axicabatagene	JJ
10_1101-2020_01_28_923532	632	2	ciloleucel	ciloleucel	NN
10_1101-2020_01_28_923532	632	3	CAR	car	NN
10_1101-2020_01_28_923532	632	4	T	t	NN
10_1101-2020_01_28_923532	632	5	-	-	HYPH
10_1101-2020_01_28_923532	632	6	cell	cell	NN
10_1101-2020_01_28_923532	632	7	therapy	therapy	NN
10_1101-2020_01_28_923532	632	8	in	in	IN
10_1101-2020_01_28_923532	632	9	refractory	refractory	JJ
10_1101-2020_01_28_923532	632	10	large	large	JJ
10_1101-2020_01_28_923532	632	11	B	b	NN
10_1101-2020_01_28_923532	632	12	-	-	HYPH
10_1101-2020_01_28_923532	632	13	cell	cell	NN
10_1101-2020_01_28_923532	632	14	lymphoma	lymphoma	NN
10_1101-2020_01_28_923532	632	15	.	.	.
10_1101-2020_01_28_923532	633	1	New	New	NNP
10_1101-2020_01_28_923532	633	2	Engl	Engl	NNP
10_1101-2020_01_28_923532	633	3	.	.	.
10_1101-2020_01_28_923532	634	1	J.	J.	NNP
10_1101-2020_01_28_923532	634	2	Med	Med	NNP
10_1101-2020_01_28_923532	634	3	.	.	.
10_1101-2020_01_28_923532	635	1	377(26):2531	377(26):2531	CD
10_1101-2020_01_28_923532	635	2	-	-	HYPH
10_1101-2020_01_28_923532	635	3	2544	2544	CD
10_1101-2020_01_28_923532	635	4	,	,	,
10_1101-2020_01_28_923532	635	5	2017	2017	CD
10_1101-2020_01_28_923532	635	6	.	.	.
10_1101-2020_01_28_923532	636	1	17	17	CD
10_1101-2020_01_28_923532	636	2	.	.	.
10_1101-2020_01_28_923532	637	1	Bjorn	Bjorn	NNP
10_1101-2020_01_28_923532	637	2	,	,	,
10_1101-2020_01_28_923532	637	3	M.J.	M.J.	NNP
10_1101-2020_01_28_923532	637	4	,	,	,
10_1101-2020_01_28_923532	637	5	Ring	Ring	NNP
10_1101-2020_01_28_923532	637	6	,	,	,
10_1101-2020_01_28_923532	637	7	D.	D.	NNP
10_1101-2020_01_28_923532	637	8	&	&	CC
10_1101-2020_01_28_923532	637	9	Frankel	Frankel	NNP
10_1101-2020_01_28_923532	637	10	,	,	,
10_1101-2020_01_28_923532	637	11	A.	a.	NN
10_1101-2020_01_28_923532	638	1	Evaluation	evaluation	NN
10_1101-2020_01_28_923532	638	2	of	of	IN
10_1101-2020_01_28_923532	638	3	monoclonal	monoclonal	JJ
10_1101-2020_01_28_923532	638	4	antibodies	antibody	NNS
10_1101-2020_01_28_923532	638	5	for	for	IN
10_1101-2020_01_28_923532	638	6	the	the	DT
10_1101-2020_01_28_923532	638	7	development	development	NN
10_1101-2020_01_28_923532	638	8	of	of	IN
10_1101-2020_01_28_923532	638	9	breast	breast	NN
10_1101-2020_01_28_923532	638	10	cancer	cancer	NN
10_1101-2020_01_28_923532	638	11	immunotoxins	immunotoxin	NNS
10_1101-2020_01_28_923532	638	12	.	.	.
10_1101-2020_01_28_923532	639	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	639	2	Res	Res	NNP
10_1101-2020_01_28_923532	639	3	.	.	.
10_1101-2020_01_28_923532	640	1	45(3	45(3	LS
10_1101-2020_01_28_923532	640	2	)	)	-RRB-
10_1101-2020_01_28_923532	640	3	,	,	,
10_1101-2020_01_28_923532	640	4	1214	1214	CD
10_1101-2020_01_28_923532	640	5	-	-	SYM
10_1101-2020_01_28_923532	640	6	1221	1221	CD
10_1101-2020_01_28_923532	640	7	(	(	-LRB-
10_1101-2020_01_28_923532	640	8	1985	1985	CD
10_1101-2020_01_28_923532	640	9	)	)	-RRB-
10_1101-2020_01_28_923532	640	10	.	.	.
10_1101-2020_01_28_923532	641	1	18	18	CD
10_1101-2020_01_28_923532	641	2	.	.	.
10_1101-2020_01_28_923532	642	1	Pastan	Pastan	NNP
10_1101-2020_01_28_923532	642	2	,	,	,
10_1101-2020_01_28_923532	642	3	I.	I.	NNP
10_1101-2020_01_28_923532	642	4	,	,	,
10_1101-2020_01_28_923532	642	5	Willingham	Willingham	NNP
10_1101-2020_01_28_923532	642	6	,	,	,
10_1101-2020_01_28_923532	642	7	M.C.	M.C.	NNP
10_1101-2020_01_28_923532	643	1	&	&	CC
10_1101-2020_01_28_923532	643	2	FitzGerald	FitzGerald	NNP
10_1101-2020_01_28_923532	643	3	D.J.P.	D.J.P.	NNP
10_1101-2020_01_28_923532	644	1	Immunotoxins	immunotoxin	NNS
10_1101-2020_01_28_923532	644	2	.	.	.
10_1101-2020_01_28_923532	645	1	Cell	cell	NN
10_1101-2020_01_28_923532	645	2	47(5	47(5	JJ
10_1101-2020_01_28_923532	645	3	)	)	-RRB-
10_1101-2020_01_28_923532	645	4	,	,	,
10_1101-2020_01_28_923532	645	5	641	641	CD
10_1101-2020_01_28_923532	645	6	-	-	SYM
10_1101-2020_01_28_923532	645	7	648	648	CD
10_1101-2020_01_28_923532	645	8	(	(	-LRB-
10_1101-2020_01_28_923532	645	9	1986	1986	CD
10_1101-2020_01_28_923532	645	10	)	)	-RRB-
10_1101-2020_01_28_923532	645	11	.	.	.
10_1101-2020_01_28_923532	646	1	19	19	CD
10_1101-2020_01_28_923532	646	2	.	.	.
10_1101-2020_01_28_923532	647	1	Gray	Gray	NNP
10_1101-2020_01_28_923532	647	2	,	,	,
10_1101-2020_01_28_923532	647	3	B.P.	B.P.	NNP
10_1101-2020_01_28_923532	648	1	&	&	CC
10_1101-2020_01_28_923532	648	2	Brown	Brown	NNP
10_1101-2020_01_28_923532	648	3	,	,	,
10_1101-2020_01_28_923532	648	4	K.C.	K.C.	NNP
10_1101-2020_01_28_923532	649	1	Combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	649	2	peptide	peptide	NN
10_1101-2020_01_28_923532	649	3	libraries	library	NNS
10_1101-2020_01_28_923532	649	4	:	:	:
10_1101-2020_01_28_923532	649	5	mining	mine	VBG
10_1101-2020_01_28_923532	649	6	for	for	IN
10_1101-2020_01_28_923532	649	7	cell	cell	NN
10_1101-2020_01_28_923532	649	8	-	-	HYPH
10_1101-2020_01_28_923532	649	9	binding	bind	VBG
10_1101-2020_01_28_923532	649	10	peptides	peptide	NNS
10_1101-2020_01_28_923532	649	11	.	.	.
10_1101-2020_01_28_923532	650	1	Chem	Chem	NNP
10_1101-2020_01_28_923532	650	2	.	.	.
10_1101-2020_01_28_923532	651	1	Rev.	Rev.	NNP
10_1101-2020_01_28_923532	652	1	114(2	114(2	LS
10_1101-2020_01_28_923532	652	2	)	)	-RRB-
10_1101-2020_01_28_923532	652	3	,	,	,
10_1101-2020_01_28_923532	652	4	1020	1020	CD
10_1101-2020_01_28_923532	652	5	-	-	SYM
10_1101-2020_01_28_923532	652	6	1081	1081	CD
10_1101-2020_01_28_923532	652	7	(	(	-LRB-
10_1101-2020_01_28_923532	652	8	2014	2014	CD
10_1101-2020_01_28_923532	652	9	)	)	-RRB-
10_1101-2020_01_28_923532	652	10	.	.	.
10_1101-2020_01_28_923532	653	1	20	20	CD
10_1101-2020_01_28_923532	653	2	.	.	.
10_1101-2020_01_28_923532	654	1	Liu	Liu	NNP
10_1101-2020_01_28_923532	654	2	,	,	,
10_1101-2020_01_28_923532	654	3	R.	R.	NNP
10_1101-2020_01_28_923532	654	4	,	,	,
10_1101-2020_01_28_923532	654	5	Li	Li	NNP
10_1101-2020_01_28_923532	654	6	,	,	,
10_1101-2020_01_28_923532	654	7	X.	X.	NNP
10_1101-2020_01_28_923532	654	8	,	,	,
10_1101-2020_01_28_923532	654	9	Xiao	Xiao	NNP
10_1101-2020_01_28_923532	654	10	,	,	,
10_1101-2020_01_28_923532	654	11	W.	W.	NNP
10_1101-2020_01_28_923532	654	12	&	&	CC
10_1101-2020_01_28_923532	654	13	Lam	Lam	NNP
10_1101-2020_01_28_923532	654	14	,	,	,
10_1101-2020_01_28_923532	654	15	K.S.	K.S.	NNP
10_1101-2020_01_28_923532	655	1	Tumor	tumor	NN
10_1101-2020_01_28_923532	655	2	-	-	HYPH
10_1101-2020_01_28_923532	655	3	targeting	target	VBG
10_1101-2020_01_28_923532	655	4	peptides	peptide	NNS
10_1101-2020_01_28_923532	655	5	from	from	IN
10_1101-2020_01_28_923532	655	6	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	655	7	libraries	library	NNS
10_1101-2020_01_28_923532	655	8	.	.	.
10_1101-2020_01_28_923532	656	1	Adv	Adv	NNP
10_1101-2020_01_28_923532	656	2	.	.	.
10_1101-2020_01_28_923532	657	1	Drug	Drug	NNP
10_1101-2020_01_28_923532	657	2	Delivery	Delivery	NNP
10_1101-2020_01_28_923532	657	3	Rev.	Rev.	NNP
10_1101-2020_01_28_923532	658	1	110	110	CD
10_1101-2020_01_28_923532	658	2	-	-	SYM
10_1101-2020_01_28_923532	658	3	111	111	CD
10_1101-2020_01_28_923532	658	4	,	,	,
10_1101-2020_01_28_923532	658	5	13	13	CD
10_1101-2020_01_28_923532	658	6	-	-	SYM
10_1101-2020_01_28_923532	658	7	37	37	CD
10_1101-2020_01_28_923532	658	8	(	(	-LRB-
10_1101-2020_01_28_923532	658	9	2017	2017	CD
10_1101-2020_01_28_923532	658	10	)	)	-RRB-
10_1101-2020_01_28_923532	658	11	.	.	.
10_1101-2020_01_28_923532	659	1	21	21	CD
10_1101-2020_01_28_923532	659	2	.	.	.
10_1101-2020_01_28_923532	660	1	Fisher	Fisher	NNP
10_1101-2020_01_28_923532	660	2	,	,	,
10_1101-2020_01_28_923532	660	3	S.L.	S.L.	NNP
10_1101-2020_01_28_923532	661	1	&	&	CC
10_1101-2020_01_28_923532	661	2	Phillips	Phillips	NNP
10_1101-2020_01_28_923532	661	3	,	,	,
10_1101-2020_01_28_923532	661	4	A.J.	A.J.	NNP
10_1101-2020_01_28_923532	662	1	Targeted	target	VBN
10_1101-2020_01_28_923532	662	2	protein	protein	NN
10_1101-2020_01_28_923532	662	3	degradation	degradation	NN
10_1101-2020_01_28_923532	662	4	and	and	CC
10_1101-2020_01_28_923532	662	5	the	the	DT
10_1101-2020_01_28_923532	662	6	enzymology	enzymology	NN
10_1101-2020_01_28_923532	662	7	of	of	IN
10_1101-2020_01_28_923532	662	8	degraders	degrader	NNS
10_1101-2020_01_28_923532	662	9	.	.	.
10_1101-2020_01_28_923532	663	1	Curr	curr	UH
10_1101-2020_01_28_923532	663	2	.	.	.
10_1101-2020_01_28_923532	664	1	Opin	opin	JJ
10_1101-2020_01_28_923532	664	2	.	.	.
10_1101-2020_01_28_923532	665	1	Chem	Chem	NNP
10_1101-2020_01_28_923532	665	2	.	.	.
10_1101-2020_01_28_923532	666	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	666	2	.	.	.
10_1101-2020_01_28_923532	667	1	44	44	CD
10_1101-2020_01_28_923532	667	2	,	,	,
10_1101-2020_01_28_923532	667	3	47	47	CD
10_1101-2020_01_28_923532	667	4	-	-	SYM
10_1101-2020_01_28_923532	667	5	55	55	CD
10_1101-2020_01_28_923532	667	6	(	(	-LRB-
10_1101-2020_01_28_923532	667	7	2018	2018	CD
10_1101-2020_01_28_923532	667	8	)	)	-RRB-
10_1101-2020_01_28_923532	667	9	.	.	.
10_1101-2020_01_28_923532	668	1	105	105	CD
10_1101-2020_01_28_923532	668	2	and	and	CC
10_1101-2020_01_28_923532	668	3	is	be	VBZ
10_1101-2020_01_28_923532	668	4	also	also	RB
10_1101-2020_01_28_923532	668	5	made	make	VBN
10_1101-2020_01_28_923532	668	6	available	available	JJ
10_1101-2020_01_28_923532	668	7	for	for	IN
10_1101-2020_01_28_923532	668	8	use	use	NN
10_1101-2020_01_28_923532	668	9	under	under	IN
10_1101-2020_01_28_923532	668	10	a	a	DT
10_1101-2020_01_28_923532	668	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	668	12	license	license	NN
10_1101-2020_01_28_923532	668	13	.	.	.
10_1101-2020_01_28_923532	669	1	(	(	-LRB-
10_1101-2020_01_28_923532	669	2	which	which	WDT
10_1101-2020_01_28_923532	669	3	was	be	VBD
10_1101-2020_01_28_923532	669	4	not	not	RB
10_1101-2020_01_28_923532	669	5	certified	certify	VBN
10_1101-2020_01_28_923532	669	6	by	by	IN
10_1101-2020_01_28_923532	669	7	peer	peer	NN
10_1101-2020_01_28_923532	669	8	review	review	NN
10_1101-2020_01_28_923532	669	9	)	)	-RRB-
10_1101-2020_01_28_923532	669	10	is	be	VBZ
10_1101-2020_01_28_923532	669	11	the	the	DT
10_1101-2020_01_28_923532	669	12	author	author	NN
10_1101-2020_01_28_923532	669	13	/	/	SYM
10_1101-2020_01_28_923532	669	14	funder	funder	NN
10_1101-2020_01_28_923532	669	15	.	.	.
10_1101-2020_01_28_923532	670	1	This	this	DT
10_1101-2020_01_28_923532	670	2	article	article	NN
10_1101-2020_01_28_923532	670	3	is	be	VBZ
10_1101-2020_01_28_923532	670	4	a	a	DT
10_1101-2020_01_28_923532	670	5	US	US	NNP
10_1101-2020_01_28_923532	670	6	Government	Government	NNP
10_1101-2020_01_28_923532	670	7	work	work	NN
10_1101-2020_01_28_923532	670	8	.	.	.
10_1101-2020_01_28_923532	671	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	671	2	is	be	VBZ
10_1101-2020_01_28_923532	671	3	not	not	RB
10_1101-2020_01_28_923532	671	4	subject	subject	JJ
10_1101-2020_01_28_923532	671	5	to	to	IN
10_1101-2020_01_28_923532	671	6	copyright	copyright	NN
10_1101-2020_01_28_923532	671	7	under	under	IN
10_1101-2020_01_28_923532	671	8	17	17	CD
10_1101-2020_01_28_923532	671	9	USC	usc	NN
10_1101-2020_01_28_923532	671	10	The	the	DT
10_1101-2020_01_28_923532	671	11	copyright	copyright	NN
10_1101-2020_01_28_923532	671	12	holder	holder	NN
10_1101-2020_01_28_923532	671	13	for	for	IN
10_1101-2020_01_28_923532	671	14	this	this	DT
10_1101-2020_01_28_923532	671	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	671	16	version	version	NN
10_1101-2020_01_28_923532	671	17	posted	post	VBD
10_1101-2020_01_28_923532	671	18	February	February	NNP
10_1101-2020_01_28_923532	671	19	12	12	CD
10_1101-2020_01_28_923532	671	20	,	,	,
10_1101-2020_01_28_923532	671	21	2021	2021	CD
10_1101-2020_01_28_923532	671	22	.	.	.
10_1101-2020_01_28_923532	671	23	;	;	:
10_1101-2020_01_28_923532	671	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	671	25	:	:	:
10_1101-2020_01_28_923532	671	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	671	27	preprint	preprint	NN
10_1101-2020_01_28_923532	671	28	https://www.ncbi.nlm.nih.gov/pubmed/28595192	https://www.ncbi.nlm.nih.gov/pubmed/28595192	-LRB-
10_1101-2020_01_28_923532	671	29	https://www.ncbi.nlm.nih.gov/pubmed/?term=Jameson%20GS%5BAuthor%5D&cauthor=true&cauthor_uid=25209003	https://www.ncbi.nlm.nih.gov/pubmed/?term=Jameson%20GS%5BAuthor%5D&cauthor=true&cauthor_uid=25209003	NNP
10_1101-2020_01_28_923532	671	30	https://www.ncbi.nlm.nih.gov/pubmed/?term=Jameson+GS%5Bauth%5D+2014	https://www.ncbi.nlm.nih.gov/pubmed/?term=jameson+gs%5bauth%5d+2014	CD
10_1101-2020_01_28_923532	671	31	https://www.ncbi.nlm.nih.gov/pubmed/25720842	https://www.ncbi.nlm.nih.gov/pubmed/25720842	UH
10_1101-2020_01_28_923532	671	32	https://www.ncbi.nlm.nih.gov/pubmed/25720842	https://www.ncbi.nlm.nih.gov/pubmed/25720842	UH
10_1101-2020_01_28_923532	671	33	https://www.ncbi.nlm.nih.gov/pubmed/27273579	https://www.ncbi.nlm.nih.gov/pubmed/27273579	ADD
10_1101-2020_01_28_923532	671	34	https://www.ncbi.nlm.nih.gov/pubmed/27273579	https://www.ncbi.nlm.nih.gov/pubmed/27273579	ADD
10_1101-2020_01_28_923532	671	35	https://www.ncbi.nlm.nih.gov/pubmed/28424323	https://www.ncbi.nlm.nih.gov/pubmed/28424323	NNP
10_1101-2020_01_28_923532	671	36	https://www.ncbi.nlm.nih.gov/pubmed/28424323	https://www.ncbi.nlm.nih.gov/pubmed/28424323	NNP
10_1101-2020_01_28_923532	671	37	https://www.ncbi.nlm.nih.gov/pubmed/25144266	https://www.ncbi.nlm.nih.gov/pubmed/25144266	NNP
10_1101-2020_01_28_923532	671	38	https://www.ncbi.nlm.nih.gov/pubmed/25144266	https://www.ncbi.nlm.nih.gov/pubmed/25144266	IN
10_1101-2020_01_28_923532	671	39	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	ADD
10_1101-2020_01_28_923532	671	40	43	43	CD
10_1101-2020_01_28_923532	671	41	22	22	CD
10_1101-2020_01_28_923532	671	42	.	.	.
10_1101-2020_01_28_923532	672	1	Plückthun	Plückthun	NNP
10_1101-2020_01_28_923532	672	2	A.	A.	NNP
10_1101-2020_01_28_923532	673	1	Designed	design	VBN
10_1101-2020_01_28_923532	673	2	ankyrin	ankyrin	NN
10_1101-2020_01_28_923532	673	3	repeat	repeat	NN
10_1101-2020_01_28_923532	673	4	proteins	protein	NNS
10_1101-2020_01_28_923532	673	5	(	(	-LRB-
10_1101-2020_01_28_923532	673	6	DARPins	darpin	NNS
10_1101-2020_01_28_923532	673	7	)	)	-RRB-
10_1101-2020_01_28_923532	673	8	:	:	:
10_1101-2020_01_28_923532	673	9	binding	bind	VBG
10_1101-2020_01_28_923532	673	10	proteins	protein	NNS
10_1101-2020_01_28_923532	673	11	for	for	IN
10_1101-2020_01_28_923532	673	12	research	research	NN
10_1101-2020_01_28_923532	673	13	,	,	,
10_1101-2020_01_28_923532	673	14	diagnostics	diagnostic	NNS
10_1101-2020_01_28_923532	673	15	,	,	,
10_1101-2020_01_28_923532	673	16	and	and	CC
10_1101-2020_01_28_923532	673	17	therapy	therapy	NN
10_1101-2020_01_28_923532	673	18	.	.	.
10_1101-2020_01_28_923532	674	1	Annu	Annu	NNP
10_1101-2020_01_28_923532	674	2	.	.	.
10_1101-2020_01_28_923532	675	1	Rev.	Rev.	NNP
10_1101-2020_01_28_923532	676	1	Pharmacol	Pharmacol	NNP
10_1101-2020_01_28_923532	676	2	.	.	.
10_1101-2020_01_28_923532	677	1	Toxicol	Toxicol	NNP
10_1101-2020_01_28_923532	677	2	.	.	.
10_1101-2020_01_28_923532	678	1	55	55	CD
10_1101-2020_01_28_923532	678	2	,	,	,
10_1101-2020_01_28_923532	678	3	489	489	CD
10_1101-2020_01_28_923532	678	4	-	-	SYM
10_1101-2020_01_28_923532	678	5	511	511	CD
10_1101-2020_01_28_923532	678	6	(	(	-LRB-
10_1101-2020_01_28_923532	678	7	2015	2015	CD
10_1101-2020_01_28_923532	678	8	)	)	-RRB-
10_1101-2020_01_28_923532	678	9	.	.	.
10_1101-2020_01_28_923532	679	1	23	23	CD
10_1101-2020_01_28_923532	679	2	.	.	.
10_1101-2020_01_28_923532	680	1	Sokolova	Sokolova	NNP
10_1101-2020_01_28_923532	680	2	,	,	,
10_1101-2020_01_28_923532	680	3	E.A.	E.A.	NNP
10_1101-2020_01_28_923532	680	4	,	,	,
10_1101-2020_01_28_923532	680	5	et	et	NNP
10_1101-2020_01_28_923532	680	6	al	al	NNP
10_1101-2020_01_28_923532	680	7	.	.	.
10_1101-2020_01_28_923532	681	1	HER2-specific	HER2-specific	NNP
10_1101-2020_01_28_923532	681	2	targeted	target	VBD
10_1101-2020_01_28_923532	681	3	toxin	toxin	NN
10_1101-2020_01_28_923532	681	4	DARPin	DARPin	NNP
10_1101-2020_01_28_923532	681	5	-	-	HYPH
10_1101-2020_01_28_923532	681	6	LoPE	LoPE	NNP
10_1101-2020_01_28_923532	681	7	:	:	:
10_1101-2020_01_28_923532	681	8	Immunogenicity	immunogenicity	NN
10_1101-2020_01_28_923532	681	9	and	and	CC
10_1101-2020_01_28_923532	681	10	antitumor	antitumor	NN
10_1101-2020_01_28_923532	681	11	effect	effect	NN
10_1101-2020_01_28_923532	681	12	on	on	IN
10_1101-2020_01_28_923532	681	13	intraperitoneal	intraperitoneal	JJ
10_1101-2020_01_28_923532	681	14	ovarian	ovarian	JJ
10_1101-2020_01_28_923532	681	15	cancer	cancer	NN
10_1101-2020_01_28_923532	681	16	xenograft	xenograft	NNP
10_1101-2020_01_28_923532	681	17	model	model	NN
10_1101-2020_01_28_923532	681	18	.	.	.
10_1101-2020_01_28_923532	682	1	Int	Int	NNP
10_1101-2020_01_28_923532	682	2	.	.	.
10_1101-2020_01_28_923532	683	1	J.	J.	NNP
10_1101-2020_01_28_923532	683	2	Mol	Mol	NNP
10_1101-2020_01_28_923532	683	3	.	.	.
10_1101-2020_01_28_923532	684	1	Sci	Sci	NNP
10_1101-2020_01_28_923532	684	2	.	.	.
10_1101-2020_01_28_923532	685	1	20(10	20(10	LS
10_1101-2020_01_28_923532	685	2	)	)	-RRB-
10_1101-2020_01_28_923532	685	3	.	.	.
10_1101-2020_01_28_923532	686	1	pii	pii	NNP
10_1101-2020_01_28_923532	686	2	:	:	:
10_1101-2020_01_28_923532	686	3	E2399	E2399	NNP
10_1101-2020_01_28_923532	686	4	(	(	-LRB-
10_1101-2020_01_28_923532	686	5	2019	2019	CD
10_1101-2020_01_28_923532	686	6	)	)	-RRB-
10_1101-2020_01_28_923532	686	7	.	.	.
10_1101-2020_01_28_923532	687	1	24	24	CD
10_1101-2020_01_28_923532	687	2	.	.	.
10_1101-2020_01_28_923532	688	1	Dannenfelser	Dannenfelser	NNP
10_1101-2020_01_28_923532	688	2	,	,	,
10_1101-2020_01_28_923532	688	3	R.	R.	NNP
10_1101-2020_01_28_923532	688	4	,	,	,
10_1101-2020_01_28_923532	688	5	et	et	NNP
10_1101-2020_01_28_923532	688	6	al	al	NNP
10_1101-2020_01_28_923532	688	7	.	.	NNP
10_1101-2020_01_28_923532	688	8	,	,	,
10_1101-2020_01_28_923532	688	9	Discriminatory	Discriminatory	NNP
10_1101-2020_01_28_923532	688	10	power	power	NN
10_1101-2020_01_28_923532	688	11	of	of	IN
10_1101-2020_01_28_923532	688	12	combinatorial	combinatorial	NNP
10_1101-2020_01_28_923532	688	13	antigen	antigen	NNP
10_1101-2020_01_28_923532	688	14	recognition	recognition	NNP
10_1101-2020_01_28_923532	688	15	in	in	IN
10_1101-2020_01_28_923532	688	16	cancer	cancer	NN
10_1101-2020_01_28_923532	688	17	T	T	NNP
10_1101-2020_01_28_923532	688	18	cell	cell	NN
10_1101-2020_01_28_923532	688	19	therapies	therapy	NNS
10_1101-2020_01_28_923532	688	20	.	.	.
10_1101-2020_01_28_923532	689	1	Cell	Cell	NNP
10_1101-2020_01_28_923532	689	2	Syst	Syst	NNP
10_1101-2020_01_28_923532	689	3	.	.	.
10_1101-2020_01_28_923532	690	1	11(3):215	11(3):215	CD
10_1101-2020_01_28_923532	690	2	-	-	SYM
10_1101-2020_01_28_923532	690	3	228	228	CD
10_1101-2020_01_28_923532	690	4	(	(	-LRB-
10_1101-2020_01_28_923532	690	5	2020	2020	CD
10_1101-2020_01_28_923532	690	6	)	)	-RRB-
10_1101-2020_01_28_923532	690	7	.	.	.
10_1101-2020_01_28_923532	691	1	25	25	CD
10_1101-2020_01_28_923532	691	2	.	.	.
10_1101-2020_01_28_923532	692	1	MacKay	MacKay	NNP
10_1101-2020_01_28_923532	692	2	,	,	,
10_1101-2020_01_28_923532	692	3	M.	M.	NNP
10_1101-2020_01_28_923532	692	4	,	,	,
10_1101-2020_01_28_923532	692	5	et	et	NNP
10_1101-2020_01_28_923532	692	6	al	al	NNP
10_1101-2020_01_28_923532	692	7	.	.	.
10_1101-2020_01_28_923532	693	1	The	the	DT
10_1101-2020_01_28_923532	693	2	therapeutic	therapeutic	JJ
10_1101-2020_01_28_923532	693	3	landscape	landscape	NN
10_1101-2020_01_28_923532	693	4	for	for	IN
10_1101-2020_01_28_923532	693	5	cells	cell	NNS
10_1101-2020_01_28_923532	693	6	engineered	engineer	VBN
10_1101-2020_01_28_923532	693	7	with	with	IN
10_1101-2020_01_28_923532	693	8	chimeric	chimeric	JJ
10_1101-2020_01_28_923532	693	9	antigen	antigen	NNP
10_1101-2020_01_28_923532	693	10	receptors	receptor	NNS
10_1101-2020_01_28_923532	693	11	.	.	.
10_1101-2020_01_28_923532	694	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	694	2	.	.	.
10_1101-2020_01_28_923532	695	1	Biotech	Biotech	NNP
10_1101-2020_01_28_923532	695	2	.	.	.
10_1101-2020_01_28_923532	696	1	38(2	38(2	LS
10_1101-2020_01_28_923532	696	2	)	)	-RRB-
10_1101-2020_01_28_923532	696	3	,	,	,
10_1101-2020_01_28_923532	696	4	233	233	CD
10_1101-2020_01_28_923532	696	5	-	-	HYPH
10_1101-2020_01_28_923532	696	6	244	244	CD
10_1101-2020_01_28_923532	696	7	(	(	-LRB-
10_1101-2020_01_28_923532	696	8	2020	2020	CD
10_1101-2020_01_28_923532	696	9	)	)	-RRB-
10_1101-2020_01_28_923532	696	10	.	.	.
10_1101-2020_01_28_923532	697	1	26	26	CD
10_1101-2020_01_28_923532	697	2	.	.	.
10_1101-2020_01_28_923532	698	1	Maude	Maude	NNP
10_1101-2020_01_28_923532	698	2	,	,	,
10_1101-2020_01_28_923532	698	3	S.L.	S.L.	NNP
10_1101-2020_01_28_923532	698	4	,	,	,
10_1101-2020_01_28_923532	698	5	et	et	NNP
10_1101-2020_01_28_923532	698	6	al	al	NNP
10_1101-2020_01_28_923532	698	7	.	.	.
10_1101-2020_01_28_923532	699	1	Tisagenlecleusel	tisagenlecleusel	NN
10_1101-2020_01_28_923532	699	2	in	in	IN
10_1101-2020_01_28_923532	699	3	children	child	NNS
10_1101-2020_01_28_923532	699	4	and	and	CC
10_1101-2020_01_28_923532	699	5	young	young	JJ
10_1101-2020_01_28_923532	699	6	adults	adult	NNS
10_1101-2020_01_28_923532	699	7	with	with	IN
10_1101-2020_01_28_923532	699	8	B	b	NN
10_1101-2020_01_28_923532	699	9	-	-	HYPH
10_1101-2020_01_28_923532	699	10	cell	cell	NN
10_1101-2020_01_28_923532	699	11	lymphoblastic	lymphoblastic	NN
10_1101-2020_01_28_923532	699	12	leukemia	leukemia	NN
10_1101-2020_01_28_923532	699	13	.	.	.
10_1101-2020_01_28_923532	700	1	New	New	NNP
10_1101-2020_01_28_923532	700	2	Engl	Engl	NNP
10_1101-2020_01_28_923532	700	3	.	.	.
10_1101-2020_01_28_923532	701	1	J.	J.	NNP
10_1101-2020_01_28_923532	701	2	Med	Med	NNP
10_1101-2020_01_28_923532	701	3	.	.	.
10_1101-2020_01_28_923532	702	1	378(5):439	378(5):439	NNP
10_1101-2020_01_28_923532	702	2	-	-	SYM
10_1101-2020_01_28_923532	702	3	448	448	CD
10_1101-2020_01_28_923532	702	4	(	(	-LRB-
10_1101-2020_01_28_923532	702	5	2018	2018	CD
10_1101-2020_01_28_923532	702	6	)	)	-RRB-
10_1101-2020_01_28_923532	702	7	.	.	.
10_1101-2020_01_28_923532	703	1	27	27	CD
10_1101-2020_01_28_923532	703	2	.	.	.
10_1101-2020_01_28_923532	704	1	Lamers	Lamers	NNP
10_1101-2020_01_28_923532	704	2	,	,	,
10_1101-2020_01_28_923532	704	3	C.H.	C.H.	NNP
10_1101-2020_01_28_923532	704	4	,	,	,
10_1101-2020_01_28_923532	704	5	et	et	NNP
10_1101-2020_01_28_923532	704	6	al	al	NNP
10_1101-2020_01_28_923532	704	7	.	.	.
10_1101-2020_01_28_923532	705	1	Treatment	treatment	NN
10_1101-2020_01_28_923532	705	2	of	of	IN
10_1101-2020_01_28_923532	705	3	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	705	4	renal	renal	JJ
10_1101-2020_01_28_923532	705	5	cell	cell	NN
10_1101-2020_01_28_923532	705	6	carcinoma	carcinoma	NN
10_1101-2020_01_28_923532	705	7	with	with	IN
10_1101-2020_01_28_923532	705	8	CAIX	CAIX	NNP
10_1101-2020_01_28_923532	705	9	CAR-	CAR-	NNP
10_1101-2020_01_28_923532	705	10	engineered	engineer	VBN
10_1101-2020_01_28_923532	705	11	T	t	NN
10_1101-2020_01_28_923532	705	12	cells	cell	NNS
10_1101-2020_01_28_923532	705	13	:	:	:
10_1101-2020_01_28_923532	705	14	clinical	clinical	JJ
10_1101-2020_01_28_923532	705	15	evaluation	evaluation	NN
10_1101-2020_01_28_923532	705	16	and	and	CC
10_1101-2020_01_28_923532	705	17	management	management	NN
10_1101-2020_01_28_923532	705	18	of	of	IN
10_1101-2020_01_28_923532	705	19	on	on	IN
10_1101-2020_01_28_923532	705	20	-	-	HYPH
10_1101-2020_01_28_923532	705	21	target	target	NN
10_1101-2020_01_28_923532	705	22	toxicity	toxicity	NN
10_1101-2020_01_28_923532	705	23	.	.	.
10_1101-2020_01_28_923532	706	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	706	2	.	.	.
10_1101-2020_01_28_923532	707	1	Ther	ther	RB
10_1101-2020_01_28_923532	707	2	.	.	.
10_1101-2020_01_28_923532	708	1	21(4):904	21(4):904	LS
10_1101-2020_01_28_923532	708	2	-	-	SYM
10_1101-2020_01_28_923532	708	3	912	912	CD
10_1101-2020_01_28_923532	708	4	(	(	-LRB-
10_1101-2020_01_28_923532	708	5	2013	2013	CD
10_1101-2020_01_28_923532	708	6	)	)	-RRB-
10_1101-2020_01_28_923532	708	7	.	.	.
10_1101-2020_01_28_923532	709	1	28	28	CD
10_1101-2020_01_28_923532	709	2	.	.	.
10_1101-2020_01_28_923532	710	1	Thistlethwaite	Thistlethwaite	NNP
10_1101-2020_01_28_923532	710	2	,	,	,
10_1101-2020_01_28_923532	710	3	F.C.	F.C.	NNP
10_1101-2020_01_28_923532	710	4	,	,	,
10_1101-2020_01_28_923532	710	5	et	et	NNP
10_1101-2020_01_28_923532	710	6	al	al	NNP
10_1101-2020_01_28_923532	710	7	.	.	.
10_1101-2020_01_28_923532	711	1	The	the	DT
10_1101-2020_01_28_923532	711	2	clinical	clinical	JJ
10_1101-2020_01_28_923532	711	3	efficacy	efficacy	NN
10_1101-2020_01_28_923532	711	4	of	of	IN
10_1101-2020_01_28_923532	711	5	first	first	JJ
10_1101-2020_01_28_923532	711	6	-	-	HYPH
10_1101-2020_01_28_923532	711	7	generation	generation	NN
10_1101-2020_01_28_923532	711	8	carcinoembryonic	carcinoembryonic	JJ
10_1101-2020_01_28_923532	711	9	antigen	antigen	NN
10_1101-2020_01_28_923532	711	10	(	(	-LRB-
10_1101-2020_01_28_923532	711	11	CEACAM5)-specific	CEACAM5)-specific	NNP
10_1101-2020_01_28_923532	711	12	CAR	car	NN
10_1101-2020_01_28_923532	711	13	T	t	NN
10_1101-2020_01_28_923532	711	14	cells	cell	NNS
10_1101-2020_01_28_923532	711	15	is	be	VBZ
10_1101-2020_01_28_923532	711	16	limited	limit	VBN
10_1101-2020_01_28_923532	711	17	by	by	IN
10_1101-2020_01_28_923532	711	18	poor	poor	JJ
10_1101-2020_01_28_923532	711	19	persistence	persistence	NN
10_1101-2020_01_28_923532	711	20	and	and	CC
10_1101-2020_01_28_923532	711	21	transient	transient	JJ
10_1101-2020_01_28_923532	711	22	pre-	pre-	NN
10_1101-2020_01_28_923532	711	23	conditioning	conditioning	NN
10_1101-2020_01_28_923532	711	24	-	-	HYPH
10_1101-2020_01_28_923532	711	25	dependent	dependent	JJ
10_1101-2020_01_28_923532	711	26	respiratory	respiratory	JJ
10_1101-2020_01_28_923532	711	27	toxicity	toxicity	NN
10_1101-2020_01_28_923532	711	28	.	.	.
10_1101-2020_01_28_923532	712	1	Cancer	Cancer	NNP
10_1101-2020_01_28_923532	712	2	Immunol	Immunol	NNP
10_1101-2020_01_28_923532	712	3	.	.	.
10_1101-2020_01_28_923532	713	1	Immunother	immunother	NN
10_1101-2020_01_28_923532	713	2	.	.	.
10_1101-2020_01_28_923532	714	1	66(11):1425-	66(11):1425-	CD
10_1101-2020_01_28_923532	714	2	1436	1436	CD
10_1101-2020_01_28_923532	714	3	(	(	-LRB-
10_1101-2020_01_28_923532	714	4	2017	2017	CD
10_1101-2020_01_28_923532	714	5	)	)	-RRB-
10_1101-2020_01_28_923532	714	6	.	.	.
10_1101-2020_01_28_923532	715	1	29	29	CD
10_1101-2020_01_28_923532	715	2	.	.	.
10_1101-2020_01_28_923532	716	1	Fedorov	Fedorov	NNP
10_1101-2020_01_28_923532	716	2	,	,	,
10_1101-2020_01_28_923532	716	3	V.D.	V.D.	NNP
10_1101-2020_01_28_923532	716	4	,	,	,
10_1101-2020_01_28_923532	716	5	Themeli	Themeli	NNP
10_1101-2020_01_28_923532	716	6	,	,	,
10_1101-2020_01_28_923532	716	7	M.	M.	NNP
10_1101-2020_01_28_923532	716	8	,	,	,
10_1101-2020_01_28_923532	716	9	Sadelain	Sadelain	NNP
10_1101-2020_01_28_923532	716	10	,	,	,
10_1101-2020_01_28_923532	716	11	M.	M.	NNP
10_1101-2020_01_28_923532	716	12	PD-1-	PD-1-	NNP
10_1101-2020_01_28_923532	716	13	and	and	CC
10_1101-2020_01_28_923532	716	14	CTLA-4-based	ctla-4-base	VBD
10_1101-2020_01_28_923532	716	15	inhibitory	inhibitory	NNP
10_1101-2020_01_28_923532	716	16	chimeric	chimeric	NNP
10_1101-2020_01_28_923532	716	17	antigen	antigen	NNP
10_1101-2020_01_28_923532	716	18	receptors	receptors	NNP
10_1101-2020_01_28_923532	716	19	(	(	-LRB-
10_1101-2020_01_28_923532	716	20	iCARs	iCARs	NNP
10_1101-2020_01_28_923532	716	21	)	)	-RRB-
10_1101-2020_01_28_923532	716	22	divert	divert	VB
10_1101-2020_01_28_923532	716	23	off	off	IN
10_1101-2020_01_28_923532	716	24	-	-	HYPH
10_1101-2020_01_28_923532	716	25	target	target	NN
10_1101-2020_01_28_923532	716	26	immunotherapy	immunotherapy	NN
10_1101-2020_01_28_923532	716	27	responses	response	NNS
10_1101-2020_01_28_923532	716	28	.	.	.
10_1101-2020_01_28_923532	717	1	Sci	Sci	NNP
10_1101-2020_01_28_923532	717	2	.	.	.
10_1101-2020_01_28_923532	718	1	Transl	Transl	NNP
10_1101-2020_01_28_923532	718	2	.	.	.
10_1101-2020_01_28_923532	719	1	Med	Med	NNP
10_1101-2020_01_28_923532	719	2	.	.	.
10_1101-2020_01_28_923532	720	1	5(215):215ra172	5(215):215ra172	CD
10_1101-2020_01_28_923532	720	2	(	(	-LRB-
10_1101-2020_01_28_923532	720	3	2013	2013	CD
10_1101-2020_01_28_923532	720	4	)	)	-RRB-
10_1101-2020_01_28_923532	720	5	.	.	.
10_1101-2020_01_28_923532	721	1	30	30	CD
10_1101-2020_01_28_923532	721	2	.	.	.
10_1101-2020_01_28_923532	722	1	Grada	Grada	NNP
10_1101-2020_01_28_923532	722	2	,	,	,
10_1101-2020_01_28_923532	722	3	Z.	Z.	NNP
10_1101-2020_01_28_923532	722	4	,	,	,
10_1101-2020_01_28_923532	722	5	et	et	NNP
10_1101-2020_01_28_923532	722	6	al	al	NNP
10_1101-2020_01_28_923532	722	7	.	.	.
10_1101-2020_01_28_923532	723	1	TanCAR	tancar	XX
10_1101-2020_01_28_923532	723	2	:	:	:
10_1101-2020_01_28_923532	723	3	A	a	DT
10_1101-2020_01_28_923532	723	4	novel	novel	JJ
10_1101-2020_01_28_923532	723	5	bispecific	bispecific	NN
10_1101-2020_01_28_923532	723	6	chimeric	chimeric	NNP
10_1101-2020_01_28_923532	723	7	antigen	antigen	NNP
10_1101-2020_01_28_923532	723	8	receptor	receptor	NN
10_1101-2020_01_28_923532	723	9	for	for	IN
10_1101-2020_01_28_923532	723	10	cancer	cancer	NN
10_1101-2020_01_28_923532	723	11	immunotherapy	immunotherapy	NN
10_1101-2020_01_28_923532	723	12	.	.	.
10_1101-2020_01_28_923532	724	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	724	2	.	.	.
10_1101-2020_01_28_923532	725	1	Ther	ther	RB
10_1101-2020_01_28_923532	725	2	.	.	.
10_1101-2020_01_28_923532	726	1	Nucl	Nucl	NNP
10_1101-2020_01_28_923532	726	2	.	.	.
10_1101-2020_01_28_923532	727	1	Acids	acid	NNS
10_1101-2020_01_28_923532	727	2	2	2	CD
10_1101-2020_01_28_923532	727	3	:	:	:
10_1101-2020_01_28_923532	727	4	e105	e105	NNP
10_1101-2020_01_28_923532	727	5	(	(	-LRB-
10_1101-2020_01_28_923532	727	6	2013	2013	CD
10_1101-2020_01_28_923532	727	7	)	)	-RRB-
10_1101-2020_01_28_923532	727	8	.	.	.
10_1101-2020_01_28_923532	728	1	31	31	CD
10_1101-2020_01_28_923532	728	2	.	.	.
10_1101-2020_01_28_923532	729	1	Hegde	Hegde	NNP
10_1101-2020_01_28_923532	729	2	,	,	,
10_1101-2020_01_28_923532	729	3	M.	M.	NNP
10_1101-2020_01_28_923532	729	4	,	,	,
10_1101-2020_01_28_923532	729	5	et	et	NNP
10_1101-2020_01_28_923532	729	6	al	al	NNP
10_1101-2020_01_28_923532	729	7	.	.	.
10_1101-2020_01_28_923532	730	1	Combinational	combinational	JJ
10_1101-2020_01_28_923532	730	2	targeting	targeting	NN
10_1101-2020_01_28_923532	730	3	offsets	offset	VBZ
10_1101-2020_01_28_923532	730	4	antigen	antigen	NNP
10_1101-2020_01_28_923532	730	5	escape	escape	NNP
10_1101-2020_01_28_923532	730	6	and	and	CC
10_1101-2020_01_28_923532	730	7	enhances	enhance	VBZ
10_1101-2020_01_28_923532	730	8	effector	effector	NN
10_1101-2020_01_28_923532	730	9	function	function	NN
10_1101-2020_01_28_923532	730	10	of	of	IN
10_1101-2020_01_28_923532	730	11	adoptively	adoptively	RB
10_1101-2020_01_28_923532	730	12	transferred	transfer	VBN
10_1101-2020_01_28_923532	730	13	T	T	NNP
10_1101-2020_01_28_923532	730	14	cells	cell	NNS
10_1101-2020_01_28_923532	730	15	in	in	IN
10_1101-2020_01_28_923532	730	16	glioblastoma	glioblastoma	NNP
10_1101-2020_01_28_923532	730	17	.	.	.
10_1101-2020_01_28_923532	731	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	731	2	.	.	.
10_1101-2020_01_28_923532	732	1	Ther	ther	RB
10_1101-2020_01_28_923532	732	2	.	.	.
10_1101-2020_01_28_923532	733	1	21(11):2087	21(11):2087	LS
10_1101-2020_01_28_923532	733	2	-	-	SYM
10_1101-2020_01_28_923532	733	3	2101	2101	CD
10_1101-2020_01_28_923532	733	4	(	(	-LRB-
10_1101-2020_01_28_923532	733	5	2013	2013	CD
10_1101-2020_01_28_923532	733	6	)	)	-RRB-
10_1101-2020_01_28_923532	733	7	.	.	.
10_1101-2020_01_28_923532	734	1	32	32	CD
10_1101-2020_01_28_923532	734	2	.	.	.
10_1101-2020_01_28_923532	735	1	Roybal	Roybal	NNP
10_1101-2020_01_28_923532	735	2	,	,	,
10_1101-2020_01_28_923532	735	3	K.T.	K.T.	NNP
10_1101-2020_01_28_923532	735	4	,	,	,
10_1101-2020_01_28_923532	735	5	et	et	NNP
10_1101-2020_01_28_923532	735	6	al	al	NNP
10_1101-2020_01_28_923532	735	7	.	.	.
10_1101-2020_01_28_923532	736	1	Engineering	engineer	VBG
10_1101-2020_01_28_923532	736	2	T	t	NN
10_1101-2020_01_28_923532	736	3	cells	cell	NNS
10_1101-2020_01_28_923532	736	4	with	with	IN
10_1101-2020_01_28_923532	736	5	customized	customized	JJ
10_1101-2020_01_28_923532	736	6	therapeutic	therapeutic	JJ
10_1101-2020_01_28_923532	736	7	response	response	NN
10_1101-2020_01_28_923532	736	8	using	use	VBG
10_1101-2020_01_28_923532	736	9	synthetic	synthetic	JJ
10_1101-2020_01_28_923532	736	10	Notch	Notch	NNP
10_1101-2020_01_28_923532	736	11	receptors	receptor	NNS
10_1101-2020_01_28_923532	736	12	.	.	.
10_1101-2020_01_28_923532	737	1	Cell	Cell	NNP
10_1101-2020_01_28_923532	737	2	167(2):419	167(2):419	NNP
10_1101-2020_01_28_923532	737	3	-	-	HYPH
10_1101-2020_01_28_923532	737	4	43.e16	43.e16	CD
10_1101-2020_01_28_923532	737	5	(	(	-LRB-
10_1101-2020_01_28_923532	737	6	2016	2016	CD
10_1101-2020_01_28_923532	737	7	)	)	-RRB-
10_1101-2020_01_28_923532	737	8	.	.	.
10_1101-2020_01_28_923532	738	1	33	33	CD
10_1101-2020_01_28_923532	738	2	.	.	.
10_1101-2020_01_28_923532	739	1	Williams	Williams	NNP
10_1101-2020_01_28_923532	739	2	,	,	,
10_1101-2020_01_28_923532	739	3	J.Z.	J.Z.	NNP
10_1101-2020_01_28_923532	739	4	,	,	,
10_1101-2020_01_28_923532	739	5	et	et	NNP
10_1101-2020_01_28_923532	739	6	al	al	NNP
10_1101-2020_01_28_923532	739	7	.	.	.
10_1101-2020_01_28_923532	740	1	Precise	precise	JJ
10_1101-2020_01_28_923532	740	2	T	T	NNP
10_1101-2020_01_28_923532	740	3	cell	cell	NN
10_1101-2020_01_28_923532	740	4	recognition	recognition	NN
10_1101-2020_01_28_923532	740	5	programs	program	NNS
10_1101-2020_01_28_923532	740	6	designed	design	VBN
10_1101-2020_01_28_923532	740	7	by	by	IN
10_1101-2020_01_28_923532	740	8	transcriptionally	transcriptionally	RB
10_1101-2020_01_28_923532	740	9	linking	link	VBG
10_1101-2020_01_28_923532	740	10	multiple	multiple	JJ
10_1101-2020_01_28_923532	740	11	receptors	receptor	NNS
10_1101-2020_01_28_923532	740	12	.	.	.
10_1101-2020_01_28_923532	741	1	Science	Science	NNP
10_1101-2020_01_28_923532	741	2	370(6520):1099	370(6520):1099	CD
10_1101-2020_01_28_923532	741	3	-	-	HYPH
10_1101-2020_01_28_923532	741	4	1104	1104	CD
10_1101-2020_01_28_923532	741	5	(	(	-LRB-
10_1101-2020_01_28_923532	741	6	2020	2020	CD
10_1101-2020_01_28_923532	741	7	)	)	-RRB-
10_1101-2020_01_28_923532	741	8	.	.	.
10_1101-2020_01_28_923532	742	1	34	34	CD
10_1101-2020_01_28_923532	742	2	.	.	.
10_1101-2020_01_28_923532	743	1	Říhová	Říhová	NNP
10_1101-2020_01_28_923532	743	2	,	,	,
10_1101-2020_01_28_923532	743	3	B.	B.	NNP
10_1101-2020_01_28_923532	743	4	Receptor	Receptor	NNP
10_1101-2020_01_28_923532	743	5	-	-	HYPH
10_1101-2020_01_28_923532	743	6	mediated	mediate	VBN
10_1101-2020_01_28_923532	743	7	targeted	target	VBD
10_1101-2020_01_28_923532	743	8	drug	drug	NN
10_1101-2020_01_28_923532	743	9	or	or	CC
10_1101-2020_01_28_923532	743	10	toxin	toxin	NN
10_1101-2020_01_28_923532	743	11	delivery	delivery	NN
10_1101-2020_01_28_923532	743	12	.	.	.
10_1101-2020_01_28_923532	744	1	Adv	Adv	NNP
10_1101-2020_01_28_923532	744	2	.	.	.
10_1101-2020_01_28_923532	745	1	Drug	Drug	NNP
10_1101-2020_01_28_923532	745	2	Deliv	Deliv	NNP
10_1101-2020_01_28_923532	745	3	.	.	.
10_1101-2020_01_28_923532	746	1	Rev.	Rev.	NNP
10_1101-2020_01_28_923532	747	1	29(3	29(3	LS
10_1101-2020_01_28_923532	747	2	)	)	-RRB-
10_1101-2020_01_28_923532	747	3	,	,	,
10_1101-2020_01_28_923532	747	4	273	273	CD
10_1101-2020_01_28_923532	747	5	-	-	SYM
10_1101-2020_01_28_923532	747	6	289	289	CD
10_1101-2020_01_28_923532	747	7	(	(	-LRB-
10_1101-2020_01_28_923532	747	8	1998	1998	CD
10_1101-2020_01_28_923532	747	9	)	)	-RRB-
10_1101-2020_01_28_923532	747	10	.	.	.
10_1101-2020_01_28_923532	748	1	35	35	CD
10_1101-2020_01_28_923532	748	2	.	.	.
10_1101-2020_01_28_923532	749	1	Tortorella	Tortorella	NNP
10_1101-2020_01_28_923532	749	2	,	,	,
10_1101-2020_01_28_923532	749	3	S.	S.	NNP
10_1101-2020_01_28_923532	749	4	&	&	CC
10_1101-2020_01_28_923532	749	5	Karagiannis	Karagiannis	NNP
10_1101-2020_01_28_923532	749	6	,	,	,
10_1101-2020_01_28_923532	749	7	T.C.	T.C.	NNP
10_1101-2020_01_28_923532	750	1	Transferrin	Transferrin	NNP
10_1101-2020_01_28_923532	750	2	receptor	receptor	NN
10_1101-2020_01_28_923532	750	3	-	-	HYPH
10_1101-2020_01_28_923532	750	4	mediated	mediate	VBN
10_1101-2020_01_28_923532	750	5	endocytosis	endocytosis	NN
10_1101-2020_01_28_923532	750	6	:	:	:
10_1101-2020_01_28_923532	750	7	a	a	DT
10_1101-2020_01_28_923532	750	8	useful	useful	JJ
10_1101-2020_01_28_923532	750	9	target	target	NN
10_1101-2020_01_28_923532	750	10	for	for	IN
10_1101-2020_01_28_923532	750	11	cancer	cancer	NN
10_1101-2020_01_28_923532	750	12	therapy	therapy	NN
10_1101-2020_01_28_923532	750	13	.	.	.
10_1101-2020_01_28_923532	751	1	J.	J.	NNP
10_1101-2020_01_28_923532	751	2	Membr	Membr	NNP
10_1101-2020_01_28_923532	751	3	.	.	.
10_1101-2020_01_28_923532	752	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	752	2	.	.	.
10_1101-2020_01_28_923532	753	1	247(4	247(4	CD
10_1101-2020_01_28_923532	753	2	)	)	-RRB-
10_1101-2020_01_28_923532	753	3	,	,	,
10_1101-2020_01_28_923532	753	4	291	291	CD
10_1101-2020_01_28_923532	753	5	-	-	SYM
10_1101-2020_01_28_923532	753	6	307	307	CD
10_1101-2020_01_28_923532	753	7	(	(	-LRB-
10_1101-2020_01_28_923532	753	8	2014	2014	CD
10_1101-2020_01_28_923532	753	9	)	)	-RRB-
10_1101-2020_01_28_923532	753	10	.	.	.
10_1101-2020_01_28_923532	754	1	36	36	CD
10_1101-2020_01_28_923532	754	2	.	.	.
10_1101-2020_01_28_923532	755	1	Karp	Karp	NNP
10_1101-2020_01_28_923532	755	2	,	,	,
10_1101-2020_01_28_923532	755	3	R.M.	R.M.	NNP
10_1101-2020_01_28_923532	756	1	Reducibility	reducibility	NN
10_1101-2020_01_28_923532	756	2	among	among	IN
10_1101-2020_01_28_923532	756	3	combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	756	4	problems	problem	NNS
10_1101-2020_01_28_923532	756	5	.	.	.
10_1101-2020_01_28_923532	757	1	In	in	IN
10_1101-2020_01_28_923532	757	2	Complexity	complexity	NN
10_1101-2020_01_28_923532	757	3	of	of	IN
10_1101-2020_01_28_923532	757	4	Computer	Computer	NNP
10_1101-2020_01_28_923532	757	5	Computations	Computations	NNPS
10_1101-2020_01_28_923532	757	6	,	,	,
10_1101-2020_01_28_923532	757	7	pp	pp	NNP
10_1101-2020_01_28_923532	757	8	.	.	.
10_1101-2020_01_28_923532	758	1	85	85	CD
10_1101-2020_01_28_923532	758	2	-	-	SYM
10_1101-2020_01_28_923532	758	3	103	103	CD
10_1101-2020_01_28_923532	758	4	(	(	-LRB-
10_1101-2020_01_28_923532	758	5	Plenum	Plenum	NNP
10_1101-2020_01_28_923532	758	6	Press	Press	NNP
10_1101-2020_01_28_923532	758	7	,	,	,
10_1101-2020_01_28_923532	758	8	New	New	NNP
10_1101-2020_01_28_923532	758	9	York	York	NNP
10_1101-2020_01_28_923532	758	10	,	,	,
10_1101-2020_01_28_923532	758	11	1972	1972	CD
10_1101-2020_01_28_923532	758	12	)	)	-RRB-
10_1101-2020_01_28_923532	758	13	.	.	.
10_1101-2020_01_28_923532	759	1	37	37	CD
10_1101-2020_01_28_923532	759	2	.	.	.
10_1101-2020_01_28_923532	760	1	Martinez	Martinez	NNP
10_1101-2020_01_28_923532	760	2	-	-	HYPH
10_1101-2020_01_28_923532	760	3	Veracoechea	Veracoechea	NNP
10_1101-2020_01_28_923532	760	4	,	,	,
10_1101-2020_01_28_923532	760	5	F.J.	F.J.	NNP
10_1101-2020_01_28_923532	760	6	&	&	CC
10_1101-2020_01_28_923532	760	7	Frenkel	Frenkel	NNP
10_1101-2020_01_28_923532	760	8	,	,	,
10_1101-2020_01_28_923532	760	9	D.	D.	NNP
10_1101-2020_01_28_923532	760	10	Designing	Designing	NNP
10_1101-2020_01_28_923532	760	11	super	super	JJ
10_1101-2020_01_28_923532	760	12	selectivity	selectivity	NN
10_1101-2020_01_28_923532	760	13	in	in	IN
10_1101-2020_01_28_923532	760	14	multivalent	multivalent	NN
10_1101-2020_01_28_923532	760	15	nano-	nano-	NNP
10_1101-2020_01_28_923532	760	16	particle	particle	NN
10_1101-2020_01_28_923532	760	17	binding	binding	NN
10_1101-2020_01_28_923532	760	18	.	.	.
10_1101-2020_01_28_923532	761	1	Proc	Proc	NNP
10_1101-2020_01_28_923532	761	2	.	.	.
10_1101-2020_01_28_923532	762	1	Natl	Natl	NNP
10_1101-2020_01_28_923532	762	2	Acad	Acad	NNP
10_1101-2020_01_28_923532	762	3	.	.	.
10_1101-2020_01_28_923532	763	1	Sci	Sci	NNP
10_1101-2020_01_28_923532	763	2	.	.	.
10_1101-2020_01_28_923532	764	1	USA	USA	NNP
10_1101-2020_01_28_923532	764	2	108	108	CD
10_1101-2020_01_28_923532	764	3	,	,	,
10_1101-2020_01_28_923532	764	4	10963	10963	CD
10_1101-2020_01_28_923532	764	5	-	-	SYM
10_1101-2020_01_28_923532	764	6	10968	10968	CD
10_1101-2020_01_28_923532	764	7	(	(	-LRB-
10_1101-2020_01_28_923532	764	8	2011	2011	CD
10_1101-2020_01_28_923532	764	9	)	)	-RRB-
10_1101-2020_01_28_923532	764	10	.	.	.
10_1101-2020_01_28_923532	765	1	38	38	CD
10_1101-2020_01_28_923532	765	2	.	.	.
10_1101-2020_01_28_923532	766	1	Delaney	Delaney	NNP
10_1101-2020_01_28_923532	766	2	,	,	,
10_1101-2020_01_28_923532	766	3	C.	C.	NNP
10_1101-2020_01_28_923532	766	4	,	,	,
10_1101-2020_01_28_923532	766	5	et	et	NNP
10_1101-2020_01_28_923532	766	6	al	al	NNP
10_1101-2020_01_28_923532	766	7	.	.	.
10_1101-2020_01_28_923532	767	1	Combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	767	2	prediction	prediction	NN
10_1101-2020_01_28_923532	767	3	of	of	IN
10_1101-2020_01_28_923532	767	4	marker	marker	NN
10_1101-2020_01_28_923532	767	5	panels	panel	NNS
10_1101-2020_01_28_923532	767	6	from	from	IN
10_1101-2020_01_28_923532	767	7	single	single	JJ
10_1101-2020_01_28_923532	767	8	-	-	HYPH
10_1101-2020_01_28_923532	767	9	cell	cell	NN
10_1101-2020_01_28_923532	767	10	transcriptomic	transcriptomic	JJ
10_1101-2020_01_28_923532	767	11	data	datum	NNS
10_1101-2020_01_28_923532	767	12	.	.	.
10_1101-2020_01_28_923532	768	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	768	2	.	.	.
10_1101-2020_01_28_923532	769	1	Syst	Syst	NNP
10_1101-2020_01_28_923532	769	2	.	.	.
10_1101-2020_01_28_923532	770	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	770	2	.	.	.
10_1101-2020_01_28_923532	771	1	15(10	15(10	LS
10_1101-2020_01_28_923532	771	2	)	)	-RRB-
10_1101-2020_01_28_923532	771	3	,	,	,
10_1101-2020_01_28_923532	771	4	e9005	e9005	NNP
10_1101-2020_01_28_923532	771	5	(	(	-LRB-
10_1101-2020_01_28_923532	771	6	2019	2019	CD
10_1101-2020_01_28_923532	771	7	)	)	-RRB-
10_1101-2020_01_28_923532	771	8	.	.	.
10_1101-2020_01_28_923532	772	1	39	39	CD
10_1101-2020_01_28_923532	772	2	.	.	.
10_1101-2020_01_28_923532	773	1	Müller	Müller	NNP
10_1101-2020_01_28_923532	773	2	,	,	,
10_1101-2020_01_28_923532	773	3	S.	S.	NNP
10_1101-2020_01_28_923532	773	4	,	,	,
10_1101-2020_01_28_923532	773	5	et	et	NNP
10_1101-2020_01_28_923532	773	6	al	al	NNP
10_1101-2020_01_28_923532	773	7	.	.	.
10_1101-2020_01_28_923532	774	1	A	a	DT
10_1101-2020_01_28_923532	774	2	role	role	NN
10_1101-2020_01_28_923532	774	3	for	for	IN
10_1101-2020_01_28_923532	774	4	receptor	receptor	NN
10_1101-2020_01_28_923532	774	5	tyrosine	tyrosine	NN
10_1101-2020_01_28_923532	774	6	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	774	7	zeta	zeta	NNP
10_1101-2020_01_28_923532	774	8	in	in	IN
10_1101-2020_01_28_923532	774	9	glioma	glioma	NNP
10_1101-2020_01_28_923532	774	10	cell	cell	NN
10_1101-2020_01_28_923532	774	11	migration	migration	NN
10_1101-2020_01_28_923532	774	12	.	.	.
10_1101-2020_01_28_923532	775	1	Oncogene	oncogene	NN
10_1101-2020_01_28_923532	775	2	22(43	22(43	CD
10_1101-2020_01_28_923532	775	3	)	)	-RRB-
10_1101-2020_01_28_923532	775	4	,	,	,
10_1101-2020_01_28_923532	775	5	661	661	CD
10_1101-2020_01_28_923532	775	6	-	-	SYM
10_1101-2020_01_28_923532	775	7	668	668	CD
10_1101-2020_01_28_923532	775	8	(	(	-LRB-
10_1101-2020_01_28_923532	775	9	2003	2003	CD
10_1101-2020_01_28_923532	775	10	)	)	-RRB-
10_1101-2020_01_28_923532	775	11	.	.	.
10_1101-2020_01_28_923532	776	1	40	40	CD
10_1101-2020_01_28_923532	776	2	.	.	.
10_1101-2020_01_28_923532	777	1	Ulbricht	Ulbricht	NNP
10_1101-2020_01_28_923532	777	2	,	,	,
10_1101-2020_01_28_923532	777	3	U.	U.	NNP
10_1101-2020_01_28_923532	777	4	et	et	NNP
10_1101-2020_01_28_923532	777	5	al	al	NNP
10_1101-2020_01_28_923532	777	6	.	.	.
10_1101-2020_01_28_923532	778	1	Expression	expression	NN
10_1101-2020_01_28_923532	778	2	and	and	CC
10_1101-2020_01_28_923532	778	3	function	function	NN
10_1101-2020_01_28_923532	778	4	of	of	IN
10_1101-2020_01_28_923532	778	5	the	the	DT
10_1101-2020_01_28_923532	778	6	receptor	receptor	NN
10_1101-2020_01_28_923532	778	7	protein	protein	NN
10_1101-2020_01_28_923532	778	8	tyrosine	tyrosine	NNP
10_1101-2020_01_28_923532	778	9	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	778	10	zeta	zeta	NNP
10_1101-2020_01_28_923532	778	11	and	and	CC
10_1101-2020_01_28_923532	778	12	its	-PRON-	PRP$
10_1101-2020_01_28_923532	778	13	ligand	ligand	NN
10_1101-2020_01_28_923532	778	14	pleiotrophin	pleiotrophin	NN
10_1101-2020_01_28_923532	778	15	in	in	IN
10_1101-2020_01_28_923532	778	16	human	human	JJ
10_1101-2020_01_28_923532	778	17	astrocytomas	astrocytoma	NNS
10_1101-2020_01_28_923532	778	18	.	.	.
10_1101-2020_01_28_923532	779	1	J.	J.	NNP
10_1101-2020_01_28_923532	779	2	Neuropathol	Neuropathol	NNP
10_1101-2020_01_28_923532	779	3	.	.	.
10_1101-2020_01_28_923532	780	1	Exp	Exp	NNP
10_1101-2020_01_28_923532	780	2	.	.	.
10_1101-2020_01_28_923532	781	1	Neurol	Neurol	NNP
10_1101-2020_01_28_923532	781	2	.	.	.
10_1101-2020_01_28_923532	782	1	62(12	62(12	LS
10_1101-2020_01_28_923532	782	2	)	)	-RRB-
10_1101-2020_01_28_923532	782	3	,	,	,
10_1101-2020_01_28_923532	782	4	1265	1265	CD
10_1101-2020_01_28_923532	782	5	-	-	SYM
10_1101-2020_01_28_923532	782	6	1275	1275	CD
10_1101-2020_01_28_923532	782	7	(	(	-LRB-
10_1101-2020_01_28_923532	782	8	2003	2003	CD
10_1101-2020_01_28_923532	782	9	)	)	-RRB-
10_1101-2020_01_28_923532	782	10	.	.	.
10_1101-2020_01_28_923532	783	1	105	105	CD
10_1101-2020_01_28_923532	783	2	and	and	CC
10_1101-2020_01_28_923532	783	3	is	be	VBZ
10_1101-2020_01_28_923532	783	4	also	also	RB
10_1101-2020_01_28_923532	783	5	made	make	VBN
10_1101-2020_01_28_923532	783	6	available	available	JJ
10_1101-2020_01_28_923532	783	7	for	for	IN
10_1101-2020_01_28_923532	783	8	use	use	NN
10_1101-2020_01_28_923532	783	9	under	under	IN
10_1101-2020_01_28_923532	783	10	a	a	DT
10_1101-2020_01_28_923532	783	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	783	12	license	license	NN
10_1101-2020_01_28_923532	783	13	.	.	.
10_1101-2020_01_28_923532	784	1	(	(	-LRB-
10_1101-2020_01_28_923532	784	2	which	which	WDT
10_1101-2020_01_28_923532	784	3	was	be	VBD
10_1101-2020_01_28_923532	784	4	not	not	RB
10_1101-2020_01_28_923532	784	5	certified	certify	VBN
10_1101-2020_01_28_923532	784	6	by	by	IN
10_1101-2020_01_28_923532	784	7	peer	peer	NN
10_1101-2020_01_28_923532	784	8	review	review	NN
10_1101-2020_01_28_923532	784	9	)	)	-RRB-
10_1101-2020_01_28_923532	784	10	is	be	VBZ
10_1101-2020_01_28_923532	784	11	the	the	DT
10_1101-2020_01_28_923532	784	12	author	author	NN
10_1101-2020_01_28_923532	784	13	/	/	SYM
10_1101-2020_01_28_923532	784	14	funder	funder	NN
10_1101-2020_01_28_923532	784	15	.	.	.
10_1101-2020_01_28_923532	785	1	This	this	DT
10_1101-2020_01_28_923532	785	2	article	article	NN
10_1101-2020_01_28_923532	785	3	is	be	VBZ
10_1101-2020_01_28_923532	785	4	a	a	DT
10_1101-2020_01_28_923532	785	5	US	US	NNP
10_1101-2020_01_28_923532	785	6	Government	Government	NNP
10_1101-2020_01_28_923532	785	7	work	work	NN
10_1101-2020_01_28_923532	785	8	.	.	.
10_1101-2020_01_28_923532	786	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	786	2	is	be	VBZ
10_1101-2020_01_28_923532	786	3	not	not	RB
10_1101-2020_01_28_923532	786	4	subject	subject	JJ
10_1101-2020_01_28_923532	786	5	to	to	IN
10_1101-2020_01_28_923532	786	6	copyright	copyright	NN
10_1101-2020_01_28_923532	786	7	under	under	IN
10_1101-2020_01_28_923532	786	8	17	17	CD
10_1101-2020_01_28_923532	786	9	USC	usc	NN
10_1101-2020_01_28_923532	786	10	The	the	DT
10_1101-2020_01_28_923532	786	11	copyright	copyright	NN
10_1101-2020_01_28_923532	786	12	holder	holder	NN
10_1101-2020_01_28_923532	786	13	for	for	IN
10_1101-2020_01_28_923532	786	14	this	this	DT
10_1101-2020_01_28_923532	786	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	786	16	version	version	NN
10_1101-2020_01_28_923532	786	17	posted	post	VBD
10_1101-2020_01_28_923532	786	18	February	February	NNP
10_1101-2020_01_28_923532	786	19	12	12	CD
10_1101-2020_01_28_923532	786	20	,	,	,
10_1101-2020_01_28_923532	786	21	2021	2021	CD
10_1101-2020_01_28_923532	786	22	.	.	.
10_1101-2020_01_28_923532	786	23	;	;	:
10_1101-2020_01_28_923532	786	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	786	25	:	:	:
10_1101-2020_01_28_923532	786	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	786	27	preprint	preprint	NN
10_1101-2020_01_28_923532	786	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	PRP
10_1101-2020_01_28_923532	786	29	44	44	CD
10_1101-2020_01_28_923532	786	30	41	41	CD
10_1101-2020_01_28_923532	786	31	.	.	.
10_1101-2020_01_28_923532	787	1	Chen	Chen	NNP
10_1101-2020_01_28_923532	787	2	,	,	,
10_1101-2020_01_28_923532	787	3	H.M.	H.M.	NNP
10_1101-2020_01_28_923532	787	4	,	,	,
10_1101-2020_01_28_923532	787	5	et	et	NNP
10_1101-2020_01_28_923532	787	6	al	al	NNP
10_1101-2020_01_28_923532	787	7	.	.	.
10_1101-2020_01_28_923532	788	1	Enhanced	enhance	VBN
10_1101-2020_01_28_923532	788	2	expression	expression	NN
10_1101-2020_01_28_923532	788	3	and	and	CC
10_1101-2020_01_28_923532	788	4	phosphorylation	phosphorylation	NN
10_1101-2020_01_28_923532	788	5	of	of	IN
10_1101-2020_01_28_923532	788	6	the	the	DT
10_1101-2020_01_28_923532	788	7	MET	MET	NNP
10_1101-2020_01_28_923532	788	8	oncoprotein	oncoprotein	RB
10_1101-2020_01_28_923532	788	9	by	by	IN
10_1101-2020_01_28_923532	788	10	glioma	glioma	NNP
10_1101-2020_01_28_923532	788	11	-	-	HYPH
10_1101-2020_01_28_923532	788	12	specific	specific	JJ
10_1101-2020_01_28_923532	788	13	PTPRZ1-MET	ptprz1-met	JJ
10_1101-2020_01_28_923532	788	14	fusions	fusion	NNS
10_1101-2020_01_28_923532	788	15	.	.	.
10_1101-2020_01_28_923532	789	1	FEBS	FEBS	NNP
10_1101-2020_01_28_923532	789	2	Lett	Lett	NNP
10_1101-2020_01_28_923532	789	3	.	.	.
10_1101-2020_01_28_923532	790	1	589(13):1437	589(13):1437	CD
10_1101-2020_01_28_923532	790	2	-	-	HYPH
10_1101-2020_01_28_923532	790	3	1443	1443	CD
10_1101-2020_01_28_923532	790	4	(	(	-LRB-
10_1101-2020_01_28_923532	790	5	2015	2015	CD
10_1101-2020_01_28_923532	790	6	)	)	-RRB-
10_1101-2020_01_28_923532	790	7	.	.	.
10_1101-2020_01_28_923532	791	1	42	42	CD
10_1101-2020_01_28_923532	791	2	.	.	.
10_1101-2020_01_28_923532	792	1	Ulbricht	Ulbricht	NNP
10_1101-2020_01_28_923532	792	2	,	,	,
10_1101-2020_01_28_923532	792	3	U.	U.	NNP
10_1101-2020_01_28_923532	792	4	,	,	,
10_1101-2020_01_28_923532	792	5	Eckerich	Eckerich	NNP
10_1101-2020_01_28_923532	792	6	,	,	,
10_1101-2020_01_28_923532	792	7	C.	C.	NNP
10_1101-2020_01_28_923532	792	8	,	,	,
10_1101-2020_01_28_923532	792	9	Fillbrandt	Fillbrandt	NNP
10_1101-2020_01_28_923532	792	10	,	,	,
10_1101-2020_01_28_923532	792	11	R.	R.	NNP
10_1101-2020_01_28_923532	792	12	,	,	,
10_1101-2020_01_28_923532	792	13	Westphal	Westphal	NNP
10_1101-2020_01_28_923532	792	14	,	,	,
10_1101-2020_01_28_923532	792	15	M.	M.	NNP
10_1101-2020_01_28_923532	792	16	&	&	CC
10_1101-2020_01_28_923532	792	17	Lamszus	Lamszus	NNP
10_1101-2020_01_28_923532	792	18	,	,	,
10_1101-2020_01_28_923532	792	19	K.	K.	NNP
10_1101-2020_01_28_923532	792	20	RNA	RNA	NNP
10_1101-2020_01_28_923532	792	21	interference	interference	NN
10_1101-2020_01_28_923532	792	22	targeting	target	VBG
10_1101-2020_01_28_923532	792	23	protein	protein	NN
10_1101-2020_01_28_923532	792	24	tyrosine	tyrosine	NN
10_1101-2020_01_28_923532	792	25	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	792	26	zeta	zeta	NNP
10_1101-2020_01_28_923532	792	27	/	/	SYM
10_1101-2020_01_28_923532	792	28	receptor	receptor	NN
10_1101-2020_01_28_923532	792	29	-	-	HYPH
10_1101-2020_01_28_923532	792	30	type	type	NN
10_1101-2020_01_28_923532	792	31	protein	protein	NN
10_1101-2020_01_28_923532	792	32	tyrosine	tyrosine	NN
10_1101-2020_01_28_923532	792	33	phosphatase	phosphatase	NN
10_1101-2020_01_28_923532	792	34	beta	beta	NN
10_1101-2020_01_28_923532	792	35	suppresses	suppresse	NNS
10_1101-2020_01_28_923532	792	36	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	792	37	growth	growth	NN
10_1101-2020_01_28_923532	792	38	in	in	IN
10_1101-2020_01_28_923532	792	39	vitro	vitro	FW
10_1101-2020_01_28_923532	792	40	and	and	CC
10_1101-2020_01_28_923532	792	41	in	in	IN
10_1101-2020_01_28_923532	792	42	vivo	vivo	NNP
10_1101-2020_01_28_923532	792	43	.	.	.
10_1101-2020_01_28_923532	793	1	J.	J.	NNP
10_1101-2020_01_28_923532	793	2	Neurochem	Neurochem	NNP
10_1101-2020_01_28_923532	793	3	.	.	.
10_1101-2020_01_28_923532	794	1	98	98	CD
10_1101-2020_01_28_923532	794	2	,	,	,
10_1101-2020_01_28_923532	794	3	1497–1506	1497–1506	CD
10_1101-2020_01_28_923532	794	4	(	(	-LRB-
10_1101-2020_01_28_923532	794	5	2006	2006	CD
10_1101-2020_01_28_923532	794	6	)	)	-RRB-
10_1101-2020_01_28_923532	794	7	.	.	.
10_1101-2020_01_28_923532	795	1	43	43	CD
10_1101-2020_01_28_923532	795	2	.	.	.
10_1101-2020_01_28_923532	796	1	Bourgonje	bourgonje	JJ
10_1101-2020_01_28_923532	796	2	.	.	.
10_1101-2020_01_28_923532	797	1	A.M.	A.M.	NNP
10_1101-2020_01_28_923532	797	2	,	,	,
10_1101-2020_01_28_923532	797	3	et	et	NNP
10_1101-2020_01_28_923532	797	4	al	al	NNP
10_1101-2020_01_28_923532	797	5	.	.	.
10_1101-2020_01_28_923532	798	1	Intracellular	Intracellular	NNP
10_1101-2020_01_28_923532	798	2	and	and	CC
10_1101-2020_01_28_923532	798	3	extracellular	extracellular	JJ
10_1101-2020_01_28_923532	798	4	domains	domain	NNS
10_1101-2020_01_28_923532	798	5	of	of	IN
10_1101-2020_01_28_923532	798	6	protein	protein	NN
10_1101-2020_01_28_923532	798	7	tyrosine	tyrosine	NN
10_1101-2020_01_28_923532	798	8	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	798	9	PTPRZ	PTPRZ	NNP
10_1101-2020_01_28_923532	798	10	-	-	HYPH
10_1101-2020_01_28_923532	798	11	B	B	NNP
10_1101-2020_01_28_923532	798	12	differentially	differentially	RB
10_1101-2020_01_28_923532	798	13	regulate	regulate	VB
10_1101-2020_01_28_923532	798	14	glioma	glioma	NNP
10_1101-2020_01_28_923532	798	15	cell	cell	NN
10_1101-2020_01_28_923532	798	16	growth	growth	NN
10_1101-2020_01_28_923532	798	17	and	and	CC
10_1101-2020_01_28_923532	798	18	motility	motility	NN
10_1101-2020_01_28_923532	798	19	.	.	.
10_1101-2020_01_28_923532	799	1	Oncotarget	Oncotarget	NNP
10_1101-2020_01_28_923532	799	2	5(18	5(18	NNP
10_1101-2020_01_28_923532	799	3	)	)	-RRB-
10_1101-2020_01_28_923532	799	4	,	,	,
10_1101-2020_01_28_923532	799	5	8690	8690	CD
10_1101-2020_01_28_923532	799	6	-	-	SYM
10_1101-2020_01_28_923532	799	7	8702	8702	CD
10_1101-2020_01_28_923532	799	8	(	(	-LRB-
10_1101-2020_01_28_923532	799	9	2014	2014	CD
10_1101-2020_01_28_923532	799	10	)	)	-RRB-
10_1101-2020_01_28_923532	799	11	.	.	.
10_1101-2020_01_28_923532	800	1	44	44	CD
10_1101-2020_01_28_923532	800	2	.	.	.
10_1101-2020_01_28_923532	801	1	Fujikawa	Fujikawa	NNP
10_1101-2020_01_28_923532	801	2	,	,	,
10_1101-2020_01_28_923532	801	3	A.	A.	NNP
10_1101-2020_01_28_923532	801	4	,	,	,
10_1101-2020_01_28_923532	801	5	et	et	NNP
10_1101-2020_01_28_923532	801	6	al	al	NNP
10_1101-2020_01_28_923532	801	7	.	.	.
10_1101-2020_01_28_923532	802	1	Targeting	Targeting	NNP
10_1101-2020_01_28_923532	802	2	PTPRZ	PTPRZ	NNP
10_1101-2020_01_28_923532	802	3	inhibits	inhibit	VBZ
10_1101-2020_01_28_923532	802	4	stem	stem	NN
10_1101-2020_01_28_923532	802	5	cell	cell	NN
10_1101-2020_01_28_923532	802	6	-	-	HYPH
10_1101-2020_01_28_923532	802	7	like	like	JJ
10_1101-2020_01_28_923532	802	8	properties	property	NNS
10_1101-2020_01_28_923532	802	9	and	and	CC
10_1101-2020_01_28_923532	802	10	tumorigenicity	tumorigenicity	NN
10_1101-2020_01_28_923532	802	11	in	in	IN
10_1101-2020_01_28_923532	802	12	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	802	13	cells	cell	NNS
10_1101-2020_01_28_923532	802	14	.	.	.
10_1101-2020_01_28_923532	803	1	Sci	Sci	NNP
10_1101-2020_01_28_923532	803	2	.	.	.
10_1101-2020_01_28_923532	804	1	Rep.	Rep.	NNP
10_1101-2020_01_28_923532	804	2	7:5609	7:5609	CD
10_1101-2020_01_28_923532	804	3	(	(	-LRB-
10_1101-2020_01_28_923532	804	4	2017	2017	CD
10_1101-2020_01_28_923532	804	5	)	)	-RRB-
10_1101-2020_01_28_923532	804	6	.	.	.
10_1101-2020_01_28_923532	805	1	45	45	CD
10_1101-2020_01_28_923532	805	2	.	.	.
10_1101-2020_01_28_923532	806	1	Pastor	Pastor	NNP
10_1101-2020_01_28_923532	806	2	,	,	,
10_1101-2020_01_28_923532	806	3	M.	M.	NNP
10_1101-2020_01_28_923532	806	4	,	,	,
10_1101-2020_01_28_923532	806	5	et	et	NNP
10_1101-2020_01_28_923532	806	6	al	al	NNP
10_1101-2020_01_28_923532	806	7	.	.	.
10_1101-2020_01_28_923532	807	1	Development	development	NN
10_1101-2020_01_28_923532	807	2	of	of	IN
10_1101-2020_01_28_923532	807	3	inhibitors	inhibitor	NNS
10_1101-2020_01_28_923532	807	4	of	of	IN
10_1101-2020_01_28_923532	807	5	receptor	receptor	NN
10_1101-2020_01_28_923532	807	6	protein	protein	NN
10_1101-2020_01_28_923532	807	7	tyrosine	tyrosine	NN
10_1101-2020_01_28_923532	807	8	phosphatase	phosphatase	NNP
10_1101-2020_01_28_923532	807	9	β	β	NNP
10_1101-2020_01_28_923532	807	10	/	/	SYM
10_1101-2020_01_28_923532	807	11	ζ	ζ	NNP
10_1101-2020_01_28_923532	807	12	(	(	-LRB-
10_1101-2020_01_28_923532	807	13	PTPRZ1	ptprz1	NN
10_1101-2020_01_28_923532	807	14	)	)	-RRB-
10_1101-2020_01_28_923532	807	15	as	as	IN
10_1101-2020_01_28_923532	807	16	candidates	candidate	NNS
10_1101-2020_01_28_923532	807	17	for	for	IN
10_1101-2020_01_28_923532	807	18	CNS	CNS	NNP
10_1101-2020_01_28_923532	807	19	disorders	disorder	NNS
10_1101-2020_01_28_923532	807	20	.	.	.
10_1101-2020_01_28_923532	808	1	Eur	Eur	NNP
10_1101-2020_01_28_923532	808	2	.	.	.
10_1101-2020_01_28_923532	809	1	J.	J.	NNP
10_1101-2020_01_28_923532	809	2	Med	Med	NNP
10_1101-2020_01_28_923532	809	3	.	.	.
10_1101-2020_01_28_923532	810	1	Chem	Chem	NNP
10_1101-2020_01_28_923532	810	2	.	.	.
10_1101-2020_01_28_923532	811	1	144:318	144:318	CD
10_1101-2020_01_28_923532	811	2	-	-	SYM
10_1101-2020_01_28_923532	811	3	329	329	CD
10_1101-2020_01_28_923532	811	4	(	(	-LRB-
10_1101-2020_01_28_923532	811	5	2018	2018	CD
10_1101-2020_01_28_923532	811	6	)	)	-RRB-
10_1101-2020_01_28_923532	811	7	.	.	.
10_1101-2020_01_28_923532	812	1	46	46	CD
10_1101-2020_01_28_923532	812	2	.	.	.
10_1101-2020_01_28_923532	813	1	Darmanis	Darmanis	NNP
10_1101-2020_01_28_923532	813	2	,	,	,
10_1101-2020_01_28_923532	813	3	S.	S.	NNP
10_1101-2020_01_28_923532	813	4	,	,	,
10_1101-2020_01_28_923532	813	5	et	et	NNP
10_1101-2020_01_28_923532	813	6	al	al	NNP
10_1101-2020_01_28_923532	813	7	.	.	.
10_1101-2020_01_28_923532	814	1	Single	single	JJ
10_1101-2020_01_28_923532	814	2	-	-	HYPH
10_1101-2020_01_28_923532	814	3	cell	cell	NN
10_1101-2020_01_28_923532	814	4	RNA	RNA	NNP
10_1101-2020_01_28_923532	814	5	-	-	HYPH
10_1101-2020_01_28_923532	814	6	Seq	Seq	NNP
10_1101-2020_01_28_923532	814	7	analysis	analysis	NN
10_1101-2020_01_28_923532	814	8	of	of	IN
10_1101-2020_01_28_923532	814	9	infiltrating	infiltrate	VBG
10_1101-2020_01_28_923532	814	10	neoplastic	neoplastic	JJ
10_1101-2020_01_28_923532	814	11	cells	cell	NNS
10_1101-2020_01_28_923532	814	12	at	at	IN
10_1101-2020_01_28_923532	814	13	the	the	DT
10_1101-2020_01_28_923532	814	14	migrating	migrate	VBG
10_1101-2020_01_28_923532	814	15	front	front	NN
10_1101-2020_01_28_923532	814	16	of	of	IN
10_1101-2020_01_28_923532	814	17	human	human	JJ
10_1101-2020_01_28_923532	814	18	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	814	19	.	.	.
10_1101-2020_01_28_923532	815	1	Cell	Cell	NNP
10_1101-2020_01_28_923532	815	2	Rep.	Rep.	NNP
10_1101-2020_01_28_923532	815	3	21	21	CD
10_1101-2020_01_28_923532	815	4	,	,	,
10_1101-2020_01_28_923532	815	5	1399	1399	CD
10_1101-2020_01_28_923532	815	6	-	-	SYM
10_1101-2020_01_28_923532	815	7	1410	1410	CD
10_1101-2020_01_28_923532	815	8	(	(	-LRB-
10_1101-2020_01_28_923532	815	9	2017	2017	CD
10_1101-2020_01_28_923532	815	10	)	)	-RRB-
10_1101-2020_01_28_923532	815	11	.	.	.
10_1101-2020_01_28_923532	816	1	47	47	CD
10_1101-2020_01_28_923532	816	2	.	.	.
10_1101-2020_01_28_923532	817	1	Bergelson	Bergelson	NNP
10_1101-2020_01_28_923532	817	2	,	,	,
10_1101-2020_01_28_923532	817	3	J.M.	J.M.	NNP
10_1101-2020_01_28_923532	817	4	,	,	,
10_1101-2020_01_28_923532	817	5	et	et	NNP
10_1101-2020_01_28_923532	817	6	al	al	NNP
10_1101-2020_01_28_923532	817	7	.	.	.
10_1101-2020_01_28_923532	818	1	Isolation	isolation	NN
10_1101-2020_01_28_923532	818	2	of	of	IN
10_1101-2020_01_28_923532	818	3	a	a	DT
10_1101-2020_01_28_923532	818	4	common	common	JJ
10_1101-2020_01_28_923532	818	5	receptor	receptor	NN
10_1101-2020_01_28_923532	818	6	for	for	IN
10_1101-2020_01_28_923532	818	7	coxsackie	coxsackie	NNP
10_1101-2020_01_28_923532	818	8	B	B	NNP
10_1101-2020_01_28_923532	818	9	viruses	virus	NNS
10_1101-2020_01_28_923532	818	10	and	and	CC
10_1101-2020_01_28_923532	818	11	adenoviruses	adenoviruses	RB
10_1101-2020_01_28_923532	818	12	2	2	CD
10_1101-2020_01_28_923532	818	13	and	and	CC
10_1101-2020_01_28_923532	818	14	5	5	CD
10_1101-2020_01_28_923532	818	15	.	.	.
10_1101-2020_01_28_923532	819	1	Science	Science	NNP
10_1101-2020_01_28_923532	819	2	275(5304	275(5304	NNP
10_1101-2020_01_28_923532	819	3	)	)	-RRB-
10_1101-2020_01_28_923532	819	4	:	:	:
10_1101-2020_01_28_923532	819	5	1320	1320	CD
10_1101-2020_01_28_923532	819	6	-	-	SYM
10_1101-2020_01_28_923532	819	7	1323	1323	CD
10_1101-2020_01_28_923532	819	8	(	(	-LRB-
10_1101-2020_01_28_923532	819	9	1997	1997	CD
10_1101-2020_01_28_923532	819	10	)	)	-RRB-
10_1101-2020_01_28_923532	819	11	.	.	.
10_1101-2020_01_28_923532	820	1	48	48	CD
10_1101-2020_01_28_923532	820	2	.	.	.
10_1101-2020_01_28_923532	821	1	Nilchian	Nilchian	NNP
10_1101-2020_01_28_923532	821	2	,	,	,
10_1101-2020_01_28_923532	821	3	A.	A.	NNP
10_1101-2020_01_28_923532	821	4	,	,	,
10_1101-2020_01_28_923532	821	5	et	et	NNP
10_1101-2020_01_28_923532	821	6	al	al	NNP
10_1101-2020_01_28_923532	821	7	.	.	.
10_1101-2020_01_28_923532	822	1	CXADR	CXADR	NNP
10_1101-2020_01_28_923532	822	2	-	-	HYPH
10_1101-2020_01_28_923532	822	3	mediated	mediate	VBN
10_1101-2020_01_28_923532	822	4	formation	formation	NN
10_1101-2020_01_28_923532	822	5	of	of	IN
10_1101-2020_01_28_923532	822	6	an	an	DT
10_1101-2020_01_28_923532	822	7	AKT	AKT	NNP
10_1101-2020_01_28_923532	822	8	inhibitory	inhibitory	NN
10_1101-2020_01_28_923532	822	9	signalosome	signalosome	JJ
10_1101-2020_01_28_923532	822	10	at	at	IN
10_1101-2020_01_28_923532	822	11	tight	tight	JJ
10_1101-2020_01_28_923532	822	12	junctions	junction	NNS
10_1101-2020_01_28_923532	822	13	controls	control	VBZ
10_1101-2020_01_28_923532	822	14	epithelial	epithelial	JJ
10_1101-2020_01_28_923532	822	15	-	-	HYPH
10_1101-2020_01_28_923532	822	16	mesenchymal	mesenchymal	JJ
10_1101-2020_01_28_923532	822	17	plasticity	plasticity	NN
10_1101-2020_01_28_923532	822	18	in	in	IN
10_1101-2020_01_28_923532	822	19	breast	breast	NN
10_1101-2020_01_28_923532	822	20	cancer	cancer	NN
10_1101-2020_01_28_923532	822	21	.	.	.
10_1101-2020_01_28_923532	823	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	823	2	Res	Res	NNP
10_1101-2020_01_28_923532	823	3	.	.	.
10_1101-2020_01_28_923532	824	1	79(1):47-	79(1):47-	CD
10_1101-2020_01_28_923532	824	2	60	60	CD
10_1101-2020_01_28_923532	824	3	(	(	-LRB-
10_1101-2020_01_28_923532	824	4	2019	2019	CD
10_1101-2020_01_28_923532	824	5	)	)	-RRB-
10_1101-2020_01_28_923532	824	6	.	.	.
10_1101-2020_01_28_923532	825	1	49	49	CD
10_1101-2020_01_28_923532	825	2	.	.	.
10_1101-2020_01_28_923532	826	1	Arfelt	Arfelt	NNP
10_1101-2020_01_28_923532	826	2	K.N.	K.N.	NNP
10_1101-2020_01_28_923532	826	3	,	,	,
10_1101-2020_01_28_923532	826	4	et	et	NNP
10_1101-2020_01_28_923532	826	5	al	al	NNP
10_1101-2020_01_28_923532	826	6	.	.	.
10_1101-2020_01_28_923532	827	1	Signaling	signal	VBG
10_1101-2020_01_28_923532	827	2	via	via	IN
10_1101-2020_01_28_923532	827	3	G	g	NN
10_1101-2020_01_28_923532	827	4	proteins	protein	NNS
10_1101-2020_01_28_923532	827	5	mediates	mediate	VBZ
10_1101-2020_01_28_923532	827	6	tumorigenic	tumorigenic	JJ
10_1101-2020_01_28_923532	827	7	effects	effect	NNS
10_1101-2020_01_28_923532	827	8	of	of	IN
10_1101-2020_01_28_923532	827	9	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	827	10	.	.	.
10_1101-2020_01_28_923532	828	1	Cell	cell	NN
10_1101-2020_01_28_923532	828	2	.	.	.
10_1101-2020_01_28_923532	829	1	Signal	Signal	NNP
10_1101-2020_01_28_923532	829	2	.	.	.
10_1101-2020_01_28_923532	830	1	30:9	30:9	CD
10_1101-2020_01_28_923532	830	2	-	-	SYM
10_1101-2020_01_28_923532	830	3	18	18	CD
10_1101-2020_01_28_923532	830	4	(	(	-LRB-
10_1101-2020_01_28_923532	830	5	2017	2017	CD
10_1101-2020_01_28_923532	830	6	)	)	-RRB-
10_1101-2020_01_28_923532	830	7	.	.	.
10_1101-2020_01_28_923532	831	1	50	50	CD
10_1101-2020_01_28_923532	831	2	.	.	.
10_1101-2020_01_28_923532	832	1	Zhang	Zhang	NNP
10_1101-2020_01_28_923532	832	2	,	,	,
10_1101-2020_01_28_923532	832	3	Y.	Y.	NNP
10_1101-2020_01_28_923532	832	4	,	,	,
10_1101-2020_01_28_923532	832	5	Qian	Qian	NNP
10_1101-2020_01_28_923532	832	6	,	,	,
10_1101-2020_01_28_923532	832	7	Y.	Y.	NNP
10_1101-2020_01_28_923532	832	8	,	,	,
10_1101-2020_01_28_923532	832	9	Lu	Lu	NNP
10_1101-2020_01_28_923532	832	10	,	,	,
10_1101-2020_01_28_923532	832	11	W.	W.	NNP
10_1101-2020_01_28_923532	832	12	,	,	,
10_1101-2020_01_28_923532	832	13	Chen	Chen	NNP
10_1101-2020_01_28_923532	832	14	,	,	,
10_1101-2020_01_28_923532	832	15	X.	X.	NNP
10_1101-2020_01_28_923532	833	1	The	the	DT
10_1101-2020_01_28_923532	833	2	G	G	NNP
10_1101-2020_01_28_923532	833	3	protein	protein	NN
10_1101-2020_01_28_923532	833	4	-	-	HYPH
10_1101-2020_01_28_923532	833	5	coupled	couple	VBN
10_1101-2020_01_28_923532	833	6	receptor	receptor	NN
10_1101-2020_01_28_923532	833	7	87	87	CD
10_1101-2020_01_28_923532	833	8	is	be	VBZ
10_1101-2020_01_28_923532	833	9	necessary	necessary	JJ
10_1101-2020_01_28_923532	833	10	for	for	IN
10_1101-2020_01_28_923532	833	11	p53-dependent	p53-dependent	HYPH
10_1101-2020_01_28_923532	833	12	cell	cell	NN
10_1101-2020_01_28_923532	833	13	survival	survival	NN
10_1101-2020_01_28_923532	833	14	in	in	IN
10_1101-2020_01_28_923532	833	15	response	response	NN
10_1101-2020_01_28_923532	833	16	to	to	IN
10_1101-2020_01_28_923532	833	17	genotoxic	genotoxic	JJ
10_1101-2020_01_28_923532	833	18	stress	stress	NN
10_1101-2020_01_28_923532	833	19	.	.	.
10_1101-2020_01_28_923532	834	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	834	2	Res	Res	NNP
10_1101-2020_01_28_923532	834	3	.	.	.
10_1101-2020_01_28_923532	835	1	69(15):6049	69(15):6049	CD
10_1101-2020_01_28_923532	835	2	-	-	SYM
10_1101-2020_01_28_923532	835	3	6056	6056	CD
10_1101-2020_01_28_923532	835	4	(	(	-LRB-
10_1101-2020_01_28_923532	835	5	2009	2009	CD
10_1101-2020_01_28_923532	835	6	)	)	-RRB-
10_1101-2020_01_28_923532	835	7	.	.	.
10_1101-2020_01_28_923532	836	1	51	51	CD
10_1101-2020_01_28_923532	836	2	.	.	.
10_1101-2020_01_28_923532	837	1	Wang	Wang	NNP
10_1101-2020_01_28_923532	837	2	,	,	,
10_1101-2020_01_28_923532	837	3	L.	L.	NNP
10_1101-2020_01_28_923532	837	4	,	,	,
10_1101-2020_01_28_923532	837	5	et	et	NNP
10_1101-2020_01_28_923532	837	6	al	al	NNP
10_1101-2020_01_28_923532	837	7	.	.	.
10_1101-2020_01_28_923532	838	1	Overexpression	overexpression	NN
10_1101-2020_01_28_923532	838	2	of	of	IN
10_1101-2020_01_28_923532	838	3	G	g	NN
10_1101-2020_01_28_923532	838	4	protein	protein	NN
10_1101-2020_01_28_923532	838	5	-	-	HYPH
10_1101-2020_01_28_923532	838	6	coupled	couple	VBN
10_1101-2020_01_28_923532	838	7	receptor	receptor	NN
10_1101-2020_01_28_923532	838	8	GPR87	GPR87	NNP
10_1101-2020_01_28_923532	838	9	promotes	promote	VBZ
10_1101-2020_01_28_923532	838	10	pancreatic	pancreatic	JJ
10_1101-2020_01_28_923532	838	11	cancer	cancer	NN
10_1101-2020_01_28_923532	838	12	aggressiveness	aggressiveness	NN
10_1101-2020_01_28_923532	838	13	and	and	CC
10_1101-2020_01_28_923532	838	14	activates	activate	VBZ
10_1101-2020_01_28_923532	838	15	NF	NF	NNP
10_1101-2020_01_28_923532	838	16	-	-	HYPH
10_1101-2020_01_28_923532	838	17	κB	κB	NNP
10_1101-2020_01_28_923532	838	18	signaling	signaling	NN
10_1101-2020_01_28_923532	838	19	pathway	pathway	NN
10_1101-2020_01_28_923532	838	20	.	.	.
10_1101-2020_01_28_923532	839	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	839	2	.	.	.
10_1101-2020_01_28_923532	840	1	Cancer	cancer	NN
10_1101-2020_01_28_923532	840	2	16:61	16:61	CD
10_1101-2020_01_28_923532	840	3	(	(	-LRB-
10_1101-2020_01_28_923532	840	4	2017	2017	CD
10_1101-2020_01_28_923532	840	5	)	)	-RRB-
10_1101-2020_01_28_923532	840	6	.	.	.
10_1101-2020_01_28_923532	841	1	52	52	CD
10_1101-2020_01_28_923532	841	2	.	.	.
10_1101-2020_01_28_923532	842	1	Szklarczyk	Szklarczyk	NNP
10_1101-2020_01_28_923532	842	2	,	,	,
10_1101-2020_01_28_923532	842	3	D.	D.	NNP
10_1101-2020_01_28_923532	842	4	,	,	,
10_1101-2020_01_28_923532	842	5	et	et	NNP
10_1101-2020_01_28_923532	842	6	al	al	NNP
10_1101-2020_01_28_923532	842	7	.	.	.
10_1101-2020_01_28_923532	843	1	STRING	string	NN
10_1101-2020_01_28_923532	843	2	v11	v11	NN
10_1101-2020_01_28_923532	843	3	:	:	:
10_1101-2020_01_28_923532	843	4	protein	protein	NN
10_1101-2020_01_28_923532	843	5	-	-	HYPH
10_1101-2020_01_28_923532	843	6	protein	protein	NNP
10_1101-2020_01_28_923532	843	7	association	association	NNP
10_1101-2020_01_28_923532	843	8	networks	network	NNS
10_1101-2020_01_28_923532	843	9	with	with	IN
10_1101-2020_01_28_923532	843	10	increased	increase	VBN
10_1101-2020_01_28_923532	843	11	coverage	coverage	NN
10_1101-2020_01_28_923532	843	12	,	,	,
10_1101-2020_01_28_923532	843	13	supporting	support	VBG
10_1101-2020_01_28_923532	843	14	functional	functional	JJ
10_1101-2020_01_28_923532	843	15	discovery	discovery	NN
10_1101-2020_01_28_923532	843	16	in	in	IN
10_1101-2020_01_28_923532	843	17	genome	genome	NN
10_1101-2020_01_28_923532	843	18	-	-	HYPH
10_1101-2020_01_28_923532	843	19	wide	wide	JJ
10_1101-2020_01_28_923532	843	20	experimental	experimental	JJ
10_1101-2020_01_28_923532	843	21	datasets	dataset	NNS
10_1101-2020_01_28_923532	843	22	.	.	.
10_1101-2020_01_28_923532	844	1	Nucleic	Nucleic	NNP
10_1101-2020_01_28_923532	844	2	Acids	Acids	NNPS
10_1101-2020_01_28_923532	844	3	Res	Res	NNP
10_1101-2020_01_28_923532	844	4	.	.	.
10_1101-2020_01_28_923532	845	1	2019	2019	CD
10_1101-2020_01_28_923532	845	2	;	;	:
10_1101-2020_01_28_923532	845	3	47(D1	47(d1	CD
10_1101-2020_01_28_923532	845	4	)	)	-RRB-
10_1101-2020_01_28_923532	845	5	,	,	,
10_1101-2020_01_28_923532	845	6	D607-D613	D607-D613	NNP
10_1101-2020_01_28_923532	845	7	(	(	-LRB-
10_1101-2020_01_28_923532	845	8	2019	2019	CD
10_1101-2020_01_28_923532	845	9	)	)	-RRB-
10_1101-2020_01_28_923532	845	10	.	.	.
10_1101-2020_01_28_923532	846	1	53	53	CD
10_1101-2020_01_28_923532	846	2	.	.	.
10_1101-2020_01_28_923532	847	1	Seoane	Seoane	NNP
10_1101-2020_01_28_923532	847	2	,	,	,
10_1101-2020_01_28_923532	847	3	J.	J.	NNP
10_1101-2020_01_28_923532	848	1	&	&	CC
10_1101-2020_01_28_923532	848	2	De	De	NNP
10_1101-2020_01_28_923532	848	3	Mattos	Mattos	NNP
10_1101-2020_01_28_923532	848	4	-	-	HYPH
10_1101-2020_01_28_923532	848	5	Arruda	Arruda	NNP
10_1101-2020_01_28_923532	848	6	L.	L.	NNP
10_1101-2020_01_28_923532	848	7	The	the	DT
10_1101-2020_01_28_923532	848	8	challenge	challenge	NN
10_1101-2020_01_28_923532	848	9	of	of	IN
10_1101-2020_01_28_923532	848	10	intratumour	intratumour	NN
10_1101-2020_01_28_923532	848	11	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	848	12	in	in	IN
10_1101-2020_01_28_923532	848	13	precision	precision	NN
10_1101-2020_01_28_923532	848	14	medicine	medicine	NN
10_1101-2020_01_28_923532	848	15	.	.	.
10_1101-2020_01_28_923532	849	1	J.	J.	NNP
10_1101-2020_01_28_923532	849	2	Intern	Intern	NNP
10_1101-2020_01_28_923532	849	3	.	.	.
10_1101-2020_01_28_923532	850	1	Med	Med	NNP
10_1101-2020_01_28_923532	850	2	.	.	.
10_1101-2020_01_28_923532	851	1	276(1	276(1	LS
10_1101-2020_01_28_923532	851	2	)	)	-RRB-
10_1101-2020_01_28_923532	851	3	,	,	,
10_1101-2020_01_28_923532	851	4	41	41	CD
10_1101-2020_01_28_923532	851	5	-	-	SYM
10_1101-2020_01_28_923532	851	6	51	51	CD
10_1101-2020_01_28_923532	851	7	(	(	-LRB-
10_1101-2020_01_28_923532	851	8	2014	2014	CD
10_1101-2020_01_28_923532	851	9	)	)	-RRB-
10_1101-2020_01_28_923532	851	10	.	.	.
10_1101-2020_01_28_923532	852	1	54	54	CD
10_1101-2020_01_28_923532	852	2	.	.	.
10_1101-2020_01_28_923532	853	1	Van	Van	NNP
10_1101-2020_01_28_923532	853	2	Dijk	Dijk	NNP
10_1101-2020_01_28_923532	853	3	D	D	NNP
10_1101-2020_01_28_923532	853	4	,	,	,
10_1101-2020_01_28_923532	853	5	et	et	NNP
10_1101-2020_01_28_923532	853	6	al	al	NNP
10_1101-2020_01_28_923532	853	7	.	.	.
10_1101-2020_01_28_923532	854	1	Recovering	recover	VBG
10_1101-2020_01_28_923532	854	2	gene	gene	NN
10_1101-2020_01_28_923532	854	3	interactions	interaction	NNS
10_1101-2020_01_28_923532	854	4	from	from	IN
10_1101-2020_01_28_923532	854	5	single	single	JJ
10_1101-2020_01_28_923532	854	6	-	-	HYPH
10_1101-2020_01_28_923532	854	7	cell	cell	NN
10_1101-2020_01_28_923532	854	8	data	datum	NNS
10_1101-2020_01_28_923532	854	9	using	use	VBG
10_1101-2020_01_28_923532	854	10	data	datum	NNS
10_1101-2020_01_28_923532	854	11	diffusion	diffusion	NN
10_1101-2020_01_28_923532	854	12	.	.	.
10_1101-2020_01_28_923532	855	1	Cell	Cell	NNP
10_1101-2020_01_28_923532	855	2	174(3):716	174(3):716	NNP
10_1101-2020_01_28_923532	855	3	-	-	HYPH
10_1101-2020_01_28_923532	855	4	729.e27	729.e27	NNP
10_1101-2020_01_28_923532	855	5	(	(	-LRB-
10_1101-2020_01_28_923532	855	6	2018	2018	CD
10_1101-2020_01_28_923532	855	7	)	)	-RRB-
10_1101-2020_01_28_923532	855	8	.	.	.
10_1101-2020_01_28_923532	856	1	55	55	CD
10_1101-2020_01_28_923532	856	2	.	.	.
10_1101-2020_01_28_923532	857	1	Li	Li	NNP
10_1101-2020_01_28_923532	857	2	,	,	,
10_1101-2020_01_28_923532	857	3	W.V.	W.V.	NNP
10_1101-2020_01_28_923532	858	1	&	&	CC
10_1101-2020_01_28_923532	858	2	Li	Li	NNP
10_1101-2020_01_28_923532	858	3	,	,	,
10_1101-2020_01_28_923532	858	4	J.J.	J.J.	NNP
10_1101-2020_01_28_923532	858	5	An	an	DT
10_1101-2020_01_28_923532	858	6	accurate	accurate	JJ
10_1101-2020_01_28_923532	858	7	and	and	CC
10_1101-2020_01_28_923532	858	8	robust	robust	JJ
10_1101-2020_01_28_923532	858	9	imputation	imputation	NN
10_1101-2020_01_28_923532	858	10	method	method	NN
10_1101-2020_01_28_923532	858	11	scImpute	scimpute	VB
10_1101-2020_01_28_923532	858	12	for	for	IN
10_1101-2020_01_28_923532	858	13	single	single	JJ
10_1101-2020_01_28_923532	858	14	-	-	HYPH
10_1101-2020_01_28_923532	858	15	cell	cell	NN
10_1101-2020_01_28_923532	858	16	RNA-	RNA-	NNP
10_1101-2020_01_28_923532	858	17	seq	seq	NN
10_1101-2020_01_28_923532	858	18	data	datum	NNS
10_1101-2020_01_28_923532	858	19	.	.	.
10_1101-2020_01_28_923532	859	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	859	2	.	.	.
10_1101-2020_01_28_923532	860	1	Comm	Comm	NNP
10_1101-2020_01_28_923532	860	2	.	.	.
10_1101-2020_01_28_923532	861	1	9	9	CD
10_1101-2020_01_28_923532	861	2	,	,	,
10_1101-2020_01_28_923532	861	3	997	997	CD
10_1101-2020_01_28_923532	861	4	(	(	-LRB-
10_1101-2020_01_28_923532	861	5	2018	2018	CD
10_1101-2020_01_28_923532	861	6	)	)	-RRB-
10_1101-2020_01_28_923532	861	7	.	.	.
10_1101-2020_01_28_923532	862	1	56	56	CD
10_1101-2020_01_28_923532	862	2	.	.	.
10_1101-2020_01_28_923532	863	1	Raj	Raj	NNP
10_1101-2020_01_28_923532	863	2	,	,	,
10_1101-2020_01_28_923532	863	3	A.	a.	NN
10_1101-2020_01_28_923532	864	1	&	&	CC
10_1101-2020_01_28_923532	864	2	van	van	NNP
10_1101-2020_01_28_923532	864	3	Oudenaarden	Oudenaarden	NNP
10_1101-2020_01_28_923532	864	4	,	,	,
10_1101-2020_01_28_923532	864	5	A.	a.	JJ
10_1101-2020_01_28_923532	864	6	Stochastic	stochastic	JJ
10_1101-2020_01_28_923532	864	7	gene	gene	NN
10_1101-2020_01_28_923532	864	8	expression	expression	NN
10_1101-2020_01_28_923532	864	9	and	and	CC
10_1101-2020_01_28_923532	864	10	its	-PRON-	PRP$
10_1101-2020_01_28_923532	864	11	consequences	consequence	NNS
10_1101-2020_01_28_923532	864	12	.	.	.
10_1101-2020_01_28_923532	865	1	Cell	cell	NN
10_1101-2020_01_28_923532	865	2	135(2	135(2	CD
10_1101-2020_01_28_923532	865	3	)	)	-RRB-
10_1101-2020_01_28_923532	865	4	:	:	:
10_1101-2020_01_28_923532	865	5	216	216	CD
10_1101-2020_01_28_923532	865	6	-	-	HYPH
10_1101-2020_01_28_923532	865	7	226	226	CD
10_1101-2020_01_28_923532	865	8	(	(	-LRB-
10_1101-2020_01_28_923532	865	9	2008	2008	CD
10_1101-2020_01_28_923532	865	10	)	)	-RRB-
10_1101-2020_01_28_923532	865	11	.	.	.
10_1101-2020_01_28_923532	866	1	57	57	CD
10_1101-2020_01_28_923532	866	2	.	.	.
10_1101-2020_01_28_923532	867	1	Kim	Kim	NNP
10_1101-2020_01_28_923532	867	2	,	,	,
10_1101-2020_01_28_923532	867	3	J.Y.	J.Y.	NNP
10_1101-2020_01_28_923532	868	1	&	&	CC
10_1101-2020_01_28_923532	868	2	Marioni	Marioni	NNP
10_1101-2020_01_28_923532	868	3	,	,	,
10_1101-2020_01_28_923532	868	4	J.C.	J.C.	NNP
10_1101-2020_01_28_923532	868	5	Inferring	infer	VBG
10_1101-2020_01_28_923532	868	6	the	the	DT
10_1101-2020_01_28_923532	868	7	kinetics	kinetic	NNS
10_1101-2020_01_28_923532	868	8	of	of	IN
10_1101-2020_01_28_923532	868	9	stochastic	stochastic	JJ
10_1101-2020_01_28_923532	868	10	gene	gene	NN
10_1101-2020_01_28_923532	868	11	expression	expression	NN
10_1101-2020_01_28_923532	868	12	from	from	IN
10_1101-2020_01_28_923532	868	13	single-	single-	NNP
10_1101-2020_01_28_923532	868	14	cell	cell	NN
10_1101-2020_01_28_923532	868	15	RNA	RNA	NNP
10_1101-2020_01_28_923532	868	16	-	-	HYPH
10_1101-2020_01_28_923532	868	17	sequencing	sequence	VBG
10_1101-2020_01_28_923532	868	18	data	datum	NNS
10_1101-2020_01_28_923532	868	19	.	.	.
10_1101-2020_01_28_923532	869	1	Genome	Genome	NNP
10_1101-2020_01_28_923532	869	2	Biol	Biol	NNP
10_1101-2020_01_28_923532	869	3	.	.	.
10_1101-2020_01_28_923532	870	1	14	14	CD
10_1101-2020_01_28_923532	870	2	,	,	,
10_1101-2020_01_28_923532	870	3	R7	R7	NNP
10_1101-2020_01_28_923532	870	4	(	(	-LRB-
10_1101-2020_01_28_923532	870	5	2013	2013	CD
10_1101-2020_01_28_923532	870	6	)	)	-RRB-
10_1101-2020_01_28_923532	870	7	.	.	.
10_1101-2020_01_28_923532	871	1	58	58	CD
10_1101-2020_01_28_923532	871	2	.	.	.
10_1101-2020_01_28_923532	872	1	Clough	Clough	NNP
10_1101-2020_01_28_923532	872	2	,	,	,
10_1101-2020_01_28_923532	872	3	E.	E.	NNP
10_1101-2020_01_28_923532	872	4	&	&	CC
10_1101-2020_01_28_923532	872	5	Barrett	Barrett	NNP
10_1101-2020_01_28_923532	872	6	,	,	,
10_1101-2020_01_28_923532	872	7	T.	T.	NNP
10_1101-2020_01_28_923532	872	8	The	the	DT
10_1101-2020_01_28_923532	872	9	Gene	Gene	NNP
10_1101-2020_01_28_923532	872	10	Expression	Expression	NNP
10_1101-2020_01_28_923532	872	11	Omnibus	Omnibus	NNP
10_1101-2020_01_28_923532	872	12	Database	Database	NNP
10_1101-2020_01_28_923532	872	13	.	.	.
10_1101-2020_01_28_923532	873	1	Meth	Meth	NNP
10_1101-2020_01_28_923532	873	2	.	.	.
10_1101-2020_01_28_923532	874	1	Mol	Mol	NNP
10_1101-2020_01_28_923532	874	2	.	.	.
10_1101-2020_01_28_923532	875	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	875	2	.	.	.
10_1101-2020_01_28_923532	876	1	1418	1418	CD
10_1101-2020_01_28_923532	876	2	,	,	,
10_1101-2020_01_28_923532	876	3	93	93	CD
10_1101-2020_01_28_923532	876	4	-	-	SYM
10_1101-2020_01_28_923532	876	5	110	110	CD
10_1101-2020_01_28_923532	876	6	(	(	-LRB-
10_1101-2020_01_28_923532	876	7	2016	2016	CD
10_1101-2020_01_28_923532	876	8	)	)	-RRB-
10_1101-2020_01_28_923532	876	9	.	.	.
10_1101-2020_01_28_923532	877	1	59	59	CD
10_1101-2020_01_28_923532	877	2	.	.	.
10_1101-2020_01_28_923532	878	1	Kolesnikov	Kolesnikov	NNP
10_1101-2020_01_28_923532	878	2	,	,	,
10_1101-2020_01_28_923532	878	3	N.	N.	NNP
10_1101-2020_01_28_923532	878	4	,	,	,
10_1101-2020_01_28_923532	878	5	et	et	NNP
10_1101-2020_01_28_923532	878	6	al	al	NNP
10_1101-2020_01_28_923532	878	7	.	.	.
10_1101-2020_01_28_923532	879	1	ArrayExpress	ArrayExpress	NNP
10_1101-2020_01_28_923532	879	2	update	update	NN
10_1101-2020_01_28_923532	879	3	--	--	:
10_1101-2020_01_28_923532	879	4	simplifying	simplify	VBG
10_1101-2020_01_28_923532	879	5	data	datum	NNS
10_1101-2020_01_28_923532	879	6	submissions	submission	NNS
10_1101-2020_01_28_923532	879	7	.	.	.
10_1101-2020_01_28_923532	880	1	Nucleic	Nucleic	NNP
10_1101-2020_01_28_923532	880	2	Acids	Acids	NNPS
10_1101-2020_01_28_923532	880	3	Res	Res	NNP
10_1101-2020_01_28_923532	880	4	.	.	.
10_1101-2020_01_28_923532	881	1	43(Database	43(database	CD
10_1101-2020_01_28_923532	881	2	Issue	issue	NN
10_1101-2020_01_28_923532	881	3	)	)	-RRB-
10_1101-2020_01_28_923532	881	4	,	,	,
10_1101-2020_01_28_923532	881	5	D1113-D1116	D1113-D1116	NNP
10_1101-2020_01_28_923532	881	6	(	(	-LRB-
10_1101-2020_01_28_923532	881	7	2015	2015	CD
10_1101-2020_01_28_923532	881	8	)	)	-RRB-
10_1101-2020_01_28_923532	881	9	.	.	.
10_1101-2020_01_28_923532	882	1	60	60	CD
10_1101-2020_01_28_923532	882	2	.	.	.
10_1101-2020_01_28_923532	883	1	Cao	Cao	NNP
10_1101-2020_01_28_923532	883	2	,	,	,
10_1101-2020_01_28_923532	883	3	Y.	Y.	NNP
10_1101-2020_01_28_923532	883	4	,	,	,
10_1101-2020_01_28_923532	883	5	Zhu	Zhu	NNP
10_1101-2020_01_28_923532	883	6	,	,	,
10_1101-2020_01_28_923532	883	7	J.	J.	NNP
10_1101-2020_01_28_923532	883	8	,	,	,
10_1101-2020_01_28_923532	883	9	Jia	Jia	NNP
10_1101-2020_01_28_923532	883	10	,	,	,
10_1101-2020_01_28_923532	883	11	P.	P.	NNP
10_1101-2020_01_28_923532	883	12	&	&	CC
10_1101-2020_01_28_923532	883	13	Zhao	Zhao	NNP
10_1101-2020_01_28_923532	883	14	Z.	Z.	NNP
10_1101-2020_01_28_923532	883	15	scRNASeqDB	scrnaseqdb	NN
10_1101-2020_01_28_923532	883	16	:	:	:
10_1101-2020_01_28_923532	883	17	A	a	DT
10_1101-2020_01_28_923532	883	18	database	database	NN
10_1101-2020_01_28_923532	883	19	for	for	IN
10_1101-2020_01_28_923532	883	20	RNA	RNA	NNP
10_1101-2020_01_28_923532	883	21	-	-	HYPH
10_1101-2020_01_28_923532	883	22	seq	seq	NNP
10_1101-2020_01_28_923532	883	23	based	base	VBN
10_1101-2020_01_28_923532	883	24	gene	gene	NN
10_1101-2020_01_28_923532	883	25	expression	expression	NN
10_1101-2020_01_28_923532	883	26	profiles	profile	NNS
10_1101-2020_01_28_923532	883	27	in	in	IN
10_1101-2020_01_28_923532	883	28	human	human	JJ
10_1101-2020_01_28_923532	883	29	single	single	JJ
10_1101-2020_01_28_923532	883	30	cells	cell	NNS
10_1101-2020_01_28_923532	883	31	.	.	.
10_1101-2020_01_28_923532	884	1	Genes	gene	NNS
10_1101-2020_01_28_923532	884	2	8(12	8(12	NNP
10_1101-2020_01_28_923532	884	3	)	)	-RRB-
10_1101-2020_01_28_923532	884	4	,	,	,
10_1101-2020_01_28_923532	884	5	368	368	CD
10_1101-2020_01_28_923532	884	6	(	(	-LRB-
10_1101-2020_01_28_923532	884	7	2017	2017	CD
10_1101-2020_01_28_923532	884	8	)	)	-RRB-
10_1101-2020_01_28_923532	884	9	.	.	.
10_1101-2020_01_28_923532	885	1	105	105	CD
10_1101-2020_01_28_923532	885	2	and	and	CC
10_1101-2020_01_28_923532	885	3	is	be	VBZ
10_1101-2020_01_28_923532	885	4	also	also	RB
10_1101-2020_01_28_923532	885	5	made	make	VBN
10_1101-2020_01_28_923532	885	6	available	available	JJ
10_1101-2020_01_28_923532	885	7	for	for	IN
10_1101-2020_01_28_923532	885	8	use	use	NN
10_1101-2020_01_28_923532	885	9	under	under	IN
10_1101-2020_01_28_923532	885	10	a	a	DT
10_1101-2020_01_28_923532	885	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	885	12	license	license	NN
10_1101-2020_01_28_923532	885	13	.	.	.
10_1101-2020_01_28_923532	886	1	(	(	-LRB-
10_1101-2020_01_28_923532	886	2	which	which	WDT
10_1101-2020_01_28_923532	886	3	was	be	VBD
10_1101-2020_01_28_923532	886	4	not	not	RB
10_1101-2020_01_28_923532	886	5	certified	certify	VBN
10_1101-2020_01_28_923532	886	6	by	by	IN
10_1101-2020_01_28_923532	886	7	peer	peer	NN
10_1101-2020_01_28_923532	886	8	review	review	NN
10_1101-2020_01_28_923532	886	9	)	)	-RRB-
10_1101-2020_01_28_923532	886	10	is	be	VBZ
10_1101-2020_01_28_923532	886	11	the	the	DT
10_1101-2020_01_28_923532	886	12	author	author	NN
10_1101-2020_01_28_923532	886	13	/	/	SYM
10_1101-2020_01_28_923532	886	14	funder	funder	NN
10_1101-2020_01_28_923532	886	15	.	.	.
10_1101-2020_01_28_923532	887	1	This	this	DT
10_1101-2020_01_28_923532	887	2	article	article	NN
10_1101-2020_01_28_923532	887	3	is	be	VBZ
10_1101-2020_01_28_923532	887	4	a	a	DT
10_1101-2020_01_28_923532	887	5	US	US	NNP
10_1101-2020_01_28_923532	887	6	Government	Government	NNP
10_1101-2020_01_28_923532	887	7	work	work	NN
10_1101-2020_01_28_923532	887	8	.	.	.
10_1101-2020_01_28_923532	888	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	888	2	is	be	VBZ
10_1101-2020_01_28_923532	888	3	not	not	RB
10_1101-2020_01_28_923532	888	4	subject	subject	JJ
10_1101-2020_01_28_923532	888	5	to	to	IN
10_1101-2020_01_28_923532	888	6	copyright	copyright	NN
10_1101-2020_01_28_923532	888	7	under	under	IN
10_1101-2020_01_28_923532	888	8	17	17	CD
10_1101-2020_01_28_923532	888	9	USC	usc	NN
10_1101-2020_01_28_923532	888	10	The	the	DT
10_1101-2020_01_28_923532	888	11	copyright	copyright	NN
10_1101-2020_01_28_923532	888	12	holder	holder	NN
10_1101-2020_01_28_923532	888	13	for	for	IN
10_1101-2020_01_28_923532	888	14	this	this	DT
10_1101-2020_01_28_923532	888	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	888	16	version	version	NN
10_1101-2020_01_28_923532	888	17	posted	post	VBD
10_1101-2020_01_28_923532	888	18	February	February	NNP
10_1101-2020_01_28_923532	888	19	12	12	CD
10_1101-2020_01_28_923532	888	20	,	,	,
10_1101-2020_01_28_923532	888	21	2021	2021	CD
10_1101-2020_01_28_923532	888	22	.	.	.
10_1101-2020_01_28_923532	888	23	;	;	:
10_1101-2020_01_28_923532	888	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	888	25	:	:	:
10_1101-2020_01_28_923532	888	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	888	27	preprint	preprint	NN
10_1101-2020_01_28_923532	888	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	888	29	45	45	CD
10_1101-2020_01_28_923532	888	30	61	61	CD
10_1101-2020_01_28_923532	888	31	.	.	.
10_1101-2020_01_28_923532	889	1	Yuan	Yuan	NNP
10_1101-2020_01_28_923532	889	2	J	J	NNP
10_1101-2020_01_28_923532	889	3	,	,	,
10_1101-2020_01_28_923532	889	4	et	et	NNP
10_1101-2020_01_28_923532	889	5	al	al	NNP
10_1101-2020_01_28_923532	889	6	.	.	.
10_1101-2020_01_28_923532	890	1	Single	single	JJ
10_1101-2020_01_28_923532	890	2	-	-	HYPH
10_1101-2020_01_28_923532	890	3	cell	cell	NN
10_1101-2020_01_28_923532	890	4	transcriptome	transcriptome	DT
10_1101-2020_01_28_923532	890	5	analysis	analysis	NN
10_1101-2020_01_28_923532	890	6	of	of	IN
10_1101-2020_01_28_923532	890	7	lineage	lineage	NN
10_1101-2020_01_28_923532	890	8	diversity	diversity	NN
10_1101-2020_01_28_923532	890	9	in	in	IN
10_1101-2020_01_28_923532	890	10	high	high	JJ
10_1101-2020_01_28_923532	890	11	-	-	HYPH
10_1101-2020_01_28_923532	890	12	grade	grade	NN
10_1101-2020_01_28_923532	890	13	glioma	glioma	NN
10_1101-2020_01_28_923532	890	14	.	.	.
10_1101-2020_01_28_923532	891	1	Genome	genome	JJ
10_1101-2020_01_28_923532	891	2	Med	Med	NNP
10_1101-2020_01_28_923532	891	3	.	.	.
10_1101-2020_01_28_923532	892	1	10(1	10(1	LS
10_1101-2020_01_28_923532	892	2	)	)	-RRB-
10_1101-2020_01_28_923532	892	3	,	,	,
10_1101-2020_01_28_923532	892	4	57	57	CD
10_1101-2020_01_28_923532	892	5	(	(	-LRB-
10_1101-2020_01_28_923532	892	6	2018	2018	CD
10_1101-2020_01_28_923532	892	7	)	)	-RRB-
10_1101-2020_01_28_923532	892	8	.	.	.
10_1101-2020_01_28_923532	893	1	62	62	CD
10_1101-2020_01_28_923532	893	2	.	.	.
10_1101-2020_01_28_923532	894	1	Karaayvaz	Karaayvaz	NNP
10_1101-2020_01_28_923532	894	2	,	,	,
10_1101-2020_01_28_923532	894	3	M.	M.	NNP
10_1101-2020_01_28_923532	894	4	,	,	,
10_1101-2020_01_28_923532	894	5	et	et	NNP
10_1101-2020_01_28_923532	894	6	al	al	NNP
10_1101-2020_01_28_923532	894	7	.	.	.
10_1101-2020_01_28_923532	895	1	Unravelling	unravel	VBG
10_1101-2020_01_28_923532	895	2	subclonal	subclonal	JJ
10_1101-2020_01_28_923532	895	3	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	895	4	and	and	CC
10_1101-2020_01_28_923532	895	5	aggressive	aggressive	JJ
10_1101-2020_01_28_923532	895	6	disease	disease	NN
10_1101-2020_01_28_923532	895	7	states	state	NNS
10_1101-2020_01_28_923532	895	8	in	in	IN
10_1101-2020_01_28_923532	895	9	TNBC	tnbc	NN
10_1101-2020_01_28_923532	895	10	through	through	IN
10_1101-2020_01_28_923532	895	11	single	single	JJ
10_1101-2020_01_28_923532	895	12	-	-	HYPH
10_1101-2020_01_28_923532	895	13	cell	cell	NN
10_1101-2020_01_28_923532	895	14	RNA	RNA	NNP
10_1101-2020_01_28_923532	895	15	-	-	HYPH
10_1101-2020_01_28_923532	895	16	seq	seq	NN
10_1101-2020_01_28_923532	895	17	.	.	.
10_1101-2020_01_28_923532	896	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	896	2	.	.	.
10_1101-2020_01_28_923532	897	1	Comm	Comm	NNP
10_1101-2020_01_28_923532	897	2	.	.	.
10_1101-2020_01_28_923532	898	1	9(1	9(1	NN
10_1101-2020_01_28_923532	898	2	)	)	-RRB-
10_1101-2020_01_28_923532	898	3	,	,	,
10_1101-2020_01_28_923532	898	4	3588	3588	CD
10_1101-2020_01_28_923532	898	5	(	(	-LRB-
10_1101-2020_01_28_923532	898	6	2018	2018	CD
10_1101-2020_01_28_923532	898	7	)	)	-RRB-
10_1101-2020_01_28_923532	898	8	.	.	.
10_1101-2020_01_28_923532	899	1	63	63	CD
10_1101-2020_01_28_923532	899	2	.	.	.
10_1101-2020_01_28_923532	900	1	Jerby	Jerby	NNP
10_1101-2020_01_28_923532	900	2	-	-	HYPH
10_1101-2020_01_28_923532	900	3	Arnon	Arnon	NNP
10_1101-2020_01_28_923532	900	4	,	,	,
10_1101-2020_01_28_923532	900	5	L.	L.	NNP
10_1101-2020_01_28_923532	900	6	,	,	,
10_1101-2020_01_28_923532	900	7	et	et	NNP
10_1101-2020_01_28_923532	900	8	al	al	NNP
10_1101-2020_01_28_923532	900	9	.	.	.
10_1101-2020_01_28_923532	901	1	A	a	DT
10_1101-2020_01_28_923532	901	2	cancer	cancer	NN
10_1101-2020_01_28_923532	901	3	cell	cell	NN
10_1101-2020_01_28_923532	901	4	program	program	NN
10_1101-2020_01_28_923532	901	5	promotes	promote	VBZ
10_1101-2020_01_28_923532	901	6	T	T	NNP
10_1101-2020_01_28_923532	901	7	cell	cell	NN
10_1101-2020_01_28_923532	901	8	exclusion	exclusion	NN
10_1101-2020_01_28_923532	901	9	and	and	CC
10_1101-2020_01_28_923532	901	10	resistance	resistance	NN
10_1101-2020_01_28_923532	901	11	to	to	IN
10_1101-2020_01_28_923532	901	12	checkpoint	checkpoint	JJ
10_1101-2020_01_28_923532	901	13	blockade	blockade	NN
10_1101-2020_01_28_923532	901	14	.	.	.
10_1101-2020_01_28_923532	902	1	Cell	Cell	NNP
10_1101-2020_01_28_923532	902	2	175(4):984	175(4):984	NNP
10_1101-2020_01_28_923532	902	3	-	-	HYPH
10_1101-2020_01_28_923532	902	4	997.e24	997.e24	NNP
10_1101-2020_01_28_923532	902	5	(	(	-LRB-
10_1101-2020_01_28_923532	902	6	2018	2018	CD
10_1101-2020_01_28_923532	902	7	)	)	-RRB-
10_1101-2020_01_28_923532	902	8	.	.	.
10_1101-2020_01_28_923532	903	1	64	64	CD
10_1101-2020_01_28_923532	903	2	.	.	.
10_1101-2020_01_28_923532	904	1	Tirosh	Tirosh	NNP
10_1101-2020_01_28_923532	904	2	,	,	,
10_1101-2020_01_28_923532	904	3	I.	I.	NNP
10_1101-2020_01_28_923532	904	4	,	,	,
10_1101-2020_01_28_923532	904	5	et	et	NNP
10_1101-2020_01_28_923532	904	6	al	al	NNP
10_1101-2020_01_28_923532	904	7	.	.	.
10_1101-2020_01_28_923532	905	1	Dissecting	dissect	VBG
10_1101-2020_01_28_923532	905	2	the	the	DT
10_1101-2020_01_28_923532	905	3	multicellular	multicellular	JJ
10_1101-2020_01_28_923532	905	4	ecosystem	ecosystem	NN
10_1101-2020_01_28_923532	905	5	of	of	IN
10_1101-2020_01_28_923532	905	6	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	905	7	melanoma	melanoma	NN
10_1101-2020_01_28_923532	905	8	by	by	IN
10_1101-2020_01_28_923532	905	9	single	single	JJ
10_1101-2020_01_28_923532	905	10	-	-	HYPH
10_1101-2020_01_28_923532	905	11	cell	cell	NN
10_1101-2020_01_28_923532	905	12	RNA	RNA	NNP
10_1101-2020_01_28_923532	905	13	-	-	HYPH
10_1101-2020_01_28_923532	905	14	seq	seq	NN
10_1101-2020_01_28_923532	905	15	.	.	.
10_1101-2020_01_28_923532	906	1	Science	Science	NNP
10_1101-2020_01_28_923532	906	2	352(6282	352(6282	NNP
10_1101-2020_01_28_923532	906	3	)	)	-RRB-
10_1101-2020_01_28_923532	906	4	,	,	,
10_1101-2020_01_28_923532	906	5	189	189	CD
10_1101-2020_01_28_923532	906	6	-	-	SYM
10_1101-2020_01_28_923532	906	7	196	196	CD
10_1101-2020_01_28_923532	906	8	(	(	-LRB-
10_1101-2020_01_28_923532	906	9	2016	2016	CD
10_1101-2020_01_28_923532	906	10	)	)	-RRB-
10_1101-2020_01_28_923532	906	11	.	.	.
10_1101-2020_01_28_923532	907	1	65	65	CD
10_1101-2020_01_28_923532	907	2	.	.	.
10_1101-2020_01_28_923532	908	1	Chung	Chung	NNP
10_1101-2020_01_28_923532	908	2	,	,	,
10_1101-2020_01_28_923532	908	3	W.	W.	NNP
10_1101-2020_01_28_923532	908	4	,	,	,
10_1101-2020_01_28_923532	908	5	et	et	NNP
10_1101-2020_01_28_923532	908	6	al	al	NNP
10_1101-2020_01_28_923532	908	7	.	.	.
10_1101-2020_01_28_923532	909	1	Single	single	JJ
10_1101-2020_01_28_923532	909	2	-	-	HYPH
10_1101-2020_01_28_923532	909	3	cell	cell	NN
10_1101-2020_01_28_923532	909	4	RNA	RNA	NNP
10_1101-2020_01_28_923532	909	5	-	-	HYPH
10_1101-2020_01_28_923532	909	6	seq	seq	NN
10_1101-2020_01_28_923532	909	7	enables	enable	NNS
10_1101-2020_01_28_923532	909	8	comprehensive	comprehensive	JJ
10_1101-2020_01_28_923532	909	9	tumour	tumour	NN
10_1101-2020_01_28_923532	909	10	and	and	CC
10_1101-2020_01_28_923532	909	11	immune	immune	JJ
10_1101-2020_01_28_923532	909	12	cell	cell	NN
10_1101-2020_01_28_923532	909	13	profiling	profiling	NN
10_1101-2020_01_28_923532	909	14	in	in	IN
10_1101-2020_01_28_923532	909	15	primary	primary	JJ
10_1101-2020_01_28_923532	909	16	breast	breast	NN
10_1101-2020_01_28_923532	909	17	cancer	cancer	NN
10_1101-2020_01_28_923532	909	18	.	.	.
10_1101-2020_01_28_923532	910	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	910	2	.	.	.
10_1101-2020_01_28_923532	911	1	Comm	Comm	NNP
10_1101-2020_01_28_923532	911	2	.	.	.
10_1101-2020_01_28_923532	912	1	8,15081	8,15081	NNP
10_1101-2020_01_28_923532	912	2	(	(	-LRB-
10_1101-2020_01_28_923532	912	3	2017	2017	CD
10_1101-2020_01_28_923532	912	4	)	)	-RRB-
10_1101-2020_01_28_923532	912	5	.	.	.
10_1101-2020_01_28_923532	913	1	66	66	CD
10_1101-2020_01_28_923532	913	2	.	.	.
10_1101-2020_01_28_923532	914	1	Venteicher	Venteicher	NNP
10_1101-2020_01_28_923532	914	2	,	,	,
10_1101-2020_01_28_923532	914	3	A.S.	A.S.	NNP
10_1101-2020_01_28_923532	914	4	,	,	,
10_1101-2020_01_28_923532	914	5	et	et	NNP
10_1101-2020_01_28_923532	914	6	al	al	NNP
10_1101-2020_01_28_923532	914	7	.	.	.
10_1101-2020_01_28_923532	915	1	Decoupling	decouple	VBG
10_1101-2020_01_28_923532	915	2	genetics	genetic	NNS
10_1101-2020_01_28_923532	915	3	,	,	,
10_1101-2020_01_28_923532	915	4	lineages	lineage	NNS
10_1101-2020_01_28_923532	915	5	,	,	,
10_1101-2020_01_28_923532	915	6	and	and	CC
10_1101-2020_01_28_923532	915	7	microenvironment	microenvironment	NN
10_1101-2020_01_28_923532	915	8	in	in	IN
10_1101-2020_01_28_923532	915	9	IDH	IDH	NNP
10_1101-2020_01_28_923532	915	10	-	-	HYPH
10_1101-2020_01_28_923532	915	11	mutant	mutant	JJ
10_1101-2020_01_28_923532	915	12	gliomas	glioma	NNS
10_1101-2020_01_28_923532	915	13	by	by	IN
10_1101-2020_01_28_923532	915	14	single	single	JJ
10_1101-2020_01_28_923532	915	15	-	-	HYPH
10_1101-2020_01_28_923532	915	16	cell	cell	NN
10_1101-2020_01_28_923532	915	17	RNA	RNA	NNP
10_1101-2020_01_28_923532	915	18	-	-	HYPH
10_1101-2020_01_28_923532	915	19	seq	seq	NN
10_1101-2020_01_28_923532	915	20	.	.	.
10_1101-2020_01_28_923532	916	1	Science	science	NN
10_1101-2020_01_28_923532	916	2	355(6332	355(6332	NNP
10_1101-2020_01_28_923532	916	3	)	)	-RRB-
10_1101-2020_01_28_923532	916	4	:	:	:
10_1101-2020_01_28_923532	916	5	pii	pii	NN
10_1101-2020_01_28_923532	916	6	:	:	:
10_1101-2020_01_28_923532	916	7	eaai8478	eaai8478	NNP
10_1101-2020_01_28_923532	916	8	(	(	-LRB-
10_1101-2020_01_28_923532	916	9	2017	2017	CD
10_1101-2020_01_28_923532	916	10	)	)	-RRB-
10_1101-2020_01_28_923532	916	11	.	.	.
10_1101-2020_01_28_923532	917	1	67	67	CD
10_1101-2020_01_28_923532	917	2	.	.	.
10_1101-2020_01_28_923532	918	1	Tirosh	Tirosh	NNP
10_1101-2020_01_28_923532	918	2	,	,	,
10_1101-2020_01_28_923532	918	3	I.	I.	NNP
10_1101-2020_01_28_923532	918	4	,	,	,
10_1101-2020_01_28_923532	918	5	et	et	NNP
10_1101-2020_01_28_923532	918	6	al	al	NNP
10_1101-2020_01_28_923532	918	7	.	.	.
10_1101-2020_01_28_923532	919	1	Single	single	JJ
10_1101-2020_01_28_923532	919	2	-	-	HYPH
10_1101-2020_01_28_923532	919	3	cell	cell	NN
10_1101-2020_01_28_923532	919	4	RNA	RNA	NNP
10_1101-2020_01_28_923532	919	5	-	-	HYPH
10_1101-2020_01_28_923532	919	6	seq	seq	NN
10_1101-2020_01_28_923532	919	7	supports	support	VBZ
10_1101-2020_01_28_923532	919	8	a	a	DT
10_1101-2020_01_28_923532	919	9	developmental	developmental	JJ
10_1101-2020_01_28_923532	919	10	hierarchy	hierarchy	NN
10_1101-2020_01_28_923532	919	11	in	in	IN
10_1101-2020_01_28_923532	919	12	human	human	JJ
10_1101-2020_01_28_923532	919	13	oligodendroglioma	oligodendroglioma	NN
10_1101-2020_01_28_923532	919	14	.	.	.
10_1101-2020_01_28_923532	920	1	Nature	nature	NN
10_1101-2020_01_28_923532	920	2	539(7628	539(7628	NNP
10_1101-2020_01_28_923532	920	3	)	)	-RRB-
10_1101-2020_01_28_923532	920	4	,	,	,
10_1101-2020_01_28_923532	920	5	309	309	CD
10_1101-2020_01_28_923532	920	6	-	-	SYM
10_1101-2020_01_28_923532	920	7	313	313	CD
10_1101-2020_01_28_923532	920	8	(	(	-LRB-
10_1101-2020_01_28_923532	920	9	2016a	2016a	CD
10_1101-2020_01_28_923532	920	10	)	)	-RRB-
10_1101-2020_01_28_923532	920	11	.	.	.
10_1101-2020_01_28_923532	921	1	68	68	CD
10_1101-2020_01_28_923532	921	2	.	.	.
10_1101-2020_01_28_923532	922	1	Patel	Patel	NNP
10_1101-2020_01_28_923532	922	2	,	,	,
10_1101-2020_01_28_923532	922	3	A.P.	A.P.	NNP
10_1101-2020_01_28_923532	922	4	,	,	,
10_1101-2020_01_28_923532	922	5	et	et	NNP
10_1101-2020_01_28_923532	922	6	al	al	NNP
10_1101-2020_01_28_923532	922	7	.	.	.
10_1101-2020_01_28_923532	923	1	Single	single	JJ
10_1101-2020_01_28_923532	923	2	-	-	HYPH
10_1101-2020_01_28_923532	923	3	cell	cell	NN
10_1101-2020_01_28_923532	923	4	RNA	RNA	NNP
10_1101-2020_01_28_923532	923	5	-	-	HYPH
10_1101-2020_01_28_923532	923	6	seq	seq	NN
10_1101-2020_01_28_923532	923	7	highlights	highlight	NNS
10_1101-2020_01_28_923532	923	8	intratumoral	intratumoral	JJ
10_1101-2020_01_28_923532	923	9	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	923	10	in	in	IN
10_1101-2020_01_28_923532	923	11	primary	primary	JJ
10_1101-2020_01_28_923532	923	12	glioblastoma	glioblastoma	NN
10_1101-2020_01_28_923532	923	13	.	.	.
10_1101-2020_01_28_923532	924	1	Science	science	NN
10_1101-2020_01_28_923532	924	2	344(6190	344(6190	NNP
10_1101-2020_01_28_923532	924	3	)	)	-RRB-
10_1101-2020_01_28_923532	924	4	,	,	,
10_1101-2020_01_28_923532	924	5	1396	1396	CD
10_1101-2020_01_28_923532	924	6	-	-	SYM
10_1101-2020_01_28_923532	924	7	1401	1401	CD
10_1101-2020_01_28_923532	924	8	(	(	-LRB-
10_1101-2020_01_28_923532	924	9	2014	2014	CD
10_1101-2020_01_28_923532	924	10	)	)	-RRB-
10_1101-2020_01_28_923532	924	11	.	.	.
10_1101-2020_01_28_923532	925	1	69	69	CD
10_1101-2020_01_28_923532	925	2	.	.	.
10_1101-2020_01_28_923532	926	1	Filbin	Filbin	NNP
10_1101-2020_01_28_923532	926	2	,	,	,
10_1101-2020_01_28_923532	926	3	M.G.	M.G.	NNP
10_1101-2020_01_28_923532	926	4	,	,	,
10_1101-2020_01_28_923532	926	5	et	et	NNP
10_1101-2020_01_28_923532	926	6	al	al	NNP
10_1101-2020_01_28_923532	926	7	.	.	.
10_1101-2020_01_28_923532	927	1	Developmental	developmental	JJ
10_1101-2020_01_28_923532	927	2	and	and	CC
10_1101-2020_01_28_923532	927	3	oncogenic	oncogenic	JJ
10_1101-2020_01_28_923532	927	4	programs	program	NNS
10_1101-2020_01_28_923532	927	5	in	in	IN
10_1101-2020_01_28_923532	927	6	H3K27	H3K27	NNP
10_1101-2020_01_28_923532	927	7	M	M	NNP
10_1101-2020_01_28_923532	927	8	gliomas	gliomas	NNP
10_1101-2020_01_28_923532	927	9	dissected	dissect	VBN
10_1101-2020_01_28_923532	927	10	by	by	IN
10_1101-2020_01_28_923532	927	11	single	single	JJ
10_1101-2020_01_28_923532	927	12	-	-	HYPH
10_1101-2020_01_28_923532	927	13	cell	cell	NN
10_1101-2020_01_28_923532	927	14	RNA	RNA	NNP
10_1101-2020_01_28_923532	927	15	-	-	HYPH
10_1101-2020_01_28_923532	927	16	seq	seq	NN
10_1101-2020_01_28_923532	927	17	.	.	.
10_1101-2020_01_28_923532	928	1	Science	science	NN
10_1101-2020_01_28_923532	928	2	360(6386	360(6386	NNP
10_1101-2020_01_28_923532	928	3	)	)	-RRB-
10_1101-2020_01_28_923532	928	4	,	,	,
10_1101-2020_01_28_923532	928	5	331	331	CD
10_1101-2020_01_28_923532	928	6	-	-	HYPH
10_1101-2020_01_28_923532	928	7	335	335	CD
10_1101-2020_01_28_923532	928	8	(	(	-LRB-
10_1101-2020_01_28_923532	928	9	2018	2018	CD
10_1101-2020_01_28_923532	928	10	)	)	-RRB-
10_1101-2020_01_28_923532	928	11	.	.	.
10_1101-2020_01_28_923532	929	1	70	70	CD
10_1101-2020_01_28_923532	929	2	.	.	.
10_1101-2020_01_28_923532	930	1	Li	Li	NNP
10_1101-2020_01_28_923532	930	2	,	,	,
10_1101-2020_01_28_923532	930	3	H.	H.	NNP
10_1101-2020_01_28_923532	930	4	,	,	,
10_1101-2020_01_28_923532	930	5	et	et	NNP
10_1101-2020_01_28_923532	930	6	al	al	NNP
10_1101-2020_01_28_923532	930	7	.	.	.
10_1101-2020_01_28_923532	931	1	Reference	reference	NN
10_1101-2020_01_28_923532	931	2	component	component	NN
10_1101-2020_01_28_923532	931	3	analysis	analysis	NN
10_1101-2020_01_28_923532	931	4	of	of	IN
10_1101-2020_01_28_923532	931	5	single	single	JJ
10_1101-2020_01_28_923532	931	6	-	-	HYPH
10_1101-2020_01_28_923532	931	7	cell	cell	NN
10_1101-2020_01_28_923532	931	8	transcriptomes	transcriptome	NNS
10_1101-2020_01_28_923532	931	9	elucidates	elucidate	VBZ
10_1101-2020_01_28_923532	931	10	cellular	cellular	JJ
10_1101-2020_01_28_923532	931	11	heterogeneity	heterogeneity	NN
10_1101-2020_01_28_923532	931	12	in	in	IN
10_1101-2020_01_28_923532	931	13	human	human	JJ
10_1101-2020_01_28_923532	931	14	colorectal	colorectal	JJ
10_1101-2020_01_28_923532	931	15	tumors	tumor	NNS
10_1101-2020_01_28_923532	931	16	.	.	.
10_1101-2020_01_28_923532	932	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	932	2	.	.	.
10_1101-2020_01_28_923532	933	1	Genet	Genet	NNP
10_1101-2020_01_28_923532	933	2	.	.	.
10_1101-2020_01_28_923532	934	1	49(5	49(5	LS
10_1101-2020_01_28_923532	934	2	)	)	-RRB-
10_1101-2020_01_28_923532	934	3	,	,	,
10_1101-2020_01_28_923532	934	4	708	708	CD
10_1101-2020_01_28_923532	934	5	-	-	HYPH
10_1101-2020_01_28_923532	934	6	718	718	CD
10_1101-2020_01_28_923532	934	7	(	(	-LRB-
10_1101-2020_01_28_923532	934	8	2017	2017	CD
10_1101-2020_01_28_923532	934	9	)	)	-RRB-
10_1101-2020_01_28_923532	934	10	.	.	.
10_1101-2020_01_28_923532	935	1	71	71	CD
10_1101-2020_01_28_923532	935	2	.	.	.
10_1101-2020_01_28_923532	936	1	Puram	Puram	NNP
10_1101-2020_01_28_923532	936	2	,	,	,
10_1101-2020_01_28_923532	936	3	S.V.	S.V.	NNP
10_1101-2020_01_28_923532	936	4	,	,	,
10_1101-2020_01_28_923532	936	5	et	et	NNP
10_1101-2020_01_28_923532	936	6	al	al	NNP
10_1101-2020_01_28_923532	936	7	.	.	.
10_1101-2020_01_28_923532	937	1	Single	single	JJ
10_1101-2020_01_28_923532	937	2	-	-	HYPH
10_1101-2020_01_28_923532	937	3	cell	cell	NN
10_1101-2020_01_28_923532	937	4	transcriptomic	transcriptomic	JJ
10_1101-2020_01_28_923532	937	5	analysis	analysis	NN
10_1101-2020_01_28_923532	937	6	of	of	IN
10_1101-2020_01_28_923532	937	7	primary	primary	JJ
10_1101-2020_01_28_923532	937	8	and	and	CC
10_1101-2020_01_28_923532	937	9	metastatic	metastatic	JJ
10_1101-2020_01_28_923532	937	10	tumor	tumor	NN
10_1101-2020_01_28_923532	937	11	ecosystems	ecosystem	NNS
10_1101-2020_01_28_923532	937	12	in	in	IN
10_1101-2020_01_28_923532	937	13	head	head	NN
10_1101-2020_01_28_923532	937	14	and	and	CC
10_1101-2020_01_28_923532	937	15	neck	neck	NN
10_1101-2020_01_28_923532	937	16	cancer	cancer	NN
10_1101-2020_01_28_923532	937	17	.	.	.
10_1101-2020_01_28_923532	938	1	Cell	cell	NN
10_1101-2020_01_28_923532	938	2	171(7	171(7	CD
10_1101-2020_01_28_923532	938	3	)	)	-RRB-
10_1101-2020_01_28_923532	938	4	,	,	,
10_1101-2020_01_28_923532	938	5	1611	1611	CD
10_1101-2020_01_28_923532	938	6	-	-	SYM
10_1101-2020_01_28_923532	938	7	1624.e24	1624.e24	CD
10_1101-2020_01_28_923532	938	8	(	(	-LRB-
10_1101-2020_01_28_923532	938	9	2017	2017	CD
10_1101-2020_01_28_923532	938	10	)	)	-RRB-
10_1101-2020_01_28_923532	938	11	.	.	.
10_1101-2020_01_28_923532	939	1	72	72	CD
10_1101-2020_01_28_923532	939	2	.	.	.
10_1101-2020_01_28_923532	940	1	Shih	Shih	NNP
10_1101-2020_01_28_923532	940	2	,	,	,
10_1101-2020_01_28_923532	940	3	A.J.	A.J.	NNP
10_1101-2020_01_28_923532	940	4	,	,	,
10_1101-2020_01_28_923532	940	5	et	et	NNP
10_1101-2020_01_28_923532	940	6	al	al	NNP
10_1101-2020_01_28_923532	940	7	.	.	.
10_1101-2020_01_28_923532	941	1	Identification	identification	NN
10_1101-2020_01_28_923532	941	2	of	of	IN
10_1101-2020_01_28_923532	941	3	grade	grade	NN
10_1101-2020_01_28_923532	941	4	and	and	CC
10_1101-2020_01_28_923532	941	5	origin	origin	NN
10_1101-2020_01_28_923532	941	6	specific	specific	JJ
10_1101-2020_01_28_923532	941	7	cell	cell	NN
10_1101-2020_01_28_923532	941	8	populations	population	NNS
10_1101-2020_01_28_923532	941	9	in	in	IN
10_1101-2020_01_28_923532	941	10	serous	serous	JJ
10_1101-2020_01_28_923532	941	11	epithelial	epithelial	JJ
10_1101-2020_01_28_923532	941	12	ovarian	ovarian	JJ
10_1101-2020_01_28_923532	941	13	cancer	cancer	NN
10_1101-2020_01_28_923532	941	14	by	by	IN
10_1101-2020_01_28_923532	941	15	single	single	JJ
10_1101-2020_01_28_923532	941	16	cell	cell	NN
10_1101-2020_01_28_923532	941	17	RNA	RNA	NNP
10_1101-2020_01_28_923532	941	18	-	-	HYPH
10_1101-2020_01_28_923532	941	19	seq	seq	NNP
10_1101-2020_01_28_923532	941	20	.	.	.
10_1101-2020_01_28_923532	942	1	PLoS	PLoS	:
10_1101-2020_01_28_923532	942	2	ONE	one	CD
10_1101-2020_01_28_923532	942	3	13(11	13(11	CD
10_1101-2020_01_28_923532	942	4	)	)	-RRB-
10_1101-2020_01_28_923532	942	5	,	,	,
10_1101-2020_01_28_923532	942	6	e0208778	e0208778	NNP
10_1101-2020_01_28_923532	942	7	(	(	-LRB-
10_1101-2020_01_28_923532	942	8	2018	2018	CD
10_1101-2020_01_28_923532	942	9	)	)	-RRB-
10_1101-2020_01_28_923532	942	10	.	.	.
10_1101-2020_01_28_923532	943	1	73	73	CD
10_1101-2020_01_28_923532	943	2	.	.	.
10_1101-2020_01_28_923532	944	1	Miyamoto	Miyamoto	NNP
10_1101-2020_01_28_923532	944	2	,	,	,
10_1101-2020_01_28_923532	944	3	D.T.	D.T.	NNP
10_1101-2020_01_28_923532	944	4	,	,	,
10_1101-2020_01_28_923532	944	5	et	et	NNP
10_1101-2020_01_28_923532	944	6	al	al	NNP
10_1101-2020_01_28_923532	944	7	.	.	.
10_1101-2020_01_28_923532	945	1	RNA	RNA	NNP
10_1101-2020_01_28_923532	945	2	-	-	HYPH
10_1101-2020_01_28_923532	945	3	Seq	Seq	NNP
10_1101-2020_01_28_923532	945	4	of	of	IN
10_1101-2020_01_28_923532	945	5	single	single	JJ
10_1101-2020_01_28_923532	945	6	prostate	prostate	NN
10_1101-2020_01_28_923532	945	7	CTCs	ctc	NNS
10_1101-2020_01_28_923532	945	8	implicates	implicate	VBZ
10_1101-2020_01_28_923532	945	9	noncanonical	noncanonical	JJ
10_1101-2020_01_28_923532	945	10	Wnt	Wnt	NNP
10_1101-2020_01_28_923532	945	11	signaling	signal	VBG
10_1101-2020_01_28_923532	945	12	in	in	IN
10_1101-2020_01_28_923532	945	13	antiandrogen	antiandrogen	NN
10_1101-2020_01_28_923532	945	14	resistance	resistance	NN
10_1101-2020_01_28_923532	945	15	.	.	.
10_1101-2020_01_28_923532	946	1	Science	science	NN
10_1101-2020_01_28_923532	946	2	349	349	CD
10_1101-2020_01_28_923532	946	3	,	,	,
10_1101-2020_01_28_923532	946	4	1351	1351	CD
10_1101-2020_01_28_923532	946	5	-	-	SYM
10_1101-2020_01_28_923532	946	6	1356	1356	CD
10_1101-2020_01_28_923532	946	7	(	(	-LRB-
10_1101-2020_01_28_923532	946	8	2015	2015	CD
10_1101-2020_01_28_923532	946	9	)	)	-RRB-
10_1101-2020_01_28_923532	946	10	.	.	.
10_1101-2020_01_28_923532	947	1	74	74	CD
10_1101-2020_01_28_923532	947	2	.	.	.
10_1101-2020_01_28_923532	948	1	Lambrechts	Lambrechts	NNP
10_1101-2020_01_28_923532	948	2	,	,	,
10_1101-2020_01_28_923532	948	3	D.	D.	NNP
10_1101-2020_01_28_923532	948	4	,	,	,
10_1101-2020_01_28_923532	948	5	et	et	NNP
10_1101-2020_01_28_923532	948	6	al	al	NNP
10_1101-2020_01_28_923532	948	7	.	.	.
10_1101-2020_01_28_923532	949	1	Phenotype	phenotype	NN
10_1101-2020_01_28_923532	949	2	molding	molding	NN
10_1101-2020_01_28_923532	949	3	of	of	IN
10_1101-2020_01_28_923532	949	4	stromal	stromal	JJ
10_1101-2020_01_28_923532	949	5	cells	cell	NNS
10_1101-2020_01_28_923532	949	6	in	in	IN
10_1101-2020_01_28_923532	949	7	the	the	DT
10_1101-2020_01_28_923532	949	8	lung	lung	NN
10_1101-2020_01_28_923532	949	9	tumor	tumor	NN
10_1101-2020_01_28_923532	949	10	microenvironment	microenvironment	NNP
10_1101-2020_01_28_923532	949	11	.	.	.
10_1101-2020_01_28_923532	950	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	950	2	.	.	.
10_1101-2020_01_28_923532	951	1	Med	Med	NNP
10_1101-2020_01_28_923532	951	2	.	.	.
10_1101-2020_01_28_923532	952	1	24	24	CD
10_1101-2020_01_28_923532	952	2	,	,	,
10_1101-2020_01_28_923532	952	3	1277	1277	CD
10_1101-2020_01_28_923532	952	4	-	-	SYM
10_1101-2020_01_28_923532	952	5	1289	1289	CD
10_1101-2020_01_28_923532	952	6	(	(	-LRB-
10_1101-2020_01_28_923532	952	7	2018	2018	CD
10_1101-2020_01_28_923532	952	8	)	)	-RRB-
10_1101-2020_01_28_923532	952	9	.	.	.
10_1101-2020_01_28_923532	953	1	75	75	CD
10_1101-2020_01_28_923532	953	2	.	.	.
10_1101-2020_01_28_923532	954	1	Uhlén	Uhlén	NNP
10_1101-2020_01_28_923532	954	2	,	,	,
10_1101-2020_01_28_923532	954	3	M.	M.	NNP
10_1101-2020_01_28_923532	954	4	,	,	,
10_1101-2020_01_28_923532	954	5	et	et	NNP
10_1101-2020_01_28_923532	954	6	al	al	NNP
10_1101-2020_01_28_923532	954	7	.	.	.
10_1101-2020_01_28_923532	955	1	Tissue	tissue	NN
10_1101-2020_01_28_923532	955	2	-	-	HYPH
10_1101-2020_01_28_923532	955	3	based	base	VBN
10_1101-2020_01_28_923532	955	4	map	map	NN
10_1101-2020_01_28_923532	955	5	of	of	IN
10_1101-2020_01_28_923532	955	6	the	the	DT
10_1101-2020_01_28_923532	955	7	human	human	JJ
10_1101-2020_01_28_923532	955	8	proteome	proteome	NN
10_1101-2020_01_28_923532	955	9	.	.	.
10_1101-2020_01_28_923532	956	1	Science	Science	NNP
10_1101-2020_01_28_923532	956	2	347(6220	347(6220	NNP
10_1101-2020_01_28_923532	956	3	)	)	-RRB-
10_1101-2020_01_28_923532	956	4	,	,	,
10_1101-2020_01_28_923532	956	5	1260419	1260419	CD
10_1101-2020_01_28_923532	956	6	(	(	-LRB-
10_1101-2020_01_28_923532	956	7	2015	2015	CD
10_1101-2020_01_28_923532	956	8	)	)	-RRB-
10_1101-2020_01_28_923532	956	9	.	.	.
10_1101-2020_01_28_923532	957	1	76	76	CD
10_1101-2020_01_28_923532	957	2	.	.	.
10_1101-2020_01_28_923532	958	1	The	the	DT
10_1101-2020_01_28_923532	958	2	GTEx	GTEx	NNP
10_1101-2020_01_28_923532	958	3	Consortium	Consortium	NNP
10_1101-2020_01_28_923532	958	4	.	.	.
10_1101-2020_01_28_923532	959	1	The	the	DT
10_1101-2020_01_28_923532	959	2	genotype	genotype	NN
10_1101-2020_01_28_923532	959	3	-	-	HYPH
10_1101-2020_01_28_923532	959	4	tissue	tissue	NN
10_1101-2020_01_28_923532	959	5	expression	expression	NN
10_1101-2020_01_28_923532	959	6	(	(	-LRB-
10_1101-2020_01_28_923532	959	7	GTEx	GTEx	NNP
10_1101-2020_01_28_923532	959	8	)	)	-RRB-
10_1101-2020_01_28_923532	959	9	project	project	NN
10_1101-2020_01_28_923532	959	10	.	.	.
10_1101-2020_01_28_923532	960	1	Nat	Nat	NNP
10_1101-2020_01_28_923532	960	2	.	.	.
10_1101-2020_01_28_923532	961	1	Genet	Genet	NNP
10_1101-2020_01_28_923532	961	2	.	.	.
10_1101-2020_01_28_923532	962	1	45(6	45(6	LS
10_1101-2020_01_28_923532	962	2	)	)	-RRB-
10_1101-2020_01_28_923532	962	3	,	,	,
10_1101-2020_01_28_923532	962	4	580	580	CD
10_1101-2020_01_28_923532	962	5	-	-	SYM
10_1101-2020_01_28_923532	962	6	585	585	CD
10_1101-2020_01_28_923532	962	7	(	(	-LRB-
10_1101-2020_01_28_923532	962	8	2013	2013	CD
10_1101-2020_01_28_923532	962	9	)	)	-RRB-
10_1101-2020_01_28_923532	962	10	.	.	.
10_1101-2020_01_28_923532	963	1	77	77	CD
10_1101-2020_01_28_923532	963	2	.	.	.
10_1101-2020_01_28_923532	964	1	Bausch	Bausch	NNP
10_1101-2020_01_28_923532	964	2	-	-	HYPH
10_1101-2020_01_28_923532	964	3	Fluck	Fluck	NNP
10_1101-2020_01_28_923532	964	4	,	,	,
10_1101-2020_01_28_923532	964	5	D.	D.	NNP
10_1101-2020_01_28_923532	964	6	,	,	,
10_1101-2020_01_28_923532	964	7	et	et	NNP
10_1101-2020_01_28_923532	964	8	al	al	NNP
10_1101-2020_01_28_923532	964	9	.	.	.
10_1101-2020_01_28_923532	965	1	The	the	DT
10_1101-2020_01_28_923532	965	2	in	in	IN
10_1101-2020_01_28_923532	965	3	silico	silico	NNP
10_1101-2020_01_28_923532	965	4	human	human	JJ
10_1101-2020_01_28_923532	965	5	surfaceome	surfaceome	NN
10_1101-2020_01_28_923532	965	6	.	.	.
10_1101-2020_01_28_923532	966	1	Proc	Proc	NNP
10_1101-2020_01_28_923532	966	2	.	.	.
10_1101-2020_01_28_923532	967	1	Natl	Natl	NNP
10_1101-2020_01_28_923532	967	2	.	.	.
10_1101-2020_01_28_923532	968	1	Acad	Acad	NNS
10_1101-2020_01_28_923532	968	2	.	.	.
10_1101-2020_01_28_923532	969	1	Sci	Sci	NNP
10_1101-2020_01_28_923532	969	2	USA	USA	NNP
10_1101-2020_01_28_923532	969	3	115	115	CD
10_1101-2020_01_28_923532	969	4	,	,	,
10_1101-2020_01_28_923532	969	5	E10988-E10997	E10988-E10997	NNP
10_1101-2020_01_28_923532	969	6	(	(	-LRB-
10_1101-2020_01_28_923532	969	7	2018	2018	CD
10_1101-2020_01_28_923532	969	8	)	)	-RRB-
10_1101-2020_01_28_923532	969	9	.	.	.
10_1101-2020_01_28_923532	970	1	78	78	CD
10_1101-2020_01_28_923532	970	2	.	.	.
10_1101-2020_01_28_923532	971	1	Gainer	Gainer	NNP
10_1101-2020_01_28_923532	971	2	-	-	HYPH
10_1101-2020_01_28_923532	971	3	Dewar	Dewar	NNP
10_1101-2020_01_28_923532	971	4	,	,	,
10_1101-2020_01_28_923532	971	5	A.	a.	NN
10_1101-2020_01_28_923532	972	1	&	&	CC
10_1101-2020_01_28_923532	972	2	Vera	Vera	NNP
10_1101-2020_01_28_923532	972	3	-	-	HYPH
10_1101-2020_01_28_923532	972	4	Lincona	Lincona	NNP
10_1101-2020_01_28_923532	972	5	,	,	,
10_1101-2020_01_28_923532	972	6	P.	P.	NNP
10_1101-2020_01_28_923532	972	7	The	the	DT
10_1101-2020_01_28_923532	972	8	minimal	minimal	JJ
10_1101-2020_01_28_923532	972	9	hitting	hit	VBG
10_1101-2020_01_28_923532	972	10	set	set	NN
10_1101-2020_01_28_923532	972	11	generation	generation	NN
10_1101-2020_01_28_923532	972	12	problem	problem	NN
10_1101-2020_01_28_923532	972	13	:	:	:
10_1101-2020_01_28_923532	972	14	Algorithms	Algorithms	NNP
10_1101-2020_01_28_923532	972	15	and	and	CC
10_1101-2020_01_28_923532	972	16	computation	computation	NN
10_1101-2020_01_28_923532	972	17	.	.	.
10_1101-2020_01_28_923532	973	1	SIAM	SIAM	NNP
10_1101-2020_01_28_923532	973	2	J.	J.	NNP
10_1101-2020_01_28_923532	973	3	Discr	Discr	NNP
10_1101-2020_01_28_923532	973	4	.	.	.
10_1101-2020_01_28_923532	974	1	Math	math	NN
10_1101-2020_01_28_923532	974	2	.	.	.
10_1101-2020_01_28_923532	975	1	31	31	CD
10_1101-2020_01_28_923532	975	2	,	,	,
10_1101-2020_01_28_923532	975	3	63	63	CD
10_1101-2020_01_28_923532	975	4	-	-	SYM
10_1101-2020_01_28_923532	975	5	100	100	CD
10_1101-2020_01_28_923532	975	6	(	(	-LRB-
10_1101-2020_01_28_923532	975	7	2017	2017	CD
10_1101-2020_01_28_923532	975	8	)	)	-RRB-
10_1101-2020_01_28_923532	975	9	.	.	.
10_1101-2020_01_28_923532	976	1	79	79	CD
10_1101-2020_01_28_923532	976	2	.	.	.
10_1101-2020_01_28_923532	977	1	Haedlicke	Haedlicke	NNP
10_1101-2020_01_28_923532	977	2	,	,	,
10_1101-2020_01_28_923532	977	3	O.	O.	NNP
10_1101-2020_01_28_923532	978	1	&	&	CC
10_1101-2020_01_28_923532	978	2	Klamt	Klamt	NNP
10_1101-2020_01_28_923532	978	3	,	,	,
10_1101-2020_01_28_923532	978	4	S.	S.	NNP
10_1101-2020_01_28_923532	978	5	Computing	Computing	NNP
10_1101-2020_01_28_923532	978	6	complex	complex	JJ
10_1101-2020_01_28_923532	978	7	metabolic	metabolic	JJ
10_1101-2020_01_28_923532	978	8	intervention	intervention	NN
10_1101-2020_01_28_923532	978	9	strategies	strategy	NNS
10_1101-2020_01_28_923532	978	10	using	use	VBG
10_1101-2020_01_28_923532	978	11	constrained	constrain	VBN
10_1101-2020_01_28_923532	978	12	minimal	minimal	JJ
10_1101-2020_01_28_923532	978	13	cut	cut	NN
10_1101-2020_01_28_923532	978	14	sets	set	NNS
10_1101-2020_01_28_923532	978	15	.	.	.
10_1101-2020_01_28_923532	979	1	Metabolic	Metabolic	NNP
10_1101-2020_01_28_923532	979	2	Eng	Eng	NNP
10_1101-2020_01_28_923532	979	3	.	.	.
10_1101-2020_01_28_923532	980	1	13	13	CD
10_1101-2020_01_28_923532	980	2	,	,	,
10_1101-2020_01_28_923532	980	3	204	204	CD
10_1101-2020_01_28_923532	980	4	-	-	SYM
10_1101-2020_01_28_923532	980	5	213	213	CD
10_1101-2020_01_28_923532	980	6	(	(	-LRB-
10_1101-2020_01_28_923532	980	7	2011	2011	CD
10_1101-2020_01_28_923532	980	8	)	)	-RRB-
10_1101-2020_01_28_923532	980	9	.	.	.
10_1101-2020_01_28_923532	981	1	80	80	CD
10_1101-2020_01_28_923532	981	2	.	.	.
10_1101-2020_01_28_923532	982	1	Haus	Haus	NNP
10_1101-2020_01_28_923532	982	2	,	,	,
10_1101-2020_01_28_923532	982	3	U.-U.	U.-U.	NNP
10_1101-2020_01_28_923532	982	4	,	,	,
10_1101-2020_01_28_923532	982	5	Klamt	Klamt	NNP
10_1101-2020_01_28_923532	982	6	,	,	,
10_1101-2020_01_28_923532	982	7	S.	S.	NNP
10_1101-2020_01_28_923532	982	8	&	&	CC
10_1101-2020_01_28_923532	982	9	Stephen	Stephen	NNP
10_1101-2020_01_28_923532	982	10	,	,	,
10_1101-2020_01_28_923532	982	11	T.	T.	NNP
10_1101-2020_01_28_923532	982	12	Computing	Computing	NNP
10_1101-2020_01_28_923532	982	13	knock	knock	NN
10_1101-2020_01_28_923532	982	14	-	-	HYPH
10_1101-2020_01_28_923532	982	15	out	out	RP
10_1101-2020_01_28_923532	982	16	strategies	strategy	NNS
10_1101-2020_01_28_923532	982	17	in	in	IN
10_1101-2020_01_28_923532	982	18	metabolic	metabolic	JJ
10_1101-2020_01_28_923532	982	19	networks	network	NNS
10_1101-2020_01_28_923532	982	20	.	.	.
10_1101-2020_01_28_923532	983	1	J.	J.	NNP
10_1101-2020_01_28_923532	983	2	Comput	Comput	NNP
10_1101-2020_01_28_923532	983	3	.	.	.
10_1101-2020_01_28_923532	984	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	984	2	.	.	.
10_1101-2020_01_28_923532	985	1	15(3	15(3	LS
10_1101-2020_01_28_923532	985	2	)	)	-RRB-
10_1101-2020_01_28_923532	985	3	,	,	,
10_1101-2020_01_28_923532	985	4	259	259	CD
10_1101-2020_01_28_923532	985	5	-	-	SYM
10_1101-2020_01_28_923532	985	6	268	268	CD
10_1101-2020_01_28_923532	985	7	(	(	-LRB-
10_1101-2020_01_28_923532	985	8	2008	2008	CD
10_1101-2020_01_28_923532	985	9	)	)	-RRB-
10_1101-2020_01_28_923532	985	10	.	.	.
10_1101-2020_01_28_923532	986	1	81	81	CD
10_1101-2020_01_28_923532	986	2	.	.	.
10_1101-2020_01_28_923532	987	1	Jarrah	Jarrah	NNP
10_1101-2020_01_28_923532	987	2	,	,	,
10_1101-2020_01_28_923532	987	3	A.S.	A.S.	NNP
10_1101-2020_01_28_923532	987	4	,	,	,
10_1101-2020_01_28_923532	987	5	Laubenbacher	Laubenbacher	NNP
10_1101-2020_01_28_923532	987	6	,	,	,
10_1101-2020_01_28_923532	987	7	R.	R.	NNP
10_1101-2020_01_28_923532	987	8	,	,	,
10_1101-2020_01_28_923532	987	9	Stigler	Stigler	NNP
10_1101-2020_01_28_923532	987	10	,	,	,
10_1101-2020_01_28_923532	987	11	B.	B.	NNP
10_1101-2020_01_28_923532	988	1	&	&	CC
10_1101-2020_01_28_923532	988	2	Stillman	Stillman	NNP
10_1101-2020_01_28_923532	988	3	,	,	,
10_1101-2020_01_28_923532	988	4	M.	M.	NNP
10_1101-2020_01_28_923532	988	5	Reverse	Reverse	NNP
10_1101-2020_01_28_923532	988	6	-	-	HYPH
10_1101-2020_01_28_923532	988	7	engineering	engineering	NN
10_1101-2020_01_28_923532	988	8	of	of	IN
10_1101-2020_01_28_923532	988	9	polynomial	polynomial	JJ
10_1101-2020_01_28_923532	988	10	dynamical	dynamical	JJ
10_1101-2020_01_28_923532	988	11	systems	system	NNS
10_1101-2020_01_28_923532	988	12	.	.	.
10_1101-2020_01_28_923532	989	1	Adv	Adv	NNP
10_1101-2020_01_28_923532	989	2	.	.	.
10_1101-2020_01_28_923532	990	1	Appl	Appl	NNP
10_1101-2020_01_28_923532	990	2	.	.	.
10_1101-2020_01_28_923532	991	1	Math	math	NN
10_1101-2020_01_28_923532	991	2	.	.	.
10_1101-2020_01_28_923532	992	1	39	39	CD
10_1101-2020_01_28_923532	992	2	,	,	,
10_1101-2020_01_28_923532	992	3	477	477	CD
10_1101-2020_01_28_923532	992	4	-	-	SYM
10_1101-2020_01_28_923532	992	5	489	489	CD
10_1101-2020_01_28_923532	992	6	(	(	-LRB-
10_1101-2020_01_28_923532	992	7	2007	2007	CD
10_1101-2020_01_28_923532	992	8	)	)	-RRB-
10_1101-2020_01_28_923532	992	9	.	.	.
10_1101-2020_01_28_923532	993	1	82	82	CD
10_1101-2020_01_28_923532	993	2	.	.	.
10_1101-2020_01_28_923532	994	1	Klamt	Klamt	NNP
10_1101-2020_01_28_923532	994	2	,	,	,
10_1101-2020_01_28_923532	994	3	S.	S.	NNP
10_1101-2020_01_28_923532	994	4	&	&	CC
10_1101-2020_01_28_923532	994	5	Gilles	Gilles	NNP
10_1101-2020_01_28_923532	994	6	,	,	,
10_1101-2020_01_28_923532	994	7	E.D.	E.D.	NNP
10_1101-2020_01_28_923532	995	1	Minimal	minimal	JJ
10_1101-2020_01_28_923532	995	2	cut	cut	VBD
10_1101-2020_01_28_923532	995	3	sets	set	NNS
10_1101-2020_01_28_923532	995	4	in	in	IN
10_1101-2020_01_28_923532	995	5	biochemical	biochemical	JJ
10_1101-2020_01_28_923532	995	6	reaction	reaction	NN
10_1101-2020_01_28_923532	995	7	networks	network	NNS
10_1101-2020_01_28_923532	995	8	.	.	.
10_1101-2020_01_28_923532	996	1	Bioinformatics	Bioinformatics	NNP
10_1101-2020_01_28_923532	996	2	20	20	CD
10_1101-2020_01_28_923532	996	3	,	,	,
10_1101-2020_01_28_923532	996	4	226	226	CD
10_1101-2020_01_28_923532	996	5	-	-	HYPH
10_1101-2020_01_28_923532	996	6	234	234	CD
10_1101-2020_01_28_923532	996	7	(	(	-LRB-
10_1101-2020_01_28_923532	996	8	2004	2004	CD
10_1101-2020_01_28_923532	996	9	)	)	-RRB-
10_1101-2020_01_28_923532	996	10	.	.	.
10_1101-2020_01_28_923532	997	1	105	105	CD
10_1101-2020_01_28_923532	997	2	and	and	CC
10_1101-2020_01_28_923532	997	3	is	be	VBZ
10_1101-2020_01_28_923532	997	4	also	also	RB
10_1101-2020_01_28_923532	997	5	made	make	VBN
10_1101-2020_01_28_923532	997	6	available	available	JJ
10_1101-2020_01_28_923532	997	7	for	for	IN
10_1101-2020_01_28_923532	997	8	use	use	NN
10_1101-2020_01_28_923532	997	9	under	under	IN
10_1101-2020_01_28_923532	997	10	a	a	DT
10_1101-2020_01_28_923532	997	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	997	12	license	license	NN
10_1101-2020_01_28_923532	997	13	.	.	.
10_1101-2020_01_28_923532	998	1	(	(	-LRB-
10_1101-2020_01_28_923532	998	2	which	which	WDT
10_1101-2020_01_28_923532	998	3	was	be	VBD
10_1101-2020_01_28_923532	998	4	not	not	RB
10_1101-2020_01_28_923532	998	5	certified	certify	VBN
10_1101-2020_01_28_923532	998	6	by	by	IN
10_1101-2020_01_28_923532	998	7	peer	peer	NN
10_1101-2020_01_28_923532	998	8	review	review	NN
10_1101-2020_01_28_923532	998	9	)	)	-RRB-
10_1101-2020_01_28_923532	998	10	is	be	VBZ
10_1101-2020_01_28_923532	998	11	the	the	DT
10_1101-2020_01_28_923532	998	12	author	author	NN
10_1101-2020_01_28_923532	998	13	/	/	SYM
10_1101-2020_01_28_923532	998	14	funder	funder	NN
10_1101-2020_01_28_923532	998	15	.	.	.
10_1101-2020_01_28_923532	999	1	This	this	DT
10_1101-2020_01_28_923532	999	2	article	article	NN
10_1101-2020_01_28_923532	999	3	is	be	VBZ
10_1101-2020_01_28_923532	999	4	a	a	DT
10_1101-2020_01_28_923532	999	5	US	US	NNP
10_1101-2020_01_28_923532	999	6	Government	Government	NNP
10_1101-2020_01_28_923532	999	7	work	work	NN
10_1101-2020_01_28_923532	999	8	.	.	.
10_1101-2020_01_28_923532	1000	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	1000	2	is	be	VBZ
10_1101-2020_01_28_923532	1000	3	not	not	RB
10_1101-2020_01_28_923532	1000	4	subject	subject	JJ
10_1101-2020_01_28_923532	1000	5	to	to	IN
10_1101-2020_01_28_923532	1000	6	copyright	copyright	NN
10_1101-2020_01_28_923532	1000	7	under	under	IN
10_1101-2020_01_28_923532	1000	8	17	17	CD
10_1101-2020_01_28_923532	1000	9	USC	usc	NN
10_1101-2020_01_28_923532	1000	10	The	the	DT
10_1101-2020_01_28_923532	1000	11	copyright	copyright	NN
10_1101-2020_01_28_923532	1000	12	holder	holder	NN
10_1101-2020_01_28_923532	1000	13	for	for	IN
10_1101-2020_01_28_923532	1000	14	this	this	DT
10_1101-2020_01_28_923532	1000	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	1000	16	version	version	NN
10_1101-2020_01_28_923532	1000	17	posted	post	VBD
10_1101-2020_01_28_923532	1000	18	February	February	NNP
10_1101-2020_01_28_923532	1000	19	12	12	CD
10_1101-2020_01_28_923532	1000	20	,	,	,
10_1101-2020_01_28_923532	1000	21	2021	2021	CD
10_1101-2020_01_28_923532	1000	22	.	.	.
10_1101-2020_01_28_923532	1000	23	;	;	:
10_1101-2020_01_28_923532	1000	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	1000	25	:	:	:
10_1101-2020_01_28_923532	1000	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	1000	27	preprint	preprint	NN
10_1101-2020_01_28_923532	1000	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	UH
10_1101-2020_01_28_923532	1000	29	46	46	CD
10_1101-2020_01_28_923532	1000	30	83	83	CD
10_1101-2020_01_28_923532	1000	31	.	.	.
10_1101-2020_01_28_923532	1001	1	Trinh	Trinh	NNP
10_1101-2020_01_28_923532	1001	2	,	,	,
10_1101-2020_01_28_923532	1001	3	C.T.	C.T.	NNP
10_1101-2020_01_28_923532	1001	4	,	,	,
10_1101-2020_01_28_923532	1001	5	Wlaschin	Wlaschin	NNP
10_1101-2020_01_28_923532	1001	6	,	,	,
10_1101-2020_01_28_923532	1001	7	A.	a.	NN
10_1101-2020_01_28_923532	1002	1	&	&	CC
10_1101-2020_01_28_923532	1002	2	Srienc	Srienc	NNP
10_1101-2020_01_28_923532	1002	3	F.	F.	NNP
10_1101-2020_01_28_923532	1002	4	Elementary	Elementary	NNP
10_1101-2020_01_28_923532	1002	5	mode	mode	NN
10_1101-2020_01_28_923532	1002	6	analysis	analysis	NN
10_1101-2020_01_28_923532	1002	7	:	:	:
10_1101-2020_01_28_923532	1002	8	a	a	DT
10_1101-2020_01_28_923532	1002	9	useful	useful	JJ
10_1101-2020_01_28_923532	1002	10	metabolic	metabolic	JJ
10_1101-2020_01_28_923532	1002	11	pathway	pathway	NN
10_1101-2020_01_28_923532	1002	12	analysis	analysis	NN
10_1101-2020_01_28_923532	1002	13	tool	tool	NN
10_1101-2020_01_28_923532	1002	14	for	for	IN
10_1101-2020_01_28_923532	1002	15	characterizing	characterize	VBG
10_1101-2020_01_28_923532	1002	16	cellular	cellular	JJ
10_1101-2020_01_28_923532	1002	17	metabolism	metabolism	NN
10_1101-2020_01_28_923532	1002	18	.	.	.
10_1101-2020_01_28_923532	1003	1	Appl	Appl	NNP
10_1101-2020_01_28_923532	1003	2	.	.	.
10_1101-2020_01_28_923532	1004	1	Microbiol	Microbiol	NNP
10_1101-2020_01_28_923532	1004	2	.	.	.
10_1101-2020_01_28_923532	1005	1	Biotech	Biotech	NNP
10_1101-2020_01_28_923532	1005	2	.	.	.
10_1101-2020_01_28_923532	1006	1	81	81	CD
10_1101-2020_01_28_923532	1006	2	,	,	,
10_1101-2020_01_28_923532	1006	3	813	813	CD
10_1101-2020_01_28_923532	1006	4	-	-	HYPH
10_1101-2020_01_28_923532	1006	5	826	826	CD
10_1101-2020_01_28_923532	1006	6	(	(	-LRB-
10_1101-2020_01_28_923532	1006	7	2009	2009	CD
10_1101-2020_01_28_923532	1006	8	)	)	-RRB-
10_1101-2020_01_28_923532	1006	9	.	.	.
10_1101-2020_01_28_923532	1007	1	84	84	CD
10_1101-2020_01_28_923532	1007	2	.	.	.
10_1101-2020_01_28_923532	1008	1	Ideker	Ideker	NNP
10_1101-2020_01_28_923532	1008	2	,	,	,
10_1101-2020_01_28_923532	1008	3	T.	T.	NNP
10_1101-2020_01_28_923532	1008	4	Discovery	Discovery	NNP
10_1101-2020_01_28_923532	1008	5	of	of	IN
10_1101-2020_01_28_923532	1008	6	regulatory	regulatory	JJ
10_1101-2020_01_28_923532	1008	7	interactions	interaction	NNS
10_1101-2020_01_28_923532	1008	8	through	through	IN
10_1101-2020_01_28_923532	1008	9	perturbation	perturbation	NN
10_1101-2020_01_28_923532	1008	10	:	:	:
10_1101-2020_01_28_923532	1008	11	inference	inference	NN
10_1101-2020_01_28_923532	1008	12	and	and	CC
10_1101-2020_01_28_923532	1008	13	experimental	experimental	JJ
10_1101-2020_01_28_923532	1008	14	design	design	NN
10_1101-2020_01_28_923532	1008	15	.	.	.
10_1101-2020_01_28_923532	1009	1	Pac	Pac	NNP
10_1101-2020_01_28_923532	1009	2	.	.	.
10_1101-2020_01_28_923532	1010	1	Symp	Symp	VBN
10_1101-2020_01_28_923532	1010	2	.	.	.
10_1101-2020_01_28_923532	1011	1	Biocomput	biocomput	NN
10_1101-2020_01_28_923532	1011	2	.	.	.
10_1101-2020_01_28_923532	1012	1	5	5	CD
10_1101-2020_01_28_923532	1012	2	,	,	,
10_1101-2020_01_28_923532	1012	3	302	302	CD
10_1101-2020_01_28_923532	1012	4	-	-	HYPH
10_1101-2020_01_28_923532	1012	5	313	313	CD
10_1101-2020_01_28_923532	1012	6	(	(	-LRB-
10_1101-2020_01_28_923532	1012	7	2000	2000	CD
10_1101-2020_01_28_923532	1012	8	)	)	-RRB-
10_1101-2020_01_28_923532	1012	9	.	.	.
10_1101-2020_01_28_923532	1013	1	85	85	CD
10_1101-2020_01_28_923532	1013	2	.	.	.
10_1101-2020_01_28_923532	1014	1	Wang	Wang	NNP
10_1101-2020_01_28_923532	1014	2	,	,	,
10_1101-2020_01_28_923532	1014	3	R.S.	R.S.	NNP
10_1101-2020_01_28_923532	1015	1	&	&	CC
10_1101-2020_01_28_923532	1015	2	Albert	Albert	NNP
10_1101-2020_01_28_923532	1015	3	,	,	,
10_1101-2020_01_28_923532	1015	4	R.	R.	NNP
10_1101-2020_01_28_923532	1015	5	Elementary	Elementary	NNP
10_1101-2020_01_28_923532	1015	6	signaling	signal	VBG
10_1101-2020_01_28_923532	1015	7	modes	mode	NNS
10_1101-2020_01_28_923532	1015	8	predict	predict	VBP
10_1101-2020_01_28_923532	1015	9	the	the	DT
10_1101-2020_01_28_923532	1015	10	essentiality	essentiality	NN
10_1101-2020_01_28_923532	1015	11	of	of	IN
10_1101-2020_01_28_923532	1015	12	signal	signal	NNP
10_1101-2020_01_28_923532	1015	13	transduction	transduction	NNP
10_1101-2020_01_28_923532	1015	14	network	network	NN
10_1101-2020_01_28_923532	1015	15	components	component	NNS
10_1101-2020_01_28_923532	1015	16	.	.	.
10_1101-2020_01_28_923532	1016	1	BMC	BMC	NNP
10_1101-2020_01_28_923532	1016	2	Syst	Syst	NNP
10_1101-2020_01_28_923532	1016	3	.	.	.
10_1101-2020_01_28_923532	1017	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	1017	2	.	.	.
10_1101-2020_01_28_923532	1018	1	5	5	CD
10_1101-2020_01_28_923532	1018	2	,	,	,
10_1101-2020_01_28_923532	1018	3	44	44	CD
10_1101-2020_01_28_923532	1018	4	(	(	-LRB-
10_1101-2020_01_28_923532	1018	5	2011	2011	CD
10_1101-2020_01_28_923532	1018	6	)	)	-RRB-
10_1101-2020_01_28_923532	1018	7	.	.	.
10_1101-2020_01_28_923532	1019	1	86	86	CD
10_1101-2020_01_28_923532	1019	2	.	.	.
10_1101-2020_01_28_923532	1020	1	Zvedei	Zvedei	NNP
10_1101-2020_01_28_923532	1020	2	-	-	HYPH
10_1101-2020_01_28_923532	1020	3	Oancea	Oancea	NNP
10_1101-2020_01_28_923532	1020	4	,	,	,
10_1101-2020_01_28_923532	1020	5	I.	I.	NNP
10_1101-2020_01_28_923532	1021	1	&	&	CC
10_1101-2020_01_28_923532	1021	2	Schuster	Schuster	NNP
10_1101-2020_01_28_923532	1021	3	,	,	,
10_1101-2020_01_28_923532	1021	4	S.	S.	NNP
10_1101-2020_01_28_923532	1021	5	A	a	DT
10_1101-2020_01_28_923532	1021	6	theoretical	theoretical	JJ
10_1101-2020_01_28_923532	1021	7	framework	framework	NN
10_1101-2020_01_28_923532	1021	8	for	for	IN
10_1101-2020_01_28_923532	1021	9	detecting	detect	VBG
10_1101-2020_01_28_923532	1021	10	signal	signal	NN
10_1101-2020_01_28_923532	1021	11	transfer	transfer	NN
10_1101-2020_01_28_923532	1021	12	routes	route	NNS
10_1101-2020_01_28_923532	1021	13	in	in	IN
10_1101-2020_01_28_923532	1021	14	signaling	signal	VBG
10_1101-2020_01_28_923532	1021	15	networks	network	NNS
10_1101-2020_01_28_923532	1021	16	.	.	.
10_1101-2020_01_28_923532	1022	1	Comput	comput	NN
10_1101-2020_01_28_923532	1022	2	.	.	.
10_1101-2020_01_28_923532	1023	1	Chem	Chem	NNP
10_1101-2020_01_28_923532	1023	2	.	.	.
10_1101-2020_01_28_923532	1024	1	Engineer	engineer	NN
10_1101-2020_01_28_923532	1024	2	.	.	.
10_1101-2020_01_28_923532	1025	1	29	29	CD
10_1101-2020_01_28_923532	1025	2	,	,	,
10_1101-2020_01_28_923532	1025	3	597	597	CD
10_1101-2020_01_28_923532	1025	4	-	-	HYPH
10_1101-2020_01_28_923532	1025	5	617	617	CD
10_1101-2020_01_28_923532	1025	6	(	(	-LRB-
10_1101-2020_01_28_923532	1025	7	2005	2005	CD
10_1101-2020_01_28_923532	1025	8	)	)	-RRB-
10_1101-2020_01_28_923532	1025	9	.	.	.
10_1101-2020_01_28_923532	1026	1	87	87	CD
10_1101-2020_01_28_923532	1026	2	.	.	.
10_1101-2020_01_28_923532	1027	1	Vazquez	Vazquez	NNP
10_1101-2020_01_28_923532	1027	2	A.	A.	NNP
10_1101-2020_01_28_923532	1027	3	Optimal	Optimal	NNP
10_1101-2020_01_28_923532	1027	4	drug	drug	NN
10_1101-2020_01_28_923532	1027	5	combinations	combination	NNS
10_1101-2020_01_28_923532	1027	6	and	and	CC
10_1101-2020_01_28_923532	1027	7	minimal	minimal	JJ
10_1101-2020_01_28_923532	1027	8	hitting	hitting	NN
10_1101-2020_01_28_923532	1027	9	sets	set	NNS
10_1101-2020_01_28_923532	1027	10	.	.	.
10_1101-2020_01_28_923532	1028	1	BMC	BMC	NNP
10_1101-2020_01_28_923532	1028	2	Syst	Syst	NNP
10_1101-2020_01_28_923532	1028	3	.	.	.
10_1101-2020_01_28_923532	1029	1	Biol	Biol	NNP
10_1101-2020_01_28_923532	1029	2	.	.	.
10_1101-2020_01_28_923532	1029	3	,	,	,
10_1101-2020_01_28_923532	1029	4	3	3	CD
10_1101-2020_01_28_923532	1029	5	,	,	,
10_1101-2020_01_28_923532	1029	6	81	81	CD
10_1101-2020_01_28_923532	1029	7	(	(	-LRB-
10_1101-2020_01_28_923532	1029	8	2009	2009	CD
10_1101-2020_01_28_923532	1029	9	)	)	-RRB-
10_1101-2020_01_28_923532	1029	10	.	.	.
10_1101-2020_01_28_923532	1030	1	88	88	CD
10_1101-2020_01_28_923532	1030	2	.	.	.
10_1101-2020_01_28_923532	1031	1	Mellor	Mellor	NNP
10_1101-2020_01_28_923532	1031	2	,	,	,
10_1101-2020_01_28_923532	1031	3	D.	D.	NNP
10_1101-2020_01_28_923532	1031	4	,	,	,
10_1101-2020_01_28_923532	1031	5	Prieto	Prieto	NNP
10_1101-2020_01_28_923532	1031	6	,	,	,
10_1101-2020_01_28_923532	1031	7	E.	E.	NNP
10_1101-2020_01_28_923532	1031	8	,	,	,
10_1101-2020_01_28_923532	1031	9	Mathieson	Mathieson	NNP
10_1101-2020_01_28_923532	1031	10	,	,	,
10_1101-2020_01_28_923532	1031	11	L.	L.	NNP
10_1101-2020_01_28_923532	1031	12	&	&	CC
10_1101-2020_01_28_923532	1031	13	Moscato	Moscato	NNP
10_1101-2020_01_28_923532	1031	14	,	,	,
10_1101-2020_01_28_923532	1031	15	P.	P.	NNP
10_1101-2020_01_28_923532	1031	16	A	A	NNP
10_1101-2020_01_28_923532	1031	17	kernelisation	kernelisation	NN
10_1101-2020_01_28_923532	1031	18	approach	approach	NN
10_1101-2020_01_28_923532	1031	19	for	for	IN
10_1101-2020_01_28_923532	1031	20	multiple	multiple	JJ
10_1101-2020_01_28_923532	1031	21	d-	d-	XX
10_1101-2020_01_28_923532	1031	22	hitting	hit	VBG
10_1101-2020_01_28_923532	1031	23	set	set	VBN
10_1101-2020_01_28_923532	1031	24	and	and	CC
10_1101-2020_01_28_923532	1031	25	its	-PRON-	PRP$
10_1101-2020_01_28_923532	1031	26	application	application	NN
10_1101-2020_01_28_923532	1031	27	in	in	IN
10_1101-2020_01_28_923532	1031	28	optimal	optimal	JJ
10_1101-2020_01_28_923532	1031	29	multi	multi	JJ
10_1101-2020_01_28_923532	1031	30	-	-	JJ
10_1101-2020_01_28_923532	1031	31	drug	drug	JJ
10_1101-2020_01_28_923532	1031	32	therapeutic	therapeutic	JJ
10_1101-2020_01_28_923532	1031	33	combinations	combination	NNS
10_1101-2020_01_28_923532	1031	34	.	.	.
10_1101-2020_01_28_923532	1032	1	PLoS	PLoS	:
10_1101-2020_01_28_923532	1032	2	ONE	one	CD
10_1101-2020_01_28_923532	1032	3	5(10	5(10	CD
10_1101-2020_01_28_923532	1032	4	)	)	-RRB-
10_1101-2020_01_28_923532	1032	5	,	,	,
10_1101-2020_01_28_923532	1032	6	e13055	e13055	NNP
10_1101-2020_01_28_923532	1032	7	(	(	-LRB-
10_1101-2020_01_28_923532	1032	8	2010	2010	CD
10_1101-2020_01_28_923532	1032	9	)	)	-RRB-
10_1101-2020_01_28_923532	1032	10	.	.	.
10_1101-2020_01_28_923532	1033	1	89	89	CD
10_1101-2020_01_28_923532	1033	2	.	.	.
10_1101-2020_01_28_923532	1034	1	Vera	Vera	NNP
10_1101-2020_01_28_923532	1034	2	-	-	HYPH
10_1101-2020_01_28_923532	1034	3	Licona	Licona	NNP
10_1101-2020_01_28_923532	1034	4	,	,	,
10_1101-2020_01_28_923532	1034	5	P.	P.	NNP
10_1101-2020_01_28_923532	1034	6	,	,	,
10_1101-2020_01_28_923532	1034	7	Bonnet	Bonnet	NNP
10_1101-2020_01_28_923532	1034	8	,	,	,
10_1101-2020_01_28_923532	1034	9	E.	E.	NNP
10_1101-2020_01_28_923532	1034	10	,	,	,
10_1101-2020_01_28_923532	1034	11	Brillot	Brillot	NNP
10_1101-2020_01_28_923532	1034	12	,	,	,
10_1101-2020_01_28_923532	1034	13	E	E	NNP
10_1101-2020_01_28_923532	1034	14	&	&	CC
10_1101-2020_01_28_923532	1034	15	Zinovyev	Zinovyev	NNP
10_1101-2020_01_28_923532	1034	16	,	,	,
10_1101-2020_01_28_923532	1034	17	A.	A.	NNP
10_1101-2020_01_28_923532	1034	18	OCSANA	ocsana	NN
10_1101-2020_01_28_923532	1034	19	:	:	:
10_1101-2020_01_28_923532	1034	20	optimal	optimal	JJ
10_1101-2020_01_28_923532	1034	21	combinations	combination	NNS
10_1101-2020_01_28_923532	1034	22	of	of	IN
10_1101-2020_01_28_923532	1034	23	interventions	intervention	NNS
10_1101-2020_01_28_923532	1034	24	from	from	IN
10_1101-2020_01_28_923532	1034	25	network	network	NN
10_1101-2020_01_28_923532	1034	26	analysis	analysis	NN
10_1101-2020_01_28_923532	1034	27	.	.	.
10_1101-2020_01_28_923532	1035	1	Bioinformatics	Bioinformatics	NNP
10_1101-2020_01_28_923532	1035	2	29	29	CD
10_1101-2020_01_28_923532	1035	3	,	,	,
10_1101-2020_01_28_923532	1035	4	1571	1571	CD
10_1101-2020_01_28_923532	1035	5	-	-	SYM
10_1101-2020_01_28_923532	1035	6	1573	1573	CD
10_1101-2020_01_28_923532	1035	7	(	(	-LRB-
10_1101-2020_01_28_923532	1035	8	2013	2013	CD
10_1101-2020_01_28_923532	1035	9	)	)	-RRB-
10_1101-2020_01_28_923532	1035	10	.	.	.
10_1101-2020_01_28_923532	1036	1	90	90	CD
10_1101-2020_01_28_923532	1036	2	.	.	.
10_1101-2020_01_28_923532	1037	1	Pang	Pang	NNP
10_1101-2020_01_28_923532	1037	2	,	,	,
10_1101-2020_01_28_923532	1037	3	K.	K.	NNP
10_1101-2020_01_28_923532	1037	4	,	,	,
10_1101-2020_01_28_923532	1037	5	et	et	NNP
10_1101-2020_01_28_923532	1037	6	al	al	NNP
10_1101-2020_01_28_923532	1037	7	.	.	.
10_1101-2020_01_28_923532	1038	1	Combinatorial	combinatorial	JJ
10_1101-2020_01_28_923532	1038	2	therapy	therapy	NN
10_1101-2020_01_28_923532	1038	3	discovery	discovery	NN
10_1101-2020_01_28_923532	1038	4	using	use	VBG
10_1101-2020_01_28_923532	1038	5	mixed	mixed	JJ
10_1101-2020_01_28_923532	1038	6	integer	integer	NN
10_1101-2020_01_28_923532	1038	7	linear	linear	JJ
10_1101-2020_01_28_923532	1038	8	programming	programming	NN
10_1101-2020_01_28_923532	1038	9	.	.	.
10_1101-2020_01_28_923532	1039	1	Bioinformatics	Bioinformatics	NNP
10_1101-2020_01_28_923532	1039	2	30	30	CD
10_1101-2020_01_28_923532	1039	3	,	,	,
10_1101-2020_01_28_923532	1039	4	1456	1456	CD
10_1101-2020_01_28_923532	1039	5	-	-	SYM
10_1101-2020_01_28_923532	1039	6	1463	1463	CD
10_1101-2020_01_28_923532	1039	7	(	(	-LRB-
10_1101-2020_01_28_923532	1039	8	2014	2014	CD
10_1101-2020_01_28_923532	1039	9	)	)	-RRB-
10_1101-2020_01_28_923532	1039	10	.	.	.
10_1101-2020_01_28_923532	1040	1	91	91	CD
10_1101-2020_01_28_923532	1040	2	.	.	.
10_1101-2020_01_28_923532	1041	1	Achterberg	Achterberg	NNP
10_1101-2020_01_28_923532	1041	2	,	,	,
10_1101-2020_01_28_923532	1041	3	T.	T.	NNP
10_1101-2020_01_28_923532	1041	4	SCIP	SCIP	NNP
10_1101-2020_01_28_923532	1041	5	:	:	:
10_1101-2020_01_28_923532	1041	6	Solving	solve	VBG
10_1101-2020_01_28_923532	1041	7	constraint	constraint	NN
10_1101-2020_01_28_923532	1041	8	integer	integer	NN
10_1101-2020_01_28_923532	1041	9	programs	program	NNS
10_1101-2020_01_28_923532	1041	10	.	.	.
10_1101-2020_01_28_923532	1042	1	Math	math	NN
10_1101-2020_01_28_923532	1042	2	.	.	.
10_1101-2020_01_28_923532	1043	1	Program	program	NN
10_1101-2020_01_28_923532	1043	2	.	.	.
10_1101-2020_01_28_923532	1044	1	Comput	comput	NN
10_1101-2020_01_28_923532	1044	2	.	.	.
10_1101-2020_01_28_923532	1045	1	1(1	1(1	NNP
10_1101-2020_01_28_923532	1045	2	)	)	-RRB-
10_1101-2020_01_28_923532	1045	3	,	,	.
10_1101-2020_01_28_923532	1045	4	1-	1-	NNP
10_1101-2020_01_28_923532	1045	5	41	41	CD
10_1101-2020_01_28_923532	1045	6	(	(	-LRB-
10_1101-2020_01_28_923532	1045	7	2009	2009	CD
10_1101-2020_01_28_923532	1045	8	)	)	-RRB-
10_1101-2020_01_28_923532	1045	9	.	.	.
10_1101-2020_01_28_923532	1046	1	105	105	CD
10_1101-2020_01_28_923532	1046	2	and	and	CC
10_1101-2020_01_28_923532	1046	3	is	be	VBZ
10_1101-2020_01_28_923532	1046	4	also	also	RB
10_1101-2020_01_28_923532	1046	5	made	make	VBN
10_1101-2020_01_28_923532	1046	6	available	available	JJ
10_1101-2020_01_28_923532	1046	7	for	for	IN
10_1101-2020_01_28_923532	1046	8	use	use	NN
10_1101-2020_01_28_923532	1046	9	under	under	IN
10_1101-2020_01_28_923532	1046	10	a	a	DT
10_1101-2020_01_28_923532	1046	11	CC0	CC0	NNP
10_1101-2020_01_28_923532	1046	12	license	license	NN
10_1101-2020_01_28_923532	1046	13	.	.	.
10_1101-2020_01_28_923532	1047	1	(	(	-LRB-
10_1101-2020_01_28_923532	1047	2	which	which	WDT
10_1101-2020_01_28_923532	1047	3	was	be	VBD
10_1101-2020_01_28_923532	1047	4	not	not	RB
10_1101-2020_01_28_923532	1047	5	certified	certify	VBN
10_1101-2020_01_28_923532	1047	6	by	by	IN
10_1101-2020_01_28_923532	1047	7	peer	peer	NN
10_1101-2020_01_28_923532	1047	8	review	review	NN
10_1101-2020_01_28_923532	1047	9	)	)	-RRB-
10_1101-2020_01_28_923532	1047	10	is	be	VBZ
10_1101-2020_01_28_923532	1047	11	the	the	DT
10_1101-2020_01_28_923532	1047	12	author	author	NN
10_1101-2020_01_28_923532	1047	13	/	/	SYM
10_1101-2020_01_28_923532	1047	14	funder	funder	NN
10_1101-2020_01_28_923532	1047	15	.	.	.
10_1101-2020_01_28_923532	1048	1	This	this	DT
10_1101-2020_01_28_923532	1048	2	article	article	NN
10_1101-2020_01_28_923532	1048	3	is	be	VBZ
10_1101-2020_01_28_923532	1048	4	a	a	DT
10_1101-2020_01_28_923532	1048	5	US	US	NNP
10_1101-2020_01_28_923532	1048	6	Government	Government	NNP
10_1101-2020_01_28_923532	1048	7	work	work	NN
10_1101-2020_01_28_923532	1048	8	.	.	.
10_1101-2020_01_28_923532	1049	1	It	-PRON-	PRP
10_1101-2020_01_28_923532	1049	2	is	be	VBZ
10_1101-2020_01_28_923532	1049	3	not	not	RB
10_1101-2020_01_28_923532	1049	4	subject	subject	JJ
10_1101-2020_01_28_923532	1049	5	to	to	IN
10_1101-2020_01_28_923532	1049	6	copyright	copyright	NN
10_1101-2020_01_28_923532	1049	7	under	under	IN
10_1101-2020_01_28_923532	1049	8	17	17	CD
10_1101-2020_01_28_923532	1049	9	USC	usc	NN
10_1101-2020_01_28_923532	1049	10	The	the	DT
10_1101-2020_01_28_923532	1049	11	copyright	copyright	NN
10_1101-2020_01_28_923532	1049	12	holder	holder	NN
10_1101-2020_01_28_923532	1049	13	for	for	IN
10_1101-2020_01_28_923532	1049	14	this	this	DT
10_1101-2020_01_28_923532	1049	15	preprintthis	preprintthis	NN
10_1101-2020_01_28_923532	1049	16	version	version	NN
10_1101-2020_01_28_923532	1049	17	posted	post	VBD
10_1101-2020_01_28_923532	1049	18	February	February	NNP
10_1101-2020_01_28_923532	1049	19	12	12	CD
10_1101-2020_01_28_923532	1049	20	,	,	,
10_1101-2020_01_28_923532	1049	21	2021	2021	CD
10_1101-2020_01_28_923532	1049	22	.	.	.
10_1101-2020_01_28_923532	1049	23	;	;	:
10_1101-2020_01_28_923532	1049	24	https://doi.org/10.1101/2020.01.28.923532doi	https://doi.org/10.1101/2020.01.28.923532doi	ADD
10_1101-2020_01_28_923532	1049	25	:	:	:
10_1101-2020_01_28_923532	1049	26	bioRxiv	biorxiv	VB
10_1101-2020_01_28_923532	1049	27	preprint	preprint	NN
10_1101-2020_01_28_923532	1049	28	https://doi.org/10.1101/2020.01.28.923532	https://doi.org/10.1101/2020.01.28.923532	XX